Final Program - American Society of Gene & Cell Therapy
Final Program - American Society of Gene & Cell Therapy
Final Program - American Society of Gene & Cell Therapy
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Final</strong> <strong>Program</strong><br />
AMERICAN SOCIET Y OF GENE & CELL THERAPY<br />
14 th Annual Meeting<br />
SEAT TLE, WA | MAY 18-21, 2 011<br />
Jointly sponsored by Indiana University<br />
School <strong>of</strong> Medicine and the<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
ASGCT Officers and<br />
Board <strong>of</strong> Directors<br />
President (10/11)<br />
Barrie J. Carter, PhD<br />
President-Elect (10/11)<br />
R. Jude Samulski, PhD<br />
Vice President (10/11)<br />
Xandra O. Breakefield, PhD<br />
Secretary (13)<br />
John J. Rossi, PhD<br />
Treasurer (11)<br />
Beverly L. Davidson, PhD<br />
Board Members<br />
Christopher Baum, MD<br />
Fabio Candotti, MD<br />
Roberto Cattaneo, PhD<br />
Cynthia Dunbar, MD<br />
Helen E. Heslop, MD<br />
Brendan Lee, MD, PhD<br />
Stephen J. Russell, MD, PhD<br />
Brian P. Sorrentino, MD<br />
Samuel C. Wadsworth, PhD<br />
Mark A. Kay, MD, PhD<br />
Chair, Advisory Council<br />
(ex-<strong>of</strong>ficio)<br />
Malcolm K. Brenner, MD, PhD<br />
Editor-in-Chief, Molecular <strong>Therapy</strong><br />
(ex-<strong>of</strong>ficio)<br />
ASGCT<br />
Executive Office<br />
555 East Wells Street, Suite 1100<br />
Milwaukee, WI 53202<br />
Phone: 414.278.1341 | Fax: 414.276.3349<br />
info@asgct.org | www.asgct.org<br />
Mary Dean – Executive Director<br />
Erin Hankey – Administrative Coordinator<br />
Ken Janowski – <strong>Program</strong> Manager<br />
Roseann Marotz – Meetings Manager<br />
David Wood – Senior Meetings and Membership Manager<br />
Tara Withington, CAE – Consulting Partner<br />
Contents<br />
A Welcome from Barrie J. Carter, PhD . . . . . . . . . . . . . . . . . . . .2<br />
Annual Meeting Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3<br />
Annual Meeting Exhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4<br />
Committee Meeting Schedule . . . . . . . . . . . . . . . . . . . . . . . . . .5<br />
Committee Rosters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6<br />
Abstract Planning Committee<br />
& Group Coordinating Reviewers . . . . . . . . . . . . . . . . . . . . . . 11<br />
Excellence in Research Award<br />
& Travel Grant Recipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Outstanding New Investigator<br />
& Outstanding Achievement Awards Recipients . . . . . . . 14<br />
Faculty Listing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15<br />
<strong>Gene</strong>ral Meeting Information . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
Washington State Convention Center Floor Plans. . . . . . 24<br />
Schedule-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29<br />
Detailed <strong>Program</strong> Schedule . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Exhibit Hall Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77<br />
Exhibitor Descriptions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78<br />
Exhibitor Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84<br />
Seattle Fun Facts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Housing Information and Map <strong>of</strong> Seattle . . . . . . . . . . . . . . 86<br />
Abstract Directory. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Abstract Author Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 1
2<br />
A Welcome from Barrie J. Carter, PhD<br />
Dear Colleagues,<br />
On behalf <strong>of</strong> the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>, welcome to the <strong>Society</strong>’s<br />
14 th Annual Meeting in ASGCT’s founding city, Seattle, Washington, USA. As I look<br />
back to the last time ASGCT was in Seattle, I’m impressed with how far our field has<br />
advanced since 2007. We have seen significant progress in gene and cell therapy for<br />
immune deficiency diseases, including most recently Wiskott Aldrich Syndrome as<br />
well as for retinal degeneration, Parkinson’s disease, and a variety <strong>of</strong> other inherited<br />
and acquired diseases. We have also seen the first cell therapy product approved for<br />
cancer and other remarkable progress in cellular therapies, particularly those based<br />
on modified T cells. In addition, oncolytic viruses are progressing rapidly to advanced<br />
clinical trials. As a result <strong>of</strong> this broad ranging progress, we are beginning to see<br />
investments by large Pharma and Biotech in the arena.<br />
The Annual Meeting program features many <strong>of</strong> the developments in the field over the<br />
past year in 27 scientific symposia, 10 education sessions, 28 oral abstract sessions, 3<br />
poster sessions, and 5 meet-the-investigator lunch sessions.<br />
I am honored to have Dr. Victor Dzau present the keynote lecture during the George<br />
Stamatoyannopoulos Lecture and Dr. George Daley to present on combining gene<br />
and cell therapy using iPS cells during the Presidential Symposium. In addition, Dr.<br />
Malcolm Brenner, the 2011 Outstanding Achievement Award winner, will give a<br />
retrospective <strong>of</strong> his contributions to the field.<br />
I emphatically thank the many groups who have come together to support the<br />
Annual Meeting: the generosity <strong>of</strong> the exhibitors, non-pr<strong>of</strong>it organizations and<br />
industry supporters contributes greatly to the overall success <strong>of</strong> ASGCT’s conference.<br />
Please be sure to take time to visit the vendors in the exhibit hall this year.<br />
Thank you also to the Annual Meeting faculty for sharing their expertise and time to<br />
make this a truly unique event.<br />
And finally, thank you, the Annual Meeting participants, for attending the <strong>Society</strong>’s<br />
Annual Meeting. Welcome to my hometown!<br />
Sincerely,<br />
Barrie J. Carter, PhD<br />
President, ASGCT<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Annual Meeting Supporters (as <strong>of</strong> April 2011)<br />
Our grateful acknowledgement to the following for their educational grant in support <strong>of</strong> this program:<br />
Partner Level Support<br />
Registration Bags<br />
Contributor Level Support<br />
Notebook and Exhibit Hall Guide C<strong>of</strong>fee Mugs Printing <strong>of</strong> the <strong>Final</strong> <strong>Program</strong><br />
Patron Level Support<br />
Conference Grant Support Outstanding New Investigator Awards (2) Travel Grants (5)<br />
Excellence in Research Award (1)<br />
Excellence in Research Award (1) Travel Grant (1) <strong>Gene</strong>ral Meeting Support<br />
Travel Grants (2) Outstanding New Investigator Award (1) <strong>Gene</strong>ral Meeting Support Travel Grants (3)<br />
Excellence in Research Award (1)<br />
and Travel Grants (3)<br />
Conference Grant Support<br />
Excellence in Research Awards (2)<br />
Travel Grants (4)<br />
Travel Grant (1)<br />
Job Bank Booklet<br />
Supported in part by March <strong>of</strong> Dimes<br />
Foundation Grant No. 4-FY11-533.<br />
Excellence in Research Award (1)<br />
Travel Grants (10)<br />
Marketing Support<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 3
4<br />
Annual Meeting Exhibitors<br />
The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> would like to acknowledge the<br />
following exhibitors that are exhibiting at the ASGCT 14th Annual Meeting.<br />
Adaptive TCR Technologies<br />
Aldevron<br />
AltheaDx<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Axis-Shield PoC<br />
BioSpherix<br />
Caliper Life Sciences<br />
Center for <strong>Cell</strong>ular and Molecular<br />
Therapeutics at the Children’s Hospital <strong>of</strong><br />
Philadelphia<br />
Data Unlimited International, Inc.<br />
Freezerworks – A Division <strong>of</strong> Dataworks<br />
Development, Inc.<br />
GENE TOOLS, LLC<br />
GENEWIZ, Inc.<br />
Horizon Discovery Ltd<br />
Lonza<br />
Lovelace Respiratory Research Institute<br />
Mary Ann Liebert, Inc.<br />
Meridian Life Science, Inc.<br />
MolMed S.p.A.<br />
NanoSight<br />
National <strong>Gene</strong> Vector Biorepository<br />
(NGVB)<br />
Nature Publishing Group<br />
Nature Technology Corporation<br />
Nexcelom Bioscience<br />
NHLBI <strong>Gene</strong> <strong>Therapy</strong> Resource <strong>Program</strong><br />
NIH Office <strong>of</strong> Biotechnology Activities<br />
Omnia Biologics, Inc.<br />
Penn Vector Core, University <strong>of</strong><br />
Pennsylvania<br />
Polyplus-transfection<br />
Production Assistance for <strong>Cell</strong>ular<br />
Therapies (PACT)<br />
ReGenX Biosciences<br />
Social & Scientific Systems, Inc.<br />
St. Jude Children’s Research Hospital<br />
Techulon, Inc.<br />
TriLink BioTechnologies, Inc.<br />
Waisman Biomanufacturing<br />
Make time each day to peruse the products, services and publications <strong>of</strong>fered by the<br />
exhibiting companies. Network and meet new colleagues in a relaxed atmosphere.<br />
Stop by the Job Exchange Area.<br />
Thank you 14 th Annual Meeting Exhibitors!<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Committee Meeting Schedule<br />
Committee terms technically commence and conclude at the Annual Meeting. Incoming chair and committee member terms<br />
<strong>of</strong>ficially go into effect on May 21, 2011 at the Business Meeting. All meetings will be held at the Washington State Convention<br />
Center unless otherwise noted.<br />
WEDNESDAY, MAY 18 th<br />
12:00 pm – 1:15 pm Translational Science & Product Development<br />
Committee Meeting<br />
THURSDAY, MAY 19 th<br />
WSCC Room 211<br />
Publications Committee Meeting WSCC Room 212<br />
1:00 pm – 2:30 pm Ethics Committee Meeting WSCC Room 211<br />
Education Committee Meeting WSCC Room 212<br />
7:00 pm – 8:30 pm Molecular <strong>Therapy</strong> Editorial Board Meeting Sheraton Seattle, Cirrus Room<br />
FRIDAY, MAY 20 th<br />
12:00 pm – 1:15 pm Bio-Industry Liaison Committee Meeting WSCC Room 211<br />
SATURDAY, MAY 21 st<br />
International Committee Meeting WSCC Room 212<br />
Advisory Council Meeting WSCC Room 213<br />
7:30 am – 8:00 am <strong>Society</strong> Annual Business Meeting WSCC 618-620<br />
12:15 pm – 1:45 pm Membership Committee Meeting WSCC Room 212<br />
SOCIETY ANNUAL BUSINESS MEETING<br />
Scientific Committee Meetings<br />
Cancer <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>; Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>;<br />
Chemical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>; <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> <strong>Gene</strong>tic<br />
Diseases; <strong>Gene</strong>tic Vaccines; Physical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> &<br />
Vectorology; Respiratory Tract <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>; Stem <strong>Cell</strong>; Viral<br />
<strong>Gene</strong> Transfer Vectors<br />
WSCC 6E<br />
The ASGCT Business Meeting will be conducted on Saturday, May 21, 7:30 am – 8:00 am. A continental breakfast will be served at<br />
7:15 am in the Room 618-620.<br />
All ASGCT members are welcome to attend. Election results will be announced, new <strong>of</strong>ficers will be installed and the <strong>Society</strong>’s<br />
finances and membership statistics will be reviewed. We welcome your input and participation!<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 5
6<br />
Committee Rosters<br />
Advisory Council<br />
Chair<br />
Mark A. Kay, MD, PhD (2010 - 2011)<br />
Katherine P. Ponder, MD (2011 - 2012)<br />
Members<br />
David M. Bodine, PhD (2009 - 2014)<br />
Barrie J. Carter, PhD (2011 - 2016)<br />
Kenneth Cornetta, MD (2010 - 2015)<br />
Theodore Friedmann, MD (2007 - 2012)<br />
Leaf Huang, PhD (2006 - 2011)<br />
Carl H. June, MD (2010 - 2015)<br />
Andra E. Miller, PhD (2007 - 2012)<br />
Luigi M. Naldini, MD, PhD (2008 - 2013)<br />
Arthur W. Nienhuis, MD (2008 - 2013)<br />
Katherine P. Ponder, MD (2009 - 2014)<br />
Bio-Industry Liaison Committee<br />
Chair<br />
Seng H. Cheng, PhD (2010 - 2012)<br />
Members<br />
Estuardo Aguilar-Cordova, PhD (2008 - 2014)<br />
Dale Ando, MD (2010 - 2013)<br />
Joseph T. Bruder, PhD (2010 - 2013)<br />
Anthony T. Cheung, PhD (2008 - 2014)<br />
Michael Fons, PhD (2007 - 2013)<br />
Joyce L. Frey-Vasconcells, PhD (2009 - 2012)<br />
William F. Kaemmerer, PhD (2010 - 2013)<br />
Karen Kozarsky, PhD (2007 - 2013)<br />
Brett P. Monia, PhD (2010 - 2013)<br />
Jeffrey M. Ostrove, PhD (2008 - 2011)<br />
Gabor M. Rubanyi, MD, PhD (2010 - 2013)<br />
Vladimir Slepushkin, MD, PhD (2006 - 2012)<br />
Sean M. Sullivan, PhD (2010 - 2013)<br />
Ge<strong>of</strong>f P. Symonds, PhD (2006 - 2012)<br />
Thomas Tillett (2010 - 2013)<br />
Cancer <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee<br />
Chair<br />
Margaret Black, PhD (2011 - 2012)<br />
Laurence JN Cooper, MD, PhD (2009 - 2011)<br />
Members<br />
Karen S. Aboody, MD (2011 - 2014)<br />
Chiara Bonini, MD (2009 - 2012)<br />
Renier J. Brentjens, MD, PhD (2010 - 2013)<br />
Laurence JN Cooper, MD, PhD (2011 - 2012)<br />
Evanthia Galanis, MD, DSc (2011 - 2014)<br />
Stephen Gottschalk, MD (2007 - 2013)<br />
Paola Grandi, PhD (2011 - 2014)<br />
Maciej S. Lesniak, MD, MHCM, FACS (2009 - 2012)<br />
Richard A. Morgan, PhD (2009 - 2012)<br />
John J. Nemunaitis, MD (2008 - 2014)<br />
Daniel H. Sterman, MD (2007 - 2013)<br />
Bakhos A. Tannous, PhD (2011 - 2014)<br />
Savio L.C. Woo, PhD (2010 - 2013)<br />
Lily Wu, MD, PhD (2010 - 2013)<br />
Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Committee<br />
Chair<br />
Barry J. Byrne, MD, PhD (2010 - 2012)<br />
Members<br />
David A. Dichek, MD (2010 - 2013)<br />
Michael P. Murphy, MD (2009 - 2012)<br />
Timothy O’Brien, MD, PhD (2009 - 2012)<br />
Michael J. Passineau, PhD (2010 - 2013)<br />
Gabor M. Rubanyi, MD, PhD (2010 - 2013)<br />
Matthew L. Springer, PhD (2007 - 2013)<br />
Karen A. Vincent, PhD (2008 - 2014)<br />
Krisztina M. Zsebo, PhD (2011 - 2014)<br />
Chemical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Committee<br />
Chair<br />
Ian MacLachlan, PhD (2011 - 2012)<br />
Theresa M. Reineke, PhD (2010 - 2011)<br />
Members<br />
Roger C. Adami, Ph.D. (2007 - 2013)<br />
Todd Giorgio, PhD (2010 - 2011)<br />
Stephen L. Hart, PhD (2011 - 2014)<br />
James G. Hecker, MD, PhD (2006 - 2012)<br />
Ian MacLachlan, PhD (2010 - 2013)<br />
Suzie H. Pun, PhD (2007 - 2013)<br />
Theresa M. Reineke, PhD (2011 - 2012)<br />
Kevin G. Rice, PhD (2010 - 2013)<br />
Cyrus R. Safinya, PhD (2010 - 2013)<br />
Millicent O. Sullivan, PhD (2010 - 2013)<br />
David B. Weiner, PhD (2010 - 2013)<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Committee Rosters<br />
Clinical Trials and Regulatory Affairs<br />
Committee<br />
Chair<br />
Carl H. June, MD (2009 - 2011)<br />
Members<br />
Dale Ando, MD (2010 - 2013)<br />
Jacqueline Corrigan-Curay, MD, JD (2008 - 2014)<br />
Carl H. June, MD (2011 - 2012)<br />
Elizabeth Kang, MD (2009 - 2012)<br />
Thomas M. Miller, PhD (2008 - 2011)<br />
Glenn F. Pierce, MD, PhD (2011 - 2014)<br />
Daniel M. Takefman, PhD (2009 - 2012)<br />
Peter K. Working, PhD, DABT (2010 - 2013)<br />
J. Fraser Wright, PhD (2009 - 2012)<br />
Education Committee<br />
Co-Chairs<br />
Linda B. Couto, PhD (2010 - 2012)<br />
Fulvio Mavilio, PhD (2009 - 2011)<br />
Sonia I. Skarlatos, PhD (2011 - 2012)<br />
Members<br />
William F. Goins, PhD (2007 - 2013)<br />
Scott Q. Harper, PhD (2010 - 2013)<br />
Tal Kafri, MD, PhD (2007 - 2013)<br />
Harry L. Malech, MD (2010 - 2013)<br />
Matthew H. Porteus, MD, PhD (2010 - 2013)<br />
Suzie H. Pun, PhD (2009 - 2012)<br />
Luk H. Vandenberghe, PhD (2010 - 2013)<br />
Ethics Committee<br />
Chair<br />
Nelson Wivel, MD (2010 - 2012)<br />
Members<br />
Roger H. Bertolotti, PhD (2009 - 2012)<br />
R. Michael Blaese, MD (2010 - 2013)<br />
Theodore Friedmann, MD (2008 - 2014)<br />
Edward I. Ginns, MD, PhD (2009 - 2012)<br />
Dieter C. Gruenert, PhD (2010 - 2013)<br />
Nelson Wivel, MD (2009 - 2012)<br />
Financial Affairs Committee<br />
Chair<br />
Barrie J. Carter, PhD (2010 - 2011)<br />
Members<br />
Xandra O. Breakefield, PhD (2010 - 2012)<br />
Beverly L. Davidson, PhD (2009 - 2011)<br />
John J. Rossi, PhD (2010 - 2013)<br />
R. Jude Samulski, PhD (2009 - 2011)<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> <strong>Gene</strong>tic and<br />
Metabolic Diseases Committee<br />
Chair<br />
Valder Arruda, MD, PhD (2010 - 2012)<br />
Members<br />
Alessandra Biffi, MD (2011 - 2014)<br />
Fatima Bosch, PhD (2010 - 2013)<br />
Fabio Candotti, MD (2010 - 2011)<br />
Lawrence C. Chan, MD (2010 - 2013)<br />
Stephanie Cherqui, PhD (2011 - 2014)<br />
Andrew M. David<strong>of</strong>f, MD (2010 - 2013)<br />
Nuria Morral, PhD (2009 - 2012)<br />
Sihong Song, PhD (2011 - 2014)<br />
Thierry C. VandenDriessche, PhD (2009 - 2012)<br />
Charles P. Venditti, MD, PhD (2008 - 2014)<br />
Robin Ziegler, MS (2010 - 2013)<br />
<strong>Gene</strong>tic Vaccines Committee<br />
Chair<br />
Helen E. Heslop, MD (2009 - 2011)<br />
Jeffrey J. Molldrem, MD (2011 - 2012)<br />
Members<br />
Ronald Alvarez, MD (2006 - 2012)<br />
Austin J. Barrett, MD (2010 - 2013)<br />
Si-Yi Chen, MD, PhD (2010 - 2013)<br />
Jeffrey J. Molldrem, MD (2010 - 2013)<br />
Sattva S. Neelapu, MD (2010 - 2013)<br />
Hematologic and Immunologic <strong>Gene</strong> and<br />
<strong>Cell</strong> <strong>Therapy</strong> Committee<br />
Chair<br />
Michel Sadelain, MD, PhD (2010 - 2012)<br />
Members<br />
Alessandro Aiuti, MD, PhD (2008 - 2014)<br />
Gianpietro Dotti, MD (2010 - 2013)<br />
David W. Emery, PhD (2006 - 2012)<br />
Karin M.L. Gaensler, MD (2006 - 2012)<br />
John T. Gray, PhD (2011 - 2014)<br />
Manuel Grez, PhD (2009 - 2012)<br />
Helen E. Heslop, MD (2011 - 2014)<br />
Paris Margaritis, D.Phil (2011 - 2014)<br />
Derek A. Persons, MD, PhD (2007 - 2013)<br />
Karen E. Pollok, PhD (2006 - 2012)<br />
Barbara Savoldo, MD, PhD (2010 - 2013)<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 7
8<br />
Committee Rosters<br />
Immune Responses to <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Committee<br />
Chair<br />
Pedro Lowenstein, MD, PhD (2011 - 2012)<br />
Adrian J. Thrasher, MD, PhD (2009 - 2011)<br />
Members<br />
Andrea Amalfitano, DO, PhD (2010 - 2013)<br />
Catherine M. Bollard, MBChB, FRACP, FRCPA (2011 - 2014)<br />
Andrew Byrnes, PhD (2010 - 2013)<br />
Roland W. Herzog, PhD (2010 - 2013)<br />
Shulin Li, PhD (2011 - 2014)<br />
Gerald S. Lipshutz, MD (2010 - 2013)<br />
John D. Mountz, MD, PhD (2007 - 2013)<br />
Denise Sabatino, PhD (2008 - 2014)<br />
Yiping Yang, MD, PhD (2010 - 2013)<br />
Infectious Diseases and Vaccines Committee<br />
Chair<br />
Roberto Cattaneo, PhD (2009 - 2011)<br />
Margaret A. Liu, MD (2011 - 2012)<br />
Members<br />
Roberto Cattaneo, PhD (2011 - 2012)<br />
Philip R. Johnson, MD (2010 - 2013)<br />
Wayne A. Marasco, MD, PhD (2006 - 2012)<br />
Eric Poeschla, MD (2010 - 2013)<br />
Steven Polyak, MD (2010 - 2013)<br />
Bruce E. Torbett, PhD, MSPH (2009 - 2012)<br />
James M. Wilson, MD, PhD (2007 - 2013)<br />
Stefan Worgall, MD, PhD (2006 - 2012)<br />
International Committee<br />
Chair<br />
John Rasko, MBBS, PhD (2009 - 2011)<br />
Thierry C. VandenDriessche, PhD (2011 - 2012)<br />
Members<br />
Alberto Auricchio, MD (2010 - 2013)<br />
Christopher Baum, MD (2010 - 2013)<br />
Guangping Gao, PhD (2009 - 2012)<br />
Bobby Gaspar, MD, PhD (2008 - 2014)<br />
Salima Hacein-Bey Abina, PhD (2008 - 2014)<br />
Amit Nathwani, MD, PhD (2011 - 2014)<br />
John Rasko, MBBS, PhD (2011 - 2012)<br />
Takashi Shimada, MD, PhD (2009 - 2012)<br />
Sander van Deventer, MD, PhD (2007 - 2013)<br />
Thierry C. VandenDriessche, PhD (2010 - 2013)<br />
Seppo Ylä-Herttuala, MD, PhD, FESC (2005 - 2011)<br />
Membership Committee<br />
Chair<br />
Guangping Gao, PhD (2011 - 2012)<br />
Dexi Liu, PhD (2010 - 2011)<br />
Members<br />
Donna Armentano, PhD (2011 - 2014)<br />
Alberto Auricchio, MD (2011 - 2014)<br />
Margaret Black, PhD (2010 - 2013)<br />
Michele P. Calos, PhD (2010 - 2013)<br />
Dexi Liu, PhD (2006 - 2012)<br />
Toya Ohashi, MD (2008 - 2014)<br />
Keiya Ozawa, MD, PhD (2011 - 2014)<br />
Maria-Grazia Roncarolo, MD, PhD (2005 - 2011)<br />
John J. Rossi, PhD (2005 - 2011)<br />
Junzhi Wang, PhD (2011 - 2014)<br />
Savio L.C. Woo, PhD (2010 - 2011)<br />
Ex-Officio<br />
Robert M. Frederickson, PhD (2005 - 2012)<br />
Musculo-Skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Committee<br />
Chair<br />
Jerry R. Mendell, MD (2010 - 2012)<br />
Members<br />
Jeffrey Chamberlain, PhD (2010 - 2013)<br />
Alan R. Davis, PhD (2007 - 2013)<br />
Richard J. Gregory, PhD (2010 - 2013)<br />
Dwight Koeberl, MD, PhD (2010 - 2013)<br />
Alan J. Nixon, DVM, MS (2007 - 2013)<br />
Shin’ichi Takeda, MD, PhD (2010 - 2013)<br />
Kathryn Wagner, MD, PhD (2011 - 2014)<br />
Bing Wang, MD, PhD (2010 - 2013)<br />
Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong><br />
<strong>Therapy</strong> Committee<br />
Chair<br />
Maria G. Castro, PhD (2009 - 2011)<br />
Mark H. Tusznski (2011 - 2012)<br />
Members<br />
Robin R. Ali, PhD (2010 - 2013)<br />
Alessandra Biffi, MD (2011 - 2014)<br />
William J. Bowers, PhD (2009 - 2012)<br />
Xandra O. Breakefield, PhD (2009 - 2012)<br />
Maria G. Castro, PhD (2011 - 2012)<br />
Thomas W. Chalberg, PhD (2011 - 2014)<br />
Beverly L. Davidson, PhD (2008 - 2011)<br />
Florian Eichler, MD (2011 - 2014)<br />
David J. Fink, MD (2010 - 2013)<br />
William Hauswirth, PhD (2010 - 2013)<br />
Anne Messer, PhD (2010 - 2013)<br />
Seshidhar Reddy Police, DVM, MS, PhD (2011 - 2014)<br />
Deborah J. Watson, PhD (2009 - 2012)<br />
John H. Wolfe, VMD, PhD (2010 - 2013)<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Committee Rosters<br />
Nominating Committee<br />
Chair<br />
David M. Bodine, PhD (2010 - 2012)<br />
Members<br />
Christopher Baum, MD (2010 - 2011)<br />
Michele P. Calos, PhD (2010 - 2011)<br />
Roland W. Herzog, PhD (2010 - 2011)<br />
Maria-Grazia Roncarolo, MD, PhD (2010 - 2011)<br />
Oligonucleotide and RNAi Therapeutics<br />
Committee<br />
Chair<br />
Kevin V. Morris, PhD (2011 - 2012)<br />
Bruce Sullenger, PhD (2009 - 2011)<br />
Members<br />
C. Frank Bennett, PhD (2010 - 2013)<br />
Brian D. Brown, PhD (2010 - 2013)<br />
Dirk Grimm, PhD (2010 - 2013)<br />
Ryszard Kole, PhD (2011 - 2014)<br />
Matthew Levy, PhD (2011 - 2014)<br />
Paul B. McCray, Jr., MD (2008 - 2014)<br />
Kevin V. Morris, PhD (2010 - 2013)<br />
Bruce Sullenger, PhD (2011 - 2012)<br />
Marco Weinberg, PhD (2010 - 2013)<br />
Physical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> and<br />
Vectorology Committee<br />
Chair<br />
Richard Heller, PhD (2011 - 2012)<br />
Shulin Li, PhD (2009 - 2011)<br />
Members<br />
Michele P. Calos, PhD (2007 - 2013)<br />
Michael Fons, PhD (2009 - 2011)<br />
Richard Heller, PhD (2009 - 2012)<br />
Amir S. Khan, PhD (2011 - 2012)<br />
Shulin Li, PhD (2011 - 2012)<br />
R. Scott McIvor, PhD (2009 - 2012)<br />
Carol H. Miao, PhD (2009 - 2012)<br />
Lluis M. Mir, PhD, DSc (2009 - 2012)<br />
Matthew H. Porteus, MD, PhD (2010 - 2012)<br />
Sean M. Sullivan, PhD (2010 - 2013)<br />
<strong>Program</strong> Committee<br />
Co-Chairs<br />
Barrie J. Carter, PhD (2010 - 2011)<br />
Maria G. Castro, PhD (2011 - 2012)<br />
Kenneth Cornetta, MD (2010 - 2011)<br />
Gay Crooks, MD (2011 - 2012)<br />
Ronald G. Crystal, MD (2010 - 2012)<br />
John F. Engelhardt, PhD (2010 - 2011)<br />
R. Jude Samulski, PhD (2011 - 2012)<br />
Members<br />
Valder Arruda, MD, PhD (2010 - 2012)<br />
Margaret Black, PhD (2011 - 2012)<br />
Bruce A. Bunnell, PhD (2009 - 2011)<br />
Barry J. Byrne, MD, PhD (2010 - 2012)<br />
Maria G. Castro, PhD (2009 - 2011)<br />
Roberto Cattaneo, PhD (2009 - 2011)<br />
Seng H. Cheng, PhD (2010 - 2012)<br />
Laurence JN Cooper, MD, PhD (2009 - 2011)<br />
Linda B. Couto, PhD (2010 - 2012)<br />
Larry A. Couture, PhD (2010 - 2012)<br />
Gay Crooks, MD (2009 - 2011)<br />
Terence R. Flotte, MD (2011 - 2012)<br />
Richard Heller, PhD (2011 - 2012)<br />
Helen E. Heslop, MD (2009 - 2011)<br />
Carl H. June, MD (2009 - 2011)<br />
Jane S. Lebkowski, PhD (2011 - 2012)<br />
Shulin Li, PhD (2009 - 2011)<br />
Margaret A. Liu, MD (2011 - 2012)<br />
Pedro Lowenstein, MD, PhD (2011 - 2012)<br />
Fulvio Mavilio, PhD (2009 - 2011)<br />
Jerry R. Mendell, MD (2010 - 2012)<br />
Jeffrey J. Molldrem, MD (2011 - 2012)<br />
Kevin V. Morris, PhD (2011 - 2012)<br />
Luigi M. Naldini, MD, PhD (2010 - 2012)<br />
John Rasko, MBBS, PhD (2009 - 2011)<br />
Theresa M. Reineke, PhD (2010 - 2011)<br />
Michel Sadelain, MD, PhD (2010 - 2012)<br />
Daniel R. Salomon, MD (2010 - 2011)<br />
Sonia I. Skarlatos, PhD (2011 - 2012)<br />
Bruce Sullenger, PhD (2009 - 2011)<br />
Adrian J. Thrasher, MD, PhD (2009 - 2011)<br />
Thierry C. VandenDriessche, PhD (2011 - 2012)<br />
Nelson Wivel, MD (2010 - 2012)<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 9
10<br />
Committee Rosters<br />
Publications Committee<br />
Chair<br />
Donald B. Kohn, MD (2009 - 2011)<br />
Francis C. Szoka, Jr., PhD (2011 - 2012)<br />
Members<br />
Hans-Peter Kiem, MD, FACP (2007 - 2013)<br />
Donald B. Kohn, MD (2011 - 2012)<br />
Arthur W. Nienhuis, MD (2010 - 2013)<br />
Michel Sadelain, MD, PhD (2007 - 2013)<br />
Rachel Salzman, DVM (2008 - 2014)<br />
Francis C. Szoka, Jr., PhD (2008 - 2011)<br />
Respiratory Tract <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Committee<br />
Chair<br />
Bruce A. Bunnell, PhD (2009 - 2011)<br />
Terence R. Flotte, MD (2011 - 2012)<br />
Members<br />
Bruce A. Bunnell, PhD (2011 - 2012)<br />
David A. Dean, PhD (2010 - 2013)<br />
John F. Engelhardt, PhD (2010 - 2013)<br />
Terence R. Flotte, MD (2010 - 2013)<br />
Deborah Gill, PhD (2008 - 2014)<br />
Uta Griesenbach, PhD (2010 - 2013)<br />
Jay K. Kolls, MD (2007 - 2013)<br />
David W. Parsons, PhD (2007 - 2013)<br />
Susan D. Reynolds, PhD (2011 - 2014)<br />
Stem <strong>Cell</strong> Committee<br />
Chair<br />
Gay Crooks, MD (2009 - 2011)<br />
Jane S. Lebkowski, PhD (2011 - 2012)<br />
Members<br />
Karen S. Aboody, MD (2009 - 2012)<br />
Fernando D. Camargo, PhD (2009 - 2012)<br />
Gay Crooks, MD (2011 - 2012)<br />
James Ellis, PhD (2009 - 2012)<br />
Jane S. Lebkowski, PhD (2010 - 2013)<br />
Kazuo Ohashi, MD, PhD (2006 - 2012)<br />
Evan Y. Snyder, MD, PhD, FAAP (2009 - 2012)<br />
Alice F. Tarantal, PhD (2009 - 2012)<br />
Tissue Engineering Committee<br />
Chair<br />
Daniel R. Salomon, MD (2010 - 2011)<br />
Members<br />
Dan Gazit, DMD, PhD (2010 - 2013)<br />
William V. Giannobile, DDS, DMedSc (2010 - 2013)<br />
Bruce L. Levine, PhD (2010 - 2013)<br />
Paul Y. Liu, MD, FACS (2010 - 2013)<br />
Tatiana Segura, PhD (2010 - 2013)<br />
Stephanie Simek, PhD (2010 - 2013)<br />
Translational Science and Product<br />
Development Committee<br />
Chair<br />
Larry A. Couture, PhD (2010 - 2012)<br />
Members<br />
Joy Cavagnaro, PhD, DABT, RAC, FATS (2010 - 2013)<br />
Kenneth Cornetta, MD (2010 - 2013)<br />
Boro Dropulic, PhD (2011 - 2014)<br />
Derek J. Hei, PhD (2010 - 2013)<br />
Douglas J. Jolly, PhD (2010 - 2013)<br />
Ian MacLachlan, PhD (2010 - 2013)<br />
Alain Rolland, PharmD, PhD (2010 - 2013)<br />
Richard O. Snyder, PhD (2010 - 2013)<br />
Viral <strong>Gene</strong> Transfer Vectors Committee<br />
Chair<br />
Luigi M. Naldini, MD, PhD (2010 - 2012)<br />
Members<br />
Mavis Agbandje-McKenna, PhD (2010 - 2013)<br />
Ian E. Alexander, MBBS (2011 - 2014)<br />
John A. Chiorini, PhD (2010 - 2013)<br />
John T. Gray, PhD (2007 - 2013)<br />
Brendan Lee, MD, PhD (2008 - 2011)<br />
Luigi M. Naldini, MD, PhD (2008 - 2011)<br />
Philip Ng, PhD (2009 - 2012)<br />
Samuel D. Rabkin, PhD (2009 - 2012)<br />
Stephen J. Russell, MD, PhD (2010 - 2013)<br />
Dmitry M. Shayakhmetov, PhD (2009 - 2012)<br />
Jackie Sheng, PhD (2011 - 2014)<br />
David Strayer, MD, PhD (2009 - 2012)<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Planning Committee<br />
Each year this committee, which is made up <strong>of</strong> the ASGCT President, President-Elect, Secretary, <strong>Program</strong> Committee Co-Chairs<br />
and two invited members, reviews abstracts that are suggested by the various categories for the Presidential Symposium and the<br />
Clinical Oral Abstract Session.<br />
Barrie J. Carter, PhD<br />
Carter BioConsulting<br />
Seattle, WA<br />
Ronald G. Crystal, MD<br />
Weill Medical College <strong>of</strong><br />
Cornell University<br />
New York, NY<br />
Abstract Reviewers<br />
Committee Chair<br />
John J. Rossi, PhD<br />
RNA Virus Vectors<br />
Coordinating Reviewer<br />
Grant D. Trobridge, PhD<br />
Reviewers<br />
Brian D. Brown, PhD<br />
Boris Fehse, PhD<br />
Karen E. Pollok, PhD<br />
Jiing-Kuan Yee, PhD<br />
AAV Vectors<br />
Coordinating Reviewer<br />
Saswati Chatterjee, PhD<br />
Reviewers<br />
Douglas M. McCarty, PhD<br />
Selvarangan Ponnazhagan, PhD<br />
Kirsten AK Weigel-Van Aken, MD<br />
Weidong Xiao, PhD<br />
Adenovirus and Other DNA<br />
Virus Vectors<br />
Coordinating Reviewer<br />
Joseph C. Glorioso, III, PhD<br />
Reviewers<br />
Terence R. Flotte, MD<br />
Steven C. Ghivizzani, PhD<br />
Matthew D. Weitzman, PhD<br />
James M. Wilson, MD, PhD<br />
John F. Engelhardt, PhD<br />
University <strong>of</strong> Iowa College <strong>of</strong> Medicine<br />
Iowa City, IA<br />
Donald B. Kohn, MD<br />
University <strong>of</strong> California, Los Angeles<br />
Los Angeles, CA<br />
John J. Rossi, PhD<br />
Beckman Research Institute City <strong>of</strong> Hope<br />
Duarte, CA<br />
DNA Vectorology<br />
& <strong>Gene</strong> Targeting<br />
Coordinating Reviewer<br />
Perry B. Hackett, PhD<br />
Reviewers<br />
Carlos F. Barbas, III, PhD<br />
Paula M. Cannon, PhD<br />
Zoltan Ivics, PhD<br />
Matthew H. Wilson, MD, PhD<br />
Physical Methods<br />
<strong>of</strong> Delivery<br />
Coordinating Reviewer<br />
Daniel G. Anderson, PhD<br />
Reviewers<br />
Guangping Gao, PhD<br />
Jordan J. Green, PhD<br />
Matthew H. Porteus, MD, PhD<br />
Mark Tracy, PhD<br />
Chemical and<br />
Molecular Conjugates<br />
Coordinating Reviewer<br />
Sean M. Sullivan, PhD<br />
Reviewers<br />
Arash Hatefi, PhD, PharmD<br />
Young Jik Kwon, PhD<br />
Suzie H. Pun, PhD<br />
Kevin G. Rice, PhD<br />
R. Jude Samulski, PhD<br />
University <strong>of</strong> North Carolina at Chapel Hill<br />
Chapel Hill, NC<br />
Sean M. Sullivan, PhD<br />
Vical, Inc.<br />
San Diego, CA<br />
<strong>Gene</strong>tic and Metabolic<br />
Diseases <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Coordinating Reviewer<br />
Valder Arruda, MD, PhD<br />
Reviewers<br />
Christopher Doering, MD<br />
Daniel G. Miller, MD, PhD<br />
Nuria Morral, PhD<br />
Katherine P. Ponder, MD<br />
Cardiovascular<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Coordinating Reviewer<br />
K. K. Wong, MD<br />
Reviewers<br />
Barry J. Byrne, MD, PhD<br />
Dongsheng Duan, PhD<br />
Roger J. Hajjar, MD<br />
Prediman K. Shah, MD<br />
Neurologic & Ophthalmic<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Coordinating Reviewer<br />
Alessandra Biffi, MD<br />
Reviewers<br />
Robin R. Ali, PhD<br />
Alberto Auricchio, MD<br />
Kryst<strong>of</strong> Bankiewicz, MD, PhD<br />
Nathalie Cartier-Lacave, MD<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 11
12<br />
Abstract Reviewers<br />
Musculo-skeletal<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Coordinating Reviewer<br />
Jacques P. Tremblay, PhD<br />
Reviewers<br />
Jeffrey Chamberlain, PhD<br />
Paula Clemens, MD<br />
Johnny Huard, PhD<br />
Xiao Xiao, PhD<br />
Infectious Diseases<br />
and Vaccines<br />
Coordinating Reviewer<br />
Bruce L. Levine, PhD<br />
Reviewers<br />
Don J. Diamond, PhD<br />
Stephen M. Kaminsky, PhD<br />
Patric J. S. Lundberg, PhD<br />
J. Fraser Wright, PhD<br />
Cancer - Immunotherapy<br />
Coordinating Reviewer<br />
Michael Jensen, MD<br />
Reviewers<br />
Laurence J.N. Cooper, MD, PhD<br />
Lawrence S. Lamb, Jr., PhD<br />
Daniel Powell, PhD<br />
Barbara Savoldo, MD, PhD<br />
Cancer – Oncolytic Viruses<br />
Coordinating Reviewer<br />
Patrick B. Arbuthnot, MD, PhD<br />
Reviewers<br />
E. Antonio Chiocca, MD, PhD<br />
Evanthia Galanis, MD, DSc<br />
David H. Kirn, MD<br />
Takafumi Nakamura, PhD<br />
Cancer - Targeted<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Coordinating Reviewer<br />
Stephen J. Forman, MD<br />
Reviewers<br />
Joseph S. Anderson, PhD<br />
Catherine M. Bollard, MBChB, FRACP, FRCPA<br />
David L. Porter, MD<br />
Michel Sadelain, MD, PhD<br />
Hematologic and Immunologic<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Coordinating Reviewer<br />
Donald B. Kohn, MD<br />
Reviewers<br />
Fabio Candotti, MD<br />
Salima Hacein-Bey Abina, PhD<br />
Eirini P. Papapetrou, MD, PhD<br />
Derek A. Persons, MD, PhD<br />
Lung and Respiratory<br />
Disease <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Coordinating Reviewer<br />
Bruce A. Bunnell, PhD<br />
Reviewers<br />
David A. Dean, PhD<br />
Uta Griesenbach, PhD<br />
Larry G. Johnson, MD<br />
Deborah E. Sullivan, PhD<br />
Immunologic<br />
& Host Responses in<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Coordinating Reviewer<br />
Si-Yi Chen, MD, PhD<br />
Reviewers<br />
Michael A. Barry, PhD<br />
Nicholas Restifo, MD<br />
Xiao-Tong Song, PhD<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
<strong>Gene</strong> Regulation<br />
Coordinating Reviewer<br />
Philip D. Gregory, PhD<br />
Reviewers<br />
Donna Armentano, PhD<br />
Michele P. Calos, PhD<br />
John Forsayeth, PhD<br />
Bruce E. Torbett, PhD, MSPH<br />
Oligonucleotide<br />
& RNAi Therapeutics<br />
Coordinating Reviewer<br />
Mark A. Kay, MD, PhD<br />
Reviewers<br />
C. Frank Bennett, PhD<br />
Joel R. Chamberlain, PhD<br />
Dirk Grimm, PhD<br />
Kevin V. Morris, PhD<br />
Stem <strong>Cell</strong> Therapies<br />
Coordinating Reviewer<br />
John A. Zaia, MD<br />
Reviewers<br />
Walter J. Koch, PhD<br />
Ann M. Leen, PhD<br />
Punam Malik, MD<br />
Dorothee von Laer, MD<br />
<strong>Cell</strong> Processing and Vector<br />
Production<br />
Coordinating Reviewer<br />
Larry A. Couture, PhD<br />
Reviewers<br />
Lorraine A. Matheson, MS<br />
Isabelle Rivière, PhD<br />
William P. Swaney, MS<br />
Johannes C.M. van der Loo, PhD<br />
Special thanks to the abstract reviewers for their time and expertise.
Excellence in Research Award<br />
& Travel Grant Recipients<br />
Excellence in Research Awards – For Students and Postdoctoral Fellows<br />
Christie Bell<br />
University <strong>of</strong> Pennsylvania<br />
Adeno-Associated Virus Serotype 9 Uses Galactose as a <strong>Cell</strong>ular<br />
Receptor To Transduce Conducting Airway<br />
Miguel Mano<br />
ICGEB - International Centre for <strong>Gene</strong>tic Engineering and<br />
Biotechnology<br />
High-Throughput Genome-Wide siRNA Screening Unravels <strong>Cell</strong>ular<br />
Factors Critical for AAV Transduction<br />
Stefania Merella<br />
San Raffaele Telethon Institute for <strong>Gene</strong> <strong>Therapy</strong><br />
Assessing the Impact <strong>of</strong> Lentiviral Vector Integration on Splicing <strong>of</strong><br />
<strong>Cell</strong>ular <strong>Gene</strong>s at the Genome-Wide Level<br />
Travel Awards – For Students and Postdoctoral Fellows<br />
Jennifer E. Adair<br />
Sonny O. Ang<br />
Cynthia C. Bartholomae<br />
Etiena Basner-Tschakarjan<br />
Troy Brady<br />
Michael J. Castle<br />
Marcela P. Cataldi<br />
Daniela Cesana<br />
Diptiman Chanda<br />
Szu-Ting Chou<br />
Darin J. Falk<br />
Anthony S. Fargnoli<br />
Richard Gabriel<br />
Bernhard R. Gentner<br />
Zakaria Grada<br />
Katrin Hacke<br />
Nilesh P. Ingle<br />
Mahesh Jonnalagadda<br />
Sunitha Kakarla<br />
The Excellence in Research Awards and Travel Grants<br />
were made possible through grant support from:<br />
Travel Grants (5)<br />
Lotta M. Kangasniemi<br />
Hirotaka Kawano<br />
Matthias W. Kron<br />
Marven Lamarre<br />
Chin-Yu Lin<br />
Bridget Lins<br />
Leszek Lisowski<br />
Angelo L. Lombardo<br />
Jiamiao Lu<br />
Anna Manfredi<br />
Maria D I Manunta<br />
Citra N. Mattar<br />
Harald G. Messer<br />
Annarita Miccio<br />
Joel Montane<br />
Claudio Mussolino<br />
Shruthi Naik<br />
Md Nasimuzzaman<br />
Anna Paruzynski<br />
Christina Rauschhuber<br />
Max von Pettenk<strong>of</strong>er-Institute<br />
Micro RNA Knockdown Significantly Enhances Adenovirus<br />
Replication and Vector Production<br />
Samantha Scaramuzza<br />
San Raffaele Telethon Institute for <strong>Gene</strong> therapy<br />
<strong>Gene</strong> <strong>Therapy</strong> with Lentiviral Vector Transduced CD34+ <strong>Cell</strong>s for the<br />
Treatment <strong>of</strong> Wiskott-Aldrich Syndrome<br />
Paul N. Valdmanis<br />
Stanford University<br />
Role <strong>of</strong> Ago2 and microRNAs in Mammalian Development<br />
Nicole K. Paulk<br />
Karin Pike-Overzet<br />
Valentina Poletti<br />
Nagesh Pulicherla<br />
Marco Ranzani<br />
Diana Rommelfanger<br />
Shoshannah L. Roth<br />
Ivette M. Sandoval<br />
Erica B. Schleifman<br />
Shen Shen<br />
Laura J. Smith<br />
Masataka Suzuki<br />
Hiroki Torikai<br />
Yu-Shan Tseng<br />
Lindsay M. Wallace<br />
Hongjie Wang<br />
Jiehua Zhou<br />
Qinghui Zhou<br />
Excellence in Research Award (1) Excellence in Research Award (1) Travel Grant (1) Excellence in Research Award (1) Travel Grants (2)<br />
Travel Grants (3) Excellence in Research Award (1)<br />
and Travel Grants (3)<br />
Excellence in Research Awards (2)<br />
Travel Grant (1)<br />
Travel Grants (10)<br />
Travel Grants (4)<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 13
14<br />
Outstanding New Investigator<br />
& Outstanding Achievement Awards Recipients<br />
Outstanding New Investigator Award Winners<br />
The following Outstanding New Investigator Award winners were selected by the Advisory Council based on merit and their<br />
contributions to the field <strong>of</strong> gene and cell therapy. The recipients will present their work at the special Outstanding New<br />
Investigator Symposium on Saturday, May 21st at 8:00 am.<br />
Hiroyuki Nakai, MD, PhD<br />
University <strong>of</strong> Pittsburgh<br />
School <strong>of</strong> Medicine<br />
Pittsburgh, Pennsylvania<br />
In Vivo Viral Genome and Capsid Biology<br />
<strong>of</strong> Recombinant AAV Vectors<br />
The Outstanding New Investigator Awards were made possible through grant support from:<br />
Outstanding Achievement Award Winner<br />
The Outstanding Achievement Award winner was selected by the ASGCT Advisory Council as an example <strong>of</strong> an ASGCT member<br />
who has achieved a pioneering research success through a lifetime <strong>of</strong> significant scientific contributions to the field <strong>of</strong> gene and<br />
cell therapy. The Outstanding Achievement Award winner will present the talk <strong>Cell</strong> and <strong>Gene</strong> <strong>Therapy</strong> - Putting it Together during a<br />
special Outstanding Achievement Award plenary lecture on Friday, May 20th at 3:45 pm.<br />
Malcolm K. Brenner, MD, PhD<br />
Baylor College <strong>of</strong> Medicine<br />
Houston, Texas<br />
Miguel Sena-Esteves, PhD<br />
University <strong>of</strong> Massachusetts<br />
Medical School<br />
Worcester, Massachusetts<br />
AAV-Mediated <strong>Gene</strong> <strong>Therapy</strong> for Neuro-<br />
Metabolic Diseases and Brain Tumors<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Qizhen Shi, MD, PhD<br />
Medical College <strong>of</strong> Wisconsin<br />
Milwaukee, Wisconsin<br />
Targeting Factor VIII (FVIII) Expression<br />
to Platelets for <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong><br />
Hemophilia A with Inhibitors
Faculty Listing<br />
Annemieke Aartsma-Rus,<br />
PhD<br />
Leiden University Medical<br />
Center<br />
Leiden, Netherlands<br />
Karen S. Aboody, MD<br />
City <strong>of</strong> Hope National Medical<br />
Center<br />
Duarte, CA<br />
Roger C. Adami, PhD<br />
Marina Biotech<br />
Bothell, WA<br />
Laura K. Aguilar, MD, PhD<br />
Advantagene, Inc.<br />
Waban, MA<br />
Estuardo Aguilar-Cordova,<br />
PhD<br />
Advantagene, Inc.<br />
Waban, MA<br />
Robin R. Ali, PhD<br />
University College London<br />
London, United Kingdom<br />
Andrea Amalfitano, DO, PhD<br />
Michigan State University<br />
East Lansing, MI<br />
Brian H. Annex, MD<br />
University <strong>of</strong> Virginia School <strong>of</strong><br />
Medicine<br />
Charlottesville, VA<br />
Donna Armentano, PhD<br />
Genzyme Corporation<br />
Framingham, MA<br />
Valder Arruda, MD, PhD<br />
University <strong>of</strong> Pennsylvania<br />
School <strong>of</strong> Medicine<br />
Philadelphia, PA<br />
Alberto Auricchio, MD<br />
Telethon Institute <strong>of</strong> <strong>Gene</strong>tics<br />
& Medicine<br />
Rome, Italy<br />
Kryst<strong>of</strong> Bankiewicz, MD,<br />
PhD<br />
University <strong>of</strong> California San<br />
Francisco<br />
San Francisco, CA<br />
Glen Barber, PhD<br />
University <strong>of</strong> Miami School <strong>of</strong><br />
Medicine<br />
Miami, FL<br />
Richard C. Becker, MD<br />
Duke Heart Center<br />
Durham, NC<br />
C. Frank Bennett, PhD<br />
Isis Pharmaceuticals, Inc.<br />
Carlsbad, CA<br />
Alessandra Biffi, MD<br />
San Raffaele Telethon Institute<br />
for <strong>Gene</strong> <strong>Therapy</strong> (HSR-TIGET)<br />
Milano, Italy<br />
Adam Bogdanove, PhD<br />
Iowa State University<br />
Ames, IA<br />
Fatima Bosch, PhD<br />
Universitat Autonoma de<br />
Barcelona<br />
Bellaterra, Spain<br />
Marnix Bosch, PhD, MBA<br />
Northwest Biotherapeutics<br />
Bethesda, MD<br />
Nicholas Boulis, MD<br />
Emory University School <strong>of</strong><br />
Medicine<br />
Atlanta, GA<br />
Malcolm K. Brenner, MD,<br />
PhD<br />
Baylor College <strong>of</strong> Medicine<br />
Houston, TX<br />
Renier J. Brentjens, MD, PhD<br />
Memorial Sloan Kettering<br />
Cancer Center<br />
New York, NY<br />
Brian D. Brown, PhD<br />
Mt. Sinai School <strong>of</strong> Medicine<br />
New York, NY<br />
Christine Brown, PhD<br />
City <strong>of</strong> Hope National Medical<br />
Center<br />
Duarte, CA<br />
Wilson W. Bryan, MD<br />
Food and Drug Administration<br />
Rockville, MD<br />
Barry J. Byrne, MD, PhD<br />
University <strong>of</strong> Florida College <strong>of</strong><br />
Medicine<br />
Gainesville, FL<br />
Michele P. Calos, PhD<br />
Stanford University School <strong>of</strong><br />
Medicine<br />
Stanford, CA<br />
Fabio Candotti, MD<br />
NIH/NHGRI<br />
Bethesda, MD<br />
Paula M. Cannon, PhD<br />
University <strong>of</strong> Southern<br />
California<br />
Los Angeles, CA<br />
Barrie J. Carter, PhD<br />
Carter BioConsulting<br />
Seattle, WA<br />
Nathalie Cartier-Lacave, MD<br />
INSERM<br />
Paris, France<br />
Maria G. Castro, PhD<br />
Cedars-Sinai Medical Center,<br />
UCLA<br />
Los Angeles, CA<br />
Toni Cathomen, PhD<br />
Hannover Medical School<br />
Hannover, Germany<br />
Roberto Cattaneo, PhD<br />
Mayo Clinic<br />
Rochester, MN<br />
Marina Cavazzana-Calvo,<br />
MD, PhD<br />
Hopital Necker<br />
Enfants-Malades<br />
Paris, France<br />
Joel R. Chamberlain, PhD<br />
University <strong>of</strong> Washington<br />
School <strong>of</strong> Medicine<br />
Seattle, WA<br />
Seng H. Cheng, PhD<br />
Genzyme Corporation<br />
Framingham, MA<br />
Kim N. Chi, MD<br />
BC Cancer Agency Research<br />
Vancouver, Canada<br />
Karen L. Christman, PhD<br />
University <strong>of</strong> California,<br />
San Diego<br />
La Jolla, CA<br />
Laurence JN Cooper, MD,<br />
PhD<br />
University <strong>of</strong> Texas M.D.<br />
Anderson Cancer Center<br />
Houston, TX<br />
Lawrence Corey, MD<br />
Fred Hutchinson Cancer<br />
Research Center<br />
Seattle, WA<br />
Larry A. Couture, PhD<br />
Beckman Research Institute <strong>of</strong><br />
City <strong>of</strong> Hope<br />
Duarte, CA<br />
Ronald G. Crystal, MD<br />
Weill Medical College <strong>of</strong><br />
Cornell University<br />
New York, NY<br />
George Q. Daley, MD, PhD<br />
Children’s Hospital Boston<br />
Boston, MA<br />
Kevin D’Amour, PhD<br />
ViaCyte, Inc.<br />
San Diego, CA<br />
Andrew M. David<strong>of</strong>f, MD<br />
St. Jude Children’s Research<br />
Hospital<br />
Memphis, TN<br />
Beverly L. Davidson, PhD<br />
University <strong>of</strong> Iowa Carver<br />
College <strong>of</strong> Medicine<br />
Iowa City, IA<br />
David A. Dean, PhD<br />
University <strong>of</strong> Rochester<br />
Rochester, NY<br />
David L. DiGiusto, PhD<br />
City <strong>of</strong> Hope<br />
Duarte, CA<br />
Christopher Doering, PhD<br />
Emory University<br />
Atlanta, GA<br />
Dongsheng Duan, PhD<br />
University <strong>of</strong> Missouri School<br />
<strong>of</strong> Medicine<br />
Columbia, MO<br />
Victor J. Dzau, MD<br />
Duke University<br />
Durham, NC<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 15
16<br />
Faculty List<br />
James Ellis, PhD<br />
Hospital for Sick Children<br />
Toronto, Canada<br />
Michael Emerman, PhD<br />
Fred Hutchinson Cancer<br />
Research Center<br />
Seattle, WA<br />
David W. Emery, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
John F. Engelhardt, PhD<br />
University <strong>of</strong> Iowa Carver<br />
College <strong>of</strong> Medicine<br />
Iowa City, IA<br />
Eva L. Feldman, MD, PhD<br />
University <strong>of</strong> Michigan<br />
Ann Arbor, MI<br />
Mitchell H. Finer, PhD<br />
bluebird bio<br />
Cambridge, MA<br />
Kevin M. Flanigan, MD<br />
Nationwide Children’s<br />
Research Institute<br />
Columbus, OH<br />
Terence R. Flotte, MD<br />
University <strong>of</strong> Massachusetts<br />
Medical School<br />
Worcester, MA<br />
Toshiyoshi Fujiwara, MD,<br />
PhD<br />
Okayama University Graduate<br />
School<br />
Okayama, Japan<br />
Karin M.L. Gaensler, MD<br />
University <strong>of</strong> California San<br />
Francisco<br />
San Francisco, CA<br />
Evanthia Galanis, MD, DSc<br />
Mayo Clinic<br />
Rochester, MN<br />
Doina Ganea, PhD<br />
Temple University School <strong>of</strong><br />
Medicine<br />
Philadelphia, PA<br />
Guangping Gao, PhD<br />
University <strong>of</strong> Massachusetts<br />
Medical School<br />
Worcester, MA<br />
Richard S. Geary, PhD<br />
Isis Pharmaceuticals, Inc.<br />
Carlsbad, CA<br />
Julie Gehl, MD, PhD<br />
Copenhagen University<br />
Hospital Herlev<br />
Herlev, Denmark<br />
Steven Craig Ghivizzani,<br />
PhD<br />
University <strong>of</strong> Florida<br />
Gainesville, FL<br />
Joseph C. Glorioso, III, PhD<br />
University <strong>of</strong> Pittsburgh<br />
Pittsburgh, PA<br />
William F. Goins, PhD<br />
University <strong>of</strong> Pittsburgh School<br />
<strong>of</strong> Medicine<br />
Pittsburgh, PA<br />
Stephen Gottschalk, MD<br />
Baylor College <strong>of</strong> Medicine<br />
Houston, TX<br />
John T. Gray, PhD<br />
St. Jude Childrens Research<br />
Hospital<br />
Memphis, TN<br />
Paul A. Grayburn, MD, FACC<br />
Cardiology Consultants <strong>of</strong><br />
Texas<br />
Dallas, TX<br />
Henry T. Greely, JD<br />
Stanford University Law School<br />
Palo Alto, CA<br />
Philip Greenberg, MD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Uta Griesenbach, PhD<br />
Imperial College Faculty <strong>of</strong><br />
Medicine<br />
London, United Kingdom<br />
Dirk Grimm, PhD<br />
University <strong>of</strong> Heidelberg<br />
Heidelberg, Germany<br />
Robert E. Guldberg, PhD<br />
Georgia Tech<br />
Atlanta, GA<br />
Ge<strong>of</strong>frey Gurtner, MD<br />
Stanford Hospital & Clinics<br />
Stanford, CA<br />
Hideyoshi Harashima, PhD<br />
Hokkaido University<br />
Sapporo, Japan<br />
Mirjam H.M. Heemskerk,<br />
PhD<br />
Leiden University Medical<br />
Center<br />
Leiden, Netherlands<br />
Akseli Hemminki, MD, PhD<br />
University <strong>of</strong> Helsinki<br />
Helsinki, Finland<br />
Serge Herson, MD<br />
Hopital Pitie-Salpetriere<br />
Paris, France<br />
Roland W. Herzog, PhD<br />
University <strong>of</strong> Florida<br />
Gainesville, FL<br />
Michael C. Holmes, PhD<br />
Sangamo BioSciences, Inc<br />
Richmond, CA<br />
Wenlin Huang, PhD<br />
Sun Yat-Sen University Cancer<br />
Center<br />
Guangzhou, Peoples Republic<br />
<strong>of</strong> China<br />
Johnny Huard, PhD<br />
University <strong>of</strong> Pittsburgh<br />
Pittsburgh, PA<br />
Michael Jensen, MD<br />
Seattle Children’s Research<br />
Institute<br />
Seattle, WA<br />
Larry G. Johnson, MD<br />
University <strong>of</strong> Arkansas for<br />
Medical Sciences<br />
Little Rock, AR<br />
Philip R. Johnson, MD<br />
The Children’s Hospital <strong>of</strong><br />
Philadelphia<br />
Philadelphia, PA<br />
Douglas J. Jolly, PhD<br />
Tocagen, Inc.<br />
San Diego, CA<br />
Eric Juengst, PhD<br />
University <strong>of</strong> North Carolina at<br />
Chapel Hill<br />
Chapel Hill, NC<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Carl H. June, MD<br />
University <strong>of</strong> Pennsylvania<br />
Philadelphia, PA<br />
William F. Kaemmerer, PhD<br />
Medtronic, Inc.<br />
Minneapolis, MN<br />
Tal Kafri, MD, PhD<br />
University <strong>of</strong> North Carolina at<br />
Chapel Hill<br />
Chapel Hill, NC<br />
Alexander Kalinkovich, PhD<br />
Weizmann Institute <strong>of</strong> Science<br />
Rehovot, Israel<br />
Stephen M. Kaminsky, PhD<br />
Weill Cornell Medical College<br />
New York, NY<br />
Elizabeth Kang, MD<br />
NIH/NIAID<br />
Bethesda, MD<br />
Michael Kaplitt, MD, PhD<br />
Weill Medical College <strong>of</strong><br />
Cornell University<br />
New York, NY<br />
Howard L. Kaufman, MD<br />
Rush University Cancer Center<br />
at Rush University Medical<br />
Center<br />
Chicago, IL<br />
Mark A. Kay, MD, PhD<br />
Stanford University School <strong>of</strong><br />
Medicine<br />
Stanford, CA<br />
Hans-Peter Kiem, MD<br />
Fred Hutchinson Cancer<br />
Research Center<br />
Seattle, WA<br />
Nancy M.P. King, JD<br />
Wake Forest University School<br />
<strong>of</strong> Medicine<br />
Winston-Salem, NC<br />
David H. Kirn, MD<br />
JENNEREX Biotherapeutics,<br />
Incorporated<br />
San Francisco, CA<br />
Dwight Koeberl, MD, PhD<br />
Duke University Medical<br />
Center<br />
Durham, NC
Faculty List<br />
Ryszard Kole, PhD<br />
AVI BioPharma<br />
Bothell, WA<br />
Young Jik Kwon, PhD<br />
UC Irvine<br />
Irvine, CA<br />
Lawrence S. Lamb, Jr., PhD<br />
University <strong>of</strong> Alabama at<br />
Birmingham<br />
Birmingham, AL<br />
Jane S. Lebkowski, PhD<br />
Geron Corp<br />
Menlo Park, CA<br />
Ann Leen, PhD<br />
Baylor College <strong>of</strong> Medicine<br />
- CAGT<br />
Houston, TX<br />
Arthur Levin, PhD<br />
Santaris Pharma A/s<br />
San Diego, CA<br />
Shulin Li, PhD<br />
MD Anderson Cancer Center<br />
Houston, TX<br />
Brian Lichty, PhD<br />
McMaster University<br />
Hamilton, Canada<br />
Andre Lieber, MD, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Jay R. Lieberman, MD<br />
University <strong>of</strong> Connecticut<br />
Health Center<br />
Farmington, CT<br />
Dexi Liu, PhD<br />
University <strong>of</strong> Pittsburgh<br />
Pittsburgh, PA<br />
Paul Y. Liu, MD, FACS<br />
Roger Williams Medical Center<br />
Providence, RI<br />
Christian L. Lorson, PhD<br />
University <strong>of</strong> Missouri<br />
Columbia, MO<br />
Pedro Lowenstein, MD, PhD<br />
Cedars Sinai Medical Center,<br />
UCLA<br />
Los Angeles, CA<br />
Paolo Macchiarini, MD, PhD<br />
Karolinska Institutet<br />
Stockholm, Sweden<br />
Harry L. Malech, MD<br />
NIH/NIAID Laboratory <strong>of</strong> Host<br />
Defenses<br />
Bethesda, MD<br />
Punam Malik, MD<br />
Cincinnati Children’s Hospital<br />
Cincinnati, OH<br />
Lorraine Matheson<br />
Indiana University<br />
Indianapolis, IN<br />
Sebastien Maury, MD, PhD<br />
Assistance Publique -<br />
Hopitaux De Paris<br />
Paris, France<br />
Anton P. McCaffrey, PhD<br />
Trilink Biotechnologies<br />
San Diego, CA<br />
Douglas M. McCarty, PhD<br />
The Research Institute at<br />
Nationwide Children’s Hospital<br />
Columbus, OH<br />
Grant McFadden, PhD<br />
University <strong>of</strong> Florida<br />
Gainesville, FL<br />
Jerry R. Mendell, MD<br />
The Research Institute at<br />
Nationwide Children’s Hospital<br />
Columbus, OH<br />
Carol H. Miao, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Daniel G. Miller, MD, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Thomas Miller, PhD<br />
National Institutes <strong>of</strong> Health<br />
Bethesda, MD<br />
Jeffrey J. Molldrem, MD<br />
M.D. Anderson Cancer Center<br />
Houston, TX<br />
Richard A. Morgan, PhD<br />
National Cancer Institute<br />
Columbia, MD<br />
Nuria Morral, PhD<br />
Indiana University School <strong>of</strong><br />
Medicine<br />
Indianapolis, IN<br />
Lindsey A. Muir<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Charles E. Murry, MD, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Hiroyuki Nakai, MD, PhD<br />
University <strong>of</strong> Pittsburgh School<br />
<strong>of</strong> Medicine<br />
Pittsburgh, PA<br />
Luigi M. Naldini, MD, PhD<br />
University Vita-Salute San<br />
Raffaele<br />
Milano, Italy<br />
John J. Nemunaitis, MD<br />
Mary Crowley Cancer Research<br />
Centers<br />
Dallas, TX<br />
Philip Ng, PhD<br />
Baylor College <strong>of</strong> Medicine<br />
Houston, TX<br />
John M. Pagel, MD, PhD<br />
Fred Hutchinson Cancer<br />
Research Center<br />
Seattle, WA<br />
Eirini P. Papapetrou, MD,<br />
PhD<br />
Memorial Sloan-Kettering<br />
Cancer Center<br />
New York, NY<br />
Duanqing Pei, PhD<br />
Guangzhou Institute <strong>of</strong><br />
Biomedicine and Health, CAS<br />
Guangzhou, Peoples Republic<br />
<strong>of</strong> China<br />
Louis M. Pelus, PhD<br />
Indiana University<br />
Indianapolis, IN<br />
Marc Penn, MD, PhD<br />
Cleveland Clinic Foundation<br />
Cleveland, OH<br />
Derek A. Persons, MD, PhD<br />
St. Jude Children’s Research<br />
Hospital<br />
Memphis, TN<br />
Thomas Petersen, PhD<br />
Kirkland, WA<br />
Steven Piantadosi, MD, PhD<br />
Cedars-Sinai Medical Center<br />
Los Angeles, CA<br />
Michel Pohl, PhD<br />
INSERM<br />
Paris, France<br />
Katherine P. Ponder, MD<br />
Washington University School<br />
<strong>of</strong> Medicine<br />
St. Louis, MO<br />
Selvarangan Ponnazhagan,<br />
PhD<br />
University <strong>of</strong> Alabama at<br />
Birmingham<br />
Birmingham, AL<br />
Matthew H. Porteus, MD,<br />
PhD<br />
Stanford University School <strong>of</strong><br />
Medicine<br />
Stanford, CA<br />
Daniel J. Powell, Jr., PhD<br />
University <strong>of</strong> Pennsylvania<br />
Philadelphia, PA<br />
Suzie H. Pun, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
David J. Rawlings, MD<br />
University <strong>of</strong> Washington;<br />
Dept <strong>of</strong> Pediatrics<br />
Seattle, WA<br />
Thomas A. Reh, PhD<br />
University <strong>of</strong> Washington<br />
School <strong>of</strong> Medicine<br />
Seattle, WA<br />
Susan D. Reynolds, PhD<br />
National Jewish Health<br />
Denver, CO<br />
Stanley Riddell, MD<br />
Fred Hutchinson Cancer<br />
Research Center<br />
Seattle, WA<br />
Isabelle Rivière, PhD<br />
Memorial Sloan-Kettering<br />
Cancer Center<br />
New York, NY<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 17
18<br />
Faculty List<br />
Paul D. Robbins, PhD<br />
University <strong>of</strong> Pittsburgh<br />
Pittsburgh, PA<br />
Richard Roden, PhD<br />
The Sidney Kimmel<br />
Comprehensive Cancer<br />
Center at Johns Hopkins<br />
Baltimore, MD<br />
Alain Rolland, PharmD, PhD<br />
Vical<br />
San Diego, CA<br />
Botond Roska, PhD<br />
Friedrich Miescher Institute<br />
Basel, Switzerland<br />
John J. Rossi, PhD<br />
Beckman Research Institute<br />
City <strong>of</strong> Hope<br />
Duarte, CA<br />
Gabor M. Rubanyi, MD, PhD<br />
Cardium Therapeutics, Inc.<br />
San Diego, CA<br />
David W. Russell, MD, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Stephen J. Russell, MD, PhD<br />
Mayo Clinic<br />
Rochester, MN<br />
Michel Sadelain, MD, PhD<br />
Memorial Sloan-Kettering<br />
Cancer Center<br />
New York, NY<br />
Daniel R. Salomon, MD<br />
The Scripps Research Institute<br />
La Jolla, CA<br />
R. Jude Samulski, PhD<br />
University <strong>of</strong> North Carolina at<br />
Chapel Hill<br />
Chapel Hill, NC<br />
Brenda M. Sandmaier, MD<br />
Fred Hutchinson Cancer<br />
Research Center<br />
Seattle, WA<br />
Tatiana Segura, PhD<br />
University <strong>of</strong> California, Los<br />
Angeles<br />
Los Angeles, CA<br />
Miguel Sena-Esteves, PhD<br />
University <strong>of</strong> Massachusetts<br />
Medical School<br />
Worcester, MA<br />
Lonnie D. Shea, PhD<br />
Northwestern University<br />
Evanston, IL<br />
Qizhen Shi, MD, PhD<br />
Medical College <strong>of</strong> Wisconsin<br />
Milwaukee, WI<br />
Arun Srivastava, PhD<br />
University <strong>of</strong> Florida College <strong>of</strong><br />
Medicine<br />
Gainesville, FL<br />
Patrick S. Stayton, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Duncan J. Stewart, MD,<br />
FRCPC<br />
Ottawa Hospital Research<br />
Institute<br />
Ottawa, Canada<br />
Rainer F. Storb, MD<br />
Fred Hutchinson Cancer<br />
Research Center<br />
Seattle, WA<br />
Sean M. Sullivan, PhD<br />
Vical, Inc.<br />
San Diego, CA<br />
Daniel M. Takefman, PhD<br />
Food and Drug Administration<br />
Rockville, MD<br />
James D. Thompson, PhD<br />
Quark Pharmaceuticals Inc.<br />
Boulder, CO<br />
Adrian J. Thrasher, MD, PhD<br />
Institute <strong>of</strong> Child Health<br />
London, United Kingdom<br />
John F. Tisdale, MD<br />
NIH<br />
Bethesda, MD<br />
Bruce E. Torbett, PhD, MSPH<br />
The Scripps Research Institute<br />
La Jolla, CA<br />
Greg Towers, PhD<br />
University College London<br />
London, United Kingdom<br />
Jacques P. Tremblay, PhD<br />
Université Laval and CRCHUQ<br />
Sainte-Foy, Canada<br />
Grant D. Trobridge, PhD<br />
Washington State University<br />
Pullman, WA<br />
Luk H. Vandenberghe, PhD<br />
University <strong>of</strong> Pennsylvania<br />
Philadelphia, PA<br />
Thierry C. VandenDriessche,<br />
PhD<br />
University <strong>of</strong> Brussels<br />
Leuven, Belgium<br />
Gabriele Varani, PhD<br />
University <strong>of</strong> Washington<br />
Seattle, WA<br />
Richard G. Vile, PhD<br />
Mayo Clinic<br />
Rochester, MN<br />
Christ<strong>of</strong> von Kalle, MD, PhD<br />
NCT Heidelberg<br />
Heidelberg, Germany<br />
Samuel C. Wadsworth, PhD<br />
Genzyme Corporation<br />
Framingham, MA<br />
Christopher M. Walker, PhD<br />
The Research Institute<br />
Columbus, OH<br />
Kirsten AK Weigel-Van<br />
Aken, MD<br />
University <strong>of</strong> Florida - Cancer<br />
& <strong>Gene</strong>tics Research Complex<br />
Gainesville, FL<br />
Matthew D. Weitzman, PhD<br />
The Salk Institute<br />
San Diego, CA<br />
Dominic J. Wells, PhD<br />
Royal Veterinary College<br />
London, United Kingdom<br />
David A. Williams, MD<br />
Children’s Hospital Boston<br />
Boston, MA<br />
Andrew A. Wilson, MD<br />
Boston University School <strong>of</strong><br />
Medicine<br />
Boston, MA<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
James M. Wilson, MD, PhD<br />
University <strong>of</strong> Pennsylvania<br />
School <strong>of</strong> Medicine<br />
Philadelphia, PA<br />
Matthew H. Wilson, MD, PhD<br />
Baylor College <strong>of</strong> Medicine<br />
Houston, TX<br />
Steven P. Wilson, PhD<br />
University <strong>of</strong> South Carolina<br />
School <strong>of</strong> Medicine<br />
Columbia, SC<br />
Nelson Wivel, MD<br />
University <strong>of</strong> Pennsylvania<br />
Philadelphia, PA<br />
Darren Wolfe, PhD<br />
Diamyd Inc.<br />
Pittsburgh, PA<br />
J. Fraser Wright, PhD<br />
Children’s Hospital <strong>of</strong><br />
Philadelphia - Pathology and<br />
Laboratory Medicine<br />
Philadelphia, PA<br />
Weidong Xiao, PhD<br />
Temple University<br />
Philadelphia, PA<br />
Xiao Xiao, PhD<br />
University <strong>of</strong> North Carolina at<br />
Chapel Hill<br />
Chapel Hill, NC<br />
Masato Yamamoto, MD, PhD<br />
University <strong>of</strong> Minnesota<br />
Minneapolis, MN<br />
Masayuki Yamato, PhD<br />
Tokyo Women’s Medical<br />
University<br />
Shinjuku-ku, Japan<br />
Seppo Ylä-Herttuala, MD,<br />
PhD, FESC<br />
University <strong>of</strong> Kuopio<br />
Kuopio, Finland<br />
Joseph Zabner, MD<br />
University <strong>of</strong> Iowa<br />
Iowa City, IA<br />
John A. Zaia, MD<br />
Beckman Research Institute <strong>of</strong><br />
City <strong>of</strong> Hope<br />
Duarte, CA
<strong>Gene</strong>ral Meeting Information<br />
<strong>American</strong> <strong>Society</strong> Of <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Mission and Vision<br />
The <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>’s (ASGCT) mission<br />
is to advance knowledge, awareness, and education leading<br />
to the discovery and clinical application <strong>of</strong> genetic and cellular<br />
therapies to alleviate human disease.<br />
ASGCT’s vision is to be a catalyst for bringing together scientists,<br />
physicians, patient advocates, and other stakeholders to<br />
transform the practice <strong>of</strong> medicine by incorporating the use <strong>of</strong><br />
genetic and cellular therapies to control and cure human disease.<br />
Abstract Volume - Molecular <strong>Therapy</strong><br />
All abstracts, except Late Abstract Submissions, accepted for<br />
presentation at the ASGCT 14 th Annual Meeting have been<br />
published in the May supplement <strong>of</strong> Molecular <strong>Therapy</strong>. Each<br />
attendee will receive one copy <strong>of</strong> the supplement along<br />
with their registration materials. Late Abstract Submissions<br />
accepted for presentation have been printed in a booklet<br />
that will be distributed to each attendee. In addition, the<br />
Late Abstract Submissions will be published in the July 2011<br />
issue <strong>of</strong> Molecular <strong>Therapy</strong>. The option for itinerary download<br />
for Personal Digital Assistants (PDAs) is also available. Please<br />
contact ASGCT for a link at (414) 278-1341 or info@asgct.org.<br />
Admission<br />
Official name badges will be required for admission to all<br />
ASGCT sessions. All Annual Meeting attendees receive a name<br />
badge with their registration bag. Name badges should be<br />
worn at all times inside the convention center, as badges will be<br />
used to control access to sessions and activities. Attendees are<br />
cautioned against wearing their name badges while away from<br />
the convention center as badges may draw unwanted attention<br />
to your status as visitors to Seattle, Washington.<br />
Boxed Lunches<br />
Pre-ordered boxed lunches will be available for pick-up at the<br />
registration desk according to the schedule below:<br />
Wednesday, May 18 12:00 pm – 12:30 pm<br />
Thursday, May 19 1:00 pm – 1:30 pm<br />
Friday, May 20 12:00 pm – 12:30 pm<br />
Saturday, May 21 12:15 pm – 12:45 pm<br />
All boxed lunches must have been pre-ordered via the Annual<br />
Meeing registration form before May 9 and pick-up <strong>of</strong> boxed<br />
lunches is by ticket only.<br />
Business Center (FedEx Office)<br />
There is a FedEx Office located in the Washington State<br />
Convention Center in the Upper Pike Street Lobby. It is open<br />
Monday – Friday from 7:00 am to 9:00 pm and Saturday and<br />
Sunday from 9:00 am to 6:00 pm. Phone: (206) 467-1767.<br />
Business Meeting<br />
Join the <strong>Society</strong>’s leadership for a business meeting and<br />
continental breakfast.<br />
Saturday, May 21, 2011<br />
7:30 am – 8:00 am (Light continental breakfast at 7:15 am)<br />
Room 618-620, Level Six<br />
All members are welcome. See page 5 for more details.<br />
Camera/Recording Policy<br />
It is the policy <strong>of</strong> ASGCT that no cameras are permitted in<br />
the meeting sessions, exhibit hall, or poster sessions, with the<br />
exception <strong>of</strong> a pr<strong>of</strong>essional photographer hired by ASGCT to<br />
capture images for use in <strong>Society</strong> archival and promotional<br />
materials. Please refrain from taking any photos in those<br />
locations. Audio and/or videotaping is strictly prohibited.<br />
Your attendance at ASGCT events implies your permission for<br />
images captured during these events to be used for the purposes<br />
<strong>of</strong> ASGCT archival and promotional materials and waives your<br />
rights for compensation or ownership <strong>of</strong> these images.<br />
<strong>Cell</strong> Phones & PDAs<br />
As a courtesy to all presenters and attendees, please ensure that<br />
cell phone and PDA ringers are turned <strong>of</strong>f or silenced during all<br />
sessions as they may interfere with session audio.<br />
Committee Meetings<br />
Most standing and scientific committees will meet during<br />
the Annual Meeting. See page 5 for Committee Meeting<br />
information.<br />
Concierge Desk<br />
Seattle <strong>of</strong>fers a wide variety <strong>of</strong> activities and restaurants to meet<br />
all tastes and budgets. A Concierge Desk is located in the Upper<br />
Pike Street Lobby <strong>of</strong> the Washington State Convention Center,<br />
staffed by the Seattle Convention and Visitors Bureau, who can<br />
help you with your city needs and reservations.<br />
Concierge Desk Hours<br />
Sunday through Saturday 9:00 am – 5:00 pm<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 19
20<br />
<strong>Gene</strong>ral Meeting Information<br />
Continuing Medical Education<br />
Accreditation Statement<br />
This activity has been planned and implemented in accordance<br />
with the Essential Areas and policies <strong>of</strong> the Accreditation<br />
Council for Continuing Medical Education (ACCME) through the<br />
joint sponsorship <strong>of</strong> Indiana University School <strong>of</strong> Medicine and<br />
the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>. Indiana University<br />
School <strong>of</strong> Medicine is accredited by the ACCME to provide<br />
continuing medical education for physicians.<br />
NOTE: Sessions marked with an asterisk (*) are not part <strong>of</strong> the<br />
CME program.<br />
Designation Statement<br />
Indiana University School <strong>of</strong> Medicine designates this live<br />
activity for a maximum <strong>of</strong> 28.5 AMA PRA Category 1 Credits.<br />
Physicians should only claim credit commensurate with the<br />
extent <strong>of</strong> their participation in the activity.<br />
CME Certificates<br />
Participants requiring CME certificates must go to the<br />
Registration Desk and complete a CME form. CME certificates<br />
will be mailed to participants after the meeting. There is a CME<br />
fee <strong>of</strong> $65 USD for the 14 th Annual Meeting.<br />
Disclosure<br />
In accordance with the Accreditation Council for Continuing<br />
Medical Education (ACCME) Standards for Commercial Support,<br />
educational programs sponsored by Indiana University School<br />
<strong>of</strong> Medicine (IUSM) must demonstrate balance, independence,<br />
objectivity, and scientific rigor. All faculty, authors, editors,<br />
and planning committee members participating in an IUSMsponsored<br />
activity are required to disclose any relevant financial<br />
interest or other relationship with the manufacturer(s) <strong>of</strong><br />
any commercial product(s) and/or provider(s) <strong>of</strong> commercial<br />
services that are discussed in an educational activity.<br />
Note<br />
While it <strong>of</strong>fers CME credits, this activity is not intended to<br />
provide extensive training or certification in the field.<br />
Educational Methods and Materials<br />
Lectures, Case Presentations, Panel Discussions, Question and<br />
Answer Sessions, Audio/Video Presentations, Abstracts, Posters<br />
Educational Objectives<br />
At the conclusion <strong>of</strong> the activity, the participant should be able to:<br />
• Provide advice to patients who inquire about the potential<br />
<strong>of</strong> gene and cell therapy or the availability <strong>of</strong> open clinical<br />
trials, based on their exposure to the current clinical trials in<br />
gene and cell therapies.<br />
• Review state-<strong>of</strong>-the-art basic science and clinical trials data<br />
presented at this meeting with students in medical school<br />
and other health venues.<br />
• Use the latest advances in gene and cell therapy to enhance<br />
their research mission, as physician scientists conducting<br />
basic and clinical research.<br />
• Demonstrate improved regulatory compliance in conducting<br />
gene and cell therapy clinical trials, through exposure to NIH<br />
and FDA faculty during the educational program.<br />
Evaluation Method<br />
Evaluation by questionnaire will address program content,<br />
presentation, and possible bias.<br />
Needs<br />
Clinical gene transfer has become more and more complex<br />
due to ongoing developments in the fields <strong>of</strong> gene and cell<br />
therapy itself, together with bioethics, research integrity, and<br />
financial conflicts, as well as federal mandates, regulations<br />
and guidelines. Oligonucleotide Therapies, Novel Vector<br />
Development, Host-Vector Interactions and Vaccine Therapies<br />
will be discussed as well as many other scientific topics. This<br />
meeting will provide an educational forum for scientists<br />
and clinicians to expand their knowledge about the broad<br />
developments in these fields.<br />
Target Audience<br />
The target audience includes basic science and translational<br />
researchers, clinical investigators, physicians, postdoctoral<br />
fellows, graduate students, employees <strong>of</strong> federal government<br />
and regulatory agencies, and other healthcare pr<strong>of</strong>essionals<br />
with an interest in the latest advancements in the field <strong>of</strong> gene<br />
and cell therapy.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Gene</strong>ral Meeting Information<br />
Dates<br />
The ASGCT 14 th Annual Meeting will begin the morning <strong>of</strong><br />
Wednesday, May 18 and continue through the evening <strong>of</strong><br />
Saturday, May 21, 2011. Exhibits will be open Wednesday, May<br />
18 through Friday, May 20.<br />
Exhibits<br />
Exhibits will be located in Exhibit Hall 4B, Level Four, <strong>of</strong> the<br />
Washington State Convention Center. The companies,<br />
organizations and institutions exhibiting at the ASGCT Annual<br />
Meeting will be providing you with the latest information on<br />
products and services directly related to your pr<strong>of</strong>essional needs,<br />
as well as recruiting for open positions. An Exhibit Hall Social will<br />
be held on Wednesday evening and a c<strong>of</strong>fee social will be <strong>of</strong>fered<br />
on Thursday and Friday in the exhibit hall. All participants are<br />
urged to allow adequate time in your daily schedule to visit the<br />
exhibits, as they are an integral part <strong>of</strong> the success <strong>of</strong> the meeting.<br />
Exhibit Hall Hours<br />
Exhibits will be open Wednesday, May 18 through Friday,<br />
May 20, 2011.<br />
Wednesday, May 18 5:15 pm – 7:15 pm<br />
Thursday, May 19 10:15 am – 11:00 am<br />
Thursday, May 19 4:40 pm – 6:40 pm<br />
Friday, May 20 9:15 am – 10:00 am<br />
Friday, May 20 4:40 pm – 6:40 pm<br />
Guest Attendance<br />
ASGCT asks registered attendees to refrain from taking children,<br />
spouses, or guests to any educational session or functions<br />
<strong>of</strong>fered at the 14 th Annual Meeting.<br />
Internet Access & Policy<br />
Internet access will be available at the Washington State<br />
Convention Center to all meeting attendees. Limited computer<br />
stations will be provided in the South Lobby, outside Hall 4B.<br />
When others are waiting at the internet kiosks, please limit your<br />
Internet use to 15 minutes at a time so other attendees can<br />
access the internet as well.<br />
Job Bank<br />
At the 14 th Annual Meeting, there will be a forum for academic<br />
institutions and companies to promote open positions to<br />
meeting attendees. If you have open positions, please bring<br />
multiple copies <strong>of</strong> your job posting to the meeting. Similarly,<br />
if you are seeking a job, please bring multiple copies <strong>of</strong> your<br />
résumé to submit. ASGCT will not take responsibility for<br />
résumés sent to the ASGCT <strong>of</strong>fice in response to a job posting.<br />
If you would like more information about this service, please<br />
contact Erin Hankey at ehankey@asgct.org. The Job Exchange<br />
area will be located inside Exhibit Hall 4B.<br />
Lead Retrieval<br />
A lead retrieval system has been made available to all exhibitors<br />
<strong>of</strong> the ASGCT 14 th Annual Meeting. Exhibitors may ask to scan<br />
attendee name badges with a hand held scanner in order to<br />
obtain attendee contact information.<br />
Location<br />
• The 14 th Annual Meeting will be held at the Washington<br />
State Convention Center, 800 Convention Place, Seattle, WA<br />
98101, USA.<br />
• Exhibits and Posters will take place in Hall 4B – Level Four.<br />
• Registration will be located in the South Lobby, just outside<br />
Hall 4B – Level Four.<br />
Materials Distribution<br />
Please refrain from distributing promotional materials<br />
throughout the meeting; these may only be distributed from an<br />
exhibit booth in Hall 4B – Level Four.<br />
Media<br />
Members <strong>of</strong> the working media may register for the 14 th Annual<br />
Meeting in the Press Room – Room 309 (Level Three). Interview<br />
space, computers and internet services are available for the<br />
convenience <strong>of</strong> media representatives covering the meeting.<br />
Press must register, provide credentials, and wear their press<br />
badge for admittance to ASGCT sessions. Assistance will be<br />
provided to members <strong>of</strong> the media that would like to schedule<br />
interviews.<br />
No Smoking<br />
Smoking is prohibited at all 14 th Annual Meeting sessions<br />
and events.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 21
22<br />
<strong>Gene</strong>ral Meeting Information<br />
Posters<br />
Abstract Posters will be on display in Hall 4B (Level Four).<br />
Thursday, May 19<br />
Abstract Poster Session I<br />
10:00 am – 12:00 pm Poster Setup by Authors<br />
1:00 pm – 6:40 pm Poster Viewing<br />
(authors present from 4:40 pm – 6:40 pm)<br />
4:40 pm – 6:40 pm Exhibit Hall Open: Networking Reception,<br />
Exhibits, and Poster Session<br />
6:40 pm – 7:00 pm Authors Remove Posters<br />
Friday, May 20<br />
Abstract Poster Session II<br />
7:00 am – 12:00 pm Poster Setup by Authors<br />
12:00 pm – 6:40 pm Poster Viewing<br />
(authors present from 4:40 pm – 6:40 pm)<br />
4:40 pm – 6:40 pm Exhibit Hall Open: Networking Reception,<br />
Exhibits, and Poster Session<br />
6:40 pm – 7:00 pm Authors Remove Posters<br />
Saturday, May 21<br />
Abstract Poster Session III<br />
7:00 am – 12:00 pm Poster Setup by Authors<br />
12:15 pm – 8:15 pm Poster Viewing<br />
(authors present from 6:15 pm – 8:15 pm)<br />
6:15 pm – 8:15 pm Poster Session<br />
8:15 pm – 8:45 pm Authors Remove Posters<br />
Call4Posters® Pick-up Schedule<br />
This year the ASGCT arranged with Marathon Multimedia to<br />
provide poster authors with the opportunity to create their<br />
poster online using the Call4Posters® service. Poster presenters<br />
who took advantage <strong>of</strong> this service may pick-up their preordered<br />
poster at the ASGCT Registration Desk during the<br />
following hours.<br />
Tuesday, May 17 5:00 pm – 7:00 pm<br />
Wednesday, May 18 7:00 am – 8:00 pm<br />
Thursday, May 19 7:00 am – 5:00 pm<br />
Friday, May 20 7:30 am – 5:00 pm<br />
Saturday, May 21 7:30 am – 5:00 pm<br />
Press Room<br />
The Press Room is located in the Washington State Convention<br />
Center, Room 309 (Level Three).<br />
Press Room Hours<br />
Wednesday, May 18 3:00 pm – 6:00 pm<br />
Thursday, May 19 8:00 am – 5:00 pm<br />
Friday, May 20 8:00 am – 5:00 pm<br />
Saturday, May 21 8:00 am – 5:00 pm<br />
Registration Desk<br />
Name badges, final programs, and abstract supplements will be<br />
distributed at the registration desk located outside <strong>of</strong> Hall 4B, in<br />
the South Lobby <strong>of</strong> the Washington State Convention Center.<br />
Registration Desk Hours<br />
Tuesday, May 17 5:00 pm – 7:00 pm<br />
Wednesday, May 18 7:00 am – 8:00 pm<br />
Thursday, May 19 7:00 am – 5:00 pm<br />
Friday, May 20 7:30 am – 5:00 pm<br />
Saturday, May 21 7:30 am – 5:00 pm<br />
Cancellation Refund Policy<br />
Refund requests should have been submitted in writing to the<br />
ASGCT Executive Office prior to May 9, 2011. A $35 processing fee<br />
will be charged for all refunds. We regret that refunds cannot be<br />
allowed for requests postmarked or received after May 8, 2011.<br />
Seattle Information<br />
Please note, the City <strong>of</strong> Seattle issues jaywalking tickets to<br />
individuals who do not follow the traffic laws. Therefore, please<br />
abide by the traffic signs and lights and utilize the designated<br />
crosswalks at all times. See Seattle Fun Facts on page 85 for<br />
more information on Seattle.<br />
Shuttle Bus<br />
ASGCT will not be providing shuttle transportation for the<br />
14 th Annual Meeting. The Washington State Convention Center<br />
is located within 1-4 blocks <strong>of</strong> the ASGCT Annual Meeting<br />
hotel block.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Gene</strong>ral Meeting Information<br />
Speaker Ready Room<br />
There will be a Speaker Ready Room located in the Washington<br />
State Convention Center, Room 613-614 (Level Six).<br />
All faculty, including oral abstract presenters, must deliver<br />
their presentations to the Speaker Ready Room the day before<br />
their session or at least four hours prior to their presentations.<br />
Equipment is available for faculty to review their materials.<br />
Audiovisual personnel will be available for assistance. Please<br />
mark your materials (your name, session and speaker order)<br />
so the materials can be returned to you. The <strong>Society</strong> strongly<br />
encourages faculty to pre-load presentations in the Speaker<br />
Ready Room; those faculty who load presentations in the<br />
meeting rooms during the sessions will have that time<br />
deducted from their presentation time by the Chair.<br />
ASGCT strongly encourages faculty presenting on Wednesday<br />
<strong>of</strong> the Annual Meeting to check in at the Speaker Ready Room<br />
on Tuesday, May 17 to avoid congestion.<br />
Avoid delays and check-in early!<br />
Speaker Ready Room Hours<br />
Tuesday, May 17 5:00 pm – 7:00 pm<br />
Wednesday, May 18 6:30 am – 8:00 pm<br />
Thursday, May 19 6:30 am – 7:00 pm<br />
Friday, May 20 6:30 am – 7:00 pm<br />
Saturday, May 21 7:00 am – 4:30 pm<br />
Special Accessibility Needs<br />
If you require special accommodations under the ADA in order<br />
to fully participate in the meeting or the course, please visit the<br />
Registration Desk; ASGCT staff will be happy to assist you with<br />
your specific needs.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 23
24<br />
Washington State Convention Center<br />
Level 1<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Escalators<br />
Up to ASGCT<br />
Registration
Washington State Convention Center<br />
Level 2<br />
Level 2<br />
• ASGCT Committee<br />
Meetings<br />
• Meet-the-<br />
Investigator Sessions<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 25
26<br />
Washington State Convention Center<br />
Level 3<br />
Level 3<br />
• Meet-the-Investigator<br />
Sessions<br />
• Press Room – Room 309<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Washington State Convention Center<br />
Level 4<br />
Skybridge<br />
Friday Night<br />
Party<br />
Posters<br />
Exhibits<br />
Registration<br />
Level 4<br />
• Exhibit Hall - 4B<br />
• Internet Kiosks<br />
• Job Exchange<br />
• Poster Hall - 4B<br />
• Registration Desk<br />
• Friday Night Party<br />
- Skybridge<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 27
28<br />
Washington State Convention Center<br />
Level 6<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Level 6<br />
• Plenary Lecture Hall - 6BC<br />
• Session Rooms<br />
(Education, Oral Abstracts,<br />
Scientific Symposia)<br />
• Speaker Ready Room<br />
(Room 613-614)<br />
• Committee Meetings
Schedule-at-a-Glance (This program is subject to updates/changes)<br />
Tuesday, May 17<br />
5:00 pm - 7:00 pm Registration Open<br />
Wednesday, May 18<br />
7:00 am - 8:00 pm Registration Open<br />
7:30 am - 8:00 am C<strong>of</strong>fee Break<br />
8:00 am - 10:00 am Scientific Symposia Session I<br />
10:30 am - 12:00 pm Education Session I<br />
12:00 pm - 1:15 pm Lunch Break (On Own)<br />
1:15 pm - 2:45 pm Education Session II<br />
3:15 pm - 5:15 pm Oral Abstract Session I<br />
5:15 pm - 7:15 pm Exhibit Hall Welcome Reception<br />
Thursday, May 19<br />
7:00 am - 5:00 pm Registration Open<br />
8:00 am - 10:15 am Presidential Symposium<br />
Keynote Speaker: George Q. Daley, MD, PhD: Towards Combined <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> with Pluripotent Stem <strong>Cell</strong>s<br />
10:15 am - 11:00 am Exhibit Hall C<strong>of</strong>fee Social<br />
11:00 am - 1:00 pm Scientific Symposia Session II<br />
1:00 pm - 2:30 pm Lunch Break (On Own)<br />
1:00 pm - 2:30 pm Meet-the-Investigator Sessions<br />
1:00 pm - 6:40 pm Poster Viewing (Authors present from 4:40 pm – 6:40 pm)<br />
2:30 pm - 4:30 pm Oral Abstract Session II<br />
4:40 pm - 6:40 pm Exhibit Hall Open: Networking Reception & Poster Session I<br />
Friday, May 20<br />
7:30 am - 5:00 pm Registration Open<br />
8:00 am - 9:15 am George Stamatoyannopoulos Lecture<br />
Keynote Speaker: Victor J. Dzau, MD: Paracine Mechanisms <strong>of</strong> Stem <strong>Cell</strong> Action in Tissue Repair and Regeneration<br />
9:15 am - 10:00 am Exhibit Hall C<strong>of</strong>fee Social<br />
10:00 am - 12:00 pm Scientific Symposia Session III<br />
12:00 pm - 1:15 pm Lunch Break (On Own)<br />
12:00 pm - 6:40 pm Poster Viewing (Authors present from 4:40 pm – 6:40 pm)<br />
1:15 pm - 3:15 pm Oral Abstract Session III<br />
3:45 pm - 4:30 pm Outstanding Achievement Award Lecture<br />
Keynote Speaker: Malcolm K. Brenner, MD, PhD: <strong>Cell</strong> and <strong>Gene</strong> <strong>Therapy</strong> - Putting it Together<br />
4:40 pm - 6:40 pm Exhibit Hall Open: Networking Reception & Poster Session II<br />
7:00 pm - 9:00 pm Friday Night Party<br />
Saturday, May 21<br />
7:30 am - 5:00 pm Registration Open<br />
7:30 am - 8:00 am ASGCT Business Meeting (with continental breakfast)<br />
8:00 am - 9:45 am Outstanding New Investigator Symposium<br />
10:15 am - 12:15 pm Oral Abstract Session IV<br />
12:15 pm - 1:45 pm Lunch Break (On Own)<br />
12:15 pm - 1:45 pm Meet-the-Investigator Sessions<br />
12:15 pm - 8:15 pm Poster Viewing (Authors present from 6:15 pm – 8:15 pm)<br />
1:45 pm - 3:45 pm Scientific Symposia Session IV<br />
4:15 pm - 6:15 pm Scientific Symposia Session V<br />
6:15 pm - 8:15 pm Poster Session III<br />
8:15 pm Annual Meeting Concludes<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 29
Wednesday, May 18<br />
30<br />
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
SCIENTIFIC SYMPOSIUM 100<br />
8:00 am - 10:00 am<br />
Room: 615-617<br />
Challenges in the Development <strong>of</strong> Investigational <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> Products:<br />
Perspectives from Multi Center Trials<br />
Jointly planned by the Association <strong>of</strong> Academic Biologics Manufacturers<br />
CO-CHAIRS<br />
Larry A. Couture, PhD<br />
J. Fraser Wright, PhD<br />
SPEAKERS<br />
Carl H. June, MD<br />
Can <strong>Cell</strong> Transfer <strong>Therapy</strong> Move From Wall Street to Main Street?<br />
Given that cell and gene therapies are beginning to work in a number <strong>of</strong> phase I trials, the next challenge becomes how to<br />
progress to the next step in clinical development? In this session, the approach that we have taken to conduct multicenter<br />
studies with personalized, patient specific T cells in patients with cancer will be discussed. The field must demonstrate that robust<br />
manufacturing technologies are in place in order to support the eventual wide spread application and FDA approval <strong>of</strong> therapies<br />
with customized cell and gene therapy products.<br />
Mitchell H. Finer, PhD<br />
Lessons Learned from Lentiviral <strong>Gene</strong> Transfer into Bone Marrow in Two Clinical Trials: Planning a Multi-Center<br />
International Study Leading to Product Registration<br />
Bluebird Bio (formerly <strong>Gene</strong>tix Pharmaceuticals) gained significant experience over the past five years in the clinical development <strong>of</strong><br />
Lentiviral gene therapy products for the treatment <strong>of</strong> monogenic diseases in the context <strong>of</strong> autologous bone marrow transplant. The<br />
company is currently the sponsor <strong>of</strong> a Phase I/II study for evaluation <strong>of</strong> genetic therapy <strong>of</strong> Hemoglobinopathies (β-thalassemia and<br />
sickle cell anemia) following gene transfer <strong>of</strong> a functional human β-globin gene into autologous CD34+ cells, currently being carried<br />
out in Paris. The 34 month follow-up <strong>of</strong> the first patient were published in Nature in November 2010 (Cavazzana-Calvo et al,. 2010,<br />
Nature 467:318-322) by Philippe Leboulch and Marina Cavazzana-Calvo. The company’s collaborators Patrick Aubourg and Nathalie<br />
Cartier published the results describing two year follow-up <strong>of</strong> two boys treated in a Phase I/II study for the treatment <strong>of</strong> the childhood<br />
cerebral form <strong>of</strong> Adrenoleukodystrophy (ALD) through ex vivo transfer <strong>of</strong> the ALD cDNA into autologous CD34 cells, sponsored by<br />
INSERM, in Paris (Cartier et al., 2009, Science 326:818-823). Working together with an international group <strong>of</strong> collaborators in the US and<br />
France and the experience gained from these Lentiviral clinical trials, the company is undertaking the planning and launch <strong>of</strong> a single,<br />
multi-center study designed to register a Lentiviral gene therapy-based product to be used in the context <strong>of</strong> autologous bone marrow<br />
transplantation for the treatment <strong>of</strong> the childhood cerebral form <strong>of</strong> ALD. The application <strong>of</strong> lessons learned from the previous two<br />
studies and how they facilitated the design and implementation <strong>of</strong> the upcoming international multi-center study will be presented.<br />
Michael C. Holmes, PhD<br />
John T. Gray, PhD<br />
Paper to Patient in 4 Years: Development <strong>of</strong> a Self-Complementary Serotype 8 AAV Vector for Treatment <strong>of</strong> Hemophilia B<br />
for a Multi-Center Clinical Trial in the United States and United Kingdom<br />
The manufacture <strong>of</strong> clinical grade adeno-associated virus vectors remains significantly challenging, with little consensus as to either<br />
“best practices” for the manufacturing process or clearly defined biochemical assays for ensuring final product potency. Since our<br />
publication in 2006 <strong>of</strong> a novel, self-complementary AAV vector expressing a codon-optimized human Factor IX gene, we have<br />
transitioned this vector into large scale GMP production, and gained regulatory approval in both the US and the UK for the use <strong>of</strong><br />
the resulting clinical vector in adult Hemophilia B patients. In this Symposium presentation I will summarize our vector production<br />
process, product certification, and regulatory approval. Details will be provided for multiple analytical assays that we have<br />
developed for monitoring product quality, including our observations that quantitative PCR assays can dramatically underestimate<br />
the vector genome titer <strong>of</strong> self-complementary AAV vectors.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
PANEL<br />
Estuardo Aguilar-Cordova, PhD<br />
Larry A. Couture, PhD<br />
Daniel M. Takefman, PhD<br />
SCIENTIFIC SYMPOSIUM 101<br />
8:00 am - 10:00 am<br />
Room: 6A<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Around the Globe: A Showcase <strong>of</strong> Europe<br />
Jointly planned with the European <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Thierry C. VandenDriessche, PhD<br />
Seppo Ylä-Herttuala, MD, PhD, FESC<br />
SPEAKERS<br />
Paolo Macchiarini, MD, PhD<br />
Stem-<strong>Cell</strong> Based Restoration and Replacement Therapies for Irreversible Diseases <strong>of</strong> the Airway<br />
The ramifications <strong>of</strong> stem cell research and therapy for irreversible diseases <strong>of</strong> the airway are enormous. We provided evidence<br />
that mesenchymal stem and autologous (respiratory) cells can be successfully used to reseed, either ex-vivo or in-vivo, laryngotracheal<br />
and tracheal human bioengineered scaffolds, and that this can successfully replace major airway in children and adults.<br />
However, adult stem cells have remarkable abilities to self-renew and differentiate into one or multiple types <strong>of</strong> mature cells, and<br />
that they commonly reside in specific local microenvironement, called niche. Since they have been found as well in the airway, why<br />
not speculate to use stem cell therapy for restoring cell, tissue or organ function in patients with otherwise untreatable airways<br />
diseases instead doing, and therefore avoid tissue-engineered transplantation? We currently have an ongoing phase I clinical trial<br />
that recruits and mobilizes both, dormant or silent stem cells and progenitors cells from the periphery to repair untreatable tissues<br />
or organs. This nearly eliminates any ethical or religious arguments to the stem cell treatment, and regulations. All this research will<br />
be presented.<br />
Sebastien Maury, MD, PhD<br />
Regulatory T-cell Depletion to Improve the Graft-Versus-Tumor Effect <strong>of</strong> Donor Lymphocytes after Allogeneic<br />
Hematopoietic Stem <strong>Cell</strong> Transplantation<br />
Donor T-cells play a pivotal role in the graft-versus-tumor (GVT) effect after allogeneic hematopoietic stem cell transplantation<br />
(HSCT). In the setting <strong>of</strong> donor lymphocyte infusion (DLI) after HSCT, we postulated that Treg depletion could improve alloreactivity<br />
and likewise the GVT effect <strong>of</strong> donor T-cells. In alloreactivity-resistant patients, we show that Treg-depleted DLI is a safe<br />
approach which induces GVT effect. In patients not responding to this approach, the combination <strong>of</strong> a chemotherapy-induced<br />
lymphodepletion <strong>of</strong> the recipient synergizes the effect <strong>of</strong> Treg-depleted DLI. Our findings <strong>of</strong>fer a new rational therapeutic approach<br />
for cancer cellular immunotherapy.<br />
Robin R. Ali, PhD<br />
<strong>Cell</strong> Transplantation Strategies for Repairing the Retina<br />
We have previously discovered that transplantation <strong>of</strong> rod precursor cells at a specific stage <strong>of</strong> development results in their<br />
integration and subsequent differentiation into rod photoreceptors that form synaptic connections and improve visual function<br />
in mouse models <strong>of</strong> retinal degeneration (MacLaren, et al Nature, 2006). Conversely, transplantation <strong>of</strong> progenitor or stem cells<br />
that are not at this precise ontogentic stage do not show this property and fail to integrate. These findings provide a strong basis<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 31<br />
Wednesday, May 18
Wednesday, May 18<br />
32<br />
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
for the development <strong>of</strong> a cell transplantation programme for the treatment <strong>of</strong> retinal disease. We are also developing strategies<br />
to overcome barriers present in the degenerate neural retina in order to improve the efficiency <strong>of</strong> cell integration and are testing<br />
efficacy using electrophysiology and various behavioural assessments <strong>of</strong> vision. Recently it has been shown that it is possible to<br />
generate photoreceptor cells from embryonic stem cells (Lambda et al PNAS 2006, Osakada Nat Biotech 2008) and our current<br />
work is focused on using embryonic stem cells to generate rod progenitors cells for transplantation.<br />
Dominic J. Wells, PhD<br />
Translational Studies in Duchenne’s Muscular Dystrophy<br />
The presentation will briefly review the range <strong>of</strong> experimental therapeutic options for the lethal muscle wasting disorder,<br />
Duchenne muscular dystrophy. It will then focus on antisense mediated exon-skipping to restore the open reading frame <strong>of</strong> the<br />
dystrophin mRNA. Recent clinical trials will be discussed together with the possible factors limiting the efficiency <strong>of</strong> systemic<br />
delivery <strong>of</strong> antisense reagents. Potential solutions to increase efficiency will be proposed in the light <strong>of</strong> pre-clinical experiments.<br />
<strong>Final</strong>ly the role <strong>of</strong> the immune response in the context <strong>of</strong> exon-skipping and treatment <strong>of</strong> DMD in general will be evaluated.<br />
SCIENTIFIC SYMPOSIUM 102<br />
8:00 am - 10:00 am<br />
Room: 611-612<br />
Immunosuppression for <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Roland W. Herzog, PhD<br />
Paul D. Robbins, PhD<br />
SPEAKERS<br />
Rainer F. Storb, MD<br />
Conditioning for Transplantation <strong>of</strong> Hematopoietic Stem <strong>Cell</strong>s<br />
Allogeneic hematopoietic cell therapy requires crossing a double immunologic barrier, host-versus-graft reaction and graft-versushost<br />
reaction. In order to accomplish the former, conditioning regimens have been developed that range in intensity from high,<br />
otherwise lethal doses <strong>of</strong> body irradiation or chemotherapy to use <strong>of</strong> non-toxic radiolabeled monoclonal antibodies or T-cell<br />
costimulatory blockade. The latter requires administration <strong>of</strong> immunosuppressive agents for 6-12 months after allogeneic cell<br />
transplantation, usually a combination <strong>of</strong> an anti-metabolite and a calcineurin inhibitor. During that time, tolerance <strong>of</strong> graft against<br />
host becomes established in a majority <strong>of</strong> patients.<br />
Roland W. Herzog, PhD<br />
Immune Modulation to Promote Tolerance in <strong>Gene</strong> and Protein Therapies<br />
Adaptive immune responses against therapeutic proteins limit efficacy <strong>of</strong> gene and protein replacement therapies for genetic<br />
diseases. It is therefore desirable to develop immune tolerance protocols for the specific protein antigen. This can be accomplished<br />
using specific routes/modes <strong>of</strong> antigen administration, tolerogenic gene transfer protocols, or administration <strong>of</strong> a combination<br />
<strong>of</strong> antigen and immune modulatory drugs (as well as drugs that limit inflammatory signals). Such strategies may also be helpful<br />
in reversing existing immune responses. Immune tolerance induction to coagulation factors in treatment <strong>of</strong> hemophilia will be<br />
discussed as an example for employment <strong>of</strong> such strategies.<br />
Paul D. Robbins, PhD<br />
<strong>Gene</strong> and <strong>Cell</strong> Based Therapies for Autoimmune Diseases<br />
<strong>Gene</strong> therapy approaches for treating autoimmune disorders such as rheumatoid arthritis and type I diabetes have shown<br />
significant efficacy in numerous animal models. The effective approaches include ex vivo methods involving genetically modified<br />
dendritic cells (DC), exosomes derived from genetically modified DC as well as direct, in vivo gene transfer <strong>of</strong> immunomodulatory<br />
cytokines to joints and to endogenous islets. We have performed several clinical trials for gene therapy <strong>of</strong> rheumatoid arthritis<br />
using intra-articular injection <strong>of</strong> genetically modified synovial fibroblasts expressing IL-1Ra. Currently we are developing AAV-based<br />
approaches for treating osteoarthritis by intra-articular gene transfer <strong>of</strong> IL-1Ra. The significant pre-clinical and clinical progress<br />
made towards developing viable gene therapy approaches for treating autoimmune disorders using rheumatoid arthritis and type<br />
1 diabetes as model autoimmune diseases will be presented.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
Doina Ganea, PhD<br />
<strong>Gene</strong>tically Altered Myeloid Dendritic <strong>Cell</strong>s Secreting Immunosuppressive Neuropeptides as <strong>Therapy</strong> for Inflammatory/<br />
Autoimmune Conditions<br />
Dendritic cells (DC) initiate immune responses as well as tolerance. We showed previously that the neuropeptide vasoactive<br />
intestinal peptide (VIP) suppresses innate immune responses, generates tolerogenic dendritic cells, and has therapeutic effects<br />
in models <strong>of</strong> autoimmune/inflammatory disorders. To generate tolerogenic DC that also provide VIP locally, we used lentiviral<br />
vectors to engineer VIP-expressing DC. LentiVIP-DC secrete VIP, switch from a proinflammatory to an anti-inflammatory cytokine<br />
pr<strong>of</strong>ile and lose the capacity to activate T cells. A single inoculation <strong>of</strong> LentiVIP-DC in sepsis and MS models had therapeutic effects.<br />
Local delivery <strong>of</strong> VIP by LentiVIP-DC may represent a promising therapeutic tool for the treatment <strong>of</strong> autoimmune diseases and<br />
inflammatory disorders.<br />
Education Sessions<br />
The goal <strong>of</strong> the ASGCT Education <strong>Program</strong> is to provide participants with a broad background and introduction to topics relevant<br />
to the field <strong>of</strong> gene and cell therapy. Education Sessions will be subdivided into two headings. “Topical Review” sessions will<br />
provide a broad perspective <strong>of</strong> an area <strong>of</strong> importance to the gene and cell therapy community such as major vector systems,<br />
specific target organs or diseases, and funding/regulatory issues. “Emerging Field Review” sessions will provide a broad perspective<br />
<strong>of</strong> a technological or scientific discipline that has recently become <strong>of</strong> great significance to ASGCT members.<br />
EDUCATION SESSION 110<br />
10:30 am - 12:00 pm<br />
Room: 6A<br />
Emerging Field Review: Genomics (Personalized Medicine)<br />
CHAIR<br />
Harry L. Malech, MD<br />
SPEAKERS<br />
John J. Nemunaitis, MD<br />
Clinical Development <strong>of</strong> GNE <strong>Gene</strong> Lipoplex <strong>Therapy</strong> in Hereditary Inclusion Body Myopathy<br />
Hereditary Inclusion Body Myopathy (HIBM) is an autosomal recessive adult onset myopathy due to mutations in the GNE (UDP-<br />
N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase) gene. Affected patients have no therapeutic options. A single<br />
patient with severe HIBM treated via single patient IND safely received seven escalated doses <strong>of</strong> GNE gene lipoplex via intravenous<br />
infusion. Quadriceps muscle expression <strong>of</strong> the delivered GNE, plasmid and RNA were observed 24 hours after the 5.0 mg dose and<br />
at significantly greater levels 72 hours after the 7.0 mg infusion in comparison to expression in quadriceps muscle immediately<br />
before infusion. Clinical safety and activity is demonstrated with intravenous infusion <strong>of</strong> GNE gene lipoplex supporting further<br />
assessment involving Phase I trial.<br />
Stanley Riddell, MD<br />
Functional Heterogeneity in T <strong>Cell</strong> Subsets - Implications for Adoptive Immunotherapy with <strong>Gene</strong>tically Re-targeted T <strong>Cell</strong>s<br />
The adoptive transfer <strong>of</strong> T cells that are isolated from the blood and retargeted to recognize tumor cells by transferring genes that<br />
encode an αβ T cell receptor or a chimeric antigen receptor is a rapidly emerging therapy for human malignancy. The simplest<br />
iteration <strong>of</strong> this approach is to genetically modify peripheral blood T cells that have not been selected based on any particular<br />
phenotypic or functional properties. In this presentation, we will discuss the rapid evolution in our understanding <strong>of</strong> heterogeneity<br />
within human peripheral blood T cells, which includes subsets that are distinctly programmed for survival and inflammatory<br />
cytokine production, and suggests that selection <strong>of</strong> defined populations for gene modification may be necessary to fully capitalize<br />
on the opportunities for cancer immunotherapy. Clinical investigation <strong>of</strong> defined cell populations will require the development <strong>of</strong><br />
improved cell selection technologies that do not compromise function. It is also imperative that future clinical trials incorporate<br />
detailed characterization <strong>of</strong> the cell products that are infused and sophisticated monitoring <strong>of</strong> their fate, migration and function in<br />
vivo in each patient, to provide insight into the basis for therapeutic success and toxicity, and direct subsequent investigation.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 33<br />
Wednesday, May 18
Wednesday, May 18<br />
34<br />
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
Kevin M. Flanigan, MD<br />
Identifying Patient-Specific Mutations in the DMD <strong>Gene</strong>: Implications for Phenotype and Therapies<br />
New methods <strong>of</strong> molecular diagnosis have facilitated the identification <strong>of</strong> rare or unique mutations in the DMD gene that result<br />
in the dystrophinopathies Duchenne and Becker Muscular Dystrophy. Cataloging these mutations has widened the mutational<br />
spectrum associated with these diseases, and has led to the increased recognition <strong>of</strong> certain mutational classes. New data has<br />
emerged to explain the mechanisms by which mutations predicted from genomic testing to result in reading frame termination<br />
are instead associated with expression <strong>of</strong> partially functional dystrophin and a milder disease course. These mechanisms may<br />
have implications for the implementation <strong>of</strong> therapies already in clinical trials, including nonsense mutation suppression, exon<br />
skipping, and gene replacement. In this talk I will summarize diagnostic advances, review molecular mechanisms <strong>of</strong> phenotypic<br />
amelioration, and discuss the therapeutic implications for Duchenne Muscular Dystrophy.<br />
EDUCATION SESSION 111<br />
10:30 am - 12:00 pm<br />
Room: 608-609<br />
Emerging Field Review: HIV <strong>Gene</strong> <strong>Therapy</strong><br />
This session will discuss the biology <strong>of</strong> HIV-1, the practicalities <strong>of</strong> performing clinical trials in HIV patients and latest results from<br />
both T cell and stem cell based trials. Dr. Paula Cannon will introduce the session by describing key features <strong>of</strong> the HIV-1 lifecycle<br />
and cellular anti-viral defenses that are being exploited in gene therapy approaches and the use <strong>of</strong> humanized mouse<br />
models for pre-clinical evaluation. Dr. Carl June will describe T cell based gene therapies, including an update <strong>of</strong> ongoing T cell trials<br />
using zinc finger nucleases directed against CCR5. Dr. Dave DiGiusto will focus on some <strong>of</strong> the practical aspects <strong>of</strong> running a clinical<br />
trial, in particular the isolation and manipulation <strong>of</strong> hematopoietic stem cells from HIV-infected patients.<br />
CHAIR<br />
Paula M. Cannon, PhD<br />
SPEAKERS<br />
Paula M. Cannon, PhD<br />
Targets and Tools for anti-HIV <strong>Gene</strong> <strong>Therapy</strong><br />
This talk will provide an introduction to anti-HIV gene and cell therapies. Features <strong>of</strong> the HIV-1 life-cycle and cellular antiviral<br />
defenses that can be exploited by gene therapy will be highlighted, as well as progress in the use <strong>of</strong> humanized mouse<br />
models for pre-clinical evaluation. The application <strong>of</strong> zinc finger nucleases targeting the CCR5 co-receptor to engineer<br />
hematopoietic stem cells will be described.<br />
Carl H. June, MD<br />
T <strong>Cell</strong> Engineering for HIV - Update<br />
The development <strong>of</strong> HIV therapy has been a triumph in that a formerly universally fatal infection is now managed by a cocktail <strong>of</strong><br />
antiretroviral drugs that prevent progression the infection. The challenge to the field is that the current therapies are not curative,<br />
and that even with the best antiviral therapies, the present therapies are not curative since the reservoir <strong>of</strong> HIV infection is not<br />
reduced, and a significant morbidity from the infection and the treatment remain. New cell and gene therapy based approaches<br />
have the potential to address this shortfall, and should be focused on the development <strong>of</strong> transformative therapies that are<br />
potentially curative. The results from a pilot trial using CCR5 deficient T cells will be reviewed as an example <strong>of</strong> the new cell and<br />
gene therapies that are on the horizon.<br />
David L. DiGiusto, PhD<br />
<strong>Gene</strong> <strong>Therapy</strong> for HIV, Progress, Promise and Practicality<br />
Stem cell-based gene therapy for HIV has been under investigation for over 20 years and <strong>of</strong>fers great promise as a “functional<br />
cure” for AIDS. Among the many issues for this type <strong>of</strong> therapy are questions related to best therapeutic entity, gene delivery to<br />
stem cells, preparative regimen for transplant, persistence <strong>of</strong> cells in vivo and the potential for treatment related malignancies.<br />
This session will focus on the practical aspects <strong>of</strong> stem cell isolation, genetic modification and transplant and feature a review <strong>of</strong><br />
published data that outline the problems encountered and potential solutions. At the completion, participants will have a better<br />
understanding <strong>of</strong> the advantages and limitations <strong>of</strong> gene modified stem cell therapies and potential pathways forward in this<br />
intriguing field <strong>of</strong> investigation.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
EDUCATION SESSION 112<br />
10:30 am - 12:00 pm<br />
Room: 606-607<br />
Topical Review: <strong>Cell</strong>ular Based Therapies<br />
To date, stem cell therapies have focused on hematopoietic stem cells used in patients with malignancies or marrow failure,<br />
and requiring high dose conditioning regimens to prepare the recipient. The majority <strong>of</strong> these transplants were done using<br />
cells collected from related donors. In this session we will describe other indications for stem cell based therapies such as nonmalignant<br />
hematologic disorders, the use <strong>of</strong> nonmyeloablative regimens and the use <strong>of</strong> alternative, ie non-related donors. <strong>Final</strong>ly<br />
we will discuss the use <strong>of</strong> stem cell therapy in a non-hematologic setting.<br />
CHAIR<br />
Elizabeth Kang, MD<br />
SPEAKERS<br />
John F. Tisdale, MD<br />
Nonmyeloablative Transplantation for Non Malignant Hematologic Disorders<br />
HLA-matched allogeneic hematopoietic stem cell transplantation is an established curative approach to children with sickle cell<br />
disease. Disease burden in has historically prohibited this approach in adults due to anticipated excess toxicity. This talk will focus<br />
on new conditioning regimens that we have recently developed that allow safe and effective application in adult patients. The<br />
limitations <strong>of</strong> this and other approaches will be discussed, along with new areas <strong>of</strong> research, including the development <strong>of</strong> haploidentical<br />
transplantation strategies.<br />
Brenda M. Sandmaier, MD<br />
Nonmyeloablative Regimens for Alternative Donor Hematopoietic <strong>Cell</strong> Transplantation<br />
Allogeneic hematopoietic cell transplantation can be a curative approach for patients with both malignant and nonmalignant<br />
hematopoietic diseases including immunodeficiency disorders and hemoglobinopathies. By introducing nonmyeloablative<br />
or minimal-intensity conditioning regimens, significant progress has been made in reducing transplant-related mortality. The<br />
reduction in toxicity has allowed us to extend allogeneic hematopoietic cell transplantation to older patients and those with<br />
comorbidities. Of equal importance, donor choices have been expanded by developing less toxic regimens for unrelated donors,<br />
HLA-haploidentical related donors, and unrelated cord blood grafts. Lastly, improvements in prophylaxis <strong>of</strong> graft versus host disease<br />
have contributed to the improved outcomes using alternative donors.<br />
Lindsey A. Muir<br />
Considerations for the Clinical Application <strong>of</strong> Myogenic Stem <strong>Cell</strong>s in Muscular Dystrophy<br />
In the context <strong>of</strong> neuromuscular disorders such as Duchenne muscular dystrophy, many cell populations have been investigated<br />
for their potential to contribute to repair and regeneration <strong>of</strong> skeletal muscle. Some promising cell types will be discussed to<br />
illustrate important features that must be considered for eventual use in the clinic, including cell source, potency, engraftment<br />
efficiency, delivery, and evaluation <strong>of</strong> their contribution to muscle function following transplantation into animal models.<br />
EDUCATION SESSION 113<br />
10:30 am - 12:00 pm<br />
Room: 611-612<br />
Topical Review: <strong>Gene</strong> <strong>Therapy</strong> Strategies for Lysosomal Storage Diseases<br />
Lysosomal storage diseases (LSDs) are due to the primary genetic deficiency <strong>of</strong> a lysosomal enzyme, <strong>of</strong>ten causing accumulation<br />
<strong>of</strong> undegraded substrates within the lysosome that contributes to the disease phenotype. Viral-mediated gene therapy strategies<br />
have been developed for many <strong>of</strong> these diseases, several <strong>of</strong> which are currently in or close to the clinics. Common and specific<br />
aspects <strong>of</strong> these pathologies will be presented. Ex vivo and in vivo gene therapy approaches that are currently evaluated will be<br />
discussed. A special focus will be made on AAV and retroviral approaches. Results in animal models and clinical applications will be<br />
presented, particularly for mucopolysaccharidosis and metachromatic leukodystrophy.<br />
CHAIR<br />
Nathalie Cartier-Lacave, MD<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 35<br />
Wednesday, May 18
Wednesday, May 18<br />
36<br />
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
SPEAKERS<br />
Nathalie Cartier-Lacave, MD<br />
<strong>Gene</strong> <strong>Therapy</strong> Strategies for Lysosomal Storage Diseases : <strong>Gene</strong>ral Aspects and Application to Metachromatic<br />
Leukodystrophy<br />
Metachromatic leukodystrophy is a severe neurodegenerative disease <strong>of</strong> the central nervous system due to the deficiency or aryl<br />
sulfatase A enzyme that leads to the accumulation <strong>of</strong> sulfatide in neurons and glial cells. Ex vivo gene therapy clinical application<br />
based on autologous transplantation <strong>of</strong> hematopoietic stem cells corrected with a lentiviral vector is currently ongoing. In situ<br />
delivery <strong>of</strong> AAV-ARSA vector to the brain has also been evaluated in animal models. Clinical application in rapidly progressive forms<br />
<strong>of</strong> the disease should be soon initiated.<br />
Barry J. Byrne, MD, PhD<br />
Targeting the CNS in Pompe Disease: Count Every Breath You Take<br />
The approval <strong>of</strong> enzyme replacement therapy for the severe form <strong>of</strong> muscular dystrophy know as Pompe disease has lead to a new<br />
natural history for a condition which previously lead to uniform mortality in infancy. New findings in an animal model and patients<br />
on current therapy have revealed a major component <strong>of</strong> the weakness is due to lower motor neuron dysfunction. In an effort to<br />
treat respiratory failure associated with neural dysfunction in Pompe disease, we have initiated a Phase I/II clinical study <strong>of</strong> AAVmediated<br />
replacement <strong>of</strong> the defective gene in order to target both the diaphragm and phrenic nerve responsible for respiration.<br />
Katherine P. Ponder, MD<br />
<strong>Gene</strong> <strong>Therapy</strong> for Mucopolysaccharidosis<br />
EDUCATION SESSION 114<br />
10:30 am - 12:00 pm<br />
Room: 615-617<br />
Topical Review: Vector Design<br />
From the birth <strong>of</strong> gene therapy, research has been focused on the development <strong>of</strong> novel vector systems, and the optimization <strong>of</strong><br />
existing ones. A major impetus has been the improvement <strong>of</strong> the efficiency <strong>of</strong> delivery and gene expression, but more recently,<br />
vector design has been found to also impact safety and manufacturing aspects <strong>of</strong> a gene therapeutic. Here, an overview is<br />
provided on the advances over the past decades in design <strong>of</strong> a viral gene transfer vector from envelope and capsid, to expression<br />
cassette components and transgene modifications.<br />
CO-CHAIRS<br />
Dirk Grimm, PhD<br />
Luk H. Vandenberghe, PhD<br />
SPEAKERS<br />
Dirk Grimm, PhD<br />
AAV and Adeno Vector Design<br />
Over the past decade, gene transfer vehicles based on engineered Adenoviruses (Ad) and Adeno-associated viruses (AAV) have<br />
consistently emerged as therapeutic vectors <strong>of</strong> choice for a broad range <strong>of</strong> genetic and chronic diseases in humans. Most recently,<br />
their already vast potential as recombinant in vivo gene and cell therapeutics has been further bolstered by continued progress in<br />
designing even safer, more efficient, more specific and hence more clinically applicable novel vector generations. Most notable<br />
advances include ingenious new approaches to re-program Ad vector tropisms using arrays <strong>of</strong> genetic and physical strategies, to<br />
develop gutless vectors devoid <strong>of</strong> all viral genes, or to directly develop the genuine viruses as cytotoxic agents for oncolytic viral<br />
therapies. Likewise, the already immensely broad utility and relevance <strong>of</strong> AAV vectors has recently been further expanded via the<br />
generation and selection <strong>of</strong> batteries <strong>of</strong> moleculary evolved synthetic capsids, by the engineering <strong>of</strong> self-complementary genomes<br />
for potent and persistent long-term RNAi expression, as well as by the exploitation <strong>of</strong> endogenous microRNAs as means to control<br />
vector tropism and to segregate AAV transgene expression. The aim <strong>of</strong> this educational lecture is to provide a comprehensive<br />
up-to-date overview over these exciting latest conceptual and technical advances in the fields <strong>of</strong> Ad and AAV vectors, supported<br />
by selected examples for the use <strong>of</strong> these newest promising vector generations for cancer treatments, gene correction and<br />
replacement strategies, iPS cell generation or in vivo RNAi-based therapies.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
Adrian J. Thrasher, MD, PhD<br />
Designing Retroviral Vectors for Reliable <strong>Gene</strong> Expression<br />
David W. Emery, PhD<br />
Safe and Effective Transgene Cassette Design<br />
This education presentation will focus on three aspects <strong>of</strong> safe and effective transgene cassette design. The first will entail a broad<br />
overview <strong>of</strong> the basic elements <strong>of</strong> an effective expression cassette, including the basic rules for promoters, coding sequences,<br />
RNA processing signals, and translational processing signals. The second will briefly cover some recent advances toward assuring<br />
constitutive or tissue-specific expression, including the use <strong>of</strong> specific promoter/enhancer elements, targets for tissue-specific<br />
microRNAs, and barrier chromatin insulators. The third will briefly cover some recent advances toward reducing the genotoxic<br />
potential <strong>of</strong> transgene expression cassettes, including the use <strong>of</strong> cellular or tissue-specific promoters, vectors with alternative<br />
integration site preferences, and enhancer-blocking insulators. Although specific examples will involve the setting <strong>of</strong> retroviral<br />
vectors, the underlying themes can be applied broadly to most gene transfer applications.<br />
LUNCH BREAK (ON OWN)<br />
12:00 pm - 1:15 pm<br />
EDUCATION SESSION 120<br />
1:15 pm - 2:45 pm<br />
Room: 6A<br />
Emerging Field Review: <strong>Cell</strong> Based Therapies Using ES/iPS <strong>Cell</strong>s<br />
One <strong>of</strong> the most exciting advances in the recent years has been the discovery that somatic cells can be converted to<br />
pluripotent cells (called iPS cells) by the expression <strong>of</strong> a small number <strong>of</strong> defined transcription factors. The ability to generate<br />
iPS cells from somatic cells means that the ethical issues <strong>of</strong> deriving human embryonic stem cells from blastocysts has been<br />
circumscribed. There are important challenges, however, in translating the use <strong>of</strong> iPS cells to the clinic and in this session, the<br />
speakers will focus on several <strong>of</strong> these issues.<br />
CHAIR<br />
Matthew H. Porteus, MD, PhD<br />
SPEAKERS<br />
James Ellis, PhD<br />
Basic Issues in Creating iPS <strong>Cell</strong>s<br />
The ability to reprogram somatic cells into induced pluripotent stem (iPS) cells has tremendous potential for developing novel<br />
cell based therapies. However, there are several basic issues that must be carefully addressed to generate and use clinical grade<br />
patient-specific iPS cells. Prior to reprogramming it is essential to obtain appropriate consent and decide on the best cell type<br />
to acquire from the patient. Ideally, the primary cells should be isolated and reprogrammed in xenogenic factor-free conditions<br />
using one <strong>of</strong> several methods that may be compatible with clinical use. Once iPS cell lines are expanded, their pluripotency status<br />
and differentiation capacity needs to be rigourously evaluated using well defined criteria, and concerns about their safety posttransplantation<br />
and the ability to track their progeny cells in vivo addressed.<br />
Charles E. Murry, MD, PhD<br />
ES/iPS <strong>Cell</strong>s for Cardiac Repair<br />
Human embryonic stem cells and induced pluripotent stem cells (hESCs and hiPSCs) can be directed to differentiate into<br />
mesodermal cardiovascular progenitors and definitive cardiomyocytes using members <strong>of</strong> the TGF-b family (activin A and BMP4)<br />
and Wnt family. We have learned how to keep the cells alive after transplantation into infarcted hearts and shown that they form<br />
human myocardium that prevents the development <strong>of</strong> heart failure. Tissue engineering studies demonstrate that including<br />
stromal and vascular cells markedly enhances survival <strong>of</strong> myocardial tissue grafts. Endothelial and stromal cells self-assemble<br />
into networks, which form definitive blood vessels with connections to the host after transplantation. Current efforts are focused<br />
on electrical integration <strong>of</strong> human cardiac grafts, using genetically encoded calcium indicators to assess synchrony <strong>of</strong> beating<br />
between graft and host myocardium.<br />
Michel Sadelain, MD, PhD<br />
<strong>Gene</strong>ration and <strong>Gene</strong>tic Modification <strong>of</strong> Human iPS <strong>Cell</strong>s<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 37<br />
Wednesday, May 18
Wednesday, May 18<br />
38<br />
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
EDUCATION SESSION 121<br />
1:15 pm - 2:45 pm<br />
Room: 615-617<br />
Emerging Field Review: Progress in <strong>Gene</strong> <strong>Therapy</strong> for Pain<br />
Chronic pain represents a major cause <strong>of</strong> morbidity, significantly impairing individual quality <strong>of</strong> life and imposing a substantial<br />
burden on society. Numerous drugs such as NSAIDs and opioids have been approved for the treatment <strong>of</strong> chronic pain, yet<br />
they show limited efficacy either due to a lack <strong>of</strong> response to the drug regimen, or in most cases the patients develop tolerance<br />
to the drug, requiring ever increasing doses. The need for alternative therapies to treat chronic inflammatory and neuropathic<br />
painhas led to the development <strong>of</strong> gene therapy approaches using various viral (HSV, AAV, AdV, LV) and non-viral delivery systems.<br />
Vectors expressing inhibitory neurotransmitters (enkephalin, GAD65/67, ß-endorphin, endomorphin-2) or genes that modify<br />
neurotransmitters involved in nociception (glutamate transporter, µ-opiod receptor), trophic factors (NGF, BDNF, GDNF, HGF, VEGF),<br />
channels (Nav1.7, GlyR, Kir2.1) or a series <strong>of</strong> anti-inflammatory molecules (IL-4, IL-10, IL-2, TNFαsR) have been employed in a variety<br />
<strong>of</strong> animal models <strong>of</strong> persistent pain with remarkable success. Recently, two FDA-approved Phase-I trials for treating chronic pain<br />
ensued. The presenters in this session will cover the use <strong>of</strong> different vector systems and therapeutic gene products for treating<br />
chronic inflammatory and neuropathic pain in both animal models and finally in human Phase-I trials.<br />
CHAIR<br />
William F. Goins, PhD<br />
SPEAKERS<br />
Darren Wolfe, PhD<br />
NP2 <strong>Therapy</strong> for Severe Pain<br />
HSV vectors have proved effective at treating a large number <strong>of</strong> nervous system disorders in preclinical models. Target diseases<br />
include pain, neuropathy, cancer, and central nervous system diseases such as Parkinsons. Diamyd Inc has developed replication<br />
defective HSV vectors for clinical use and have recently completed our first clinical trial with intractable pain as an indication.<br />
Results <strong>of</strong> the study will be presented that demonstrate the safety <strong>of</strong> the platform as well as substantial and sustained pain relief in<br />
subjects with terminal cancer pain.<br />
Michel Pohl, PhD<br />
Lentiviral Vectors for Targeted Therapeutic Intervention into the Spinal Cord Glial <strong>Cell</strong>s<br />
Clinical management <strong>of</strong> pathological pain, that frequently develops after alteration <strong>of</strong> peripheral nerves, remains challenging.<br />
We know today that neuropathic pain is associated with important changes <strong>of</strong> systems involved in pain processing, especially in<br />
the spinal cord where central afferents <strong>of</strong> sensory nerves project. Here, immune cell infiltration, glial activation and nerve tissue<br />
plasticity participate in induction <strong>of</strong> pain and its maintenance. This focal neuro-inflammatory context is associated with differential<br />
expression <strong>of</strong> many genes, production and release <strong>of</strong> signaling molecules and activation <strong>of</strong> various intracellular signaling pathways.<br />
The idea <strong>of</strong> local and possibly cell type specific intervention to modulate these systems and even to restore their physiologic<br />
function is tempting as a therapeutic option. This presentation will describe lentiviral-derived vectors as one <strong>of</strong> the promising tools<br />
for spinal cord local and cell targeted delivery <strong>of</strong> therapeutic molecules.<br />
Steven P. Wilson, PhD<br />
Controlling Pain by Herpesvirus-mediated Manipulation <strong>of</strong> <strong>Gene</strong> Expression in Primary Afferents<br />
A number <strong>of</strong> laboratories have exploited the natural tendency <strong>of</strong> herpes simplex virus to stably transduce sensory neurons, with<br />
the goal <strong>of</strong> changing the phenotypes <strong>of</strong> primary afferent, nociceptive neurons. The most commonly employed strategy is to use<br />
recombinant viruses designed to over-express antinociceptive peptides, such as enkephalins, in these neurons. Another strategy is<br />
to knock down expression <strong>of</strong> pronociceptive peptides using RNA interference methods. Additional strategies include manipulating<br />
the expression <strong>of</strong> receptors, ion channels or intracellular signaling molecules to modulate the activities <strong>of</strong> the primary afferents.<br />
The ultimate goal <strong>of</strong> these approaches is to develop therapies that will modulate pain.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
EDUCATION SESSION 122<br />
1:15 pm - 2:45 pm<br />
Room: 606-607<br />
Topical Review: Cancer Adoptive Immunotherapy with <strong>Gene</strong>tically Modified Lymphocytes<br />
CHAIR<br />
Philip Greenberg, MD<br />
SPEAKERS<br />
Philip Greenberg, MD<br />
<strong>Gene</strong>tically Modifying T cells to Target Tumors: It Starts with the TCR<br />
The use <strong>of</strong> strategies to characterize differential expression <strong>of</strong> proteins in tumors compared to normal cells has provided candidate<br />
antigens for targeting, and the development <strong>of</strong> methods to isolate and expand T cells recognizing such antigens has provided<br />
means to generate potential therapeutic reagents. However, most <strong>of</strong> these antigens represent normal self-proteins that are overexpressed<br />
by the tumor but still found in normal tissues, and thus most high avidity T cells have either been deleted or anergized.<br />
Strategies to isolate naturally occurring high affinity TCRs, including by rescue <strong>of</strong> tolerant T cells, or to mutate TCRs to improve<br />
affinity, and then express these TCRs in patient T cells to reproducibly provide a T cell reagent that can more effectively target<br />
human malignant cells will be discussed. Such T cells expressing introduced high affinity TCRs have the potential to mediate<br />
toxicity to normal tissues after transfer, and approaches to improve and screen for safety will also be discussed.<br />
Renier J. Brentjens, MD, PhD<br />
Adoptive <strong>Therapy</strong> <strong>of</strong> Cancer with T cells <strong>Gene</strong>tically Targeted to Tumor Associated Antigens through the Introduction <strong>of</strong><br />
Chimeric Antigen Receptors (CARs): Trafficking, Persistence, and Perseverance<br />
A patient’s own T cells may be genetically modified to target tumor associated antigens (TAAs) through the introduction <strong>of</strong> genes<br />
encoding artificial T cell receptors termed chimeric antigen receptors. CAR modified T cells subsequently recognize tumor cells<br />
which express the targeted TAA in a non-HLA dependent manner. Promising pre-clinical studies using this approach has recently<br />
prompted the initiation <strong>of</strong> a series <strong>of</strong> early phase clinical trials at multiple centers using this technology and targeting a number<br />
<strong>of</strong> TAAs expressed on a wide variety <strong>of</strong> malignancies. Early reports from these clinical trials give hope for efficacy <strong>of</strong> this approach<br />
in the future, and provide insight into the optimal application <strong>of</strong> this therapy in second generation clinical trials. Specifically, CAR<br />
design, the tumor microenvironment, prior lymphodepletion, and in vivo modified T cell persistence will be discussed.<br />
Mirjam H.M. Heemskerk, PhD<br />
TCR <strong>Gene</strong> <strong>Therapy</strong> for Cancer<br />
TCR gene transfer is an attractive strategy to equip T-cells with defined antigen-specific TCRs using short-term in vitro procedures.<br />
Introduction <strong>of</strong> a well characterized high affinity TCR may result in an <strong>of</strong>f-the shelf therapy with potent anti-tumor reactivity.<br />
However, some potential drawbacks to TCR gene transfer exist. TCR transfer leads to lower expression <strong>of</strong> the introduced TCR<br />
compared to parental T-cell clone due to competition for cell surface expression with the endogenous TCR and mixed TCR dimers.<br />
High affinity TCR are necessary to overcome this problem. High affinity TCRs directed against minor histocompatibility antigens<br />
and virus antigens are available, however identification <strong>of</strong> high affinity TCRs specific for tumor associated self-antigens is a critical<br />
bottleneck in this strategy. In addition, TCR transfer may lead to the formation <strong>of</strong> mixed TCR dimers, composed <strong>of</strong> introduced TCR<br />
chains pairing with the endogenous TCRα or ß chain, harbouring potentially harmful new reactivities. In this presentation the<br />
benefits and threats <strong>of</strong> TCR gene transfer and possible solutions will be presented.<br />
EDUCATION SESSION 123<br />
1:15 pm - 2:45 pm<br />
Room: 611-612<br />
Topical Review: Lessons from Large Animal Models in <strong>Gene</strong> <strong>Therapy</strong><br />
The topical review session, entitled “Lessons From Large Animal Models in <strong>Gene</strong> <strong>Therapy</strong>,” will focus on the development and<br />
utilization <strong>of</strong> large-animal models in preclinical trials using lenti-, adeno- and AAV- based vectors for gene-therapy applications. The<br />
session will concentrate on the advantages and limitations <strong>of</strong> various large animal models as a means <strong>of</strong> studying the efficacy and<br />
safety <strong>of</strong> viral vectors in clinical trials. The session will comprise three talks:<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 39<br />
Wednesday, May 18
Wednesday, May 18<br />
40<br />
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
CO-CHAIRS<br />
Tal Kafri, MD, PhD<br />
Hans-Peter Kiem, MD<br />
SPEAKERS<br />
Hans-Peter Kiem, MD<br />
Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> in Large Animal Models<br />
Philip Ng, PhD<br />
Adenoviral Vectors in Non-Human Primates<br />
Nonhuman primates have been used extensively to evaluate adenoviral vectors for gene therapy. This education session will<br />
discuss why nonhuman primates are used, important lessons that have been learned as well as some associated pitfalls. Practical<br />
information for those contemplating research using nonhuman primates will also be discussed.<br />
James M. Wilson, MD, PhD<br />
The Challenge <strong>of</strong> Developing Animal Models <strong>of</strong> Human <strong>Gene</strong> <strong>Therapy</strong> with AAV<br />
Translation <strong>of</strong> gene therapy into the clinic relys on preclinical data, at least until there is a robust clinical experience with the<br />
platform vector technologies. Our experience is that vector efficacy in humans is well modeled in animals although host vector<br />
interactions are not.<br />
EDUCATION SESSION 124<br />
1:15 pm - 2:45 pm<br />
Room: 608-609<br />
Topical Review: Regulatory RNAs<br />
In this session we will hear from three renowned scientists about the latest insights emerging from studies <strong>of</strong> RNA biology and the<br />
newest technologies being developed to exploit these findings for gene and cell therapy. Dr. Anton McCaffrey will describe recent<br />
discoveries in RNA interference which are enabling better and safer applications <strong>of</strong> RNAi in the lab and in the clinic. Dr. Stephen<br />
Russell will detail the complex biology <strong>of</strong> microRNAs, and how this level <strong>of</strong> regulation can be used to control the tropism <strong>of</strong> viruses<br />
and vectors. <strong>Final</strong>ly, Dr. Gabriele Varani will speak about some <strong>of</strong> the major new structural insights being uncovered about RNA<br />
binding proteins, and how these findings are helping to expand our global understanding <strong>of</strong> RNA regulation.<br />
CHAIR<br />
Brian D. Brown, PhD<br />
SPEAKERS<br />
Stephen J. Russell, MD, PhD<br />
Micro RNA Targeting <strong>of</strong> Oncolytic Viruses<br />
Anton P. McCaffrey, PhD<br />
RNA Interference Basics<br />
The purpose <strong>of</strong> this presentation is to provide a tutorial on RNA interference (RNAi). This will include background on the RNAi<br />
pathway as well as a discussion <strong>of</strong> opportunities for use <strong>of</strong> RNAi as a research tool and a therapeutic. Non-viral and viral approaches<br />
for delivery <strong>of</strong> RNAi will be covered. Limitations <strong>of</strong> RNAi and possible solutions will also be discussed.<br />
Gabriele Varani, PhD<br />
RNA-binding Proteins in Normal and Aberrant RNA Biogenesis<br />
The biogenesis <strong>of</strong> all cellular RNAs (mRNA, non-coding RNA, microRNA and stable nuclear species), rely on their association with<br />
RNA-binding proteins to control and regulate every maturation step. Because <strong>of</strong> their widespread role in gene expression, many<br />
human diseases are associated with mutation or aberrant expression in RNA-binding proteins. These proteins have modular<br />
structures, being composed <strong>of</strong> multiple repeats <strong>of</strong> just a few very frequent domains that are arranged in a variety <strong>of</strong> ways to satisfy<br />
their diverse functional requirements. The modules cooperate in regulating RNA binding and biological activity, and are <strong>of</strong>ten<br />
paired with enzymatic domains to regulate the catalytic activity <strong>of</strong> enzymes acting upon RNA. In this presentation, I will review the<br />
current knowledge <strong>of</strong> the structure function <strong>of</strong> these proteins and its relationship to normal and aberrant RNA biogenesis.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
ORAL ABSTRACT SESSION 130<br />
3:15 pm - 5:15 pm<br />
Room: 606-607<br />
Adenovirus and Other DNA Virus Vectors I: Virus Entry<br />
CO-CHAIRS<br />
Joseph C. Glorioso, III, PhD<br />
Matthew D. Weitzman, PhD<br />
(Abstracts 1-8; see page 87)<br />
ORAL ABSTRACT SESSION 131<br />
3:15 pm - 5:15 pm<br />
Room: 6A<br />
DNA Vectorology<br />
CHAIR<br />
Matthew H. Wilson, MD, PhD<br />
(Abstracts 9-16; see page 87)<br />
ORAL ABSTRACT SESSION 132<br />
3:15 pm - 5:15 pm<br />
Room: 615-617<br />
Infectious Diseases and Vaccines<br />
CO-CHAIRS<br />
Stephen M. Kaminsky, PhD<br />
J. Fraser Wright, PhD<br />
(Abstracts 17-24; see page 88)<br />
ORAL ABSTRACT SESSION 133<br />
3:15 pm - 5:15 pm<br />
Room: 611-612<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
CO-CHAIRS<br />
Renier J. Brentjens, MD, PhD<br />
Christine Brown, PhD<br />
(Abstracts 25-32; see pages 88-89)<br />
ORAL ABSTRACT SESSION 134<br />
3:15 pm - 5:15 pm<br />
Room: 618-620<br />
Novel Approaches for <strong>Gene</strong> Regulation & Genome Modification<br />
CO-CHAIRS<br />
Donna Armentano, PhD<br />
Bruce E. Torbett, PhD, MSPH<br />
(Abstracts 33-40; see page 89)<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 41<br />
Wednesday, May 18
Wednesday, May 18<br />
42<br />
<strong>Program</strong> Schedule Wednesday, May 18, 2011<br />
ORAL ABSTRACT SESSION 135<br />
3:15 pm - 5:15 pm<br />
Room: 608-609<br />
<strong>Gene</strong>tic and Metabolic Diseases <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
CO-CHAIRS<br />
Valder Arruda, MD, PhD<br />
Christopher Doering, PhD<br />
(Abstracts 41-48; see pages 89-90)<br />
ORAL ABSTRACT SESSION 136<br />
3:15 pm - 5:15 pm<br />
Room: 602-604<br />
Late Abstract Session<br />
CO-CHAIRS<br />
John J. Rossi, PhD<br />
Sean M. Sullivan, PhD<br />
(Abstracts 867-874; see page 90)<br />
Exhibit Hall Open & Welcome Reception<br />
5:15 pm - 7:15 pm<br />
Room: Hall 4B<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
PRESIDENTIAL SYMPOSIUM 200<br />
8:00 am - 10:15 am<br />
Room: 6BC<br />
Presidential Symposium<br />
CHAIR<br />
Barrie J. Carter, PhD<br />
SPEAKERS<br />
Barrie J. Carter, PhD<br />
Presidential Address<br />
George Q. Daley, MD, PhD<br />
Towards Combined <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> with Pluripotent Stem <strong>Cell</strong>s<br />
A major goal <strong>of</strong> stem cell research is the creation <strong>of</strong> customized stem cells for use in disease modeling and as a foundation for<br />
autologous cell therapy. Understanding the principles <strong>of</strong> stem cell derivation, and defining whether embryonic stem (ES) cells<br />
and induced pluripotent stem (iPS) are equivalent remains a pressing issue. We have derived human and mouse ES cells and iPS<br />
cells from various human and mouse tissues, and compared their differentiation capacity and epigenome to determine whether<br />
iPS cells are functional and molecular equivalents <strong>of</strong> ES cells, and whether iPS cells retain an “epigenetic memory” <strong>of</strong> their tissue <strong>of</strong><br />
origin. Aspects <strong>of</strong> iPS cell derivation from normal and diseased tissues will be discussed, as will data comparing ES and iPS cells.<br />
Presentation <strong>of</strong> Top Abstracts<br />
Michael C. Holmes, PhD<br />
Abstract 49: In Vivo Delivery <strong>of</strong> Zinc Finger Nucleases Mediates Genome Editing to Correct <strong>Gene</strong>tic Diseases<br />
David H. Kirn, MD<br />
Abstract 50: Demonstration <strong>of</strong> Safety and Antitumoral Activity <strong>of</strong> JX-594, a Targeted Multi-Mechanistic Oncolytic<br />
Poxvirus, Following Intravenous Infusion and/or Intratumoral Injections in Patients with Refractory Metastatic Cancers<br />
Serge Herson, MD<br />
Abstract 51: A Phase I Dose-Escalating Study <strong>of</strong> AAV1 - γ-Sarcoglycan <strong>Gene</strong> <strong>Therapy</strong> for Limb Girdle Muscular Dystrophy<br />
Type 2C<br />
Xiao Xiao, PhD<br />
Abstract 52: Efficient Long-Term Bodywide Expression <strong>of</strong> an AAV9-Minidystrophin in the Muscle and Heart <strong>of</strong> Young Adult<br />
GRMD Dogs after Intravascular Injection without Immune Suppression<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 43<br />
Thursday, May 19
Thursday, May 19<br />
44<br />
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
EXHIBIT HALL COFFEE SOCIAL<br />
10:15 am - 11:00 am<br />
Room: Hall 4B<br />
SCIENTIFIC SYMPOSIUM 210<br />
11:00 am - 1:00 pm<br />
Room: 6A<br />
Clinical Studies with Oligonucleotides<br />
CHAIR<br />
C. Frank Bennett, PhD<br />
SPEAKERS<br />
Ryszard Kole, PhD<br />
Progress in Exon Skipping <strong>Therapy</strong> for Duchenne Muscular Dystrophy<br />
Oligonucleotide-induced exon skipping in human dystrophin pre-mRNA is being tested in animal models and in a clinical trial<br />
involving patients with Duchenne muscular dystrophy. Systemic delivery <strong>of</strong> AVI-4658, a phosphorodiamidate morpholino oligomer,<br />
shows that this compound induced skipping in dystrophin pre-mRNA in muscles <strong>of</strong> the affected individuals. As a result, the<br />
translation reading frame <strong>of</strong> the defective mRNA is repaired and dystrophin production is restored. Although patient response was<br />
variable, dystrophin levels reached up to 50% <strong>of</strong> normal level <strong>of</strong> this protein.<br />
Richard C. Becker, MD<br />
Current State <strong>of</strong> RNA Oligonucleotides as Regulatable Anticoagulants<br />
The management <strong>of</strong> patients with acute thrombotic disorders has been hampered by anticoagulants with a narrow therapeutic<br />
window for safety and efficacy. We have developed a factor IX/IXa aptamer and complementary reversal oligonucleotide, with a<br />
goal <strong>of</strong> filling an unmet need in clinical practice. Phase 1, 2a and 2b studies have been completed and will be presented at the<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong>’s 14th Annual meeting.<br />
James D. Thompson, PhD<br />
Clinical Development <strong>of</strong> Synthetic siRNAs<br />
Quark Pharmaceuticals currently has three synthetic siRNAs in clinical development that include PF-655 licensed by Pfizer that is<br />
being evaluated in Phase 2 studies for two ocular indications, QPI-1002 that Novartis has taken an option to license that is being<br />
evaluated in Phase 2 studies for renal diseases, and QPI-1007 in Phase I/II studies that is being developed as a neuroprotective<br />
agent for eye diseases. Quark is also collaborating with Nitto Denko to develop siRNA therapies to treat fibrosis. Quark has<br />
developed proprietary chemical compositions that abrogate <strong>of</strong>f-target and immunostimulatory activity while preserving RNAi<br />
activity. Nonclinical and clinical data from these various programs will be presented.<br />
Kim N. Chi, MD<br />
OGX-011: An Antisense Therapeutic Against Cluster in Clinical Development for Cancer<br />
Clusterin is an ATP-independent chaperone that promotes cancer cell survival through NF-kB and AKT signaling, inhibition<br />
<strong>of</strong> apoptosis through activated Bax and prevents stress-induced protein aggregation. OGX-011 is a second generation<br />
phosphorothioate antisense oligonucleotide with 2’-meothxyethyl modifications that potently inhibits clusterin expression in<br />
vitro, in vivo, and in humans. Phase 2 trials with OGX-011-chemotherapy combinations have been performed in patients with<br />
breast, lung and castration resistant prostate cancer (CRPC). In a randomized phase 2 study in patients with CRPC, the median<br />
overall survival for patients treated with docetaxel+OGX-011 was 23.8 vs. 16.9 months for those patients receiving docetaxel alone<br />
(HR=0.50; 95%CI: 0.29-0.87). Phase 3 studies with OGX-011 are now ongoing.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
SCIENTIFIC SYMPOSIUM 211<br />
11:00 am - 1:00 pm<br />
Room: 611-612<br />
Earlier Stage Industry Clinical Trials<br />
CHAIR<br />
William F. Kaemmerer, PhD<br />
SPEAKERS<br />
Douglas J. Jolly, PhD<br />
Alain Rolland, PharmD, PhD<br />
TransVax, a Therapeutic DNA Vaccine for Control <strong>of</strong> Cytomegalovirus in Hematopoietic <strong>Cell</strong> Transplant Recipients:<br />
Results <strong>of</strong> a Phase 2 Clinical Trial<br />
CMV reactivation occurs in 60-70% <strong>of</strong> CMV-seropositive hematopoietic cell transplant (HCT) cancer patients (with leukemia and<br />
lymphoma) within 6 months <strong>of</strong> transplant. Preemptive antiviral therapy limits CMV disease, but is accompanied by the risk <strong>of</strong> drug<br />
toxicity. Control <strong>of</strong> viremia is dependent on CMV-specific T cells and a vaccine that increases cellular immune responses could<br />
decrease CMV reactivation, reducing the need for antiviral drugs and risk <strong>of</strong> CMV disease. In a double-blind, placebo-controlled,<br />
exploratory Phase 2 trial, CMV-seropositive recipients <strong>of</strong> allogeneic HCT were administered TransVax, a CMV therapeutic DNA<br />
vaccine containing plasmids encoding CMV glycoprotein B (gB) and phosphoprotein 65 (pp65) formulated with poloxamer<br />
CRL1005 (n=42) or placebo (n=38) just before conditioning and at 1, 3, and 6 months after transplant. TransVax appeared to be<br />
safe and immunogenic, resulting in protection <strong>of</strong> HCT recipients from recurrent CMV viremia. This is the first successful pro<strong>of</strong>-<strong>of</strong>concept<br />
trial <strong>of</strong> a CMV vaccine in HCT and the results support further development.<br />
Ronald G. Crystal, MD<br />
Vaccines for Addictive Drugs<br />
Cocaine addiction is a major international problem for which there are no therapies. By taking advantage <strong>of</strong> the immunogenic<br />
properties <strong>of</strong> adenovirus gene transfer vectors and linking a cocaine analog to the capsid proteins, we have developed an anticocaine<br />
vaccine that prevents cocaine from reaching its receptors in the CNS. In a parallel strategy, we have modified adenoassociated<br />
virus vectors to genetically deliver an anti-cocaine monoclonal that also protects the brain from administered cocaine.<br />
Michael Kaplitt, MD, PhD<br />
AAV-GAD <strong>Gene</strong> <strong>Therapy</strong> for Parkinson’s Disease: Phase 2 Trial Results and Lessons Learned<br />
SCIENTIFIC SYMPOSIUM 212<br />
11:00 am - 1:00 pm<br />
Room: 608-609<br />
Emerging Conditioning and Hematopoietic Stem <strong>Cell</strong> Engraftment Strategies<br />
CHAIR<br />
Hans-Peter Kiem, MD<br />
SPEAKERS<br />
Hans-Peter Kiem, MD<br />
In Vivo Selection <strong>of</strong> Hematopoietic Stem <strong>Cell</strong>s<br />
Louis M. Pelus, PhD<br />
Prostaglandines Enhance HSC Function: Strategies to Improve Transduced HSC Engraftment<br />
Prostaglandins and other members <strong>of</strong> the eicosanoid family play physiological roles in regulating hematopoietic stem and<br />
progenitor cell function. We have recently shown that prostaglandin E2 (PGE2) up regulates transcription and expression <strong>of</strong><br />
the CXCR4 receptor on hematopoietic stem cells (HSC), as well as increasing expression <strong>of</strong> the endogenous caspase-3 inhibitor<br />
Survivin. PGE2 can also initiate self-renewal <strong>of</strong> HSC. Ex vivo treatment <strong>of</strong> mouse HSC, umbilical cord blood CD34+ cells as well as<br />
G-CSF mobilized peripheral blood CD34+ cells with PGE2 enhances migration in transwell cultures and engraftment <strong>of</strong> mouse<br />
HSC in congenic transplantation models and human CD34+ cells in immunodeficient mice. Blockade <strong>of</strong> prostaglandin signaling<br />
within the hematopoietic niche using non-steroidal anti-inflammatory drugs (NSAIDs) facilitates release <strong>of</strong> HSC and synergistic<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 45<br />
Thursday, May 19
Thursday, May 19<br />
46<br />
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
mobilization in combination with G-CSF. Application <strong>of</strong> these strategies <strong>of</strong>fers the means to acquire more HSC for transduction<br />
protocols and to enhance function/engraftment <strong>of</strong> gene-transduced hematopoietic HSC.<br />
Alexander Kalinkovich, PhD<br />
Regulation <strong>of</strong> Progenitor <strong>Cell</strong> Mobilization, Homing and Repopulation via SDF-1/CXCR4 Interactions<br />
Success in clinical transplantation <strong>of</strong> hematopoietic stem/progenitor cells (HSPCs) depends on their efficient mobilization, homing<br />
and engraftment in the recipient’s bone marrow. The chemokine SDF-1 (CXCL12) and its major receptor CXCR4 together with<br />
adhesion molecules and proteolytic enzymes are key elements in HSPC quiescence, retention and trafficking. Disruption <strong>of</strong> HSPC<br />
retention by CXCR4 antagonists such as AMD3100 (Plerixafor) induces rapid HSPC mobilization, mediated by SDF-1 secretion to<br />
the circulation from bone marrow stromal cells and uPA activation. Clinical HSPC transplantation protocols require the recipient’s<br />
preconditioning with DNA damaging agents, which cause a dramatic and transient elevation in SDF-1 levels in the bone marrow,<br />
followed by SDF-1 cleavage and degradation by a wide range <strong>of</strong> proteolytic enzymes, thus providing appropriate conditions for<br />
efficient, time dependent homing and engraftment <strong>of</strong> transplanted CXCR4 expressing HSPCs. Recently discovered mechanisms <strong>of</strong><br />
HSPC mobilization, homing and engraftment (repopulation) mediated by the dynamic SDF-1/CXCR4 interactions will be discussed.<br />
John M. Pagel, MD, PhD<br />
Radioimmunotherapy for Leukemias<br />
Recent developments in pretargeting and engineered and low-molecular weight agents in radionuclide therapy will be reviewed.<br />
SCIENTIFIC SYMPOSIUM 213<br />
11:00 am - 1:00 pm<br />
Room: 615-617<br />
Musculoskeletal Repair Mechanisms and Immune Obstacles<br />
CHAIR<br />
Jerry R. Mendell, MD<br />
SPEAKERS<br />
Christopher M. Walker, PhD<br />
<strong>Gene</strong> Delivery to the Muscle in Health and Disease<br />
The muscle is an important target for transgene delivery using recombinant adeno-associated virus (rAAV) vectors. T cell mediated<br />
immunity against encoded transgene products is a poorly understood but potentially important variable in the outcome <strong>of</strong> therapy.<br />
This presentation will review the nature <strong>of</strong> T cell responses elicited by rAAV-mediated gene delivery to muscle. Topics to be highlighted<br />
include (i) the function and differentiation <strong>of</strong> T cells primed by transgene products and (ii) the risk <strong>of</strong> developing a response when the<br />
therapeutic and defective host genes differ by a little (for example, a misssense mutation) or a lot (large frame-shifting mutations). A<br />
final point <strong>of</strong> discussion is whether T cell priming and effector function is equivalent when transgenes are delivered to healthy muscles<br />
versus those that are chronically inflamed in neuromuscular diseases like Duchenne Muscular Dystrophy.<br />
Annemieke Aartsma-Rus, PhD<br />
Learning from Exon Skipping Trials for Duchenne Muscular Dystrophy<br />
Antisense-mediated exon skipping is a promising therapeutic approach for Duchenne muscular dystrophy (DMD). It uses antisense<br />
oligonucleotides (AONs) to modulate pre-mRNA splicing so that a specific exon is skipped and the disrupted dystrophin reading<br />
frame restored allowing the production <strong>of</strong> internally deleted, partially functional dystrophins and potentially the conversion <strong>of</strong> a<br />
severe Duchenne into a milder Becker phenotype. This approach is currently in early phase clinical trials for two AON chemistries<br />
and targeting two different exons. While early results are encouraging, larger and longer trials are necessary to demonstrate clinical<br />
efficacy that AON treatment results in slowing disease progression and improving or maintaining muscle function in the absence<br />
<strong>of</strong> adverse effects. Furthermore, since exon skipping is a mutation specific approach, drugs to induce skipping <strong>of</strong> additional exons<br />
need to be developed as well to allow benefit <strong>of</strong> a large group <strong>of</strong> patients.<br />
Johnny Huard, PhD<br />
The Use <strong>of</strong> Muscle Stem <strong>Cell</strong>s for Musculoskeletal Repair<br />
I will discuss the use <strong>of</strong> muscle derived progenitor cells in gene therapy and tissue engineering applications designed to improve<br />
bone and articular cartilage healing through the genetic modification <strong>of</strong> MDSCs to express osteogenic proteins (BMP2 and -4) and<br />
the angiogenic factor VEGF. I will discuss potential features <strong>of</strong> these muscle progenitor cells including their potential relationship<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
with other stem cell populations as well as behavior (resistance to stress) that may be useful to facilitate their isolation. I will<br />
describe mechanisms <strong>of</strong> action by which the cells induce tissue repair including the trans-differentiation <strong>of</strong> the cells as well as the<br />
chemo-attraction <strong>of</strong> the host cells during the repair process. I will also outline in my presentation new results obtained with human<br />
muscle derived stem cells, which we believe will open new avenues by which researchers could use muscle stem cell-based gene<br />
therapy and tissue engineering to improve bone repair and regeneration.<br />
Jay R. Lieberman, MD<br />
Novel Strategies to Enhance Bone Repair: Lessons Learned<br />
Regional gene therapy has been developed to enhance bone repair using a variety <strong>of</strong> different vectors in pre-clinical models.<br />
The data from these experiments have shed light on the influence <strong>of</strong> the duration and the amount protein expression on the<br />
enhancement <strong>of</strong> bone repair. Although the use <strong>of</strong> gene therapy to promote bone repair has clinical potential issues related to<br />
safety and cost effective strategies need further development. These issues will be reviewed during this seminar.<br />
SCIENTIFIC SYMPOSIUM 214<br />
11:00 am - 1:00 pm<br />
Room: 602-604<br />
Potential Use and Abuse <strong>of</strong> <strong>Gene</strong>tic Testing in Personalized Medicine: Is it Premature?<br />
CHAIR<br />
Nelson Wivel, MD<br />
SPEAKERS<br />
Henry T. Greely, JD<br />
Open Questions in <strong>Gene</strong>tically Personalized Medicine<br />
The use <strong>of</strong> genetic test results to personalize medicine has been a hot discussion topic for more than a decade. As their actual use<br />
now begins to become common, important questions remain unanswered. The questions are becoming even more challenging<br />
as genetic testing moves from single gene tests, to array-based comprehensive genomic hybridization, SNP chips, and ultimately<br />
full genome sequencing. This presentation will deal with several <strong>of</strong> those issues, including confidentiality, research uses, and<br />
informed consent.<br />
Eric Juengst, PhD<br />
Personalized Genomic Medicine: Ethical Conundrums<br />
“Personalized genomic medicine” (PGM) is being promoted as a “new paradigm for health care” and a major goal for translational<br />
genomic research. In addition to overcoming remaining scientific hurdles, achieving that goal will involve addressing a number<br />
<strong>of</strong> ethical, legal and social challenges. Some <strong>of</strong> those challenges reflect the ways that different social policies and health care<br />
economies will complicate our ability to realize PGM as a viable health care paradigm. But other challenges might emerge<br />
from the goal itself, depending on how PGM is interpreted by those who shape it as a social practice. PGM is a goal that unites<br />
a wide array <strong>of</strong> biomedical initiatives, from medical sequencing, gene expression, and pharmacogenomics research to public<br />
health, clinical, and commercial services. Its promissory virtues are precision diagnosis and risk prediction, individualized therapy,<br />
prevention, health promotion, and patient empowerment. Different proponents <strong>of</strong> PGM interpret and rank these promises<br />
differently, with different implications for the realization <strong>of</strong> PGM as a health care paradigm. As a result, the “translational pipeline”<br />
<strong>of</strong> genomic research will have many branches towards its distal end. The purpose <strong>of</strong> this project is to study how some <strong>of</strong> the most<br />
influential parties in promoting, implementing, providing and using “personalized genomic medicine” understand its promises<br />
and potential pitfalls, in order to draw out the policy choices that lie ahead for researchers, health care providers and the public as<br />
translational genomic research moves closer to its goal.<br />
Nancy M.P. King, JD<br />
Evaluating and Valuing Personalized Genomic Information<br />
This presentation addresses (1) the difficulty in interpreting risk information in personalized genetic screening and testing and<br />
(2) the contested meaning <strong>of</strong> risk as applied to the common complex disorders that are most <strong>of</strong>ten tested for currently and are<br />
probably <strong>of</strong> greatest interest to a general population. Does personalized genetic information really matter for most people? If not,<br />
why not? If it does matter, why and how does it matter? And how can genetics and bioethics practitioners educate the public (and<br />
each other) about its meaning and value (or lack there<strong>of</strong>)?<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 47<br />
Thursday, May 19
Thursday, May 19<br />
48<br />
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
SCIENTIFIC SYMPOSIUM 215<br />
11:00 am - 1:00 pm<br />
Room: 606-607<br />
Viral Vectorology from Surface Targeting to Cytoplasmic Restriction<br />
CHAIR<br />
Arun Srivastava, PhD<br />
SPEAKERS<br />
Mark A. Kay, MD, PhD<br />
Multi-species Based AAV Capsid Evolution Using Various Selection Parameters: New AAV Vectors for <strong>Gene</strong> <strong>Therapy</strong><br />
We have previously shown that AAV capsid DNA libraries can be used to select for capsids with novel infection/transduction<br />
properties (Grimm et al., 2008). We constructed new AAV capsid libraries starting with 10 multi-species variant capsid genes. These<br />
DNAs were randomly digested and re-assembled using PCR, and each unique sequence was cloned into an AAV genome. We<br />
selected for viruses that were able to efficiently replicate in primary human hepatocytes in vivo or in human pulmonary arterial<br />
endothelial cells in culture. At each round <strong>of</strong> selection, the changing population and capsid composition <strong>of</strong> each chimeric AAV<br />
sequence was determined. The emergence and biological significance <strong>of</strong> specific capsid clones will be discussed as well as the<br />
gene transfer properties <strong>of</strong> vectors packaged with selected chimeric capsids <strong>of</strong> interest.<br />
Glen Barber, PhD<br />
Intracellular DNA-Sensing Pathways that Trigger Innate Immune Responses<br />
The innate immune system is critical for the early detection <strong>of</strong> invading pathogens and for initiating cellular host defence<br />
countermeasures which includes the production <strong>of</strong> type I interferon (IFN). While significant progress has been made into determining<br />
cellular processes underlining the detection <strong>of</strong> RNA viruses, less is known about how the innate immune system is galvanized to respond<br />
to DNA based microbes or intracellular plasmid DNA, sensing pathways that can effect gene therapy strategies. Recently, we reported<br />
that STING (stimulator <strong>of</strong> interferon genes) is critical for the induction <strong>of</strong> IFN by non-CpG, intracellular DNA species produced by various<br />
DNA pathogens and vectors following infection. Murine embryonic fibroblasts (MEFs) lacking STING, as well as antigen presenting cells<br />
(APCs) such as macrophages and dendritic cells (DC’s) exposed to intracellular B-form DNA, herpes simplex virus 1 (HSV-1) or Listeria<br />
were unable to produce IFN or other key innate immune genes. STING’s importance in mediating DNA innate immune responses was<br />
also made evident since CTL–responses induced by plasmid DNA vaccination were reduced in STING deficient animals. In the presence<br />
<strong>of</strong> intracellular DNA, STING relocalized with tank-binding kinase 1 (TBK1) from the endoplasmic reticulum (ER) and association with ERmembrane<br />
associated mitochondria (MAM), to endosome vesicles. Our data indicates that STING is essential for host defense against a<br />
variety <strong>of</strong> DNA pathogens and also required for effective innate immune responses that facilitate effective DNA vaccination.<br />
Greg Towers, PhD<br />
Restriction <strong>of</strong> HIV and Retargeting <strong>of</strong> HIV Integration<br />
We have sought a role for cyclophilin proteins in the replication <strong>of</strong> HIV-1. We have shown that several cyclophilins recruit to the<br />
incoming HIV-1 core and impact on the choice <strong>of</strong> pathway by which HIV-1 enters the nucleus. The use <strong>of</strong> different pathways leads<br />
to integration into different sites in the host cell genome and this in turn influences replication capacity. The interaction between<br />
HIV-1 capsid and cyclophilins can be manipulated by capsid mutation. Thus capsid mutation can be used to retarget HIV-1<br />
integration and may be useful in targeting/re-targeting HIV-1 based gene therapy vectors.<br />
Stephen J. Russell, MD, PhD<br />
Targeting Lentiviral Vectors with Engineered Measles Virus Glycoproteins<br />
LUNCH BREAK (ON OWN)<br />
1:00 pm - 2:30 pm<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
MEET-THE-INVESTIGATOR LUNCH SESSION 220<br />
1:00 pm - 2:30 pm<br />
Room: 303<br />
Career Development: Academic vs. Industry<br />
SPEAKERS<br />
Seng H. Cheng, PhD<br />
Ronald G. Crystal, MD<br />
MEET-THE-INVESTIGATOR LUNCH SESSION 221<br />
1:00 pm - 2:30 pm<br />
Room: 304<br />
Translational Research<br />
SPEAKERS<br />
Alberto Auricchio, MD<br />
Joseph Zabner, MD<br />
MEET-THE-INVESTIGATOR LUNCH SESSION 222<br />
1:00 pm - 2:30 pm<br />
Room: Meet at the Registration Desk by 1:05pm<br />
Ellison Stem <strong>Cell</strong> Core Facility Tour<br />
SPEAKERS<br />
C. Anthony Blau, MD<br />
Carol B. Ware, PhD<br />
ORAL ABSTRACT SESSION 230<br />
2:30 pm - 4:30 pm<br />
Room: 615-617<br />
Adenovirus and Other DNA Virus Vectors II: Response to Vectors<br />
CO-CHAIRS<br />
Steven Craig Ghivizzani, PhD<br />
Philip Ng, PhD<br />
(Abstracts 53-60; see pages 91-92)<br />
ORAL ABSTRACT SESSION 231<br />
2:30 pm - 4:30 pm<br />
Room: 611-612<br />
Chemical and Molecular Conjugates<br />
CO-CHAIRS<br />
Young Jik Kwon, PhD<br />
Sean M. Sullivan, PhD<br />
(Abstracts 61-68; see page 92)<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 49<br />
Thursday, May 19
Thursday, May 19<br />
50<br />
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
ORAL ABSTRACT SESSION 232<br />
2:30 pm - 4:30 pm<br />
Room: 618-620<br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Jacques P. Tremblay, PhD<br />
Xiao Xiao, PhD<br />
(Abstracts 69-76; see pages 92-93)<br />
ORAL ABSTRACT SESSION 233<br />
2:30 pm - 4:30 pm<br />
Room: 6A<br />
Cancer Immunotherapy - Emphasis on Vaccines and Adjuvants<br />
CO-CHAIRS<br />
Lawrence S. Lamb, Jr., PhD<br />
Daniel J. Powell, Jr., PhD<br />
(Abstracts 77-84; see page 93)<br />
ORAL ABSTRACT SESSION 234<br />
2:30 pm - 4:30 pm<br />
Room: 606-607<br />
Small RNA and Oligonucleotide Based Therapeutics<br />
CO-CHAIRS<br />
Joel R. Chamberlain, PhD<br />
Dirk Grimm, PhD<br />
(Abstracts 85-92; see pages 93-94)<br />
ORAL ABSTRACT SESSION 235<br />
2:30 pm - 4:30 pm<br />
Room: 608-609<br />
Stem <strong>Cell</strong> Therapies I<br />
CO-CHAIRS<br />
Ann Leen, PhD<br />
Punam Malik, MD<br />
(Abstracts 93-100; see pages 94-95)<br />
ORAL ABSTRACT SESSION 236<br />
2:30 pm - 3:30 pm<br />
Room: 602-604<br />
Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Barry J. Byrne, MD, PhD<br />
Dongsheng Duan, PhD<br />
(Abstracts 101-104; see page 95)<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Thursday, May 19, 2011<br />
ORAL ABSTRACT SESSION 237<br />
3:40 pm - 4:40 pm<br />
Room: 602-604<br />
Lung and Respiratory Disease <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
David A. Dean, PhD<br />
Larry G. Johnson, MD<br />
(Abstracts 105-108; see page 95)<br />
EXHIBIT HALL OPEN & NETWORKING RECEPTION<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
POSTER SESSION I<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
RNA Virus Vectors I<br />
(Abstracts 109-119; see pages 95-96)<br />
AAV Genome & Host Interactions<br />
(Abstracts 120-134; see pages 96-97)<br />
Adenovirus and Other DNA Virus Vectors I<br />
(Abstracts 135-148; see pages 97-98)<br />
Chemical and Molecular Conjugates<br />
(Abstracts 149-182 and Abstract 914 from Poster Session III; see pages 98-100)<br />
<strong>Gene</strong>tic and Metabolic Diseases <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
(Abstracts 183-193 and Abstract 464 which moved from Poster Session II; see pages 100-101)<br />
Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
(Abstracts 194-207; Abstract 197 withdrawn; see page 101)<br />
Infectious Diseases and Vaccines I<br />
(Abstracts 208-219; see page 102)<br />
Cancer - Immunotherapy I<br />
(Abstracts 220-237; see pages 102-103)<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
(Abstracts 238-249; see pages 103-104)<br />
Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
(Abstracts 250-269 and Abstract 831 from Poster Session III; see pages 104-106)<br />
Lung and Respiratory Disease <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
(Abstracts 270-282; see page 106)<br />
Immunologic Host Responses in <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
(Abstracts 283-297; see page 107)<br />
<strong>Gene</strong> Regulation I<br />
(Abstracts 298-309; see page 108)<br />
Stem <strong>Cell</strong> Therapies I<br />
(Abstracts 310-325; Abstract 320 withdrawn; see pages 108-109)<br />
Late Abstracts I<br />
(Abstracts 875-888; see pages 109-110)<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 51<br />
Thursday, May 19
Friday, May 20<br />
52<br />
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
GEORGE STAMATOYANNOPOULOS LECTURE 300<br />
8:00 am - 9:15 am<br />
Room: 6BC<br />
George Stamatoyannopoulos Lecture<br />
CHAIR<br />
R. Jude Samulski, PhD<br />
SPEAKERS<br />
Victor J. Dzau, MD<br />
Paracine Mechanisms <strong>of</strong> Stem <strong>Cell</strong> Action in Tissue Repair and Regeneration<br />
Numerous studies by our group and others have demonstrated that stem cells contribute to tissue repair and regeneration by<br />
releasing important paracrine factors in a dynamic spatial-temporal manner that can lead to cell survival, angiogenesis, tissue repair<br />
and remodeling, as well as cellular regeneration. This presentation will provide an overview <strong>of</strong> the current status <strong>of</strong> the field as well<br />
an update on our work regarding the characterization <strong>of</strong> those factors.<br />
EXHIBIT HALL COFFEE SOCIAL<br />
9:15 am - 10:00 am<br />
Room: Hall 4B<br />
SCIENTIFIC SYMPOSIUM 310<br />
10:00 am - 12:00 pm<br />
Room: 6A<br />
Clinical Trials<br />
CHAIR<br />
Ronald G. Crystal, MD<br />
SPEAKERS<br />
Samuel C. Wadsworth, PhD<br />
AAV <strong>Gene</strong> <strong>Therapy</strong> for Age Related Macular Degeneration<br />
The neovascular form <strong>of</strong> age related macular degeneration (AMD) is the leading cause <strong>of</strong> blindness <strong>of</strong> persons over 65 years <strong>of</strong> age.<br />
Injectable anti-VEGF agents are approved for AMD treatment and are quite effective resulting in vision stabilization or even vision<br />
improvement in AMD patients. However, for maximum efficacy these agents must be injected on a monthly basis, thus presenting<br />
a significant challenge to patients, caregivers and the healthcare system. We are developing an AAV2 mediated AMD gene therapy<br />
product for sustained expression <strong>of</strong> an anti-VEGF protein which has completed rodent and non-human primate testing. An update<br />
on the clinical trial progress <strong>of</strong> this product candidate will be given.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
Andrew M. David<strong>of</strong>f, MD<br />
Phase I/II Clinical Trial <strong>of</strong> AAV8 FIX for Hemophilia B<br />
We are currently conducting a phase I/II clinical trial <strong>of</strong> AAV-mediated, liver-targeted transfer <strong>of</strong> the cDNA for clotting factor IX (FIX)<br />
in subjects with hemophilia B. Unique aspects <strong>of</strong> the clinical trial include the use <strong>of</strong> vector pseudotyped with serotype 8 capsid, a<br />
self complementary vector genome, codon optimized FIX coding sequence and vector administration via peripheral vein. Thus far,<br />
six subjects have received vector, two at each <strong>of</strong> three dose levels (2x10^10 pcr-vp/kg, 6x10^10 pcr-vp/kg and 2x10^11pcr-vp/kg).<br />
Interim results including safety, efficacy, vector clearance and immune response will be presented. In addition, future plans for the<br />
continued conduct <strong>of</strong> this clinical trial, as well as future ones, will be discussed.<br />
Christ<strong>of</strong> von Kalle, MD PhD<br />
<strong>Gene</strong> <strong>Therapy</strong> for Wiskott Aldrich Syndrome<br />
Wiskott Aldrich Syndrome is a life-threatening immune-disorder characterized by bleeding secondary to microthrombocytopenia,<br />
immunodeficiency, autoimmunity, and susceptibility to lymphoma. A clinical gene therapy protocol using transplantation <strong>of</strong><br />
autologous hematopoietic stem cells transduced with a GALV pseudotyped MLV-derived retroviral vector was developed at<br />
Hannover Medical School. Ten patients treated in this trial between 2006 and 2009 received 3 – 23 x 10e6 genetically modified<br />
hematopoietic progenitor cells upon partial myeloablative busulfan (8 mg/kg). 9/10 patients had evidence <strong>of</strong> sustained<br />
engraftment <strong>of</strong> WASP-positive hematopoietic progenitor cells. WASP expression was detected in 10% to 60% in myeloid cells, most<br />
platelets, and increased in T lymphocytes and NK cells to more than 80% after one year. Functional immune reconstitution was<br />
documented. A clinical benefit was notable in all 9 patients with sustained engraftment: eczema, bleeding diathesis, autoimmune<br />
phenomena and immunodeficiency resolved. One patient developed a vector associated T ALL, currently undergoing treatment.<br />
Comprehensive insertion site analysis demonstrated vector integration that targeted multiple genes controlling growth,<br />
development and immunological responses in a persistently polyclonal hematopoiesis. These data provide the first pro<strong>of</strong>-<strong>of</strong>principle<br />
for gene therapy in Wiskott-Aldrich syndrome as a disorder involving autoimmunity and/or platelets. Prospective clinical<br />
monitoring is required to determine the long-term efficacy and safety pr<strong>of</strong>ile <strong>of</strong> this experimental therapy.<br />
Arthur Levin, PhD<br />
From Bench to Bedside, the Progress <strong>of</strong> a Mir122 Inhibitor, Miravirsen<br />
MicroRNAs are non-coding RNAs that can modulate the translation <strong>of</strong> multiple mRNAs <strong>of</strong>ten whole in biochemical pathways.<br />
The modulation <strong>of</strong> mRNAs by miRNAs is <strong>of</strong>ten described as fine tuning the expression, and as such miRNAs are interesting targets<br />
for therapeutic intervention. Using Locked Nucleic Acid modified oligonucleotides (LNAs) it is possible to create high affinity<br />
miRNA antagonists that bind and sequester specific miRNAs or specific miRNA families. Sequestration <strong>of</strong> a miRNA in a LNA-miRNA<br />
heteroduplex effectively inhibits the activity <strong>of</strong> the miRNA. miR-122 is a hepatic specific miRNA that is known to be a co-factor for the<br />
accumulation <strong>of</strong> hepatitis C virus and it is also known to control energy and lipid metabolism. Miravirsen is an 15-mer LNA-modified<br />
oligonucleotide that binds to and sequesters miR-122. Miravirsen is the first miRNA-targeting drug in clinical trials and the data<br />
obtained in laboratory studies and in clinical trials supports the concept that miRNAs can be utilized as therapeutic targets.<br />
SCIENTIFIC SYMPOSIUM 311<br />
10:00 am - 12:00 pm<br />
Room: 615-617<br />
Clinical Trials on Stem <strong>Cell</strong>s<br />
CO-CHAIRS<br />
Karen S. Aboody, MD<br />
Karin M.L. Gaensler, MD<br />
SPEAKERS<br />
Karen S. Aboody, MD<br />
Neural Stem <strong>Cell</strong>-Mediated <strong>Therapy</strong> for High Grade Gliomas<br />
Neural stem cells (NSCs) display inherent tumor-tropic properties that can be exploited for targeted delivery <strong>of</strong> anti-cancer<br />
agents to invasive and metastatic solid tumors. NSCs are not impeded by the BBB and can target brain tumor sites whether<br />
administered intracranially or intravenously. Significant therapeutic efficacy has been achieved with modified NSCs in preclinical<br />
models <strong>of</strong> glioma, melanoma brain metastases, and medulloblastoma. We now present a first-in-human clinical trial using a<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 53<br />
Friday, May 20
Friday, May 20<br />
54<br />
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
v-myc immortalized, clonal human NSC line, modified to express cytosine deaminase, an enzyme that converts the prodrug<br />
5-Fluorocytosine (5-FC) to the active chemotherapeutic 5-Fluorouracil (5-FU), in patients with recurrent high-grade glioma.<br />
Jane S. Lebkowski, PhD<br />
Development <strong>of</strong> Human Embryonic Stem <strong>Cell</strong>-Based Therapies for the Treatment <strong>of</strong> Human Degenerative Diseases<br />
Human embryonic stem cells have the ability to differentiate into essentially all cell types <strong>of</strong> the body providing therapeutic<br />
potential for numerous diseases. The spectrum <strong>of</strong> hESC-based cell therapy products currently under development span diverse<br />
applications including: cardiomyocytes for heart failure, islets for diabetes, chondrocytes for chondral defects, dendritic cells for<br />
the active immunotherapy, endothelial cells for blood vessels, and dopaminergic neurons for Parkinson’s disease. Preclinical testing<br />
<strong>of</strong> hESC-based therapeutic products must address the activity, biodistribution, phenotype, proliferation capacity, immunogenicity,<br />
and toxicological potential <strong>of</strong> the cells. In addition, developments <strong>of</strong> controlled processes to manufacture and characterize these<br />
products are critical for providing a reproducible and reliable therapeutic supply. An update on hESC-based therapies in or nearing<br />
clinic testing will be provided.<br />
Nicholas Boulis, MD<br />
Spinal Cord Surgery for <strong>Cell</strong>ular and Molecular Segmental ALS <strong>Therapy</strong><br />
Current pro<strong>of</strong> <strong>of</strong> principle data supporting direct spinal cord injection <strong>of</strong> stem cell and gene therapies for motor neuron protection<br />
will be reviewed. Human translation <strong>of</strong> these approaches required the development <strong>of</strong> techniques and devices to facilitate<br />
safe and accurate spinal cord injection. The development <strong>of</strong> these techniques and devices will be reviewed. In 2010, this work<br />
culminated in the first spinal cord transplantation trial for ALS. Clinical trial design will be discussed as well as an update on<br />
progress to date.<br />
Kevin D’Amour, PhD<br />
Developing an Encapsulated Stem <strong>Cell</strong> <strong>Therapy</strong> for Diabetes<br />
ViaCyte is a preclinical therapeutic company developing an encapsulated cell therapy for the treatment <strong>of</strong> insulin-dependent<br />
diabetes. The therapy is based on the differentiation <strong>of</strong> embryonic stem cells into pancreatic beta cell precursors (Pro-Islet) and<br />
we have demonstrated that his progenitor based therapeutic approach consistently produces therapeutically relevant levels <strong>of</strong><br />
insulin in response to blood glucose and sustains diabetic animals. ViaCyte has GMP hESC banks and has developed methods for<br />
large-scale manufacture <strong>of</strong> hESC cultures and Pro-Islet cell products (capable <strong>of</strong> 20 Billion Pro-Islet cells in ~4 weeks). In addition,<br />
ViaCyte is developing a retrievable, non-biodegradable, encapsulation device (Encaptra) that enables implanted Pro-Islet to<br />
survive and differentiate into functioning islet cells. The Encaptra system is manufactured from FDA compliant implant grade<br />
materials and is being designed with the goal <strong>of</strong> eliminating the need for long-term immunosuppressant drugs.<br />
SCIENTIFIC SYMPOSIUM 312<br />
10:00 am - 12:00 pm<br />
Room: 611-612<br />
Cutting Edge Vectors and New Advances in Physical <strong>Gene</strong> Delivery<br />
CHAIR<br />
Shulin Li, PhD<br />
SPEAKERS<br />
Adam Bogdanove, PhD<br />
TAL Effector Nucleases for Genome Editing<br />
TAL effector nucleases (TALENs) are a new class <strong>of</strong> engineered, highly targetable protein for genome editing that promise to<br />
greatly accelerate the pace <strong>of</strong> discovery and the development <strong>of</strong> therapeutic approaches to genetic disorders. Fusions <strong>of</strong> the<br />
sequence-specific DNA binding domain <strong>of</strong> transcription activator-like (TAL) effectors from plant pathogenic Xanthomonas spp.<br />
to the sequence non-specific catalytic domain <strong>of</strong> the FokI nuclease, TALENs create targeted double strand breaks in DNA in vivo<br />
that can be exploited for gene disruption, insertion, or replacement. DNA targeting is modular, based on an apparently contextindependent,<br />
one-to-one association between polymorphic repeats in the TAL effector domain and nucleotides in the target, so<br />
TALENs can be customized to recognize new targets without the empirical or selection-based protocols required for alternatives<br />
such as zinc finger nucleases and homing endonucleases. This presentation will review advances in the development and use <strong>of</strong><br />
TALENs for genome editing, including an examination <strong>of</strong> their potential limitations, as well as the use <strong>of</strong> TAL effectors in other DNA<br />
targeting applications.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
Paul A. Grayburn, MD, FACC<br />
Islet Regeneration in Severe Diabetes by <strong>Gene</strong> <strong>Therapy</strong> Targeted to the Pancreas with Ultrasonic Microbubble Destruction<br />
Ultrasound-targeted microbubble destruction (UTMD) can be used to selectively deliver gene (or drug) therapy to specific<br />
organs. Gas-filled microbubbles are loaded with plasmid or naked DNA and circulated intravenously. Ultrasound is used to disrupt<br />
the microbubbles in a specific organ or tissue, thereby resulting in organ-specific delivery. This presentation will discuss the use <strong>of</strong><br />
UTMD to deliver gene therapy to the pancreas <strong>of</strong> diabetic animals to achieve regeneration <strong>of</strong> islets and cure <strong>of</strong> diabetes.<br />
Dexi Liu, PhD<br />
12 Years <strong>of</strong> Hydrodynamic <strong>Gene</strong> Delivery: How Close are We from Clinical Use?<br />
The past 12 years have marked significant progress in establishing the concept and methodology <strong>of</strong> hydrodynamic gene<br />
delivery as a simple and effective procedure for intravascular gene delivery in rodents. Various applications <strong>of</strong> this method have<br />
been reported, including therapeutic gene discovery in vivo; development <strong>of</strong> optimal plasmid for desirable gene expression;<br />
identification <strong>of</strong> therapeutic siRNAs; and establishment <strong>of</strong> animal models for human viral infection. This talk will focus on recent<br />
progress toward developing a clinically applicable hydrodynamic procedure for human gene therapy. Recent results from<br />
experiments designed to assess safety and effectiveness <strong>of</strong> a computer assisted image-guided hydrodynamic gene delivery<br />
procedure in pigs, dogs and baboons will be presented.<br />
Julie Gehl, MD, PhD<br />
Drug and <strong>Gene</strong> Delivery to the Brain: Results from a Novel Brain Electroporation Electrode<br />
<strong>Gene</strong> electrotransfer is increasingly being used for gene delivery to a number <strong>of</strong> different tissues, and clinical studies have been<br />
performed on gene electrotransfer to tumors, skin and muscle. <strong>Gene</strong> electrotransfer to brain has awaited development <strong>of</strong> electrode<br />
technology. We have been performing electroporation for drug and gene delivery in the treatment <strong>of</strong> cancer patients for over a<br />
decade. Based on our experience we have developed an electrode for drug and gene delivery to brain tissue and brain tumors,<br />
which is now ready for clinical use. Preclinical data on an experimental brain tumor model will be presented, as well as a peak into<br />
the first clinical trial experience.<br />
SCIENTIFIC SYMPOSIUM 313<br />
10:00 am - 12:00 pm<br />
Room: 606-607<br />
Early Virus-Host Interactions<br />
CHAIR<br />
Roberto Cattaneo, PhD<br />
SPEAKERS<br />
Michael Emerman, PhD<br />
Evolution and Function <strong>of</strong> Host Defenses against Retroviruses<br />
We can trace the history some ancient viral infections from “fossils” left behind in primate genomes in the form <strong>of</strong> defective<br />
integrated proviruses. However, other ancient viral infections can be inferred from their effects on the evolution <strong>of</strong> host antiviral<br />
genes. The genetic conflict <strong>of</strong> antiviral genes with virally-encoded antagonists <strong>of</strong> these host defenses viruses results in patterns<br />
<strong>of</strong> adaptive evolution <strong>of</strong> the host genes which can be used to deduce when a given gene was under positive selection, and<br />
consequently when possible Darwinian selection due to a pathogenic viral challenge acted during primate evolution. In this talk I<br />
will explore the ideas <strong>of</strong> restriction factors against retroviruses and the interplay between ancient infection events and modern viral<br />
infections. These ideas are important in understanding how to optimize viral-mediated gene therapy approaches for humans and<br />
model systems.<br />
Grant McFadden, PhD<br />
The Curious Road from Poxvirus Tropism to Oncolytic Virotherapy<br />
Poxviruses have been developed as cancer therapy vector platforms in several ways: vaccination strategies targeted against cancer<br />
cell antigens, delivery vehicles for anti-cancer cytokines or immunotherapeutics, and as direct oncolytic virotherapeutics to target<br />
cancer cells for elimination. This presentation will summarize the progress in our lab to adapt one specific nonhuman poxvirus,<br />
myxoma virus, as an oncolytic virotherapeutic against human cancer. Recent preclinical progress in utilizing this virus to treat<br />
disseminated pancreatic cancer, and as a purging reagent to eliminate contaminating cancer cells from autologous hematopoietic<br />
stem cell transplants, will be summarized.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 55<br />
Friday, May 20
Friday, May 20<br />
56<br />
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
Andrea Amalfitano, DO, PhD<br />
Innate Immune Responses and <strong>Gene</strong> Transfer<br />
The innate immune system has evolved to detect low levels <strong>of</strong> higher order “non-self” molecular structures, as well as DNA or<br />
RNA molecules present in inappropriate subcellular locations. Therefore, the in vivo use <strong>of</strong> any gene transfer vector (virus, non<br />
viral) will result in activation <strong>of</strong> several arms <strong>of</strong> the innate immune system. Extracellular pathogen motif detectors in the blood<br />
stream, such as the complement system, rapidly bind and direct gene transfer vectors to the reticuloendothelial system prior to<br />
vector interaction with critically important cells <strong>of</strong> the host. Overwhelming these systems with extremely high levels <strong>of</strong> a virus or<br />
liposome will allow for transduction <strong>of</strong> cells beyond the RES, but not without significant activation <strong>of</strong> the innate immune system<br />
as well. Additionally, many cells targeted for gene transduction by vectors maintain a varied repertoire <strong>of</strong> membrane bound and<br />
intracellular pathogen detectors, such as the TLRs. In this talk, results gained from the use <strong>of</strong> Adenovirus vectors in innate immune<br />
responsive murine and human models will be highlighted to demonstrate the complexity <strong>of</strong> these responses, as well how gene<br />
transfer efficacy or safety outcomes can be improved by molecularly targeting elements <strong>of</strong> the innate immune system.<br />
Arun Srivastava, PhD<br />
Role <strong>of</strong> <strong>Cell</strong>ular Proteins in Intracellular Trafficking <strong>of</strong> AAV Vectors<br />
For nearly three decades, infection by AAV was assumed to be non-specific, given its broad host-range, which transcends the species<br />
barrier. In 1996, we provided the first evidence that AAV infection is receptor-mediated, which was subsequently identified to be<br />
heparan sulfate proteoglycan (HSPG) in Dr. Jude Samulski’s laboratory. In 1999, we also identified fibroblast growth factor receptor 1<br />
(FGFR1) as a cellular co-receptor for AAV, and others subsequently described the identification <strong>of</strong> at least five additional cellular coreceptors.<br />
Post-receptor/co-receptor entry <strong>of</strong> AAV, we characterized a number <strong>of</strong> cellular proteins that interact with the viral capsid<br />
and the viral genome that significantly impact intracellular trafficking as well as AAV-mediated transgene expression. Our more recent<br />
studies, to be presented at the meeting, have yielded insights into the role <strong>of</strong> additional cellular proteins that play a key role in various<br />
steps in the life cycle <strong>of</strong> AAV, which have implications in the optimal use <strong>of</strong> AAV vectors in gene therapy <strong>of</strong> human diseases.<br />
SCIENTIFIC SYMPOSIUM 314<br />
10:00 am - 12:00 pm<br />
Room: 602-604<br />
Novel <strong>Cell</strong>ular and Molecular Therapies in the Lung: Branching out for Inspiration<br />
CO-CHAIRS<br />
John F. Engelhardt, PhD<br />
Uta Griesenbach, PhD<br />
SPEAKERS<br />
Susan D. Reynolds, PhD<br />
Repair Fosters Regeneration <strong>of</strong> the Airway Epithelium<br />
Identification <strong>of</strong> a TSC requires analysis <strong>of</strong> an individual cell and comparison <strong>of</strong> its proliferation and differentiation capacity with that<br />
<strong>of</strong> other cells within a phenotypically homogenous cell population. Although the existence <strong>of</strong> TSC from tracheobronchial epithelium<br />
and a specific niche had been postulated, three essential functions <strong>of</strong> a stem cell (self-renewal, label-retention and multipotential<br />
differentiation) were not described simultaneously. Therefore the goal <strong>of</strong> the present study was to identify tracheal TSC and study<br />
their interaction with the niche. We demonstrate that CD49f bright /Sca1 + /Aldefluor + mouse tracheal basal cells exhibit both stem cell<br />
characteristics and niche forming function in vitro. This unique basal cell subtype generates three dimensional rimmed clones that<br />
harbor label-retaining TSC and label-diluting transit amplifying cells (TAC). Homogenous rim clones can be passaged at clonal density<br />
five times resulting in generation <strong>of</strong> 40 X 10 6 progeny. Homogenous rim clones are refractory to differentiation signals. However, the<br />
cycle <strong>of</strong> proliferation can be broken by interactions with unfractionated tracheal cells. This modified niche is permissive for generation<br />
<strong>of</strong> secretory and ciliated cells, the differentiated cell types found in the tracheal epithelium. We conclude that: 1) the tracheal stem cell<br />
creates the niche; 2) proliferation <strong>of</strong> TAC is the default state <strong>of</strong> the niche-stem cell interaction; and 3) interactions with non-niche cells<br />
generate a modified environment that is permissive for differentiation.<br />
Andrew A. Wilson, MD<br />
Manipulation and Tracking <strong>of</strong> Alveolar Macrophage <strong>Gene</strong> Expression In Vivo<br />
The ability to manipulate gene expression in a targeted fashion in vivo has been a longstanding goal for medical researchers and<br />
practitioners. We have developed lentivirus-based methods to overexpress or downregulate gene expression specifically in alveolar<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
macrophages. We have found that alveolar macrophages are long-lived cells, thus establishing them as potential targets for lungfocused<br />
gene therapy. Through the use <strong>of</strong> a novel lentiviral reporter vector, we are able to use in vivo imaging technology to track<br />
knockdown <strong>of</strong> transcription factor activation in live animals in real time.<br />
Terence R. Flotte, MD<br />
Phase 2 Trial <strong>of</strong> rAAV1 <strong>Gene</strong> <strong>Therapy</strong> for Alpha-1 Antitrypsin Deficiency<br />
Recombinant adeno-associated virus (rAAV) vectors <strong>of</strong>fer promise for gene therapy <strong>of</strong> alpha-1 antitrypsin (AAT) deficiency. In<br />
a previous clinical trial, a rAAV vector expressing human AAT (rAAV1-CB-hAAT), produced using plasmid transfection, was<br />
administered by intramuscular (IM) injection at a maximum dose <strong>of</strong> 8.7 x 10 11 vector genomes (vg)/kg and demonstrated AAT<br />
expression at low levels that was sustained for >1 year. In this clinical trial, the same vector produced using a herpes simplex<br />
virus complementation system was administered by IM injection at doses <strong>of</strong> 6.0 x 10 11 , 1.9 x 10 12 and 6.0 x 10 12 vg /kg. Vector<br />
administration was well tolerated, with only mild local reactions and no serious adverse events. Serum creatine kinase (CK) levels<br />
were elevated at Day 30 in 5 <strong>of</strong> 6 subjects in the higher dose groups and were normal at Day 45 and beyond. Expression <strong>of</strong><br />
M-specific AAT in serum was dose-dependent, peaked at Day 30, and persisted at lower levels through Day 90. As expected, all<br />
subjects developed anti-AAV antibodies and IFN-γ ELISPOT responses to AAV peptides. None <strong>of</strong> the subjects developed antibodies<br />
to AAT. One subject in the mid-dose group developed an IFN-γ ELISPOT response to AAT peptides that was not associated<br />
with any untoward clinical effects. Muscle biopsies at Day 90 showed a varying degree <strong>of</strong> inflammatory infiltrates and strong<br />
immunostaining for AAT. These results provide additional evidence <strong>of</strong> the safety <strong>of</strong> AAV gene therapy, and indicate that serum<br />
levels <strong>of</strong> transgene expression >20 µg/mL can be achieved. However, further improvements in the design or delivery <strong>of</strong> rAAV-AAT<br />
vectors will be required to achieve therapeutic target serum AAT concentrations.<br />
Thomas Petersen, PhD<br />
Whole Lung Regeneration: Roles <strong>of</strong> Matrix Cues and Physical Stimuli<br />
We have recently demonstrated that decellularized lung matrices can serve as the basis for engineering whole lung tissue, and the<br />
resultant engineered lungs can participate efficiently in gas exchange when implanted in vivo. However, the specific roles <strong>of</strong> the<br />
extracellular matrix and <strong>of</strong> physical forces in directing cell adherence and differentiation in engineered lung tissues will be key to longterm<br />
success. The application <strong>of</strong> physiological physical forces and culture conditions have significant impacts on the repopulating<br />
epithelium and endothelium, including effects on cell adherence, survival, and differentiation state. Additionally, data indicates that<br />
repopulating epithelial and endothelial cells adhere or differentiate based on specific cues from localized matrix components.<br />
SCIENTIFIC SYMPOSIUM 315<br />
10:00 am - 12:00 pm<br />
Room: 608-609<br />
Viral Vectors for Immunomodulation <strong>of</strong> Cancer: From Bench to Bed<br />
CHAIR<br />
Masato Yamamoto, MD, PhD<br />
SPEAKERS<br />
Pedro Lowenstein, MD, PhD<br />
Stimulation <strong>of</strong> Anti-Brain Tumor Immune Responses Through Recruitment <strong>of</strong> Exogenous Dendritic <strong>Cell</strong>s:<br />
At the Threshold <strong>of</strong> a Phase I Trial<br />
The brain is devoid <strong>of</strong> classical naïve afferent antigen presenting cells. Through intratumoral expression <strong>of</strong> Flt3L, we have<br />
reconstituted the efferent antigen presenting immune loop, which is absent from the normal brain. Together with strategies to<br />
facilitate presentation <strong>of</strong> tumor antigens, we have achieved a therapeutic approach which is effective in a large variety <strong>of</strong> tumor<br />
models. The transition to a Phase I clinical trial will be described during the talk.<br />
Masato Yamamoto, MD, PhD<br />
Immunomodulation in Oncolytic Virus Systems<br />
Virus vectors are frequently used for cancer gene therapy. The functionality <strong>of</strong> such interventions not only are affected by<br />
immunological circumstances but also can be enhanced by immunomodilation with the transgene on the vector. Such situations<br />
will be explained with examples and the design <strong>of</strong> the future cancer gene therapy modality will be discussed.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 57<br />
Friday, May 20
Friday, May 20<br />
58<br />
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
Toshiyoshi Fujiwara, MD, PhD<br />
Telomerase - Specific Oncolytic Adenovirus for Human Cancer <strong>Therapy</strong> and Diagnostic Imaging<br />
Telomelysin (OBP-301) is an attenuated oncolytic adenovirus, in which the telomerase promoter drives expression <strong>of</strong> E1<br />
genes. A phase I dose-escalation study <strong>of</strong> intratumoral injection <strong>of</strong> Telomelysin demonstrated the safety, tolerability, and<br />
feasibility <strong>of</strong> the agent for various solid tumors. We also modified the E3 region <strong>of</strong> Telomelysin to contain green fluorescent<br />
protein (GFP) gene for monitoring viral replication (TelomeScan, OBP-401). Following intratumoral injection <strong>of</strong> TelomeScan,<br />
it causes viral spread into the regional lymphatic area and selectively replicates in neoplastic lesions, resulting in GFP<br />
expression in metastatic lymph nodes. This technology has the potential to allow surgeons to provide optimal treatment as a<br />
surgical navigation system.<br />
Andre Lieber, MD, PhD<br />
Hematopoietic Stem <strong>Cell</strong> Based Relaxin <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Breast Cancer<br />
Extracellular matrix (ECM) in solid tumors affects the effectiveness <strong>of</strong> therapeutics through blocking <strong>of</strong> intratumoral diffusion and/<br />
or physical masking <strong>of</strong> target receptors on malignant cells. This includes receptors for therapeutic monoclonal antibodies and<br />
adenovirus vectors. We tested whether intratumoral expression <strong>of</strong> the peptide hormone relaxin would result in ECM degradation<br />
and the improvement <strong>of</strong> immune therapy. As viral gene delivery into epithelial tumors with extensive tumor ECM is inefficient,<br />
we used a hematopoietic stem cell (HSC)-based approach to deliver the relaxin gene to the tumor. We show in syngeneic tumor<br />
models that this approach facilitates pre-existing or transplanted anti-tumor T-cells to control tumor growth. Furthermore, in<br />
xenograft models with Her2/neu-positive breast cancer cells, HSC-mediated relaxin expression improved the anti-tumor efficacy <strong>of</strong><br />
trastuzumab/Herceptin.<br />
SCIENTIFIC SYMPOSIUM 316<br />
10:00 am - 12:00 pm<br />
Room: 618-620<br />
State-<strong>of</strong>-the-Art in Tissue Engineering: Implications for <strong>Gene</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Daniel R. Salomon, MD<br />
Tatiana Segura, PhD<br />
SPEAKERS<br />
Robert E. Guldberg, PhD<br />
Promoting Endogenous Bone Regeneration<br />
Biomaterial scaffolds functionalized to stimulate endogenous repair mechanisms via incorporation <strong>of</strong> osteogenic cues <strong>of</strong>fer a<br />
potential alternative to bone grafting for treatment <strong>of</strong> large bone defects. We first quantified the ability <strong>of</strong> a self-complimentary<br />
adeno-associated viral vector encoding for bone morphogenetic protein 2 (scAAV2.5-BMP2) to enhance human stem cell<br />
osteogenic differentiation in 2D and 3D culture in vitro. Next, we tested the ability <strong>of</strong> biomaterials mediated delivery <strong>of</strong> scAAV2.5-<br />
BMP2 to repair large bone defects in vivo and compared the results to current protein delivery methods used clinically. The results<br />
showed that biodegradable porous polymer scaffolds coated by thermostable, lyophilized scAAV2.5-BMP2 enhanced osteogenic<br />
differentiation in vitro and significantly increased bone regeneration in vivo.<br />
Ge<strong>of</strong>frey Gurtner, MD<br />
Biologic Brachytherapy: Ex vivo Transduction <strong>of</strong> Microvascular Free Flaps for Targeted <strong>Gene</strong> <strong>Therapy</strong><br />
<strong>Gene</strong> therapy remains a promising modality for the treatment <strong>of</strong> local diseases (solid tumors, recalcitrant infection) but has been<br />
hampered by difficulties in achieving robust and targeted therapeutic production with acceptable systemic exposure and toxicity.<br />
Microvascular free flaps are routinely performed clinically in the treatment <strong>of</strong> patients with these conditions. Free flaps require<br />
the auto-transplantation <strong>of</strong> composite tissue (skin, muscle, fat) from one anatomic region to another. Since these free flaps are<br />
detached from the systemic circulation (ex vivo) for a finite period <strong>of</strong> time, surgeons have a unique opportunity to treat these flaps<br />
with transfection/transduction protocols that would be unacceptable in vivo because <strong>of</strong> potential toxicity. Preclinical work suggests<br />
that this approach holds the potential to provide high level targeted therapeutic production with minimal systemic toxicity.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
Lonnie D. Shea, PhD<br />
Advancing Islet Transplantation: From Engraftment to the Immune Response<br />
The promise and progress <strong>of</strong> islet transplantation for treating type-1 diabetes has been challenged by obstacles to patient<br />
accessibility and long-term graft function that may be overcome by integrating emerging technologies in gene delivery,<br />
biomaterials, and immunomodulation. The microenvironment <strong>of</strong> islets following hepatic infusion and traditional systemic<br />
immunosuppression stress the vulnerable islets and contribute to limiting success. Locally delivering trophic factors can<br />
enhance transplantation at extrahepatic sites by promoting islet engraftment, revascularization and long-term function while<br />
avoiding unintended systemic effects. <strong>Cell</strong>- and cytokine-based therapies for immune cell recruitment and reprogramming can<br />
inhibit local and systemic immune system activation that normally attacks transplanted islets. Combined with antigen-specific<br />
immunotherapies, states <strong>of</strong> operational tolerance may be achievable, reducing or eliminating the long-term pharmaceutical<br />
burden. Integration <strong>of</strong> these technologies to enhance engraftment and combat rejection may produce transformative advances to<br />
the therapeutic efficacy and availability <strong>of</strong> islet transplantation.<br />
LUNCH BREAK (ON OWN)<br />
12:00 pm - 1:15 pm<br />
ORAL ABSTRACT SESSION 320<br />
1:15 pm - 3:15 pm<br />
Room: 6A<br />
AAV Capsids & Trafficking<br />
CO-CHAIRS<br />
Kirsten AK Weigel-Van Aken, MD<br />
Weidong Xiao, PhD<br />
(Abstracts 326-333; see page 111)<br />
ORAL ABSTRACT SESSION 321<br />
1:15 pm - 3:15 pm<br />
Room: 606-607<br />
<strong>Gene</strong>tic and Metabolic Diseases <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
CO-CHAIRS<br />
Daniel G. Miller, MD, PhD<br />
Nuria Morral, PhD<br />
(Abstracts 334-341; see pages 111-112)<br />
ORAL ABSTRACT SESSION 322<br />
1:15 pm - 3:15 pm<br />
Room: 611-612<br />
Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Fabio Candotti, MD<br />
Eirini P. Papapetrou, MD, PhD<br />
(Abstracts 342-349; see page 112)<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 59<br />
Friday, May 20
Friday, May 20<br />
60<br />
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
ORAL ABSTRACT SESSION 323<br />
1:15 pm - 3:15 pm<br />
Room: 608-609<br />
Cancer Immunotherapy - Emphasis on Adoptive T <strong>Cell</strong> Transfer<br />
CO-CHAIRS<br />
Laurence JN Cooper, MD, PhD<br />
Michael Jensen, MD<br />
(Abstracts 350-357; see pages 112-113)<br />
ORAL ABSTRACT SESSION 324<br />
1:15 pm - 3:15 pm<br />
Room: 618-620<br />
Cancer-Oncolytic Viruses<br />
CO-CHAIRS<br />
Evanthia Galanis, MD, DSc<br />
David H. Kirn, MD<br />
(Abstracts 358-365; see page 113)<br />
ORAL ABSTRACT SESSION 325<br />
1:15 pm - 3:15 pm<br />
Room: 615-617<br />
Stem <strong>Cell</strong> Therapies II<br />
CO-CHAIRS<br />
Michael C. Holmes, PhD<br />
John A. Zaia, MD<br />
(Abstracts 366-373; see pages 113-114)<br />
ORAL ABSTRACT SESSION 326<br />
1:15 pm - 2:15 pm<br />
Room: 602-604<br />
Immunologic & Host Responses in <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Stephen Gottschalk, MD<br />
Richard A. Morgan, PhD<br />
(Abstracts 374-377; see page 114)<br />
ORAL ABSTRACT SESSION 327<br />
2:30 pm - 3:30 pm<br />
Room: 602-604<br />
<strong>Cell</strong> Processing and Vector Production<br />
CO-CHAIRS<br />
Larry A. Couture, PhD<br />
Lorraine Matheson<br />
(Abstracts 378-381; see pages 114-115)<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
OUTSTANDING ACHIEVEMENT AWARD LECTURE 330<br />
3:45 pm - 4:30 pm<br />
Room: 6BC<br />
Outstanding Achievement Award Lecture<br />
CHAIR<br />
Mark A. Kay, MD, PhD<br />
SPEAKER<br />
Malcolm K. Brenner, MD, PhD<br />
<strong>Cell</strong> and <strong>Gene</strong> <strong>Therapy</strong> - Putting it Together<br />
I entered the field <strong>of</strong> gene therapy more than 20 years ago, led by my previous experience in clinical and translational bone<br />
marrow transplantation. I appreciated how the stem cells within the harvested marrow would be excellent targets for gene<br />
transfer, because in principle a single corrected or modified cell could provide lifelong repopulation <strong>of</strong> the host with modified<br />
cells and could benefit multiple lineages. So I have been a long-term believer that cellular and gene therapies are a highly<br />
complementary pairing. In today’s presentation, I will describe how the barriers to broader introduction <strong>of</strong> gene-modified cells<br />
into clinical practice are progressively being overcome. Although genetically modified cells are “complex biologicals” or “advanced<br />
therapeutic medicinal products” and therefore face many practical, regulatory and economic barriers to their application,<br />
increasing success and (surprisingly) the changing healthcare environment are beginning to show us how we can effectively<br />
exploit this combination <strong>of</strong> approaches, thereby validating both the overall concept - and the society’s new name!<br />
EXHIBIT HALL OPEN & NETWORKING RECEPTION<br />
4:40 pm - 6:40 pm<br />
Room: Hall 4B<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 61<br />
Friday, May 20
Friday, May 20<br />
62<br />
<strong>Program</strong> Schedule Friday, May 20, 2011<br />
POSTER SESSION II<br />
4:40 pm - 6:40 pm<br />
Room: Hall 4B<br />
RNA Virus Vectors II<br />
(Abstracts 382-391; Abstract 388 withdrawn; see page 115)<br />
AAV Capsids & Trafficking<br />
(Abstracts 392-408; see pages 115-116)<br />
Adenovirus and Other DNA Virus Vectors II<br />
(Abstracts 409-421; see pages 116-117)<br />
DNA Vectorology & <strong>Gene</strong> Targeting - I<br />
(Abstracts 422-438 and Abstract 699 which moved from Poster Session III; Abstract 431 withdrawn; see pages 117-118)<br />
Physical Methods <strong>of</strong> Delivery I<br />
(Abstracts 440-450; Abstract 439 Moved to Oral Abstract Session 413; Abstract 448 withdrawn; see pages 118-119)<br />
<strong>Gene</strong>tic and Metabolic Diseases <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
(Abstracts 451-465.5; Abstract 465 withdrawn; see pages 119-120)<br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
(Abstracts 466-483; Abstract 468 moved to Poster Session I; see pages 120-121)<br />
Infectious Diseases and Vaccines II<br />
(Abstracts 484-494; Abstract 488 withdrawn; see pages 121-122)<br />
Cancer-Immunotherapy II<br />
(Abstracts 495-513; see pages 122-123)<br />
Cancer-Oncolytic Viruses I<br />
(Abstracts 514-530; see pages 123-124)<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
(Abstracts 531-541; Abstracts 539 and 540 withdrawn; see pages 124-125)<br />
<strong>Gene</strong> Regulation II<br />
(Abstracts 542-551; see page 125)<br />
Oligonucleotide & RNAi Therapeutics I<br />
(Abstracts 553- 570 and Abstract 837 which moved from Poster Session III; Abstract 552 withdrawn; see pages 125-126)<br />
Stem <strong>Cell</strong> Therapies II<br />
(Abstracts 571-584; see page 127)<br />
<strong>Cell</strong> Processing and Vector Production<br />
(Abstracts 585-597; see pages 127-128)<br />
Late Abstracts II<br />
(Abstracts 889-910; Abstract 890 withdrwan; see pages 128-129)<br />
FRIDAY NIGHT PARTY<br />
7:00 pm - 9:00 pm<br />
Room: Skybridge (Level Four)<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
ASGCT BUSINESS MEETING<br />
7:30 am - 8:00 am<br />
Room: 618-620<br />
A light continental breakfast and c<strong>of</strong>fee will be served at 7:15 am.<br />
OUTSTANDING NEW INVESTIGATOR SYMPOSIUM 400<br />
8:00 am - 9:45 am<br />
Room: 6BC<br />
Outstanding New Investigator Symposium<br />
CHAIR<br />
Mark A. Kay, MD, PhD<br />
SPEAKERS<br />
Hiroyuki Nakai, MD, PhD<br />
In Vivo Viral Genome and Capsid Biology <strong>of</strong> Recombinant AAV Vectors<br />
Recombinant AAV (rAAV) has gained increasing attention as a promising in vivo gene delivery vehicle. To exert its function in<br />
targeted cells in vivo, rAAV viral coat overcomes various intra- and extra-cellular barriers, and rAAV viral genome undergoes<br />
processing primarily by DNA repair machinery. However, the underlying molecular and cellular mechanisms in rAAV-mediated in<br />
vivo gene delivery and transduction have not been clearly understood. We have addressed how rAAV genomes recombine and<br />
integrate in murine tissues to understand the in vivo viral genome biology, and more recently developed a new high-throughput<br />
system that integrates next generation sequencing technologies to further understand the complicated in vivo AAV capsid<br />
biology. Such basic studies on rAAV vectors in the in vivo context will help develop next generation <strong>of</strong> rAAV vectors, broaden their<br />
application, and significantly contribute to successful human gene therapy with rAAV vectors.<br />
Miguel Sena-Esteves, PhD<br />
AAV-Mediated <strong>Gene</strong> <strong>Therapy</strong> for Neuro-Metabolic Diseases and Brain Tumors<br />
Work in our laboratory centers on devising gene therapy strategies for lysosomal storage diseases and brain tumors. The etiology<br />
<strong>of</strong> these diseases is obviously unrelated, but they share a common widespread phenotype. Lysosomal storage diseases with<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 63<br />
Saturday, May 21
Saturday, May 21<br />
64<br />
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
neurological involvement usually affect most structures in the brain; the hallmark <strong>of</strong> glioblastoma multiforme (GBM) cells is<br />
their remarkable ability to infiltrate normal tissue and migrate long distances away from the main tumor mass leading to tumor<br />
recurrence. We are using direct infusion <strong>of</strong> AAV vectors into brain parenchyma to develop new therapies for these diseases. GM1gangliosidosis<br />
(GM1) and Tay-Sachs disease (TSD) are lysosomal storage diseases caused by deficiencies <strong>of</strong> acid β-galactosidase<br />
or β-hexosaminidase A, respectively, resulting in progressive accumulation <strong>of</strong> gangliosides (GM1 or GM2) in the CNS. These<br />
diseases are characterized by moderate to severe neurological impairment depending on the age <strong>of</strong> onset. We have develop a<br />
strategy <strong>of</strong> targeting AAV gene delivery to highly interconnected structures in the brain to achieve global distribution <strong>of</strong> lysosomal<br />
enzymes throughout the CNS. Based on this principle we developed an AAV-based gene transfer approach targeting 2 sites per<br />
brain hemisphere to achieve global distribution <strong>of</strong> lysosomal enzymes throughout the CNS <strong>of</strong> large animal models with dramatic<br />
phenotypic improvements and extension in lifespan. For brain tumor therapy we are exploring the concept <strong>of</strong> using AAV vectors<br />
to create a zone <strong>of</strong> resistance to tumor growth by transducing normal cells in the brain to express anti-tumor proteins. We have<br />
demonstrated the effectiveness <strong>of</strong> this principle in different brain tumor models.<br />
Qizhen Shi, MD, PhD<br />
Targeting Factor VIII (FVIII) Expression to Platelets for <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Hemophilia A with Inhibitors<br />
The development <strong>of</strong> inhibitory antibodies to exogenous factor VIII (FVIII) is considered a severe and important complication <strong>of</strong><br />
FVIII infusion in hemophilia A patients. <strong>Gene</strong> therapy <strong>of</strong> hemophilia A with inhibitor is especially challenging because inhibitory<br />
antibodies in blood circulation may inactivate functional FVIII activity if it is constitutively secrete into plasma. We have developed<br />
a vector (2bF8) that targets human FVIII expression to platelets under control <strong>of</strong> the platelet-specific αIIb gene promoter. Using<br />
this construct, we can correct the murine hemophilia A phenotype even in the presence <strong>of</strong> high titer inhibitory antibodies in<br />
a transgenic mouse model. To apply this unique approach to real-life gene therapy, we use lentivirus-mediated bone marrow<br />
transduction and syngeneic transplantation to introduce platelet-FVIII expression. Our studies have demonstrated that 2bF8<br />
lentivirus-mediated gene transfer into hematopoietic stem cells can provide sustained improvement <strong>of</strong> hemostasis in hemophilia A<br />
mice with pre-existing anti-FVIII immunity, indicating that this platelet-dependent approach may be promising for gene therapy <strong>of</strong><br />
hemophilia A with inhibitors.<br />
ORAL ABSTRACT SESSION 410<br />
10:15 am - 12:15 pm<br />
Room: 606-607<br />
Clinical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Terence R. Flotte, MD<br />
Harry L. Malech, MD<br />
(Abstracts 598-605; see page 130)<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
ORAL ABSTRACT SESSION 411<br />
10:15 am - 12:15 pm<br />
Room: 615-617<br />
RNA Virus Vectors<br />
CO-CHAIRS<br />
Brian D. Brown, PhD<br />
Grant D. Trobridge, PhD<br />
(Abstracts 606-613; see pages 130-131)<br />
ORAL ABSTRACT SESSION 412<br />
10:15 am - 12:15 pm<br />
Room: 6A<br />
AAV Genome & Host Interactions<br />
CO-CHAIRS<br />
Douglas M. McCarty, PhD<br />
Selvarangan Ponnazhagan, PhD<br />
(Abstracts 614-621; see page 131)<br />
ORAL ABSTRACT SESSION 413<br />
10:15 am - 12:15 pm<br />
Room: 611-612<br />
Physical Methods <strong>of</strong> Delivery<br />
CO-CHAIRS<br />
Guangping Gao, PhD<br />
Carol H. Miao, PhD<br />
(Abstracts 622-629; Abstract 628 withdrawn and Abstract 439 moved from Poster Session II.; see pages 131-132)<br />
ORAL ABSTRACT SESSION 414<br />
10:15 am - 12:15 pm<br />
Room: 608-609<br />
<strong>Gene</strong> Targeting<br />
CO-CHAIRS<br />
Paula M. Cannon, PhD<br />
Michael C. Holmes, PhD<br />
(Abstracts 630-637; see page 132)<br />
ORAL ABSTRACT SESSION 415<br />
10:15 am - 12:15 pm<br />
Room: 602-604<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
CO-CHAIRS<br />
Karen S. Aboody, MD<br />
Richard G. Vile, PhD<br />
(Abstracts 638-645; see page 133)<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 65<br />
Saturday, May 21
Saturday, May 21<br />
66<br />
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
ORAL ABSTRACT SESSION 416<br />
10:15 am - 12:15 pm<br />
Room: 618-620<br />
Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Kryst<strong>of</strong> Bankiewicz, MD, PhD<br />
Nathalie Cartier-Lacave, MD<br />
(Abstracts 646-653; see pages 133-134)<br />
LUNCH BREAK (ON OWN)<br />
12:15 pm - 1:45 pm<br />
MEET-THE-INVESTIGATOR LUNCH SESSION 420<br />
12:15 pm - 1:45 pm<br />
Room: 211<br />
Regulated Expression<br />
SPEAKERS<br />
Mark A. Kay, MD, PhD<br />
James M. Wilson, MD, PhD<br />
MEET-THE-INVESTIGATOR LUNCH SESSION 421<br />
12:15 pm - 1:45 pm<br />
Room: 401<br />
Targeted Vectors<br />
SPEAKERS<br />
Michele P. Calos, PhD<br />
Beverly L. Davidson, PhD<br />
SCIENTIFIC SYMPOSIUM 430<br />
1:45 pm - 3:45 pm<br />
Room: 602-604<br />
Cardiovascular <strong>Cell</strong> and <strong>Gene</strong> <strong>Therapy</strong>: State-<strong>of</strong>-the-Art Pre-clinical and Clinical Studies<br />
CO-CHAIRS<br />
Barry J. Byrne, MD, PhD<br />
Marc Penn, MD, PhD<br />
SPEAKERS<br />
Marc Penn, MD, PhD<br />
Role <strong>of</strong> SDF-1:CXCR4 Axis in Tissue Repair<br />
Duncan J. Stewart, MD, FRCPC<br />
Initial Clinical Experience with a <strong>Gene</strong>-Enhanced Progenitor <strong>Cell</strong> <strong>Therapy</strong> for Refractory Pulmonary Hypertension<br />
Pulmonary artery hypertension (PAH) is a devastating and progressive disease that which there are no truly effective therapies.<br />
Recent insights suggest that distal arteriolar pruning initiated by endothelial cells (EC) apoptosis plays a major role in the<br />
pathogenesis <strong>of</strong> this disease. Therefore we have explored the possibility that vascular repair and regeneration may represent a<br />
potentially transformative therapy with the potential to restore normal lung vascular structure and function. Preclincial studies<br />
demonstrated the ability <strong>of</strong> endothelial progenitor cells (EPC) to prevent monocrotaline-induced PAH and the superiority <strong>of</strong><br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
endothelial NO-synthase (eNOS) gene-enhanced EPCs in the reversal <strong>of</strong> established disease in the treatment model. A fist in<br />
human dose-escalation, tolerability study (PHACeT) is now underway and the preliminary results will be presented.<br />
Brian H. Annex, MD<br />
<strong>Cell</strong> and <strong>Gene</strong> <strong>Therapy</strong> for Lower Extremity Ischemia<br />
Peripheral arterial disease (PAD) occurs when atherosclerosis leads to occlusions in a major vascular bed other than the heart<br />
and the lower extremity is the most frequent site for PAD. Patients with PAD suffer from a range <strong>of</strong> symptoms that are all due to<br />
reductions in blood flow to the leg. While attempts to treat PAD by gene transfer have been met with only limited success, there<br />
are still efforts underway. <strong>Cell</strong> therapy is currently an area <strong>of</strong> interest and excitement and we will review the latest information on<br />
this subject.<br />
Karen L. Christman, PhD<br />
Injectable Extracellular Matrix Based Hydrogels for Cardiac Tissue Engineering<br />
The extracellular matrix (ECM) is nature’s scaffold, and in recent years, researchers have isolated these scaffolds for tissue<br />
engineering applications by removing all <strong>of</strong> the cellular components, a process called decellularization. These scaffolds are<br />
known to promote cell influx, regeneration, and healing in a variety <strong>of</strong> tissues, and their degradation products have angiogenic,<br />
chemoattractant, and antimicrobial properties, as well as promote cell migration and proliferation. While these scaffolds retain the<br />
native ECM structure, they are not amenable to minimally invasive, injectable procedures. We have recently developed a variety<br />
<strong>of</strong> injectable ECM derived materials that self-assemble to form porous, nan<strong>of</strong>ibrous scaffolds once injected in vivo or brought to<br />
physiological temperature. These scaffolds are showing great promise for cardiac tissue engineering.<br />
SCIENTIFIC SYMPOSIUM 431<br />
1:45 pm - 3:45 pm<br />
Room: 606-607<br />
Clinical and Translational Studies for <strong>Gene</strong>tic and Metabolic Diseases<br />
CO-CHAIRS<br />
Valder Arruda, MD, PhD<br />
Thierry C. VandenDriessche, PhD<br />
SPEAKERS<br />
John F. Engelhardt, PhD<br />
New Era for Preclinical Studies <strong>of</strong> <strong>Gene</strong>tic Diseases in Larger Animal Models: The Cystic Fibrosis Example<br />
Improved gene targeting methodologies in somatic cells and single cell embryos have opened the door to rapidly generate larger<br />
animal models <strong>of</strong> genetic disease. <strong>Gene</strong> targeting with recombinant adeno-associated virus and zinc finger nuclease has been<br />
employed to generate non-rodent disease models. The field <strong>of</strong> cystic fibrosis has been the recent beneficiary <strong>of</strong> this technology<br />
with the creation <strong>of</strong> new cystic fibrosis models in the pig and ferret. These models are now helping to dissect difficult questions<br />
about disease pathogenesis, while also serving as a platform for the preclinical development <strong>of</strong> gene and cell therapies.<br />
Dwight Koeberl, MD, PhD<br />
Rescue Administration <strong>of</strong> DNA Viral Vectors in Canine Glycogen Storage Disease Type Ia<br />
The focus <strong>of</strong> our research has been the development <strong>of</strong> new therapy for inherited disorders <strong>of</strong> metabolism, especially glycogen<br />
storage disease (GSD) Ia. Glucose-6-phosphatase (G6Pase) deficiency in GSD-Ia affects primarily liver and kidney. We have<br />
developed gene therapy with adeno-associated virus (AAV) vectors and helper-dependent adenovirus (HDAd) vectors. G6Paseknockout<br />
mice and GSD-Ia dogs provided models for the biochemical abnormalities <strong>of</strong> GSD-Ia, although early mortality<br />
complicates research with the murine and canine models <strong>of</strong> GSD-Ia. The biochemical abnormalities in GSD-Ia provided<br />
robust endpoints for demonstrating efficacy following vector administration, including the correction <strong>of</strong> hypoglycemia and<br />
hyperlipidemia, lactic aciduria, G6Pase deficiency, and glycogen accumulations in the liver and kidney. We demonstrated that both<br />
an AAV8-pseudotyped AAV vector encoding human G6Pase and an HDAd vector encoding canine G6Pase prolonged the survival<br />
and reversed the biochemical abnormalities in mice and dogs with GSD-Ia for > 1 year. More recently, the efficacy <strong>of</strong> AAV7 and<br />
AAV9 vectors have been evaluated in mice and dogs with GSD-Ia with regard to the prevention <strong>of</strong> hypoglycemia during prolonged<br />
fasting, and the prevention <strong>of</strong> long-term complications <strong>of</strong> GSD-Ia including renal dysfunction.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 67<br />
Saturday, May 21
Saturday, May 21<br />
68<br />
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
Fatima Bosch, PhD<br />
<strong>Gene</strong> <strong>Therapy</strong> for Diabetes: Moving to Clinic?<br />
Diabetes mellitus is a chronic disease with severe secondary complications for which there is no cure. To counteract diabetic<br />
hyperglycemia by increasing glucose uptake, we generated in skeletal muscle a “glucose sensor” as a result <strong>of</strong> the co-expression <strong>of</strong><br />
insulin and glucokinase via AAV1 vectors. This is a safe approach that allows long-term reversal <strong>of</strong> diabetic alterations and survival<br />
(>3 years) in Beagle diabetic dogs demonstrating the potential <strong>of</strong> this therapy.<br />
Marina Cavazzana-Calvo, MD, PhD<br />
<strong>Gene</strong> <strong>Therapy</strong> for Haematopoietic Diseases : New Data on Ongoing Clinical Trials<br />
SCIENTIFIC SYMPOSIUM 432<br />
1:45 pm - 3:45 pm<br />
Room: 6A<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> Around the Globe: A Showcase <strong>of</strong> Asia<br />
CHAIR<br />
Guangping Gao, PhD<br />
SPEAKERS<br />
Hideyoshi Harashima, PhD<br />
Controlled Intracellular Trafficking <strong>of</strong> Non-viral Vectors<br />
It is widely known that viral vectors are much more efficient than non-viral vectors, however, little is known about which process<br />
is responsible for this difference. We addressed this question by developing a quantitative intracellular imaging method for pDNA<br />
and compared efficiency between viral and non-viral vectors. As a result, intranuclear disposition such as transcriptional and<br />
translational processes can be rate-limiting processes for non-viral vectors. We have developed original non-viral vector named as<br />
Multifunctional Envelope-type Nano Device (MEND) and optimized MEND to overcome the rate-limiting step to achieve antigen<br />
presentation in primary dendritic cells as well as to induce antitumor effects. These results indicate that the optimized MEND can<br />
be a breakthrough technology for DNA vaccine.<br />
Masayuki Yamato, PhD<br />
Current Status <strong>of</strong> Clinical Applications <strong>of</strong> <strong>Cell</strong> Sheet Engineering for Regenerative Medicine<br />
We will show the pipelines and current status <strong>of</strong> clinical applications <strong>of</strong> regenerative medicine using cell sheet engineering. Skin,<br />
cornea, heart, and esophagus have been treated with transplantable cell sheets fabricated on temperature-responsive culture<br />
surfaces in human clinical settings.<br />
Duanqing Pei, PhD<br />
Improving Reprogramming Through Culture Changes<br />
We have established a robust platform for the generation <strong>of</strong> patient specific pluripotent stem cells by defined factors. A bank<br />
<strong>of</strong> those iPSCs have been created in our institute. We are performing gene corrections for the genetic mutations. We will try to<br />
establish protocols to differentiate those iPSCs for therapeutical applications.<br />
Wenlin Huang, PhD<br />
A Multicenter, Open-label, Randomized Phase II Trial <strong>of</strong> Adenovirus-mediated Endostatin <strong>Gene</strong> <strong>Therapy</strong> in Combination<br />
with Paclitaxel and Cisplatin Chemotherapy in Advanced Head and Neck Carcinoma: Preliminary Results<br />
Background: E10A is an adenovirus containing human endostatin gene (Ad-rhE). The phase I clinical trial <strong>of</strong> E10A revealed that<br />
weekly intratumoral injection <strong>of</strong> up to 1 × 10 12 VP <strong>of</strong> E10A to patients with solid tumor is a feasible and well-tolerated procedure<br />
that exerts mild antitumor effects. In this trial, we aimed to evaluate the safety and efficacy <strong>of</strong> E10A combined with paclitaxel/<br />
cisplatin chemotherapy in advanced head and neck carcinoma (ClinicalTrials.gov identifier: NCT00634595).<br />
Methods: Patients treated with chemotherapy alone were given paclitaxel (160mg/m 2 on d1) and cisplatin (25mg/m2 on d1, d2<br />
and d3) every 21 days. Patients in combination group received two intratumral injections <strong>of</strong> E10A on days 1 and 8, combined with<br />
paclitaxel (160mg/m 2 on d3) and cisplatin (25mg/m2 on d3, d4 and d5), and then every 21 days as long as no PD or untolerable<br />
toxicity occurred. The primary efficacy criterion was response rate (CR/PR) determined in cycle 2 to cycle 4. Patients were assessed<br />
for toxicity and viral shedding, and antitumor response was evaluated by imaging techniques and tumor biopsy.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
Results: As <strong>of</strong> November 2010, evaluable population included 120 subjects. In combination group, 1/59 had CR and 25/59 had PR.<br />
For patients received chemotherapy alone, 0/61 had CR and 14/61 had PR. The most effects. frequent adverse events associated<br />
with E10A were fever and local reaction <strong>of</strong> injection site, primarily grades 1 and 2.<br />
Conclusions: Intratumoral injection <strong>of</strong> E10A is feasible and well tolerated and shows encouraging antitumor effects.<br />
SCIENTIFIC SYMPOSIUM 433<br />
1:45 pm - 3:45 pm<br />
Room: 611-612<br />
<strong>Gene</strong>tic Vaccines<br />
CHAIR<br />
Jeffrey J. Molldrem, MD<br />
SPEAKERS<br />
Lawrence Corey, MD<br />
HIV Vaccine Development<br />
Efficacy trials <strong>of</strong> preventive HIV vaccines continue to provide surprising yet critical insights for future HIV vaccines. Vaccine regimens<br />
with easily measurable immune responses <strong>of</strong> high magnitude and frequency, such as the Merck Ad5 gag-pol-nef vaccine,<br />
provided little protection from infection or long term immune control. However, a recent vaccine regimen <strong>of</strong> a canarypox gp 120<br />
combination vaccine provided nearly 60% efficacy in the first year after vaccination and 30% efficacy overall. This regimen elicited<br />
poor CD8+ and mediocre CD4+ T cell responses in phase I and II evaluations. Recent analyses <strong>of</strong> the longer term follow up <strong>of</strong> the<br />
Step trial indicate an interaction between receipt <strong>of</strong> vaccine and lack <strong>of</strong> circumcision as well as Ad5 seropositivity. The mechanisms<br />
<strong>of</strong> these effects are unclear. Similarly, while NHP models <strong>of</strong> acquisition are being developed, they are not validated with regards<br />
to their predictive efficacy. The above data all indicate that our assays and our current animal models to measure immunogenicity<br />
are poor predictors <strong>of</strong> HIV vaccine efficacy in a human population. The pace <strong>of</strong> HIV vaccine efficacy trials has been slow (currently<br />
one trial every 5 to 7 years). If we are to achieve a globally effective vaccine, we need to develop a system to conduct, monitor and<br />
analyze efficacy trials in a more efficient and expedient manner, linking laboratory and clinical services more effectively. Adaptive<br />
trial designs <strong>of</strong>fer a major advantage over fixed “traditional” models in weeding out ineffective vaccines and providing initial reads<br />
on potentially effective vaccine regimens. The use <strong>of</strong> adaptive designs will be discussed in the context <strong>of</strong> a more rapid and efficient<br />
global clinical trials program.<br />
Jeffrey J. Molldrem, MD<br />
T <strong>Cell</strong>s and TCR-Like Antibodies to Treat Leukemia<br />
The potent T cell-mediated graft-versus-leukemia (GVL) effect observed after allogeneic stem cell transplantation contributes<br />
to improved relapse-free survival for patients with myeloid leukemia. If donor T cells that mediate GVL could be separated from<br />
T cells that mediate graft-versus-host disease (GVHD) based on antigen specificity, then enrichment <strong>of</strong> GVL T cells in the donor<br />
allograft could be devised that might increase GVL and reduce GVHD. Examples <strong>of</strong> acknowledged GVL T cells target minor<br />
histocompatibility antigens (e.g. HA-1) and self-antigens (e.g. PR1, WT1) that are expressed in hematopoietic tissues. A limitation to<br />
selecting PR1-specific cytotoxic T lymphocytes (PR1-CTL) to mediate GVL is their low precursor frequency and relative low avidity<br />
T cell receptors (TCRs) compared to TCRs specific for non-self peptides. 8F4, a TCR-like anti-PR1/HLA-A2 monoclonal antibody that<br />
has 3-log higher affinity for PR1/HLA-A2 compared to PR1-TCR, mediates CDC against primary AML and leukemia stem cells (LCSs)<br />
and preferentially inhibits AML progenitors. This suggests that 8F4 might be useful in the treatment <strong>of</strong> leukemia. The biological<br />
basis <strong>of</strong> treatment strategies with PR1-CTL and 8F4 will be discussed.<br />
Philip R. Johnson, MD<br />
Removing the Roadblock to an HIV Vaccine<br />
The holy grail <strong>of</strong> HIV vaccine development is an immunogen that elicits antibodies which broadly neutralize field strains <strong>of</strong> the<br />
virus. While tremendous insights have been gained into the structure and function <strong>of</strong> the HIV envelope glycoprotein, precious<br />
little progress has been made in designing such immunogens. In fact, it remains formally possible that with current technologies,<br />
engagement <strong>of</strong> the adaptive immune system will not lead to an effective HIV vaccine. The mechanisms behind this immune<br />
evasion will be discussed, along with potential ways around this formidable roadblock.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 69<br />
Saturday, May 21
Saturday, May 21<br />
70<br />
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
Richard Roden, PhD<br />
Next <strong>Gene</strong>ration HPV Vaccines<br />
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary but insufficient cause <strong>of</strong> virtually all cervical cancers.<br />
Thus cervical cancer is entirely preventable through vaccination. However, cervical cancer remains the third most common cause<br />
<strong>of</strong> cancer death among women, and reducing this will require broader access to HPV vaccines, especially in the developing world<br />
where the implementation <strong>of</strong> secondary screening has met with limited success. We are developing vaccines targeting the minor<br />
capsid protein L2 to induce protective immunity, as well as therapeutic immune responses to the viral oncoproteins E6 and E7.<br />
<strong>Gene</strong>tic vaccination shows promise as a low cost approach to deliver such second generation HPV vaccines.<br />
SCIENTIFIC SYMPOSIUM 434<br />
1:45 pm - 3:45 pm<br />
Room: 615-617<br />
Late Stage Industry Clinical Trials<br />
CO-CHAIRS<br />
Estuardo Aguilar-Cordova, PhD<br />
Gabor M. Rubanyi, MD, PhD<br />
SPEAKERS<br />
Laura K. Aguilar, MD, PhD<br />
A Randomized Controlled Trial <strong>of</strong> ProstAtak as Adjuvant to Up-front Radiation <strong>Therapy</strong> for Localized Prostate Cancer<br />
Prostate cancer is the second leading cause <strong>of</strong> cancer death in men in the US. More than 50,000 men suffer from prostate cancer<br />
recurrence each year for which no curative therapy exists. ProstAtak is a cytotoxic immunotherapy agent composed <strong>of</strong> an<br />
adenoviral vector expressing the Herpes thymidine kinase gene (AdV-tk) injected into the tumor followed by oral administration <strong>of</strong><br />
valacyclovir, an anti-herpetic prodrug. ProstAtak works synergistically with radiation to kill tumor cells as well as stimulate the invivo<br />
formation <strong>of</strong> a tumor-specific vaccine to combat micrometastases and recurrence from residual disease. Safety and potential<br />
efficacy have been demonstrated in Phase 1 and 2 trials with more than 250 patient doses delivered to more than 100 patients<br />
with prostate cancer. A completely blinded, randomized, placebo controlled trial will definitively evaluate the efficacy <strong>of</strong> ProstAtak<br />
in combination with standard external beam radiation therapy in up-front prostate cancer.<br />
Marnix Bosch, PhD, MBA<br />
Autologous Dendritic <strong>Cell</strong>s for Glioblastoma<br />
DCVax-Brain is an autologous cell therapy product for patients with malignant glioma, that has shown significant and meaningful<br />
clinical benefit in early trials. Northwest Biotherapeutics has designed and initiated a multi-center, placebo controlled double<br />
blind Phase II trial to test the efficacy and safety <strong>of</strong> this product. The trial was initiated in 13 sites around the US but enrollment was<br />
temporarily put on hold due to economic circumstances. At this point the company is resuming enrollment. Further details <strong>of</strong> trial<br />
design and the rationale behind it will be presented, as well as an update on clinical data gathered to date.<br />
Richard S. Geary, PhD<br />
Mipomersen, an Antisense Oligonucleotide Inhibiting apoB Synthesis, for Familial Hypercholesterolemia<br />
Isis and Genzyme have successfully completed four Phase 3 studies examining the safety and efficacy <strong>of</strong> the antisense, apoB<br />
synthesis inhibitor, mipomersen, in patients whose severe hypercholesterolemia was not adequately controlled on an existing<br />
regimen <strong>of</strong> maximally tolerated lipid-lowering therapy. In all <strong>of</strong> these studies, mipomersen significantly reduced all atherogenic<br />
lipids including LDL-C, apoB and Lp(a), and had no effect on HDL. The most common adverse event was local injection site<br />
reactions. Liver enzymes (ALT) were elevated ≥3X ULN for at least 7 days in 8% <strong>of</strong> mipomersen-treated patients. A detailed<br />
summary <strong>of</strong> the safety and efficacy pr<strong>of</strong>ile for the Phase 3 mipomersen program will be presented. Overall, the data support the<br />
potential utility <strong>of</strong> mipomersen as a pharmacologic option to provide additional LDL-C lowering in hypercholesterolemic patients<br />
not adequately controlled on existing lipid-lowering medications.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
Seppo Ylä-Herttuala, MD, PhD, FESC<br />
Ad5-VEGF-D for Graft Stenosis<br />
Vascular access stenosis is a significant problem in dialysis patients. Local gene transfer could be used for the treatment<br />
<strong>of</strong> the stenosis at the vascular access site. Safety and efficacy information currently available about the use <strong>of</strong> Ad-VEGF-D<br />
vasculoprotective gene transfer for this condition will be described.<br />
SCIENTIFIC SYMPOSIUM 435<br />
1:45 pm - 3:45 pm<br />
Room: 608-609<br />
New Therapeutic Strategies for Neuro-Ophthalmic Diseases<br />
CHAIR<br />
Maria G. Castro, PhD<br />
SPEAKERS<br />
Christian L. Lorson, PhD<br />
RNA-based Strategies for Increasing SMN Production in Spinal Muscular Atrophy: Trans-splicing<br />
Nucleic acid-based therapeutics are an expanding area <strong>of</strong> investigation and Spinal Muscular Atrophy (SMA) is well suited for a<br />
variety <strong>of</strong> these applications. While loss <strong>of</strong> SMN1 results in SMA, the existence <strong>of</strong> a nearly identical, but alternatively spliced SMN2<br />
gene, has made it possible to specifically target SMN2 for a variety <strong>of</strong> therapeutic strategies that are designed to redirect the<br />
SMN2 alternative splicing event. Our lab utilizes several strategies to modulate SMN2 pre-mRNA splicing, including trans-splicing,<br />
antisense oligonucleotides, and bifunctional RNAs. The molecular genetics <strong>of</strong> SMA and an analysis <strong>of</strong> nucleic acid-based strategies<br />
from the test tube to animal models will be discussed.<br />
Thomas A. Reh, PhD<br />
The Use <strong>of</strong> Embryonic Stem <strong>Cell</strong>s in the Treatment <strong>of</strong> Retinal Degenerations<br />
We are developing methods for the use <strong>of</strong> human embryonic stem cells in the repair <strong>of</strong> retinal degenerations. Using what we<br />
learned from studying retinal stem/progenitors in vitro over many years, we have developed a technique for directing hES cells<br />
to the retinal progenitor cell fate (Lamba et al, 2006; P.N.A.S.; 2009, <strong>Cell</strong> Stem <strong>Cell</strong>; 2010 PlosOne) and expanding these cells in vitro.<br />
We now have the capacity to generate large numbers <strong>of</strong> human retinal progenitors and retinal neurons in vitro and we are<br />
investigating their ability to replace lost photoreceptors or ganglion cells in mouse models <strong>of</strong> macular degeneration or glaucoma.<br />
Botond Roska, PhD<br />
Targeting Microbial Light Sensors to Retinal <strong>Cell</strong> Types to Restore Visual Function in Retinitis Pigmentosa<br />
Retinitis pigmentosa is a hereditary eye disease that affects photoreceptors and leads to blindness. The discovery <strong>of</strong> a microbial<br />
light-gated channel and the subsequent development <strong>of</strong> similar “optogenetic” sensors opened the door for creating artificial<br />
photoreceptors in the remaining retinal circuits <strong>of</strong> retinitis pigmentosa retinas via gene therapy. I will show how we combine the<br />
understanding <strong>of</strong> retinal cell types, circuits and computations with the ability to equip cell types with optogenetic sensors in order<br />
to restore visual activity in animal models <strong>of</strong> retinitis pigmentosa. I then discuss the first translational steps towards therapy.<br />
SCIENTIFIC SYMPOSIUM 440<br />
4:15 pm - 6:15 pm<br />
Room: 611-612<br />
Chemical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
CHAIR<br />
Suzie H. Pun, PhD<br />
SPEAKERS<br />
Sean M. Sullivan, PhD<br />
Clinical Development <strong>of</strong> Plasmid DNA-based Vaccines for Treatment <strong>of</strong> Cancer and Infectious Disease<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 71<br />
Saturday, May 21
Saturday, May 21<br />
72<br />
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
Roger C. Adami, Ph.D.<br />
Highly Potent DiAlkylated Amino-Acid (DiLA2) Based Formulations for Systemic Liver Delivery<br />
Highly effective and well tolerated systemic delivery systems remains one <strong>of</strong> the main hurdles to establishing RNA-based<br />
therapeutics. Toward this objective, we developed an innovative dialkylated amino acid-based (DiLA2) delivery system that<br />
provides both efficient hepatocellular uptake and endosomal escape. The resulting particles were between 60 to 80 nm and had<br />
> 90% <strong>of</strong> the siRNA encapsulated. Using these particles we obtained an ED50 <strong>of</strong> 30 µg/kg in mice delivering a Factor VII UsiRNA.<br />
Complement activation assays with these particles demonstrated C3a levels remain below the buffer treated baseline, suggesting<br />
minimal to no potential for alternative complement pathway activation. These new DiLA2 systems provide a basis for design and<br />
development <strong>of</strong> robust, well tolerated RNA and oligonucleotide delivery systems.<br />
David A. Dean, PhD<br />
The Importins <strong>of</strong> DNA Nuclear Localization<br />
Entry <strong>of</strong> plasmids into the nucleus is a required step in all DNA-based transfections and has been seen as one <strong>of</strong> the greatest<br />
barriers to effective gene transfer. Our studies over the years have focused on elucidating the mechanisms <strong>of</strong> plasmid nuclear<br />
import in non-dividing cells, a key cell target for gene therapy. I will discuss the roles <strong>of</strong> transcription factors and other proteins in<br />
the nuclear localization <strong>of</strong> plasmids, both using in vitro cell culture systems and animal models.<br />
Patrick S. Stayton, PhD<br />
pH-Responsive Carriers for Nucleic Acid Delivery<br />
The long-term objective <strong>of</strong> our research is to develop new drug delivery systems for macromolecular drugs that must reach<br />
intracellular targets for efficacy. Biotherapeutics such as siRNA have significant therapeutic potential, but effectively formulating<br />
and delivering them remains a widely recognized challenge. We have been developing synthetic polymeric carriers that mimic<br />
the highly efficient intracellular delivery systems found in pathogenic viruses and organisms. Their most important property ties<br />
together the sensing <strong>of</strong> pH changes to membrane destabilizing activity, and the carriers thus possess a hidden functionality that<br />
is expressed in the endosomal compartment to increase cytosolic delivery <strong>of</strong> macromolecules. The carriers are applicable to a<br />
wide range <strong>of</strong> biotherapeutics, and might open up new families <strong>of</strong> peptide, antibody or nucleic acid drug candidates that attack<br />
previously inaccessible intracellular targets<br />
SCIENTIFIC SYMPOSIUM 441<br />
4:15 pm - 6:15 pm<br />
Room: 6A<br />
Emerging Hematopoietic Clinical Studies: Challenges and Advances<br />
CHAIR<br />
David A. Williams, MD<br />
SPEAKERS<br />
Alessandra Biffi, MD<br />
HSC <strong>Gene</strong> <strong>Therapy</strong> for Metachromatic Leukodystrophy<br />
Metachromatic Leukodystrophy (MLD) is a demyelinating lysosomal storage disorder due to deficiency <strong>of</strong> arylsulfatase A (ARSA)<br />
lacking effective therapies. According to relevant preclinical data, a Phase I/II clinical trial <strong>of</strong> hematopoietic stem cell (HSC) gene<br />
therapy employing lentiviral vectors (LVs) was recently approved for the treatment <strong>of</strong> MLD and the first patient was treated in our<br />
Institute in May 2010. Upon administration <strong>of</strong> a myeloablative dose <strong>of</strong> busulfan, the patient received autologous BM HSC freshly<br />
and efficiently transduced with ARSA-encoding LVs. No serious adverse events were reported in the peri- and post-transplant<br />
phase; a sustained engraftment <strong>of</strong> the transduced cells and a sustained, above-normal ARSA activity were observed in all blood<br />
lineages and in BM CD34+ cells up to 6 months follow up. These marking levels far exceed those reported in previous trials using<br />
gamma-retroviral vectors or LV and, if maintained long-term, would suggest a substantial gain in gene marking efficacy. Thus far,<br />
the follow up <strong>of</strong> this patient demonstrates the short-term safety and feasibility <strong>of</strong> the procedure, but only long-term evaluation will<br />
establish its safety and efficacy.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
Isabelle Rivière, PhD<br />
Beta-globin <strong>Gene</strong> Transfer for the Treatment <strong>of</strong> Beta-Thalassemia<br />
The beta-thalassemias are inherited anemias caused by the insufficient production <strong>of</strong> the beta-chain <strong>of</strong> hemoglobin. The<br />
transplantation <strong>of</strong> autologous CD34+ hematopoietic stem cells genetically modified with recombinant lentiviral vectors encoding<br />
the human beta-globin gene represents a potential curative therapy for patients lacking an HLA-matched donor. We have shown<br />
in murine models that beta-thalassemia can be cured upon the transduction <strong>of</strong> bone marrow cells with optimized TNS9-derived<br />
lentiviral vectors. Based on these preliminary data, we have conducted a pilot trial in patients with β- thalassemia major to<br />
primarily investigate the feasibility and safety <strong>of</strong> peripheral blood hematopoietic progenitor cell (HPC) mobilization with G-CSF and<br />
determine the yield <strong>of</strong> mobilized CD34+ HPCs. A secondary objective was to determine whether the collected HPCs are amenable<br />
to effective transduction with the clinical TNS9.3.55 lentiviral vector that has been manufactured for the planned therapeutic trial.<br />
Our studies demonstrate that high-level beta-globin transgene expression is maintained in erythroid cells derived from thalassemic<br />
CD34+ cells. Update will be given on the trials, the yield <strong>of</strong> CD34+ HPCs, the efficiency <strong>of</strong> transduction and the level <strong>of</strong> globin<br />
expression in patient cells.<br />
David A. Williams, MD<br />
New Approaches to <strong>Gene</strong>tic Correction in Fanconi Anemia<br />
Previous attempts at genetic correction in Fanconi anemia patients have been unsuccessful, largely due to a reduced numbers <strong>of</strong><br />
hematopoietic stem cell (HSC) targets and the loss <strong>of</strong> HSCs during in vitro manipulations required for gene transfer. This session will<br />
review new approaches to address these issues: i) the application <strong>of</strong> new vector systems that require less in vitro manipulations,<br />
such as lentivirus vectors, allowing very short ex vivo culture periods; and ii) the development <strong>of</strong> somatic cell reprogramming that<br />
allows the generation <strong>of</strong> unlimited numbers <strong>of</strong> stem cell targets. These reprogrammed stem cells called induced pluripotent stem<br />
(iPS) cells can be differentiated into hematopoietic progenitor cells and have the added advantages <strong>of</strong> unlimited expansion and<br />
clonability which could facilitate full molecular characterization <strong>of</strong> genetically corrected cellular products.<br />
Derek A. Persons, MD, PhD<br />
Lentiviral <strong>Gene</strong> Transfer for Beta-Thalassemia<br />
SCIENTIFIC SYMPOSIUM 442<br />
4:15 pm - 6:15 pm<br />
Room: 618-620<br />
Advancing <strong>Gene</strong>s and <strong>Cell</strong>s into the Clinic - Delivery on Target for CNS Disorders<br />
CO-CHAIRS<br />
Thomas Miller, PhD<br />
J. Fraser Wright, PhD<br />
SPEAKERS<br />
Kryst<strong>of</strong> Bankiewicz, MD, PhD<br />
Importance <strong>of</strong> Precise Vector Delivery and Axonal Transport in <strong>Gene</strong> <strong>Therapy</strong> Trials for Parkinson’s Disease<br />
Optimal viral vector delivery into the brain is challenging and brain distribution <strong>of</strong> viral vectors is uncertain. To address this issue we<br />
developed viral vector delivery system that permits direct MRI monitoring <strong>of</strong> vector distribution within the brain in real-time. This<br />
significant advance allows for the first time to adjust parameters <strong>of</strong> vector infusion while delivering gene therapy, giving surgeon<br />
full control over gene transfer technology. Description and performance <strong>of</strong> this now FDA approved system for viral vector delivery<br />
to the brain will be presented.<br />
Eva L. Feldman, MD, PhD<br />
Intraspinal Stem <strong>Cell</strong> Transplantation for Amyotrophic Lateral Sclerosis<br />
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that lead to the specific loss <strong>of</strong> motor neurons.<br />
Recently stem cell technologies have been developed for the investigation and treatment <strong>of</strong> neurodegenerative diseases. I<br />
will discuss the different stem cells currently being studied for mechanistic discovery and therapeutic development, including<br />
embryonic, adult and induced pluripotent stem cells. I will also present supporting evidence for the utilization <strong>of</strong> stem cell<br />
technology in the treatment <strong>of</strong> ALS, and describe key issues that must be considered for the transition <strong>of</strong> stem cell therapies for<br />
MN diseases from bench to bedside. <strong>Final</strong>ly, I will discuss the first-in-human Phase I trial currently underway examining the safety<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 73<br />
Saturday, May 21
Saturday, May 21<br />
74<br />
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
and feasibility <strong>of</strong> intraspinal stem cell injections in ALS patients as a foundation for translating stem cell therapies for various<br />
neurological diseases.<br />
Wilson W. Bryan, MD<br />
Efficient Drug Development<br />
The objective <strong>of</strong> drug development is to deliver safe and effective products to the public. However, development <strong>of</strong> a product<br />
from the point <strong>of</strong> conception through FDA marketing approval requires substantial expenditures <strong>of</strong> time and money. Sponsors<br />
can decrease the time and expense by planning ahead for subsequent steps in drug development. Such planning should be a<br />
collaboration that includes scientists, clinicians, and regulators. This presentation will describe the drug development process,<br />
focusing on opportunities for sponsor-regulator interactions that can facilitate efficient drug development.<br />
Steven Piantadosi, MD, PhD<br />
Impact <strong>of</strong> <strong>Therapy</strong> Delivery on Clinical Trial Design<br />
Panel Discussion<br />
SCIENTIFIC SYMPOSIUM 443<br />
4:15 pm - 6:15 pm<br />
Room: 606-607<br />
Viral Vectors for <strong>Gene</strong> Targeting and Homologous Recombination in <strong>Gene</strong> <strong>Therapy</strong><br />
CO-CHAIRS<br />
Paula M. Cannon, PhD<br />
Luigi M. Naldini, MD, PhD<br />
SPEAKERS<br />
Luigi M. Naldini, MD, PhD<br />
Sustainable <strong>Gene</strong> Transfer and <strong>Gene</strong> Correction in Stem <strong>Cell</strong>s<br />
Engineered Zinc Finger Nucleases (ZFNs) are powerful new tools for gene targeting. We have optimized the application <strong>of</strong> ZFNmediated<br />
gene editing to several cell types, including human primary lymphocytes, fibroblasts, neural stem cells and induced<br />
Pluripotent Stem cells (iPSC), and demonstrated the feasibility, efficiency and specificity <strong>of</strong> gene disruption and site-specific<br />
integration. We studied the transcriptional and epigenetic impact <strong>of</strong> different transgene expression cassettes targeted into<br />
different genomic loci and tailored locus choice and cassette design to achieve robust and uniform transgene expression without<br />
inducing detectable transcriptional perturbation <strong>of</strong> the targeted locus and its flanking genes. These studies provide a framework<br />
for “sustainable” gene transfer that can be exploited in novel experimental paradigms and safer therapeutic applications. We have<br />
combined gene correction with strategies for safe genetic reprogramming <strong>of</strong> patient-derived fibroblasts to iPSC, in order to provide<br />
an alternative and potentially unlimited source <strong>of</strong> patient-derived, gene-corrected, reprogramming factor free stem cells. These<br />
iPSC represent invaluable tools to explore methods for inducing their differentiation into hematopoietic cell types and design new<br />
cell replacement approaches.<br />
David J. Rawlings, MD<br />
Modeling Homing Endonuclease <strong>Gene</strong> Targeting in Primary <strong>Cell</strong>s<br />
Rare cutting homing endonucleases (HE) represent a promising technology for site-specific genome engineering. However, successful<br />
application <strong>of</strong> this technology requires both improved methods for determining the variables that facilitate nuclease-induced gene<br />
repair and application <strong>of</strong> this knowledge to use in primary cells populations. To address these goals we will present data describing: 1)<br />
a novel genome engineering reporter system, that supports rapid flow cytometry analysis <strong>of</strong> repair pathway choice at individual DNA<br />
breaks: and 2) progress in applying viral gene modification strategies in a primary cell models <strong>of</strong> immune deficiency disease.<br />
Toni Cathomen, PhD<br />
Exploring and Exploiting Designer Nucleases for Targeted Genome Editing<br />
Designer nucleases, such as zinc-finger nucleases (ZFNs), are a powerful tool to edit the genome <strong>of</strong> complex organisms at will.<br />
As a consequence, designer nucleases have developed into a major playmaker in the genome engineering field and have been<br />
employed to trigger the targeted editing <strong>of</strong> genomes at over 50 different gene loci in more than 10 organisms, including human<br />
stem cells. In my talk, I will summarize the technological innovations that have successfully catapulted ZFNs into the gene therapy<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
arena and provide an overview <strong>of</strong> parameters that determine ZFN activity and ZFN-associated toxicity, both key qualities in any<br />
therapeutic application involving designer nucleases. As a final point, I will present data that introduce TALe-based nucleases as a<br />
valuable alternative to ZFNs.<br />
David W. Russell, MD, PhD<br />
<strong>Gene</strong> Targeting with Adeno-Associated Virus Vectors<br />
AAV vectors efficiently recombine with homologous chromosomal sequences in mammalian cells. Up to 1% <strong>of</strong> the entire cell<br />
population exposed to vector particles undergoes gene targeting under optimal conditions. Insertions, deletions and substitutions<br />
can all be introduced with high fidelity. The technique works well in many cell types, including transformed cell lines, stem cells,<br />
and even in vivo in murine hepatocytes. In human pluripotent stem cells we have used AAV vectors to target disease-causing<br />
genes and manipulate chromosomes.<br />
SCIENTIFIC SYMPOSIUM 444<br />
4:15 pm - 6:15 pm<br />
Room: 608-609<br />
Viral Vectors for Immunomodulation <strong>of</strong> Cancer: From Bed to Bench<br />
CHAIR<br />
Laurence JN Cooper, MD, PhD<br />
SPEAKERS<br />
Howard L. Kaufman, MD<br />
Oncolytic Herpes Simplex Virus-1 Encoding GM-CSF for the Treatment <strong>of</strong> Malignant Melanoma<br />
Oncovex GM-CSF is an oncolytic herpes simplex virus-1 (HSV-1) in which the ICP 34.5 and ICP47 genes have been deleted and human<br />
GM-CSF has been inserted. The vector demonstrated therapeutic activity and an acceptable safety pr<strong>of</strong>ile in a multi-institutional<br />
Phase II clinical trial. Treatment was associated with local and systemic melanoma-specific CD8+ T cell responses and decreases in<br />
CD4+CD25+FoxP3+ regulatory T cells and myeloid-derived suppressor cells. An international prospective randomized Phase III clinical<br />
trial is being conducted. The background rationale, study design, current status and future plans for Oncovex GM-CSF will be discussed.<br />
Brian Lichty, PhD<br />
Boosting Anti-tumour Immunity with Oncolytic Vaccine Vectors<br />
Replicating viral vectors are attractive candidate cancer therapeutics as they can directly mediate tumour destruction via viral<br />
oncolysis while inducing anti-tumour immunity. These two means <strong>of</strong> tumour destruction work together to mediate optimal<br />
therapeutic impact and a reduction in either can reduce efficacy. It is however challenging to develop anti-tumour immune<br />
responses with replicating viral vectors as these are highly immunogenic and anti-viral immune responses will dominate. We have<br />
shown that oncolytic rhabdoviral vaccine vectors are very potent boosters <strong>of</strong> tumour vaccines able to generate massive antitumour<br />
immune responses in tumour-bearing hosts. The mechanisms underlying these effects and additional means to further<br />
enhance the effects will be presented.<br />
Richard G. Vile, PhD<br />
Oncolytic Virotherapy and the Immune System: Montague and Capulet or Yin and Yang?<br />
The efficacy <strong>of</strong> oncolytic virotherapy for cancer is inextricably linked to the interaction between the virus, the tumor cells and<br />
the immune system. Immune reactivity to the virus will clearly hinder anti tumor efficacy in as far as it inhibits delivery (through<br />
neutralising antibody) as well as intra-tumral spread and replication (through the activity <strong>of</strong> both innate effectors as well as<br />
anti-viral adpative T cell responses). Conversely, innate and adaptive effectors to the virus can contribute significantly to tumor<br />
clearance, can lead to the generation <strong>of</strong> adaptive responses directed against tumor cells and can even enhance systemic delivery<br />
<strong>of</strong> viruses by protecting them from neutralization. Data will be presented showing how the tension between oncolytic virotherapy<br />
and the immune system can be reconciled to generate more effective anti tumor therapies.<br />
Akseli Hemminki, MD, PhD<br />
Personalized Cancer <strong>Therapy</strong> with Oncolytic Adenoviruses<br />
The attractiveness <strong>of</strong> personalized medicine with oncolytic adenoviruses has been recognized by EU legislators and patient-bypatient<br />
treatments are regulated by the Advanced Therapies directive (EU 1394/2007), which has allowed us to treat more than 240<br />
patients with 10 different viruses in an Advanced <strong>Therapy</strong> Access <strong>Program</strong> (also known as “hospital exemption” or “named patient<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 75<br />
Saturday, May 21
Saturday, May 21<br />
76<br />
<strong>Program</strong> Schedule Saturday, May 21, 2011<br />
basis”). The optimal virus capsid, tumor specific promoter, arming device and virus sensitizers (temozolomide, 3 different schedules<br />
<strong>of</strong> cyclophosphamide) are selected based on preclinical and clinical data, taking into account the nature <strong>of</strong> the clinical problem in<br />
each patient, while switching the viral capsid has been utilized to enhance systemic delivery. Injections have been performed in<br />
ultrasound, visual or CT guidance, intratumorally, intracavitary and/or intravenously on an individual basis. Both archival and fresh<br />
pretreatment tumor samples have been studied by microarray, transduction, cell killing and immunohistochemistry for selecting<br />
the optimal virus and for prediction <strong>of</strong> efficacy. Safety, efficacy, biological, virological and immunological data will be reported.<br />
POSTER HALL SOCIAL<br />
6:15 pm - 8:15 pm<br />
Room: Hall 4B<br />
POSTER SESSION III<br />
6:15 pm - 8:15 pm<br />
Room: Hall 4B<br />
AAV Experimental Therapeutics<br />
(Abstracts 654-672; see pages 134-135)<br />
Adenovirus and Other DNA Virus Vectors III<br />
(Abstracts 673-685; see pages 135-136)<br />
DNA Vectorology & <strong>Gene</strong> Targeting - II<br />
(Abstracts 686-700; Abstract 699 moved to Poster Session II; see page 136)<br />
Physical Methods <strong>of</strong> Delivery II<br />
(Abstracts 701-711; see page 137)<br />
<strong>Gene</strong>tic and Metabolic Diseases <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> III<br />
(Abstracts 712-724; Abstract 712 moved to Poster Session I; see pages 137-138)<br />
Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
(Abstracts 725-743; see pages 138-139)<br />
Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
(Abstracts 744-756; see page 140)<br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
(Abstracts 757-774; Abstract 772 withdrawn; see pages 140-141)<br />
Cancer-Immunotherapy III<br />
(Abstracts 775-792; see pages 141-143)<br />
Cancer-Oncolytic Viruses II<br />
(Abstracts 793-808; see pages 143-144)<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> III<br />
(Abstracts 809-819; see page 144)<br />
Hematologic and Immunologic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
(Abstracts 820-833; Abstract 831 moved to Poster Session I; see page 145)<br />
Oligonucleotide & RNAi Therapeutics II<br />
(Abstracts 834-851; Abstract 837 moved to Poster Session II; see pages 145-147)<br />
Stem <strong>Cell</strong> Therapies III<br />
(Abstracts 852-866; Abstract 856 withdrawn; see page 147)<br />
Late Abstract III<br />
(Abstracts 911-932; Abstract 914 moved to Poster Session I; see pages 148-149)<br />
ANNUAL MEETING CONCLUDES<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Exhibit Hall Floor Plan<br />
S<br />
4 1 2<br />
F<br />
EXIT<br />
GATE 7<br />
WOMEN MEN<br />
WOMEN<br />
F<br />
4C-2<br />
4C-1<br />
FE<br />
FHC<br />
CWF<br />
EXIT<br />
MEN<br />
FHC<br />
D<br />
FE<br />
FHC<br />
GATE 6<br />
D<br />
18' VERTICAL CLEARANCE<br />
THIS AREA<br />
FE<br />
FHC<br />
F<br />
FHC<br />
FE<br />
CWF<br />
ESCALATORS<br />
FLOORS 4 & 6<br />
ONLY<br />
EXIT DELI "B"<br />
EXIT<br />
EXIT<br />
WOMEN<br />
F<br />
FE<br />
FHC<br />
UP<br />
DOWN<br />
MEN<br />
498.1<br />
EXIT<br />
UP TO 5<br />
SHOW<br />
COATS<br />
EXIT<br />
F<br />
FHC<br />
EXIT<br />
GATE 5<br />
12’ 10’<br />
Job Exchange<br />
22’<br />
213<br />
211<br />
209<br />
207<br />
205<br />
203<br />
201<br />
F<br />
Aisle 200<br />
10’<br />
214<br />
212<br />
204<br />
202<br />
ENTRANCE<br />
SCALE<br />
0' 5' 10' 15' 20' 30' 40' 50' 60'<br />
313<br />
311<br />
FHC<br />
FE<br />
F<br />
Food & Beverage<br />
303<br />
301<br />
HALLS 4A & 4B<br />
44-10x10 booths<br />
154-4x8 posters<br />
Ceiling Height 25'<br />
Aisle widths 10' unless noted<br />
ASGT 14th Annual Meeting<br />
May 18-21. 2011<br />
Washington State Convention & Trade Center<br />
Seattle, Washington<br />
Aisle 300<br />
10’<br />
NORTH<br />
314<br />
312<br />
304<br />
302<br />
15’<br />
F<br />
15’<br />
413<br />
411<br />
403<br />
401<br />
10’<br />
10’<br />
10’<br />
10’<br />
10’<br />
10’<br />
10’<br />
10’<br />
12’<br />
10’<br />
10’<br />
Aisle 400 10’<br />
FHC<br />
FE<br />
414 513<br />
412 511<br />
410 509<br />
408 507<br />
406 505<br />
404 503<br />
402 501<br />
F<br />
PUBLIC<br />
PHONES<br />
ENTRANCE<br />
Aisle 500<br />
10’<br />
F<br />
SOUTH SERVICE CORRIDOR<br />
514<br />
512<br />
510<br />
508<br />
506<br />
504<br />
502<br />
439<br />
South<br />
Lobby<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 77<br />
40'<br />
Fill-in<br />
Kiosk<br />
FE<br />
FE<br />
FHC<br />
FE<br />
FE<br />
FHC<br />
438<br />
Internet Kiosks<br />
& Message Board<br />
PUBLIC<br />
PHONES<br />
Registration<br />
Storage Area<br />
BALCONY LINE ABOVE<br />
F<br />
F<br />
FHC<br />
FE<br />
EXIT<br />
UP TO 5<br />
FHC F SHOW<br />
EXIT<br />
F<br />
F<br />
CWF<br />
UP TO 5 & 6<br />
EXIT<br />
4A<br />
GATE 4<br />
EXIT<br />
MEN<br />
GRAND<br />
STAIRWAY<br />
FHC<br />
FE<br />
WOMEN<br />
GRAND<br />
STAIRWAY<br />
LOUNGE<br />
EXIT<br />
PU<br />
PH
78<br />
Exhibitor Descriptions<br />
Adaptive TCR Technologies<br />
307 Westlake Avenue N<br />
Suite 300<br />
Seattle, WA 98109<br />
Phone: (206) 659-0521<br />
Fax: (206) 659-0667<br />
E-mail: cdesmarais@adaptivetcr.com<br />
Website: www.adaptivetcr.com<br />
Booth Number: 504<br />
Adaptive’s TCR Pr<strong>of</strong>iling service provides a biochemical method<br />
for parallel sequencing <strong>of</strong> millions <strong>of</strong> TCRs with the data<br />
analysis capability <strong>of</strong> a secure proprietary relational database<br />
management system. Adaptive’s immunoSEQ system combines<br />
the capabilities <strong>of</strong> ultrahigh-throughput DNA sequencing<br />
with a proprietary sequencing methodology and a powerful<br />
bioinformatics s<strong>of</strong>tware suite to provide exceptionally deep<br />
access to T cell repertoires.<br />
Aldevron<br />
3233 15th Street South<br />
Fargo, ND 58104<br />
Phone: (701) 499-7300<br />
Fax: (701) 280-1642<br />
E-mail: halland@aldevron.com<br />
Website: www.aldevron.com<br />
Booth Number: 207<br />
Aldevron is a world-leader in plasmid DNA, protein, and<br />
antibody production. Aldevron also provides DNA vaccine<br />
screening and genetic immunization (GIA) services. We<br />
manufacture biologics for research, clinical, and diagnostic<br />
applications. Aldevron also <strong>of</strong>fers a broad portfolio <strong>of</strong> readyto-use<br />
plasmids including AAV helper, cytokine, and reporter<br />
vectors. Aldevron’s capacity and throughput capabilities support<br />
any project in bacterial, insect, and mammalian cell systems. By<br />
combining innovative technologies with best-in-class project<br />
management, our team ensures that we consistently exceed<br />
your expectations.<br />
AltheaDx<br />
3550 Dunhill Street<br />
San Diego, CA 92121<br />
Phone: (916) 812-0813<br />
E-mail: mclendenin@altheadx.com<br />
Website: www.altheadx.com<br />
Booth Number: 313<br />
AltheaDx is bringing theranostics into clinical use, with six<br />
companion diagnostic projects currently underway. The goal<br />
<strong>of</strong> AltheaDx is to reduce the time, risk, and cost <strong>of</strong> therapeutic<br />
development for our partners and to provide a clear path for<br />
development and commercialization <strong>of</strong> high-value companion<br />
diagnostic tests.<br />
<strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
555 East Wells Street<br />
Suite 1100<br />
Milwaukee, WI 53202<br />
Phone: (414) 278-1341<br />
Fax: (414) 276-3349<br />
E-mail: info@asgct.org<br />
Website: www.asgct.org<br />
Booth Number: 505 & 507<br />
Stop by the ASGCT membership booth to find out where the<br />
2012 Annual Meeting will be held, pick up a copy <strong>of</strong> Molecular<br />
<strong>Therapy</strong>, and learn about the <strong>Society</strong>’s new strategic plan!<br />
Axis-Shield PoC<br />
PO Box 6863 Rodelokka<br />
Oslo, 0504<br />
Norway<br />
Phone: +4724056000<br />
Fax: +4724056010<br />
E-mail: bjh@axis-shield.com<br />
Website: www.axis-shield-density-gradient-media.com<br />
Booth Number: 413<br />
Axis-Shield will display a range <strong>of</strong> Density Gradient Media<br />
for the isolation <strong>of</strong> biological particles using centrifugation<br />
techniques.<br />
BioSpherix<br />
19 Demott Street<br />
Lacona, NY 13145<br />
Phone: (315) 387-3414 x 206<br />
Fax: (315) 387-3415<br />
E-mail: kbenedict@biospherix.com<br />
Website: www.biospherix.com<br />
Booth Number: 301<br />
BioSpherix will be exhibiting the Xvivo System, the world’s<br />
first and only point-<strong>of</strong>-care cGMP compliant cell and tissue<br />
incubation and processing systems for cell and gene therapy.<br />
For any application: explants or implants; minimal or maximal<br />
manipulation; autologous or allogeneic cells; pre or post<br />
biorepository. Stop by BioSpherix booth #301.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Exhibitor Descriptions<br />
Caliper Life Sciences<br />
68 Elm Street<br />
Hopkinton, MA 01748<br />
Phone: (508) 435-9500<br />
Fax: (508) 435-3439<br />
Website: www.caliperls.com<br />
Booth Number: 411<br />
Caliper Life Sciences is a leading supplier <strong>of</strong> technology for in<br />
vitro and in vivo applications in life science and drug discovery<br />
research. Caliper Products include both the IVIS and Maestro in<br />
vivo imaging platforms, and the Nuance multispectral imaging<br />
system for multiplexed fluorescence microscopy applications<br />
to study processes like disease progression or stem cell<br />
engraftment.<br />
Center for <strong>Cell</strong>ular and Molecular<br />
Therapeutics at the Children’s Hospital <strong>of</strong><br />
Philadelphia<br />
3501 Civic Center Blvd., Room 5059<br />
Colket Translational Research Building<br />
Philadelphia, PA 19104<br />
Phone: (267) 426-5256<br />
Fax: (215) 590-3660<br />
E-mail: sunj@email.chop.edu<br />
Booth Number: 209<br />
Our Center is dedicated to the understanding, development,<br />
and application <strong>of</strong> gene and cell therapies and the promotion<br />
<strong>of</strong> pr<strong>of</strong>essional and public education in the field. The Center<br />
fosters a multidisciplinary approach to discover gene and cell<br />
therapies in search <strong>of</strong> cures for debilitating and life threatening<br />
childhood disorders.<br />
Data Unlimited International, Inc.<br />
15881-B Crabbs Branch Way<br />
Rockville, MD 20855<br />
Phone: (240) 631-7933<br />
Fax: (240) 631-7937<br />
E-mail: fkan@duii.com<br />
Website: www.duii.com<br />
Booth Number: 203<br />
Starfruit Technologies ® is s<strong>of</strong>tware/database/computer/barcode<br />
for DNA diagnostic, genome/cancer research, immunogenetic<br />
labs – enables sample, patient, biorepository, billing databases;<br />
mutation, variant, disease, genotype databases, SNP databank;<br />
instrument interface, barcode, electronic signature, QA/<br />
QC; worksheet, workflow, inventory, protocol, image;<br />
epidemiological frequency, trend, geographical distribution,<br />
disease/disorder susceptibility, reporting; comply with 21CFR11,<br />
CAP, CLIA, HIPPA, PHI.<br />
Freezerworks<br />
A Division <strong>of</strong> Dataworks Development, Inc.<br />
PO Box 174<br />
Mountlake Terrace, WA 98043<br />
Phone: (425) 673-1974<br />
Fax: (425) 673-2506<br />
E-mail: sales@freezerworks.com<br />
Website: www.freezerworks.com<br />
Booth Number: 211<br />
Specializes in sample management s<strong>of</strong>tware and services<br />
in support <strong>of</strong> biorepositories, clinical trials and cancer<br />
research. Fully user configurable, Freezerworks safeguards<br />
data with powerful user and group security, integration<br />
tools, 21 CFR part 11 compliance, and cryogenic-safe bar code<br />
labeling. CaBig compatible.<br />
GENE TOOLS, LLC<br />
1001 Summerton Way<br />
Philomath, OR 97370<br />
Phone: (541) 929-7840 Ext. 1011<br />
Fax: (541) 929-7841<br />
E-mail: zli@gene-tools.com<br />
Website: www.gene-tools.com<br />
Booth Number: 202<br />
<strong>Gene</strong> Tools manufactures Morpholino oligos for blocking<br />
translation, modifying splicing or inhibiting miRNA activity.<br />
Morpholinos are used in cell cultures, embryos or, as Vivo-<br />
Morpholinos, in adult animals. Morpholinos are effective,<br />
specific, stable and non-toxic. Backed by Ph.D.-level customer<br />
support, <strong>Gene</strong> Tools designs and synthesizes Morpholinos and<br />
<strong>of</strong>fers cytosolic delivery options.<br />
GENEWIZ, Inc.<br />
115 Corporate Blvd.<br />
South Plainfield, NJ 07080<br />
Phone: (877) 436-3949 Ext. 3206<br />
Fax: (908) 333-4511<br />
E-mail: jeffrey.shaman@genewiz.com<br />
Website: www.genewiz.com<br />
Booth Number: 204<br />
GENEWIZ, Inc. supports your needs for regulatory services<br />
from pre-clinical testing through biomanufacturing. Our DNA<br />
sequencing and molecular biology GLP services allow our<br />
clients to focus on their core capabilities while getting the<br />
design, preparation, testing, and data for the biologics needed<br />
in their therapeutic and diagnostic applications. For more<br />
information, contact GLP@genewiz.com.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 79
80<br />
Exhibitor Descriptions<br />
Horizon Discovery Ltd<br />
Building 7300<br />
IQ Cambridge<br />
Cambridge, Cambridgeshire CB25 9TL<br />
United Kingdom<br />
Phone: 0044 1223655580<br />
Fax: 0044 1223862240<br />
E-mail: info@horizondiscovery.com<br />
Website: www.horizondiscovery.com<br />
Booth Number: 501<br />
Horizon Discovery employs its proprietary rAAV genome editing<br />
platform to modify human and mammalian cell lines. Products<br />
and services include OTS & custom X-MAN (gene-X, mutant<br />
and normal) isogenic human cell-lines, assays and diagnostic<br />
reagents. Horizon is applying its gene editing platform into<br />
additional areas including bioproduction and regenerative<br />
medicine.<br />
Lonza<br />
8830 Biggs Ford Rd.<br />
Walkersville, MD 21793<br />
Phone: (301) 898-7025<br />
Fax: (301) 845-4024<br />
E-mail: celltherapy@lonza.com<br />
Website: www.lonza.com<br />
Booth Number: 311<br />
Lonza <strong>of</strong>fers world class technology platforms in the areas <strong>of</strong><br />
GMP cell culture and viral-based therapeutic manufacturing,<br />
custom biotherapeutic culture media, a large selection <strong>of</strong><br />
primary and stem cells and a full line <strong>of</strong> custom bioassays.<br />
Our extensive experience in <strong>Cell</strong> and <strong>Gene</strong><strong>Therapy</strong> process<br />
optimization and scale-up innovation helps clients to safely and<br />
effectively advance their products through all phases <strong>of</strong> the<br />
commercial pipeline and maximize their return on investment.<br />
Lovelace Respiratory Research Institute<br />
2425 Ridgecrest Drive SE<br />
Albuquerque, NM 87108<br />
Phone: (505) 348-9456<br />
Fax: (505) 348-4983<br />
E-mail: wbechtol@lrri.org<br />
Website: www.lrri.org<br />
Booth Number: 404<br />
The Lovelace Respiratory Research Institute is a private not-forpr<strong>of</strong>it<br />
biomedical research organization. Lovelace <strong>of</strong>fers animal<br />
models <strong>of</strong> disease, evaluation <strong>of</strong> efficacy <strong>of</strong> potential new<br />
therapeutics, and pre-clinical assessments including evaluation<br />
<strong>of</strong> pharmacokinetics/biodistribution in large and small animal<br />
models. Studies are routinely performed under GLP guidelines.<br />
Mary Ann Liebert, Inc.<br />
140 Huguenot Street, 3 rd Floor<br />
New Rochelle, NY 10801<br />
Phone: (914) 740-2100<br />
Fax: (914) 740-2101<br />
E-mail: info@liebertpub.com<br />
Website: www.liebertpub.com<br />
Booth Number: 412<br />
Mary Ann Liebert, Inc., publishes authoritative journals in<br />
new and promising areas <strong>of</strong> science and biomedical research<br />
including Human <strong>Gene</strong> <strong>Therapy</strong>, (www.liebertpub.com/hum);<br />
<strong>of</strong>ficial journal <strong>of</strong> 9 international societies; named one <strong>of</strong> the<br />
100 most influential Journals in Biology & Medicine over the last<br />
100 years! Visit us at booth #412.<br />
Meridian Life Science, Inc.<br />
3471 River Hills Drive<br />
Cincinnati, OH 45244<br />
Phone: (513) 271-3700<br />
Fax: (513) 271-3762<br />
E-mail: shirley.torrence@meridianbioscience.com<br />
Website: www.meridianlifescience.com<br />
Booth Number: 403<br />
MolMed S.p.A.<br />
Via Olgetinna, 58<br />
Milan, 20132<br />
Italy<br />
Phone: +39 0221277257<br />
Fax: +39 0221277325<br />
Email: simona.laseta@molmed.com<br />
Website: www.molmed.com<br />
Booth Number: 511<br />
MolMed is a medical biotechnology company focused<br />
on research, development and clinical validation <strong>of</strong> novel<br />
antitcancer therapies with also key expertise in cell and gene<br />
therapy. MolMed’s service area, GMP Solutions, provides tailormade<br />
services for manufacturing <strong>of</strong> patient-specific cells<br />
and genetically modified cells, and active pharmaceutical<br />
ingredients for clinical use.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Exhibitor Descriptions<br />
NanoSight<br />
6660 N. High Street, Suite 2A<br />
Worthington, OH 43085<br />
Phone: (614) 888-0023<br />
Fax: (614) 987-0045<br />
E-mail: colleen.munhall@nanosight.com<br />
Website: www.nanosight.com<br />
Booth Number: 212<br />
NanoSight manufactures instruments for Counting, Sizing and<br />
Visualizing Nanoparticles from 10 nm to 2.0 µm. Applications<br />
include measuring viral titre, Labeled and unlabeled Exosomes,<br />
Protein aggregation kinetics and all types <strong>of</strong> metal colloids.<br />
Nanoparticle Tracking Analysis (NTA) visualizes the particles being<br />
analyzed which enables the operator to perform an immediate<br />
qualitative examination <strong>of</strong> the particles being measured.<br />
National <strong>Gene</strong> Vector Biorepository (NGVB)<br />
980 W. Walnut Street, R3 C602<br />
Indianapolis, IN 46202-5188<br />
Phone: (317) 274-4519<br />
Fax: (317) 278-3327<br />
E-mail: lrubin@iupui.edu<br />
Website: https://www.ngvbcc.org<br />
Booth Number: 205<br />
The National <strong>Gene</strong> Vector Biorepository provides support for<br />
gene therapy research by <strong>of</strong>fering several services. Check out<br />
the reagent repository comprising cell lines, plasmids and other<br />
tools used in gene therapy research. There are archiving services<br />
to meet FDA requirements. The NGVB will store clinical post-trial<br />
samples, final product reserves, and master cell banks as well<br />
as pharmacology/toxicology samples. A pharm/tox database<br />
containing gene therapy tox studies is a valuable resource. We<br />
<strong>of</strong>fer assistance with insertional mutagenesis analysis through<br />
the SeqMap Bioinformatic Tool as well as LAM-PCR and other<br />
testing services. Go to https://www.ngvbcc.org or come and<br />
see us in Booth 205.<br />
Nature Publishing Group<br />
75 Varick Street, 9 th Floor<br />
New York, NY 10013<br />
Phone: (212) 726-9200<br />
E-mail: institutions@nature.com<br />
Website: www.nature.com<br />
Booth Number: 402<br />
Nature Publishing Group brings leading scientific and medical<br />
research to your desk top. The NPG portfolio combines the<br />
continued excellence <strong>of</strong> Nature, its associated research and<br />
review journals, and 50 leading academic and society journals<br />
in the life, physical and clinical sciences. Visit Booth 402 for free<br />
sample copies.<br />
Nature Technology Corporation<br />
4701 Innovation Dr.<br />
Lincoln, NE 68521<br />
Phone: (402) 472-6530<br />
Fax: (402) 472-6532<br />
E-mail: jvincent@natx.com<br />
Website: www.natx.com<br />
Booth Number: 303<br />
Nature Technology Corporation is a discovery-based<br />
bioengineering technology company, providing industry<br />
partners with safe and efficacious non-viral vectors (plasmids)<br />
and processes for gene therapy and DNA vaccination research.<br />
NTC’s molecular services include vector construction, plasmid<br />
DNA manufacturing and recombinant proteins.<br />
Nexcelom Bioscience<br />
360 Merrimack Street, Bldg. #9<br />
2nd Floor<br />
Lawrence, MA 01843<br />
Phone: (978) 327-5340<br />
Fax: (978) 327-5341<br />
E-mail: lvavra@nexcelom.com<br />
Website: www.nexcelom.com<br />
Booth Number: 401<br />
Nexcelom’s <strong>Cell</strong>ometer line <strong>of</strong> simple-to-use cell counters<br />
automate manual cell counting procedures by obtaining<br />
accurate counts, viability, and cell sizes in less than 30 seconds &<br />
only 20uL <strong>of</strong> sample. Fluorescence detection capabilities enable<br />
fast & simple determination <strong>of</strong> GFP transfection rates, PI-viability,<br />
& direct counting <strong>of</strong> WBCs without lysing.<br />
NHLBI <strong>Gene</strong> <strong>Therapy</strong> Resource <strong>Program</strong><br />
2 Rockledge Center<br />
6701 Rockledge Drive<br />
Bethesda, MD 20892-7940<br />
Phone: (301) 435-0477<br />
Fax: (301) 628-1929<br />
E-mail: gtrpccc@s-3.com<br />
Website: www.gtrp.org<br />
Booth Number: 408<br />
The NHLBI <strong>Gene</strong> <strong>Therapy</strong> Resource <strong>Program</strong> (GTRP) facilitates<br />
the translation <strong>of</strong> gene therapy research into clinical<br />
interventions primarily in heart, lung, and blood diseases.<br />
Services provided by the <strong>Program</strong> include preclinical and<br />
clinical-grade vector production, pharmacology/toxicology<br />
testing, immunology testing, regulatory support, and clinical<br />
trial funding assistance.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 81
82<br />
Exhibitor Descriptions<br />
NIH Office <strong>of</strong> Biotechnology Activities<br />
6705 Rockledge Dr., Suite 750<br />
Bethesda, MD 20892-7985<br />
Phone: (301) 496-9838<br />
Fax: (301) 496-9839<br />
E-mail: oba@od.nih.gov<br />
Website: http://oba.od.nih.gov<br />
Booth Number: 503<br />
NIH Office <strong>of</strong> Biotechnology Activities staff will be available<br />
to answer questions about the oversight <strong>of</strong> recombinant<br />
DNA research and the requirements for Institutional<br />
Biosafety Committees (IBCs) under the NIH Guidelines for<br />
Research Involving Recombinant DNA Molecules. In addition,<br />
information will be available on dual use research in the life<br />
Sciences. Informative materials and handouts related to both<br />
recombinant DNA and dual use research will be available.<br />
Omnia Biologics, Inc.<br />
12111 Parklawn Drive<br />
Rockville, MD 20852<br />
Phone: (301) 984-5928<br />
Fax: (301) 984-2515<br />
E-mail: scardak@omniabiologics.com<br />
Website: www.omniabiologics.com<br />
Booth Number: 302<br />
Omnia Biologics provides cost effective outsourcing <strong>of</strong> product<br />
development services to the biotechnology, pharmaceutical,<br />
and academic biologic drug developers. These services<br />
include process development, cGMP cell and virus banking,<br />
comprehensive cGMP manufacturing services, BSL-3<br />
containment, assay development, formulation and fill/finish.<br />
Omnia has experience with a variety <strong>of</strong> vaccine, gene therapy<br />
and protein therapeutic platforms.<br />
Penn Vector Core, University <strong>of</strong> Pennsylvania<br />
<strong>Gene</strong> <strong>Therapy</strong> <strong>Program</strong><br />
125 South 31st Street, Suite 2000<br />
Philadelphia, PA 19104-3403<br />
Phone: (215) 573-0633<br />
Fax: (215) 573-0300<br />
E-mail: aksandhu@mail.med.upenn.edu<br />
Website: http://www.med.upenn.edu/gtp/vectorcore/<br />
Booth Number: 410<br />
The Penn Vector Core is a full service viral vector core facility<br />
specializing in the production <strong>of</strong> novel AAV serotype vectors. With<br />
over a decade <strong>of</strong> production and development experience, the<br />
Core is a key resource for investigators interested in the use <strong>of</strong><br />
vector tools for gene transfer applications.<br />
Polyplus-transfection<br />
Blvd S. Brant<br />
Bioparc<br />
Illkirch<br />
Bas Rhin<br />
67400<br />
France<br />
Phone:+33 (0) 390 406 474<br />
Fax: +33 (0) 390 406 181<br />
E-mail: latayi@polyplus-transfection.com<br />
Website: www.polyplus-transfection.com<br />
Booth Number: 214<br />
Polyplus-transfection is a Biotech company dedicated to the R<br />
& D and marketing <strong>of</strong> transfection reagents. Polyplus provides<br />
state-<strong>of</strong>-the-art quality reagents for standard in vitro DNA<br />
transfection to human gene therapy, as well as for protein<br />
production in synthetic medium, siRNA delivery and protein<br />
delivery in living cells.<br />
Production Assistance for <strong>Cell</strong>ular<br />
Therapies (PACT)<br />
401 N. Washington Street, Suite 700<br />
Rockville, MD 20850<br />
Phone: (301) 251-1161<br />
Fax: (240) 306-2527<br />
E-mail: pactinfo@pactgroup.net<br />
Website: www.pactgroup.net<br />
Booth Number: 201<br />
The Production Assistance for <strong>Cell</strong>ular Therapies (PACT) program<br />
is an NHLBI-funded initiative created to provide assistance with<br />
cellular therapy translational research and the manufacture <strong>of</strong><br />
cellular therapy products through funded contracts with five<br />
GMP cell processing facilities and a Coordinating Center. Visit<br />
the PACT website at www.pactgroup.net for more information.<br />
ReGenX Biosciences<br />
750 17th Street, NW, Suite 1100<br />
Washington, DC 20006<br />
Phone: (202) 778-2365<br />
Fax: (202) 785-7439<br />
E-mail: jbrown@regenxbio.com<br />
Website: www.regenxbio.com<br />
Booth Number: 304<br />
ReGenX BioSciences is leading the effort to translate promising<br />
gene delivery applications into a pipeline <strong>of</strong> next generation<br />
personalized therapies for a range <strong>of</strong> severe diseases with<br />
serious unmet needs. ReGenX’s NAV gene delivery technology<br />
includes recombinant adeno-associated viral (rAAV) vectors that<br />
<strong>of</strong>fer a platform for safer, highly efficient and specific expression<br />
<strong>of</strong> biologics with therapeutic effect.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Exhibitor Descriptions<br />
Social & Scientific Systems, Inc.<br />
8757 Georgia Avenue, 12th Floor<br />
Silver Spring, MD 20910<br />
Phone: (301) 628-3000<br />
Fax: (301) 628-3001<br />
E-mail: tcockrell@s-3.com<br />
Website: www.s-3.com<br />
Booth Number: 509<br />
St. Jude Children’s Research Hospital<br />
262 Danny Thomas Place<br />
Memphis, TN 38105<br />
Phone: (901) 595-2750<br />
Fax: (901) 595-5376<br />
E-mail: fellowships@stjude.org<br />
Website: www.stjude.org/fellowships<br />
Booth Number: 414<br />
St Jude Children’s Research Hospital is a non-pr<strong>of</strong>it biomedical<br />
research institution in Memphis, TN, where 190 basic science<br />
and clinical researchers investigate the molecular basis <strong>of</strong> both<br />
normal cellular and diseased processes. Visit our booth to<br />
discuss and apply for Postdoctoral Fellowship positions.<br />
Techulon, Inc.<br />
2200 Kraft Drive, Suite 2475<br />
Blacksburg, VA 24060<br />
Phone: (415) 602-0481<br />
Fax: (206) 202-0418<br />
E-mail: frank.akers@techulon.com<br />
Website: www.techulon.com<br />
Booth Number: 312<br />
Techulon provides Glyc<strong>of</strong>ect polymer-based transfection<br />
reagents that deliver DNA and RNA into cells with lower cell<br />
toxicity and high protein expression. In addition to selling<br />
delivery reagents Techulon is seeking collaborators for<br />
therapeutically relevant applications. Free samples are available<br />
for a limited time.<br />
TriLink BioTechnologies, Inc.<br />
9955 Mesa Rim Road<br />
San Diego, CA 92121<br />
Phone: (858) 546-0004<br />
Fax: (858) 546-0020<br />
E-mail: bgrajkowski@trilinkbiotech.com<br />
Website: www.trilinkbiotech.com<br />
Booth Number: 406<br />
TriLink BioTechnologies manufactures custom oligonucleotides,<br />
modified nucleoside triphosphates and CleanAmp PCR<br />
products. In addition, custom chemistry, contract research<br />
services and ISO/QSR compliant cGMP production facilities<br />
are <strong>of</strong>fered. TriLink’s strong pr<strong>of</strong>iciency in nucleoside and<br />
oligonucleotide chemistry means high purity, modified<br />
compounds and expert technical support. For more information<br />
visit www.trilinkbiotech.com.<br />
Waisman Biomanufacturing<br />
1500 Highland Avenue<br />
Madison, WI 53705<br />
Phone: (608) 263-8940<br />
Fax: (608) 263-5725<br />
E-mail: info@GMPbio.org<br />
Website: www.GMPbio.org<br />
Booth Number: 213<br />
Waisman Biomanufacturing is a dedicated manufacturing<br />
facility that provides cGMP manufacturing services for<br />
producing gene and cell therapeutics for early-stage human<br />
clinical trials. Services that are provided by the WCBF range from<br />
process development to clinical production and product fill and<br />
finish and release testing, with full quality system support.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 83
84<br />
Exhibitor Information<br />
<strong>Gene</strong>ral Information<br />
The Exhibit Hall is located in Hall 4B <strong>of</strong> the Washington<br />
State Convention Center. All participants are urged to allow<br />
adequate time in your daily schedule to visit the exhibits. The<br />
companies, organizations and institutions exhibiting at the<br />
ASGCT 14 th Annual Meeting will be providing you with the latest<br />
information on products and services directly related to your<br />
pr<strong>of</strong>essional needs, as well as recruiting for open positions.<br />
Exhibit Dates<br />
Exhibits will be open Wednesday, May 18 through Friday, May<br />
20, 2011.<br />
Exhibitor Registration<br />
The Exhibitor Registration Desk is located across the hallway<br />
from Hall 4B.<br />
Exhibitor Registration Desk Hours<br />
Tuesday, May 17 5:00 pm – 7:00 pm<br />
Wednesday, May 18 7:00 am – 8:00 pm<br />
Thursday, May 19 7:00 am – 5:00 pm<br />
Friday, May 20 7:30 am – 5:00 pm<br />
Exhibit Move In<br />
Wednesday, May 18 9:00 am – 5:00 pm<br />
Exhibit Hall Hours<br />
Wednesday, May 18 5:15 pm – 7:15 pm<br />
Thursday, May 19 10:15 am – 11:00 am<br />
Thursday, May 19 4:40 pm – 6:40 pm<br />
Friday, May 20 9:15 am – 10:00 am<br />
Friday, May 20 4:40 pm – 6:40 pm<br />
Exhibit Move Out<br />
Friday, May 20 6:40 pm – 9:00 pm<br />
Note: All exhibit booths must be staffed during hall hours.<br />
Packing <strong>of</strong> equipment/literature and the dismantling <strong>of</strong> exhibits<br />
will not be permitted until after 6:40 pm on Friday, May 20, 2011.<br />
Exhibitor Badge Policy<br />
Admission to the Exhibit Hall will be by name badge only.<br />
Security guards will monitor exhibit hall entrances for proper I.D.<br />
Exhibit booth personnel must show an <strong>of</strong>ficial ASGCT exhibitor<br />
name badge in order to gain access to the exhibit hall during<br />
installation, show, or dismantlement hours. Independent<br />
contractor personnel, hired by an exhibitor to install and<br />
dismantle their display, do not need to show exhibitor badges,<br />
but should possess identification that they are employed by<br />
the independent contractor. If independent contractors do not<br />
possess proper identification, they should obtain a name badge<br />
at the on-site exhibitor registration desk.<br />
Endorsement Disclaimer<br />
Products and services displayed in the Exhibit Hall or advertised<br />
in this program occur by contractual business arrangements<br />
between the ASGCT and participating companies and<br />
organizations. These arrangements do not constitute or imply<br />
an endorsement by the ASGCT <strong>of</strong> these products and services.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Seattle Fun Facts<br />
Seattle Information<br />
Seattle is two cities in one. It’s a world-class metropolis set within wild, beautiful natural surroundings, <strong>of</strong>fering the best <strong>of</strong> urban<br />
lifestyle while embracing the rugged outdoors—Seattle is a true metronatural city.<br />
Many <strong>of</strong> Seattle’s top visitor attractions are within mere blocks <strong>of</strong> the Washington State Convention Center, including the Pike<br />
Place Market, Pioneer Square, Seattle Art Museum, Seattle Symphony, water tours, ferries, world-class restaurants and repertory<br />
and musical theaters. Three national parks lie within a two-hour drive <strong>of</strong> Seattle and the city is a gateway to the San Juan Islands,<br />
Olympic Peninsula, Washington Wine Country and British Columbia.<br />
Pike Place Market – Situated just above the waterfront, the<br />
market is popular with natives and tourists alike. A vital part<br />
<strong>of</strong> Seattle’s economy, the market features more than 200<br />
businesses, including farmers and merchants <strong>of</strong>fering fresh<br />
vegetables, seafood, food bars, cafes, restaurants, crafts, art work,<br />
and gifts. Home <strong>of</strong> the original Starbucks®, the market was born<br />
in 1907 and is the oldest continually operating farmers’ market<br />
in the USA.<br />
Pioneer Square – Seattle’s oldest neighborhood is a 20-squareblock<br />
National Historic District. Its charming buildings have<br />
been restored and now hold a great arts, café, shopping, and<br />
nightlife scene.<br />
Seattle Center & the Space Needle – The Seattle Center was<br />
built as the United States Science Pavilion for the Seattle World’s<br />
Fair <strong>of</strong> 1962. This complex on 74-acres is home to the 11 theaters,<br />
five gardens, six fountains, restaurants, a skate park and an events<br />
area. The center is also home to The Space Needle, which opened<br />
on the first day <strong>of</strong> the World Fair, features an observation deck,<br />
restaurant and cocktail bar. This most recognizable landmark<br />
in Seattle can be reached by a 90-second monorail ride from<br />
downtown’s Westlake shopping center.<br />
The Seattle Waterfront – The waterfront is a bustling<br />
collection <strong>of</strong> attractions, restaurants and shopping. It is also the<br />
starting point for ferries and cruise ships, including the Victoria<br />
Clipper and Argosy boat tours which are located here. Feed the<br />
seagulls, stroll by the wooden piers <strong>of</strong> Waterfront Park, admire<br />
the view or shop for souvenirs. Also located on the waterfront is<br />
the Olympic Sculpture Park, a must-do for visitors who want<br />
to experience art outdoors while enjoying incredible views<br />
<strong>of</strong> the Olympic Park Mountains, Puget Sound, and Seattle’s<br />
cityscape.<br />
For more information on Seattle, WA and area attractions stop<br />
by the Seattle Convention & Visitors Bureau’s Concierge<br />
Desk in the Washington State Convention Center or your hotel’s<br />
concierge desk.<br />
Please note, the City <strong>of</strong> Seattle issues jaywalking tickets to<br />
individuals who do not follow the traffic laws. Therefore, please<br />
abide by the traffic signs and lights and utilize the designated<br />
crosswalks at all times.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 85
86<br />
Housing Information and Map <strong>of</strong> Seattle<br />
1) Sheraton Seattle – Headquarters Hotel<br />
1400 Sixth Avenue<br />
Seattle, Washington 98101<br />
Phone: (206) 621-9000<br />
2) Grand Hyatt Seattle<br />
721 Pine Street<br />
Seattle, Washington 98101<br />
Phone: (206) 774-1234<br />
W Republican St<br />
W Harrison St<br />
W Thomas St<br />
John St<br />
Elliott Avenue<br />
Terminal 91<br />
Pier 70<br />
Queen Anne<br />
Ave N<br />
Olympic<br />
Sculpture Park<br />
Victoria Clipper<br />
1st Ave N<br />
Pier 69<br />
Pier 67<br />
Roy St<br />
SEATTLE<br />
CENTER<br />
2nd Ave N<br />
Broad St<br />
Alaskan Way<br />
Cedar St<br />
Vine St<br />
Wall St<br />
Mercer St<br />
Clay St 6th Ave N<br />
Bell Harbor International<br />
Conference Center<br />
Pier 66/Bell St.<br />
Cruise Terminal<br />
Ferry to Tillicum Village<br />
*<br />
Space<br />
Needle<br />
Experience<br />
Music Project<br />
Tilikum Place<br />
Battery St<br />
Pier 62 & 63<br />
Elliott Bay<br />
Republican St<br />
Harrison St<br />
5th Ave N<br />
Taylor Ave N<br />
Bell St<br />
Western Ave<br />
Ferry to Bainbridge Island<br />
Denny Way<br />
5th Ave<br />
Blanchard St<br />
Pier 59<br />
4th Ave<br />
Lenora St<br />
1st Ave<br />
Seattle Aquarium<br />
Ferry to Bremerton<br />
Regrade Park<br />
Steinbrueck<br />
Park<br />
Waterfront Park<br />
Pier 57<br />
Pier 56<br />
Pier 55<br />
sland<br />
Aurora Ave N<br />
6th Ave<br />
2nd Ave<br />
3) Hyatt at Olive 8<br />
1635 8th Avenue<br />
Seattle, Washington 98101<br />
Phone: (206) 695-1234<br />
4) The Westin Seattle<br />
1900 5th Avenue<br />
Seattle, Washington 98101<br />
Phone: (206) 728-1000<br />
To Lake Union<br />
Dexter Ave N<br />
Thomas St<br />
7th Ave<br />
3rd Ave<br />
Pier 54<br />
John St<br />
PIKE PLACE MARKET<br />
Pier 52<br />
8th Ave<br />
WA State<br />
Ferries<br />
Pine St<br />
9th Ave<br />
Union St<br />
Post Alley<br />
Virginia St<br />
Terry Ave<br />
Olive Way<br />
University St<br />
Seneca St<br />
Spring St<br />
Marion St<br />
Madison St<br />
Columbia St<br />
Minor Ave<br />
Howell St<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
8th Ave N<br />
Pier 48<br />
9th Ave N<br />
Pike St<br />
Westlake Ave N<br />
4<br />
Terry Ave N<br />
Westlake<br />
Park<br />
Boren Ave N<br />
Stewart St<br />
Fairview Ave N<br />
Bus<br />
Terminal<br />
Pioneer<br />
Square Park<br />
LEGEND<br />
1. Sheraton Seattle Hotel<br />
2. Grand Hyatt Seattle<br />
3. Hyatt at Olive 8<br />
4. Westin Seattle Hotel<br />
3<br />
1<br />
2<br />
Occidental<br />
Square<br />
Minor Ave N<br />
4th Ave<br />
PIONEER<br />
CONVENTION CENTER<br />
Citywide Concierge<br />
& Visitor Center<br />
5th Ave<br />
City Hall<br />
Park<br />
Freeway Park<br />
6th Ave<br />
7th Ave<br />
8th Ave<br />
Jefferson St<br />
3rd Ave S<br />
2nd Ave S<br />
Boren-Pike-Pine Park<br />
Terrace<br />
9th Ave<br />
Terry Ave<br />
Cherry St<br />
NORTH<br />
James St<br />
Kobe<br />
Terrace<br />
Park<br />
Summit Ave<br />
Boren Ave<br />
Boylston Ave<br />
Minor Ave<br />
Alder St<br />
Yesler Way<br />
Broadway Ave<br />
S Washington St<br />
S Main St<br />
S Jackson St
Abstract Directory Wednesday, May 18, 2011<br />
ORAL ABSTRACT SESSION 130<br />
Adenovirus and Other DNA Virus Vectors I:<br />
Virus Entry<br />
3:15 PM - 5:15 PM<br />
Room: 606-607<br />
1 3:15 PM<br />
Retargeting Parvovirus B19 to HER2/neu-Positive <strong>Cell</strong>s for<br />
Breast Cancer Treatment<br />
Harald G. P. Messer, Yiwen Xiang, Mavis Agbandje-McKenna,<br />
Kirsten A. K. Weigel-Van Aken.<br />
2 3:30 PM<br />
Identification <strong>of</strong> the Receptor for Adenovirus Serotypes 3,<br />
7, 11, and 14: Structural Analysis <strong>of</strong> Adenovirus – Receptor<br />
Interaction<br />
Hongjie Wang, ZongYi Li, Jonas Persson, Ines Beyer, Robert<br />
Strauss, Akseli Hemminki, Pascal Fender, Andre Lieber.<br />
3 3:45 PM<br />
Multi-Year Transgene Expression in Nonhuman Primates<br />
Following Hepatic Transduction with Helper-Dependent<br />
Adenoviral Vectors<br />
Nicola Brunetti-Pierri, Gary Stapleton, Thomas Ng, David<br />
Iannitti, William Ci<strong>of</strong>fi, Mark Law, John Breinholt, Donna<br />
Palmer, Nathan Grove, Milton Finegold, Arthur Beaudet,<br />
Charles Mullins, Philip Ng.<br />
4 4:00 PM<br />
The Refinement <strong>of</strong> the Molecular Model <strong>of</strong> Adenovirus<br />
Binding to Blood Coagulation Factors and the Role <strong>of</strong> This<br />
Interaction in Virus Recognition by the Host<br />
Konstantin Doronin, Justin Flatt, Steffen Lindert, Dewight R.<br />
Williams, Phoebe L. Stewart, Dmitry M. Shayakhmetov.<br />
5 4:15 PM<br />
Suppression <strong>of</strong> Protein Phosphatase 2A Activity Enhances<br />
Ad5/F35 Adenovirus Transduction Efficiency in Human<br />
Normal B Lymphocytes and <strong>Cell</strong> Lines<br />
Marie-Pierre Cayer, Mélanie Samson, Claudia Bertrand, Nellie<br />
Dumont, Mathieu Drouin, Daniel Jung.<br />
6 4:30 PM<br />
Basic Residues in the Heparin-Binding Exosite <strong>of</strong> the<br />
Factor X Serine Protease Domain Mediate Ad5/FX Complex<br />
Binding to Hepatocytes<br />
Margaret R. Duffy, Angela C. Bradshaw, John H. McVey, Alan L.<br />
Parker, Andrew H. Baker.<br />
7 4:45 PM<br />
GSK3beta-Mediated Regulation <strong>of</strong> the Coxsackie-<br />
Adenovirus Receptor Influences Adenovirus Infection<br />
Priyanka Sharma, Kathleen Frondorf, Katherine J. D. A.<br />
Exc<strong>of</strong>fon.<br />
8 5:00 PM<br />
Mining the Adeno-”Virome” for Effective Oncolytics<br />
Against Solid Tumors and Leukemias<br />
Chris Y. Chen, Julien S. Senac, Eric A. Weaver, Reeti Khare,<br />
Shannon M. May, Michael A. Barry.<br />
ORAL ABSTRACT SESSION 131<br />
DNA Vectorology<br />
3:15 PM - 5:15 PM<br />
Room: 6A<br />
9 3:15 PM<br />
Chromatin Structure Effects on Integration <strong>of</strong><br />
Gammaretroviruses MLV and XMRV<br />
Shoshannah L. Roth, Nirav Malani, Troy Brady, Charles Berry,<br />
Frederic Bushman.<br />
10 3:30 PM<br />
Elimination <strong>of</strong> <strong>Gene</strong> Targeted Chromosome in Trisomic <strong>Cell</strong>s<br />
Li Li, Kai-Hsin Chang, Roli Hirata, Gaoying Ren, Andy Herman,<br />
Thalia Papayannopoulou, David Russell.<br />
11 3:45 PM<br />
Towards Eliciting the Mechanism <strong>of</strong> Plasmid DNA Silencing<br />
In Vivo<br />
Jiamiao Lu, Mark Kay.<br />
12 4:00 PM<br />
Development <strong>of</strong> a High-Throughput Quantitative Method<br />
for Assessing Plasmid Nuclear Import<br />
Holly M. Reynolds, David A. Dean.<br />
13 4:15 PM<br />
Robust Long-Term <strong>Gene</strong> Expression in Mouse Liver Via the<br />
Novel hAT Transposon TcBuster<br />
Lauren E. Woodard, Aparna Kaja, Robert H. Hice, Peter W.<br />
Atkinson, Nancy L. Craig, Matthew H. Wilson.<br />
14 4:30 PM<br />
Immunosuppression with Cyclophosphamide Significantly<br />
Prolongs High-Level Expression <strong>of</strong> IDUA Mediated by the<br />
Sleeping Beauty Transposon System<br />
Elena L. Aronovich, Jason B. Bell, Kelly M. Podetz-Pedersen,<br />
Brenda L. Koniar, R. Scott McIvor, Perry B. Hackett.<br />
15 4:45 PM<br />
Evaluating the Safety <strong>of</strong> PiggyBac Mediated <strong>Gene</strong> Transfer<br />
in Human <strong>Cell</strong>s<br />
Sunandan Saha, Aparna Kaja, Cliona M. Rooney, Matthew H.<br />
Wilson.<br />
16 5:00 PM<br />
Development <strong>of</strong> a Sleeping Beauty Transposon-Based<br />
Integration System for <strong>Gene</strong> Transfer in Human Epithelial<br />
<strong>Cell</strong>s<br />
Giandomenico Turchiano, Maria Carmela Latella, Zsuzsanna<br />
Izsvak, Zoltan Ivics, Fulvio Mavilio, Alessandra Recchia.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 87<br />
Wednesday, May 18
Wednesday, May 18<br />
88<br />
Abstract Directory Wednesday, May 18, 2011<br />
ORAL ABSTRACT SESSION 132<br />
Infectious Diseases and Vaccines<br />
3:15 PM - 5:15 PM<br />
Room: 615-617<br />
17 3:15 PM<br />
Induction <strong>of</strong> T <strong>Cell</strong> Dysfunction by AAV-Mediated Hepatitis<br />
B Virus Infection<br />
Mi-Hua Tao, Ya-Hui Huang, Ho-Yuan Chou, Cheng-Chieh Fang.<br />
18 3:30 PM<br />
Desmoglein 2 Is a Receptor for Adenovirus Serotypes 3, 7,<br />
11, and 14: Implications for Pathogenesis <strong>of</strong> Adenovirus<br />
Infections and Cancer Treatment<br />
Hongjie Wang, ZongYi Li, Jonas Persson, Ines Beyer, Robert<br />
Strauss, Akseli Hemminki, Pascal Fender, Andre Lieber.<br />
19 3:45 PM<br />
Increased Mucosal CD4 + T <strong>Cell</strong> Activation Following<br />
Vaccination with a Species-Specific Adenovirus Vector in<br />
Rhesus Macaques<br />
Roberto Calcedo, Irene Bukh, Soumitra Roy, Diane G.<br />
Carnathan, Rebecca Grant, Sarah J. Rutcliffe, James M. Wilson,<br />
Michael R. Betts.<br />
20 4:00 PM<br />
Most Closely HLA-Matched Allogeneic Virus Specific<br />
Cytotoxic T-Lymphocytes (CTL) To Treat Persistent<br />
Reactivation or Infection with Adenovirus, CMV and EBV<br />
after Hemopoietic Stem <strong>Cell</strong> Transplantation (HSCT)<br />
Ann M. Leen, Catherine M. Bollard, Adam M. Mendizabal,<br />
Elizabeth J. Shpall, Paul Szabolcs, Joseph Antin, Neena<br />
Kapoor, Sung-Yun Pai, Bambi Grilley, Adrian P. Gee, Malcolm<br />
K. Brenner, Cliona M. Rooney, Helen E. Heslop.<br />
21 4:15 PM<br />
Modeling <strong>Gene</strong>tic Protection Against AIDS: Viral Restriction<br />
Factor Transgenesis in the Domestic Cat<br />
Pimprapar Wongsrikeao, Dyana T. Saenz, Tommy Rinkoski,<br />
Takeshige Otoi, Eric M. Poeschla.<br />
22 4:30 PM<br />
Induction <strong>of</strong> Strong <strong>Cell</strong>ular and Humoral Immune<br />
Responses Following Immunotherapy <strong>of</strong> Post-LEEP CIN 2/3<br />
with HPV 16 & 18 E6/E7 DNA Vaccines<br />
Jian Yan, Xuefei Shen, Mary Giffear, Jessica Lee, Amir S. Khan,<br />
Dawn Harris, Panyupa Pankhong, Devon Shedlock, Jean<br />
Boyer, David B. Weiner, Mark Bagarazzi, Niranjan Y. Sardesai.<br />
23 4:45 PM<br />
Enhanced Immunogenicity <strong>of</strong> Measles Virus Constructs<br />
Encoding Helicobacter pylori Neutrophil-Activating Protein<br />
as Vaccine Platforms<br />
Ianko D. Iankov, Mark J. Federspiel, Evanthia Galanis.<br />
24 5:00 PM<br />
In Vivo Safety and Efficacy <strong>of</strong> a Combination Anti-HIV<br />
Lentiviral Vector in RAG1 Mice for HIV <strong>Gene</strong> <strong>Therapy</strong><br />
Jon Walker, Brian Fury, Jeannine McGee, Gerhard Bauer, Jan A.<br />
Nolta, Joseph S. Anderson.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
ORAL ABSTRACT SESSION 133<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
3:15 PM - 5:15 PM<br />
Room: 611-612<br />
25 3:15 PM<br />
<strong>Gene</strong>tically Modified T <strong>Cell</strong>s Directed to Glioblastoma<br />
Suppress Tumor Growth in a Rodent Glioma Model<br />
Seogkyoung Kong, Betty Tyler, Jinyuan Zhou, Bob S. Carter,<br />
Henry Brem, Richard P. Junghans, Prakash Sampath.<br />
26 3:30 PM<br />
Disruption <strong>of</strong> HLA Expression To Enable Allogeneic <strong>Cell</strong>s To<br />
Escape Immune Recognition<br />
Hiroki Torikai, Andreas Reik, Frank Soldner, Carrie Yuen,<br />
Yuanyue Zhou, Denise Kellar, Helen Huls, Edus H. Warren,<br />
Scott S. Tykodi, Michael C. Holmes, Edward J. Rebar, Dean A.<br />
Lee, Richard E. Champlin, Philip D. Gregory, Rudolf Jaenisch,<br />
Laurence J. N. Cooper.<br />
27 3:45 PM<br />
A Chimeric Antigen Receptor Molecule Mediates Bispecific<br />
Activation and Targeting <strong>of</strong> T Lymphocytes<br />
Zakaria Grada, Meenakshi Hegde, Donald R. Shaffer, Alexia<br />
Ghazi, Tiara Byrd, Giampietro Dotti, Winfried Wels, Matthew<br />
Baker, Helen E. Heslop, Stephen Gottschalk, Nabil Ahmed.<br />
28 4:00 PM<br />
Drug Resistant γδ T <strong>Cell</strong>s Are Required to Efficiently<br />
Kill Drug Resistant Glioblastoma Multiforme during a<br />
Chemotherapy Challenge<br />
Anindya Dasgupta, Harold T. Spencer, George Y. Gillespie, Yun<br />
Su, Joscelyn E. Bowersock, Lawrence S. Lamb.<br />
29 4:15 PM<br />
Redirected Allogeneic T <strong>Cell</strong>s for Adoptive <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong><br />
Cancer<br />
Assaf Marcus, Tova Waks, Zelig Eshhar.<br />
30 4:30 PM<br />
Optimization <strong>of</strong> a Gamma-Retroviral Vector Co-Expressing<br />
a Prostate-Specific Membrane Antigen-Targeted Chimeric<br />
Antigen Receptor (PSMA-CAR) and HSVTK for the<br />
Treatment <strong>of</strong> Metastatic Prostate Cancer<br />
Xiuyan Wang, Oriana Borquez-Ojeda, Jolanta Stefansk, Jason<br />
Plotkin, Steven Poon, Jinrong Qu, Teresa Wasielewska, Larrisa<br />
Shenker, Vladimi Ponomarev, Susan Slovin, Michel Sadelain,<br />
Isabelle Rivière.
Abstract Directory Wednesday, May 18, 2011<br />
ORAL ABSTRACT SESSION 133 — continued<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
3:15 PM - 5:15 PM<br />
Room: 611-612<br />
31 4:45 PM<br />
Specific Targeting <strong>of</strong> Interleukin-13 (IL-13) Receptor α2-<br />
Positive Tumor <strong>Cell</strong>s with Lentiviral Vectors Displaying IL-13<br />
Wu Ou, Michael P. Marino, Bharat Joshi, Andrea Maisner,<br />
Evanthia Galanis, Raj K. Puri, Jakob Reiser.<br />
32 5:00 PM<br />
Serial Transplantation <strong>of</strong> MGMTP140K-Transduced Bone<br />
Marrow and Dose-Intense Chemotherapy Selects for<br />
Clones with Distinct Insertions<br />
Frank A. Giordano, Ursula R. Sorg, Jens-Uwe Appelt, Nico<br />
Lachmann, Stephanie Bleier, Ingo Roeder, Veronika Kleff, W.<br />
Jens Zeller, Heike Allgayer, Christ<strong>of</strong> von Kalle, Stefan Fruehauf,<br />
Thomas Moritz, Stephanie Laufs.<br />
ORAL ABSTRACT SESSION 134<br />
Novel Approaches for <strong>Gene</strong> Regulation &<br />
Genome Modification<br />
3:15 PM - 5:15 PM<br />
Room: 618-620<br />
33 3:15 PM<br />
Identification and Characterization <strong>of</strong> New Chromatin<br />
Insulators for <strong>Gene</strong> <strong>Therapy</strong> Vectors<br />
David W. Emery, Amy C. Groth, Mingdong Liu, Hao Wang,<br />
John Stamatoyannopoulos, George Stamatoyannopoulos.<br />
34 3:30 PM<br />
TALE-Based Designer Nucleases: A Novel Platform To Edit<br />
the Human Genome<br />
Claudio Mussolino, Fabienne Luetge, Robert Morbitzer,<br />
Thomas Lahaye, Toni Cathomen.<br />
35 3:45 PM<br />
Engineering XID(Btk) Site Specific I-Anil Homing<br />
Endonuclease for <strong>Gene</strong> Repair in Hematopoietic Stem <strong>Cell</strong>s<br />
Yupeng Wang, Jordan Jarjour, James Havranek, Summer<br />
Thyme, David Baker, Andrew M. Scharenberg, David J.<br />
Rawlings.<br />
36 4:00 PM<br />
Human Cardiac Troponin T Regulatory Cassettes Facilitate<br />
High-Level Transient Expression in Differentiating Skeletal<br />
Muscle and Continuous Expression in Cardiac Muscle<br />
Xiaolan Chen, Quynh V. Nguyen, Guy L. Odom, Eric E. Finn,<br />
Robert E. Welikson, John C. Angello, Jeffrey S. Chamberlain,<br />
Stephen D. Hauschka.<br />
37 4:15 PM<br />
Modifying Target Structure Greatly Improves the Efficiency<br />
<strong>of</strong> microRNA-Regulated Vectors<br />
Alessia Baccarini, Hemangina Chauhan, Thomas Gardner,<br />
Albert Ruzo, Ravi Sachidanandam, Brian Brown.<br />
38 4:30 PM<br />
A Transgene Encoded <strong>Cell</strong> Surface EGFR Polypeptide for<br />
Selection, In Vivo Tracking and Ablation <strong>of</strong> Engineered <strong>Cell</strong>s<br />
Xiuli Wang, Wen-Chung Chang, ChingLam W. Wong, David<br />
Colcher, Mark Sherman, Julie R. Ostberg, Stanley R. Riddell,<br />
Stephen J. Forman, Michael C. Jensen.<br />
39 4:45 PM<br />
Evaluation <strong>of</strong> an AAV2-Based Rapamycin-Regulated Glial<br />
<strong>Cell</strong>-Derived Neurotrophic Factor (GDNF) Expression Vector<br />
System<br />
Piotr Hadaczek, Janine Beyer, Wade Narrow, William Bowers,<br />
Howard J. Feder<strong>of</strong>f, John Forsayeth, Kryst<strong>of</strong> S. Bankiewicz.<br />
40 5:00 PM<br />
Targeted Delivery <strong>of</strong> IDUA across the Blood-Brain Barrier<br />
for Treatment <strong>of</strong> MPS Type I<br />
Daren Wang, Alex Kuan, David Hui, Dao Pan.<br />
ORAL ABSTRACT SESSION 135<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
3:15 PM - 5:15 PM<br />
Room: 608-609<br />
41 3:15 PM<br />
Correction <strong>of</strong> Murine Rag Deficiencies by Self-Inactivating<br />
Lentiviral Vector-Mediated <strong>Gene</strong> Transfer<br />
Karin Pike-Overzet, Mark Rodijk, Yuk-Yin Ng, Miranda R. M.<br />
Baert, Chantal Lagresle, Axel Schambach, Rob C. Hoeben,<br />
Salima Hacein-Bey-Abina, Arjen C. Lankester, Robbert G. M.<br />
Bredius, Gertjan J. A. Driessen, Christopher Baum, Marina<br />
Cavazzana-Calvo, Jacques J. M. van Dongen, Frank J. T. Staal.<br />
42 3:30 PM<br />
Distribution <strong>of</strong> Lentiviral Vectors in <strong>Gene</strong> <strong>Therapy</strong> for<br />
X-Adrenoleukodystrophy<br />
Cynthia C. Bartholomae, Nathalie Cartier, Salima Hacein-Bey<br />
Abina, Ina Kutschera, Maximilian Schliesser, Bruno l’Homme,<br />
Alain Fischer, Marina Cavazzana-Calvo, Patrick Aubourg,<br />
Manfred Schmidt, Christ<strong>of</strong> von Kalle.<br />
43 3:45 PM<br />
Integration Site Analysis in a Benign Hemangioma<br />
That Developed in the Spleen at 8 Years after Neonatal<br />
IV Injection <strong>of</strong> a gamma Retroviral Vector into a<br />
Mucopolysaccharidosis VII Dog<br />
Katherine P. Ponder, Thomas O’Malley, Anna Paruzynski,<br />
Christina Lulay, Manfred Schmidt, Christ<strong>of</strong> von Kalle, Patricia<br />
O’Donnell, Mark E. Haskins.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 89<br />
Wednesday, May 18
Wednesday, May 18<br />
90<br />
Abstract Directory Wednesday, May 18, 2011<br />
ORAL ABSTRACT SESSION 135 — continued<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
3:15 PM - 5:15 PM<br />
Room: 608-609<br />
44 4:00 PM<br />
Repeated Lentivirus-Mediated G-CSF Delivery To Treat<br />
Canine Cyclic Neutropenia<br />
Ofer Yanay, Cheryl Adler, David C. Dale, William R. Osborne.<br />
45 4:15 PM<br />
Balloon Delivery <strong>of</strong> Helper-Dependent Adenoviral Vector<br />
Results in Sustained hFIX Expression in Rhesus Macaques<br />
Nicola Brunetti-Pierri, Amiee Liou, Priti Patel, Donna Palmer,<br />
Nathan Grove, Karen Rice, Milton Finegold, Arthur Beaudet,<br />
Charles Mullins, Philip Ng.<br />
46 4:30 PM<br />
Outcomes <strong>of</strong> AAV8 and AAV5-Mediated Fetal <strong>Gene</strong> Transfer<br />
at 0.9G in Non-Human Primates<br />
Citra N. Mattar, Amit Nathwani, Simon Waddington, Niraja<br />
Dighe, Christine Kaeppel, Ali Nowrouzi, Jenny Mcintosh,<br />
Nuryanti Johana, Nicholas Fisk, Andrew David<strong>of</strong>f, Jens-Uwe<br />
Appelt, Christ<strong>of</strong> von Kalle, Manfred Schmidt, Arijit Biswas,<br />
Mahesh Choolani, Jerry K. Y. Chan.<br />
47 4:45 PM<br />
Longterm and Sustained Knockdown <strong>of</strong> Mutant AAT along<br />
with Simultaneous Augmentation <strong>of</strong> Wildtype AAT with a<br />
Single Dual Function Vector Has Minimal Effect on Global<br />
Liver miRNA Pr<strong>of</strong>iles<br />
Christian Muller, Qiushi Tang, Lina Song, Phillip D. Zamore,<br />
Terence R. Flotte.<br />
48 5:00 PM<br />
In Vivo AAV-Mediated <strong>Gene</strong> Repair Is Enhanced by the DNA-<br />
PK Inhibitor Vanillin<br />
Nicole K. Paulk, Milton Finegold, Markus Grompe.<br />
ORAL ABSTRACT SESSION 136<br />
Late Oral Abstract Session<br />
3:15 PM - 5:15 PM<br />
Room: 602-604<br />
867 3:15 PM<br />
Tumor Suppressor Properties <strong>of</strong> miR-122 and Its Biological<br />
Function in Mouse Liver<br />
Janaiah Kota, Shu-hao Hsu, Bo Wang, Huban Kutay, Stefan<br />
Costinean, Shoumei Bai, Lianbo Yu, Krista La Perle, Raghu R.<br />
Chivukula, K. Reed Clark, Samson T. Jacob, Jerry R. Mendell,<br />
Kalpana Ghoshal, Joshua T. Mendell.<br />
868 3:30 PM<br />
Encapsulated hESC Derived Islets as a Transplantation<br />
<strong>Therapy</strong> for Diabetes without Immunosuppression<br />
Kaitlyn Kirk, Ergeng Hao, Laura Martinson, Evert Kroon,<br />
Pamela Itkin-Ansari.<br />
869 3:45 PM<br />
Improved Retroviral Replicating Vectors for Prodrug-<br />
Activator <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Cancer<br />
Noriyuki Kasahara, Douglas J. Jolly, Daniel Pertschuk,<br />
Debra Gessner, Christopher Logg, Kei Hiraoka, Akihito<br />
Inagaki, Shuichi Kamijima, Ryan Burnett, Ching-I Chen, Pelle<br />
Pettersson, Derek Ostertag, Amy Lin, Walter Günzburg, Brian<br />
Salmons, Mitchel Berger,.<br />
870 4:00 PM<br />
CSF-Mediated Distribution <strong>of</strong> TPP1 from AAV Transduced<br />
Brain Ependyma Promotes Widespread Enzyme Activity in<br />
Nonhuman Primate Brain and Improves CNS Phenotypes in<br />
LINCL Dogs<br />
Martin L Katz, Luis Tecedor, Fred A Wininger, Joan R. Coates,<br />
Camille A. Flournoy, Katie Nice, Jeffrey Kordower, Beverly L<br />
Davidson.<br />
871 4:15 PM<br />
<strong>Gene</strong> <strong>Therapy</strong> Approach to Treat Osteoarthritis Using<br />
AAVIRAP<br />
LR Goodrich, CW McIlwraith, JN Phillips, SB Foti, RJ Samulski.<br />
872 4:30 PM<br />
Developing Photoreceptor Targeted AAV Varient by<br />
Directed Evolution<br />
D. Dalkara, R. Klimczak, M. Visel, D. Schaffer, J. Flannery.<br />
873 4:45 PM<br />
Postnatal Transplantation <strong>of</strong> FVIII-Expressing MSC<br />
Phenotypically Corrects Hemophilia A<br />
C. D. Porada, C. Sanda, C-J. Kuo, E. Colleti, R. Moot, C. Doering,<br />
H.T. Spencer, G. Almeida-Porada.<br />
874 5:00 PM<br />
Influence <strong>of</strong> Pre-Existing Neutralizing Antibodies on <strong>Gene</strong><br />
Expression Following Intramuscular Administration <strong>of</strong> AAV<br />
Vectors<br />
Jenny A. Greig, Deirdre McMenamin, James M. Wilson.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Thursday, May 19, 2011<br />
PRESIDENTIAL SYMPOSIUM 200<br />
Presidential Symposium<br />
8:00 AM - 10:15 AM<br />
Room: 6BC<br />
49 8:45 AM<br />
In Vivo Delivery <strong>of</strong> Zinc Finger Nucleases Mediates Genome<br />
Editing To Correct <strong>Gene</strong>tic Disease<br />
Michael Holmes, Hojun Li, Virginia Haurigot, Yannick Doyon,<br />
James Li, Anand Bhagwat, Sunnie Wong, Xavier Anguela,<br />
Rajiv Sharma, Sam Murphy, Fayaz Khazi, Shangzhen Zhou,<br />
David Paschon, Ed Rebar, Philip Gregory, Katherine High.<br />
50 9:05 AM<br />
Demonstration <strong>of</strong> Safety and Antitumoral Activity <strong>of</strong> JX-<br />
594, a Targeted Multi-Mechanistic Oncolytic Poxvirus,<br />
Following Intravenous Infusion and/or Intratumoral<br />
Injections in Patients with Refractory Metastatic Cancers<br />
Caroline Breitbach, James Burke, Anne Moon, Tae-Ho Hwang,<br />
John C. Bell, David H. Kirn.<br />
51 9:25 AM<br />
A Phase I Dose-Escalating Study <strong>of</strong> AAV1 – γ-Sarcoglycan<br />
<strong>Gene</strong> <strong>Therapy</strong> for Limb Girdle Muscular Dystrophy Type 2C<br />
Serge Herson, Fayçal Hentati, Aude Rigolet, Norma B.<br />
Romero, Anthony Behin, France Leturcq, Pascal Laforet,<br />
Thierry Maisonobe, Rim Amouri, Hafedh Haddad, Muriel<br />
Audit, Marie-Françoise Rosier-Montus, Bernard Gjata, Carole<br />
Masurier, François M. Lemoine, Pierre Carlier, Jean-Yves<br />
Hogrel, Bruno Eymard, Lee Sweeney, Richard Mulligan, David<br />
Klatzmann, Mustapha Cheraï, Didier Caizergues, Thomas Voït,<br />
Olivier Benveniste.<br />
52 9:45 AM<br />
Efficient Long-Term Bodywide Expression <strong>of</strong> an AAV9-<br />
Minidystrophin in the Muscle and Heart <strong>of</strong> Young Adult<br />
GRMD Dogs after Intravascular Injection without Immune<br />
Suppression<br />
Juan Li, Chunping Qiao, Janet Bogan, Dan Bogan, Ruhang<br />
Tang, JianBin Li, Chunlian Chen, Hui Zheng, Jennifer Dow, Joe<br />
N. Kornegay, Xiao Xiao.<br />
ORAL ABSTRACT SESSION 230<br />
Adenovirus and Other DNA Virus Vectors II:<br />
Response to Vectors<br />
2:30 PM - 4:30 PM<br />
Room: 615-617<br />
53 2:30 PM<br />
An HSV Based Selection Method for Isolation <strong>of</strong> Negative<br />
Regulators <strong>of</strong> TRPV1<br />
Bonnie Reinhart, Asaff Harel, Justus B. Cohen, Joseph C.<br />
Glorioso.<br />
54 2:45 PM<br />
Interaction <strong>of</strong> Adenoviral Particles with Scavenger<br />
Receptors on Kupffer <strong>Cell</strong>s Stimulates an Early, MyD88<br />
Dependent Innate Immune Response In Vivo<br />
Masataka Suzuki, Terry K. Bertin, Donna J. Palmer, Racel G.<br />
Cela, Margaretha Guenther, Ming-Ming Jiang, Kilian Guse,<br />
Phil Ng, Brendan H. I. Lee.<br />
55 3:00 PM<br />
Arming Adenovirus with CpG Motifs To Stimulate Innate<br />
and Adaptive Immune Response To Enhance Anti-Tumor<br />
Efficacy<br />
Vincenzo Cerullo, Valentina Romano, Iulia Diaconu, Matteo<br />
Ugolini, Noora Rouvinen-Lagerström, Akseli Hemminki.<br />
56 3:15 PM<br />
MicroRNA Control <strong>of</strong> HSV-1 Replication for the Treatment<br />
<strong>of</strong> Glioblastoma Multiforme<br />
Lucia Mazzacurati, Marco Marzulli, Bonnie Reinhart, Justus B.<br />
Cohen, Joseph C. Glorioso, Paola Grandi.<br />
57 3:30 PM<br />
High-Capacity Adenoviral Vectors Induce Multispecific CD8<br />
T <strong>Cell</strong> Responses and Show Improved Properties over 1st-<br />
<strong>Gene</strong>ration Vectors as <strong>Gene</strong>tic Vaccines<br />
Matthias W. Kron, Tatjana Engler, Schmidt Erika, Reinhold<br />
Schirmbeck, Stefan Kochanek, Florian Kreppel.<br />
58 3:45 PM<br />
Oncolytic Adenovirus Expressing a Dual-Function <strong>Gene</strong> To<br />
Diagnose and Treat Pancreatic Cancer<br />
Julia Davydova, Miguel Trujillo, Samantha McDonough,<br />
Michael Oneal, Eric Brown, Joohee Han, Selwyn Vickers, John<br />
Morris, Masato Yamamoto.<br />
59 4:00 PM<br />
<strong>Gene</strong> <strong>Therapy</strong>-Mediated Delivery <strong>of</strong> Targeted Cytotoxins<br />
for Glioma Therapeutics: Efficacy in the Absence <strong>of</strong><br />
Neurotoxicity<br />
Marianela Candolfi, Weidong Xiong, Kader Yagiz, Chunyan Liu, A.<br />
K. M. G. Muhammad, Mariana Puntel, David Foulad, Ali Zadmehr,<br />
Gabrielle Alzadeh, Kurt M. Kroeger, Matthew Tesarfreund,<br />
Sharon Lee, Waldemar Debinski, Dhruv Sareen, Clive Svendsen,<br />
Ron Rodriguez, Pedro R. Lowenstein, Maria G. Castro.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 91<br />
Thursday, May 19
Thursday, May 19<br />
92<br />
Abstract Directory Thursday, May 19, 2011<br />
ORAL ABSTRACT SESSION 230 — continued<br />
Adenovirus and Other DNA Virus Vectors II:<br />
Response to Vectors<br />
2:30 PM - 4:30 PM<br />
Room: 615-617<br />
60 4:15 PM<br />
Kupffer <strong>Cell</strong> Evasion by a Hypervariable Region-Modified<br />
Adenovirus Vector<br />
Reeti Khare, Michael A. Barry.<br />
ORAL ABSTRACT SESSION 231<br />
Chemical and Molecular Conjugates<br />
2:30 PM - 4:30 PM<br />
Room: 611-612<br />
61 2:30 PM<br />
Combinatorial Use <strong>of</strong> Block- and Homo-Polycation To Form<br />
DNA Polyplex Enhances Transgene Expressions in Mouse<br />
Lung with Minimal Toxicity<br />
Satoshi Uchida, Keiji Itaka, Qixian Chen, Kensuke Osada,<br />
Takehiko Ishii, Mariko Harada-Shiba, Masa-Aki Shibata,<br />
Kazunori Kataoka.<br />
62 2:45 PM<br />
Polymeric Delivery <strong>of</strong> siRNA for P-Glycoprotein Down-<br />
Regulation in a Xenograft Tumor Model in NOD-SCID Mice<br />
Meysam Abbasi, Hamid M. Aliabadi, Elaine Moase, Kamaljit<br />
Kaur, Charles Doillon, Raymond Lai, Afsaneh Lavasanifar,<br />
Hasan Uludag.<br />
63 3:00 PM<br />
<strong>Gene</strong> <strong>Therapy</strong> with Antibody Targeted Immunoliposome<br />
Rescue Experimental Parkinson’s Disease<br />
Qinghui Zhou, Ailing Fu, Boado Ruben, William M. Pardridge.<br />
64 3:15 PM<br />
Subcellular Trafficking and Transfection Efficacy <strong>of</strong> PEI-PEG<br />
Polyplex Nanoparticles with a Ligand to Melanocortin-1<br />
Receptors<br />
Alexey V. Ulasov, Yuri V. Khramtsov, Elena A. Beletkaia, Nikita<br />
S. Rodichenko, Georgiy A. Trusov, Mikhail O. Durymanov,<br />
Andrey A. Rosenkranz, Eugene D. Sverdlov, Alexander S.<br />
Sobolev.<br />
65 3:30 PM<br />
Cathepsin B-Labile Polymers for Endosome/Lysosome-<br />
Specific Degradation and Nucleic Acid Release<br />
David S. Chu, Russell N. Johnson, Suzie H. Pun.<br />
66 3:45 PM<br />
A Modified HK Carrier <strong>of</strong> siRNA Enhances Silencing <strong>of</strong><br />
Tumor Targets In Vivo<br />
Szu-Ting Chou, Qixin Leng, Puthupparampil Scari, Archibald<br />
J. Mixson.<br />
67 4:00 PM<br />
Subcutaneous Delivery <strong>of</strong> Plasmid DNA to Hepatocytes by<br />
Ligand-Targeted Sub-50 nm Capsules<br />
B. T. Kren, V. L. Korman, D. Tolbot, G. M. Unger.<br />
68 4:15 PM<br />
Methods To Observe Intracellular Trafficking <strong>of</strong> Non-Viral<br />
Delivery Vehicles in 3D<br />
Nilesh P. Ingle, Theresa M. Reineke.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
ORAL ABSTRACT SESSION 232<br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
2:30 PM - 4:30 PM<br />
Room: 618-620<br />
69 2:30 PM<br />
Exploring the Potential <strong>of</strong> Plasma Pheresis To Circumvent<br />
Pre-Existing Antibodies to AAV8 on Transgene Expression<br />
Following Targeted Vascular Delivery<br />
Louis G. Chicoine, Louise R. Rodino-Klapac, K. Reed Clark,<br />
Chrystal L. Montgomery, Thomas J. Preston, William G.<br />
Bremer, Katherine J. Campbell, Zarife Sahenk, Paul T. Martin,<br />
Christopher M. Walker, Jerry R. Mendell.<br />
70 2:45 PM<br />
Acceleration and Augmentation <strong>of</strong> Femoral Segmental<br />
Bone Healing by Adipose-Derived Stem <strong>Cell</strong>s Engineered<br />
with Hybrid Baculovirus Vectors Conferring Sustained<br />
Transgene Expression<br />
Chin-Yu Lin, Kun-Ju Lin, Chun-Yu Kao, Tzu-Chen Yen, Yu-Han<br />
Chang, Yu-Chen Hu.<br />
71 3:00 PM<br />
Restoration <strong>of</strong> Dystrophin Expression in the mdx Mouse<br />
Model for Duchenne Muscular Dystrophy (DMD) Induced<br />
by RTC13<br />
Refik Kayali, Liutao Du, Jin-Mo Ku, Gladys Completo, Olga<br />
Prikhodko, Yosuf Subat, Hailiang Hu, Michael Jung, Richard A.<br />
Gatti, Carmen Bertoni.<br />
72 3:15 PM<br />
Effective Limb Transduction and Phenotypic Correction<br />
after Injection <strong>of</strong> rAAV8-U7 snRNA in GRMD Dogs<br />
Caroline Le Guiner, Marie Montus, Laurent Servais, Luis<br />
Garcia, Yves Fromes, Jean-Yves Hogrel, Pierre Carlier, Yan<br />
Cherel, Philippe Moullier, Thomas Voit, The AFM-Sponsored<br />
Duchenne Consortium.<br />
73 3:30 PM<br />
Inhibition <strong>of</strong> CD26 Activity Enhances Engraftment <strong>of</strong> Donor<br />
<strong>Cell</strong>s to Regenerating and Dystrophic Skeletal Muscle<br />
Maura H. Parker, Carol Loretz, Rainer Storb, Stephen J.<br />
Tapscott.
Abstract Directory Thursday, May 19, 2011<br />
ORAL ABSTRACT SESSION 232 — continued<br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
2:30 PM - 4:30 PM<br />
Room: 618-620<br />
74 3:45 PM<br />
Addition <strong>of</strong> Peptide <strong>Therapy</strong> To Inhibit NF-κB Activation<br />
to AAV Serotype 9 Mini-Dystrophin <strong>Gene</strong> Transfer To Treat<br />
Muscular Dystrophy in mdx Mice<br />
Daniel P. Reay, Gabriela A. Niizawa, Jon F. Watchko, Molly<br />
Daood, Eugene Raggi, Paula R. Clemens.<br />
75 4:00 PM<br />
RNA Interference Improves Myopathic Phenotypes in Mice<br />
Over-Expressing Facioscapulohumeral Muscular Dystrophy<br />
Region <strong>Gene</strong> 1 (FRG1)<br />
Lindsay M. Wallace, Sara E. Garwick-Coppens, Scott Q. Harper.<br />
76 4:15 PM<br />
Sustained Expression <strong>of</strong> Canine Micro-Dystrophin and<br />
Amelioration <strong>of</strong> Muscle Function in Dystrophic Dogs<br />
Following Large Scale AAV-Mediated Treatment<br />
Zejing Wang, Rainer Storb, Donghoon Lee, Christine Halbert,<br />
Martine K. Childers, Glen Banks, James Allen, Eric Finn, Martin<br />
Kushmeric, Dusty Miller, Jeffery S. Chamberlain, Stephen J.<br />
Tapscott.<br />
ORAL ABSTRACT SESSION 233<br />
Cancer Immunotherapy - Emphasis on<br />
Vaccines and Adjuvants<br />
2:30 PM - 4:30 PM<br />
Room: 6A<br />
77 2:30 PM<br />
Serial Treatment <strong>of</strong> Refractory Cancer Patients with GM-CSF<br />
Expressing Oncolytic Adenovirus Enhances Immunological<br />
Response and Survival without Compromising Safety<br />
Petri Nokisalmi, Anniina Koski, Anna Kanerva, Lotta<br />
Kangasniemi, Iulia Diaconu, Sari Pesonen, Vincenzo Cerullo,<br />
Timo Joensuu, Akseli Hemminki.<br />
78 2:45 PM<br />
Preclinical Efficacy and Safety Studies <strong>of</strong> a Monoclonal<br />
Antibody Co-<strong>Therapy</strong> for Cancer<br />
Roma Yumul, Hongjie Wang, Ines Beyer, Jonas Persson, Andre<br />
Lieber.<br />
79 3:00 PM<br />
Phase I Trial <strong>of</strong> <strong>Gene</strong> Mediated Cytotoxic Immunotherapy<br />
in Combination with Chemoradiation for Locally Advanced<br />
Pancreatic Cancer<br />
Mark Bloomston, Christopher Marsh, Jon Walker, Walter<br />
Coyle, Howard Marx, Sanaa Tahiri, Claudia Moran Cruz, Laura<br />
K. Aguilar, Estuardo Aguilar-Cordova, Vincent Chung.<br />
80 3:15 PM<br />
How To Improve Adoptive T <strong>Cell</strong> Immune-<strong>Gene</strong> <strong>Therapy</strong>:<br />
The Importance <strong>of</strong> Be(ginn)ing Naïve<br />
Nicoletta Cieri, Barbara Camisa, Elena Provasi, Zulma<br />
Magnani, Anna Mondino, Attilio Bondanza, Chiara Bonini.<br />
81 3:30 PM<br />
IL15-VAX: A Prostate Cancer <strong>Cell</strong>ular Vaccine Expressing IL-<br />
15 and IL-15Ralpha<br />
Jason C. Steel, Charmaine A. Ramlogan, Ping Yu, Thomas A.<br />
Waldmann, John C. Morris.<br />
82 3:45 PM<br />
A Phase 1-2 Clinical Study <strong>of</strong> MGN1601, a Tumor Vaccine<br />
Comprising Allogeneic, <strong>Gene</strong>-Modified and Irradiated<br />
Tumor <strong>Cell</strong>s in Combination with an Immunomodulator, in<br />
Patients with Metastatic Renal <strong>Cell</strong> Carcinoma (ASET Study)<br />
– Preliminary Results<br />
S. Weikert, M. Tschaika, E. Weith, V. Grünwald, M. Schr<strong>of</strong>f, B.<br />
Wittig, M. Schmidt.<br />
83 4:00 PM<br />
DC-NILV: Dendritic <strong>Cell</strong> Targeting Non-Integrating<br />
Lentiviral Vector Platform for Direct Administration in<br />
Immunotherapeutic Clinical Settings<br />
N. Van Hoeven, J. Odegard, C. Nicolai, P. McGowan, M.<br />
Slough, D. Campbell, C. Vin, S. Tareen, S. Robbins, P. Wang, D.<br />
Baltimore, S. Reed, V. Slepushkin, T. Dubensky.<br />
84 4:15 PM<br />
T <strong>Cell</strong>s Modified To Express Tumor Associated Antigens and<br />
Dendritic <strong>Cell</strong>-Activating Molecules for Cancer Vaccination<br />
Adham S. Bear, Meghan E. Turnis, Xiao-Tong Song, Conrad R.<br />
Cruz, An Lu, Gottschalk M. Stephen, Cliona M. Rooney, Aaron<br />
E. Foster.<br />
ORAL ABSTRACT SESSION 234<br />
Small RNA and<br />
Oligonucleotide Based Therapeutics<br />
2:30 PM - 4:30 PM<br />
Room: 606-607<br />
85 2:30 PM<br />
Systemic Delivery <strong>of</strong> RNase H-Active Antisense Oligos in a<br />
Transgenic Mouse Model <strong>of</strong> Myotonic Dystrophy Type 1<br />
Thurman M. Wheeler, Andrew J. Leger, Sanjay K. Pandey, A.<br />
Robert MacLeod, Masayuki Nakamori, Seng H. Cheng, C.<br />
Frank Bennett, Bruce M. Wentworth, Charles A. Thornton.<br />
86 2:45 PM<br />
Role <strong>of</strong> Ago2 and microRNAs in Mammalian Development<br />
Paul N. Valdmanis, Hakkyun Kim, Yannick Pouliot, Mark A. Kay.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 93<br />
Thursday, May 19
Thursday, May 19<br />
94<br />
Abstract Directory Thursday, May 19, 2011<br />
ORAL ABSTRACT SESSION 234 — continued<br />
Small RNA and<br />
Oligonucleotide Based Therapeutics<br />
2:30 PM - 4:30 PM<br />
Room: 606-607<br />
87 3:00 PM<br />
First Results <strong>of</strong> a Phase 2-3 Clinical Study with the<br />
Immunomodulator MGN1703 in Patients with Advanced<br />
Colorectal Carcinoma (IMPACT Study)<br />
M. Schmidt, H. J. Schmoll, F. Mayer, J. Riera-Knorrenschild, G.<br />
Hapke, B. Hildebrandt, W. Eisterer, J. Andel, R. Ziebermayr, E.<br />
Weith, M. Schr<strong>of</strong>f, B. Wittig, M. Tschaika.<br />
88 3:15 PM<br />
ShRNA-Mediated <strong>Gene</strong> Silencing in Primetes with AAV8<br />
Takayuki Kubodera, Shinga Ohira, Yuko Katakai, Hiroaki<br />
Mizukami, Yukihiko Hirai, Michio Imamura, Kazuaki Chayama,<br />
Takashi Shimada, Keiya Ozawa, Hidehiro Mizusawa, Takanori<br />
Yokota.<br />
89 3:30 PM<br />
Dual Functional BAFF Receptor Aptamers Inhibit Ligand<br />
Induced Proliferation and Deliver siRNAs to NHL <strong>Cell</strong>s<br />
Katrin Tiemann, Piotr Swiderski, Stephen Forman, John Rossi,<br />
Jiehua Zhou.<br />
90 3:45 PM<br />
Nanoparticle Delivery <strong>of</strong> PNA and Donor DNA for Genomic<br />
Modification and Inactivation <strong>of</strong> the CCR5 <strong>Gene</strong><br />
Erica B. Schleifman, Nicole Ali McNeer, Andrew Jackson, Jean<br />
Leif, Christopher Cheng, Ranjit S. Bindra, Leonard D. Shultz,<br />
Dale L. Greiner, Priti Kumar, W. Mark Saltzman, Peter M. Glazer.<br />
91 4:00 PM<br />
In Vivo HIV Inhibition by CCR5 Knock-Down by RNA<br />
Interference through Stem <strong>Cell</strong> Based <strong>Gene</strong> <strong>Therapy</strong><br />
Approach in the Humanized NSG BLT Mouse Model<br />
Saki Shimizu, Ruth Cortado, Emily Lowe, Anna Sahakyan,<br />
Joshua Boyer, Tom Suree, Dong Sung An.<br />
92 4:15 PM<br />
Efficient In Vivo Delivery <strong>of</strong> Vitamin E-Conjugated siRNA<br />
from Colorectum to Liver<br />
Kazutaka Nishina, Masahiro Murakami, Kie Yoshida, Hiroya<br />
Kuwahara, Hidehiro Mizusawa, Takanori Yokota.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
ORAL ABSTRACT SESSION 235<br />
Stem <strong>Cell</strong> Therapies I<br />
2:30 PM - 4:30 PM<br />
Room: 608-609<br />
93 2:30 PM<br />
<strong>Gene</strong>ration <strong>of</strong> <strong>Gene</strong>-Corrected, Vector- and<br />
Reprogramming Factor-Free iPS <strong>Cell</strong>s from SCID-X1<br />
Patients<br />
Angelo Lombardo, Pietro Lo Riso, Bruno Di Stefano, Mario<br />
Amendola, Michael C. Holmes, Philip D. Gregory, Andrew R.<br />
Gennery, Vania Broccoli, Luigi Naldini.<br />
94 2:45 PM<br />
microRNA-126 Modulates the Sensitivity <strong>of</strong> Hematopoietic<br />
Stem and Progenitor <strong>Cell</strong>s to Environmental Signals<br />
Bernhard Gentner, Alice Giustacchini, Francesco Boccalatte,<br />
Massimo Saini, Eric Lechman, John E. Dick, Luigi Naldini.<br />
95 3:00 PM<br />
Highly Efficient Hematopoietic Reconstitution by In Vivo<br />
Chemoselection <strong>of</strong> HPRT-Deficient Bone Marrow with<br />
6-Thioguanine<br />
Katrin Hacke, Akos Szakmary, Andrew R. Cuddihy, Janet A.<br />
Treger, Brooke T. Bogan, Nora Rozengurt, Nathan A. Lemp, Jiri<br />
Aubrecht, Gregory W. Lawson, Nagesh P. Rao, Gay M. Crooks,<br />
Robert H. Schiestl, Noriyuki Kasahara.<br />
96 3:15 PM<br />
Stem <strong>Cell</strong>s Isolated from p65 Deficient Mice Improved the<br />
Histopathology <strong>of</strong> Skeletal Muscle in Dystrophic Mice<br />
Aiping Lu, Ying Tang, Minakshi Poddar, Bing Wang, Denis C.<br />
Guttridge, Paul D. Robbins, Johnny Huard.<br />
97 3:30 PM<br />
LYL1, a Basic Helix-Loop-Helix Transcription Factor,<br />
Promotes Hematopoietic Differentiation <strong>of</strong> Common<br />
Marmoset Embryonic Stem <strong>Cell</strong>s<br />
Hirotaka Kawano, Tomotoshi Marumoto, Michiyo Okada,<br />
Tomoko Inoue, Takenobu Nii, Jiyuan Liao, Saori Yamaguchi,<br />
Yoko Nagai, Hiroyuki Inoue, Atsushi Takahashi, Erika Sasaki,<br />
Yoshie Miura, Kenzaburo Tani.<br />
98 3:45 PM<br />
Genome-Wide Definition <strong>of</strong> Transcriptionally Active<br />
Regulatory Elements in Human Stem <strong>Cell</strong>s by Retroviral<br />
Scanning<br />
Valentina Poletti, Alessia Cavazza, Annarita Miccio, Danilo<br />
Pellin, Ermanno Rizzi, Giorgio Corti, Clelia Di Serio, Gianluca<br />
De Bellis, Fulvio Mavilio.
Abstract Directory Thursday, May 19, 2011<br />
ORAL ABSTRACT SESSION 235 — continued<br />
Stem <strong>Cell</strong> Therapies I<br />
2:30 PM - 4:30 PM<br />
Room: 608-609<br />
99 4:00 PM<br />
Zinc Finger Nuclease Mediated Genomic Editing <strong>of</strong> CCR5 in<br />
Human Hematopoietic Stem <strong>Cell</strong>s for Clinical Application in<br />
HIV <strong>Gene</strong> <strong>Therapy</strong><br />
Lijing Li, Anitha Rao, Lan-Feng Cao, Kenneth Kim, Ursula<br />
H<strong>of</strong>er, Paula Cannon, Philip D. Gregory, Michael C. Holmes,<br />
John Zaia, Qing Liu, John Rossi, David DiGiusto.<br />
100 4:15 PM<br />
Human Neural Stem <strong>Cell</strong>s <strong>of</strong> Parthenogenetic Origin<br />
Ruslan Semechkin, Dmitry Isaev, Tatiana Abramihina, Nikolay<br />
Turovets, Richard A. West, Tatjana Zogovic-Kapsalis, Adnrey<br />
Semechkin.<br />
ORAL ABSTRACT SESSION 236<br />
Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
2:30 PM - 3:30 PM<br />
Room: 602-604<br />
101 2:30 PM<br />
Initial Results from a First-in-Man Study Delivering Non-<br />
Viral <strong>Gene</strong> <strong>Therapy</strong> JVS-100 To Treat Ischemic Heart Failure<br />
Marc S. Penn, Joseph Pastore, Rahul Aras, Didier Rouy, Gary<br />
Schaer, MaryJane Farr, Warren Sherman, Farrell Mendelsohn,<br />
Douglas Losordo.<br />
102 2:45 PM<br />
AAV8 <strong>Gene</strong> <strong>Therapy</strong> Leads to Significant Lowering<br />
<strong>of</strong> Plasma Cholesterol Levels in Humanized Mouse<br />
Models <strong>of</strong> Homozygous and Heterozygous Familial<br />
Hypercholesterolemia<br />
Sadik H. Kassim, Hui Li, Dawn Marchadier, Peter Bell, Scott<br />
Kobner, James M. Wilson, Daniel J. Rader.<br />
103 3:00 PM<br />
Phase I/IIa, Open-Labeled, Dose Escalation Clinical Study<br />
Using DVC1-0101 (F-<strong>Gene</strong>-Deleted Non-Transmissible<br />
Recombinant Sendai Virus Vector Expressing Human FGF-<br />
2) To Treat Peripheral Arterial Disease<br />
Yoshikazu Yonemitsu, Takuya Matsumoto, Hiroyuki Itoh,<br />
Jin Okazaki, Makiko Uchiyama, Kumi Yoshida, Toshihiro<br />
Onohara, Hiroyuki Inoguchi, Ryoichi Kyuragi, Atsushi Guntani,<br />
Mototsugu Shimokawa, Mitsuho Onimaru, Hiroshi Ban,<br />
Makoto Inoue, Tsugumine Zhu, Mamoru Hasegawa, Yoichi<br />
Nakanishi, Yoshihiko Maehara.<br />
104 3:15 PM<br />
Intrathoracic Administration <strong>of</strong> AAV9 Reverses Neural and<br />
Cardiorespiratory Dysfunction in Pompe Disease<br />
Darin J. Falk, Cathryn S. Mah, Meghan S. Soustek, Kun-Ze Lee,<br />
Denise A. Cloutier, Mai K. Elmallah, Kirsten E. Erger, Thomas J.<br />
Conlon, David D. Fuller, Barry J. Byrne.<br />
ORAL ABSTRACT SESSION 237<br />
Lung and Respiratory Disease<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
3:40 PM - 4:40 PM<br />
Room: 602-604<br />
105 3:40 PM<br />
Human Multipotent Stromal <strong>Cell</strong>s Attenuate LPS-Induced<br />
Acute Lung Injury in Mice Via Secretion <strong>of</strong> TNF-alpha-<br />
Induced Protein 6<br />
Svitlana Danchuk, Joni H. Ylostalo, Fokhrul M. Hossain, Randy<br />
Sorge, Austin Ramsey, Joseph A. Laskey, Bruce A. Bunnell,<br />
David A. Welsh, Darwin J. Prockop, Deborah E. Sullivan.<br />
106 3:55 PM<br />
In Vivo Site-Specific Delivery <strong>of</strong> Nanoparticles to Airway<br />
Epithelium Monitored by Scintigraphy<br />
Maria Manunta, Robin McAnulty, Aristides Tagalakis, Amy<br />
McDowell, John Fleming, Livia Bolt, Lorenzo Biassoni,<br />
Cristopher O’Callaghan, Stephen Hart.<br />
107 4:10 PM<br />
<strong>Gene</strong> Transfer <strong>of</strong> the Epithelial Sodium Channel (ENaC)<br />
alpha1 Subunit Using Electroporation Protects from<br />
Lipopolysaccaride (LPS)-Induced Acute Lung Injury<br />
Xin Lin, David A. Dean.<br />
108 4:25 PM<br />
Self-Reactive T <strong>Cell</strong>s to CFTR in Cystic Fibrosis (CF) and Non-<br />
CF Humans: Implications for <strong>Gene</strong> <strong>Therapy</strong><br />
Maria P. Limberis, Roberto Calcedo, Uta Griesenback, Eric W.<br />
Alton, James M. Wilson.<br />
POSTER SESSION I<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
RNA Virus Vectors I<br />
109<br />
DNA-Recognizing Integrase Fusion Protein Alters<br />
Integration Pattern <strong>of</strong> HIV-1 Based Vector<br />
Vesa Turkki, Diana Schenkwein, Mervi Ahlroth, Seppo<br />
Ylä-Herttuala.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 95<br />
Thursday, May 19
Thursday, May 19<br />
96<br />
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
RNA Virus Vectors I<br />
110<br />
Development and Characterization <strong>of</strong> Targeted Lentiviral<br />
Vectors Pseudotyped with the Tupaia paramyxovirus<br />
Glycoproteins<br />
Theresa Enkirch, Sabrina Kneissl, Birgit Hoyler, Wolfgang<br />
Stremmel, Christian J. Buchholz, Christoph Springfeld.<br />
111<br />
Reliability Metrics for LM/LAM/nrLAM-PCR Coupled with<br />
High Throughput Sequencing<br />
Troy B. Hawkins, Aparna Jasti, Aaron Ernstberger, Keithanne<br />
Mockaitis, Kenneth Cornetta.<br />
112<br />
Assessing Potency in Lentiviral Vectors Pseudotyped with<br />
VSV-G, RD114 or FV Envelope Glycoproteins<br />
Anna C. Pulliam-Leath, Aparna Jasti, Helmut Hanenberg, Dirk<br />
Lindemann, Kenneth Cornetta.<br />
113<br />
Tracking Retroviral-Integrated Clones with Modified Non-<br />
Restriction Enzyme LAM-PCR Technology<br />
Chuanfeng Wu, Alexander Jares, Thomas Winkler, Jianjun Xie,<br />
Andre Larochelle, Cynthia E. Dunbar.<br />
114<br />
GP64 Pseudotyped Feline Immunodeficiency Virus-Based<br />
Vector Transduces Murine Primary Nasal Epithelial <strong>Cell</strong>s<br />
with Greater Efficacy Than Primary Tracheal Epithelial <strong>Cell</strong>s<br />
Mayumi Oakland, Paul B. McCray, Patrick L. Sinn.<br />
115<br />
Safety Evaluation <strong>of</strong> <strong>Gene</strong> Transfer Vectors for <strong>Gene</strong><br />
<strong>Therapy</strong> <strong>of</strong> Wiskott-Aldrich Syndrome<br />
Yasuhiro Ikawa, Toru Uchiyama, Fabio Candotti.<br />
116<br />
Retrovirus with the Bioorthogonally Functionalized<br />
Envelope for Efficient, Convenient, and Versatile Labeling,<br />
Purification, and Targeted Delivery<br />
Shirley Wong, Haley Phan, Min Suk Shim, Young Jik Kwon.<br />
117<br />
Decitabine Effects on Lentiviral Transduction for Human<br />
CD34 + <strong>Cell</strong>s<br />
Naoya Uchida, Matthew M. Hsieh, John F. Tisdale.<br />
118<br />
A New Lentiviral Based RNAi Platform Used in <strong>Gene</strong><br />
Validation in Tuberculosis Research and Effects <strong>of</strong><br />
Modifications in the Transgene 3’ UTR<br />
Ulrike Jung, Kellen C. Fae, Juan P. Patron, John J. Rossi, Stefan<br />
H. E. Kaufmann.<br />
119<br />
Reducing Immune Response to Lentiviral Vectors by the<br />
Display <strong>of</strong> Human Self’ Marker, CD47 on Vector Envelope<br />
Nisha Sosale, Richard K. Tsai, Irena Ivanovska, Philip W.<br />
Zoltick, Dennis E. Discher.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
AAV Genome & Host Interactions<br />
120<br />
Hepatocellular Carcinoma Due to Targeted Promoter<br />
Insertion by AAV Vectors<br />
Mei Xu, Peirong Wang, Yi Li, David W. Russell.<br />
121<br />
Regulation <strong>of</strong> AAV Mediated Transgene Expression by a<br />
Host <strong>Cell</strong> Transcriptional Repressor PARP-1<br />
Sangeetha Hareendran, Nishanth Gabriel, Arun Srivastava,<br />
Alok Srivastava, Giridhara Rao Jayandharan.<br />
122<br />
AAV-Mediated <strong>Gene</strong> Delivery and <strong>Gene</strong> Targeting in<br />
Human Embryonic Stem <strong>Cell</strong>s<br />
Prashanth Asuri, Melissa A. Bartel, Jae-Hyung Jang, David V.<br />
Schaffer.<br />
123<br />
Absence <strong>of</strong> Integration Hotspots in Mice after<br />
Intramuscular Injection <strong>of</strong> AAV1-LPL S447X<br />
C. Kaeppel, S. Beattie, A. Nowrouzi, U. Appelt, R. Kirsten, H.<br />
Glimm, J. Snapper, C. von Kalle, H. Petry, M. Schmidt.<br />
124<br />
Adeno-Associated Viral Vector DNA Is Insensitive to De<br />
Novo CpG Methylation but Rapidly Associates with Histone<br />
Modifications in Liver and Skeletal Muscle<br />
Adrien Léger, Caroline Le Guiner, Michael L. Nickerson,<br />
Nicolas Ferry, Philippe Moullier, Richard O. Snyder, Magalie<br />
Penaud-Budloo.<br />
125<br />
AAV-Mediated <strong>Gene</strong> Correction for the Treatment <strong>of</strong><br />
Recessive Dystrophic Epidermolysis Bullosa<br />
Rowan Flynn, Lisa M. Petek, Andrew P. South, Daniel G. Miller.<br />
126<br />
A Distinctive Fate <strong>of</strong> rAAV Vector Genomes in the Liver<br />
Transduced with Very Low Doses <strong>of</strong> rAAV8 in Mice<br />
Kei Adachi, Hiroyuki Nakai.
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
AAV Genome & Host Interactions<br />
127<br />
AAV-Mediated shRNA Integration into an Endogenous<br />
miRNA Locus as a New Strategy for Safe, Specific and<br />
Persistent Therapeutic RNAi<br />
Stefan Mockenhaupt, Dirk Grimm.<br />
128<br />
Naturally Occurring Non-Functional Mutations <strong>of</strong> the AAV<br />
ITR<br />
Cameron Mroske, Hector Rivera, Taihra Ul-Hassan, Saswati<br />
Chatterjee, K. K. Wong, Jr.<br />
129<br />
Establishment and Use <strong>of</strong> a Configuration-Specific Method<br />
To Determine the Structure <strong>of</strong> AAV-ITRs Recombined by<br />
DNA Repair Pathways<br />
Baocheng Huang, Hiroyuki Nakai.<br />
130<br />
AAV Vectors Copurify with Microvesicles in Producer<br />
<strong>Cell</strong> Media: Implications for <strong>Gene</strong> Transfer and Vector<br />
Purification<br />
Casey A. Maguire, Leonora Balaj, Sara Sivaraman, Johan<br />
Skog, Miguel Sena-Esteves, Xandra O. Breakefield, Bakhos A.<br />
Tannous.<br />
131<br />
A Simple Strategy To Increase the Transduction Efficiency<br />
<strong>of</strong> Single-Stranded AAV Vectors In Vitro and In Vivo<br />
Wenqin Ma, Baozheng Li, Chen Ling, Giridhara R.<br />
Jayandharan, Arun Srivastava, Barry J. Byrne.<br />
132<br />
Site-Specific Modification <strong>of</strong> AAV2 Vector by Using the<br />
<strong>Gene</strong>tically Encoded Aldehyde Tag<br />
Yarong Liu, Kye-Il Joo, Pin Wang.<br />
133<br />
Construction <strong>of</strong> (Multi) Monomeric Duplex Adeno-<br />
Associated Vectors for Human <strong>Gene</strong> <strong>Therapy</strong><br />
Jacek Lubelski, Yvet Noordman, Bas Bosma, Larbi Afia, Harald<br />
Petry, Andrew Bakker.<br />
134<br />
Targeted Integration <strong>of</strong> an rAAV Vector into the AAVS1 Site:<br />
Measurement <strong>of</strong> the Integration Rate without Selection<br />
Peter Ward, Christopher E. Walsh.<br />
Adenovirus and Other DNA Virus Vectors I<br />
135<br />
Microscopy Analysis <strong>of</strong> Adenovirus Serotype 3 Interaction<br />
with its Receptor Desmoglein 2<br />
Zong-Yi Li, Hongjie Wang, Ines Beyer, Pascal Fender, Andre<br />
Lieber.<br />
136<br />
The Role <strong>of</strong> Endosomal Escape and Mitogen Activated<br />
Protein Kinases in Adenoviral Activation <strong>of</strong> the Innate<br />
Immune Response<br />
Jeffrey S. Smith, Zhili Xu, Jie Tian, Donna J. Palmer, Philip Ng,<br />
Andrew P. Byrnes.<br />
137<br />
The Sequential Proteolysis and Liberation <strong>of</strong> the<br />
Intracellular Domain <strong>of</strong> CD44 Modulates Adenoviral Vector<br />
Transgene Expression and Replication <strong>of</strong> Adenovirus<br />
Wesley S. Bond, Cristhian J. Ildefonso, Mary Y. Hurwitz,<br />
Richard L. Hurwitz.<br />
138<br />
Enhanced Transduction <strong>of</strong> Fiber Modified Ad in Canine<br />
Lymphoma <strong>Cell</strong> Lines<br />
Ann Marie O’Neill, David T. Curiel, Bruce F. Smith.<br />
139<br />
Simultaneous <strong>Gene</strong>tic Peptide Targeting <strong>of</strong> Adenovirus<br />
Subtype 5 towards Two Different Receptors<br />
Michael Behr, Maximilian Richter, Martin A. Häusl, Philipp<br />
Fieger, Sarah Engelhardt, Carolin Stegmüller, Alexander H.<br />
Enk, Anja Ehrhardt, Dirk M. Nettelbeck.<br />
140<br />
Augmentation <strong>of</strong> Rat Skin Flap Viability by Relaxin-<br />
Expressing Adenovirus<br />
Il-Kyu Choi, Won Jai Lee, In Sik Yun, Yong-Oock Kim, Tae Jin<br />
Yun, Dong Kyun Rah, Chae-Ok Yun.<br />
141<br />
A Rapid, PCR-Based Method for Direct In-Vitro Cloning into<br />
Recombinant Adenoviral Vectors<br />
Thomas P. Quinn, Lily Lee, Mei Fong, Michael Haugwitz,<br />
Hiroaki Sagawa.<br />
142<br />
Differential Effects <strong>of</strong> Murine and Human Factor X on<br />
Adenovirus Transduction Via <strong>Cell</strong> Surface Heparan Sulfate<br />
Anne K. Zaiss, Roger Lawrence, David Elash<strong>of</strong>f, Jeffrey D. Esko,<br />
Harvey R. Herschman.<br />
143<br />
Improved Tropism <strong>of</strong> Adenoviral Vectors for Muscle <strong>Cell</strong>s<br />
Using an IGF-1R Targeted Bispecific Ligand<br />
Maxime Pinard, Birgit Kastberger, Yue Zeng, Nancy Larochelle,<br />
Josephine Nalbantoglu, Bernard Massie, Rénald Gilbert.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 97<br />
Thursday, May 19
Thursday, May 19<br />
98<br />
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Adenovirus and Other DNA Virus Vectors I<br />
144<br />
An Alternate Method for Efficient Delivery <strong>of</strong> Catalyzing<br />
Enzymes<br />
Andrew D. Fontes, Rene Quintanilla, Michael Poderycki, Jon<br />
Chesnut, Uma Lakshmipathy.<br />
145<br />
A Hypoxia and α-Fetoprotein-Dependent Oncolytic<br />
Adenovirus Exhibits Specific Killing <strong>of</strong> Hepatocellular<br />
Carcinomas<br />
Oh-Joon Kwon, Pyung-Hwan Kim, Steven Huyn, Lily Wu,<br />
Minjung Kim, Chae-Ok Yun.<br />
146<br />
Quantification <strong>of</strong> Wild Type Replicative Adenovirus<br />
Contamination That Results from Amplification <strong>of</strong><br />
Conditionally Replicative Adenovirus<br />
Eric J. Brown, Julia Davydova, Masato Yamamoto, Selwyn M.<br />
Vickers.<br />
147<br />
Specific Modification <strong>of</strong> Hexon with 5KDa PEG Improves<br />
the Therapeutic Index <strong>of</strong> Helper-Dependent Ad Vector for<br />
Liver-Directed <strong>Gene</strong> <strong>Therapy</strong><br />
Francesco Vetrini, Donna J. Palmer, Nathan C. Grove, Amanda<br />
Rosewell, Florian Kreppel, Philip Ng.<br />
148<br />
Multi-Modal Imaging Reveals Sites <strong>of</strong> <strong>Cell</strong>ular<br />
Reprogramming in Treatment <strong>of</strong> Type-1 Diabetes<br />
Neil Phillips, Mark Kay.<br />
Chemical and Molecular Conjugates<br />
149<br />
T1α Promoter-Mediated <strong>Gene</strong> Delivery into Alveolar<br />
Epithelial Type I <strong>Cell</strong>s<br />
Lynn F. Gottfried, David A. Dean.<br />
150<br />
New <strong>Gene</strong> Regulation Delivery System Using Peptide-<br />
Pendant Polyethyleneimine for Cancer <strong>Cell</strong>-Specific<br />
<strong>Therapy</strong> and Imaging<br />
Yoshiki Katayama, Riki Toita, Leong-Hun Kang, Takeshi Mori,<br />
Takuro Niidome.<br />
151<br />
<strong>Gene</strong> Delivery to Oral Cancer <strong>Cell</strong>s by Transferrin-<br />
Polyplexes and Tat-Peptide-Lipoplexes<br />
Senait Gebremedhin, Stephen Koons, Krystyna Konopka,<br />
Nejat Duzgunes.<br />
152<br />
Highly Effective Non-Viral Antitumor <strong>Gene</strong> <strong>Therapy</strong><br />
System Comprising Biocompatible Small Plasmid Complex<br />
Particles<br />
Chieko Yoshihara, Tomoko Ito, Yoshiyuki Koyama.<br />
153<br />
Characterization <strong>of</strong> Lipoplex Properties and <strong>Gene</strong> Transfer<br />
Efficiency <strong>of</strong> a Novel Family <strong>of</strong> Cationic Carotenoid Lipids<br />
Natalia Bilchuk, Matthew S. Adams, Rachel Jones, Alexandra<br />
M. Liberski, Christer L. Øpstad, Vassilia Partali, Hans-Richard<br />
Sliwka, Howard H. Lou, Michael D. Pungente, Philip L.<br />
Leopold.<br />
154<br />
Preparation <strong>of</strong> Hydroxyapatite Nanocapsule Including<br />
DNA/PEI/Hyaluronic Acid Ternary Complex for Durable<br />
<strong>Gene</strong> Delivery<br />
Tomoko Ito, Makoto Otsuka.<br />
155<br />
Lipopolymer Mediated siRNA Delivery Strategy for Acute<br />
Myeloid Leukemia <strong>Cell</strong>s<br />
Breanne Landry, Hamidreza Montazeri Aliabadi, Hasan<br />
Uludag.<br />
156<br />
Development <strong>of</strong> Nanocomplexes for Targeted siRNA Delivery<br />
Aristides D. Tagalakis, Luisa Saraiva, Stephen L. Hart.<br />
157<br />
Designing DNA-Doped Biomineral Nanocomposites for<br />
Effective and Safe <strong>Gene</strong> Delivery<br />
Bingbing Sun, Hong Shen.<br />
158<br />
Tumor-Directed Small Interfering RNA Delivery by Anti-<br />
EGFR Immunonanoplexes<br />
Jung Seol Kim, Yeon Kyung Lee, Hwa Yeon Jeong, Young Eun<br />
Shin, Keun Sik Kim, Yong Serk Park.<br />
159<br />
Reducible Poly(Amido Ethyleneimine)s Affect <strong>Cell</strong>ular<br />
Redox Potentials through Copper Mediated Enzymes<br />
James W. Yockman, Young Won Lee, Jonathan H. Brumbach,<br />
Katherine S. Blevins, Zachary J. Robbins, Sung Wan Kim.<br />
160<br />
EGFR-Mediated <strong>Gene</strong> Delivery Using Anti-EGFR<br />
Immunonanoparticles<br />
Jung Seok Kim, Yeon Kyung Lee, Wha Yeon Jeong, Young Eun<br />
Shin, Keun Sik Kim, Yong Serk Park.<br />
161<br />
Bioreducible Polymer Conjugated <strong>Cell</strong> Penetrating<br />
Peptides for siRNA Delivery<br />
Hye Yeong Nam, Sung Wan Kim, David A. Bull.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Chemical and Molecular Conjugates<br />
162<br />
Polymeric Delivery <strong>of</strong> a Bone Morphogenetic Protein-2<br />
Plasmid at Rat Subcutaneous Site<br />
Laura Rose, Cezary Kucharski, Hasan Uludag.<br />
163<br />
Developing Magnetic Nanoparticles for Targeted Nucleic<br />
Acid Delivery and Detection<br />
Andrew M. Prantner, Jun Chen, Christopher B. Murray,<br />
Nathalie Scholler.<br />
164<br />
Acid-Transforming Polypeptide for Efficient, Targeted, and<br />
Molecularly Tunable Nonviral <strong>Gene</strong> Delivery<br />
Min Suk Shim, Young Jik Kwon.<br />
165<br />
The Nuclear Pore Dilating Agent TCHD Increases <strong>Gene</strong><br />
Transfer into Differentiated Airway Epithelium Ex Vivo, But<br />
Has No Effect In Vivo<br />
Uta Griesenbach, Katherine M. Wilson, Raymond Farley,<br />
Cuixiang Meng, Ronald K. Scheule, Seng H. Cheng, Eric W. F.<br />
W. Alton.<br />
166<br />
Stimuli-Sensitive Copolymer Nanocapsules for Nontoxic<br />
and Efficient Non-Viral <strong>Gene</strong> Delivery<br />
Min Sang Lee, Yeon Lim Jang, Myung Goo Kim, Dai Phu<br />
Huynh, Cong Truc Huynh, Yuhan Lee, Su Young Chae, Sun<br />
Hwa Kim, Tae Gwan Park, Doo Sung Lee, Ji Hoon Jeong.<br />
167<br />
Non-Viral <strong>Gene</strong> Delivery with 25-kD PEI and G4 PAMAM<br />
Are Dependent on Active Clathrin and Caveolar Trafficking<br />
Pathways<br />
Mark E. Hwang, Rahul K. Keswani, Daniel W. Pack.<br />
168<br />
RhoGTPases Modulate Non-Viral <strong>Gene</strong> Delivery<br />
Anandika Dhaliwal, Maricela Maldonado, Clayton Lin, Tatiana<br />
Segura.<br />
169<br />
Tailorable PNA-Based siRNA Nanoconjugates for <strong>Cell</strong>-<br />
Responsive <strong>Gene</strong> Silencing<br />
Abbygail A. Palmer, Millicent O. Sullivan.<br />
170<br />
Disrupted Adenovirus-Based Nicotine Conjugate Vaccine<br />
To Treat Nicotine Addiction<br />
Bishnu P. De, Martin L. Hicks, Jonathan B. Rosenberg, Amira Y.<br />
Moreno, Kim Janda, Stephen M. Kaminsky, Ronald G. Crystal.<br />
171<br />
Transfection <strong>of</strong> <strong>Cell</strong>s by RGD-Tagged PEGylated Lipid-DNA<br />
Nanoparticles in Serum<br />
Chia-Ling Chan, Ramsey N. Majzoub, Kai K. Ewert, Keng-San<br />
Liang, Cyrus R. Safinya.<br />
172<br />
A “S<strong>of</strong>t Polyplex” <strong>of</strong> Oligoarginine-Grafted Polymers<br />
Affording a Protein Kinase-Responsive <strong>Gene</strong> Expression<br />
Takeshi Mori, Hiroyuki Tanaka, Riki Toita, Takuro Niidome,<br />
Yoshiki Katayama.<br />
173<br />
Directed Movement and Velocity <strong>of</strong> Transfected Plasmids Is<br />
Enhanced on Acetylated Microtubules<br />
Melissa A. Badding, David A. Dean.<br />
174<br />
Quantification <strong>of</strong> Intracellular Polyplex Distribution Via<br />
Subcellular Fractionation Techniques<br />
Julie Shi, Brian Chou, David Chu, Russell N. Johnson, Suzie H.<br />
Pun.<br />
175<br />
Histone-Mimetic Polyplexes as Self-Activating and<br />
Tailorable Non-Viral <strong>Gene</strong> Delivery Vehicles<br />
Meghan J. Reilly, Millicent O. Sullivan.<br />
914 (MOVED FROM POSTER SESSION III)<br />
Intracellular Trafficking <strong>of</strong> a Histone-Mimetic Polyplex to<br />
Promote Nucleus-Specific Self-Unpackaging<br />
Meghan J. Reilly, John D. Larsen, Millicent O. Sullivan.<br />
176<br />
Oligonucleotide-Conjugated Silver Nanoparticles for<br />
Photoactivated <strong>Gene</strong> Silencing<br />
Paige K. Brown, Ammar T. Qureshi, Alyson L. Moll, Daniel J.<br />
Hayes, W. Todd Monroe.<br />
177<br />
Development <strong>of</strong> Peptide-Based HPMA-Copolymers for<br />
Nucleic Acid Delivery<br />
Russell N. Johnson, Dave Chu, Julie Shi, Suzie H. Pun.<br />
178<br />
Multifunctional Nanocarriers for Enhancing Suicide <strong>Gene</strong><br />
<strong>Therapy</strong><br />
Jiesheng Wang, Jen-I. Hsu, Ching-An Peng.<br />
179<br />
Enhanced Stability and Knockdown Efficiency <strong>of</strong><br />
Poly(ethylene Glycol)-b-Polyphosphoramidate/siRNA<br />
Micellar Nanoparticles by Co-Condensation with Sodium<br />
Triphosphate<br />
Masataka Nakanishi, Rajesh Patil, Yong Ren, Hai-Quan Mao.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 99<br />
Thursday, May 19
Thursday, May 19<br />
100<br />
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Chemical and Molecular Conjugates<br />
180<br />
Aromatic Self-Assembling Polyethylenimines Are<br />
Efficacious siRNA Delivery Reagents<br />
Guy Zuber, Benoit Frisch, Gaelle Creusat.<br />
181<br />
Liver Targeted siRNA Delivery by Different Polymeric<br />
Carriers Containing Monosaccharide or Polysaccharide<br />
Tetsuji Yamaoka, Wakako Kamata, Yoichi Tachibana, Mariko<br />
Harada-Shiba, Jeong-hun Kang.<br />
182<br />
Cutaneous <strong>Gene</strong> Delivery Using Pyrene-Substituted<br />
Gemini-Lipid Nanoparticles<br />
Mahmoud Elsabahy, Ildiko Badea, Ronald Verrall, Marianna<br />
Foldvari.<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
183<br />
Improved Chylomicron Clearance as a Marker for Long-<br />
Term Efficacy <strong>of</strong> Alipogene Tiparvovec (AAV1-LPL S447X <strong>Gene</strong><br />
<strong>Therapy</strong>) in LPLD Patients<br />
Jaap Twisk, Frederique Frisch, Stephen Greentree, Harald<br />
Petry, Janneke de Wal, Diane Brisson, Claude Gagné, André C.<br />
Carpentier, Daniel Gaudet.<br />
184<br />
Pharmacological Immunosuppression Fails To Improve the<br />
Outcome <strong>of</strong> AAV-Based Liver <strong>Gene</strong> Transfer in Non-Human<br />
Primates<br />
Carmen Unzu, Sandra Hervas-Stubbs, Ana Sampedro, Itsaso<br />
Mauleon, Uxua Mancheño, Carlos Alfaro, Rafael Enriquez<br />
de Salamanca, Alberto Benito, Ignacio Melero, Antonio<br />
Fontanellas.<br />
185<br />
Pre-Existing Neutralizing Antibodies to AAV Capsids in<br />
Large Animals Other Than Monkeys May Confound In Vivo<br />
<strong>Gene</strong> <strong>Therapy</strong> Studies<br />
Roberto Calcedo, Judith Franco, Qiuyue Qin, Dean W.<br />
Richardson, Jeffrey B. Mason, Surina Boyd, James M. Wilson.<br />
186<br />
Impact <strong>of</strong> Pre-Existing Neutralizing Antibodies on AAV8-<br />
Mediated, Liver-Directed <strong>Gene</strong> Transfer and Vector<br />
Biodistribution in Nonhuman Primates<br />
Lili Wang, Roberto Calcedo, Peter Bell, Jianping Lin, Rebecca<br />
Grant, Don L. Siegel, James M. Wilson.<br />
187<br />
Comprehensive Integration Site Analysis <strong>of</strong> One New <strong>Gene</strong><br />
<strong>Therapy</strong> Vector AAV-rDNA<br />
Zhongya Wang, Hiroyuki Nakai, Markus Grompe.<br />
188<br />
Relationship between Neutralizing Antibody and Factor<br />
IX Expression in Non-Human Primates Following IV<br />
Administration <strong>of</strong> AAV8 Vectors<br />
Hiroaki Mizukami, Jun Mimuro, Akira Ishiwata, Hiroya Yagi,<br />
Tsukasa Ohmori, Seiji Madoiwa, Tomonori Tsukahara, Masashi<br />
Urabe, Akihiro Kume, Yoichi Sakata, Keiya Ozawa.<br />
189<br />
Development <strong>of</strong> a Clinical HIV-Based SIN Vector Encoding a<br />
High-Expression Factor VIII Transgene for the Treatment <strong>of</strong><br />
Hemophilia A<br />
Christopher B. Doering, Gabriela Denning, Robert Moot,<br />
Jennifer Johnston, Jordan Shields, Boro Dropulic, H. Trent<br />
Spencer.<br />
190<br />
<strong>Gene</strong> and <strong>Cell</strong> <strong>Therapy</strong> for Hemophilia B Using Adipose<br />
Tissue-Derived Stem/Stromal <strong>Cell</strong>s Transduced with a Self-<br />
Inactivating SIV Lentivirus Vector<br />
Natsumi Watanabe, Kazuo Ohashi, Kohei Tatsumi, Rie Utoh,<br />
Kazuko Kanegae, Yuji Kashiwakura, Tsukasa Ohmori, Yoichi<br />
Sakata, Makoto Inoue, Mamoru Hasegawa, Teruo Okano.<br />
191<br />
Optimizing Engraftment <strong>of</strong> FANCA <strong>Gene</strong>-Modified Bone<br />
Marrow <strong>Cell</strong>s in a Mouse Model <strong>of</strong> Fanconi’s Anemia<br />
Jennifer E. Adair, Xin Zhao, Pamela S. Becker, Hans-Peter<br />
Kiem.<br />
192<br />
Mozobil-Alone or Mozobil+G-CSF Significantly Improve the<br />
Mobilization Efficiency <strong>of</strong> Thalassemic Mice: Implications<br />
for Human <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Thalassemia<br />
Evangelia Yannaki, Nikoleta Psatha, Eleni Sgouramali,<br />
Evangelia Athanasiou, Eleftheria Tsolaki, Minas<br />
Yiangou, Minas Arsenakis, Athanasios Fassas, Achilles<br />
Anagnostopoulos.<br />
193<br />
AAV Mediated Liver-Specific <strong>Gene</strong> <strong>Therapy</strong> for Thrombotic<br />
Thrombocytopenic Purpura (TTP) in a Murine Model<br />
Sheng-Yu Jin, Juan Xiao, Fraser J. Wright, X. Long Zheng.<br />
464 MOVED FROM POSTER SESSION II<br />
Hematopoietic Differentiation <strong>of</strong> Airway Epithelial <strong>Cell</strong>-Derived<br />
Cystic Fibrosis (CF) Induced Pluripotent Stem (iPS) <strong>Cell</strong>s<br />
R. Ge<strong>of</strong>frey Sargent, Yanu Yang, Albert Lee, Marcus O.<br />
Muench, Soya Kim, Arash Bedayat, Layli Jamali, Lin Ye, Judy<br />
Chang, Dieter C. Gruenert.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
712 MOVED FROM POSTER SESSION III<br />
Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> with a Lentiviral<br />
Vector for the Multi-Systemic Lysosomal Storage Disorder<br />
Cystinosis<br />
Frank Harrison, Brian A. Yeagy, Donald B. Kohn, Daniel R.<br />
Salomon, Stephanie Cherqui.<br />
Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
194<br />
Long-Term Phenotypic Correction <strong>of</strong> Feline Lysosomal<br />
Storage Disease by Intracranial AAV <strong>Gene</strong> <strong>Therapy</strong><br />
Victoria J. Jones, Allison M. Bradbury, Misako Hwang, Stanley<br />
G. Leroy, Stacy Maitland, Aime K. Johnson, Miguel Sena-<br />
Esteves, Douglas R. Martin.<br />
195<br />
Brain <strong>Gene</strong> <strong>Therapy</strong> for Metachromatic Leukodystrophy:<br />
Optimized Clinical Protocol<br />
Caroline Sevin, Françoise Piguet, Dolan Sondhi, Marie-Anne<br />
Colle, Thomas Roujeau, Sylvie Raoul, Jack-Yves Deschamps,<br />
Celine Bouquet, Ornella Ahouansou, Marie Vanier, Philippe<br />
Moullier, Yan Cherel, Neil R. Hackett, Michel Zerah, Ronald G.<br />
Crystal, Patrick Aubourg, Nathalie Cartier.<br />
196<br />
Dosage Thresholds and Vector Serotype Define AAV<br />
Targeting <strong>of</strong> Rod and Cone Photoreceptors in Non-Human<br />
Primates<br />
Luk H. Vandenberghe, Peter Bell, Albert M. Maguire, Ru Xiao,<br />
Rebecca Grant, Jean Bennett, James M. Wilson.<br />
197 ABSTRACT WITHDRAWN<br />
198<br />
RNAi <strong>Therapy</strong> for Spinocerebellar Ataxia Type 1<br />
Megan K. Keiser, Ryan L. Boudreau, Beverly L. Davidson.<br />
199<br />
Long-Term Persistence <strong>of</strong> AAV Mediated <strong>Gene</strong> <strong>Therapy</strong> for<br />
Leber Congenital Amaurosis Type 1 (LCA1)<br />
Sanford L. Boye, Thomas Conlon, Kirsten Erger, Travis<br />
Cossette, Jijing Pang, Sukanya Karan, Renee Ryals, Wolfgang<br />
Baehr, William W. Hauswirth, Shannon E. Boye.<br />
200<br />
Correction <strong>of</strong> the Lysosomal Storage Defect in Mouse<br />
Model <strong>of</strong> Juvenile Neuronal Ceroid Lip<strong>of</strong>uscinosis by<br />
Neonatal Injection <strong>of</strong> AAV Serotype rh.10 Vector Expressing<br />
the Human CLN3 <strong>Gene</strong><br />
Dolan Sondhi, Neil R. Hackett, Emma Scott, Alvin Chen, Susan<br />
Cotman, Ronald G. Crystal.<br />
201<br />
The Effect <strong>of</strong> Pre-Existing Immunity to AAV on CNS<br />
Directed <strong>Gene</strong> <strong>Therapy</strong><br />
Christopher M. Treleaven, Thomas J. Tamsett, Jonathan<br />
A. Fidler, Gregory D. Hurbult, Seng H. Cheng, Lamya S.<br />
Shihabuddin, James C. Dodge.<br />
202<br />
Microglia as an Attractive <strong>Cell</strong>ular Vehicle for <strong>Gene</strong> <strong>Therapy</strong><br />
<strong>of</strong> Parkinson’s Disease<br />
K. C. Biju, Rene A. Santacruz, Cang Chen, Robert A. Clark,<br />
Senlin Li.<br />
203<br />
Early Functional and Long-Term Rescue <strong>of</strong> the LHON Mouse<br />
with Wild-Type Human ND4 <strong>Gene</strong> Delivery<br />
Rajeshwari D. Koilkonda, Tsung-Han Chou, Marco Ruggeri,<br />
Vittorio Porciatti, William W. Hauswirth, Vince Chiodo, Sanford<br />
L. Boye, John Guy.<br />
204<br />
Adeno-Associated Virus Mediated <strong>Gene</strong> <strong>Therapy</strong> for<br />
Treatment <strong>of</strong> Autosomal Dominant Retinitis Pigmentosa<br />
(ADRP)<br />
Haoyu Mao, Marina S. Gorbatyuk, William W. Hauswirth,<br />
Alfred S. Lewin.<br />
205<br />
CNS Expression <strong>of</strong> Glucocerebrosidase Corrects<br />
Hippocampal alpha-Synuclein Aggregates and<br />
Memory Deficits in a Mouse Model <strong>of</strong> Gaucher-Related<br />
Parkinsonism<br />
Pablo S. Sardi, Lamya S. Shihabuddin, Seng H. Cheng.<br />
206<br />
Anterograde Trafficking <strong>of</strong> AAV2 Vectors in the Primate<br />
Brain<br />
Adrian P. Kells, Ernesto Aguilar Salegio, Kryst<strong>of</strong> S. Bankiewicz.<br />
207<br />
Evaluation <strong>of</strong> the Immune Responses in the Treatment<br />
<strong>of</strong> RPE65 Deficient Dogs by Subretinal Injection <strong>of</strong> a<br />
Recombinant AAV Serotype 4<br />
Nathalie Provost, Lise Libleau, Alexandra Mendes Madeira,<br />
Jack-Yves Deschamps, Michel Weber, Guylène LeMeur,<br />
Yan Cherel, Philippe Moullier, Fabienne Rolling, Christine<br />
Chauveau.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 101<br />
Thursday, May 19
Thursday, May 19<br />
102<br />
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Infectious Diseases and Vaccines I<br />
208<br />
Inhibition <strong>of</strong> Human Immunodeficiency Virus (HIV) Type 1<br />
Replication through Expression <strong>of</strong> RNAi Effectors Targeting<br />
HIV-Dependency Factor HTATSF1<br />
Victoria Green, Patrick Arbuthnot, Marco S. Weinberg.<br />
209<br />
Protection Against Divergent Influenza H1N1 Virus by a<br />
Centralized Influenza Hemagglutinin<br />
Eric A. Weaver, Richard Webby, Michael A. Barry.<br />
210<br />
Administration <strong>of</strong> AdC7-OprF Expressing the P. aeruginosa<br />
Protein OprF and Carrying the RGD Sequence in the Fiber<br />
Provides Longterm Mucosal Immunity without Increasing<br />
<strong>Cell</strong>ular Immunity<br />
Anja Krause, Wen Zhu, Yaqin Xu, Ronald G. Crystal, Stefan<br />
Worgall.<br />
211<br />
Combination <strong>of</strong> CCR5delta32 and shRNAs Targeting HIV<br />
Ekta Patel, Starlyn Okada, Yingchi Chen, Miao-Fen Chao,<br />
Qingwen Jin, Li-Min Huang, Ghalib Alkhatib, Lung-Ji Chang.<br />
212<br />
Post-Exposure Treatment with a Human Adenovirus<br />
5 Vector-Based Combination <strong>Therapy</strong> Against Zaire<br />
Ebolavirus and Avian Influenza H5N1 in Small Animals<br />
Ami Patel, Jason Richardson, Jane Ennis, Jeff Turner, Gary P.<br />
Kobinger.<br />
213<br />
Lentivector Expressing HBsAg and Immunoglobulin Fc<br />
Fusion Antigen Induces Potent Immune Responses and<br />
Results in Seroconversion in HBsAg Transgenic Mice<br />
Yuan Hong, Yibing Peng, Michael Mi, David H. Munn, Guiqiang<br />
Wang, Yukai He.<br />
214<br />
Passive Immunization Strategy for Pandemic Influenza<br />
Using AAV Delivery <strong>of</strong> Broadly-Neutralizing Antibodies<br />
Virginie S. Adam, James M. Wilson, Maria P. Limberis.<br />
215<br />
Strategies for Therapeutic Vaccination: Electroporation-<br />
Mediated Delivery <strong>of</strong> DNA Vaccines in the Woodchuck<br />
Hepatitis Model<br />
Claire F. Evans, Katherine H. Liu, Mary A. Ascenzi, Christine A.<br />
Bellezza, Abraham J. Bezuidenhout, Alain Luxembourg, Drew<br />
W. Hannaman, Paul J. Cote, Bud C. Tennant, Stephan Menne.<br />
216<br />
Porcine Adenovirus 3 or Human Adenovirus 5 Vectors<br />
Expressing HA and NP Does Not Improve Cross-Clade<br />
Protection Against Avian Influenza H5N1<br />
Ami Patel, Suresh K. Tikoo, Yan Li, Gary P. Kobinger.<br />
217<br />
HIV Latency: Overcoming Transcriptional Block (Initiation<br />
and Elongation)<br />
Suresh K. Arya.<br />
218<br />
Production and Characterization <strong>of</strong> Monoclonal Antibodies<br />
Against Brucella melitensis Bp26 for Mapping the Antigenic<br />
Epitope<br />
Jinlang Qiu, Wenjing Wang, Hui Zhang, Yuanzhi Wang, Ling<br />
Zhang, Yixin Bian, Hongwei Li, Chuangfu Chen, Chengyao Li.<br />
219<br />
GLA Synergize with Dendritic <strong>Cell</strong>-Directed LV for an<br />
Improved Immune Response<br />
Liang Xiao, Matt Lin, Jocelyn Kim, Lili Yang, Pin Wang.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Cancer - Immunotherapy I<br />
220<br />
Chemotherapy in Combination with T-<strong>Cell</strong> <strong>Therapy</strong> Results<br />
in Significant Antitumor Activity and Improved Clinical<br />
Outcomes for EBV-Associated Nasopharyngeal Carcinoma<br />
Marissa Teo, John Chia, Peter Wang, David Tai, Joanna Ng,<br />
ChitLai Chee, Fei Gao, SzeHuey Tan, SooFan Ang, Yatanar Soe,<br />
Stephen Gottschalk, HanChong Toh.<br />
221<br />
A Novel Single Chain Chimeric Antigen Receptor<br />
Framework Provides Tumor Reactivity <strong>of</strong> Retrovirally<br />
Transduced Human T <strong>Cell</strong>s towards an erbB2 + Breast<br />
Carcinoma <strong>Cell</strong> Line<br />
Ralf-Holger Voss, Winfried S. Wels, Matthias Theobald.<br />
222<br />
GM-CSF <strong>Gene</strong> Transduced Murine Cancer Stem <strong>Cell</strong>s<br />
Eliminate Tumorigenicity In Vivo<br />
Chika Sakamoto, Hiroyuki Inoue, Yusuke Murakami, Yosuke<br />
Yokota, Megumi Narusawa, Shohei Miyamoto, Ayumi<br />
Watanabe, Makoto Inoue, Koichi Takayama, Mamoru<br />
Hasegawa, Yoichi Nakanishi, Kenzaburo Tani.<br />
223<br />
Estimation <strong>of</strong> T <strong>Cell</strong> Receptor (TCR) Diversity by Next<br />
<strong>Gene</strong>ration Sequencing Technologies<br />
Eliana Ruggiero, Ali Nowrouzi, Anne Arens, Hanno Glimm,<br />
Manfred Schmidt, Christ<strong>of</strong> von Kalle.
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Cancer - Immunotherapy I<br />
224<br />
Targeting B-<strong>Cell</strong> Malignancies with Chimeric Antigen<br />
Receptor-Modified γδ T <strong>Cell</strong>s<br />
Drew C. Deniger, Harjeet Singh, Helen Huls, Simon Olivares,<br />
Laurence J. N. Cooper.<br />
225<br />
Adoptive Transfer <strong>Therapy</strong> Using Expanded Melanoma-<br />
Specific T <strong>Cell</strong>s <strong>Program</strong>med Ex Vivo for Improved Efficacy<br />
In Vivo<br />
Helen A. Andersson, Jessica A. Hernandez, Sourindra Maiti,<br />
Helen Huls, Laszlo Radvanyi, Laurence J. N. Cooper.<br />
226<br />
Intratumoral Expression <strong>of</strong> CTLA4 Monoclonal Antibody<br />
Induces Immunosuppressive NKT <strong>Cell</strong>s in a Mouse Model <strong>of</strong><br />
Breast Cancer with Tolerance to Her2/neu<br />
Jonas Persson, Ying Liu, Roma Yumul, Ines Beyer, Hans-Peter<br />
Kiem, Steve R<strong>of</strong>fler, Andre Lieber.<br />
227<br />
Efficient Eradication <strong>of</strong> Castration-Resistant Human<br />
Prostate Cancers by Inactivated Sendai Virus Particle<br />
Koji Hatano, Yoshifumi Kawaguchi, Yasuhide Miyamoto, Norio<br />
Nonomura, Yasufumi Kaneda.<br />
228<br />
Development <strong>of</strong> a T <strong>Cell</strong> Receptor Targeting the<br />
HLA-A*0201 Restricted Epitope SSX2: 41-49 for Adoptive<br />
Immunotherapy <strong>of</strong> Cancer<br />
Nachimuthu Chinnasamy, Jeremy L. Davis, Mahadev Rao,<br />
David S. Schrump, Daniel E. Speiser, Steven A. Rosenberg,<br />
Richard A. Morgan.<br />
229<br />
Apoptosis Inducer ABT-737 Enhances Efficacy <strong>of</strong><br />
Engineered CD19-Targeting T-<strong>Cell</strong>s<br />
Hannah Karlsson, Camilla Lindqvist, Gabriella Paul-<br />
Wetterberg, Per Frisk, Angelica Loskog.<br />
230<br />
Validation <strong>of</strong> Donor Derived Virus Specific T-Lymphocytes<br />
<strong>Gene</strong>tically Modified To Target the CD19 Antigen for the<br />
Treatment <strong>of</strong> Relapsed Leukemia<br />
Kevin J. Curran, Clare Taylor, Ekaterina Doubrovina, Xiuyan<br />
Wang, Richard J. O’Reilly, Michel Sadelain, Nancy A. Kernan,<br />
Renier J. Brentjens, Isabelle Riviere.<br />
231<br />
Development <strong>of</strong> <strong>Gene</strong>tically Engineered T <strong>Cell</strong>s Expressing<br />
a Chimeric Antigen Receptor Against Prostate Stem <strong>Cell</strong><br />
Antigen for the Adoptive <strong>Cell</strong> <strong>Therapy</strong> <strong>of</strong> Cancer<br />
Kiran H. Lagisetty, William R. Burns, Zheng Zhili, Steven A.<br />
Rosenberg, Richard A. Morgan.<br />
232<br />
Delivery <strong>of</strong> Dendritic <strong>Cell</strong>s Engineered To Express T-bet into<br />
Solid Murine Tumors Defines an Effective <strong>Therapy</strong><br />
Jennifer L. Taylor, Yanyan Qu, Lu Chen, Walter J. Storkus.<br />
233<br />
Comparative Microarray Analysis Implicates the Pivotal<br />
Participation <strong>of</strong> Type I Interferon Related Signaling<br />
Pathway in Antitumor Effect Provoked by In Vivo GM-CSF<br />
<strong>Gene</strong> Transduced Lung Cancer <strong>Cell</strong>s<br />
Megumi Narusawa, Hiroyuki Inoue, Yoshihiro Tanaka, Yosuke<br />
Yokota, Chika Sakamoto, Shohei Miyamoto, Tomoko Inoue,<br />
Makoto Inoue, Koichi Takayama, Mamoru Hasegawa, Yoichi<br />
Nakanishi, Kenzaburo Tani.<br />
234<br />
T <strong>Cell</strong>s <strong>Gene</strong>tically Modified To Express Chimeric Antigen<br />
Receptor Specific for EGFR for Glioma<br />
Hillary G. Caruso, Sonny Ang, Singh S. Harjeet, Simon<br />
Olivares, Laurence J. N. Cooper.<br />
235<br />
In Vivo Delivery <strong>of</strong> Interferon-alpha <strong>Gene</strong> Enhances<br />
Tumor Immunity and Suppresses Immunotolerance after<br />
Autologous Hematopoietic Stem <strong>Cell</strong> Transplantation<br />
Kenta Narumi, Takeshi Udagawa, Yoshinori Ikarashi, Takahiro<br />
Ochiya, Teruhiko Yoshida, Kazunori Aoki.<br />
236<br />
Induction <strong>of</strong> Epitope-Specific CD8+ T <strong>Cell</strong>s for Melanoma<br />
Eradication by Intratumoral Electroportation <strong>of</strong> IL-12 cDNA:<br />
A Possible Mechanism for Tumor Killing<br />
Jeong-Im Sin.<br />
237<br />
Oncolytic Plasmid System, a Novel Antitumor Strategy by<br />
Plasmid Encoding Adenovirus Protein<br />
Yoshiyuki Koyama, Chieko Yoshihara, Masahiko Tojyo,<br />
Tomoko Ito, Katsuyuki Hamada.<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
238<br />
Therapeutic Efficacy and Safety Studies <strong>of</strong> a Novel<br />
Oncolytic Adenovirus Active in Tumor-Associated Stromal<br />
<strong>Cell</strong>s and Tumor Microenvironment<br />
Diego L. Viale, Veronica M. Lopez, Eduardo G. Cafferata,<br />
David Gould, Yuti Chernajovsky, David T. Curiel, Osvaldo L.<br />
Podhajcer.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 103<br />
Thursday, May 19
Thursday, May 19<br />
104<br />
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
239<br />
Expansion and Anti-Tumor Efficacy <strong>of</strong> CD19 Targeted Cord<br />
Blood T <strong>Cell</strong>s<br />
Hollie J. Pegram, Vincent La Russa, Renier J. Brentjens.<br />
240<br />
Expression <strong>of</strong> Membrane Bound GD2 Peptide Mimic on<br />
K562 <strong>Cell</strong> Line Supports Antigen Specific Expansion <strong>of</strong> T<br />
<strong>Cell</strong>s Modified with GD2 Chimeric Antigen Receptor<br />
Srinivas S. Somanchi, Laurence J. N Cooper, Dean A. Lee.<br />
241<br />
Identification <strong>of</strong> Targeted Adenovirus Vector for Pancreatic<br />
Cancer by Screening Large Adenoviral Library with<br />
Random AB-Loop-Mutations<br />
Yoshiaki Miura, Eric Brown, Julia Davydova, Masato Yamamoto.<br />
242<br />
Insulin-Like Growth Factor Binding Protein 7 (IGFBP7): A<br />
Novel Therapeutic for Hepatocellular Carcinoma<br />
Dong Chen, Byoung Kwon Yoo, Prasanna K. Santhekadur,<br />
Rachel Gredler, Paul B. Fisher, Devanand Sarkar.<br />
243<br />
Uterine Fibroids <strong>Gene</strong> <strong>Therapy</strong>: Targeted Adenovirus<br />
Vector (Ad-SSTR-RGD-TK/GCV) Provides Superior Inhibition<br />
<strong>of</strong> Human Leiomyoma <strong>Cell</strong>s than Human Uterine Smooth<br />
Muscle <strong>Cell</strong>s<br />
Sangeeta Nair, David T. Curiel, Ayman Al-Hendy.<br />
244<br />
Telomerase Inhibition Strategies by siRNAs Against Either<br />
hTR or hTERT in Oral Squamous <strong>Cell</strong> Carcinoma<br />
Yan Li, Liying Xiao, Mingyuan Li, Gang Yao, Yun Feng.<br />
245<br />
Functional Characterization <strong>of</strong> TCRP1, a Novel <strong>Gene</strong><br />
Mediating Resistance to Cispltin in Oral Squamous <strong>Cell</strong><br />
Carcinoma <strong>Cell</strong> Line<br />
Yixue Gu, Shasha Fan, Yang Xiong, Bo Peng, Guopei Zheng,<br />
Zhimin He.<br />
246<br />
Aerosol Delivery <strong>of</strong> Small Hairpin Osteopontin Blocks<br />
Pulmonary Metastasis <strong>of</strong> Breast Cancer in Mice<br />
Kyeong-Nam Yu, Myung-Haing Cho.<br />
247<br />
A Fusion Protein, Tat-CYGB, Is a Potential Agent for Liver<br />
Cancer <strong>Therapy</strong><br />
Ruian Xu, Weijie Shi, Weidong Xiao.<br />
248<br />
Transcriptional Targeting <strong>of</strong> Retrovirus Vector through the<br />
SSX4 Tumor-Specific Promoter<br />
Toshio Yawata, Eri Ishida, Masahiro Kitahara, Keiji Shimizu.<br />
249<br />
Establishment <strong>of</strong> Transgenic Mice Expressing a Biotin Binding<br />
Targeting Construct on the Endothelium <strong>of</strong> Blood Vessels<br />
Thomas Wirth, Anke Nicolaus, Georg Breier, Seppo<br />
Ylä-Herttuala.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Hematologic and Immunologic<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
250<br />
MGMT P140K and TK HSV Chemoselection <strong>of</strong> Allogeneic<br />
HSC and Correction <strong>of</strong> β-Thalassemia after Neonatal<br />
Transplantation without Myeloablation or Post-Transplant<br />
Immunosuppression<br />
Rustom Falahati, Jianqing Zhang, Yimin Shi, Linda Flebbe-<br />
Rehwaldt, Stanton L. Gerson, Karin M. L. Gaensler.<br />
251<br />
Pharmacologically Regulated <strong>Cell</strong> Growth <strong>of</strong> Specific<br />
Hematopoietic Lineages<br />
David W. Emery, Brandon Thomas, Kiyoshi Okazuka, Emilie A.<br />
Lovelett, Brian C. Beard, Hans-Peter Kiem, C. Anthony Blau.<br />
252<br />
Towards Lentiviral IL2RG <strong>Gene</strong> <strong>Therapy</strong> for SCID-X1: The<br />
Importance <strong>of</strong> Pre-Transplant Conditioning and <strong>Cell</strong> Dose<br />
Marshall W. Huston, Niek P. van Til, Trudi P. Visser, Helen de<br />
Boer, Gerard Wagemaker.<br />
253<br />
A2UCOE-eGFP Confers Sustained Transgene Expression in<br />
Human Fetal Liver Hematopoietic Stem <strong>Cell</strong>s (FL-HSC)<br />
Niraja Dighe, Maroun Khoury, Mark Chong, Citra Mattar,<br />
Simon Waddington, Michael N. Antoniou, Jianzhu Chen,<br />
Mahesh Choolani, Jerry Chan.<br />
254<br />
Correction <strong>of</strong> RAG2 Severe Combined Immunodeficiency<br />
by Lentiviral <strong>Gene</strong> <strong>Therapy</strong> Requires Strong Expression <strong>of</strong><br />
RAG2<br />
Niek P. van Til, Helen de Boer, Roya Sarwari, Trudi P. Visser,<br />
Barbara Cassani, Anna Villa, Gerard Wagemaker.<br />
255<br />
Correction <strong>of</strong> X-SCID by Sleeping Beauty-Mediated <strong>Gene</strong><br />
Transfer into Hematopoietic <strong>Cell</strong>s<br />
Kendra A. Hyland, Erik R. Olson, Nicola Philpott, Xianzheng<br />
Zhou, R. Scott McIvor.
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Hematologic and Immunologic<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
256<br />
The Comparison <strong>of</strong> Various Promoters for Wiskott Aldrich<br />
Syndrome <strong>Gene</strong> <strong>Therapy</strong> Using Insulated Lentiviral Vectors<br />
Rachel M. Koldej, Gael Carney, Matthew Wielgosz,<br />
Satyanarayana Pondugula, Arthur W. Nienhuis.<br />
257<br />
In Vivo, Lineage-Directed Transgene Expression after<br />
Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> Transfer in a Large Animal<br />
Model<br />
Aravind Ramakrishnan, Beverly Torok-Stord, Mortimer Poncz,<br />
Nathaniel P. Williams, Christina Ironside, Hans-Peter Kiem,<br />
Brian C. Beard.<br />
258<br />
Non-Myeloablative Conditioning with Busulfex 8 mg/kg<br />
or 200 cGy TBI Is Equivalent in <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Canine<br />
Leukocyte Adhesion Deficiency Using Foamy Viral Vectors<br />
Thomas R. Bauer, Jr., Erik M. Olson, Laura M. Tuschong, Tanya<br />
H. Burkholder, David W. Russell, Dennis D. Hickstein.<br />
259<br />
Mouse Transplant Models for Evaluating the Safety <strong>of</strong> a<br />
SCID-X1 Lentiviral Vector<br />
Sheng Zhou, Zhijun Ma, Taihe Lu, Laura J. Janke, John T. Gray,<br />
Brian P. Sorrentino.<br />
260<br />
Balancing Efficacy and Adverse Outcomes in <strong>Gene</strong> <strong>Therapy</strong><br />
for Wiskott-Aldrich Syndrome<br />
Alexander Astrakhan, Blythe Sather, Sara Mamman, Michelle<br />
Brault, Socheath Khim, Byoung Ryu, Carol Miao, David J.<br />
Rawlings.<br />
261<br />
Further Amelioration <strong>of</strong> the Late Effects <strong>of</strong> Total<br />
Body Irradiation (TBI) by Manganesium Superoxide<br />
Dismutase Plasmid/Liposome (MnSOD-PL) <strong>Gene</strong><br />
<strong>Therapy</strong> Supplemented by a Continuous Antioxidant-<br />
Chemopreventive Diet<br />
Michael W. Epperly, Hong Wang, Jeffrey A. Jones, Tracy Dixon,<br />
Carlos A. Montesinos, Joel S. Greenberger.<br />
262<br />
High Levels <strong>of</strong> Polyclonal, Multilineage Hematopoietic<br />
<strong>Cell</strong> <strong>Gene</strong> Marking Following Lentiviral Transduction and<br />
Transplantation <strong>of</strong> Steady-State Bone Marrow CD34 + <strong>Cell</strong>s<br />
in a Non-Human Primate Model<br />
Phillip W. Hargrove, Yoon-Sang Kim, Amy Taylor, Dana<br />
Simpson, Andrew M. David<strong>of</strong>f, Perdeep K. Mehta, Derek A.<br />
Persons.<br />
263<br />
Long-Term Multi-Lineage Engraftment <strong>of</strong> NOD-scid<br />
IL2Rgnull Mice after Transplantation with <strong>Gene</strong>tically<br />
Modified b-thalassemic CD34 + <strong>Cell</strong>s<br />
Leda Ferro, Jinrong Qu, Clare Taylor, Xiuyan Wang, Aurelio<br />
Maggio, Farid Boulad, Sadelain Michel, Isabelle Riviere.<br />
264<br />
Uncovering Haemopoietic System Dynamics and Tracking<br />
Fate and Long-Term Survival <strong>of</strong> Single Progenitor Clones In<br />
Vivo in Humans by Retroviral Tagging<br />
Luca Biasco, Cristina Baricordi, Cynthia Bartholomae,<br />
Immacolata Brigida, Samantha Scaramuzza, Raffaele Fronza,<br />
Stefania Merella, Alessandro Ambrosi, Danilo Pellina, Clelia Di<br />
Serio, Eugenio Montini, Christ<strong>of</strong> von Kalle, Manfred Schmidt,<br />
Alessandro Aiuti.<br />
265<br />
Deep Sequencing Analyses <strong>of</strong> Small RNAs in HIV-1 Infected<br />
<strong>Cell</strong>s Transduced with a Triple Inhibitory RNA Lentiviral<br />
Vector<br />
Haitang Li, John Rossi.<br />
266<br />
Decade-Long Persistence <strong>of</strong> Adoptively Transferred<br />
Autologous Redirected CD4ζ Chimeric Receptor T <strong>Cell</strong>s in<br />
HIV+ Study Subjects<br />
John Scholler, Naomi Aaronson, Gabriela Plesa, Richard<br />
Carroll, Gwendolyn Binder, Kristen Hege, Steven Deeks,<br />
Ronald Mitsuyasu, Ashley Vogel, Zhaohui Zheng, Julio Cotte,<br />
Wendy Bernstein, Troy Brady, Bruce Levine, Carl June.<br />
267<br />
Development <strong>of</strong> a New Strategy for X-CGD <strong>Gene</strong> <strong>Therapy</strong><br />
Using a miRNA Regulated Lentiviral Vector<br />
Maria Chiriaco, Giada Farinelli, Bernhard Gentner, Gigliola<br />
Di Matteo, Valentina Capo, Silvia Di Cesare, Samantha<br />
Scaramuzza, Lucia Sergi Sergi, Antonella Isgrò, Didier Trono,<br />
Manuel Grez, Andrea Finocchi, Paolo Rossi, Luigi Naldini,<br />
Alessandro Aiuti.<br />
268<br />
Correction <strong>of</strong> Mouse Prkdc scid Deficiency by ZFN-Driven<br />
<strong>Gene</strong> Repair<br />
Hayder H. Abdul-Razak, Céline Rocca, Francisco Javier Molina<br />
Estévez, Guillermo Güenechea, Steven J. Howe, Chih Hao V.<br />
Gan, Alison Roberts, Michael C. Holmes, Philip D. Gregory,<br />
Adrian J. Thrasher, Juan A. Bueren, Rafael J. Yáñez-Muñoz.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 105<br />
Thursday, May 19
Thursday, May 19<br />
106<br />
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Hematologic and Immunologic<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
269<br />
Safety and Clonality Analyses for a New Vector for CGD<br />
Clinical <strong>Gene</strong> <strong>Therapy</strong><br />
Simone Scholz, Margarita Diaz, Stefan Stein, Axel Schambach,<br />
Hanno Glimm, Christ<strong>of</strong> von Kalle, Manuel Grez, Manfred<br />
Schmidt.<br />
831 (MOVED FROM POSTER SESSION III)<br />
BAFF Inhibition by Exon Skipping in Sjögren’s Syndrome<br />
Nienke Roescher, Jelle Vosters, Ghada Al Saleh, Patrick<br />
Dreyfus, Sebastien Jacques, Luis Garcia, Gilles Chiocchia,<br />
Antoine Francoise, Jean Sibilia, Paul Peter Tak, Jay Chiorini,<br />
Xavier Mariette, Jacques-Eric Gottenberg.<br />
Lung and Respiratory Disease<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
270<br />
Adeno-Associated Virus Transduction in the Ferret Airway<br />
Ziying Yan, Diana C. M. Lei-Butters, Xingshen Sun, Xiaoming<br />
Liu, Nicholas W. Keiser, John Fisher, Hongshu Sui, John F.<br />
Engelhardt.<br />
271<br />
The Airway Epithelium Differentiation State Affects<br />
Efficiency <strong>of</strong> siRNA Oligonucleotide Delivery<br />
Sateesh Krishnamurthy, Ashley Jacobi, Scott D. Rose, Mark A.<br />
Behlke, Paul B. McCray, Jr., Beverely L. Davidson.<br />
272<br />
Strain-Specific Differences in Pulmonary <strong>Gene</strong> Transfer<br />
Efficiency: Relevance for Toxicology Studies in Mice<br />
Giannoulis Legakis, Benjamin Causton, Jie Zhu, Nikki<br />
Newman, Raymond Farley, Cuixiang Meng, Clare M. Lloyd,<br />
Eric W. F. W. Alton, Uta Griesenbach.<br />
273<br />
Reporter <strong>Gene</strong> Expression Following Repeat<br />
Administration <strong>of</strong> a HIV-1 Lentiviral Vector in Mouse<br />
Airways<br />
Patricia L. Cmielewski, Don S. Anson, David W. Parsons.<br />
274<br />
<strong>Gene</strong> Transfer by Influenza HA Pseudotyped EIAV Lentiviral<br />
Vectors to the Airways <strong>of</strong> Neonatal Mice<br />
Manij Patel, John C. Olsen.<br />
275<br />
<strong>Gene</strong>ration <strong>of</strong> Inducible CFTR-Expressing Lentiviral Vectors<br />
for <strong>Gene</strong> <strong>Therapy</strong><br />
Xiaoming Liu, Meihui Luo, Yulong Zhang, John F. Engelhardt.<br />
276<br />
The Therapeutic Role <strong>of</strong> TSLP shRNA in Treating Pulmonary<br />
Fibrosis<br />
Guo-Zheng Liu, Tsung-Jen Hung, Su-Fen Liu, Tao-Chen Lee,<br />
Zih-Han Yang, Lea-Yea Chuang, Jinn-Yuh Guh, Tung-Nan Liao,<br />
Min-Yuan Hung, Yu-Lin Yang.<br />
277<br />
Efficient Transduction <strong>of</strong> Alveolar Type II Epithelial <strong>Cell</strong>s<br />
in Nonhuman Primates by Helper-Dependent Adenovirus<br />
5-Fiber 35 Chimeric Vectors<br />
Amanda Rosewell, Peter Hiatt, Ruth McConnell, Dianne<br />
Dang, Francesco Vetrini, Nathan Grove, Donna Palmer, Milton<br />
Finegold, Arthur Beaudet, Philip Ng.<br />
278<br />
Delivery Dynamics and Destination <strong>of</strong> <strong>Gene</strong> Vector<br />
Instillations in Live Mouse Airways<br />
Martin W. Donnelley, Karen K. W. Siu, R. Aidan Jamison, David<br />
W. Parsons.<br />
279<br />
Lung Epithelial Binding Peptide-Linked High Mobility<br />
Group Box-1 A Box as a Lung Epithelial <strong>Cell</strong> Targeting <strong>Gene</strong><br />
Carrier<br />
Hyun Ah Kim, Su Hee Cho, Ji Hwan Park, Minhyung Lee.<br />
280<br />
Development <strong>of</strong> a Nonviral <strong>Gene</strong> <strong>Therapy</strong> Approach for<br />
Surfactant Protein B Deficiency<br />
Rebecca C. Barnett, David A. Dean.<br />
281<br />
One Year Persistence from a Single HIV-1 Lentiviral Vector<br />
Delivery into Marmoset Lung: LacZ and Vector <strong>Gene</strong><br />
Presence<br />
David W. Parsons, Nigel Farrow, Darren Miller, Shannon Le<br />
Blanc, Richard Bright, Don S. Anson.<br />
282<br />
E1B-55kDa Deleted Adenoviruses Induce p53 Up-<br />
Regulation Resulting in Apoptosis in Human Malignant<br />
Mesothelioma<br />
Yuji Tada, Makako Yamanaka, Kiyoko Kawamura, Shinya<br />
Okamoto, Shan Yang, Atsushi Kitamura, Suguru Yamauchi,<br />
Liang Min, Hiroshi Kobayashi, Yuichi Takiguchi, Koichiro<br />
Tatsumi, Hideaki Shimada, Kenzo Hiroshima, Masatoshi Tagawa.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Immunologic & Host Responses in<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
283<br />
dAd5GNE300, a 2nd <strong>Gene</strong>ration Anti-Cocaine Adenovirus-<br />
Based Vaccine That Blocks Cocaine-Induced Activity,<br />
Reward and Drug Seeking in Rodents<br />
Jonathan B. Rosenberg, Sunmee Wee, Martin L. Hicks, Bishnu<br />
P. De, Stephen M. Kaminsky, Amira Y. Moreno, Kim Janda,<br />
George Koob, Ronald G. Crystal.<br />
284<br />
Lmo2 Over-Expression and p19 Arf Loss <strong>Gene</strong>tically<br />
Cooperate To Increase the Self-Renewal Capacity <strong>of</strong><br />
Immature Thymocytes<br />
Louise M. Treanor, Sheng Zhou, Taihe Lu, Brian P. Sorrentino.<br />
285<br />
Sequential <strong>Gene</strong> <strong>Therapy</strong> with Aumentation <strong>of</strong> Expression<br />
Is Possible with Neonatal <strong>Gene</strong> Transfer<br />
Chuhong Hu, Eun K. Lee, Gerald S. Lipshutz.<br />
286<br />
Live Oral Bacterial <strong>Cell</strong> <strong>Therapy</strong> for Term Infants with<br />
Cyanotic Congenital Heart Malformations: Investigating<br />
Hypoxia and Probiotic Induced Changes in the Intestinal<br />
Microbiota<br />
Collin L. Ellis, John C. Rutledge, Gary W. Raff, Mark A.<br />
Underwood.<br />
287<br />
Liver-Specific Expression <strong>of</strong> the Insulin Epitope 9-23 Using<br />
a Lenti-Viral, microRNA142 Regulated Vector Protects<br />
Against Autoimmune Diabetes<br />
Akbarpour Mahzad, Kevin Goudy, Naldini Luigi, Maria-Grazia<br />
Roncarolo.<br />
288<br />
The AAV2(Y-F) Mutant Capsid Causes Immune Avoidance<br />
to Killing by Capsid Specific CD8+ T <strong>Cell</strong>s and Is Further<br />
Improved by Proteasome Inhibition<br />
Ashley T. Martino, David M. Markusic, Arun Srivastava, Roland<br />
W. Herzog.<br />
289<br />
Differential Activation <strong>of</strong> Innate Immune Responses and<br />
T <strong>Cell</strong> Proliferation by Adeno-Associated Virus Vectors<br />
Containing Different Regulatory Cassettes in Murine<br />
Pompe Disease<br />
Ping Zhang, Takuya Osada, Andy Bird, Songtao Li, Timonthy<br />
Clay, Dwight Koeberl.<br />
290<br />
FoxP3-Treg Preconditioning with IL-2-IL-2 Antibody<br />
Complex Overcomes Promotes Transgene Tolerance in a<br />
Stringent Autoimmune Model after Lenti-Viral Transfer<br />
Kevin Goudy, Mahzad Akabarpur, Andrea Annoni, Luigi<br />
Naldini, Maria-Grazia Roncarolo.<br />
291<br />
The Critical Role <strong>of</strong> Activation Induced <strong>Cell</strong> Death and<br />
Passive Apoptosis in the Induction <strong>of</strong> In Vivo Tolerance<br />
toward AAV8 in the Liver<br />
Susan M. Faust, Tullia Lindstein, Craig B. Thompson, James M.<br />
Wilson.<br />
292<br />
Direct Presentation, Not Cross Presentation <strong>of</strong> AAV Capsids,<br />
Render Hepatocytes Target for CTLs in a Humanized Mouse<br />
Model<br />
Suryanarayan Somanathan, Luk Vandenberghe, Peter Bell,<br />
Soumitra Roy, James L. Riley, James M. Wilson.<br />
293<br />
Adaptive Immunity to rAAV1 Is Supported by Capsid-<br />
Specific Th1 T <strong>Cell</strong> Responses and Is Critically-Dependent<br />
upon MyD88 Signaling in B <strong>Cell</strong>s<br />
Muriel Sudres, Séverine Ciré, Virginie Vasseur, Léa Bréaut,<br />
Sylvie Darocha, Florence Boisgérault, Christine LeBec, David-<br />
Alexandre Gross, Bernard Ryffel, Anne Galy.<br />
294<br />
Development <strong>of</strong> Novel Strategies To Modulate Pre-Existing<br />
Anti-Factor VIII Immune Responses in Hemophilia A<br />
Inhibitor Mice Treated with Factor VIII Plasmid-Mediated<br />
<strong>Gene</strong> <strong>Therapy</strong><br />
Chao-Lien Liu, Peiqing Ye, Jacqueline Lin, Carol H. Miao.<br />
295<br />
Upregulation <strong>of</strong> Interferon Pathways in Tumors Resistant to<br />
Oncolytic Adenovirus<br />
Ilkka Liikanen, Vladia Monsurrò, Laura Ahtiainen, Mari Raki,<br />
Tanja Hakkarainen, Iulia Diaconu, João D. Dias, Vincenzo<br />
Cerullo, Anna Kanerva, Sari Pesonen, Daniela Marzioni, Marco<br />
Colombatti, Akseli Hemminki.<br />
296<br />
TLR9 Signaling and Regulatory T-<strong>Cell</strong>s Orchestrate the<br />
Immune Response to the Transgene Product in Muscle<br />
Brad E. H<strong>of</strong>fman, Mario Cooper, Roland W. Herzog.<br />
297<br />
Activities <strong>of</strong> Nucleic Acid Binding and Stimulation <strong>of</strong> ATP<br />
Hydrolysis by RNA Helicase RIG-I and Activation <strong>of</strong> Type I<br />
Interferon Response<br />
Sujin Yoon, Kyung-Bo Kim, Kkothanahreum Park, Keun-Sik<br />
Kim, Dong-Eun Kim.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 107<br />
Thursday, May 19
Thursday, May 19<br />
108<br />
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
<strong>Gene</strong> Regulation I<br />
298<br />
Integration <strong>of</strong> Lentiviral Vectors in Human <strong>Gene</strong>s <strong>Gene</strong>rates<br />
Abnormal Transcripts through the Usage <strong>of</strong> Constitutive<br />
and Cryptic Splice Signals<br />
Arianna Moiani, Riccardo Mezzadra, Daniela Sartori, Ylenia<br />
Paleari, Annarita Miccio, Fabienne Cocchiarella, Claudia<br />
Cattoglio, Giuliana Ferrari, Fulvio Mavilio.<br />
299<br />
The RNA Interference Pathway Is Responsible for Silencing<br />
<strong>of</strong> Transgene Expression after Sleeping Beauty Mediated<br />
Somatic Integration<br />
Christina Rauschhuber, Anja Ehrhardt.<br />
300<br />
Further Improvements and Applications <strong>of</strong> Context-<br />
Dependent Assembly (CoDA): A Publicly Available,<br />
Selection-Free Method for Engineering Zinc Finger<br />
Nucleases<br />
Jeffry D. Sander, Deepak Reyon, Ryan Kuzmickas, Cyd Khayter,<br />
Morgan L. Maeder, J. Keith Joung.<br />
301<br />
Direct Regulation <strong>of</strong> GDNF Protein Stability Using<br />
Destabilizing Domains<br />
Luis Quintino, Khalid Tai, Christina Isaksson, Tom Wandless,<br />
Cecilia Lundberg.<br />
302<br />
Interaction between LCR and a Replicator Mediated by the<br />
LARC Complex Prevents Methylation-Dependent <strong>Gene</strong><br />
Silencing<br />
Liang Huang, Haiqing Fu, Chii Mei Lin, Mirit I. Aladjem.<br />
303<br />
Multimodal Targeted In Vivo Imaging <strong>of</strong> Brain Tumors<br />
Johanna M. Niers, Mariam Kerami, John W. Chen, Ralph<br />
Weissleder, Bakhos A. Tannous.<br />
304<br />
Regulation <strong>of</strong> B23/Nucleophosmin Protein Expression and<br />
Function by HIV-1 Derived miR-TAR-5p and miR-TAR-3p<br />
Dominique L. Ouellet, John J. Rossi, Patrick Provost.<br />
305<br />
Scavenging in Reactive Oxygen Species Improves <strong>Gene</strong><br />
Expression in Polyplex Supported <strong>Gene</strong> Delivery: Nitroxyl-<br />
Radical Containing Nanoparticles Assists Non-Viral <strong>Gene</strong><br />
Delivery System<br />
Yukio Nagasaki, Kazuko Toh, Toru Yoshitomi, Yutaka Ikeda.<br />
306<br />
Gaussia Luciferase: A Biomarker for In Vivo Evaluation <strong>of</strong><br />
Systemic Protein Delivery through Circulation<br />
Salim S. El-Amouri, Phoung Cao, Dao Pan.<br />
307<br />
Multimodal In Vivo Imaging and Blood Monitoring <strong>of</strong><br />
Intrinsic and Extrinsic Apoptosis<br />
Johanna M. Niers, Mariam Kerami, Lisa Pike, Grant<br />
Lewandrowski, Bakhos A. Tannous.<br />
308<br />
Prolonged <strong>Gene</strong> Silencing Effect Using Multilayered siRNA<br />
Coated Gold Nanoparticles<br />
Seung-Koo Lee, Myung-Shin Han, Ching-Hsuan Tung.<br />
309<br />
Implication <strong>of</strong> nNOSμ Delocalization on the Muscle Force in<br />
Dystrophin Deficient and δ-Sarcoglycan Knockout Mice<br />
Dejia Li, Yongping Yue, Yi Lai, Chady H. Hakin, Dongsheng<br />
Duan.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Stem <strong>Cell</strong> Therapies I<br />
310<br />
Human Hematopoietic Stem <strong>Cell</strong>s Can Be Functionally<br />
Isolated Based on Their Low Intracellular Reactive Oxygen<br />
Species (ROS) Activity<br />
Brian Ichwan, Cynthia E. Dunbar, Andre Larochelle.<br />
311<br />
Differentiation <strong>of</strong> Diabetic Patient-Specific iPS <strong>Cell</strong>s into<br />
Insulin-Secreting <strong>Cell</strong>s<br />
Tayaramma Thatava, Karen Squillace, Adam Armstrong, Seiga<br />
Ohmine, Yogish Kudva, Yasuhiro Ikeda.<br />
312<br />
Overexpression <strong>of</strong> CXCR4 in Purified Hematopoietic Stem<br />
<strong>Cell</strong>s Led to Poor Peripheral Reconstitution with Impaired<br />
Marrow Release <strong>of</strong> Progenitor <strong>Cell</strong>s: Implications in Clinical<br />
Transplantation<br />
Chen Yi Lai, Sachie Suzuki, Motohito Okabe, Satoshi<br />
Yamazaki, Masafumi Onodera, Makoto Otsu, Hiromitsu<br />
Nakauchi.<br />
313<br />
Knockdown <strong>of</strong> p21 Cip1/Waf1 Enhances Proliferation, the<br />
Expression <strong>of</strong> Stemness Markers and Osteogenic Potential<br />
in Human Mesenchymal Stem <strong>Cell</strong>s<br />
Tu-Lai Yew, Chih-Chien Tsai, Fang-Yao Chiu, Shih-Chieh Hung.<br />
314<br />
Pre-Clinical Evaluation <strong>of</strong> Zinc Finger Nuclease-Modified<br />
Mobilized Hematopoietic Stem <strong>Cell</strong>s in NSG Mice<br />
Ursula H<strong>of</strong>er, Jill E. Henley, Kathrin A. Burke, Nathalia Holt,<br />
Lijing Li, David L. DiGiusto, John A. Zaia, Philip D. Gregory,<br />
Michael C. Holmes, Paula M. Cannon.
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
315<br />
Establishment <strong>of</strong> Human iPS <strong>Cell</strong> Lines Heterozygous for<br />
<strong>Gene</strong>s in the Non-Homologous End-Joining Pathway by<br />
Using Helper-Dependent Adenoviral Vectors<br />
Keiichiro Suzuki, Yuka Hirabayashi, Emi Aizawa, Yuzuru<br />
Iwanaga, Ayako Tokumitsu, Ko Mitani.<br />
316<br />
Combination Sox Transcription Factor and Tgf-Beta <strong>Gene</strong><br />
Transduction Drive Pre-Transplant Chondrogenesis in<br />
Adult Marrow Derived Stromal <strong>Cell</strong>s<br />
Alan J. Nixon, Jan-Jan Liu, Michael S. Scimeca, Ashlee E. Watts.<br />
317<br />
<strong>Gene</strong>ration <strong>of</strong> Induced Pluripotent Stem (iPS) <strong>Cell</strong>s Using<br />
Helper-Dependent Adenoviral Vectors<br />
Nunzia Pastore, Rosa Maria Sepe, Pasquale Piccolo, Donna<br />
Palmer, Philip Ng, Nicola Brunetti-Pierri.<br />
318<br />
Cationic-Liposome-Mediated CXCR4 <strong>Gene</strong> Delivery into<br />
Hematopoietic Stem/Progenitor <strong>Cell</strong>s: Implications for<br />
Clinical Transplantation<br />
Peng Xu, Jie Chen, James Xing, Hilal Gul.<br />
319<br />
Development <strong>of</strong> Polyamidoamine Dendrimer-Conjugated<br />
Quantum Dots for Tracing Primary Cultured Mesenchymal<br />
Stem <strong>Cell</strong>s in Mice<br />
Yuriko Higuchi, Wu Can, Shigeru Kawakami, Fumiyoshi<br />
Yamashita, Mitsuru Hashida.<br />
320 ABSTRACT WITHDRAWN<br />
Stem <strong>Cell</strong> Therapies I<br />
321<br />
<strong>Gene</strong>ration <strong>of</strong> Insulin-Producing <strong>Cell</strong>s from PDX-1 <strong>Gene</strong>-<br />
Modified Human Umbilical Cord Mesenchymal Stem <strong>Cell</strong>s<br />
Dongmei He, Juan Wang, Yangjun Gao.<br />
322<br />
New Adipose Tissue Formation by Human Adipose-Derived<br />
Stem <strong>Cell</strong> with Hyaluronic Acid Gel<br />
Shu Hung Huang, Sheng Hua Wu, Sin Daw Lin, Chung Sheng<br />
Lai.<br />
323<br />
Mobilization and Enrichment <strong>of</strong> Mesenchymal Stem <strong>Cell</strong>s<br />
In Vivo Augments Bone Healing in a Mouse Model <strong>of</strong><br />
Segmental Bone Defect<br />
Sanjay Kumar, Selvarangan Ponnazhagan.<br />
324<br />
Fully Pluripotent Patient-Specific Induced Pluripotent<br />
Stem (iPS) <strong>Cell</strong>s and In Vivo Converted <strong>Cell</strong>s: The Transient<br />
Epigenetic <strong>Gene</strong> <strong>Therapy</strong> Approach<br />
Roger Bertolotti.<br />
325<br />
Benefits <strong>of</strong> Hypoxic Culture on Bone Marrow-Derived<br />
Mesenchymal Stem <strong>Cell</strong>s<br />
Shih-Chieh Hung, Chih-Chien Tsai.<br />
Late Abstracts I<br />
875<br />
Human Papillomavirus Pseudoviruses as <strong>Gene</strong> Delivery<br />
Vectors for Murine and Human Tumors<br />
Rebecca J Cerio, Jeffrey N Roberts, Cynthia D Thompson,<br />
Douglas R Lowy, John T Schiller.<br />
876<br />
A New Surface Modified Lentivector Targets <strong>Gene</strong> Transfer<br />
Ex Vivo into hHSC in Marrow from Patients with BM Failure<br />
Syndrome and In Vivo in Humanized Mice<br />
François-Loïc Cosset, Cecilia Frecha, Caroline Costa, Didier<br />
Nègre, Fouzia Amirache, Didier Trono, Juan Bueren, Els<br />
Verhoeyen.<br />
877<br />
Role <strong>of</strong> Immune Response and Immune Tolerization in<br />
Long-Term In Vivo <strong>Gene</strong> Expression Mediated by the<br />
Sleeping Beauty Transposon System<br />
Kelly M Podetz-Pedersen, Stephen J Russell, David B<br />
Schowalter, Nikunj V Somia, R Scott McIvor.<br />
878<br />
In Vivo Targeting <strong>of</strong> microRNA 21 Using Lentiviral Vectors<br />
for the <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Pancreatic Cancer<br />
Flavie Sicard, Hubert Lulka, Louis Buscail, Pierre Cordelier.<br />
879<br />
Regulation <strong>of</strong> Endogenous GAD67 Expression Using<br />
Artificial Transcription Factors.<br />
Erika Elgstrand Wettergren, Fredrik Gussing, Maike Sest,<br />
Torbjörn Gräslund, Cecilia Lundberg.<br />
880<br />
Intracarotid Injection <strong>of</strong> Adipose Tissue-Derived PDGFRβ+<br />
<strong>Cell</strong>s Rescues Ischemic Brain with Neuro-Vasculogenic<br />
Potential<br />
Kon Chu, Keun-Hwa Jung, Soon-Tae Lee, Sang Kun Lee, Jae-<br />
Kyu Roh.<br />
881<br />
Effective and Safe <strong>Gene</strong>-Based Delivery <strong>of</strong> GLP-1 Using<br />
Chitosan/Plasmid-DNA Therapeutic Nanocomplexes in an<br />
Animal Model <strong>of</strong> Type 2 Diabetes<br />
M. Jean, M. Alameh, V. Daras, M. Lavertu, M. Thibault, M.D.<br />
Buschmann, A. Merzouki.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 109<br />
Thursday, May 19
Thursday, May 19<br />
110<br />
Abstract Directory Thursday, May 19, 2011<br />
POSTER SESSION I — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Late Abstracts I<br />
882<br />
Tight Regulation <strong>of</strong> Transgene Expression by Mifepristone-<br />
Inducible System after In Vitro Delivery by Lentiviral Vectors<br />
to Neural Progenitor <strong>Cell</strong>s<br />
Christopher Grunseich, Yijun Shi, Kenneth H. Fischbeck, Tyler<br />
M. Pierson.<br />
883<br />
Rheoswitch-Mediated Regulation <strong>of</strong> IL-12 Protein Delivered<br />
Using an Adenoviral Vector Results in Anti-Tumor Effects<br />
Across a Spectrum <strong>of</strong> Tumor Types<br />
Selva Murugesan, Mario Moreno, Sheila Connelly, Fayaz<br />
Khazi, Meixia Bi, Mini Bharathan, Charles Reed, Mark<br />
Thornton, Sunil Chada.<br />
884<br />
Knockdown <strong>of</strong> ENaCα as a Treatment for Cystic Fibrosis<br />
Lung Disease<br />
Rebekka E. Harding-Smith, Deborah R. Gill, Stephen C. Hyde.<br />
885<br />
Synergistic Effect <strong>of</strong> a Novel <strong>Gene</strong> Therapeutic Agent, VB-<br />
111, with Chemotherapy, for Treatment <strong>of</strong> Cancer<br />
Eyal Breitbart, Yael C. Cohen, Livnat Bangio.<br />
886<br />
Ad-Egr1-Luc Adenoviral Vector is Functionally Activated by<br />
UV Light<br />
Francisco Martínez-F, Araceli Barrera-L, Christian Y Lomeli-R,<br />
JA Madinaveitia-V, Erendira Estrada-V, Hugo Sandoval-Z,<br />
Hilda Villegas-C, Catalina Machuca-R, David T. Curiel, K<br />
Sakamoto.<br />
887<br />
<strong>Gene</strong> <strong>Therapy</strong> Approaches Based on Bcl-2 to Increased<br />
Resistance <strong>of</strong> Human Cultured Keratinocytes for<br />
Transplantation<br />
Francisco Martínez-F, Araceli Barrera-L, Christian Y Lomeli-R,<br />
Erendira Estrada-V, Hugo Sandoval-Z, Hilda Villegas-C,<br />
Catalina Machuca-R, David T. Curiel, JA Madinaveitia-V,<br />
Alejandro Zentella- D.<br />
888<br />
<strong>Cell</strong> Carrier-Based Protection <strong>of</strong> Vesicular Stomatitis Virus<br />
(VSV) from Immune and Nonimmune Serum-Mediated<br />
Inactivation<br />
Mulu Z. Tesfay, Mark J. Federspiel, Glen N. Barber, Kah-Whye<br />
Peng, Stephen J. Russell.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Friday, May 20, 2011<br />
ORAL ABSTRACT SESSION 320<br />
AAV Capsids & Trafficking<br />
1:15 PM - 3:15 PM<br />
Room: 6A<br />
326 1:15 PM<br />
Adeno-Associated Virus Serotype 9 Uses Galactose as a<br />
<strong>Cell</strong>ular Receptor To Transduce Conducting Airway<br />
Christie Bell, Luk Vandenberghe, Peter Bell, Maria P. Limberis,<br />
James M. Wilson.<br />
327 1:30 PM<br />
New Insight into Obstacles to Hematopoietic Stem and<br />
Progenitor <strong>Cell</strong> Transduction with rAAV2 Vectors<br />
Hao-Yuan Jiang, Yiwen Xiang, Bridget Lins, Angela E. Rivers,<br />
Mavis Agbandje-McKenna, Kirsten A. K. Weigel-Van Aken.<br />
328 1:45 PM<br />
Engineering Liver-Detargeted AAV9 Vectors for Cardiac<br />
and Musculo-Skeletal <strong>Gene</strong> Transfer<br />
Nagesh Pulicherla, Kelli D. Bryant, Sarah M. Brown, Mavis<br />
Agbandje-McKenna, Aravind Asokan.<br />
329 2:00 PM<br />
Functional Mapping <strong>of</strong> Tissue Tropism <strong>of</strong> Naturally<br />
Occurring Adeno-Associated Virus Isolates from Human<br />
Hematopoietic Stem <strong>Cell</strong>s<br />
Laura J. Smith, Kim Van Vliet, Erin Miller, M. Ariel Kauss, Taihra<br />
B. Ul-Hasan, K. K. Wong, Mavis Agbandje-McKenna, Saswati<br />
Chatterjee.<br />
330 2:15 PM<br />
Site-Directed Mutagenesis <strong>of</strong> a Surface-Exposed Serine<br />
Residue Leads to High-Efficiency Transduction by<br />
Recombinant Adeno-Associated Virus 2 Vectors<br />
George V. Aslanidi, Lakshmanan Govindasamy, Chen Ling,<br />
Sergei Zolotukhin, Mavis Agbandje-McKenna, Arun Srivastava.<br />
331 2:30 PM<br />
Shuffled AAV Library Selection on Human Hepatocytes In<br />
Vivo<br />
Leszek Lisowski, Kirk Chu, Mark A. Kay.<br />
332 2:45 PM<br />
The Crystal Structure <strong>of</strong> AAV5: Role <strong>of</strong> Variable and<br />
Conserved Regions in Capsid Function<br />
Lakshmanan Govindasamy, Michael DiMattia, Brittney L.<br />
Gurda, Robert McKenna, John A. Chiorini, Nicholas Muzyczka,<br />
Sergei Zolotukhin, Mavis Agbandje-McKenna.<br />
333 3:00 PM<br />
Selection <strong>of</strong> Neutralizing Antibody-Resistant AAV8 Variants<br />
with Structure-Guided Site-Specific Saturated Mutagenesis<br />
Qiang Wang, Brittney Gurda, Luk Vandenberghe, Jing Lu,<br />
Sheng Li, James M. Wilson.<br />
ORAL ABSTRACT SESSION 321<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
1:15 PM - 3:15 PM<br />
Room: 606-607<br />
334 1:15 PM<br />
Prevention <strong>of</strong> Murine Autoimmune Diabetes by CCL22-<br />
Mediated T Regulatory <strong>Cell</strong> Recruitment to the Islet<br />
Joel Montane, Loraine Bisch<strong>of</strong>f, Galina Soukhatcheva, Lei Dai,<br />
Paul Orban, Gijs Hardenberg, Megan Levings, Merce Obach,<br />
Rusung Tan, C. Bruce Verchere.<br />
335 1:30 PM<br />
Adeno-Associated Virus 8 (AAV8) Mediated Expression <strong>of</strong><br />
XIAP in beta <strong>Cell</strong>s Protects Islet Allografts in Diabetes<br />
Joel Montane, Merce Obach, Galina Soukhatcheva, C. Bruce<br />
Verchere.<br />
336 1:45 PM<br />
Lentiviral Vector Enhanced Haematopoietic Stem <strong>Cell</strong><br />
<strong>Gene</strong> <strong>Therapy</strong> Corrects the Neurological Phenotype <strong>of</strong><br />
Mucopolysaccharidosis IIIA Mice<br />
Alexander W. W. Langford-Smith, Fiona L. Wilkinson, Kia J.<br />
Langford-Smith, Ana Sergijenko, Rebecca Holley, William<br />
Bennett, Simon Howe, Adrian Thrasher, Catherine Merry,<br />
Simon Jones, J. Ed Wraith, Robert Wynn, Brian W. Bigger.<br />
337 2:00 PM<br />
Correction <strong>of</strong> Neurological Disease <strong>of</strong><br />
Mucopolysaccharidosis IIIB in Adult Mice by rAAV9 Trans-<br />
Blood-Brain-Barrier <strong>Gene</strong> Delivery<br />
Haiyan Fu, Juliann DiRosario, Smruti Killedar, Kimberly<br />
Zaraspe, Douglas M. McCarty.<br />
338 2:15 PM<br />
Enhancement <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> in Pompe Disease by<br />
Increased Mannose-6-Phosphate Receptor Expression in<br />
Target Tissues<br />
Dwight D. Koeberl, Baodong Sun, Jian Dai, Andrew Bird,<br />
Deeksha S. Bali.<br />
339 2:30 PM<br />
Preservation <strong>of</strong> Renal Function in Murine Glycogen Storage<br />
Disease Type I with a Double-Stranded Adeno-Associated<br />
Virus Vector<br />
Xiaoyan Luo, Songtao Li, Andrew Bird, Michelle P. Winn,<br />
Dwight D. Koeberl.<br />
340 2:45 PM<br />
Robust and Sustained Correction <strong>of</strong> OTC Deficiency<br />
in Adult Spfash Mice Using an AAV2/8-Based Vector<br />
Expressing Codon-Optimized Human OTC <strong>Gene</strong><br />
Lili Wang, Jianping Lin, Hiroki Morizono, Peter Bell, David<br />
Jones, Deirdre McMenamin, Mark Batshaw, James M. Wilson.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 111<br />
Friday, May 20
Friday, May 20<br />
112<br />
Abstract Directory Friday, May 20, 2011<br />
ORAL ABSTRACT SESSION 321 — continued<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
1:15 PM - 3:15 PM<br />
Room: 606-607<br />
341 3:00 PM<br />
Long-Term Correction <strong>of</strong> Very Long-Chain Acyl-CoA<br />
Deydrogenase Deficiency by Recombinant Adeno-<br />
Associated Virus 9 <strong>Gene</strong> <strong>Therapy</strong><br />
Allison M. Keeler, Glenn Walters, Thomas Conlon, Karin Green,<br />
Christian Mueller, Terence R. Flotte.<br />
ORAL ABSTRACT SESSION 322<br />
Hematologic and Immunologic<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
1:15 PM - 3:15 PM<br />
Room: 611-612<br />
342 1:15 PM<br />
Maintenance <strong>of</strong> Hematopoietic Polyclonality<br />
after MGMTP140K-Mediated In Vivo Selection and<br />
Chemoprotection Following Multiple Cycles <strong>of</strong><br />
Chemotherapy in Glioblastoma Patients<br />
Jennifer E. Adair, Brian C. Beard, Grant D. Trobridge, Maciej<br />
Mrugala, Hans-Peter Kiem.<br />
343 1:30 PM<br />
Molecular Follow-Up <strong>of</strong> the German WAS Clinical <strong>Gene</strong><br />
<strong>Therapy</strong> Trial<br />
Anna Paruzynski, Kaan Boztug, Claudia Ball, Ali Nowrouzi,<br />
Christina Lulay, Marie Böhm, Sonja Naundorf, Klaus Kühlcke,<br />
Rainer Blasczyk, Irina Kondratenko, Laszló Maródi, Hanno<br />
Glimm, Christoph Klein, Christ<strong>of</strong> von Kalle, Manfred Schmidt.<br />
344 1:45 PM<br />
Correction <strong>of</strong> Canine Pyuvate Kinase Deficiency by Foamy<br />
Virus Vector-Mediated MGMT-P140K Selection In Vivo<br />
Brian C. Beard, Robert A. Wu, Christina Ironside, Punam Malik,<br />
Hans-Peter Kiem, Grant D. Trobridge.<br />
345 2:00 PM<br />
Zinc Finger Nuclease Mediated Safe Harbor Targeted <strong>Gene</strong><br />
Transfer in Patient iPSCs Functionally Corrects X-Linked<br />
Chronic Granulomatous Disease<br />
Colin L. Sweeney, Jizhong Zou, Bin-Kuan Chou, Uimook Choi,<br />
Jason Pan, Hongmei Wang, Sarah N. Dowey, Linzhao Cheng,<br />
Harry L. Malech.<br />
346 2:15 PM<br />
Long-Term Correction <strong>of</strong> Canine Leukocyte Adhesion<br />
Deficiency with a SIN Lentiviral Vector Using the Human<br />
PGK Promoter Expressing Canine CD18<br />
Michael J. Hunter, Huifen Zhao, Laura M. Tuschong, Tanya H.<br />
Burkholder, Derek A. Persons, Dennis D. Hickstein.<br />
347 2:30 PM<br />
Gamma-Retroviral Salvage <strong>Gene</strong> <strong>Therapy</strong> for Two Children<br />
with Chronic Granulomatous Disease<br />
Ulrich Siler, Janine Reichenbach, Anna Pruzynski, Manfred<br />
Schmid, Christoph von Kalle, Manuel Grez, Reinhard Seger.<br />
348 2:45 PM<br />
Alpharetroviral SIN Vectors: Evaluation <strong>of</strong> Genotoxicity and<br />
Long-Term Expression in Hematopoiesis<br />
Julia D. Suerth, Ute Modlich, Martijn H. Brugman, Tobias<br />
Maetzig, Verena Thies, Kerstin Kaufmann, Manuel Grez,<br />
Christopher Baum, Axel Schambach.<br />
349 3:00 PM<br />
Lentiviral Vectors Using a Ubiquitously Acting Chromatin<br />
Opening Element and Endogenous Btk Promoter<br />
Restore B and Myeloid <strong>Cell</strong> Defects in Murine X-Linked<br />
Agammaglobulinemia<br />
Hannah Kerns, Blythe Sather, Sara Mamman, Albanus<br />
Moguche, Michelle Brault, Alexander Astrakhan, Byoung Ryu,<br />
David Rawlings.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
ORAL ABSTRACT SESSION 323<br />
Cancer Immunotherapy -<br />
Emphasis on Adoptive T <strong>Cell</strong> Transfer<br />
1:15 PM - 3:15 PM<br />
Room: 608-609<br />
350 1:15 PM<br />
Adoptive Transfer <strong>of</strong> “Stem <strong>Cell</strong>-Like” Anti-Tumor T <strong>Cell</strong>s<br />
Can Eradicate Tumors<br />
Nicholas P. Restifo, Christopher D. Morrison, Pawel Muranski,<br />
Luca Gattinoni.<br />
351 1:30 PM<br />
Adoptive Transfer <strong>of</strong> Autologous IL13-zetakine + Engineered<br />
T <strong>Cell</strong> Clones for the Treatment <strong>of</strong> Recurrent Glioblastoma:<br />
Lessons from the Clinic<br />
Christine E. Brown, Renate Starr, Araceli Naranjo, Christine<br />
Wright, James Bading, Julie A. Ressler, Massimo D’Apuzzo,<br />
Behnam Badie, Stephen J. Forman, Michael C. Jensen.<br />
352 1:45 PM<br />
In Vivo Selection <strong>of</strong> <strong>Gene</strong> Modified T <strong>Cell</strong>s by Engineering<br />
Resistance to Clinical Immunosuppressive Drugs<br />
Mycophenolate M<strong>of</strong>etil and Methotrexate<br />
Mahesh Jonnalagadda, Christine E. Brown, Julie R. Ostberg,<br />
Wen C. Chang, Stephen J. Forman, Michael C. Jensen.<br />
353 2:00 PM<br />
<strong>Gene</strong>rating a Chimeric Antigen Receptor To Redirect T-<strong>Cell</strong><br />
Specificity after Infusion<br />
Sonny O. Ang, Cassie Hartline, Tiejuan Mi, Sourindra N. Maiti,<br />
George W. Jackson, Helen Hul, Elizabeth Shpall, Dean A. Lee,<br />
Richard E. Champlin, Laurence J. N. Cooper.
Abstract Directory Friday, May 20, 2011<br />
ORAL ABSTRACT SESSION 323 — continued<br />
Cancer Immunotherapy -<br />
Emphasis on Adoptive T <strong>Cell</strong> Transfer<br />
1:15 PM - 3:15 PM<br />
Room: 608-609<br />
354 2:15 PM<br />
Improved Costimulation <strong>of</strong> CD19-Specific T <strong>Cell</strong>s<br />
Transpresenting a Membrane-Bound IL-15<br />
Lenka V. Hurton, Harjeet Singh, Simon Olivares, Laurence J. N.<br />
Cooper.<br />
355 2:30 PM<br />
<strong>Gene</strong> Transfer to Hematopoietic Stem/Progenitor <strong>Cell</strong>s as<br />
a Novel Approach for Immunotherapy Against B-Lineage<br />
Malignancies<br />
Satiro N. Oliveira, Christine Ryan, Francesca Giannoni,<br />
Cinnamon Hardee, Behrod Katebian, Arineh Sahaghian,<br />
Roger Hollis, Donald B. Kohn.<br />
356 2:45 PM<br />
CD8:Class I MHC Interactions Influence T <strong>Cell</strong> Activity<br />
Mediated by Chimeric Antigen Receptors<br />
David H. Aggen, Jennifer D. Stone, Adam S. Chervin, Andrea<br />
Schietinger, Karin Schreiber, Hans Schreiber, David M. Kranz.<br />
357 3:00 PM<br />
<strong>Gene</strong>tically Engineered T-<strong>Cell</strong>s Targeting Cancer Associated<br />
Fibroblasts for Cancer Immunotherapy<br />
Sunitha Kakarla, Lisa Wang, David Rowley, Klaus Pfizenmaier,<br />
Stephen Gottschalk.<br />
ORAL ABSTRACT SESSION 324<br />
Cancer-Oncolytic Viruses<br />
1:15 PM - 3:15 PM<br />
Room: 618-620<br />
358 1:15 PM<br />
Systemic Combination Virotherapy for Malignant<br />
Melanoma with Vesicular Stomatitis Virus and Adoptive T<br />
<strong>Cell</strong> Transfer<br />
Diana M. Rommelfanger, Phonphimon Wongthida, Karen<br />
K. Kaluza, Rosa M. Diaz, Jill M. Thompson, Timothy J. Kottke,<br />
Richard G. Vile.<br />
359 1:30 PM<br />
Enhancing Therapeutic Index <strong>of</strong> Oncolytic Vaccinia Virus<br />
through Combining MicroRNA Regulation and Thymidine<br />
Kinase Deletion<br />
Mina Hikichi, Minoru Kidokoro, Hisatoshi Shida, Hideaki<br />
Tahara, Takafumi Nakamura.<br />
360 1:45 PM<br />
Engineering Viruses To Enhance and Monitor Systemic<br />
Oncolytic Efficacy<br />
Shruthi Naik, Rebecca Nace, Glen Barber, Stephen J. Russell.<br />
361 2:00 PM<br />
Systemic Delivery <strong>of</strong> Reovirus in Combination with<br />
Carefully Scheduled Chemotherapy Cures Established<br />
Tumors<br />
Timothy Kottke, Jill Thompson, Rosa Diaz, Phonphimon<br />
Wongthida, Diana Rommelfanger, Gerry Nuovo, Matt C<strong>of</strong>fey,<br />
Peter Selby, Hardev Pandha, John Chester, Kevin Harrington,<br />
Alan Melcher, Richard Vile.<br />
362 2:15 PM<br />
Vstat120 Modulates the Innate Pro-Inflammatory Response<br />
to Oncolytic Virus<br />
Jayson Hardcastle, Jeffrey Wojton, Eric Wohleb, W. Hans<br />
Meisen, Christopher Alvarez-Breckenridge, M. Oskar Nowicki,<br />
Jonathan Godbout, Balveen Kaur.<br />
363 2:30 PM<br />
Vaccine, but Not Wild-Type, Measles Virus Infection Has<br />
Pleotropic Effects on Human Neutrophil Function – A<br />
Mechanistic Insight into the Effects <strong>of</strong> an Oncolytic Virus on<br />
the Innate Immune System<br />
Yu Zhang, Lena Rai, Bella Patel, Aditi Dey, Anna Castleton,<br />
Adele K. Fielding.<br />
364 2:45 PM<br />
Cyclophosphamide Controls the Humoral Response to<br />
Oncolytic Viruses<br />
Kah-Whye Peng, Andrew Greenslade, Rae Myers, Emily K.<br />
Mader, Suzanne M. Greiner, Mark J. Federspiel, Stephen J.<br />
Russell.<br />
365 3:00 PM<br />
Inhibition <strong>of</strong> Rho Associated Coiled-Coil Forming Kinase<br />
Increases Efficacy <strong>of</strong> Measles Virus Infection<br />
Mateusz Opyrchal, Ianko Iankov, Cory Allen, Evanthia Galanis.<br />
ORAL ABSTRACT SESSION 325<br />
Stem <strong>Cell</strong> Therapies II<br />
1:15 PM - 3:15 PM<br />
Room: 615-617<br />
366 1:15 PM<br />
Reprogramming Mouse iPS <strong>Cell</strong>s as a New Approach To<br />
Correct the Stem <strong>Cell</strong> Defect in the Mpl -/- Mouse Model<br />
Jackie Roy, Angela Epp, Junli Feng, Xiaoping Wu, Neil C.<br />
Josephson.<br />
367 1:30 PM<br />
Targeting NF-kB Enhances the Regenerative Potential <strong>of</strong><br />
Muscle Stem <strong>Cell</strong>s through Multiple Mechanisms<br />
Jonathan D. Proto, Aiping Lu, Kayla Imbrogno, Ying Tang, Paul<br />
D. Robbins, Bing Wang, Johnny Huard.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 113<br />
Friday, May 20
Friday, May 20<br />
114<br />
Abstract Directory Friday, May 20, 2011<br />
ORAL ABSTRACT SESSION 325 — continued<br />
Stem <strong>Cell</strong> Therapies II<br />
1:15 PM - 3:15 PM<br />
Room: 615-617<br />
368 1:45 PM<br />
Recombinase Strategies To Make and Modify iPS <strong>Cell</strong>s<br />
Marisa Karow, Christopher L. Chavez, Alfonso P. Farruggio,<br />
Jonathan M. Gesinger, Joseph C. Wu, Yanru Chen-Tsai,<br />
Michele P. Calos.<br />
369 2:00 PM<br />
Doxycyclin-Inducible Expression <strong>of</strong> Human Cytidine<br />
Deaminase (hCDD) in Hematopoietic <strong>Cell</strong>s Mediates<br />
Protection Against Cytosine-Arabinoside Ara-C In Vitro and<br />
In Vivo<br />
Nico Lachmann, Nils Pfaff, Sebastian Brennig, Tobias Cantz,<br />
Axel Schambach, Christopher Baum, Thomas Moritz.<br />
370 2:15 PM<br />
Enhanced <strong>Cell</strong> Survival, Differentiation and Down-<br />
Regulation <strong>of</strong> Hypoxia-Related <strong>Gene</strong>s by Increased Oxygen<br />
Supply<br />
Dmitriy Sheyn, Shimon Benjamin, Shiran Ben David, Ilan<br />
Kallai, Yoram Zilberman, Anthony Oh, Gadi Pelled, Dan Gazit,<br />
Zulma Gazit.<br />
371 2:30 PM<br />
In Vitro Reprogramming <strong>of</strong> Murine Gall Bladder <strong>Cell</strong>s to<br />
beta-Like <strong>Cell</strong>s<br />
Raymond D. Hickey, Kathryn M. Schubert, Jessie S. Coleman,<br />
Feorillo Galivo, Eric Lagasse, Markus Grompe.<br />
372 2:45 PM<br />
Improved Hematopoietic Stem/Progenitor <strong>Cell</strong><br />
Maintenance <strong>of</strong> Nonhuman Primate Marrow <strong>Cell</strong>s Via a<br />
Non-<strong>Cell</strong>-Autonomous Effect <strong>of</strong> Fos and Vps72<br />
Korashon L. Watts, Eric Deneault, Guy Sauvageau, Hans-Peter<br />
Kiem.<br />
373 3:00 PM<br />
Muscle Derived Stem <strong>Cell</strong>s Transduced with BMP4 Interact<br />
Broadly with Host <strong>Cell</strong>s To Promote Bone Healing in Critical<br />
Sized Skull Defect<br />
Xueqin Gao, Arvydas Usas, Aiping Lu, Jonathan Proto, Jessica<br />
C. Tebbets, Hongshuai Li, James H. Cummins, Mathieu Huard,<br />
Johnny Huard.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
ORAL ABSTRACT SESSION 326<br />
Immunologic & Host Responses in<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
1:15 PM - 2:15 PM<br />
Room: 602-604<br />
374 1:15 PM<br />
Characterizing AAV1 Capsid Antigenic Regions<br />
Yu-Shan Tseng, Brittney Gurda, Wendy Weichert, Colin R.<br />
Parrish, John A. Chiorini, Mavis Agbandje-McKenna.<br />
375 1:30 PM<br />
Avoiding Trangene Immune Rejection after AAV Vector<br />
Delivery to the Skeletal Muscle: Tolerogenic Dendritic <strong>Cell</strong>-<br />
Based Immunotherapy in a Nonhuman Primate Model<br />
Aurélie Moreau, Mercedes Segovia, Laurence Dubreil, Gaëlle<br />
Tilly, Jack-Yves Deschamps, Yan Cherel, Ignacio Anegon,<br />
Philippe Moullier, Maria Cristina Cuturi, Oumeya Adjali.<br />
376 1:45 PM<br />
Immunosuppressive Strategies To Protect Transgenic Skin<br />
<strong>Cell</strong>s from Immune Rejection: Implications for Cutaneous<br />
<strong>Gene</strong>/<strong>Cell</strong> <strong>Therapy</strong><br />
Soosan Ghazizadeh, Weibing Zhang, Li T. Huang.<br />
377 2:00 PM<br />
Hepatocyte-Targeted Expression by Integrase-Defective<br />
Lentiviral Vectors Induces Antigen-Specific Regulatory T<br />
<strong>Cell</strong>s and Immune Tolerance to Foreign Antigens<br />
Andrea Annoni, Alessio Cantore, Kevin Goudy, Lucia Sergi<br />
Sergi, Luigi Naldini, Maria Grazia Roncarolo.<br />
ORAL ABSTRACT SESSION 327<br />
<strong>Cell</strong> Processing and Vector Production<br />
2:30 PM - 3:30 PM<br />
Room: 602-604<br />
378 2:30 PM<br />
Micro RNA Knockdown Significantly Enhances Adenovirus<br />
Replication and Vector Production<br />
Christina Rauschhuber, Martin Hausl, Dirk Nettelbeck, Anja<br />
Ehrhardt.<br />
379 2:45 PM<br />
GMP Production <strong>of</strong> a SIN Lentiviral Vector for the Treatment<br />
<strong>of</strong> SCID-X1 Using a Stable Producer <strong>Cell</strong> Line<br />
Tim Lockey, Susan Sleep, Robert Throm, Mike Greene, Paolo<br />
Fagone, Harry Malech, Brian Sorrentino, John T. Gray.
Abstract Directory Friday, May 20, 2011<br />
ORAL ABSTRACT SESSION 327 — continued<br />
<strong>Cell</strong> Processing and Vector Production<br />
2:30 PM - 3:30 PM<br />
Room: 602-604<br />
380 3:00 PM<br />
<strong>Gene</strong>ration and Characterization <strong>of</strong> AAV Producer <strong>Cell</strong><br />
Lines<br />
John Martin, Amy Frederick, Yuxia Luo, Robert Jackson,<br />
Dianna Ambach, Christopher Renzi, Lisa Budzinski, Lois<br />
Horton, Angela Johnsen, Simon Godwin, Donna Armentano,<br />
Sam Wadsworth, Karen Vincent.<br />
381 3:15 PM<br />
A New <strong>Cell</strong> Line for Clinical Grade Production <strong>of</strong> E1-Deleted<br />
Adenovirus Encoding Toxic Proteins<br />
Rénald Gilbert, Claire Guilbault, David Gagnon, Danielle<br />
Jacob, Lucie Bourget, Amine Kamen, Bernard Massie.<br />
POSTER SESSION II<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
RNA Virus Vectors II<br />
382<br />
Rapid Titration <strong>of</strong> Lentiviral and Gamma Retroviral<br />
Vectors Using a Beta-Lactamase Protein Fragment<br />
Complementation Assay<br />
Wu Ou, Connie Lu, Jakob Reiser.<br />
383<br />
Insulated Lentiviral Vectors towards Safer <strong>Gene</strong> Transfer to<br />
Stem <strong>Cell</strong>s<br />
Caroline Duros, Alexandre Artus, Armelle Gaussin, Scholtz<br />
Simone, Daniela Cesana, Eugenio Montini, Manfred Schmidt,<br />
Christ<strong>of</strong> von Kalle, Nicolas Mermod, Odile Y. D. Cohen-<br />
Haguenauer, Odile Y. D. Cohen-Haguenauer.<br />
384<br />
<strong>Gene</strong>ration <strong>of</strong> Transgene-Free Induced Pluripotent Stem<br />
<strong>Cell</strong>s Using Polycistronic Foamy Virus Vectors<br />
Iram F. Khan, Jordan Kho, David R. Deyle, Yi Li, David W.<br />
Russell.<br />
385<br />
Increasing Lentiviral Transduction by MG132- and CSP-<br />
Induced Inhibition <strong>of</strong> the Innate Immune Response<br />
Naoya Uchida, Matthew M. Hsieh, Kareem N. Washington,<br />
John F. Tisdale.<br />
386<br />
Selective <strong>Gene</strong> Transfer Do CD105 Positive <strong>Cell</strong>s – Targeting<br />
Mesenchymal Stroma <strong>Cell</strong>s<br />
Tobias Abel, Irene Schneider, Klaus Cichutek, Christian J.<br />
Buchholz.<br />
387<br />
Engineered Lentiviral Vectors Pseudotyped with a CD4<br />
Receptor and a Fusogenic Protein Can Target <strong>Cell</strong>s<br />
Expressing HIV-1 Envelope Proteins<br />
Chi-Lin Lee, Jason Dang, Kye-Il Joo, Pin Wang.<br />
388 ABSTRACT WITHDRAWN<br />
389<br />
Directed Integration <strong>of</strong> Insulated Lentiviral Vectors to the<br />
Heterochromatin towards Safer <strong>Gene</strong> Transfer to Stem <strong>Cell</strong>s<br />
Alexandre Artus, Caroline Duros, Yaïr Botbol, Simone Scholtz,<br />
Manfred Schmidt, Christ<strong>of</strong> von Kalle, Marc Lavigne, Odile Y. D.<br />
Cohen-Haguenauer, Odile Y. D. Cohen-Haguenauer.<br />
390<br />
Retroviral Delivery <strong>of</strong> Episomal Vectors<br />
Julie Lemay, Claudia Hagedorn, Elena Kuzmenko, Hans-<br />
Joachim Lipps, Reinhard Seger, Janine Reichenbach, Ulrich<br />
Siler.<br />
391<br />
Optimal Promoter Usage for Lentiviral Vector-Mediated<br />
Transduction <strong>of</strong> Different <strong>Cell</strong> Lines<br />
Ling Zhang, Pengyu Sun, Wenjing Wang, Junwen Shi, Dong<br />
Xiao, Jinlang Qiu, Jingbo Wu, Wanlong Tan, Hongwei Li,<br />
Chengyao Li.<br />
AAV Capsids & Trafficking<br />
392<br />
Biodistribution <strong>of</strong> IV Injected AAV9 in Young Cynomolgus<br />
Macaques<br />
Kevin D. Foust, Adam K. Bevan, Lyndsey Braun, Leah<br />
Schmelzer, Pablo R. Morales, Brian K. Kaspar.<br />
393<br />
Terminal N-Linked Galactose Is the Primary Receptor for<br />
Adeno-Associated Virus Serotype 9 (AAV9)<br />
Shen Shen, Kelli D. Bryant, Sarah M. Brown, Aravind Asokan.<br />
394<br />
Rational AAV Capsid Engineering Via Peptide Insertion<br />
Reveals Critical Roles <strong>of</strong> the Underlying Vector Serotype<br />
Marina Bechtle, Eike Kienle, Teresa Pankert, Dirk Grimm.<br />
395<br />
Quantitatively Dissecting Viral Trafficking Kinetics at Single<br />
Particle Level<br />
Ping-Jie Xiao, Richard J. Samulski.<br />
396<br />
Structurally Annotating the Tropism and Transduction<br />
Determinants <strong>of</strong> AAV1 and AAV6<br />
Robert Ng, Mavis Agbandje-McKenna.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 115<br />
Friday, May 20
Friday, May 20<br />
116<br />
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
AAV Capsids & Trafficking<br />
397<br />
A Potential Breakthrough in the AAV Biology: A Novel High-<br />
Throughput Capsid Functional Analysis Using Barcoded<br />
AAV Libraries and a Deep Sequencing Technology<br />
Kei Adachi, Tatsuji Enoki, Christopher S. Naitza, Hiroyuki<br />
Nakai.<br />
398<br />
Adeno-Associated Virus 2 Infection Requires Endocytosis<br />
through the CLIC/GEEC Pathway<br />
Matthieu Nonnenmacher, Thomas Weber.<br />
399<br />
AAV2 and AAV8 as <strong>Gene</strong> <strong>Therapy</strong> Vectors Targeting Distal<br />
Lung Epithelial Progenitor <strong>Cell</strong>s<br />
Benjamin R. Steines, David D. Dickey, Boulos S. Nassar, Joseph<br />
Zabner, Xiaopeng Li.<br />
400<br />
Characterization <strong>of</strong> Chimpanzee-Derived Novel Natural<br />
Variants <strong>of</strong> AAV5<br />
Li Zhong, Mengxin Li, Jun Xie, Qin Su, Ran He, Yu Zhang,<br />
Jason Goetzmann, Terry Flotte, Guangping Gao.<br />
401<br />
Widespread Transduction <strong>of</strong> Brain Parenchyma after<br />
Intraventricular Injection <strong>of</strong> AAV9 Compared to AAV4 and<br />
AAV5<br />
Annagiusi Gargiulo, Nicolina C. Sorrentino, Carmine<br />
Spampanato, Alessandro Fraldi, Enrico M. Surace.<br />
402<br />
High-Efficiency Transduction <strong>of</strong> Primary Human<br />
Monocytes-Derived Dendritic <strong>Cell</strong>s (moDCs) by<br />
Recombinant Adeno-Associated Virus Vectors Containing a<br />
Point Mutation in the Surface-Exposed Serine Residue<br />
George V. Aslanidi, Chen Ling, Ashley T. Martino, Lakshmanan<br />
Govindasamy, Mavis Agbandje-McKenna, Roland W. Herzog,<br />
Arun Srivastava.<br />
403<br />
A Capsid Composition Variant Containing four VP Proteins<br />
Caused by a Novel Start Codon at Position 219 <strong>of</strong> the<br />
Nucleotide Sequence <strong>of</strong> AAV8 Cap<br />
Olga Zelenaia, Federico Mingozzi, Bernd Hauck, Shangzhen<br />
Zhou, Katherine A. High, J. Fraser Wright.<br />
404<br />
Systematical Evaluation <strong>of</strong> Tropism <strong>of</strong> Different AAV<br />
Serotype Vectors in Adult and Neonatal Mice Following I.V.<br />
Injections<br />
Li Zhong, Mengxin Li, Xin Mu, Christopher Boisvert, Dmitry<br />
Ratner, Qin Su, Ran He, Sheng Chen, Jun Xie, Yu Zhang,<br />
Hongwei Zhang, Daniel Lucking, Terry Flotte, Guangping Gao.<br />
405<br />
A Rationally Designed Synthetic Combinatorial AAV Capsid<br />
Library as a <strong>Gene</strong> <strong>Therapy</strong> Tool<br />
Damien Marsic, Sergei Zolotukhin, Lakshaman Govindasamy,<br />
Babak Moghimi, Daniela Hurtado.<br />
406<br />
Development <strong>of</strong> Optimized AAV3 Serotype Vectors:<br />
Mechanism <strong>of</strong> High-Efficiency Transduction <strong>of</strong> Human Liver<br />
Cancer <strong>Cell</strong>s<br />
Binbin Cheng, Chen Ling, Yao Dai, Lyudmyla G. Glushakova,<br />
Yuan Lu, Samantha W. Y. Gee, Katherine E. McGoogan, George<br />
V. Aslanidi, Morag Park, Peter W. Stacpoole, Dietmar Siemann,<br />
Arun Srivastava, Changquan Ling.<br />
407<br />
Development <strong>of</strong> a Simple and Serotype-Independent<br />
System To Assess the AAV Assembly-Activating Protein<br />
(AAP) Function<br />
Tatsuji Enoki, Kei Adachi, Christopher S. Naitza, Hiroyuki<br />
Nakai.<br />
408<br />
Directed Evolution <strong>of</strong> Adeno-Associated Virus:<br />
Construction <strong>of</strong> an Enriched Random Insertion Library<br />
and Artificial Selection To Identify Structure-Function<br />
Relationships<br />
Justin H. Judd, Jonathan Silberg, Junghae Suh.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Adenovirus and Other DNA Virus Vectors II<br />
409<br />
Necrosis and Autophagy, but Not Apoptosis, Are Induced<br />
in Macrophages In Vivo upon Interaction with Adenovirus<br />
Nelson C. Di Paolo, Dmitry M. Shayakhmetov.<br />
410<br />
Adenovirus-Mediated NIS Expression in Xenografted<br />
Prostate Tumors Requires a Minimal Threshold <strong>of</strong> Viral Dose<br />
for Efficient Radioiodine Uptake<br />
Miguel A. Trujillo, Michael J. Oneal, Samantha McDonough,<br />
John C. Morris.<br />
411<br />
Cancer Specific Peptide-Tagged Ad Vectors in Systemic<br />
<strong>Therapy</strong> <strong>of</strong> Aggressive Solid Tumors<br />
Anke Schmidt, Christian Eipel, Katharina Fürst, Nadine<br />
Sommer, Jens Pahnke, Brigitte M. Pützer.
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Adenovirus and Other DNA Virus Vectors II<br />
412<br />
Enhancing Therapeutic Effects <strong>of</strong> Oncolytic Agents through<br />
Switching <strong>of</strong> Mechanism <strong>of</strong> Tumor Killing<br />
Hannah Chen, Padma Sampath, Wei Hou, Rachel Sikorski,<br />
Stephen H. Thorne.<br />
413<br />
A Novel Adenoviral Hybrid-Vector System Carrying a<br />
Plasmid Replicon for Safe and Efficient <strong>Cell</strong> and <strong>Gene</strong><br />
Therapeutic Applications<br />
Richard Voigtlander, Martin Hausl, Rudolf Haase, Armin<br />
Baiker, Anja Ehrhardt.<br />
414<br />
Chimeric Serotype 5/6 Helper-Dependent Ad Vector<br />
Improves Therapeutic Index for Liver-Directed <strong>Gene</strong><br />
<strong>Therapy</strong><br />
Francesco Vetrini, Reeti Khare, Nathan C. Grove, Donna J.<br />
Palmer, Amanda Rosewell, Michael A. Barry, Philip Ng.<br />
415<br />
A Novel Protein Transduction Domain with Improved<br />
Secretion and Transduction Activity<br />
Ying Shen, William Yu, Poonam Nagpal, John G. Hay, Harald<br />
Sauth<strong>of</strong>f.<br />
416<br />
Traceless Bioresponsive Coating <strong>of</strong> Adenovirus Vectors<br />
Jan-Michael Prill, Vladimir Subr, Tatjana Engler, Karel Ulbrich,<br />
Stefan Kochanek, Florian Kreppel.<br />
417<br />
Scalable Production and Purification Process <strong>of</strong> Helper-<br />
Dependent Adenoviral Vectors Using a Recombinase-Free<br />
System<br />
Dan Cots, Meritxell Puig, Maria Mercedes Segura, Assumpció<br />
Bosch, Miguel Chillón.<br />
418<br />
Carrier <strong>Cell</strong>s Infected with IAI.3B Promoter-Driven<br />
Oncolytic Adenovirus Overcome Immunogenicity and<br />
Induce Complete Tumor Reduction in Oral Squamous<br />
Carcinoma <strong>Cell</strong>s<br />
Katsuyuki Hamada, Ting Zhang, Koh-ichi Nakashiro, Hiroyuki<br />
Hamakawa.<br />
419<br />
Characterization <strong>of</strong> Poly(I) as a Tool To Improve Liver<br />
Transduction by HDAd Vectors<br />
Francesco Vetrini, Nathan Grove, Donna Palmer, Philip Ng,<br />
Nicola Brunetti-Pierri.<br />
420<br />
Transient Immunossuppression with CsA in Adenovirus-<br />
Sensitized Cirrhotic Rats Increases Survival and Reduces<br />
Inflammation Maintaining Adenovector Biodistribution<br />
and Transgene Effectiveness<br />
Ana Sandoval-Rodriguez, Mayra Mena-Enriquez,<br />
Jesus Garcia-Bañuelos, Adriana Salazar-Montes, Juan<br />
Armendariz-Borunda.<br />
421<br />
Oncolytic Adenovirus Regulated by Modified AFP Promoter<br />
Induces Hepatocellular Carcinoma-Specific and Hypoxia-<br />
Independent <strong>Cell</strong> Killing<br />
Minjung Kim, Oh-Joon Kwon, Il-Kyu Choi, Ji Young Yoo,<br />
Soung-Kyung Lee, Chae-Ok Yun.<br />
DNA Vectorology & <strong>Gene</strong> Targeting - I<br />
422<br />
Targeted <strong>Gene</strong> Integration into a Mouse Safe Harbor Locus<br />
Directed by Engineered Zinc Finger Nucleases<br />
Pablo Perez-Pinera, David G. Ousterout, Matthew T. Brown,<br />
David Yudovich, Charles A. Gersbach.<br />
423<br />
Correction <strong>of</strong> Adenosine Deaminase Deficiency Using Zinc<br />
Finger Nucleases<br />
Alok V. Joglekar, Gabriela Kuftinec, Jason Sims, Andreas Reik,<br />
Colin Flinders, Michael C. Holmes, Philip D. Gregory, Roger P.<br />
Hollis, Donald B. Kohn.<br />
424<br />
An Insight into the Chromatin-Based Mechanism <strong>of</strong> In Vivo<br />
Silencing <strong>of</strong> Foreign DNA<br />
Lia E. Gracey, Zhi-Ying Chen, Neil Phillips, Jay M. Maniar,<br />
Andrew Z. Fire, Mark A. Kay.<br />
425<br />
Meganucleases for <strong>Gene</strong> <strong>Therapy</strong><br />
Julianne Smith, Cécile Schiffer-Mannioui, Laurent Poirot,<br />
Roman Galetto, Agnès Gouble, Carole Desseaux, Frédéric<br />
Paques.<br />
426<br />
Characterization <strong>of</strong> Dynamic Change in the Distribution <strong>of</strong><br />
the Integration Sites <strong>of</strong> the Sleeping Beauty Transposon<br />
Nataly A. Kacherovsky, C. Anthony Blau, Cecilia M. Giachelli,<br />
Suzie H. Pun.<br />
427<br />
Passive Topical Administration <strong>of</strong> Nucleic Acids to Targeted<br />
Skin <strong>Cell</strong>s Via Sub-50 Nanometer Capsules<br />
Gretchen M. Unger, Martha Fuentes de Albin, Roger L. Kaspar,<br />
Betsy T. Kren, Diane K. Tobolt, Michael P. Murtaugh.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 117<br />
Friday, May 20
Friday, May 20<br />
118<br />
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
DNA Vectorology & <strong>Gene</strong> Targeting - I<br />
428<br />
Sensitive Methods To Detect Mutations Induced by<br />
Meganucleases<br />
Jacques P. Tremblay, Joël Rouseau, Pierre Chapdelaine,<br />
Sébastien Boivert, Luciana Almeida, Jacques Corbeil,<br />
Alexandre Montpetit, Frédéric Pâques.<br />
429<br />
Combining Linear Expression Cassette Technology with<br />
Novel Electroporation Techniques To Deliver Influenza DNA<br />
Vaccines<br />
Xuefei Shen, Feng Lin, Gary Kobinger, Elizabeth E. Murray,<br />
Kate E. Broderick, Niranjan Y. Sardesai.<br />
430<br />
Mechanisms <strong>of</strong> Enhanced <strong>Gene</strong> Expression by <strong>Gene</strong><br />
Transfer Using Ultrasound-Responsive and Mannose-<br />
Modified <strong>Gene</strong> Carriers<br />
Keita Un, Shigeru Kawakami, Mitsuru Yoshida, Ryo Suzuki,<br />
Kazuo Maruyama, Fumiyoshi Yamashita, Mitsuru Hashida.<br />
431 ABSTRACT WITHDRAWN<br />
432<br />
Construction and Characterization <strong>of</strong> Ligand-Streptavidin<br />
Fusion Proteins for Targeting <strong>of</strong> Biotinylated DNA<br />
Nanoparticles<br />
Wenchao Sun, Pamela B. Davis.<br />
433<br />
Octaarginine- and pH Sensitive Fusogenic Peptide-<br />
Modified Nanoparticles for Liver <strong>Gene</strong> Delivery<br />
Yasuhiro Hayashi, Ryoichi Mizuno, Khalil A. Ikramy, Hideyoshi<br />
Harashima.<br />
434<br />
Oligonucleotides Delivery Using High-Pressurized<br />
Lipoplexes<br />
Tsuyoshi Kimura, Asami Sano, Kwangwoo Nam, Yoshihiro<br />
Sasaki, Kazunari Akiyoshi, Akio Kishida.<br />
435<br />
Aptamer Conjugated Liposomes (Aptamosomes) as an<br />
Efficient Detection/Delivery Nano-Vehicle toward Prostate<br />
Cancer <strong>Cell</strong>s<br />
Keun-Sik Kim, Seho Kim, Hyun-Mi Kwon, Gwang-Hyun Lee,<br />
Yong Serk Park, Dong-Eun Kim.<br />
436<br />
Dual pH Response Nanoparticles for <strong>Gene</strong> Delivery<br />
Jose M. Morachis, Enas A. Mahmoud, Jagadis<br />
Sankaranarayanan, Jenny Huang, Adah Almutairi.<br />
437<br />
The Interaction between SP100 and Rep78 Inhibits Rep-<br />
Dependent Integration and Mediates SP100 Degradation<br />
Jinzhong Chen, Yuan-Yuan Xue, Ran Wang, Yang-bo Yue, Jinglun<br />
Xue.<br />
438<br />
Rep <strong>of</strong> AAV Protects p53 from E1B Mediated p53 Nucleolus<br />
Egress and Degradation<br />
Xu Wang, Jing-lun Xue, Wenjuan Li, Jinzhong Chen, Jinjin Wang.<br />
699 (MOVED FROM POSTER SESSION III)<br />
The Role and Fate <strong>of</strong> Excess Polycations in Chitosan-Based<br />
<strong>Gene</strong> Delivery<br />
Marc Thibault, Melina Astolfi, Marc Lavertu, Vincent Darras,<br />
Michael D. Buschmann.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Physical Methods <strong>of</strong> Delivery I<br />
439 (MOVED TO ORAL ABSTRACT SESSION 413)<br />
<strong>Gene</strong>tic Electrotransfer Immunization for the Identification<br />
<strong>of</strong> Functionally Important Epitopes: The Example <strong>of</strong><br />
VAR2CSA in Placental Adhesion <strong>of</strong> Plasmodium Falciparum<br />
Infected Erythrocytes<br />
S. Gnidehou, P. Bigey, J. Doritchamou, M. Quiviger, F. Viwami,<br />
A. Couturier, A. Salanti, Daniel Scherman, P. Deloron, N. Tuikue<br />
Ndam.<br />
440<br />
Enhanced <strong>Gene</strong> Gun-Based <strong>Gene</strong> Delivery to the Liver<br />
through Trans-Peritoneal Bombardment<br />
Kohei Tatsumi, Kazuo Ohashi, Tomohiko Yamazaki, Akiyoshi<br />
Taniguchi, Teruo Okano.<br />
441<br />
Electroporation Parameters Utilized for Delivering<br />
Plasmids Encoding Cytokines Impact the Outcome <strong>of</strong><br />
Melanoma <strong>Therapy</strong><br />
Shawna A. Shirley, Richard Heller.<br />
442<br />
<strong>Gene</strong>rating Defined, Characterized Microbubbles To<br />
Enhance the Efficiency <strong>of</strong> Ultrasound-Mediated <strong>Gene</strong><br />
Delivery System In Vitro<br />
Samuel S. Sun, Misty L. Noble, Milo C. Snyder, Adrienne<br />
Rothschilds, Carol H. Miao.<br />
443<br />
phiC31 Integrase-Mediated Long-Term <strong>Gene</strong> Expression in<br />
the Cultured Renal <strong>Cell</strong> Lines and Murine Kidney<br />
Shigeru Kawakami, Yuki Otani, Hidefumi Mukai, Yoshiaki<br />
Umemoto, Fumiyoshi Yamashita, Mitsuru Hashida.<br />
444<br />
Hydrodynamic Limb Vein Injection Method Can Open an<br />
Avenue <strong>of</strong> Mitochondrial <strong>Gene</strong> Delivery In Vivo<br />
Yukari Yasuzaki, Yuma Yamada, Tsutomu Kanefuji, Dexi Liu,<br />
Hideyoshi Harashima.
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Physical Methods <strong>of</strong> Delivery I<br />
445<br />
Utilization <strong>of</strong> a Single Method for Transfection <strong>of</strong> Multi-<br />
Cistronic Plasmids, mRNA and Protein in Primary Human<br />
Dermal Fibroblasts<br />
Laura A. Vozza-Brown, Uma Lakshmipathy, Reut Mali, Kristin<br />
Wiederholt.<br />
446<br />
Therapeutic Ultrasound Promotes Plasmid DNA Uptake by<br />
Clathrin-Mediated Endocytosis<br />
Daisy Bentes de Paula, Valderez Bastos Valero-Lapchik, Edgar<br />
Julian Paredes-Gamero, Sang Won Han.<br />
447<br />
Importance <strong>of</strong> Electrode Choice on <strong>Gene</strong> Electrotransfer<br />
to Skin; Evaluated by Efficacy <strong>of</strong> Transgene Expression and<br />
Electric Field Calculation in a Porcine Model<br />
Anita Gothelf, Faisal Mahmood, Frederik Dagnaes-Hansen,<br />
Julie Gehl.<br />
448 ABSTRACT WITHDRAWN<br />
449<br />
Nanoparticle-Mediated <strong>Gene</strong> Transfer in an In Vitro Model<br />
<strong>of</strong> Human Trophoblasts<br />
Helen Jones, Donglu Shi, Foong-Yen Lim, Sundeep Keswani,<br />
Timothy Crombleholme, Mounira Habli.<br />
450<br />
Aerosol Delivery <strong>of</strong> Plasmid DNA in a Mesh Nebuliser:<br />
Formulation and Transfection Studies<br />
Eugene R. Arulmuthu, Andrew S. Tait, David J. Williams, Henk<br />
K. Versteeg, John Ward, Mike Hoare.<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
451<br />
Fetal <strong>Gene</strong> <strong>Therapy</strong> for Lethal Murine Hypophosphatasia<br />
Hanako Sugano, Tae Matsumoto, Koichi Miyake, Atsushi<br />
Watanabe, Sonoko Narisawa, José L. Millán, Yoshitaka<br />
Fukunaga, Takashi Shimada.<br />
452<br />
A Mouse Model To Test Liver-Targeted Therapies for MUT<br />
Methylmalonic Acidemia<br />
Julien S. Sénac, Justin R. Sysol, Irini Manoli, Randy J. Chandler,<br />
Charles P. Venditti.<br />
453<br />
rAAV8 <strong>Gene</strong> Delivery Demonstrates Potential Efficacy as a<br />
Treatment <strong>of</strong> Cardiomyopathy in Propionic Acidemia<br />
Randy J. Chandler, Nuria Carrillo-Carrasco, Suma<br />
Chandrasekaran, Patricia M. Zerfas, Charles P. Venditti.<br />
454<br />
AAV Mediated <strong>Gene</strong> Transfer to Skeletal Muscle Results in<br />
Sustained Reduction <strong>of</strong> Hyperbilirubinemia in an Animal<br />
Model <strong>of</strong> Crigler-Najjar Syndrome Type 1<br />
Nunzia Pastore, Rosa Maria Sepe, Francesco Vetrini, Edoardo<br />
Nusco, Alberto Auricchio, Nicola Brunetti-Pierri.<br />
455<br />
Neonatal Delivery <strong>of</strong> scAAV9-SMN: Impact <strong>of</strong> Disease<br />
Development in Two Models <strong>of</strong> Spinal Muscular Atrophy<br />
Jacqueline Glascock, Monir Shababi, Christian Lorson.<br />
456<br />
Successful Treatment <strong>of</strong> Hypophosphatasia Model Mice<br />
by a Single Intramuscular Injection <strong>of</strong> AAV Type 8 Vector<br />
Expressing Tissue-Nonspecific Alkaline Phosphatase<br />
Tae Matsumoto, Koichi Miyake, Noriko Miyake, Hideo Orimo,<br />
Sonoko Narisawa, José Millán, Yoshitaka Fukunaga, Takashi<br />
Shimada.<br />
457<br />
Successful Use <strong>of</strong> Lipoplex for Delivery <strong>of</strong> the<br />
Small Molecules ManNAc and Sialic Acid To Rescue<br />
Hyposialylation in a Mouse Model <strong>of</strong> Hereditary Inclusion<br />
Body Myopathy (HIBM)<br />
Tal Yardeni, Carla Ciccone, Shelley Hoogstraten-Miller, Daniel<br />
Darvish, Yair Anikster, John Nemunaitis, Phil Maples, Chris M.<br />
Jay, William A. Gahl, Marjan Huizing.<br />
458<br />
<strong>Gene</strong> <strong>Therapy</strong> with Small Heat Shock Protein for<br />
Huntington Disease<br />
Wuh-Liang Hwu, Yu-May Lee, Nathalie Clement, Ni-Chung<br />
Lee, Barry Byrne.<br />
459<br />
<strong>Gene</strong> Transfer <strong>of</strong> Constitutively Active Akt1 Increases Islet<br />
<strong>Cell</strong> Survival and Proliferation<br />
Robert N. Bone, Yuan Zhang, Mert Icyuz, Stacie M. J. Bryant,<br />
Henry K. Fortinberry, John A. Thompson, <strong>Gene</strong> P. Siegal,<br />
Hongju Wu.<br />
460<br />
Helper-Dependent Adenoviral Vectors for Liver-Directed<br />
<strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Primary Hyperoxaluria Type 1<br />
Raffaele Castello, Pasquale Piccolo, Roberta Borzone, Riccardo<br />
Sangermano, Donna Palmer, Philip Ng, Nicola Brunetti-Pierri.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 119<br />
Friday, May 20
Friday, May 20<br />
120<br />
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
461<br />
Administration <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> Improves Cholesterol<br />
Synthesis and Physical Outcome in a Mouse Model <strong>of</strong><br />
Smith-Lemli-Opitz Syndrome (SLOS)<br />
Lee Ying, Xavier Matabosch, Montserrat Serra, Cedric<br />
Shackleton, Gordon Watson.<br />
462<br />
Proliferative Adipocytes as Therapeutic <strong>Gene</strong> Vehicle<br />
toward Sustained Protein Replacement <strong>Therapy</strong><br />
Masayuki Kuroda, Sakiyo Asada, Yasuyuki Aoyagi, Shigeaki<br />
Tanaka, Shunichi Konno, Masami Tanio, Masayuki Aso, Yasushi<br />
Saito, Hideaki Bujo.<br />
463<br />
Knockdown <strong>of</strong> <strong>Gene</strong>s Upstream <strong>of</strong> the Tyrosine Catabolic<br />
Pathway with siRNA Can Partially Rescue the Phenotype <strong>of</strong><br />
Fah Mutant Mice<br />
Changsheng Guo, Zhongya Wang, Sally Fitch, Markus<br />
Grompe.<br />
464 (MOVED TO POSTER SESSION I AFTER ABSTRACT 193)<br />
Hematopoietic Differentiation <strong>of</strong> Airway Epithelial <strong>Cell</strong>-Derived<br />
Cystic Fibrosis (CF) Induced Pluripotent Stem (iPS) <strong>Cell</strong>s<br />
R. Ge<strong>of</strong>frey Sargent, Yanu Yang, Albert Lee, Marcus O.<br />
Muench, Soya Kim, Arash Bedayat, Layli Jamali, Lin Ye, Judy<br />
Chang, Dieter C. Gruenert.<br />
465 ABSTRACT WITHDRAWN<br />
465.5<br />
Direct <strong>Gene</strong> Transfer with Compacted DNA Nanoparticles<br />
in Retinal Pigment Epithelial <strong>Cell</strong>s: Expression, Repeat<br />
Delivery and Lack <strong>of</strong> Toxicity<br />
Zongchao Han, Adarsha Koirala, Rasha Makkia, Mark J.<br />
Cooper, Muna I. Naash<br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
466<br />
Evaluation <strong>of</strong> rAAV6-Microutrophin Expression Driven<br />
by a Highly Active Muscle Specific Regulatory Cassette in<br />
Dystrophic Mice and the Non-Human Primate<br />
Guy L. Odom, Glen B. Banks, Quynh Nguyen, Eric Finn, James<br />
M. Allen, Jacqueline Wicki, Stephen D. Hauschka, Jeffrey S.<br />
Chamberlain.<br />
467<br />
RNAi <strong>Therapy</strong> for Dominant Limb Girdle Muscular<br />
Dystrophy Type 1A<br />
Jian Liu, Lindsay M. Wallace, Sara E. Garwick-Coppens,<br />
Michael A. Hauser, Jerry R. Mendell, Scott Q. Harper.<br />
468<br />
Fukutin-Related Protein Knock-Down by Systemic AAV9shRNA<br />
Delivery or by Transgenic Knock-In Mutation<br />
Resulted in Similar Muscle and Heart Pathology <strong>of</strong> LGMD 2I<br />
Chi-Hsien Wang, Yiumo M. Chan, Bin Xiao, Chunping Qiao,<br />
Ru-Hang Tang, Hui Zheng, Elizabeth Keramaris-Vrantsis, Juan<br />
Li, Peijuan Lu, Qilong Lu, Xiao Xiao.<br />
469<br />
Regeneration <strong>of</strong> Large Segmental Bone Defects by<br />
Implantation <strong>of</strong> <strong>Gene</strong> Activated Fat Tissue<br />
Volker M. Betz, Oliver B. Betz, Peter Augat, Stefan Rammelt,<br />
Hans Zwipp.<br />
470<br />
Site Directed <strong>Gene</strong> Repair <strong>of</strong> the Dystrophin <strong>Gene</strong><br />
in Satellite <strong>Cell</strong>s Mediated by PNA-ssODNs Restores<br />
Dystrophin Expression into Skeletal Muscles <strong>of</strong> a Mouse<br />
Model for Duchenne Muscular Dystrophy<br />
Farnoosh Nik-Ahd, Refik Kayali, Carmen Bertoni.<br />
471<br />
Losartan Enhances the Success <strong>of</strong> Myoblast Transplantation<br />
Raouia Fakhfakh, Yann Lamarre, Daniel Skuk, Jacques P.<br />
Tremblay.<br />
472<br />
The Polyproline Site in Hinge 2 <strong>of</strong> Microutrophin Does<br />
Not Lead to Structural Abnormalities like That for<br />
Microdystrophin<br />
Glen B. Banks, Guy L. Odom, Eric E. Finn, Jeffrey S.<br />
Chamberlain.<br />
473<br />
Long-Term Engraftment <strong>of</strong> Mesenchymal Stromal <strong>Cell</strong>s<br />
That Can Differentiate To Form Myogenic <strong>Cell</strong>s in Dog with<br />
Duchenne Muscular Dystrophy<br />
Yuko Nitahara Kasahara, Hiromi Hayashita Kinoh, Hironori<br />
Okada, Jin-Hong Shin, Akiyo Nishiyama, Sachiko Ohshima<br />
Hosoyama, Michiko Wada Maeda, Akinori Nakamura, Takashi<br />
Okada, Shin’ichi Takeda.<br />
474<br />
<strong>Gene</strong>-Targeted Osteogenesis Imperfecta iPSCs Express<br />
Normal Collagen and Produce Bone after Mesenchymal<br />
Differentiation<br />
David R. Deyle, Iram F. Khan, Gaoying Ren, Peirong Wang,<br />
Ulrike Schwarze, Jordan Kho, Peter H. Byers, David W. Russell.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> I<br />
475<br />
Recombinant AAV6 Fails to Effectively Transduce Satellite<br />
<strong>Cell</strong>s In Vivo<br />
Patryk Konieczny, Andrea Arnett, Julian N. Ramos, Zipora<br />
Yablonka-Reuveni, Jeffrey S. Chamberlain.<br />
476<br />
Molecular Treatment <strong>of</strong> Muscle Atrophy Caused by Focal<br />
Nerve Injury<br />
Gabriela A. Niizawa, Hiroyuki Nakai, Bing Wang, Paula R.<br />
Clemens.<br />
477<br />
AAV-5 Maximizes Growth Factor Transgene Expression and<br />
Differentiated Function in Chondrocyte Monolayer and<br />
Suspension Culture<br />
Alan J. Nixon, Laila Begum, Kyla O. Ortved.<br />
478<br />
Muscle Directed <strong>Gene</strong> <strong>Therapy</strong> with Capsid Modified<br />
Helper-Dependent Adenoviral Vectors<br />
Kilian Guse, Gautam Sule, Masataka Suzuki, Vincenzo Cerullo,<br />
Akseli Hemminki, Brendan Lee.<br />
479<br />
Exploring the Role <strong>of</strong> Deubiquitinating Enzyme A20 for<br />
Treatment <strong>of</strong> Muscular Dystrophy in mdx Mice<br />
Rakshita Charan, Gabriela Niizawa, Hiroyuki Nakai, Paula R.<br />
Clemens.<br />
480<br />
Interleukin-1β and Tumor Necrosis Factor-α Knockdown<br />
in Chondrocytes by Short Interfering RNA Using a Dual<br />
Expression Long Hairpin Construct<br />
Alan J. Nixon, Michael S. Scimeca.<br />
481<br />
Low-Level Expression <strong>of</strong> a Near-Full Length Dystrophin<br />
Improves Muscle Force and Lifespan in a Strain <strong>of</strong> Severely<br />
Affected Dystrophin/Utrophin Double Knockout Mice<br />
Dejia Li, Yongping Yue, Dongsheng Duan.<br />
482<br />
Osteoinduction in Muscle Tissue after Transduction with<br />
Bone Morphogenetic Protein-9: Implications for Bone<br />
Repair<br />
Volker M. Betz, Oliver B. Betz, Irina Weinzierl, Stefan Rammelt,<br />
Peter E. Mueller, Hans Zwipp.<br />
483<br />
PMO Delivery Systems with Bubble Liposomes and<br />
Ultrasound Exposure into Skeletal Muscles <strong>of</strong> the mdx Mice<br />
Yoichi Negishi, Yuko Ishii, Shoko Sekine, Yoko Endo-Takahashi,<br />
Ryo Suzuki, Kazuo Maruyama, Yukihiko Aramaki.<br />
Infectious Diseases and Vaccines II<br />
484<br />
Zinc Finger Mediated Disruption <strong>of</strong> CXCR4 in CD4 T <strong>Cell</strong>s<br />
Allows Protection and Enrichment in Humanized Mice after<br />
HIV-1 Challenge<br />
Jinyun Yuan, Jianbin Wang, Karen Crain, Philip D. Gregory,<br />
Michel C. Holmes, Bruce E. Torbett.<br />
485<br />
Protection <strong>of</strong> CD4 + T-<strong>Cell</strong>s and Enhanced Immune Response<br />
Against SHIV-Challenge after Engraftment <strong>of</strong> <strong>Gene</strong>tically-<br />
Modified HSCs in the Pigtailed Macaque-AIDS Model<br />
Patrick Younan, Patricia Polacino, On Ho, Brian Beard, Grant<br />
Trobridge, Shiu-Lok Hu, Hans-Peter Kiem.<br />
486<br />
LEDGF/p75 Based <strong>Gene</strong> <strong>Therapy</strong> for HIV/AIDS<br />
S<strong>of</strong>ie Vets, Janine Kimpel, Dorothee von Laer, Zeger Debyser,<br />
Rik Gijsbers.<br />
487<br />
Killing One Bird with Two Stones – Single shRNA Targeting<br />
Both Strands <strong>of</strong> HCV<br />
Leszek Lisowski, Menashe Elazar, Kirk Chu, Jeffrey S. Glenn,<br />
Mark A. Kay.<br />
488 ABSTRACT WITHDRAWN<br />
489<br />
Expression <strong>of</strong> Anti-HIV-1 Short Hairpin RNAs Using PolIII-<br />
Based Transcriptions Systems<br />
Lisa J. Scherer, Karl A. Haushalter, Athena Anderson, John J.<br />
Rossi.<br />
490<br />
Epitopes Expressed in Different Loops <strong>of</strong> Adenovirus Fiber<br />
Induce Different Levels <strong>of</strong> Epitope-Specific Immunity<br />
Anurag Sharma, Anja Krause, Wen Zhu, Stefan Worgall.<br />
491<br />
The Analysis <strong>of</strong> Utility <strong>of</strong> Human Adenovirus Vectors<br />
for Killing Macrophages Infected with Mycobacterium<br />
tuberculosis<br />
Nelson C. Di Paolo, Shahin Shafiani, Kevin Urdahl, Dmitry M.<br />
Shayakhmetov.<br />
492<br />
An Enhanced DC-Targeting Lentivector Vaccine to HIV-1<br />
Gag by PD-1 Blockade<br />
Bingbing Dai, Lili Yang, Pin Wang.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 121<br />
Friday, May 20
Friday, May 20<br />
122<br />
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Infectious Diseases and Vaccines II<br />
493<br />
Muliplexing Small Nucleolar RNAs To Inhibit HIV-1<br />
Replication<br />
Janet Chung, Jane Zhang, John Rossi.<br />
494<br />
Engineering Immunity Against HIV — Lentiviral-Vector<br />
Mediated Delivery <strong>of</strong> Broadly Neutralizing Antibodies as<br />
Pre-Exposure Prophylaxis for HIV<br />
Kenneth K. Yu, Kiefer Aguilar, David Baltimore.<br />
Cancer - Immunotherapy II<br />
495<br />
Effective Eradication <strong>of</strong> Established Ovarian Murine Tumors<br />
with MUC16 Targeted T <strong>Cell</strong>s Expressing IL-12 <strong>Gene</strong><br />
Alena A. Chekmasova, Samith Sandadi, Yan Nikhamin, David<br />
R. Spriggs, Renier J. Brentjens.<br />
496<br />
T <strong>Cell</strong>s Redirected Against HER2 for the Adoptive<br />
Immunotherapy <strong>of</strong> HER2-Positive Malignancies<br />
Nabil Ahmed, Vita Salsman, Oumar Diouf, Aidin Ashoori,<br />
Claudia Gerken, Lisa Wang, Peter Anderson, Benjamin Musher,<br />
Shanda Blackmon, Teresa Hayes, John Hicks, Hao Liu, Winfried<br />
Wels, Catherine Bollard, Cliona Rooney, Gianpietro Dotti, Adrian<br />
Gee, Malcolm Brenner, Helen Heslop, Stephen Gottschalk.<br />
497<br />
A Recombinant Dimeric Ad3 Fiber Protein Triggers<br />
Opening <strong>of</strong> Epithelial Junctions in Solid Tumors and<br />
Improves Trastuzumab/Herceptin and Cetuximab/Erbitux<br />
<strong>Therapy</strong> in Mouse Models<br />
Ines Beyer, Hongjie Wang, ZongYi Li, Roma Yumul, Andre Lieber.<br />
498<br />
<strong>Gene</strong>tic Editing <strong>of</strong> T Lymphocyte Specificity for Safe and<br />
Effective Adoptive Immunotherapy<br />
Pietro Genovese, Elena Provasi, Angelo Lombardo, Zulma<br />
Magnani, Pei-Qi Liu, Andreas Reik, Victoria Chu, David E.<br />
Paschon, Lei Zhang, Jurgen Kuball, Attilio Bondanza, Giulia<br />
Casorati, Fabio Ciceri, Claudio Bordignon, Philip D. Greenberg,<br />
Michael C. Holmes, Philip D. Gregory, Luigi Naldini, Chiara Bonini.<br />
499<br />
Primary Human CD8 + T <strong>Cell</strong>s Engineered To Express a PD1-<br />
CD28 Chimeric Receptor Are Co-Stimulated through the<br />
Exploitation <strong>of</strong> Tumor Expressed PD-L1<br />
Megan E. Prosser, Christine E. Brown, Michael C. Jensen.<br />
500<br />
CD56-Specific T <strong>Cell</strong>s Can Distinguish between Allogeneic<br />
and Autologous CD56 + Targets<br />
Denise L. Kellar, Sonny Ang, Simon Olivares, Helen Huls,<br />
Laurence J. N. Cooper.<br />
501<br />
Chimeric γc-Cytokine Receptors That Support Engraftment<br />
<strong>of</strong> Human CD8 + Cytolytic T Lymphocytes<br />
Michelle R. Hunter, Vaidehi Mahadev, Christine E. Brown,<br />
Michael C. Jensen.<br />
502<br />
Novel Immunotherapy <strong>of</strong> Spontaneous Canine Malignant<br />
Melanoma: Intra Tumor Immune Stimulation and Long<br />
Term Survival with Adenovector CD40 Ligand <strong>Therapy</strong><br />
Sara Westberg, Arian Sadeghi, Angelika Loskog, Thomas<br />
Segall, Olle Korsgren, Thomas Tötterman, Henrik von Euler.<br />
503<br />
Improved Expansion and Anti-Tumor Activity <strong>of</strong> Tumor-<br />
Specific CTLs Using a Transgenic Chimeric Cytokine<br />
Receptor<br />
Ann M. Leen, Usha Katari, Jacqueline Keirnan, Cliona M.<br />
Rooney, Malcolm K. Brenner, Juan F. Vera.<br />
504<br />
Co-Delivery <strong>of</strong> PSA and PSMA DNA Vaccines with<br />
Electroporation Induces Potent Immune Responses<br />
Bernadette Ferraro, Neil J. Cisper, Kendra T. Talbott, Lindsey<br />
Philipson-Weiner, Colleen E. Lucke, Amir S. Khan, Niranjan Y.<br />
Sardesai, David B. Weiner.<br />
505<br />
Clinical and Manufacturing Update <strong>of</strong> the FANG TM<br />
Autologous Tumor <strong>Cell</strong> Vaccine<br />
Phillip B. Maples, Padmasini Kumar, Yang Yu, Fabienne<br />
Norvell, Beena O. Pappen, Nicolas Tacquet, Alex W. Tong,<br />
Gladice Wallraven, Joseph Kuhn, Minal Barve, Cynthia Bedell,<br />
John Nemunaitis, Neil Senzer.<br />
506<br />
Highly Efficient Treatment <strong>of</strong> Ph + Acute Lymphoblastic<br />
Leukemia with a DNA Vaccine and 6-Mercaptopurine in Mice<br />
Yvonne Rott, Stefanie Arndt, Christina Marschke, Melchior<br />
Lauten, Manuel Schmidt, Burghardt Wittig, Katrin Kalies,<br />
Jürgen Westermann, Joachim Köchling.<br />
507<br />
Berry Extract Enhances a Leukemia Specific DNA Vaccine in<br />
the Treatment <strong>of</strong> Minimal Residual Disease in Mice with Ph +<br />
ALL<br />
Yvonne Rott, Melchior Lauten, Hendric Ungefroren, Michael<br />
Sagner, Manuel Schmidt, Burghardt Wittig, Joachim Köchling.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Cancer - Immunotherapy II<br />
508<br />
IL-21 Has an Anti-Apoptotic Effect on NK <strong>Cell</strong>s during<br />
Activation<br />
Vladimir Senyukov, Cecele J. Denman, Laurence J. N. Cooper,<br />
Dean A. Lee.<br />
509<br />
Dose Escalation <strong>of</strong> Therapeutic High-Capacity, Gutless<br />
Adenoviral Vectors in the Naïve Rat Brain: Pre-Clinical<br />
Safety and Toxicity Evaluation as a Prelude to a Phase I<br />
Clinical Trial for Glioma<br />
A. K. M. G. Muhammad, Mariana Puntel, Weidong Xiong,<br />
Kyle Kelson, Alireza Salem, Kurt M. Kroeger, Chunyan Liu,<br />
Catherine Farrokhi, Liliana Lacayo, Robert N. Pechnick, Donna<br />
Palmer, Philip Ng, Pedro R. Lowenstein, Maria G. Castro.<br />
510<br />
Role <strong>of</strong> STAT3 Signaling in TK/Flt3L <strong>Gene</strong> <strong>Therapy</strong> Mediated<br />
Brain Tumor Regression<br />
Hikmat H. Assi, James Curtin, Chunyan Liu, Maria G. Castro,<br />
Pedro R. Lowenstein.<br />
511<br />
An Enhanced Non Viral Vector (EEV) Giving Improved<br />
Responses in Immunogene Cancer Treatment over<br />
Standard Plasmid Vectors<br />
Patrick F. Forde, Lindsay J. Hall, Marcel de Kruijf, Gerald C.<br />
O’Sullivan, Declan M. Soden.<br />
512<br />
A Novel Adjuvant Ling Zhi-8 Enhances the Efficacy <strong>of</strong> DNA<br />
Cancer Vaccine by Activating Dendritic <strong>Cell</strong>s<br />
Chi-Chen Lin, Chia-Chiao Shih, Ching-Liang Chu.<br />
513<br />
Prostate Cancer Immunotherapy Using Bi-Specific Tumor-<br />
Reactive T <strong>Cell</strong>s<br />
Robert C. Chan, Ceidy Sanchez, Anna Worth, Ann M. Leen,<br />
Malcolm K. Brenner, Ganesh Palapattu, Juan F. Vera.<br />
Cancer-Oncolytic Viruses I<br />
514<br />
microRNA-Sensitive Oncolytic Measles Viruses for Cancer-<br />
Specific Vector Tropism<br />
Mathias Felix Leber, Sascha Bossow, Vincent H. J. Leonard,<br />
Karim Zaoui, Christian Grossardt, Marie Frenzke, Tanner Miest,<br />
Stefanie Sawall, Roberto Cattaneo, Christ<strong>of</strong> von Kalle, Guy<br />
Ungerechts.<br />
515<br />
Envelope-Chimeric Entry-Targeted Measles Virus Escapes<br />
Neutralization and Achieves Oncolysis<br />
Tanner S. Miest, Koon-Chu Yaiw, Marie Frenzke, Johanna<br />
Lampe, Andrew W. Hudacek, Christoph Springfeld, Veronika<br />
von Messling, Guy Ungerechts, Roberto Cattaneo.<br />
516<br />
A Novel Therapeutic Regime To Eradicate Established<br />
Tumors with an Effective Induction <strong>of</strong> Tumor-Specific<br />
Immunity<br />
James Tysome, Xiaozhu Li, Shengdian Wang, Pengju Wang,<br />
Dongling Gao, Rathi Gangeswaran, Dong Chen, Nick R.<br />
Lemoine, Yaohe Wang.<br />
517<br />
Armed and CD20-Retargeted Moraten Strain Measles<br />
Viruses for Combination Chemo- and Radiotherapy in Non-<br />
Hodgkin’s Lymphoma<br />
Tanner S. Miest, Marie Frenzke, Roberto Cattaneo.<br />
518<br />
Radiation Combined with Oncolytic Adenovirus Vector<br />
Suppresses Tumor Growth Better than Either Treatment<br />
Alone in the Syrian Hamster Model<br />
Brittany A. Young, Jacqueline F. Spencer, Karoly Toth, William<br />
S. M. Wold.<br />
519<br />
A Novel CDC25B Promoter Based Oncolytic Adenovirus<br />
Suppresses Tumor Growth in an Orthotopic Human<br />
Pancreatic Cancer Model<br />
Helga L. Weber, Gidekel Manuel, David T. Curiel, Eduardo G.<br />
Cafferata, Osvaldo L. Podhajcer.<br />
520<br />
The Effect <strong>of</strong> Combination <strong>Therapy</strong> <strong>of</strong> Oncolytic Virus<br />
hrR 3 and Antiangiogenic <strong>Therapy</strong> Bevacizumab in an<br />
Experimental Model <strong>of</strong> Pancreatic Carcinoma<br />
Tevfik T. Sahin, Hideki Kasuya, Akiyuki Kanzaki, Kazuo<br />
Yamamura, Suguru Yamada, Takashi Sugae, Gewen Tan, Yoko<br />
Nishikawa, Tsutomu Fujii, Shuji Nomoto, Hiroyuki Sugimoto,<br />
Akimasa Nakao.<br />
521<br />
Armed and Targeted Measles Virus for Virotherapy <strong>of</strong><br />
Chemoresistant Pancreatic Cancer<br />
Christian Grossardt, Sascha Bossow, Achim Temme, Mathias F.<br />
Leber, Stefanie Sawall, Roberto Cattaneo, Christ<strong>of</strong> von Kalle,<br />
Guy Ungerechts.<br />
522<br />
Tumor-Selective Suicide <strong>Gene</strong> <strong>Therapy</strong> by Transcriptionally<br />
Targeted Replicating Retrovirus Vectors<br />
Yi-Hui Lai, Chien-Kuo Tai.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 123<br />
Friday, May 20
Friday, May 20<br />
124<br />
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Cancer-Oncolytic Viruses I<br />
523<br />
BioKnife, a Urokinase-Targeted Oncolytic Sendai Virus,<br />
Eliminates Pleural Spread <strong>of</strong> Malignant Mesothelioma<br />
Yosuke Morodomi, Tokujiro Yano, Hiroaki Kinoh, Yui Harada,<br />
Satoru Saito, Tsukihisa Yoshida, Kensaku Ito, Yasunori Shikada,<br />
Riichiroh Maruyama, Kumi Yoshida, Yasuji Ueda, Mamoru<br />
Hasegawa, Yoshihiko Maehara, Yoshikazu Yonemitsu.<br />
524<br />
Complete and Sustained Tumor Regression <strong>of</strong> Human<br />
Malignant Mesothelioma Xenografts in Athymic Nude Mice<br />
Following Local Injection <strong>of</strong> Midkine Promoter-Regulated<br />
Oncolytic Adenovirus<br />
Shuji Kubo, Atsuko Tamamoto, Nobutaka Okamura, Yoshihiro<br />
Maeyama, Masatoshi Tagawa, Noriyuki Kasahara, Nobuyuki<br />
Terada, Haruki Okamura.<br />
525<br />
Adenoviral-Mediated Interferon-alpha <strong>Gene</strong> <strong>Therapy</strong> for<br />
Pancreatic Cancer<br />
Julia Davydova, Leonard Armstrong, Eric Brown, Joohee Han,<br />
Selwyn Vickers, Masato Yamamoto.<br />
526<br />
Evaluation <strong>of</strong> the Effect <strong>of</strong> Herpes Oncolytic Virus R3616 on<br />
the Host Immune Responses<br />
Kazuo Yamamura, Hideki Kasuya, Akiyuki Kanzaki, Tevfik<br />
Tolga Sahin, Tan Gewen, Suguru Yamada, Tsutomu Fujii,<br />
Hiroyuki Sugimoto, Shuji Nomoto, Shin Takeda, Akimasa<br />
Nakao.<br />
527<br />
RdB-VSV-G, a Vesicular Stomatitis Virus Glycoprotein<br />
Epitope-Incorporated Oncolytic Adenovirus Shows Marked<br />
Enhancement in Oncolysis and Suppression <strong>of</strong> Tumor<br />
Growth<br />
A.-Rum Yoon, Jaesung Kim, Renu Wadhwa, Sunil Kaul, Chae-<br />
Ok Yun.<br />
528<br />
Oncolytic Measles Virus Fully Retargeted to the Melanoma<br />
Surface Antigen HMWMAA<br />
Johanna K. Kaufmann, Sascha Bossow, Christian Groβardt,<br />
Stefanie Sawall, Jörg Kupsch, Guy Ungerechts, Dirk M.<br />
Nettelbeck.<br />
529<br />
Modification <strong>of</strong> the Early <strong>Gene</strong> Enhancer-Promoter<br />
Improves the Oncolytic Potency <strong>of</strong> Adenovirus 11<br />
Han Hsi Wong, Guozhong Jiang, Rathi Gangeswaran, Ming<br />
Yuan, Hexiao Wang, Vipul Bhakta, Heike Muller, Nick Lemoine,<br />
Yaohe Wang.<br />
530<br />
Retargeting Oncolytic Adenoviruses to Tumors Expressing<br />
c-Met<br />
Hany I. Sakr, Shilpa Bhatia, J. Michael Mathis.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
531<br />
Stanniocalcin-1 Derived from Multi Potent Stromal <strong>Cell</strong><br />
Changes <strong>Cell</strong> Metabolism Dramatically, Decreases Reactive<br />
Oxygen Species Stress and Promotes Survival <strong>of</strong> Cancer<br />
<strong>Cell</strong>s with Uncoupling Protein 2 Upregulation<br />
Shinya Ohkouchi, Gregory J. Block, Darwin J. Prockop,<br />
Toshihiro Nukiwa.<br />
532<br />
Neuropilin-1 Expressing Mononuclear <strong>Cell</strong>s (NEMs), a<br />
Novel Population <strong>of</strong> Bone Marrow <strong>Cell</strong>s Recruited by AAV2-<br />
Sema3A, Contributes to Vessel Normalization and Inhibits<br />
Tumor Growth<br />
Serena Zacchigna, Alessandro Carrer, Silvia Moimas, Lorena<br />
Zentilin, Mauro Giacca.<br />
533<br />
Examining the Role <strong>of</strong> CD44 in the Tumor Tropism <strong>of</strong><br />
Multipotent Mesenchymal Stem <strong>Cell</strong> (MSC) for Cancer<br />
Microenvironments<br />
Erika L. Spaeth, Brian Toole, Ann Klopp, Michael Andreeff,<br />
Frank C. Marini.<br />
534<br />
Survivin Downregulation in Human Breast Cancer <strong>Cell</strong><br />
Line by siRNA Delivery Using Hydrophobically Modified<br />
Aliphatic Polymers<br />
Hamidreza Montazeri Aliabadi, Breanne Landry, Parvin<br />
Mahdipoor, Hasan Uludag.<br />
535<br />
Bacterial <strong>Cell</strong> <strong>Therapy</strong> for Cancer<br />
Michelle Cronin, Sara A. Collins, Chwanrow Baban, Akihito<br />
Inagaki, Kei Hiraoka, Noriyuki Kasahara, Kevin Francis,<br />
Ali Akin, Cormac G. M. Gahan, Gerald C. O’Sullivan, Mark<br />
Tangney.<br />
536<br />
p16-Mediated Inhibition <strong>of</strong> Hypoxia-Induced Cancer <strong>Cell</strong><br />
Migration<br />
Yi Lu, Liyuan Li.
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
537<br />
Lentivirus-Mediated DR5 Agonistic Chimeric Antibody<br />
Expression for Cancer <strong>Gene</strong> <strong>Therapy</strong><br />
Dexian Zheng, Juan Shi, Yanxin Liu, Shilian Liu.<br />
538<br />
Study <strong>of</strong> Radioisotope Uptake and Efflux in NIS Expressing<br />
<strong>Cell</strong>s Goes High-Throughput<br />
Patrycja J. Lech, David Dingli, Stephen J. Russell.<br />
539 ABSTRACT WITHDRAWN<br />
540 ABSTRACT WITHDRAWN<br />
541<br />
293T <strong>Cell</strong>s Transfected with a Degron-Conjugated Fusion<br />
Reporter Demonstrate Unexpected Increase in Reporter<br />
Activity<br />
Rehan S. Ali, Maximilian Diehn, Edward E. Graves, Ramasamy<br />
Paulmurugan.<br />
<strong>Gene</strong> Regulation II<br />
542<br />
MicroRNA-Based Transgene Regulation in the Retina<br />
Anna Manfredi, Marianthi Karali, Agostina Puppo, Elena<br />
Marrocco, Annagiusi Gargiulo, Enrico M. Surace, Sandro Banfi,<br />
Alberto Auricchio.<br />
543<br />
Creation <strong>of</strong> Structural Variations in the Human Genome<br />
Using Engineered Zinc Finger Nucleases<br />
Eunji Kim, Hyung Joo Lee, Jin-Soo Kim.<br />
544<br />
VEGF-A Zinc Finger Activator Is Neuroprotective in Rodent<br />
Preclinical Models <strong>of</strong> Stroke<br />
S. Kaye Spratt, Philippe M. D’On<strong>of</strong>rio, Mark M. Magharious,<br />
Mahinthan Thayapararajah, Richard Surosky, Gary Lee, Martin<br />
Giedlin, Dale Ando, Michael Fehlings, Paulo D. Koeberle.<br />
545<br />
Regulation <strong>of</strong> AAV-Mediated Transgene Expression in<br />
Airway Epithelium In Vivo<br />
Maria P. Limberis, Melissa Fontana, ShuJen Chen, James M.<br />
Wilson.<br />
546<br />
Development and Characterization <strong>of</strong> a New Tet-ON AAV<br />
Vector for Tightly Controlled Transgene Expression<br />
Davide Gianni, Nancy H. Tran, Dimphna H. Meijer, Miguel<br />
Sena-Esteves.<br />
547<br />
Therapeutic microRNA Delivery Suppresses Mechanical<br />
Allodynia Induced by Mononeurpathic Pain in Rats<br />
Chung-Ren Lin, Kuan-Hung Chen, Chih-Hsien Wu, Yi-Shen Chen.<br />
548<br />
Differential Regulation <strong>of</strong> Multiple Transgenes by<br />
Alternative Splicing<br />
Eun-Young Choi, Xiaohuai Zhou, Richard J. Samulski.<br />
549<br />
Hypoxia-Specific <strong>Gene</strong> Expression System Using<br />
Oxygen Dependent Degradation Domain <strong>of</strong> Activating<br />
Transcription Factor 4 for Cancer Specific <strong>Gene</strong> <strong>Therapy</strong><br />
Su Hee Cho, Hyun Ah Kim, Ji Hwan Park, Min Hyung Lee.<br />
550<br />
DNA Methylation and <strong>Gene</strong> Expression in hESCs Grown in<br />
Defined and Xeno-Free Culture Systems<br />
Joshua D. Tompkins, Christine A. Hall, Vincent C. Chen,<br />
Sylvana Couture, David Hsu, Larry A. Couture, Arthur D. Riggs.<br />
551<br />
Evaluation <strong>of</strong> the X-Protein Truncate Expression Potential<br />
from the WPRE Element in Alipogene Tiparvovec, an AAV-<br />
Based <strong>Gene</strong> <strong>Therapy</strong> Vector<br />
Jacek Lubelski, Florence Salmon, Betty Au, Larbi Afia, Andrew<br />
Bakker, Harald Petry.<br />
Oligonucleotide & RNAi Therapeutics I<br />
552 ABSTRACT WITHDRAWN<br />
553<br />
Efficient Delivery <strong>of</strong> siRNA to Brain Capillary Endothelial<br />
<strong>Cell</strong>s with Endogenous Lipoprotein In Vivo<br />
Hiroya Kuwahara, Kazutaka Nishina, Kie Yoshida, Tomoko<br />
Nishina, Wenying Piao, Hidehiro Mizusawa, Takanori Yokota.<br />
554<br />
Chemically Modified Antisense Oligonucleotides Can<br />
Direct Transcriptional Regulation <strong>of</strong> <strong>Gene</strong> Expression<br />
Stuart E. Knowling, Anne-Marie Turner, Kevin V. Morris.<br />
555<br />
AAV Vector-Mediated Efficient and Sustained miRNA<br />
Antagonism In Vivo for Studying miRNA Function and<br />
Treating Hyperlipidemia<br />
Jun Xie, Stefan Ameres, Randall Friedline, Jui-Hung Hung,<br />
Qing Xie, Li Zhong, Qin Su, Ran He, Mengxin Li, Xin Mu,<br />
Hongwei Zhang, Seemin Ahmed, Jennifer Broderick,<br />
Chengjian Li, Jsaon Kim, Zhiping Wen, Terence Flotte, Phillip<br />
Zamore, Guangping Gao.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 125<br />
Friday, May 20
Friday, May 20<br />
126<br />
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Oligonucleotide & RNAi Therapeutics I<br />
556<br />
Short Hairpin RNAs Targeted to the S Segment <strong>of</strong> Rift Valley<br />
Fever Virus Inhibits Viral Replication and Alleviates NSs-<br />
Induced Pathogenic Effects<br />
Tristan Scott, Janusz Paweska, Patrick Arbuthnot, Marco<br />
Weinberg.<br />
557<br />
Antisense Oligonucleotides Correct Aberrant PTS-Splicing:<br />
Therapeutic Potential To Treat Hyperphenylalaninemia and<br />
Brain Monoamine Neurotransmitter Deficiency<br />
Sandra Brasil, Hiu Man Viecelli, David Meili, Anahita Rassi,<br />
Lourdes R. Desviat, Belen Pérez, Magdalena Ugarte, Beat<br />
Thöny.<br />
558<br />
Mechanism <strong>of</strong> Uptaking Morpholino into Dystrophin-<br />
Deficient Muscle Fibers<br />
Yoshitsugu Aoki, Tetsuya Nagata, Toshifumi Yokota, Shinichi<br />
Takeda.<br />
559<br />
Induction <strong>of</strong> Endogenous Pluripotency Factor Expression in<br />
Human Mesenchymal Stem <strong>Cell</strong>s by Small Activating RNAs<br />
Jon Voutila, Pål Sætrom, Paul Mintz, Guihua Sun, Jessica<br />
Alluin, John J. Rossi, Noriyuki Kasahara, Nagy A. Habib.<br />
560<br />
Bioreducible Polymer-Mediated siRNA Knockdown <strong>of</strong><br />
BNIP3 in Primary Rat Ventricular Cardiomyocytes for the<br />
Prevention <strong>of</strong> Hypoxia-Induced Apoptosis<br />
Arlo N. McGinn, Tae Il Kim, David A. Bull, Sung Wan Kim.<br />
561<br />
Hepatitis C Virus Infection Down-Regulates MIR-29: Effects<br />
on Viral Fitness and Hepatic Stellate <strong>Cell</strong> Activation<br />
Sarmistha Bandyopadhyay, Robin C. Friedman, Rebecca<br />
T. Marquez, Kyle E. Brown, Christopher B. Burge, Warren N.<br />
Schmidt, Yulei Wang, Anton P. McCaffrey.<br />
562<br />
In Vivo Comparison <strong>of</strong> the Long-Term Efficacy <strong>of</strong> AAV<br />
Expressed ShRNA and MiRNA Targeting Apolipoprotein B100<br />
Piotr Maczuga, Annemart Koornneef, Richard van<br />
Logtenstein, Florie Borel, Harald Petry, Sander van Deventer,<br />
Pavlina Konstantinova.<br />
563<br />
Developing Use <strong>of</strong> Inosine-Containing siRNAs To Improve<br />
Hepatitis B Virus Silencing Specificity<br />
Justin Hean, Carol Crowther, Abdullah Ely, Piet Herdewijn,<br />
Patrick Arbuthnot.<br />
564<br />
Apolipoprotein B Knockdown by AAV-Delivered ShRNA<br />
Lowers Plasma Cholesterol in Mice<br />
Annemart Koornneef, Piotr Maczuga, Richard van<br />
Logtenstein, Florie Borel, Bas Blits, Tita Ritsema, Sander van<br />
Deventer, Harald Petry, Pavlina Konstantinova.<br />
565<br />
Assessment <strong>of</strong> Zwitterionic Lipids as Vectors for Nucleic<br />
Acid Delivery<br />
Juliane Nguyen, Colin L. Walsh, Francis C. Szoka.<br />
566<br />
Multidrug Resistance Transporters and miRNAs Expression:<br />
Changes in Hepatocellular Carcinoma<br />
Florie Borel, Harald Petry, Peter Jansen, Sander van Deventer,<br />
Pavlina Konstantinova.<br />
567<br />
Antisense Drug Development for Skipping Human<br />
Dystrophin Exons In Vitro and In Vivo Systematically<br />
Bo Wu, Ehsan Benrashid, Peijuan Lu, Caryn Cloer, Allen<br />
Zillmer, Mona Shaban, QiLong Lu.<br />
568<br />
Tracking Single Liposomes for Delivery <strong>of</strong> siRNA<br />
Matthew R. Tiffany, Francis C. Szoka.<br />
569<br />
RNAi-Mediated <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Human Diseases<br />
Annemart Koornneef, Piotr Maczuga, Florie Borel,<br />
Angelina Huseinovic, Peter Jansen, Harald Petry, Pavlina<br />
Konstantinova.<br />
570<br />
Silencing the Human Eag1 Potassium Channel in Glioma<br />
<strong>Cell</strong>s by Using Short Interfering RNA<br />
Ludmylla C. Cunha, Ana Paula P. Faria, Bruno C. Gonzaga,<br />
Elaine Del Bel, Luis A. Pardo, Walter Stühmer, Ricardo<br />
Titze-de-Almeida.<br />
837 (MOVED FROM POSTER SESSION III)<br />
Improving the Specificity <strong>of</strong> RNAi-Based Therapeutics for<br />
Huntington’s Disease<br />
Ryan L. Boudreau, Jodi L. McBride, Ryan M. Spengler, Beverly<br />
L. Davidson.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Stem <strong>Cell</strong> Therapies II<br />
571<br />
Characterization <strong>of</strong> Surface Markers and DNA Regulatory<br />
<strong>Gene</strong> Expression during Neutrophil Differentiation from<br />
Human Induced Pluripotent Stem <strong>Cell</strong>s<br />
Hongmei Wang, Colin Sweeney, Harry Malech.<br />
572<br />
Clonal <strong>Cell</strong> Tracking Based on Multi-Colour RGB Marking<br />
with LeGO Vectors<br />
Krist<strong>of</strong>fer Weber, Michael Thomaschewski, Michael Warlich,<br />
Tassilo Volz, Kerstin Cornils, Birte Niebuhr, Maike Täger, Mark<br />
Lütgehetmann, Jörg-Matthias Pollok, Carol Stocking, Maura<br />
Dandri, Daniel Benten, Boris Fehse.<br />
573<br />
Enhancement <strong>of</strong> Tumor-Killing Activity <strong>of</strong> TRAIL-Expressing<br />
MSCs by Using Trichostatin A<br />
Ryosuke Uchibori, Hiroyuki Mizuguchi, Tomonori Tsukahara,<br />
Masashi Urabe, Hiroaki Mizukami, Akihiro Kume, Keiya<br />
Ozawa.<br />
574<br />
Reprogramming <strong>of</strong> Adult Human Extrahepatic Biliary <strong>Cell</strong>s<br />
into Functional Pancreatic Beta <strong>Cell</strong>s<br />
Feorillo Galivo, Raymond Hickey, Kathryn Schubert, Rohan<br />
Manohar, Eric Lagasse, Markus Grompe.<br />
575<br />
iPS <strong>Cell</strong> Formation Invokes Shared Biological and<br />
Transcriptome Changes with Tumorigenesis<br />
John Riggs, Paul S. Knoepfler.<br />
576<br />
<strong>Gene</strong>tic Modifications at Safe Harbor Loci in Hematopoietic<br />
Stem <strong>Cell</strong>s for <strong>Gene</strong> <strong>Therapy</strong><br />
Laurent Poirot, Roman Galetto, Frédéric Lemaire, Frédéric<br />
Cédrone, Sylvain Arnoud, Agnès Gouble, Carole Desseaux,<br />
Julianne Smith, Frédéric Pâques.<br />
577<br />
Efficient <strong>Gene</strong>ration <strong>of</strong> Vector/Transgene Free Human<br />
Induced Pluripotent Stem <strong>Cell</strong>s from Intractable Disease<br />
Patients Using Non-Integrating Sendai Virus Vectors<br />
Noemi Fusaki, Hiroshi Ban, Toshiaki Tabata, Akihiro Iida,<br />
Mamoru Hasegawa, Hironobu Ihn, Takumi Era.<br />
578<br />
Towards Targeted Transgene Integration in Induced<br />
Pluripotent Stem <strong>Cell</strong>s<br />
Ruan van Rensburg, Oleg Denisenko, Karol Bomsztyk, Ines<br />
Beyer, ZongYi Li, Andre Lieber.<br />
579<br />
Scalable Expansion <strong>of</strong> Undifferentiated Human Embryonic<br />
Stem <strong>Cell</strong>s in Serum-Free and Defined Suspension Culture<br />
Vincent C. Chen, Sylvana Couture, Jingjing Ye, Joshua<br />
Tompkins, David Hsu, Melissa Carpenter, Robin<br />
Wesselschmidt, Larry Couture.<br />
580<br />
CXCR1 Mediated Migratory Capacity <strong>of</strong> Human Umbilical<br />
Cord Blood-Derived Mesenchymal Stem <strong>Cell</strong>s toward<br />
Gliomas<br />
Seong Muk Kim, Dal-Soo Kim, Chang Hyun Jeong, Sin-Soo<br />
Jeun, Wonil Oh, Jong Wook Chang.<br />
581<br />
Engraftment and Fate <strong>of</strong> Endothelial Progenitor <strong>Cell</strong>s<br />
Transplanted to Rat Hindlimb Ischemia Monitored by a<br />
Novel MRI <strong>Cell</strong> Tracking System<br />
Tetsuji Yamaoka, Carlos G. Agdelo, Hidehiro Iida, Yoichi<br />
Tachibana.<br />
582<br />
Ultrasound <strong>Gene</strong> Delivery to Mesenchymal Stem <strong>Cell</strong>s:<br />
Targeting Tumor <strong>Therapy</strong><br />
Tom Haber, Marcelle Machluf.<br />
583<br />
Universal Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> Platform: Combining<br />
Ex Vivo Strategies and Injectable Tissue/Organ-Specific<br />
Extracellular Matrix (ECM) Hydrogels<br />
Roger Bertolotti.<br />
584<br />
Regenerative <strong>Cell</strong> <strong>Therapy</strong> for Liver Diseases with Skin<br />
Adipose Tissues-Derived Stem <strong>Cell</strong>s<br />
Sin-Ting Wang, Chi-Chen Lin.<br />
<strong>Cell</strong> Processing and Vector Production<br />
585<br />
Scalable Manufacturing <strong>of</strong> Recombinant Adeno-Associated<br />
Virus Using Suspension HEK293 <strong>Cell</strong>s<br />
Joshua C. Grieger, Stephen M. Soltys, Joy R. Burleyson,<br />
Richard J. Samulski.<br />
586<br />
Use <strong>of</strong> the Counterflow Centrifugal Elutriation in the<br />
Preparation <strong>of</strong> Apheresis Products for Use in <strong>Cell</strong> <strong>Therapy</strong><br />
Applications<br />
Chy-Anh T. Tran, Monica Coronado, Agnes Gardner, Lijing Li,<br />
Anitha Rao, Lan-Feng Cao, Qing Liu, John A. Zaia, David L.<br />
DiGiusto.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 127<br />
Friday, May 20
Friday, May 20<br />
128<br />
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
<strong>Cell</strong> Processing and Vector Production<br />
587<br />
Alternative Vector Titration Methods for scAAV Vectors<br />
Eliminate Systemic Errors Caused by Template Self-<br />
Annealing during qPCR Thermocycling<br />
Paolo Fagone, Susan Sleep, James A. Allay, J. Fraser Wright,<br />
Amit C. Nathwani, Andrew M. David<strong>of</strong>f, Arthur W. Nienhuis,<br />
John T. Gray.<br />
588<br />
PK-7 and RD2-MolPack-Chim3.14, Two Packaging <strong>Cell</strong><br />
Clones for Semi-Stable and Stable Production <strong>of</strong> HIV-Based<br />
Lentiviral Vectors<br />
Anna Stornaiuolo, Bianca Piovani, Francesca Salvatori,<br />
Eleonora Zucchelli, Claudio Bordignon, Raul Ziliotto, Gian-<br />
Paolo Rizzardi, Chiara Bovolenta.<br />
589<br />
Evaluation <strong>of</strong> Biopotency <strong>of</strong> rHIV Lentiviral Vectors<br />
Produced for Ex Vivo Hematopoietic <strong>Gene</strong> <strong>Therapy</strong><br />
Sabine Charrier, Otto-Wilhelm Merten, Frédéric Barnay-<br />
Toutain, Armelle Viornery, Stéphanie Bucher-Laurent, Muriel<br />
Audit, Mehdi Gasmi, Anne Galy.<br />
590<br />
Using Pulmozyme DNase Treatment as an Alternative to<br />
Benzonase for Lentiviral Vector Supernatant Production<br />
Aaron Shaw, Daniela Bisch<strong>of</strong>, Aparna Jasti, Aaron Ernstberger,<br />
Troy Hawkins, Kenneth Cornetta.<br />
591<br />
Large Scale Production <strong>of</strong> Suspension <strong>Cell</strong>s for Clinical<br />
Application Using a Novel <strong>Cell</strong> Bioreactor<br />
Juan F. Vera, Lara Brenner, Natalia Lapteva, Ann M. Leen, John<br />
Wilson, Helen E. Heslop, Cliona M. Rooney.<br />
592<br />
Manufacturing Complex Recombinant Biopharmaceuticals<br />
Using a Lentivector-Based Production System<br />
H. Trent Spencer, Gabriela Denning, Richard E. Gautney, Kyle<br />
Harris, Andre J. Roy, Lajos Barayni, Boro Dropulic, Christopher<br />
B. Doering.<br />
593<br />
SFM rHSV-Based Production <strong>of</strong> rAAV Vectors in Suspension<br />
BHK <strong>Cell</strong>s<br />
David R. Knop, Darby L. Thomas, Charlotte Butts.<br />
594<br />
Fully-Automated <strong>Cell</strong> Selection, Cultivation and <strong>Gene</strong>tic<br />
Modification in a Closed Environment for the Flexible<br />
Manufacturing <strong>of</strong> <strong>Cell</strong>ular Products<br />
Ian C. D. Johnston, Martin Biehl, Melanie Fahrendorff, Volker<br />
Huppert, Stefan Miltenyi.<br />
595<br />
Measurement <strong>of</strong> Viral Titer by Fluorescence Nanoparticle<br />
Tracking Analysis<br />
Andrew Malloy, Duncan A. Griffiths, Patrick Hole, Bob Carr.<br />
596<br />
Where Human <strong>Gene</strong> Transfer Is Illegal: Local Regulation <strong>of</strong><br />
rDNA Clinical Research<br />
Jan P. Vleck, Gary M. Johnson, Ethan Mascoop.<br />
597<br />
Challenges in the Production <strong>of</strong> Large and Complex<br />
Plasmid Vectors for <strong>Gene</strong> <strong>Therapy</strong><br />
Ying Cai, Stephen Rodriguez, Luke Clifford, Henry L. Hebel.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Late Abstracts II<br />
889<br />
Impact <strong>of</strong> Long-Term shRNA Expression on Hepatic <strong>Gene</strong><br />
Pr<strong>of</strong>iles<br />
Miwon Ahn, Scott R. Witting, Rafaela Ruiz, Romil Saxena,<br />
Nuria Morral.<br />
890 ABSTRACT WITHDRAWN<br />
891<br />
Phase II Trial <strong>of</strong> Intravenous Administration <strong>of</strong> Reolysin<br />
(Reovirus Serotype-3-Dearing Strain) in Patients with<br />
Metastatic Melanoma<br />
E Galanis, SN Markovic, V Suman, G Nuovo, R Vile, M C<strong>of</strong>fey, G<br />
Linette, W Maples, J Zwiebel, K Kendra.<br />
892<br />
A Potential microRNA-Based <strong>Therapy</strong> for Pancreatic Ductal<br />
Adenocarcinoma Using AAV-Mediated Delivery<br />
Janaiah Kota, Raghu R. Chivukula, Oliver A. Kent, Kim M.<br />
Shontz, Anirban Maitra, K. Reed Clark, Jerry R. Mendell,<br />
Joshua T. Mendell.<br />
893<br />
Measles Virus Glycoprotein-Pseudotyped Lentiviral<br />
Vector-Mediated <strong>Gene</strong> Transfer into Quiescent T and B<br />
Lymphocytes Requires Binding to both SLAM and CD46<br />
Entry Receptors<br />
Cecilia Frecha, Camille Lévy, Caroline Costa, Didier Nègre,<br />
Fouzia Amirache, Robin Buckland, Steven J Russell, François-<br />
Loïc Cosset, Els Verhoeyen.
Abstract Directory Friday, May 20, 2011<br />
POSTER SESSION II — continued<br />
4:40 PM - 6:40 PM<br />
Room: Hall 4B<br />
Late Abstracts II<br />
894<br />
Adenoviral Vector Codifying for hBcl-2 Improves In Vivo<br />
Muscle Regeneration.<br />
Francisco Martínez-F, Araceli Barrera-L, Erendira Estrada-V,<br />
Hugo Sandoval-Z, Hilda Villegas-C, Catalina Machuca-R,<br />
David T Curiel, JA Madinaveitia-V.<br />
895<br />
Betamethasone Delays the egr-1 Promoter Response<br />
at UV Induction in Human Primary Dermal Fibroblasts<br />
Transduced with Ad-egr1-Luc<br />
Francisco Martínez-F, Araceli Barrera-L, JA Madinaveitia-V,<br />
Erendira Estrada-V, Hugo Sandoval-Z, Hilda Villegas-C,<br />
Catalina Machuca-R, David T. Curiel, K Sakamoto.<br />
896<br />
Optimization <strong>of</strong> DNA to siRNA Ratio in SNS01 – an eIF5A-<br />
Based <strong>Gene</strong> <strong>Therapy</strong> Nanoparticle Designed for the<br />
Treatment <strong>of</strong> Multiple Myeloma<br />
C. Taylor, Z. Liu, B. Ye, T. Tang, J. Thompson, R. Dondero.<br />
897<br />
Development and Testing <strong>of</strong> a Novel <strong>Gene</strong> <strong>Therapy</strong><br />
Strategy Using Secreted Proteins<br />
Alexander Falkenhagen, Jimmy Chen, Masoud Ameli, Sabah<br />
Asad, Stanley E Read, Sadhna Joshi.<br />
898<br />
HB-EGF/HGF Hepatic <strong>Gene</strong> <strong>Therapy</strong> Effectively Inhibits<br />
Bile Duct Ligated Cholestatic Liver Injury in Mice in Their<br />
Different Therapeutic Modes<br />
Ken-ichiro Kosai, Kouichi Sakamoto, Nign Cin Khai, Yuqing<br />
Wang, Rie Maezono, Kiyonori Tanoue, Hideo Takamatsu,<br />
Hiroshi Matsufuji.<br />
899<br />
Local and Systemic Anti-Tumor Immunity is Induced<br />
by Rheoswitch Regulated IL-12 Production after Intra-<br />
Tumoral Injection <strong>of</strong> Adenovirus Vector as well as Vector-<br />
Transduced Dendritic <strong>Cell</strong>s<br />
Ronald B. Herberman, Meixia Bi, Mario Moreno, Lisa<br />
Butterfield, Mary Jo Buffo, Mark Thornton, Kimberly<br />
Shafer-Weaver.<br />
900<br />
Defining Binding Sites <strong>of</strong> the Homing Endonuclease I-CreI<br />
in the Human Genome by ChIP-seq<br />
Stefan Pellenz, Hui Li , Raymond J Monnat Jr..<br />
901<br />
rAAV1 Vector-Mediated Expression <strong>of</strong> Tafazzin in Patient<br />
Fibroblasts and Murine Model <strong>of</strong> Barth Syndrome<br />
MS Soustek, DJ Falk, CS Mah, AS Lewin, BJ Byrne.<br />
902<br />
Use <strong>of</strong> Lentiviral Vectors to Sensitize Pancreatic Cancer<br />
<strong>Cell</strong>s to Chemotherapy<br />
Adeline Pointreau, Flavie Sicard, Louis Buscail, Pierre<br />
Cordelier.<br />
903<br />
<strong>Gene</strong>ration <strong>of</strong> an HLA-negative K562 Clone as Pro<strong>of</strong>-<strong>of</strong>-<br />
Principle for Targeting <strong>of</strong> HLA-C by a Novel Zinc-Finger<br />
Nuclease<br />
Howard Ros<strong>of</strong>f, Vladimir Senyukov, Hiroki Torikai, Andreas<br />
Reik, Nick Littman, Philip D. Gregory, Michael C. Holmes.<br />
904<br />
Chitosan Structure Related to Transfection Efficiency and<br />
Colloidal Stability<br />
Marc Lavertu, Surendra Nimesh, Sotcheadt Sim, Marc<br />
Thibault, Michael D Buschmann.<br />
905<br />
Effect <strong>of</strong> a DNA Nuclear Targeting Sequence on the Nuclear<br />
Translocation Efficiency <strong>of</strong> a Suicide <strong>Gene</strong> Coding Plasmid<br />
in Small <strong>Cell</strong> Lung Cancer<br />
Frederik Cramer, Camilla Laulund Christensen, David A. Dean,<br />
Hans Skovgaard Poulsen.<br />
906<br />
Targeting Regulatory T <strong>Cell</strong>s in Cancer By Selective Delivery<br />
<strong>of</strong> RNA Interference<br />
William L Byrne, Patrick F Forde, Gerald C O’Sullivan.<br />
907<br />
Differences in Retrograde Axonal Transport <strong>of</strong> AAV6<br />
Vectors<br />
Brooke R. Snyder, Deirdre M. O’Connor, Jeremiah W. Huang,<br />
Eric T. Quach, Eleanor M. Donnelly, Chalonda R. Handy,<br />
Nicholas M. Boulis.<br />
908<br />
Adeno-Associated Virus Mediated <strong>Gene</strong> Targeting by<br />
Homologous Recombination in Human Somatic <strong>Cell</strong> Lines<br />
Rob Howes, Chris Torrance.<br />
909<br />
Chitosan-Graft-Spermine as a <strong>Gene</strong> Carrier for Lung Cancer<br />
<strong>Therapy</strong><br />
Hu-Lin Jiang, Seong-Ho Hong, You-Kyoung Kim, Ji-Young<br />
Shin, Ji-Eun Kim, Kyeong-Nam Yu, Seung-Hee Chang, Chong-<br />
Su Cho, Myung-Haing Cho.<br />
910<br />
<strong>Gene</strong> Synthesis: A Cost-effective Alternative to Traditional<br />
Molecular Cloning<br />
Marc Schwartz, Hanson Lo, Jason Zhou, Ping Yang, Amy Liao.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 129<br />
Friday, May 20
Saturday, May 21<br />
130<br />
Abstract Directory Saturday, May 21, 2011<br />
ORAL ABSTRACT SESSION 410<br />
Clinical <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
10:15 AM - 12:15 PM<br />
Room: 606-607<br />
598 10:15 AM<br />
A <strong>Gene</strong> <strong>Therapy</strong> Approach to HIV: Adoptive Transfer <strong>of</strong> Zinc<br />
Finger Nuclease (ZFN) Modified Autologous CD4 T-<strong>Cell</strong>s<br />
to Aviremic HIV-Infected Subjects with Suboptimal CD4<br />
Counts (200-500 <strong>Cell</strong>s/mm3)<br />
Shelley Wang, Jay Lalezari, Ronald Mitsuyasu, Steven Deeks,<br />
Winson Tang, Gary Lee, Michael Holmes, Phillip Gregory,<br />
Marty Giedlin, Dale Ando.<br />
599 10:30 AM<br />
Clinical Trial Results: Intralesional Injection <strong>of</strong> a Tumor<br />
Selective Oncolytic Vaccinia Virus<br />
Herbert J. Zeh, Mark O’Malley, Heather Jones, David H. Kirn,<br />
Moon Anne, Hwang H. Tae, David L. Bartlett.<br />
600 10:45 AM<br />
Safety and Efficacy <strong>of</strong> Re-Administration <strong>of</strong> AAV2.hRPE65v2<br />
in Subjects with Leber Congenital Blindness Due to RPE65<br />
Mutations<br />
Jean Bennett, Albert M. Maguire, Federico Mingozzi, Eric A.<br />
Pierce, Daniel C. Chung, Jeannette Bennicelli, Junwei Sun,<br />
J. Frasier Wright, Kathleen Marshall, Jennifer M. Wellman,<br />
Katherine A. High.<br />
601 11:00 AM<br />
CUPID – A Phase 2 Trial <strong>of</strong> Intracoronary <strong>Gene</strong> <strong>Therapy</strong><br />
<strong>of</strong> Sarcoplasmic Reticulium CA2+ ATPase (SERCA2a) in<br />
Patients with Advanced Heart Failure<br />
Krisztina M. Zsebo, Mariell Jessup, Barry Greenberg, Donna<br />
Mancini, Daniel Pauly, Roger Hajjar, On Behalf <strong>of</strong> the CUPID<br />
Investigators.<br />
602 11:15 AM<br />
Dose-Dependent Activation <strong>of</strong> Capsid-Specific T <strong>Cell</strong>s after<br />
AAV Serotype 8 Vector Administration in a Clinical Study<br />
for Hemophilia B<br />
E. Basner-Tschakarjan, F. Mingozzi, Y. Chen, A. C. Nathwani,<br />
E. G. D. Tuddenham, C. Rosales, J. McIntosh, A. Riddell, P.<br />
Rustagi, B. Glader, M. A. Kay, J. Allay, J. Coleman, S. Sleep, J.<br />
Gray, U. Reiss, A. W. Nienhuis, A. M. David<strong>of</strong>f, K. A. High.<br />
603 11:30 AM<br />
ProSavin® a <strong>Gene</strong> <strong>Therapy</strong> Approach for the Treatment <strong>of</strong><br />
Parkinson Disease: Phase I Clinical Trial Update<br />
Kyriacos Mitrophanous, Bechir Jarraya, Scott Ralph, Helene<br />
Lepetit, James Miskin, Jean-Marc Gurruchaga, Gilles Fenelon,<br />
Sabrina Boulet, Caroline Jan, Gilles Bonvento, Pierre Brugiere,<br />
Susan Kingsman, Stuart Naylor, Philippe Hantraye, Philippe<br />
Remy, Stephane Palfi.<br />
604 11:45 AM<br />
<strong>Gene</strong> <strong>Therapy</strong> with Lentiviral Vector Transduced CD34 +<br />
<strong>Cell</strong>s for the Treatment <strong>of</strong> Wiskott-Aldrich Syndrome<br />
Samantha Scaramuzza, Francesca Ferrua, Maria Carmina<br />
Castiello, Luca Biasco, Marita Bosticardo, Costanza Evangelio,<br />
Maria Pia Cicalese, Miriam Casiraghi, Anna Ripamonti,<br />
Stefania Giannelli, Monica Salomoni, Andrea Finocchi,<br />
Alessandra Biffi, Fabio Ciceri, Anna Villa, Maria Grazia<br />
Roncarolo, Luigi Naldini, Alessandro Aiuti.<br />
605 12:00 PM<br />
The Infusion <strong>of</strong> Suicide <strong>Gene</strong>-Modified Donor T <strong>Cell</strong>s<br />
after Hematopoietic Stem <strong>Cell</strong> Transplantation Prompts<br />
Thymic Renewal in Adult Patients by an IL-7 Dependent<br />
Mechanism<br />
Luca Vago, Giacomo Oliveira, Maddalena Noviello, Corrado<br />
Soldati, Domenico Ghio, Immacolata Brigida, Alessandro<br />
Aiuti, Maria Tersa Lupo Stanghellini, Jacopo Peccatori, Attilio<br />
Bondanza, Alessandro Del Maschio, Claudio Bordignon, Fabio<br />
Ciceri, Chiara Bonini.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
ORAL ABSTRACT SESSION 411<br />
RNA Virus Vectors<br />
10:15 AM - 12:15 PM<br />
Room: 615-617<br />
606 10:15 AM<br />
Assessing the Impact <strong>of</strong> Lentiviral Vector Integration on<br />
Splicing <strong>of</strong> <strong>Cell</strong>ular <strong>Gene</strong>s at the Genome-Wide Level<br />
Stefania Merella, Jacopo Sgualdino, Daniela Cesana, Fabrizio<br />
Benedicenti, Simone Leo, Gianluigi Zanetti, Luigi Naldini,<br />
Eugenio Montini.<br />
607 10:30 AM<br />
Read-Through/Splicing-Capture Mechanism Is the Major<br />
Determinant <strong>of</strong> Enhancer Genotoxicity <strong>of</strong> Vectors with<br />
Active LTRs<br />
Daniela Cesana, Marco Ranzani, Cynthia Bartholomae,<br />
Monica Volpin, Stefania Merella, Fabrizio Benedicenti, Lucia<br />
Sergi Sergi, Christ<strong>of</strong> von Kalle, Manfred Schmidt, Luigi<br />
Naldini, Eugenio Montini.<br />
608 10:45 AM<br />
<strong>Cell</strong> Surface Heparan Sulfate Proteoglycan (HSPG) Is a<br />
Receptor for Foamy Virus<br />
Md Nasimuzzaman, Derek A. Persons.<br />
609 11:00 AM<br />
Gas6 Mediates Lentiviral Vector Entry through Apoptotic<br />
Mimicry by Bridging Virion Envelope Phosphatidylserine to<br />
Axl<br />
Kouki Morizono, Yiming Xie, Tove Olafsen, Benhur Lee, Asim<br />
Dasgupta, Anna M. Wu, Irvin S. Y. Chen.
Abstract Directory Saturday, May 21, 2011<br />
ORAL ABSTRACT SESSION 411 — continued<br />
RNA Virus Vectors<br />
10:15 AM - 12:15 PM<br />
Room: 615-617<br />
610 11:15 AM<br />
An Integrated Approach To Discover New Liver Cancer <strong>Gene</strong>s<br />
and Test the Genotoxicity <strong>of</strong> Vectors for Liver <strong>Gene</strong> <strong>Therapy</strong><br />
Marco Ranzani, Alessio Cantore, Daniela Cesana, Cynthia<br />
Bartholomae, Francesca Sanvito, Mauro Pala, Fabrizio<br />
Benedicenti, Monica Volpin, Pierangela Gallina, Lucia Sergi Sergi,<br />
Alessandro Bulfone, Claudio Doglioni, Christ<strong>of</strong> von Kalle, Manfred<br />
Schmidt, Giovanni Tonon, Luigi Naldini, Eugenio Montini.<br />
611 11:30 AM<br />
Lentiviral Vector Common Integration Sites in the ALD<br />
and MLD Clinical Trials and in a Preclinical Model Reflect a<br />
Benign Integration Bias and Not Oncogenic Selection<br />
Alessandra Biffi, Cynthia C. Bartolomae, Daniela Cesana, Natalie<br />
Cartier, Marco Ranzani, Martina Cesani, Fabrizio Benedicenti,<br />
Tiziana Plati, Merella Stefania, Alessia Capotondo, Jacopo<br />
Sgualdino, Patrick Aubourg, Gianluigi Zanetti, Christ<strong>of</strong> von<br />
Kalle, Manfred Schmidt, Luigi Naldini, Eugenio Montini.<br />
612 11:45 AM<br />
Defining the Lentiviral Integrome in Human Hematopoietic<br />
<strong>Cell</strong>s<br />
Alessandra Recchia, Claudia Cattoglio, Danilo Pellin, Ermanno<br />
Rizzi, Giorgio Corti, Clelia Di Serio, Nirav Malani, Frederick<br />
Bushman, Gianluca De Bellis, Fulvio Mavilio.<br />
613 12:00 PM<br />
Foamy Virus Vectors with Strong Viral Enhancers Display<br />
Low In Vitro Immortalization Potential in Primary Murine<br />
Hematopoietic Progenitor <strong>Cell</strong>s<br />
Paritha I. Arumugam, Danielle L. Lynn, Johannes C. M. van<br />
der Loo, Thomas R. Bauer, Dennis D. Hickstein, David Russell,<br />
Punam Malik.<br />
ORAL ABSTRACT SESSION 412<br />
AAV Genome & Host Interactions<br />
10:15 AM - 12:15 PM<br />
Room: 6A<br />
614 10:15 AM<br />
High-Throughput Genome-Wide siRNA Screening Unravels<br />
<strong>Cell</strong>ular Factors Critical for AAV Transduction<br />
Miguel Mano, Rudy Ippodrino, Jasmina Lovric, Lorena<br />
Zentilin, Mauro Giacca.<br />
615 10:30 AM<br />
Enhanced Transgene Expression and Site-Specific<br />
Integration <strong>of</strong> Adeno-Associated Virus Depends on<br />
Methylation Status <strong>of</strong> the Target <strong>Cell</strong><br />
Diptiman Chanda, Jonathan A. Hensel, Jerome T. Higgs, Rajat<br />
Grover, Niroop Kaza, Selvarangan Ponnazhagan.<br />
616 10:45 AM<br />
rAAV Hairpin Structure Does Not Contribute to<br />
Chromosomal Integration<br />
Marcela P. Cataldi, Douglas M. McCarty.<br />
617 11:00 AM<br />
Assessment <strong>of</strong> Oncogenic Insertional Activation Potential<br />
from rAAV Vector<br />
Lucia E. Rosas, Jessica L. Grieves, Douglas M. McCarty.<br />
618 11:15 AM<br />
Investigating the Axonal Transport <strong>of</strong> AAV Serotype 9 in a<br />
Micr<strong>of</strong>luidic System<br />
Michael J. Castle, Eran Perlson, Erika L. F. Holzbaur, John H.<br />
Wolfe.<br />
619 11:30 AM<br />
AAV Vector-Mediated Activation <strong>of</strong> Canonical and<br />
Alternative NF-κB Pathways In Vivo: Implications for Innate<br />
and Adaptive Immune Responses and <strong>Gene</strong> <strong>Therapy</strong><br />
Giridhara R. Jayandharan, George V. Aslanidi, Ashley T.<br />
Martino, Stephan C. Jahn, George Q. Perrin, Roland W.<br />
Herzog, Arun Srivastava.<br />
621 11:45 PM<br />
Assessment <strong>of</strong> Genotoxic Potential <strong>of</strong> Different AAV<br />
Serotype Vectors in Liver-Directed <strong>Gene</strong> Transfer<br />
Li Zhong, Nirav Malani, Mengxin Li, Troy Brady, Jun Xie, Peter<br />
Bell, Haven Jones, James M. Wilson, Frederick D. Bushman,<br />
Guangping Gao.<br />
620 12:00 AM<br />
“Fragmented” AAV Vectors Rely on a Novel Homologous<br />
Recombination Repair Mechanism for Efficient Large <strong>Gene</strong><br />
Delivery In Vivo<br />
Matthew L. Hirsch, Chengwen Li, R. J. Samulski.<br />
ORAL ABSTRACT SESSION 413<br />
Physical Methods <strong>of</strong> Delivery<br />
10:15 AM - 12:15 PM<br />
Room: 611-612<br />
629 10:15 AM<br />
Sustaining Cardiac Expression <strong>of</strong> Adenovirus Delivered<br />
<strong>Gene</strong>s with a Dexamethasone Releasing Hydrogel<br />
Karen Kadner, Sharma Vinod, Deon Bezuidenhout, Peter Zilla,<br />
Neil Davies.<br />
623 10:30 AM<br />
Effective <strong>Gene</strong> Transfer Using Microbubble-Assisted<br />
Ultrasound <strong>Therapy</strong> in Canine Livers<br />
Misty L. Noble, Andrew A. Brayman, Christian S. Kuhr, Scott S.<br />
Graves, George W. Keilman, Liping Chen, Keith R. Loeb, Rainer<br />
F. Strob, Carol H. Miao.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 131<br />
Saturday, May 21
Saturday, May 21<br />
132<br />
Abstract Directory Saturday, May 21, 2011<br />
ORAL ABSTRACT SESSION 413 — continued<br />
Physical Methods <strong>of</strong> Delivery<br />
10:15 AM - 12:15 PM<br />
Room: 611-612<br />
624 10:45 AM<br />
Localized <strong>Gene</strong> Modification <strong>of</strong> Muslce Tissue Using<br />
Autologous Fat Grafts as a Vehicle for Viral Vector Delivery<br />
Ergun Kocak, Katherine H. Carruthers, Matthew J. During.<br />
625 11:00 AM<br />
Optimization <strong>of</strong> High Intensity Therapeutic Ultrasound and<br />
Microbubbles for <strong>Gene</strong> Delivery into Rat Liver<br />
Shuxian Song, Misty L. Noble, Samuel Sun, Liping Chen,<br />
Andrew A. Brayman, Carol H. Miao.<br />
626 11:15 AM<br />
<strong>Gene</strong> Delivery Using a Novel Physical Mode <strong>of</strong> Transfection<br />
Based on Electrospray<br />
Michael Maguire, Heather Kavanagh, Eoin Judge, Natasha<br />
McCormack, James Egan, Shirley O’Dea.<br />
627 11:30 AM<br />
Optimization <strong>of</strong> Image-Guided Hydrodynamic <strong>Gene</strong><br />
Delivery to Liver <strong>of</strong> Large Animals<br />
Kenya Kamimura, Takeshi Suda, Tsutomu Kanefuji, Guisheng<br />
Zhang, Dexi Liu.<br />
439 11:45 AM (MOVED FROM POSTER SESSION II)<br />
<strong>Gene</strong>tic Electrotransfer Immunization for the Identification<br />
<strong>of</strong> Functionally Important Epitopes: The Example <strong>of</strong><br />
VAR2CSA in Placental Adhesion <strong>of</strong> Plasmodium Falciparum<br />
Infected Erythrocytes<br />
S. Gnidehou, P. Bigey, J. Doritchamou, M. Quiviger, F. Viwami,<br />
A. Couturier, A. Salanti, Daniel Scherman, P. Deloron, N. Tuikue<br />
Ndam.<br />
622 12:00 PM<br />
High-Resolution, Overlapping Deposition <strong>of</strong> Multiple<br />
Plasmid DNA Species on a <strong>Cell</strong> Culture Substrate for<br />
Patterned Electroporation to a <strong>Cell</strong> Monolayer<br />
Marven Lamarre, Howard H. Lou, Woo Y. Lee, Philip L. Leopold.<br />
ORAL ABSTRACT SESSION 414<br />
<strong>Gene</strong> Targeting<br />
10:15 AM - 12:15 PM<br />
Room: 608-609<br />
630 10:15 AM<br />
PhiC31 Integrase Fusion Proteins: Targeted Insertion<br />
towards Specific Genomic Sites<br />
Nadja Noske, Nina Harms, Anja Ehrhardt.<br />
631 10:30 AM<br />
Sustainable <strong>Gene</strong> Transfer by Selection <strong>of</strong> Genomic Target<br />
Site and In Situ Tailoring <strong>of</strong> Cassette Design in Human<br />
Lymphocytes and Stem <strong>Cell</strong>s<br />
Angelo Lombardo, Daniela Cesana, Pietro Genovese, Daniele<br />
Colombo, Bruno Di Stefano, Elena Provasi, Margherita Neri,<br />
Zulma Magnani, Michael C. Holmes, Philip D. Gregory, Angela<br />
Gritti, Vania Broccoli, Chiara Bonini, Luigi Naldini.<br />
632 10:45 AM<br />
Genome-Wide Determination <strong>of</strong> Induced DNA Double-<br />
Strand Breaks Reveals High Specificity <strong>of</strong> Zinc Finger<br />
Nucleases<br />
Richard Gabriel, Angelo Lombardo, Anne Arens, Jeffrey C.<br />
Miller, Pietro Genovese, Christine Kaeppel, Ali Nowrouzi,<br />
Cynthia C. Bartholomae, Jianbin Wang, Ge<strong>of</strong>frey Friedman,<br />
Michael C. Holmes, Philip D. Gregory, Hanno Glimm, Manfred<br />
Schmidt, Luigi Naldini, Christ<strong>of</strong> von Kalle.<br />
633 11:00 AM<br />
Targeted <strong>Gene</strong> Integration in Human Epidermal Stem<br />
<strong>Cell</strong>s by Zinc-Finger Nuclease-Mediated Homologous<br />
Recombination<br />
Annarita Miccio, Angelo Lombardo, Andrea Coluccio,<br />
Francesca Miselli, Michael Holmes, Philip D. Gregory, Luigi<br />
Naldini, Alessandra Recchia, Fulvio Mavilio.<br />
634 11:15 AM<br />
Zinc-Finger Nuclease-Mediated <strong>Gene</strong> Correction Using<br />
Single AAV Vector Transduction and Enhancement by FDA<br />
Approved Drugs<br />
Brian L. Ellis, Matthew L. Hirsch, Jenny Barker, Richard J.<br />
Samulski, Matthew H. Porteus.<br />
635 11:30 AM<br />
Improved Technology for Estimating the Abundance <strong>of</strong><br />
<strong>Gene</strong> Corrected Clones from Integration Site Data<br />
Troy L. Brady, Shoshannah L. Roth, Nirav Malani, Frederic D.<br />
Bushman.<br />
636 11:45 AM<br />
Using a Novel Negative Selection Based on shRNA Strategy<br />
To Enrich for Homologous Recombinants<br />
Feng Gu, Roli Hirata, David Russell.<br />
637 12:00 PM<br />
Evaluation <strong>of</strong> a Reporter System for Site-Specific I-SceI-<br />
Mediated Genome Editing in Canine Hematopoietic Stem <strong>Cell</strong>s<br />
Nina M. Muñoz, Brian C. Beard, Byoung Y. Ryu, Grant D.<br />
Trobridge, Andrew M. Scharenberg, Hans-Peter Kiem.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Saturday, May 21, 2011<br />
ORAL ABSTRACT SESSION 415<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
10:15 AM - 12:15 PM<br />
Room: 602-604<br />
638 10:15 AM<br />
Non-Viral Delivery <strong>of</strong> STICKY-SIRNA Targeting the <strong>Cell</strong><br />
Cycle Inhibits Lung Tumor Metastasis<br />
Anne-Laure Bolcato-Bellemin, Marie-Elise Bonnet, Jean-Paul<br />
Behr, Patrick Erbacher.<br />
639 10:30 AM<br />
Early Efficacy Study <strong>of</strong> Ad-p53 in Combination with<br />
Gemcitabine and Intraperitoneal Cisplatin Plus Regional<br />
Thermotherapy in Advanced Pancreatic Cancer with<br />
Ascites<br />
Yuan Qin, Dong Ren, Yufei Fan, Xiaolin Liu, Dinggang Li.<br />
640 10:45 AM<br />
Imaging and Treatment <strong>of</strong> Pancreatic Cancer Using an<br />
Oncolytic Vaccinia Virus Carrying the Human Sodium<br />
Iodide Symporter<br />
Dana Haddad, Nanhai Chen, Qian Zhang, Chun-Hao Chen,<br />
Yong A. Yu, Lorena Gonzalez, Jochen Stritzker, Jason Aguilar,<br />
Susanne G. Carpenter, Joshua Carson, Joyce Au, Arjun Mittra,<br />
Mithat Gonen, Pat B. Zanzonico, Aladar A. Szalay, Yuman Fong.<br />
641 11:00 AM<br />
TK.007 Mediates Superior Killing Efficiency and Bystander<br />
Effect in Cancer Suicide <strong>Gene</strong> <strong>Therapy</strong><br />
Ellen Preuss, Alexander Muik, Krist<strong>of</strong>fer Weber, Jürgen Otte,<br />
Dorothee von Laer, Boris Fehse.<br />
642 11:15 AM<br />
Human Antrum Mucosal Protein 18 <strong>Gene</strong> Transfer for the<br />
Prevention <strong>of</strong> Radiation-Induced Oral Mucositis in Mouse<br />
Model<br />
Changyu Zheng, Ana P. Cotrim, Abraham N. Sunshine,<br />
Fernando Velasquez, Anastasia Sowers, James B. Mitchell,<br />
Bruce J. Baum.<br />
643 11:30 AM<br />
Combined, but Not Individual, Adenoviral Delivery <strong>of</strong><br />
p19Arf and Interfon-beta Induces Massive <strong>Cell</strong> Death in a<br />
Mouse Model <strong>of</strong> Melanoma<br />
Bryan E. Strauss, Christian A. Merkel.<br />
644 11:45 AM<br />
Imaging Nitroreductase (nfnB) Reporter <strong>Gene</strong> Expression in<br />
Living Animals<br />
Thillai V. Sekar, Srabani Bhaumik, Jeannette Depuy, June<br />
Klimash, Ramasamy Paulmurugan.<br />
645 12:00 PM<br />
Dual-Therapeutic Reporter <strong>Gene</strong>s Fusion for Enhanced<br />
Cancer <strong>Gene</strong> <strong>Therapy</strong> and Imaging<br />
Ramasamy Paulmurugan, Thillai V. Sekar, Srabani Bhaumik.<br />
ORAL ABSTRACT SESSION 416<br />
Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
10:15 AM - 12:15 PM<br />
Room: 618-620<br />
646 10:15 AM<br />
Dramatic Phenotypic Improvement after Adeno-Associated<br />
Virus <strong>Gene</strong> <strong>Therapy</strong> in a Feline Model <strong>of</strong> Sandh<strong>of</strong>f Disease<br />
Aime K. Johnson, Allison M. Bradbury, Julian Arthur, Victoria<br />
J. Jones, Misako Hwang, Stanley G. Leroy, Nancy E. Morrison,<br />
Jacob A. Johnson, Peter W. Christopherson, Nancy R. Cox,<br />
Henry J. Baker, Thomas N. Seyfried, Miguel Sena-Esteves,<br />
Douglas R. Martin.<br />
647 10:30 AM<br />
Intracarotid Delivery <strong>of</strong> AAV9 Vector Is a Powerful Method<br />
for <strong>Gene</strong> Delivery to the Primate Brain<br />
Kryst<strong>of</strong> Bankiewicz, Ernesto Aguilar Salegio, John Bringas,<br />
Adrain Kells, Kevin Foust, John Forsayeth, Brian Kaspar.<br />
648 10:45 AM<br />
Zinc Finger Nuclease-Mediated Editing <strong>of</strong> Dominant<br />
Retinal Mutations in Mice<br />
Ivette M. Sandoval, Brandee A. Price, Fung Chan, Alecia K.<br />
Gross, David L. Simons, Jiuli Zhang, Steve Zhang, David E.<br />
Paschon, William W. Hauswirth, Matthew H. Porteus, Philip D.<br />
Gregory, Theodore G. Wensel, John H. Wilson.<br />
649 11:00 AM<br />
rAAV-Mediated, Systemically Delivered and miRNA-<br />
Regulated CNS <strong>Gene</strong> Transfer Effectively Correct Metabolic<br />
and Psychomotor Defect, Alleviate Neuropathology, and<br />
Prolong Survival <strong>of</strong> ASPA -/- Mice with Canvan Disease<br />
Seemin Ahmed, Sylvia Szucs, Hongwei Zhang, Qin Su, Ran<br />
He, Miguel Sena-Esteves, Terence Flotte, Reuben Matalon,<br />
Guangping Gao.<br />
650 11:15 AM<br />
Suppression <strong>of</strong> HTT in the Rhesus Macaque: Behavioral,<br />
Histological and Molecular Analysis <strong>of</strong> RNAi as a <strong>Therapy</strong><br />
for Huntington’s Disease<br />
Jodi L. McBride, Mark R. Pitzer, Ryan L. Boudreau, Brett D.<br />
Dufour, Sergio R. Ojeda, Beverly L. Davidson.<br />
651 11:30 AM<br />
Robust Motor Neuron Transduction Following Intrathecal<br />
Delivery <strong>of</strong> AAV9.GFP to Pigs<br />
Thais Federici, Jason S. Taub, Steven S. Gray, Stacey Foti, Josh<br />
Grieger, Chalonda R. Handy, Eleanor M. Donnelly, R. Jude<br />
Samulski, Nicholas M. Boulis.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 133<br />
Saturday, May 21
Saturday, May 21<br />
134<br />
Abstract Directory Saturday, May 21, 2011<br />
ORAL ABSTRACT SESSION 416 — continued<br />
Neurologic & Ophthalmic <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
10:15 AM - 12:15 PM<br />
Room: 618-620<br />
652 11:45 AM<br />
Passive Immunization with an AAV Vector Expressing<br />
an Anti-Cocaine Antibody Shields the Brain from<br />
Systematically Administered Cocaine, Suppressing<br />
Cocaine-Induced Hyperlocomotion<br />
Martin L. Hicks, Jonathan B. Rosenberg, Bishnu P. De,<br />
Esther Z. Frenk, Odelya E. Pagovich, Jianping Qiu, Stephen<br />
M. Kaminsky, Neil R. Hackett, Lisa M. Eubanks, Kim Janda,<br />
Sunmee Wee, George Koob, Ronald G. Crystal.<br />
653 12:00 PM<br />
Persistent Suppression <strong>of</strong> Ocular Neovascularization with<br />
a Single Intravitreal Administration <strong>of</strong> AAVrh.10BevMab,<br />
an Adeno-Associated Viral <strong>Gene</strong> Transfer Vector Coding for<br />
Bevacizumab<br />
Yanxiong Mao, Szilard Kiss, Julie L. Boyer, Andrew Carbone,<br />
Jason G. Mezey, Stephen M. Kaminsky, Donald J. D’Amico,<br />
Ronald G. Crystal.<br />
POSTER SESSION III<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
AAV Experimental Therapeutics<br />
654<br />
Directed Evolution <strong>of</strong> AAV in Pig Airway Epithelia In Vivo<br />
David D. Dickey, Jamie Bergen, Boulos Nassar, Benjamin<br />
Steines, Katherine J. D. A. Exc<strong>of</strong>fon, David V. Schaffer, Joseph<br />
Zabner.<br />
655<br />
ERK Inhibition Substantially Improves Early Stage Mortality<br />
in Acute Pancreatitis: The First Report <strong>of</strong> AAV Vector-<br />
Mediated <strong>Gene</strong> Modulation in an Exocrine Pancreatic<br />
Disease<br />
Zuobiao Yuan, Deborah Williard, Erik Twait, Duraisamy<br />
Kempuraj, Isaac Samuel.<br />
656<br />
Transduction <strong>of</strong> Non-Human Primate Retina with<br />
Intravitreally Administered AAV Vectors <strong>of</strong> Different<br />
Serotypes: Investigations into Inflammation and Possibility<br />
<strong>of</strong> Treatment <strong>of</strong> Contralateral Eye<br />
Michael J. Lukason, Elizabeth A. Barry, Timothy MacLachlan,<br />
Samuel C. Wadsworth, Abraham Scaria.<br />
657<br />
AAV5 Mediated Exendin-4 Transduction <strong>of</strong> Salivary Glands<br />
in Mouse and Rat Obese Models Results in Robust Systemic<br />
Secretion <strong>of</strong> Exendin-4 and Improvement <strong>of</strong> Metabolic<br />
Parameters<br />
Giovanni Di Pasquale, Ilaria Dicembrini, Changyu Zheng,<br />
Drew Michael, Laura Raimondi, Andrea Cozzi, Andrea Loreto,<br />
Elena Manni, Silvia Berretti, Claudio Pagano, Roberto Vettor,<br />
Josephine M. Egan, Bruce J. Baum, Carlo Maria Rotella, John<br />
A. Chiorini, Edoardo Mannucci.<br />
658<br />
Enhancing Systemic Delivery <strong>of</strong> Recombinant Adeno-<br />
Associated Viruses through Kupffer <strong>Cell</strong> Depletion<br />
Matthew L. Hillestad, Adam J. Guenzel, Michael A. Barry.<br />
659<br />
Development <strong>of</strong> an Effective AAV Vector-Based <strong>Gene</strong><br />
<strong>Therapy</strong> To Treat the PRKAG2-Tg Mice, an Animal Model <strong>of</strong><br />
Autosomal Dominant Progressive Cardiomyopathy<br />
Kei Adachi, Christopher S. Naitza, Xueyin N. Huang, Ferhaan<br />
Ahmad, Hiroyuki Nakai.<br />
660<br />
Rescuing Adeno-Associated Virus from the Late<br />
Endosome/Lysosome Long after Infection Improves Apical<br />
Transduction <strong>of</strong> Human Airway Epithelia<br />
Nicholas W. Keiser, Ziying Yan, Diana Lei-Butters, John F.<br />
Engelhardt.<br />
661<br />
New Proteins Providing Host Defense Functions Against<br />
rAAVs<br />
Jerome Denard, Cyriaque Beley, Robert Kotin, Philippe<br />
Moullier, Thomas Voit, Luis Garcia, Fedor Svinartchouk.<br />
662<br />
AAV <strong>Gene</strong> <strong>Therapy</strong> Augments Chemotherapy in Multi-<br />
Modal Treatment <strong>of</strong> Ovarian Carcinoma<br />
Chelsea M. Bolyard, Matthew D. Stachler, Jeffrey S. Bartlett,<br />
Douglas M. McCarty.<br />
663<br />
Therapeutic Expression <strong>of</strong> Factor IX in a Murine Hemophilia<br />
B Model Using a Novel Human Stem <strong>Cell</strong> Derived AAV<br />
Serotype<br />
David M. Markusic, Laura J. Smith, Irene Zolotukhin, Arun<br />
Srivastava, Saswati Chatterjee, Roland Herzog.<br />
664<br />
Single Amino Acid Mutations on the External Surface<br />
<strong>of</strong> AAV2 Improve Transduction <strong>of</strong> Liver and Retina and<br />
Reduce Neutralization<br />
Abraham Scaria, Gary White, Michael Lukason, Elizabeth<br />
DuFresne, Jennifer Sullivan, Samuel Wadsworth.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
AAV Experimental Therapeutics<br />
665<br />
Variables Affecting AAV8-Mediated Liver Transduction<br />
Efficiency in Rats<br />
Gabriella Cotugno, Patrizia Annunziata, Marianthi Karali,<br />
Sandro Banfi, Alberto Auricchio.<br />
666<br />
Micropatterning AAV and Extracellular Matrix Proteins for<br />
Tissue Engineering<br />
Kellie I. McConnell, John H. Slater, Jennifer L. West, Junghae<br />
Suh.<br />
667<br />
<strong>Gene</strong> Transfer to the Murine Cornea In Vivo<br />
Daniel C. Chung.<br />
668<br />
Neutralizing Factors Against Cardiotropic AAVs in Sera<br />
from Different Animal Models<br />
Kleopatra Rapti, Vedell Louis-Jeune, Erik Kohlbrenner,<br />
Kiyotake Ishikawa, Dennis Ladage, Roger J. Hajjar, Thomas<br />
Weber.<br />
669<br />
rAAV8 Mediated Negative Vaccine <strong>Therapy</strong> in NOD Mouse<br />
Model<br />
Yuanqing Lu, Linda Theisen, Christian Grimstein, Matthew<br />
Parker, Clive Wasserfall, Mark Atkinson, Sihong Song.<br />
670<br />
Effects <strong>of</strong> the MRI Contrast Agent Gadoteridol on the<br />
Integrity and Distribution <strong>of</strong> rAAV2 and rAAV5 in the Rat<br />
Striatum<br />
Susan M. Osting, Shelby T. Power, James J. Raschke,<br />
Antoinette D. Bennett, Mavis Agbandje-McKenna, Marina E.<br />
Emborg, Corinna Burger.<br />
671<br />
Cost-Effective and Facile Method <strong>of</strong> rAAV Production in<br />
Suspension-adapted HEK 293 <strong>Cell</strong>s<br />
Huiren Zhao, Thomas Wolfe, Marissa van der Valk, Plewa A.<br />
Cherylene, Jackie Sheng, Ki Jeong Lee.<br />
672<br />
P53-Dependent NF-κB Activity Influenced the Anti-Tumor<br />
Effect <strong>of</strong> AAV-Mediated BATF2 Overexpression in Lung<br />
Cancer <strong>Cell</strong>s<br />
Zhao Lu, Jing Niu, Wei Wu, Dexi Chen, Wei Ding.<br />
Adenovirus and Other DNA Virus Vectors III<br />
673<br />
Single Oral Vaccination with Human Adenovirus 40 Vector<br />
Elicits Systemic Immune Responses<br />
Satoshi Yamasaki, Eric Brown, Julia Davydova, Selwyn M.<br />
Vickers, Masato Yamamoto.<br />
674<br />
Novel Adenovirus Vector <strong>Gene</strong>rating System Enabling<br />
Adenoviral Library with 10^10 Diversity<br />
Yoshiaki Miura, Eric Brown, Julia Davydova, Kazunori Aoki,<br />
Masato Yamamoto.<br />
675<br />
Oncolytic Adenoviral-Mediated Inhibition <strong>of</strong> Established<br />
Bone Metastases: A Safe and Effective Systemic<br />
Therapeutic Approach for Breast Cancer<br />
Zebin Hu, Helen Gerseny, Zhenwei Zhang, Stuart Stock, Prem<br />
Seth.<br />
676<br />
The dNTP Binding Efficiency <strong>of</strong> Adenovirus DNA<br />
Polymerase Contributes to Virus Replication Efficiency and<br />
Host <strong>Cell</strong> Tropism<br />
Cristina Capella-Gonzalez, Michael J. Beltejar, Baek Kim,<br />
Stephen Dewhurst.<br />
677<br />
In Vitro & Vivo <strong>Gene</strong> Targeting with Adenoviral Vector<br />
Conjugated Magnetic Nanobeads for Cardiac Regeneration<br />
Yue Zhang, Wenzhong Li, Gustav Steinh<strong>of</strong>f, Nan Ma.<br />
678<br />
Oncolytic Viruses: A Novel <strong>Therapy</strong> Against Triple-Negative<br />
Breast Cancer<br />
Sepideh Gholami, Chun-Hao Chen, Joshua S. Carson, Dana<br />
Haddad, Song Taejin, Joyce Au, Jun Kwong, Yuman Fong.<br />
679<br />
<strong>Gene</strong>ration <strong>of</strong> Complex High-Capacity Adenoviral Vectors<br />
with Modified Capsids for Applications In Vitro and In Vivo<br />
Martin Hausl, Richard Voigtlander, Zsolt Ruzsics, Anja<br />
Ehrhardt.<br />
680<br />
Dual-Expression Adenoviral Vectors in Vaccine<br />
Development<br />
Xiangyang Zhou, Juliana C. Small, Dongming Zhou, Raj K.<br />
Kurupati, Heng Chen, Ang Bian, Hildegund C. Ertl.<br />
681<br />
Ad-TβRIIΔcyt Treatment Decreases Liver Steatosis<br />
and Fibrosis by Decreasing mRNA Expression <strong>of</strong> CB1<br />
Cannabinoid Receptor and TGF-β and Increasing MMP-1<br />
Mayra G. Mena, Ana S. Sandoval, Jazmin Santillan, Juan<br />
Armendariz.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 135<br />
Saturday, May 21
Saturday, May 21<br />
136<br />
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Adenovirus and Other DNA Virus Vectors III<br />
682<br />
Development <strong>of</strong> a Virus-Associated RNA-Deleted<br />
Adenovirus Vector<br />
Mitsuhiro Machitani, Kazufumi Katayama, Fuminori Sakurai,<br />
Hayato Matsui, Tomoko Yamaguchi, Takayuki Suzuki, Kenji<br />
Kawabata, Hiroyuki Mizuguchi.<br />
683<br />
Pre-Clinical Characterization <strong>of</strong> Endothelial <strong>Cell</strong>s as Carriers<br />
<strong>of</strong> Oncolytic Adenoviruses<br />
Bart Thaci, Ilya V. Ulasov, Maciej S. Lesniak.<br />
684<br />
miR122 Targets Insertion in Wild-Type Serotype 5<br />
Adenovirus To Ablate Liver Replication<br />
Sergio Lavilla-Alonso, Erkko Ylösmäki, Kalle Saksela.<br />
685<br />
TRAIL-Expressing Oncolytic Viral DNA/Liposome Hybrid<br />
Vector for Lung Cancer <strong>Gene</strong> <strong>Therapy</strong><br />
Oh-Joon Kwon, Eunah Kang, Jaerim Kim, Kyungmin Nam,<br />
Sung Wan Kim, Chae-Ok Yun.<br />
DNA Vectorology & <strong>Gene</strong> Targeting - II<br />
686<br />
Zinc Finger Nuclease <strong>Gene</strong>ration for Fanconi Anemia<br />
Mark J. Osborn, Morgan L. Maeder, J. Keith Joung, Bruce R.<br />
Blazar, Jakub Tolar.<br />
687<br />
<strong>Gene</strong> Repair in a Murine Model <strong>of</strong> SCID-X1<br />
Gabrielle M. Curinga, Michelle Brault, Jordan Jarjour, Jit Kim,<br />
Byoung Ryu, Andrew M. Scharenberg, David J. Rawlings.<br />
688<br />
Novel Dual AAV Vectors To Express an nNOS-Recruiting<br />
Mini-Dystrophin <strong>Gene</strong> for Duchenne Muscular Dystrophy<br />
<strong>Gene</strong> <strong>Therapy</strong><br />
Yadong Zhang, Dongsheng Duan.<br />
689<br />
Helper-Dependent Adenovirus with Doxycyclin-Inducible<br />
Expression <strong>of</strong> Zinc-Finger Nucleases for Targeted<br />
Transgene Integration in Hematopoietic Stem <strong>Cell</strong>s<br />
Xiaoying Yao, Hongjie Wang, Ruan van Rensburg, Michael<br />
Holmes, Philip Gregory, Andre Lieber.<br />
690<br />
Optimisation <strong>of</strong> the 2A Co-Expression System for <strong>Gene</strong><br />
Therapies<br />
Ekaterina Minskaia, Garry Luke, Martin D. Ryan.<br />
691<br />
A Modular Self-Assembling Peptide Scaffold for Tissue<br />
Engineering and Targeted <strong>Gene</strong> Delivery<br />
Joshua Z. Gasiorowski, Joel H. Collier.<br />
692<br />
Analysis <strong>of</strong> 2A-Mediated ‘Cleavage’<br />
Valerie Odon, Garry Luke, Martin D. Ryan.<br />
693<br />
A Molecular Tool for <strong>Gene</strong> Integration and <strong>Gene</strong>ration <strong>of</strong><br />
Isogenic Mammalian <strong>Cell</strong> Lines<br />
Samantha A. Stuckey, Francesca Storici.<br />
694<br />
Customized Antibiotic Free Non-Viral Plasmid Vectors for<br />
<strong>Therapy</strong> and Vaccination<br />
Jeremy M. Luke, Justin M. Vincent, Clague P. Hodgson, James<br />
A. Williams.<br />
695<br />
pFARs, Plasmids Free <strong>of</strong> Antibiotic Resistance Markers,<br />
Display High-Level Transgene Expression in Muscle, Skin<br />
and Tumour <strong>Cell</strong>s<br />
Corinne Marie, Gaëlle Vandermeulen, Mickaël Quiviger,<br />
Magali Richard, Véronique Préat, Daniel Scherman.<br />
696<br />
The p5 Promoter Sequence <strong>of</strong> AAV Genome Regulates the<br />
Direction <strong>of</strong> Transgene Insertion into the AAVS1 Site<br />
Masashi Urabe, Satsuki Miyata, Akira Onishi, Tomonori<br />
Tsukahara, Hiroaki Mizukami, Akihiro Kume, Keiya Ozawa.<br />
697<br />
Improvement <strong>of</strong> <strong>Gene</strong> Targeting at the Human rDNA Locus<br />
by Zinc Finger Nucleases<br />
Youjin Hu, Di Xiao, Xionghao Liu, Lingqian Wu, Desheng<br />
Liang.<br />
698<br />
Nonviral-Mediated Endostatin Delivery Results in<br />
Inhibition <strong>of</strong> Fibrosarcoma Growth<br />
Jianxiong Peng, Lingqian Wu, Xionghao Liu, Desheng Liang.<br />
699 (MOVED TO POSTER SESSION II AFTER ABSTRACT 438)<br />
The Role and Fate <strong>of</strong> Excess Polycations in Chitosan-Based<br />
<strong>Gene</strong> Delivery<br />
Marc Thibault, Melina Astolfi, Marc Lavertu, Vincent Darras,<br />
Michael D. Buschmann.<br />
700<br />
Rep <strong>of</strong> AAV Inhibits HSV Amplification by Degradation<br />
PML-NBs Proteins That Necessary for ICP0 Mediated Viral<br />
Processes<br />
Jinzhong Chen, Ran Wang, Jinjin Wang, Limin Wan, Jing-lun<br />
Xue.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Physical Methods <strong>of</strong> Delivery II<br />
701<br />
Piezoelectric Permeabilization <strong>of</strong> Mammalian Dermal<br />
Tissue for In Vivo DNA Delivery Leads to Enhanced Protein<br />
Expression and Increased Immunogenicity<br />
Kate E. Broderick, Thomas Kardos, Jay R. McCoy, Michael P.<br />
Fons, Stephen Kemmerrer, Niranjan Y. Sardesai.<br />
702<br />
Combination Chemo-Antiangiogenic <strong>Therapy</strong> for<br />
Metastatic Colorectal Carcinoma<br />
Lalitha Belur, Kelly M. Podetz-Petersen, Brent Sorenson,<br />
Daniel Saltzman, S. Ramakrishnan, R. Scott McIvor.<br />
703<br />
Nanosecond Electric Pulses Modulate the Expression <strong>of</strong><br />
Electrotransferred <strong>Gene</strong>s<br />
Aude Silve, Marie Gilbert, Vanessa Joubert, Julien Villemejane,<br />
Lluis M. Mir.<br />
704<br />
The Amaxa Nucle<strong>of</strong>ector System and Standard<br />
Electroporation: A Comparison <strong>of</strong> the Efficiency <strong>of</strong> DNA<br />
Nuclear Localization<br />
Marta H. Ekstrom, David A. Dean.<br />
705<br />
Development <strong>of</strong> Electromotor-Driven Injector for<br />
Hydrodynamic <strong>Gene</strong> Delivery<br />
Takeshi Yokoo, Kenya Kamimura, Takeshi Suda, Masafumi<br />
Oda, Guisheng Zhang, Dexi Liu, Yutaka Aoyagi.<br />
706<br />
Protein Transfer into Human <strong>Cell</strong>s by VSV-G Induced<br />
Nanovesicles<br />
Philippe E. Mangeot, Sandra Dollet, Mathilde Girard, Claire<br />
Ciancia, Marc Peschanski, Vincent Lotteau.<br />
707<br />
A Proteoliposome Containing Apolipoproteins A-I Mutant<br />
(V156K) Enhances Rapid Tumor Regression Activity <strong>of</strong><br />
Human Origin Oncolytic Adenovirus in Carcinogen Induced<br />
Tumor-Bearing Zebrafish<br />
Jung-Heun Park, Seori Jin, Kyung-Hyun Cho.<br />
708<br />
Delivery <strong>of</strong> VEGF165 To Enhance Healing <strong>of</strong> Ischemic Skin<br />
Flaps in Rats Using a Multi Electrode Array (MEA)<br />
Gaurav Basu, Harre Downey, Siqi Guo, Richard Heller.<br />
709<br />
Synthesis and Evaluation <strong>of</strong> Stearylated Hyaluronic Acid<br />
Material for Active Liposomal Delivery to Liver Endothelial<br />
<strong>Cell</strong>s<br />
Naoyuki Toriyabe, Yasuhiro Hayashi, Mamoru Hyodo,<br />
Hideyoshi Harashima.<br />
710<br />
Sonoporation <strong>of</strong> Plasmid DNA Driven by Glucagon<br />
Promoter to Pancreatic Islet a-<strong>Cell</strong> for Diabetes <strong>Gene</strong><br />
<strong>Therapy</strong><br />
Jeong H. Park, Minhyung Lee, Hye S. Jung, Chang S. Yoon, Tae<br />
K. Kim, Min J. Kwon, Soon H. Lee, Kyung S. Ko, Byung D. Rhee,<br />
Mi K. Kim.<br />
711<br />
Non-Invasive Electro-<strong>Gene</strong> Delivery to the Skin Using a<br />
Multiple Electrode Array<br />
Siqi Guo, Amy Donate, Gaurav Basu, Kathryn Lundberg, Loree<br />
Heller, Richard Heller.<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> III<br />
712 MOVED TO POSTER SESSION I<br />
Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> with a Lentiviral<br />
Vector for the Multi-Systemic Lysosomal Storage Disorder<br />
Cystinosis<br />
Frank Harrison, Brian A. Yeagy, Donald B. Kohn, Daniel R.<br />
Salomon, Stephanie Cherqui.<br />
713<br />
Towards Lentiviral <strong>Gene</strong> <strong>Therapy</strong> for the Treatment <strong>of</strong><br />
Pompe Disease<br />
Merel M. Stok, Helen H. de Boer, Trudi T. P. Visser, Arnold J. J.<br />
Reuser, Elza E. D. van Deel, Dirk-Jan D. J. Duncker, Niek N. P.<br />
van Til, Gerard G. Wagemaker.<br />
714<br />
Chimerism <strong>of</strong> Bone Marrow Reduces the Glycolipid Storage<br />
in Fabry Disease Mice<br />
Takayuki Yokoi, Hiroshi Kobayashi, Yoshikatsu Eto, Nobuyuki<br />
Ishige, Teruyuki Kitagawa, Makato Otsu, Hiromitsu Nakauchi,<br />
Hiroyuki Ida, Toya Ohashi.<br />
715<br />
Lentiviral Transduction <strong>of</strong> MPS1 Bone Marrow <strong>Cell</strong>s Results<br />
in High Production <strong>of</strong> alpha-L-Iduronidase In Vivo<br />
Henk Rozemuller, Petra Moerer, Niek P. van Til, JaapJan<br />
Boelens, Tom J. de Koning, Anton C. Martens, Gerard<br />
Wagemaker, Nico M. Wulffraat.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 137<br />
Saturday, May 21
Saturday, May 21<br />
138<br />
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
<strong>Gene</strong>tic and Metabolic Diseases<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> III<br />
716<br />
Optimisation <strong>of</strong> Lentiviral Transduction Conditions<br />
<strong>of</strong> Haematopoietic Stem <strong>Cell</strong>s for Treatment <strong>of</strong><br />
Mucopolysaccharidosis Type IIIA (MPSIIIA)<br />
Ana Sergijenko, Alex Langford-Smith, Kia Langford-Smith,<br />
Rob Wynn, J. Ed Wraith, Simon Jones, Fiona Wilkinson, Brian<br />
Bigger.<br />
717<br />
Disease Improvement with Neonatal Intracranial AAV and<br />
Systemic Lentiviral <strong>Gene</strong> <strong>Therapy</strong> in Sanfilippo Syndrome<br />
Type B Mice<br />
Coy D. Heldermon, Elizabeth Qin, Kevin K. Ohlemiller, Erik D.<br />
Herzog, Carole Vogler, Mark S. Sands.<br />
718<br />
Aortic Dilatation in Mucopolysaccharisosis VII Mice<br />
Cannot Be Ameliorated by Deficiency <strong>of</strong> Cathepsin S or<br />
Matrix Metalloproteinase Activity, but Can Be Markedly<br />
Amelioraged by Marked Reductions in Expression <strong>of</strong> an<br />
As-yet-Unknown <strong>Gene</strong> That Prevents Upregulation <strong>of</strong><br />
Inflamatory Pathways<br />
Guillerme Baldo, Ruth Howe, Susan Wu, Russell Knuteen,<br />
Meera Ramamoothy, Robert Q. Meecham, Katherine Ponder.<br />
719<br />
Upregulation <strong>of</strong> Inflammatory Pathways and Proteases<br />
May Lead to Aortic Valve Insufficiency in MPS VII Dogs and<br />
Can Be Prevented with Neonatal Retroviral <strong>Gene</strong> <strong>Therapy</strong><br />
Guilherme Baldo, Paul Bigg, Susan Wu, Yuli Liu, Mark Haskins,<br />
Henri Bai, Meg Sleeper, Katherine P. Ponder.<br />
720<br />
Intra-Cerebroventricular or Intravenous Injection <strong>of</strong><br />
AAVrh10 Serotype Expressing Mouse GALC Results in<br />
Increased Life-Span and Widespread GALC Activity in CNS<br />
<strong>of</strong> a Mouse Model <strong>of</strong> Globoid <strong>Cell</strong> Leukodystrophy<br />
Mohammad A. Rafi, Han Zhi Rao, Paola Luzi, David A. Wenger.<br />
721<br />
Lentiviral Mediated Neonatal <strong>Gene</strong> <strong>Therapy</strong> for Krabbe<br />
Disease Model Mouse<br />
Hiroshi Kobayashi, Masamichi Ariga, Yohta Shimada, Sayoko<br />
Izuka, Takayuki Yokoi, Takahiro Fukuda, Takeo Iwamoto,<br />
Yoshikatsu Eto, Hiroyuki Ida, Toya Ohashi.<br />
722<br />
Efficacy <strong>of</strong> a Combined Intracerebral and Systemic <strong>Gene</strong><br />
Delivery Approach for the Treatment <strong>of</strong> a Severe Lysosomal<br />
Storage Disorder<br />
Carmine Spampanato, Elvira De Leonibus, Paola Dama,<br />
Annagiusi Gargiulo, Alessandro Fraldi, Cristina N. Sorrentino,<br />
Alberto Auricchio, Andrea Ballabio, Enrico M. Surace.<br />
723<br />
Intrathecal Administration <strong>of</strong> Type 9 AAV Vector Expressing<br />
Arylsulfatase A Is Effective for Reduction <strong>of</strong> Sulfatide<br />
Storage but Not for Correction <strong>of</strong> Neurological Deficits in<br />
Adult Metachromatic Leukodystrophy Model Mice with<br />
Overt Neurological Symptoms<br />
Noriko Miyake, Koichi Miyake, Atsushi Sakai, Motoko<br />
Yamamoto, Ayumi Endo, Hidenori Suzuki, Takashi Shimada.<br />
724<br />
Alternative Splicing <strong>of</strong> the Human Iduronate 2-Sulfatase<br />
<strong>Gene</strong> and Implications in <strong>Gene</strong> <strong>Therapy</strong><br />
Ni-Chung Lee, Wuh-Liang Hwu, Lung-Ji Chang, Yin-Hsiu Chien.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
725<br />
Preliminary Results <strong>of</strong> Molecular Cardiac Surgery Mediated<br />
Transfer <strong>of</strong> scAAV6-βARKct in a Reproducible Model <strong>of</strong><br />
Ischemic Cardiomyopathy<br />
Anthony S. Fargnoli, Michael G. Katz, Elena Marusich, Jason<br />
Abramowitz, James J. Pilla, Joseph Rabinowitz, Walter J. Koch,<br />
Charles R. Bridges.<br />
726<br />
Retroviral Vector <strong>Gene</strong> <strong>Therapy</strong> Delays Mitral Valve<br />
Regurgitation in Mucopolysaccharidosis VII Dogs But<br />
Does Not Prevent Disease Long Term Due to Failure to<br />
Completely Prevent Induction <strong>of</strong> Inflammaory Pathways<br />
Paul W. Bigg, Guillerme Baldo, Meg Sleeper, Susan Wu, Yuli<br />
Liu, Henry Bai, Patricia O’Donnell, Venkata Rokkam, Mark E.<br />
Haskins, Katherine P. Ponder.<br />
727<br />
MicroRNAs 99b, 181a and 181b Potentiate Pluripotent hES<br />
<strong>Cell</strong> Endothelial Differentiation and Comprise Part <strong>of</strong> an<br />
Endothelial <strong>Cell</strong>-MicroRNA Signature Panel<br />
Nicole M. Kane, Lynsey Howard, Raya Khanin, John McClure,<br />
Christopher R. Breen, Graeme Milligan, Andrew H. Baker.<br />
728<br />
In Vivo Functional Selection Using an AAV Library Encoding<br />
the Mouse Secretome Identifies Ghrelin as a Powerful<br />
Cardioprotective Molecule<br />
Giulia Ruozi, Serena Zacchigna, Antero Macedo, Matteo<br />
Dalferro, Antonella Falcione, Lorena Zentilin, Mauro Giacca.
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Cardiovascular <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
729<br />
Investigation <strong>of</strong> miRNA Targeting Sequences for Selective<br />
Regulated <strong>Gene</strong> <strong>Therapy</strong> in Cardiomyocytes<br />
Carolyn Haggerty, Caroline Fattah, Stuart A. Nicklin.<br />
730<br />
Myocardial Infarction-Induced Acute Inflammation Impairs<br />
Therapeutic Efficacy <strong>of</strong> Bone Marrow <strong>Cell</strong>s<br />
Xiaoyin Wang, Viola C. Lam, Daniel J. Haddad, Yan Zhang,<br />
Brian C. Clifford, Kranthi Pinnamaneni, Maya J. Bartel, Richard<br />
E. Sievers, Larry Carbone, Scott Kogan, Yerem Yeghiazarians,<br />
Michelle Hermiston, Matthew L. Springer.<br />
731<br />
AAV8-Mediated Long Term Expression <strong>of</strong> Human LCAT<br />
Significantly Improves Lipid Pr<strong>of</strong>iles in hCETP; Ldlr +/- Mice<br />
Heather H. Zhou, Zhu Chen, Donald Chu, Jose Castro-Perez,<br />
Weihua Ni, Aiwu Zhang, Mihajlo L. Krsmanovic, Dan Xie, Vinit<br />
Shah, Steven J. Stout, David G. McLaren, Alice C. Stefanni, Sang<br />
Ho Lee, Andrew S. Plump, Brian K. Hubbard, Thomas F. Vogt.<br />
732<br />
Use <strong>of</strong> a Helper-Dependent Adenoviral Vector and a<br />
Rabbit Model To Test Atheroprotective <strong>Gene</strong> <strong>Therapy</strong> with<br />
Interleukin-10<br />
Liang Du, Nagadhara Dronadula, Shinji Tanaka, David A. Dichek.<br />
733<br />
Uniform Field-Controlled Magnetic Targeting Enables<br />
Efficient Site-Specific Delivery <strong>of</strong> Endothelial Progenitor<br />
<strong>Cell</strong>s to Stented Arteries in the Rat Carotid Model <strong>of</strong><br />
Restenosis<br />
Michael Chorny, Ilia Fishbein, Richard Adamo, Robert J. Levy.<br />
734<br />
Enhancing MSC-Based VEGF <strong>Gene</strong> <strong>Therapy</strong> in Rat<br />
Myocardial Infarction Model Using Facial Amphipathic Bile<br />
Acid-Conjugated Polyethyleneimine<br />
Sun Hwa Kim, Hyeong-Ho Moom, Minhyung Lee, Ji Hoon<br />
Jeong, Donghoon Choi.<br />
735<br />
<strong>Gene</strong>tically Modified Stem <strong>Cell</strong>s for the Treatment <strong>of</strong><br />
Myocardial Infarction Using Novel Lysine-Based Nonviral<br />
Carrier System<br />
Mohamed I. Nounou, Cori Wijaya, Dongling Li, Sameer<br />
Saifuddin, Yi Zheng, Guilherme Silva, Bradley McConnell,<br />
Malavosklish Bikram.<br />
736<br />
DNA Vaccine for High Blood Pressure – Anti-Angiotensin II<br />
<strong>Therapy</strong> in Spontaneously Hypertensive Rats<br />
Hiroshi Koriyama, Hironori Nakagami, Futoshi Nakagami,<br />
Yasufumi Kaneda, Ryuichi Morishita.<br />
737<br />
Hyperhomocysteinemia-Induced Endothelial Dysfunction<br />
Does Not Accelerate Progression <strong>of</strong> Atherosclerosis in<br />
Hypercholesterolemic Mice<br />
Frank Jacobs, Eline Van Craeyveld, Stephanie C. Gordts,<br />
Ilayaraja Muthuramu, Jan Emmerechts, Marc Hoylaerts, Paul<br />
Herijgers, Bart De Geest.<br />
738<br />
Effects <strong>of</strong> Tetrahydrobiopterin and Arginine on Nitric Oxide<br />
Synthesis and ROS Production in Ad-iNOS Transduced Rat<br />
Aortic Smooth Muscle and Endothelial <strong>Cell</strong>s<br />
Scott P. Forbes, Richard F. Adamo, Ricardo Corrales, Michael<br />
Chorny, Robert J. Levy, Ilia Fishbein.<br />
739<br />
Helper-Dependent Adenovirus Is a Promising Vector for<br />
Atheroprotective <strong>Gene</strong> <strong>Therapy</strong><br />
Bo Jiang, Liang Du, Kun Qian, David A. Dichek.<br />
740<br />
Anti-Apoptotic Effects <strong>of</strong> Antibody-Protein A-HSP27 Fusion<br />
Proteins in a Rat Myocardial Infarction Model<br />
Nahyun Kim, Jung Ah Shin, Min-Ji Cha, Andrew Jackson, Ki-<br />
Chul Hwang, Priti Kumar, Sang-Kyung Lee.<br />
741<br />
Engineered Monocytes To Treat Ectopic Calcification<br />
Meiting Wu, Hsueh-Ying L. Yang, Cameron Rementer,<br />
Anthony Blau, Cecilia M. Giachelli.<br />
742<br />
HGF Plasmid Electroporation for Acute Myocardial<br />
Infarction Treatment<br />
Leonardo Pinto Carvalho, Eduardo G. Yasumura, Vivian<br />
Samoto, Priscila M. A. Denapoli, Vera Saleme, Raquel Sirvente,<br />
Christina M. Takiya, Sang W. Han.<br />
743<br />
RNA Inhibitors <strong>of</strong> Intimal Hyperlasia<br />
William H. Thiel, Bojana Stanic, Jennifer Streeter, Xiuying Liu,<br />
Francis J. Miller, Jr., Paloma H. Giangrande.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 139<br />
Saturday, May 21
Saturday, May 21<br />
140<br />
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Neurologic & Ophthalmic<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
744<br />
Human MiniPromoters To Drive Selected Expression in the<br />
Brain, Spinal Cord, and Eye; an Expanded Collection<br />
Kathleen G. Banks, Stéphanie Laprise, Andrea McLeod, Douglas<br />
J. Swanson, Li Liu, Elodie Portales-Casamar, Magdalena<br />
I. Swanson, Steven J. M. Jones, Robert A. Holt, Wyeth W.<br />
Wasserman, Daniel Goldowitz, Elizabeth M. Simpson.<br />
745<br />
Comparison <strong>of</strong> AAV-Mediated Transduction <strong>of</strong> Different<br />
Brain Structures on Enzyme Distribution and Lysosomal<br />
Storage Correction in the CNS <strong>of</strong> GM1-Gangliosidosis Mice<br />
Cara M. Weismann, Miguel Sena-Esteves.<br />
746<br />
Transport <strong>of</strong> AAV Vectors within the Brain Is Serotype<br />
Dependent<br />
Adrian P. Kells, Ernesto Aguilar Salegio, John Forsayeth,<br />
Kryst<strong>of</strong> S. Bankiewicz.<br />
747<br />
Biochemical and Histological Improvements Correlate with<br />
Post-Rescue Functional Gains after Combined AAV5 <strong>Gene</strong><br />
<strong>Therapy</strong> and Copper in a Mouse Model <strong>of</strong> Menkes Disease<br />
Anthony Donsante, Patricia M. Verfas, Elisabeth J. Rushing,<br />
Stephen G. Kaler.<br />
748<br />
Compacted DNA Nanoparticles Efficiently Transfect Retinal<br />
Pigment Epithelial <strong>Cell</strong>s and Provide Long-Term Expression<br />
Adarsha Koirala, Rasha S. Makkia, Mark J. Cooper, Muna I.<br />
Naash.<br />
749<br />
Peripheral Delta Opioid Receptor-Mediated Analgesia and<br />
Neuropathic Pain: Modulation <strong>of</strong> Receptor Expression in<br />
Primary Afferents Using Herpes Simplex Virus<br />
Husam K. Mohammad, Srinivasa Raja, Steven P. Wilson, Sarah<br />
M. Sweitzer.<br />
750<br />
The Equine Infectious Anaemia Virus-Based Lentiviral<br />
Vector Is an Effective Platform for <strong>Gene</strong> <strong>Therapy</strong> for Ocular<br />
Diseases<br />
James Miskin, Peter Widdowson, Katie Binley, Scott Ellis,<br />
Jackie de Belin, Julie Loader, Georgina Ferrige, Diana<br />
Angell-Manning, Marie Carlucci, Michelle Kelleher, Kyriacos<br />
Mitrophanous, Stuart Naylor.<br />
751<br />
Corneal <strong>Gene</strong> Delivery: Chitosan Oligomer as a Carrier <strong>of</strong><br />
CpG Rich, CpG Free, or S/MAR Plasmid DNA<br />
Eytan A. Klausner, Zhong Zhang, Suet P. Wong, Robert L.<br />
Chapman, Michael V. Volin, Richard P. Harbottle.<br />
752<br />
rAAV-Mediated shRNA Knock-Down <strong>of</strong> Alpha-Synuclein<br />
in the Rat Substantia Nigra Results in Aberrant Dopamine<br />
Handling<br />
Ronald J. Mandel, Aaron C. Rising, Tahsin Khundkar, Fredric P.<br />
Manfredsson.<br />
753<br />
Neuroprotective <strong>Gene</strong> Expression with AAV8 for Oxygen-<br />
Glycose Deprivation in Organotypic Hippocampal Culture:<br />
A Model <strong>of</strong> Ischemic Stroke<br />
Juliana Adão-Novaes, Rafael Linden, Hilda Petrs-Silva.<br />
754<br />
Direct Comparison <strong>of</strong> Administration Routes for AAV 8<br />
Mediated Ocular <strong>Gene</strong> <strong>Therapy</strong><br />
Tsutomu Igarashi, Koichi Miyake, Nagisa Asakawa, Takashi<br />
Shimada, Hiroshi Takahashi.<br />
755<br />
Interplay between SNCY and LRRK2: Development <strong>of</strong> a<br />
Double Transgenic Mouse Model for PD<br />
Xiaomin Su, Hong Cao, Howard J. Feder<strong>of</strong>f.<br />
756<br />
Chemotherapeutic Drugs Enhance rAAV2 Transduction<br />
Efficiency and Improve rAAV2-CNTF Induced<br />
Photoreceptor Survival Both In Vitro and In Vivo<br />
Qian Huang.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
757<br />
Systemic Reversal <strong>of</strong> Dominant Muscle Disease in a Mouse<br />
Model <strong>of</strong> Muscular Dystrophy<br />
Sergia Bortolanza, Davide Gabellini, Joel R. Chamberlain.<br />
758<br />
Blocking the NF-κB Pathway Enhances Mini-Dystrophin<br />
Efficiency in Dystrophin/Utrophin Deficient Mice<br />
Qing Yang, Ying Tang, Anmin Chen, Fengjin Guo, Freddie H.<br />
Fu, Johnny Huard, Bing Wang.<br />
759<br />
Human Involucrin Promoter Resists Spreading Methylation<br />
and Supports Compartment Specific <strong>Gene</strong> Expression in<br />
Engineered Skin Grafts<br />
Wei Li Di, Ekaterina Semenova, Fernando Larcher, John<br />
Harper, Adrian Thrasher, Waseem Qasim.
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Musculo-skeletal <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
760<br />
AAV2 Mediated VEGF <strong>Gene</strong> Transfer Leads to Increased<br />
Bone Formation and Remodeling <strong>of</strong> Bone Allografts<br />
Mette J. Koefoed, Alexandra G. Pedersen, Kjeld Soballe,<br />
Thomas G. Jensen, Michael Ulrich-Vinther.<br />
761<br />
<strong>Gene</strong>-and-Stem <strong>Cell</strong> <strong>Therapy</strong> for Vertebral Bone Fracture<br />
Dmitriy Sheyn, Ilan Kallai, Wafa Tawackoli, Yoram Zilberman,<br />
Amir Lavi, Susan Su, Anthony Oh, Xiaoyu Da, Zulma Gazit,<br />
Gadi Pelled, Dan Gazit.<br />
762<br />
Inactivation <strong>of</strong> Dystrophin Expression Via Cre-loxP<br />
Mediated <strong>Gene</strong> Excision<br />
Julian N. Ramos, Andrea Arnett, Brian Schultz, Jeffrey S.<br />
Chamberlain.<br />
763<br />
A Miniature Muscle Model Suitable for the Rapid Screening<br />
<strong>of</strong> Virally Delivered Transgenes<br />
Rainer Ng, Jeffrey S. Chamberlain.<br />
764<br />
Immune Tolerance Induction in Canine X-Linked Muscular<br />
Dystrophy with rAAV9-Microdystrophin Transduction<br />
Hiromi Hayashita-Kinoh, Naoko Yugeta, Hironori Okada, Yuko<br />
Nitahara-Kasahara, Tomoko Chiyo, Takashi Okada, Shin’ichi<br />
Takeda.<br />
765<br />
Interference <strong>of</strong> Myostatin and TGF-beta Signaling by<br />
Antisense-Mediated Exon Skipping in ALK4/5 Receptors<br />
Dwi U. Kemaladewi, Sandra H. van Heiningen, Annemieke<br />
Aartsma-Rus, Gert-Jan B. van Ommen, Peter ten Dijke, Peter<br />
A. C. ‘t Hoen, Willem M. H. Hoogaars.<br />
766<br />
AAV9-Mediated FKRP <strong>Gene</strong> <strong>Therapy</strong> Restores the<br />
Expression <strong>of</strong> Functional Glycosylation <strong>of</strong> α-DG<br />
Lei Xu, Pei Lu, Chi-Hsien Wang, Jianbin Li, Elizabeth Keramaris,<br />
Xiao Xiao, Qi Long Lu.<br />
767<br />
Repair <strong>of</strong> Large Bone Defects Using <strong>Gene</strong> Activated Muscle<br />
Tissue Grafts<br />
Oliver B. Betz, Volker M. Betz, Peter Augat, Volkmar Jansson,<br />
Peter E. Mueller.<br />
768<br />
Defining Outcome Measures in Sporadic IBM for a<br />
Follistatin <strong>Gene</strong> Transfer Clinical Trial<br />
Linda P. Lowes, Lindsay N. Alfano, Laurence Viollet, Xiomara<br />
Q. Rosales, Brian Kasper, K. Reed Clark, Zarife Sahenk, Kevin<br />
M. Flanigan, Jerry R. Mendell.<br />
769<br />
AAV-Based shRNA Silencing <strong>of</strong> NF-κB Ameliorates Muscle<br />
Pathologies in mdx Mice<br />
Qing Yang, Ying Tang, Kara Imbrogno, Aiping Lu, Anmin Chen,<br />
Fengjin Guo, Freddie H. Fu, Johnny Huard, Bing Wang.<br />
770<br />
Muscle Fiber Type-Predominant Promoter Activity in<br />
Lentiviral-Mediated Transgenic Mouse<br />
Tomohiro Suga, En Kimura, Yuka Morioka, Masahito Ikawa,<br />
Sheng Li, Katsuhisa Uchino, Yuji Uchida, Satoshi Yamashita,<br />
Yasushi Maeda, Jeffrey S. Chamberlain, Makoto Uchino.<br />
771<br />
Noninvasive Monitoring <strong>of</strong> Whole Body Muscle Function in<br />
Dystrophin-Deficient Dogs<br />
Jin-Hong Shin, Brian B. Greer, Chady H. Hakim, Zhihai He,<br />
Dongsheng Duan.<br />
772 ABSTRACT WITHDRAWN<br />
773<br />
Comparison <strong>of</strong> Efficacy <strong>of</strong> a Novel Double-Strand AAV2<br />
Vector Harboring VEGF cDNA to AAV-SS-VEGF: In Vitro<br />
Transgene Expression and In Vivo Application To Enhance<br />
Survival <strong>of</strong> Ischemic Flaps<br />
Xiao Tian Wang, Bella Avanessian, Qiangzhong Ma, Yuqing<br />
Tang, Heather Durfee, Paul Y. Liu.<br />
774<br />
Serum Neural <strong>Cell</strong> Adhesion Molecule (NCAM) Is<br />
Hyposialylated in Hereditary Inclusion Body Myopathy<br />
(HIBM)<br />
Yadira Valles-Ayoub, Saghi Esfandiarifard, Zeshan Khokher,<br />
Pedram Sinai, Rosangela Carbajo, Daniel No, Babak Darvish,<br />
Marvin Pietruszka, Emil Kakkis, Daniel Darvish.<br />
Cancer - Immunotherapy III<br />
775<br />
Adoptive T <strong>Cell</strong> <strong>Therapy</strong> <strong>Gene</strong>rates Tumor Escape Variants<br />
through Induction <strong>of</strong> Genomic Instability<br />
Karen Kaluza, Jill Thompson, Heather Flynn Gilmer, Darlene<br />
Knutson, Richard Vile.<br />
776<br />
<strong>Gene</strong> <strong>Therapy</strong> with a Novel Fusion Protein <strong>of</strong> Interferon<br />
Alpha and Apolipoprotein A-I Exerts Antitumor Effects<br />
Jessica Fioravanti, Jose I. Quetglas, José Medina-Echeverz,<br />
Nuria Ardaiz, Jesús Prieto, Cristian Smerdou, Pedro<br />
Berraondo.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 141<br />
Saturday, May 21
Saturday, May 21<br />
142<br />
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Cancer - Immunotherapy III<br />
777<br />
Highly Efficient and Safe Vectors for TCR <strong>Gene</strong> <strong>Therapy</strong>:<br />
Silencing <strong>of</strong> Endogenous TCR Improved Expression and<br />
Anti-Tumor Reactivity <strong>of</strong> Transduced Tumor-Specific TCRs<br />
in Human Lymphocytes<br />
Sachiko Okamoto, Hiroaki Ikeda, Hiroshi Fujiwara, Ikuei<br />
Nukaya, Hir<strong>of</strong>umi Yoshioka, Masaki Yasukawa, Hiroshi Shiku,<br />
Junichi Mineno.<br />
778<br />
Development <strong>of</strong> a Drug Resistant Immunocompetent <strong>Cell</strong>-<br />
Based <strong>Therapy</strong> To Treat Neuroblastoma and Other Cancers<br />
Anindya Dasgupta, Jordan E. Shields, Robert Moot, H. Trent<br />
Spencer.<br />
779<br />
Gold Nanoshell Induced Photothermal <strong>Therapy</strong> Ablates<br />
Primary Tumors and Enhances Anti-Tumor Activity <strong>of</strong><br />
Antigen-Specific Cytotoxic T Lymphocytes<br />
Adham S. Bear, Laura C. Kennedy, Joseph K. Young, Rebekah<br />
A. Drezek, Aaron E. Foster.<br />
780<br />
Tumor Immune Evasion Enforced by Viral cDNA Library<br />
Vaccination Can be Exploited for Ambush <strong>of</strong> Emerging<br />
Tumor <strong>Cell</strong> Variants<br />
Phonphimon Wongthida, Elizabeth Ilett, Jose Pulido, Timothy<br />
Kottke, Jill Thompson, Feorillo Galivo, Peter Selby, Alan<br />
Melcher, Richard Vile.<br />
781<br />
Adoptive Immunotherapy Using EphA2-Specific T <strong>Cell</strong>s for<br />
the Treatment <strong>of</strong> Glioblastoma Multiforme<br />
Kevin K. H. Chow, Vita S. Salsman, Sunitha Kakarla, Claudia<br />
Gerken, Yvonne Kew, Robert G. Grossman, Suzanne Z. Powell,<br />
Nabil Ahmed, Stephen M. Gottschalk.<br />
782<br />
Improved T <strong>Cell</strong> Survival, Tumor Localization and Tumor<br />
Eradication by Folate Receptor-α Redirected T <strong>Cell</strong>s Is<br />
Achieved by Provision <strong>of</strong> CD137 Costimulatory Signaling<br />
Degang Song, Silvana Canevari, Carl H. June, George Coukos,<br />
Daniel J. Powell, Jr.<br />
783<br />
BPX-101 Vaccine: Regulation <strong>of</strong> CD40 Signaling in DCs In<br />
Vivo Leads to Spiking Cytokines Correlative with Objective<br />
Responses in mCRPC Patients in a Phase I/IIa Trial<br />
David M. Spencer, Natalia Lapteva, Jan O. Kemnade, Jon M.<br />
Levitt, John McMannis, Guru Sonpavde, Kevin M. Slawin.<br />
784<br />
Pre-Clinical Safety and Toxicity Dose-Finding <strong>of</strong> a Novel Bi-<br />
Cistronic High-Capacity Adenoviral Vector Encoding Flt3L<br />
and TK: Identification <strong>of</strong> a Maximally Tolerated Dose in the<br />
Brain with Restricted Biodistribution <strong>of</strong> Vector Genomes<br />
Mariana Puntel, A. K. M. G. Muhammad, Weidong Xiong,<br />
Kyle Kelson, Alireza Salem, Kurt M. Kroeger, Chunyan Liu,<br />
Catherine Farrokhi, Liliana Lacayo, Robert N. Pechnick, Donna<br />
Palmer, Philip Ng, Maria G. Castro, Pedro R. Lowenstein.<br />
785<br />
Targeting <strong>of</strong> Myeloid Leukemia Stem <strong>Cell</strong>s through <strong>Gene</strong>tic<br />
Redirection <strong>of</strong> T <strong>Cell</strong>s Against CD44 Variant 6<br />
Monica Casucci, Laura Falcone, Barbara Camisa, Zulma<br />
Magnani, Claudio Bordignon, Barbara Savoldo, Gianpietro<br />
Dotti, Chiara Bonini, Attilio Bondanza.<br />
786<br />
<strong>Gene</strong>ration <strong>of</strong> Antigen Specific T <strong>Cell</strong>s by Transplant <strong>of</strong><br />
Human Hematopoietic Stem/Progenitor <strong>Cell</strong>s (HSPC)<br />
Transduced with a Lentiviral Vector Carrying the <strong>Gene</strong>s for<br />
a T <strong>Cell</strong> Receptor Specific for MART-1<br />
Francesca Giannoni, Cinnamon L. Hardee, Jennifer P. Wherley,<br />
Don B. Kohn.<br />
787<br />
Anti-Glioma Immune Response Induced by Conditional<br />
Cytotoxic/Immune-Stimulatory <strong>Gene</strong> <strong>Therapy</strong> Requires<br />
pDC Activation Triggered by Circulating Brain Tumor DNA<br />
Marianela Candolfi, Kader Yagiz, Karthika Balasubramanian,<br />
Mariana Puntel, Gwendalyn D. King, Yohei Mineharu, A. K.<br />
M. G. Muhammad, David Foulad, Nicholas Barnett, Kurt M.<br />
Kroeger, Pedro R. Lowenstein, Maria G. Castro.<br />
788<br />
Myeloid Derived Suppressor <strong>Cell</strong>s Expand and Infiltrate<br />
Brain Tumors in Response to Circulating Glioma-Derived<br />
Factors<br />
Marianela Candolfi, Kader Yagiz, Hikmat Assi, A. K. M. G.<br />
Muhammad, Chunyan Liu, David Foulad, Gabrielle Alzadeh,<br />
Daniel A. Pisera, Kurt M. Kroeger, Pedro R. Lowenstein, Maria<br />
G. Castro.<br />
789<br />
Enhancing CD8 T <strong>Cell</strong> Function by IL-2 Potentiates the<br />
Efficacy <strong>of</strong> a Combined Cytotoxic Immunostimulatory <strong>Gene</strong><br />
<strong>Therapy</strong> in an Aggressive Glioma Model<br />
Yohei Mineharu, A. K. M. Ghulam Muhammad, Mariana<br />
Puntel, Marianela Candolfi, Weidong Xiong, Kurt M. Kroeger,<br />
Chunyan Liu, Niyati Bondale, Pedro R. Lowenstein, Maria G.<br />
Castro.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Cancer - Immunotherapy III<br />
790<br />
Tumor-Specific Viral Inflammation Facilitates Effective<br />
Dendritic <strong>Cell</strong> Cancer Immunotherapy in a Regulatory T<br />
<strong>Cell</strong>-Dependent Manner<br />
Norman Woller, Sarah Knocke, Bettina Mundt, Engin<br />
Guerlevik, Nina Struever, Michael P. Manns, Tim Sparwasser,<br />
Stefan Kubicka, Florian Kuehnel.<br />
791<br />
Anti-Tumor Activity <strong>of</strong> Engineered T Lymphocytes<br />
Expressing an Anti-CD19 CAR for B <strong>Cell</strong> Lymphoma<br />
Tomonori Tsukahara, Ken Ohmine, Ryosuke Uchibori, Masashi<br />
Urabe, Hiroaki Mizukami, Akihiro Kume, Isabelle Riviere,<br />
Michel Sadelain, Renier Brentjens, Keiya Ozawa.<br />
792<br />
Inhibition <strong>of</strong> Experimental Colon Cancer Liver Metastasis<br />
by IL-15 Immunogene <strong>Therapy</strong><br />
Xianghui He, Dongbing Zhou, Yifeng Wang, Weidong Li, Liwei<br />
Zhu.<br />
Cancer-Oncolytic Viruses II<br />
793<br />
Antifibrotic Properties <strong>of</strong> Transarterial VSV Oncolytic<br />
<strong>Therapy</strong> for Hepatocellular Carcinoma in Rats with<br />
Thioacetamide-Induced Liver Fibrosis<br />
Jennifer Altomonte, Enrico De Toni, Irene Esposito, Claus<br />
Hellerbrand, Sabrina Marozin, Oliver Ebert.<br />
794<br />
Enhancing Therapeutic Outcome Using Radiation and<br />
Measles Infected CIK <strong>Cell</strong> Carriers for the Treatment <strong>of</strong><br />
Disseminated Multiple Myeloma<br />
Yun-Wen Chen, Chunsheng Liu, Stephen J. Russell, Kah-Whye<br />
Peng.<br />
795<br />
Treatment <strong>of</strong> Cancer with Oncolytic Adenovirus Combined<br />
with Temozolomide, an Autophagy Inducer<br />
Ilkka Liikanen, Laura Ahtiainen, Vincenzo Cerullo, Petri<br />
Nokisalmi, Sophie Escutenaire, Iulia Diaconu, Sari Pesonen,<br />
Anniina Koski, Lotta Kangasniemi, Elina Haavisto, Kaarina<br />
Partanen, Timo Joensuu, Anna Kanerva, Akseli Hemminki.<br />
796<br />
Oncolytic Virus <strong>Therapy</strong> for Bladder Cancer Using a Third-<br />
<strong>Gene</strong>ration HSV-1 Armed with Interleukin 12<br />
Jiangang Hou, Hiroshi Fukuhara, Yuzuri Tsurumaki, Yukio<br />
Homma, Yasushi Ino, Tomoki Todo.<br />
797<br />
Oncolytic Adenovirus Induces Autophagic <strong>Cell</strong> Death<br />
through an E2F1-microRNA-7-Epidermal Growth Factor<br />
Receptor Axis in Human Cancer <strong>Cell</strong>s<br />
Hiroshi Tazawa, Shuya Yano, Ryosuke Yoshida, Yuuri<br />
Hashimoto, Yasuo Urata, Toshiyoshi Fujiwara.<br />
798<br />
EGFR-Targeted and Cytosine Deaminase-Armed Measles<br />
Virus in Combination with 5-Fluorocytosine as a Novel<br />
Chemovirotherapy for Head and Neck Squamous <strong>Cell</strong><br />
Carcinoma<br />
Karim Zaoui, Sascha Bossow, Christian Groβardt, Mathias<br />
F. Leber, Christoph Springfeld, Christ<strong>of</strong> von Kalle, Peter K.<br />
Plinkert, Guy Ungerechts.<br />
799<br />
<strong>Gene</strong>ration <strong>of</strong> Fiber-Modified, Conditionally-Replicating<br />
Adenovirus Vectors Expressing the Sodium Iodide<br />
Symporter for Prostate Cancer <strong>Therapy</strong><br />
Michael J. Oneal, Miguel A. Trujillo, Julia Davydova, Masato<br />
Yamamoto, John C. Morris.<br />
800<br />
Biological Effects <strong>of</strong> Oncolytic Adenovirus on Epithelial-<br />
Mesenchymal Transition in Human Lung Cancer <strong>Cell</strong>s<br />
Yuuri Hashimoto, Shuya Yano, Hiroshi Tazawa, Ryosuke<br />
Yoshida, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara.<br />
801<br />
Targeting <strong>of</strong> Prostate Cancer <strong>Cell</strong>s with the Novel<br />
Replication-Selective Adenoviral Mutant AdΔΔ in<br />
Combination with the Phytochemical Drugs Eqoul and<br />
Resveratrol<br />
Virginie S. Adam, Daniel Oberg, Nicholas Lemoine, Gunnel<br />
Halldén.<br />
802<br />
Systemically Administered Vesicular Stomatitis Virus<br />
Induces Neurotoxicity in Myeloma-Bearing Mice<br />
Danielle N. Yarde, Rebecca A. Nace, Shruthi K. Naik, Mark J.<br />
Federspiel, Stephen J. Russell.<br />
803<br />
The Effect <strong>of</strong> Combination <strong>Therapy</strong> <strong>of</strong> Oncolytic Virus hrR3<br />
and Bevacizumab in Human Gastric Cancer<br />
Gewen Tan, Hideki Kasuya, Tevfik T. Sahin, Toshio Shikano,<br />
Suguru Yamada, Akiyuki Kanzaki, Kazuo Yamamura, Tsutomu<br />
Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Yoko Nishikawa, Shin<br />
Takeda, Akimasa Nakao.<br />
804<br />
p53-Dependent Expression <strong>of</strong> the Meganuclease I-Sce I<br />
Allow Self-Restriction <strong>of</strong> Oncolytic Adenovirus in Normal<br />
Tissue<br />
Peter Schache, Engin Guerlevik, Anneliese Goez, Nina<br />
Struever, Michael P. Manns, Stefan Kubicka, Florian Kuehnel.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 143<br />
Saturday, May 21
Saturday, May 21<br />
144<br />
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Cancer-Oncolytic Viruses II<br />
805<br />
Promoter-Mediated Replication <strong>of</strong> Adenoviruses Induces<br />
Apoptosis-Independent <strong>Cell</strong> Death in p53-Null Pancreatic<br />
Carcinoma <strong>Cell</strong>s<br />
Masatoshi Tagawa, Suguru Yamauchi, Kiyoko Kawamura,<br />
Shinya Okamoto, Shan Yang, Wen Chang Li, Hiroshi<br />
Kobayashi, Shuji Kubo, Yuji Tada, Yuichi Takiguchi, Koichiro<br />
Tatsumi, Kenzo Hiroshima, Hideaki Shimada.<br />
806<br />
Active Targeting <strong>of</strong> Bioreducible Polymer Concealing<br />
Oncolytic Adenovirus to Cancer <strong>Cell</strong>s Expressing Integrins<br />
Jaesung Kim, Hye Yeong Nam, Tae-Il Kim, Pyung-Hwan Kim,<br />
Chae-Ok Yun, Sung Wan Kim.<br />
807<br />
A Replication-Selective Adenovirus Expressing the<br />
Prodrug-Converting Enzyme CD/UPRT Efficiently Inhibits<br />
Tumour Growth in Prostate Cancer Models<br />
Maria Ekblad, Daniel Oberg, Nicholas Lemoine, Gunnel<br />
Halldén.<br />
808<br />
Oncolytic Adenoviral Vector Targeted to Hepatocellular<br />
Carcinoma Expressing Low Levels <strong>of</strong> miR-122<br />
David Sharon, Michael Shumann, Sandeep Randhawa, Mary<br />
Hitt.<br />
Cancer-Targeted <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> III<br />
809<br />
E10A, an Adenovirus Carrying Endostatin <strong>Gene</strong>, Enhanced<br />
Anti-Tumor Effect <strong>of</strong> Metronomic Chemotherapy with Low<br />
Dose Cisplatin in a Xenograft Mouse Model for Head and<br />
Neck Squamous <strong>Cell</strong> Carcinoma<br />
Zainal Adhim, Xubin Lin, Wenlin Huang, Tsutomu Nakamura,<br />
Hiroyuki Yasui, Naoki Otsuki, Ken-ichi Nibu, Masato Fujisawa,<br />
Toshiro Shirakawa.<br />
810<br />
Down-Regulation <strong>of</strong> Breast Cancer Resistance Protein<br />
(BCRP) by siRNA Delivery Using Lipid-Substituted Aliphatic<br />
Polymers<br />
Hamidreza Montazeri Aliabadi, Breanne Landry, Parvin<br />
Mahdipoor, Hasan Uludag.<br />
811<br />
Experimental <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Nasopharyngeal Carcinoma<br />
Targeted to Telomerase<br />
Wen Zhong.<br />
812<br />
Design and Hydrodynamic <strong>Gene</strong> Transfer <strong>of</strong> ‘Sticky’ IFNγ<br />
for Liver-Directed <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Hepatic Metastasis <strong>of</strong><br />
Cancer <strong>Cell</strong>s<br />
Mitsuru Ando, Yuki Takahashi, Hanae Mukumoto, Makiya<br />
Nishikawa, Yoshihiko Watanabe, Yoshinobu Takakura.<br />
813<br />
Cytokine-Based Log-Scale Expansion <strong>of</strong> Functional Human<br />
Dendritic <strong>Cell</strong>s from PBMCs<br />
Yui Harada, Satoru Saito, Yosuke Morodomi, Kumi Yoshida,<br />
Tomohiko Ichikawa, Yoshikazu Yonemitsu.<br />
814<br />
A New Method To Develop <strong>Gene</strong>tically Modified Lung<br />
Cancer Stem <strong>Cell</strong>s<br />
Feridoun Karimi-Busheri, Victoria Zadorozhny, Ali Haghighi,<br />
Daniel L. Shawler, Habib Fakhrai.<br />
815<br />
miRNA from Tumor-Associated Macrophages as Serum<br />
Biomarkers for Ovarian Cancer<br />
Jonas Persson, Ines Beyer, Nicole Urban, Charles Drescher,<br />
Andre Lieber.<br />
816<br />
Increased Invasiveness and Host Vessels Co-Option after<br />
15-LO-1 and HSV-tk Combination <strong>Gene</strong> <strong>Therapy</strong> in Rat<br />
Glioma Model<br />
Agnieszka Pacholska, Haritha Samaranayake, Jere<br />
Pikkarainen, Farizan Ahmad, Thomas Wirth, Seppo<br />
Ylä-Herttuala.<br />
817<br />
Effective Sensitization <strong>of</strong> Paclitaxel-Resistant Colorectal<br />
Cancer <strong>Cell</strong>s by New Cationic Micelle-Based Combined<br />
Delivery <strong>of</strong> Paclitaxel and XIAP siRNA<br />
Yeon Lim Jang, Ui Jeong Yun, Min Sang Lee, Myung Goo Kim,<br />
Su Young Chae, Dong-Gyu Jo, Jae Hyung Park, Ji Hoon Jeong.<br />
818<br />
c-Cbl shRNA-Expressing Adenovirus Sensitizes TRAIL-<br />
Induced Apoptosis with Less Side Effects<br />
So Y. Kim, Bo K. Sun, Seeun Oh, Dongho Kim, Joo-Hang Kim,<br />
Jae J. Song.<br />
819<br />
PEI-CyD-FA Coated Adenovirus as an Effective and Safe<br />
<strong>Gene</strong> Delivery Vector<br />
Hong Yao, Julia J. Li, Wai S. Poon, Hsiang-fu Kung, Xiu Wu<br />
Bian, Marie C. Lin.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Hematologic and Immunologic<br />
<strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> II<br />
820<br />
Tolerance Induction towards Protein <strong>Therapy</strong> Using<br />
Autologous Dendritic <strong>Cell</strong>s<br />
Gautam Sule, Masataka Suzuki, Racel Cela, John Rodgers,<br />
Brendan Lee.<br />
821<br />
Rescue <strong>of</strong> the Bleeding Diathesis in Severe Von Willebrand<br />
Disease Using Lentiviral <strong>Gene</strong> Transfer<br />
Jonathan B. Rosenberg, Bishnu P. De, Lan Wang, Stephen M.<br />
Kaminsky, Ronald G. Crystal.<br />
822<br />
Blood Outgrowth Endothelial <strong>Cell</strong>s for <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong><br />
Rheumatoid Arthritis<br />
Jeana Zacharias, Jennifer L. Auger, Liming Milbauer, Robert P.<br />
Hebbel, Bryce A. Binstadt, Nicola J. Philpott.<br />
823<br />
Factor IX Expression in Skeletal Muscle <strong>of</strong> a Subject with<br />
Severe Hemophilia B Ten Years after AAV <strong>Gene</strong> Transfer<br />
George Buchlis, Gregory M. Podsak<strong>of</strong>f, Antonetta Radu, Alan<br />
W. Flake, Federico Mingozzi, Katherine A. High.<br />
824<br />
Recombinant AAV2-Mediated β-Globin Expression in<br />
Human Fetal Hematopoietic <strong>Cell</strong>s from the Aborted Fetus<br />
with β-Thalassemia<br />
Jing Tian, Feng Wang, Jin-feng Xue, Fei Zhou, Liu-jiang Song,<br />
Meng-qun Tan.<br />
825<br />
Immune Modulation in Hemophilia A Mice Using Anti-<br />
CD20 and Liver-Directed <strong>Gene</strong> Transfer<br />
Brandon K. Sack, Babak Moghimi, Roland W. Herzog.<br />
826<br />
Differential Lineage Transduction Results in Limited FVIII<br />
Expression after Ex Vivo Modification <strong>of</strong> Hematopoietic<br />
Progenitor <strong>Cell</strong>s<br />
Jennifer M. Johnston, Christopher B. Doering, H. Trent<br />
Spencer.<br />
827<br />
Development <strong>of</strong> Novel AAV Vectors for Potential In Vivo<br />
<strong>Gene</strong> transfer to Hematopoietic <strong>Cell</strong>s in Bone Marrow<br />
Mengxin Li, Qin Su, Ran He, Hongwei Zhang, Terry Flotte,<br />
Arun Srivastava, Guangping Gao, Li Zhong.<br />
828<br />
In Vivo <strong>Gene</strong> <strong>Therapy</strong> <strong>of</strong> Hemophilia A Mice by Intra-<br />
Bone Marrow Injection <strong>of</strong> Lentiviral Vectors Containing a<br />
B-Domain Variant <strong>of</strong> Human Factor VIII<br />
Xuefeng Wang, Liping Chen, Andy Chiang, Peiqing Ye, Carol<br />
H. Miao.<br />
829<br />
Evaluation <strong>of</strong> Liver <strong>Gene</strong> <strong>Therapy</strong> by Lentiviral Vectors in a<br />
Dog Model <strong>of</strong> Hemophilia B<br />
Alessio Cantore, Martina Damo, Marco Ranzani, Lucia Sergi<br />
Sergi, Marina Radrizzani, Francesca Bellintani, Brian Brown,<br />
Eugenio Montini, Timothy Nichols, Luigi Naldini.<br />
830<br />
Targeting B <strong>Cell</strong>s To Express a Tolerogenic Fusion Protein<br />
Using Pseudotyped Lentiviral Vectors Displaying a Single<br />
Chain Antibody Against Human CD20<br />
Ai-Hong (Allan) Zhang, Nana Owusu-Boaitey, Sabrina Kneissl,<br />
Christian J. Buchholz, David W. Scott.<br />
831 (MOVED TO POSTER SESSION I AFTER ABSTRACT 269)<br />
BAFF Inhibition by Exon Skipping in Sjögren’s Syndrome<br />
Nienke Roescher, Jelle Vosters, Ghada Al Saleh, Patrick<br />
Dreyfus, Sebastien Jacques, Luis Garcia, Gilles Chiocchia,<br />
Antoine Francoise, Jean Sibilia, Paul Peter Tak, Jay Chiorini,<br />
Xavier Mariette, Jacques-Eric Gottenberg.<br />
832<br />
FIX Gain <strong>of</strong> Function Mutants Augment Hemophilia B <strong>Gene</strong><br />
<strong>Therapy</strong> To Allow Minimal AAV Vector Exposure<br />
Paul E. Monahan, Tal Kafri, William Hannah, Tong Gui,<br />
Junjiang Sun, Thipparat Suwanmanee, Scott W. McPhee, R.<br />
Jude Samulski.<br />
833<br />
Valproic Acid-Mediated Retention <strong>of</strong> High Level Expression<br />
<strong>of</strong> Potential Hematopoietic Stem <strong>Cell</strong> Markers Does Not<br />
Correlate with Enhancement <strong>of</strong> Engraftment<br />
Randall K. Merling, KuyLee Han, Colin L. Sweeney, Hongmei<br />
Wang, Joseph Marcotte, Gilda F. Linton, Sherry M. Walker,<br />
Uimook Choi, Harry L. Malech.<br />
Oligonucleotide & RNAi Therapeutics II<br />
834<br />
Specific Targeting <strong>of</strong> Prostate Cancer by an Aptamer-siRNA<br />
Chimera<br />
Craig A. Howell, William M. Rockey, Xiu Y. Liu, Daniel Vaena,<br />
Paloma H. Giangrande.<br />
835<br />
<strong>Cell</strong> Penetrating Peptide-Mediated Systemic siRNA Delivery<br />
to the Liver<br />
Jun Yamauchi, Yasuhiro Hayashi, Khalil A. Ikramy, Hidetaka<br />
Akita, Kazuaki Kajimoto, Hideyoshi Harashima.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 145<br />
Saturday, May 21
Saturday, May 21<br />
146<br />
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Oligonucleotide & RNAi Therapeutics II<br />
836<br />
Subcutaneous Delivery <strong>of</strong> Hepatocyte Targeted Sub-50 nm<br />
Nanoencapsulated siRNA Mediates <strong>Gene</strong> Silencing<br />
B. T. Kren, D. Tolbot, V. Korman, G. M. Unger.<br />
837 (MOVED TO POSTER SESSION II AFTER ABSTRACT 570)<br />
Improving the Specificity <strong>of</strong> RNAi-Based Therapeutics for<br />
Huntington’s Disease<br />
Ryan L. Boudreau, Jodi L. McBride, Ryan M. Spengler, Beverly<br />
L. Davidson.<br />
838<br />
Flexible Cationic Lipids for siRNA Delivery<br />
Jeff Sparks, Gregory Slobodkin, Richard T. Congo, David<br />
Ulkoski, Majed Matar, Angela Rea-Ramsey, Casey Pence,<br />
Jennifer Rice, Diane McClure, Kevin J. Polach, Elaine<br />
Brunhoeber, Leslie Wilkinson, Khursheed Anwer, Jason G.<br />
Fewell.<br />
839<br />
Smart Nanoparticle for MMP-7 Proximity-Activated siRNA<br />
Delivery<br />
Hongmei Li, Christopher E. Nelson, Todd D. Giorgio, Craig L.<br />
Duvall.<br />
840<br />
Experimental and Computational Design <strong>of</strong> Combinatorial<br />
RNAi Therapies Against HIV<br />
Priya S. Shah, Sharon Aviran, Nhung P. Pham, Adam P. Arkin,<br />
David V. Schaffer.<br />
841<br />
Engineered Scaffold for Sustained, Local siRNA Delivery<br />
Christopher E. Nelson, Mukesh K. Gupta, Elizabeth J. Adolph,<br />
Scott A. Guelcher, Craig L. Duvall.<br />
842<br />
RNAi <strong>Therapy</strong> for Polyglutamine Expansion Disorders<br />
Pavitra Narasimha, Ryan L. Boudreau, Ryan M. Spengler,<br />
Beverly L. Davidson.<br />
843<br />
Combining Tumor-Targeting, <strong>Gene</strong> Silencing, and siRNA-<br />
Mediated Cytokine Induction in a Viral Capsid-Derived<br />
Nanoparticle<br />
David Chu, Jae Youn Hwang, Jay Lubow, Altan Rentsendorj,<br />
Lali Medina-Kauwe.<br />
844<br />
The Effect <strong>of</strong> Nan<strong>of</strong>iber Topography on Astrocyte Behavior<br />
In Vitro and the Potential Application for siRNA Delivery for<br />
CNS Regeneration<br />
Haoqing Cao, Guillaume Marcy, Eyleen Lay Keow Goh, Jun<br />
Wang, Sing Yian Chew.<br />
845<br />
Inhibition <strong>of</strong> PCBP2 Reverses the Fibrogenic Effect <strong>of</strong><br />
Alcohol on Hepatic Stellate <strong>Cell</strong>s<br />
Ravi S. Shukla, Shaoying Wang, Kun Cheng.<br />
846<br />
Expanded CAG Repeats Enhance the Production <strong>of</strong> a<br />
Pathogenic Cav2.1 Splice Variant That Can Be Selectively<br />
Targeted Using RNAi<br />
Wei-Ling Tsou, Bing-Weng Soong, Henry L. Paulson, Edgardo<br />
Rodriguez-Lebron.<br />
847<br />
Apolipoprotein B Knock-Down by AAV-Delivered sh/miRNA<br />
Lowers Plasma Cholesterol in Mice<br />
Piotr Maczuga, Annemart Koornneef, Richard van<br />
Logtenstein, Florie Borel, Bas Blits, Sander van Deventer,<br />
Harald Petry, Pavlina Konstantinova.<br />
848<br />
Double-Stranded Let-7 Mimics, Potential Candidates for<br />
Cancer <strong>Gene</strong> <strong>Therapy</strong><br />
Qizhao Wang, Chao Lu, Weidong Xiao, Ruian Xu.<br />
849<br />
Effective in vivo silencing for therapeutic application using<br />
serum stabilized, non-immunogenic and potent chemically<br />
modified siRNAs<br />
Nitin Puri, Chris Burnett, Sasha Vlassov, Angie Cheng, Varun<br />
Bagai, Xavier de Mollerat du Jeu, Kristin Wiederholt, Susan<br />
Magdaleno.<br />
850<br />
RNA Interference Effects on Neuronal Nitric Oxide Synthase<br />
Enzyme (nNOS) from Glioma <strong>Cell</strong>s in Culture<br />
Fernando F. B. Resende, Elaine Del Bel, Luis Pardo, Walter<br />
Stühmer, Ricardo Titze-de-Almeida.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
851<br />
Silencing the Expression <strong>of</strong> the alpha Is<strong>of</strong>orm <strong>of</strong> the<br />
Neuronal Nitric Oxide Synthase Enzyme (nNOS) in<br />
Neuroblastoma <strong>Cell</strong>s by Synthetic Double-Stranded siRNA<br />
Linus Q. Pereira, Luciana M. Klüppel, Nádia R. Ferreira,<br />
Simoneide S. Silva, Luis Pardo, Walter Stühmer, Elaine Del Bel,<br />
Ricardo Titze-de-Almeida.<br />
Stem <strong>Cell</strong> Therapies III<br />
852<br />
Similarities between Cancer Stem <strong>Cell</strong>s and Induced<br />
Pluripotent Stem <strong>Cell</strong>s<br />
Ruan van Rensburg, Robert Strauss, Ines Beyer, Oleg<br />
Denisenko, Karol Bomsztyk, Andre Lieber.<br />
853<br />
Transcriptional Analysis <strong>of</strong> Human Embryonic Stem<br />
<strong>Cell</strong>s and Vascular Endothelial <strong>Cell</strong>s Derived Via Directed<br />
Differentiation<br />
Lynsey Howard, Nicole M. Kane, Martin W. McBride, John<br />
McClure, Peter D. Adams, Tony McBryan, Graeme Milligan,<br />
Andrew H. Baker.<br />
854<br />
An In Vitro Analog <strong>of</strong> the Primitive Streak To Derive High-<br />
Purity Definitive Endoderm Lineages Uncontaminated by<br />
Undifferentiated <strong>Cell</strong>s<br />
Larissa Agapova, Richard West, Alina Ostrowska, Ruslan<br />
Semechkin, Vladimir Agapov, Irina Turovets, Olga Kochetkova,<br />
Jeffrey Janus, Andrey Semechkin, Nikolay Turovets.<br />
855<br />
Peptide Based Bone Marrow Targeting <strong>of</strong> Cord Blood <strong>Cell</strong>s<br />
Thomas J. Kean, James E. Dennis.<br />
856 ABSTRACT WITHDRAWN<br />
857<br />
Donor Dependency <strong>of</strong> Integrin-and Chemokine Mediated<br />
Adhesion Activation in Human Mesenchymal Stromal <strong>Cell</strong>s<br />
(MSCs)<br />
Felicia Ciuculescu, Melanie Giesen, Victoria Lang, Reinhard<br />
Henschler.<br />
858<br />
Human Liver Endothelial <strong>Cell</strong>s, but Not Macrovascular or<br />
Microvascular Endothelial <strong>Cell</strong>s, Can Inhabit the Mouse<br />
Liver Sinusoidal Endothelial Niche<br />
Ebtisam E. l. Filali, Johan Hiralall, Donna B. Stolz, Jurgen<br />
Seppen.<br />
859<br />
Immune Modulation and Control <strong>of</strong> GvHD by Mesenchymal<br />
Stem <strong>Cell</strong>s<br />
Lung-Ji Chang, Yin Liang, Weng Hang Ho, Jian-Ping Zhang,<br />
Jing-Bo Wang, Tong Wu, Chun-Rong Tong, Lu-Jia Dong, Dao-<br />
Pei Lu.<br />
860<br />
Highly Efficient Neural Lineage Induction and <strong>Gene</strong>ration<br />
<strong>of</strong> Neural Progenitor <strong>Cell</strong>s Via an Aggrewell Embryoid<br />
Body Formation System with a Novel Neural Induction<br />
Medium<br />
Alexandra A. Blak, Jennifer Antonchuk, Eileen Yoshida, Mark<br />
Fairy, Terry E. Thomas, Allen C. Eaves, Sharon A. Louis.<br />
861<br />
Oncogenic Risk <strong>of</strong> Induced Pluriptent Stem <strong>Cell</strong>s<br />
Established from Somatic <strong>Cell</strong>s with Chromosome<br />
Instability<br />
Saori Yamaguchi, Tomotoshi Marumoto, Takenobu Nii,<br />
Hirotaka Kawano, Jiyuan Liao, Yoko Nagai, Michiyo Okada,<br />
Atsushi Takahashi, Hiroyuki Inoue, Erika Sasaki, Shinji Okano,<br />
Yoshie Miura, Kenzaburo Tani.<br />
862<br />
Hypoxia Inhibits Senescence and Maintains Mesenchymal<br />
Stem <strong>Cell</strong> Properties through Downregulation <strong>of</strong> E2A-p21<br />
by HIF-TWIST<br />
Chih-Chien Tsai, Yann-Jang Chen, Tu-Lai Yew, Shih-Chieh<br />
Hung.<br />
863<br />
IPS Technology and It’s Implications for <strong>Gene</strong> and <strong>Cell</strong><br />
<strong>Therapy</strong><br />
Duanqing Pei.<br />
864<br />
A GMP-Compliant Process for the Scale-Up and Large Scale<br />
Banking <strong>of</strong> Human Embryonic Stem <strong>Cell</strong>s<br />
Lara J. Ausubel, Patricia Lopez, Rui-Lin Wu, Tania Aguilar,<br />
Jing Chai, Wei Dang, Patricia Huang, Rafat Khan, Derek Kong,<br />
Robbin Wesselschmidt, David Hsu, Larry Couture.<br />
865<br />
Safeguarding Nonhuman Primate iPS <strong>Cell</strong>s with Suicide<br />
<strong>Gene</strong>s<br />
Bonan Zhong, Korashon L. Watts, Martin E. Wohlfahrt,<br />
Jennifer E. Adair, Joerg Enssle, Hans-Peter Kiem.<br />
866<br />
Bone Marrow Derived Stem <strong>Cell</strong>s Involved in Regeneration<br />
<strong>of</strong> Epithelial <strong>Cell</strong>s through <strong>Cell</strong> Fusion<br />
Yi-ling Hsu, Xianghui He, Wei Wei, Zhixiang Zhang, Liwei Zhu.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 147<br />
Saturday, May 21
Saturday, May 21<br />
148<br />
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Late Abstracts III<br />
911<br />
Pancreatic Cancer-Selective Adenovirus Vector with<br />
Redesigned AB-loop Isolated via Adenovirus Library<br />
Screening Shows Specificity to Mesothelin Expressing <strong>Cell</strong>s<br />
Yoshiaki Miura, Eric Brown, Julia Davydova, Masato<br />
Yamamoto.<br />
912<br />
Retargeting <strong>of</strong> Adenovirus to Breast Cancer<br />
Shilpa Bhatia, Ana Nedeljkovic-Kurepa, Yoshi Odaka, Angel A.<br />
Rivera, Alexander Perebeov, David T. Curiel, J. Michael Mathis.<br />
913<br />
Targeting Tumor Heterogeneity in Glioblastoma: Bispecific<br />
T <strong>Cell</strong>s Exhibit Enhanced Effector Functions and Offset<br />
Antigen Loss Escape Variants<br />
Meenakshi Hegde, Eric Yvon, Aidin Ashoori, Malini<br />
Mukherjee, Kevin KH Chow, Claudia Gerken, Vita S Salsman,<br />
Helen E Heslop, Stephen Gottschalk, Nabil Ahmed.<br />
914 (MOVED TO POSTER SESSION I AFTER ABSTRACT 175)<br />
Intracellular Trafficking <strong>of</strong> a Histone-Mimetic Polyplex to<br />
Promote Nucleus-Specific Self-Unpackaging<br />
Meghan J. Reilly, John D. Larsen, Millicent O. Sullivan.<br />
915<br />
Neural Stem <strong>Cell</strong>-Based Carrier Enhances Antitumor<br />
Activity <strong>of</strong> Oncolytic Adenovirus and Prolongs Survival in a<br />
Orthotopic Murine Model <strong>of</strong> Human Glioblastoma<br />
Atique U. Ahmed, Nikita G. Alexiades, Bart Thaci, Yu Han, Ilya<br />
I. Ulasov, Maciej S. Lesniak.<br />
916<br />
A Recombinant Vaccinia Virus-Based T <strong>Cell</strong> Vaccine Against<br />
Influenza Virus Reduces Lung Viral Load Upon Virus<br />
Challenge<br />
Alan G. Goodman, Susana Guerra, Aneesh Vijayan, Paul P.<br />
Heinen, Carlos Oscar S. Sorzano, Mariano Esteban.<br />
917<br />
Engineering Attenuated Salmonella Typhimurium for<br />
Selective Targeting and <strong>Gene</strong> Expression in Myocardial<br />
Infarction<br />
Uyenchi N. Le, Jihwa Chung, Dukmi Kim, Jung-Joon Min.<br />
918<br />
Combined Effects <strong>of</strong> Hematopoietic Progenitor <strong>Cell</strong><br />
Mobilization from Bone Marrow by G-CSF and AMD3100,<br />
and Chemotaxis into the Brain Using SDF-1α in an<br />
Alzheimer`s Disease Mouse Model<br />
Hee Kyung Jin, Jae-Sung Bae.<br />
919<br />
Effect <strong>of</strong> a Novel Peptide Antagonizing NF-κB p65 on<br />
Maturation <strong>of</strong> Dendritic <strong>Cell</strong>s and Collagen-Induced<br />
Arthritis in Mice<br />
Huaping Liang, Yanhua Li, Xia Fan, Chun Zhang.<br />
920<br />
Over Expression <strong>of</strong> Bcl-2 Enhance Preservation <strong>of</strong> Spleen<br />
Cytoarchitecture and Promotes Lymphocyte Proliferation<br />
Francisco Martínez-F, JL Ventura-Gallegos, L Covarrubias,<br />
Erendira Estrada-V, Epifanio Cruz, M Legorreta–Herrera, A<br />
Zentella-Dehesa.<br />
921<br />
AAV Transduction Reduces Adult Neurogenesis in<br />
Hippocampus in Mice<br />
Wenting Chang, Shinghua Ding.<br />
922<br />
Development <strong>of</strong> DNA Vaccine against Avian Influenza A<br />
Virus (H5N1)<br />
Shaheen Ahmed, Tatiana K. Bronich, Alexander V. Kabanov.<br />
923<br />
Electoporation-Mediated Kallistatin <strong>Gene</strong> <strong>Therapy</strong><br />
Protected TNBS-Induced Colitis and CCl4-Induced Liver<br />
Fibrosis In Vivo<br />
Yong Diao, Yinghui Lv, Qizhao Wang, Ruian Xu.<br />
924<br />
Mesenchymal Stem <strong>Cell</strong>-Conditioned Medium Facilitates<br />
Angiogenesis and Fracture Healing in Diabetic Rats<br />
Chien-Yuan Wang, Hsiao-Bai Yang, Ling-Lan Chen, Chih-Chien<br />
Tsai, Kuo-Shu Tsai, Tu-Lai Yew, Yi-Hsuan Kao, Shih-Chieh<br />
Hung, Ying-Jiin Wang.<br />
925<br />
Inhibition <strong>of</strong> PI3K-AKT Pathway Promotes Hemangioblasts<br />
Differentiation <strong>of</strong> Common Marmoset Embryonic Stem<br />
<strong>Cell</strong>s.<br />
Takenobu Nii, Tomotoshi Marumoto, Hirotaka Kawano, Saori<br />
Yamaguchi, Yoko Nagai, Yoshie Miura, Jiyuan Liao, Mishiyo<br />
Okada, Kenzaburo Tani.<br />
926<br />
siRNA/shRNA Delivery Using Chitosan Derivatives for Lung<br />
Cancer <strong>Therapy</strong><br />
Hu-Lin Jiang, You-Kyoung Kim, Kyeong-Nam Yu, Seung-Hee<br />
Chang, Chong-Su Cho, Myung-Haing Cho.<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Directory Saturday, May 21, 2011<br />
POSTER SESSION III — continued<br />
6:15 PM – 8:15 PM<br />
Room: Hall 4B<br />
Late Abstracts III<br />
927<br />
Divalent DNA or Subunit Vaccines Against Infectious Bursal<br />
Disease and Infectious Bronchitis in Chickens<br />
Ming-Kun Hsieh, Kuang-Chung Chu, Jui-Hung Shine, Cheng-<br />
Yan Chen, Jin-Lin Liao.<br />
928<br />
Dendrimers as Nanovectors for DNA and siRNA Delivery:<br />
Promises and Challenges<br />
Xiaoxuan Liu, Miriam Yammine, Palma Rocchi, Catherine<br />
Nguyen, Ling Peng.<br />
929<br />
Beclin1 Regulates Radiation-Induced Osteopontin in<br />
Human Lung Cancer <strong>Cell</strong>s<br />
Seung-Hee Chang, Arash Minai-Tehrani, Ji-Young Shin, Sung-<br />
Jin Park, Ji-Eun Kim, Kyeong-Nam Yu, Myung-Haing Cho.<br />
930<br />
Study on Mutations <strong>of</strong> Pre-S/S Protein <strong>of</strong> Occult Hepatitis B<br />
Virus from Blood Donors<br />
Xin Zheng, Baocheng Yang, Weigang Zhu, Liang Lu, Xianlin<br />
Ye, Chengyao Li.<br />
931<br />
Nucleic Acid Amplification Testing (NAT) for Blood<br />
Screening in Shenzhen, China<br />
XL Ye, BC Yang, WG Zhu, X Zheng.<br />
932<br />
A 48 Year Old Woman with a Rare Case <strong>of</strong> a Midline<br />
Destructive Disease Presenting as Having Both Midline and<br />
Nonmidline Lesions – A Case Report<br />
Stephanie. Fernandez, Felycette G. Lapus, Marie Yvette Barez.<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 149<br />
Saturday, May 21
150<br />
Abstract Author Index<br />
A<br />
Aaronson, Naomi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Aartsma-Rus, Annemieke. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765<br />
Abbasi, Meysam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
Abdul-Razak, Hayder H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Abel, Tobias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386<br />
Abramihina, Tatiana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100<br />
Abramowitz, Jason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725<br />
Adachi, Kei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126, 397, 407, 659<br />
Adair, Jennifer E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .191, 342, 865<br />
Adam, Virginie S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214, 801<br />
Adamo, Richard F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 738<br />
Adamo, Richard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 733<br />
Adams, Matthew S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Adams, Peter D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 853<br />
Adão-Novaes, Juliana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 753<br />
Adhim, Zainal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Adjali, Oumeya. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />
Adler, Cheryl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44<br />
Adolph, Elizabeth J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 841<br />
Afia, Larbi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133, 551<br />
AFM-Sponsored Duchenne Consortium, The . . . . . . . . . . . . . . . 72<br />
Agapov, Vladimir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 854<br />
Agapova, Larissa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 854<br />
Agbandje-McKenna, Mavis . . . . . . . . . . .1, 327, 328, 329, 330, 332,<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 374, 396, 402, 670<br />
Agdelo, Carlos G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581<br />
Aggen, David H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356<br />
Aguilar Salegio, Ernesto . . . . . . . . . . . . . . . . . . . . . . . . . .206, 647, 746<br />
Aguilar, Jason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Aguilar, Kiefer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 494<br />
Aguilar, Laura K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Aguilar, Tania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Aguilar-Cordova, Estuardo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Ahlroth, Mervi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109<br />
Ahmad, Farizan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 816<br />
Ahmad, Ferhaan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 659<br />
Ahmed, Atique U. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 915<br />
Ahmed, Nabil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 496, 781, 913<br />
Ahmed, Seemin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555, 649<br />
Ahmed, Shaheen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 922<br />
Ahn, Miwon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 889<br />
Ahouansou, Ornella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Ahtiainen, Laura. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295, 795<br />
Aiuti, Alessandro . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264, 267, 604, 605<br />
Aizawa, Emi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315<br />
Akabarpur, Mahzad . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290<br />
Akin, Ali . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535<br />
Akita, Hidetaka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 835<br />
Akiyoshi, Kazunari . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434<br />
Al Saleh, Ghada . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Aladjem, Mirit I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302<br />
Alameh, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 881<br />
Alexiades, Nikita G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 915<br />
Alfano, Lindsay N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 768<br />
Alfaro, Carlos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Al-Hendy, Ayman. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 243<br />
Ali, Rehan S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 541<br />
Aliabadi, Hamid M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
Alkhatib, Ghalib . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211<br />
Allay, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Allay, James A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587<br />
Allen, Cory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 365<br />
Allen, James M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 466<br />
Allen, James. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Allgayer, Heike . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Alluin, Jessica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559<br />
Almeida, Luciana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428<br />
Almeida-Porada, G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 873<br />
Almutairi, Adah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436<br />
Altomonte, Jennifer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 793<br />
Alton, Eric W. F. W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165, 272<br />
Alton, Eric W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108<br />
Alvarez-Breckenridge, Christopher. . . . . . . . . . . . . . . . . . . . . . . . . 362<br />
Alzadeh, Gabrielle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .59, 788<br />
Ambach, Dianna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Ambrosi, Alessandro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264<br />
Ameli, Masoud . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 897<br />
Amendola, Mario. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93<br />
Ameres, Stefan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555<br />
Amirache, Fouzia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 876, 893<br />
Amouri, Rim. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
An, Dong Sung. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Anagnostopoulos, Achilles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Andel, J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Anderson, Athena. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489<br />
Anderson, Joseph S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24<br />
Anderson, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496<br />
Andersson, Helen A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225<br />
Ando, Dale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544, 598<br />
Ando, Mitsuru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 812<br />
Andreeff, Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533<br />
Anegon, Ignacio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />
Ang, Sonny O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353<br />
Ang, Sonny. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234, 500<br />
Ang, SooFan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Angell-Manning, Diana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
Angello, John C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36<br />
Anguela, Xavier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Anikster, Yair. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457<br />
Anne, Moon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599<br />
Annoni, Andrea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290, 377<br />
Annunziata, Patrizia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 665<br />
Anson, Don S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 273, 281<br />
Antin, Joseph . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Antonchuk, Jennifer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 860<br />
Antoniou, Michael N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253<br />
Anwer, Khursheed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Aoki, Kazunori. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235, 674<br />
Aoki, Yoshitsugu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 558<br />
Aoyagi, Yasuyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
Aoyagi, Yutaka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 705<br />
Appelt, Jens-Uwe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 46<br />
Appelt, U. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Aramaki, Yukihiko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483<br />
Aras, Rahul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Arbuthnot, Patrick. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208, 556, 563<br />
Ardaiz, Nuria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 776<br />
Arens, Anne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223, 632<br />
Ariga, Masamichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 721<br />
Arkin, Adam P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 840<br />
Armendariz, Juan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 681<br />
Armendariz-Borunda, Juan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420<br />
Armentano, Donna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Armstrong, Adam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311<br />
Armstrong, Leonard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 525<br />
Arndt, Stefanie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506<br />
Arnett, Andrea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 475, 762<br />
Arnoud, Sylvain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 576<br />
Aronovich, Elena L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14<br />
Arsenakis, Minas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Arthur, Julian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 646<br />
Artus, Alexandre. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383, 389<br />
Arulmuthu, Eugene R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450<br />
Arumugam, Paritha I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613<br />
Arya, Suresh K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217<br />
Asad, Sabah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 897<br />
Asada, Sakiyo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
Asakawa, Nagisa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 754<br />
Ascenzi, Mary A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Ashoori, Aidin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496, 913<br />
Aslanidi, George V.. . . . . . . . . . . . . . . . . . . . . . . . . . . 330, 402, 406, 619<br />
Aso, Masayuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
Asokan, Aravind. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328, 393<br />
Assi, Hikmat H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510<br />
Assi, Hikmat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 788<br />
Astolfi, Melina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 699<br />
Astrakhan, Alexander. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260, 349<br />
Asuri, Prashanth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122<br />
Athanasiou, Evangelia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Atkinson, Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669<br />
Atkinson, Peter W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Au, Betty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 551<br />
Au, Joyce. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640, 678<br />
Aubourg, Patrick . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42, 195, 611<br />
Aubrecht, Jiri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Audit, Muriel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .51, 589<br />
Augat, Peter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 469, 767<br />
Auger, Jennifer L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 822<br />
Auricchio, Alberto . . . . . . . . . . . . . . . . . . . . . . . . . . . 454, 542, 665, 722<br />
Ausubel, Lara J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Avanessian, Bella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 773<br />
Aviran, Sharon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 840<br />
B<br />
Baban, Chwanrow. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535<br />
Baccarini, Alessia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
Badding, Melissa A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173<br />
Badea, Ildiko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182<br />
Badie, Behnam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351<br />
Bading, James. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351<br />
Bae, Hyun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 856<br />
Bae, Jae-Sung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 918<br />
Baehr, Wolfgang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199<br />
Baert, Miranda R. M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Bagai, Varun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 849<br />
Bagarazzi, Mark. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Bai, Henri. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 719<br />
Bai, Henry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 726<br />
Bai, Shoumei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
Baiker, Armin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413<br />
Baker, Andrew H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6, 727, 853<br />
Baker, David. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />
Baker, Henry J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 646<br />
Baker, Matthew . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
Bakker, Andrew . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133, 551<br />
Balaj, Leonora . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130<br />
Balasubramanian, Karthika . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 787<br />
Baldo, Guilherme. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .718, 719, 726<br />
Bali, Deeksha S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338<br />
Ball, Claudia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Ballabio, Andrea. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 722<br />
Baltimore, D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Baltimore, David. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 494<br />
Ban, Hiroshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103, 577<br />
Bandyopadhyay, Sarmistha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561<br />
Banfi, Sandro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 542, 665<br />
Bangio, Livnat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 885<br />
Bankiewicz, Kryst<strong>of</strong> S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39, 206, 746<br />
Bankiewicz, Kryst<strong>of</strong> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 647<br />
Banks, Glen B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 466, 472<br />
Banks, Glen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Banks, Kathleen G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Barayni, Lajos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592<br />
Barber, Glen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 360, 888<br />
Barez, Marie Yvette . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 932<br />
Baricordi, Cristina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264<br />
Barker, Jenny . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 634<br />
Barnay-Toutain, Frédéric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589<br />
Barnett, Nicholas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 787<br />
Barnett, Rebecca C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 280<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 151
152<br />
Abstract Author Index<br />
Barrera-L, Araceli . . . . . . . . . . . . . . . . . . . . . . . . . . . . 886, 887, 894, 895<br />
Barry, Elizabeth A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 656<br />
Barry, Michael A.. . . . . . . . . . . . . . . . . . . . . . . 8, 60, 209, 414, 488, 658<br />
Bartel, Maya J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Bartel, Melissa A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122<br />
Bartholomae, Cynthia C.. . . . . . . . . . . . .42, 264, 607, 610, 611, 632<br />
Bartlett, David L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599<br />
Bartlett, Jeffrey S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 662<br />
Barve, Minal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Basner-Tschakarjan, E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Basu, Gaurav . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 708, 711<br />
Batshaw, Mark. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340<br />
Bauer, Gerhard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24<br />
Bauer, Jr., Thomas R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 258<br />
Bauer, Thomas R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613<br />
Baum, Bruce J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 642, 657<br />
Baum, Christopher . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 348, 369<br />
Bear, Adham S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .84, 779<br />
Beard, Brian C.. . . . . . . . . . . . . . . . . . . . . .251, 257, 342, 344, 485, 637<br />
Beattie, S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Beaudet, Arthur . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 45, 277<br />
Bechtle, Marina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 394<br />
Becker, Pamela S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191<br />
Bedayat, Arash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Bedell, Cynthia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Begum, Laila . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 477<br />
Behin, Anthony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Behlke, Mark A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271<br />
Behr, Jean-Paul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 638<br />
Behr, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139<br />
Beletkaia, Elena A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Beley, Cyriaque. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661<br />
Bell, Christie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326<br />
Bell, Jason B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14<br />
Bell, John C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50<br />
Bell, Peter . . . . . . . . . . . . . . . . . . . . .102, 186, 196, 292, 326, 340, 621<br />
Bellezza, Christine A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Bellintani, Francesca. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 829<br />
Beltejar, Michael J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 676<br />
Belur, Lalitha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 702<br />
Ben Assaf, Lior. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320<br />
Ben David, Shiran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 370<br />
Benedicenti, Fabrizio . . . . . . . . . . . . . . . . . . . . . . . . 606, 607, 610, 611<br />
Benito, Alberto . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Benjamin, Shimon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 370<br />
Bennett, Antoinette D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670<br />
Bennett, C. Frank . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Bennett, Jean . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196, 600<br />
Bennett, William. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336<br />
Bennicelli, Jeannette . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600<br />
Benrashid, Ehsan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567<br />
Benten, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Benveniste, Olivier. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Bergen, Jamie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 654<br />
Berger, Mitchel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Bernstein, Wendy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Berraondo, Pedro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 776<br />
Berretti, Silvia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Berry, Charles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9<br />
Bertin, Terry K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54<br />
Bertolotti, Roger. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324, 583<br />
Bertoni, Carmen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71, 470<br />
Bertrand, Claudia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5<br />
Betts, Michael R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
Betz, Oliver B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .469, 482, 767<br />
Betz, Volker M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .469, 482, 767<br />
Bevan, Adam K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392<br />
Beyer, Ines . . . . . . . . . . . . . . . 2, 18, 78, 135, 226, 497, 578, 815, 852<br />
Beyer, Janine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39<br />
Bezuidenhout, Abraham J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Bezuidenhout, Deon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629<br />
Bhagwat, Anand . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Bhakta, Vipul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529<br />
Bharathan, Mini . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883<br />
Bhatia, Shilpa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 530, 912<br />
Bhaumik, Srabani. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 644, 645<br />
Bi, Meixia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883, 899<br />
Bian, Ang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680<br />
Bian, Xiu Wu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 819<br />
Bian, Yixin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218<br />
Biasco, Luca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264, 604<br />
Biassoni, Lorenzo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
Biehl, Martin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594<br />
Biffi, Alessandra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604, 611<br />
Bigey, P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Bigg, Paul W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 719, 726<br />
Bigger, Brian W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336<br />
Bigger, Brian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716<br />
Biju, K. C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202<br />
Bikram, Malavosklish . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735<br />
Bilchuk, Natalia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Binder, Gwendolyn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Bindra, Ranjit S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
Binley, Katie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
Binstadt, Bryce A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 822<br />
Bird, Andrew . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338, 339<br />
Bird, Andy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289<br />
Bisch<strong>of</strong>, Daniela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 590<br />
Bisch<strong>of</strong>f, Loraine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334<br />
Biswas, Arijit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />
Blackmon, Shanda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496<br />
Blak, Alexandra A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 860<br />
Blasczyk, Rainer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Blau, Anthony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 741<br />
Blau, C. Anthony. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251, 426<br />
Blazar, Bruce R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 686<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Bleier, Stephanie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Blevins, Katherine S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159<br />
Blits, Bas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564, 847<br />
Block, Gregory J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 531<br />
Bloomston, Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Boccalatte, Francesco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
Boelens, JaapJan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 715<br />
Bogan, Brooke T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Bogan, Dan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52<br />
Bogan, Janet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52<br />
Böhm, Marie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Boisgérault, Florence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Boisvert, Christopher . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404<br />
Boivert, Sébastien . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428<br />
Bolcato-Bellemin, Anne-Laure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 638<br />
Bollard, Catherine M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20, 496<br />
Bolt, Livia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
Bolyard, Chelsea M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 662<br />
Bomsztyk, Karol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 578, 852<br />
Bond, Wesley S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137<br />
Bondale, Niyati . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 789<br />
Bondanza, Attilio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80, 498, 605, 785<br />
Bone, Robert N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459<br />
Bonini, Chiara . . . . . . . . . . . . . . . . . . . . . . . . . . . .80, 498, 605, 631, 785<br />
Bonnet, Marie-Elise. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 638<br />
Bonvento, Gilles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Bordignon, Claudio. . . . . . . . . . . . . . . . . . . . . . . . . . 498, 588, 605, 785<br />
Borel, Florie . . . . . . . . . . . . . . . . . . . . . . . . . . . . 562, 564, 566, 569, 847<br />
Borquez-Ojeda, Oriana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Bortolanza, Sergia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 757<br />
Borzone, Roberta. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 460<br />
Bosch, Assumpció. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 417<br />
Bosma, Bas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />
Bossow, Sascha. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 514, 521, 528, 798<br />
Bosticardo, Marita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Botbol, Yaïr . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389<br />
Boudreau, Ryan L. . . . . . . . . . . . . . . . . . . . . . . . . . . . 198, 650, 837, 842<br />
Boulad, Farid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263<br />
Boulet, Sabrina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Boulis, Nicholas M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651, 907<br />
Bouquet, Celine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Bourget, Lucie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381<br />
Bovolenta, Chiara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588<br />
Bowen, Nathan J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628<br />
Bowers, William . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39<br />
Bowersock, Joscelyn E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
Boyd, Surina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185<br />
Boye, Sanford L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199, 203<br />
Boye, Shannon E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199<br />
Boyer, Jean. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Boyer, Joshua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Boyer, Julie L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 653<br />
Boztug, Kaan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Bradbury, Allison M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194, 646<br />
Bradshaw, Angela C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6<br />
Brady, Troy L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 635<br />
Brady, Troy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 266, 621<br />
Brasil, Sandra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557<br />
Brault, Michelle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .260, 349, 687<br />
Braun, Lyndsey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392<br />
Brayman, Andrew A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623, 625<br />
Breakefield, Xandra O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130<br />
Bréaut, Léa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Bredius, Robbert G. M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Breen, Christopher R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 727<br />
Breier, Georg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249<br />
Breinholt, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3<br />
Breitbach, Caroline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50<br />
Breitbart, Eyal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 885<br />
Brem, Henry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
Bremer, William G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69<br />
Brenner, Lara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591<br />
Brenner, Malcolm K. . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 496, 503, 513<br />
Brennig, Sebastian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369<br />
Brentjens, Renier J. . . . . . . . . . . . . . . . . . . . . . . . . . . 230, 239, 495, 791<br />
Bridges, Charles R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725<br />
Bright, Richard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281<br />
Brigida, Immacolata . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264, 605<br />
Bringas, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 647<br />
Brisson, Diane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183<br />
Broccoli, Vania. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93, 631<br />
Broderick, Jennifer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555<br />
Broderick, Kate E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429, 701<br />
Bronich, Tatiana K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 922<br />
Brown, Brian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37, 829<br />
Brown, Christine E. . . . . . . . . . . . . . . . . . . . . . . . . . . 351, 352, 499, 501<br />
Brown, Eric J. . . . . . . . . . . . . . . . . . . . 58, 146, 241, 525, 673, 674, 911<br />
Brown, Kyle E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561<br />
Brown, Matthew T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422<br />
Brown, Paige K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176<br />
Brown, Sarah M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328, 393<br />
Brugiere, Pierre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Brugman, Martijn H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348<br />
Brumbach, Jonathan H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159<br />
Brunetti-Pierri, Nicola. . . . . . . . . . . . . . . . . . 3, 45, 317, 419, 454, 460<br />
Brunhoeber, Elaine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Bryant, Kelli D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328, 393<br />
Bryant, Stacie M. J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459<br />
Bucher-Laurent, Stéphanie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589<br />
Buchholz, Christian J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .110, 386, 830<br />
Buchlis, George . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 823<br />
Buckland, Robin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 893<br />
Budzinski, Lisa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Bueren, Juan A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268, 876<br />
Buffo, Mary Jo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 899<br />
Bujo, Hideaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 153
154<br />
Abstract Author Index<br />
Bukh, Irene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
Bulfone, Alessandro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610<br />
Bull, David A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161, 560<br />
Bunnell, Bruce A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Burge, Christopher B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561<br />
Burger, Corinna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670<br />
Burke, James . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50<br />
Burke, Kathrin A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314<br />
Burkholder, Tanya H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 258, 346<br />
Burleyson, Joy R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585<br />
Burnett, Chris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 849<br />
Burnett, Ryan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Burns, William R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231<br />
Buscail, Louis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 878, 902<br />
Buschmann, Michael D. . . . . . . . . . . . . . . . . . . . . . . . . . .699, 881, 904<br />
Bushman, Frederic D. . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 612, 621, 635<br />
Butterfield, Lisa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 899<br />
Butts, Charlotte. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 593<br />
Byers, Peter H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 474<br />
Byrd, Tiara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
Byrne, Barry J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104, 131, 458, 901<br />
Byrne, William L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 906<br />
Byrnes, Andrew P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136<br />
C<br />
Cafferata, Eduardo G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238, 519<br />
Cai, Ying. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597<br />
Caizergues, Didier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Calcedo, Roberto. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 108, 185, 186<br />
Calos, Michele P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368<br />
Camisa, Barbara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .80, 785<br />
Campbell, D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Campbell, Katherine J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69<br />
Can, Wu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 319<br />
Candolfi, Marianela. . . . . . . . . . . . . . . . . . . . . . . . . . . 59, 787, 788, 789<br />
Candotti, Fabio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115<br />
Canevari, Silvana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 782<br />
Cannon, Paula M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .99, 314<br />
Cantore, Alessio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .377, 610, 829<br />
Cantz, Tobias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369<br />
Cao, Haoqing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 844<br />
Cao, Hong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 755<br />
Cao, Lan-Feng. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .99, 586<br />
Cao, Phoung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306<br />
Capella-Gonzalez, Cristina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 676<br />
Capo, Valentina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267<br />
Capotondo, Alessia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611<br />
Carbajo, Rosangela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774<br />
Carbone, Andrew . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 653<br />
Carbone, Larry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Carlier, Pierre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 72<br />
Carlucci, Marie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
Carnathan, Diane G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
Carney, Gael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256<br />
Carpenter, Melissa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579<br />
Carpenter, Susanne G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Carpentier, André C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183<br />
Carr, Bob . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595<br />
Carrer, Alessandro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 532<br />
Carrillo-Carrasco, Nuria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 453<br />
Carroll, Richard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Carruthers, Katherine H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624<br />
Carson, Joshua S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 678<br />
Carson, Joshua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Carter, Bob S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
Cartier, Nathalie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42, 195, 611<br />
Caruso, Hillary G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234<br />
Carvalho, Leonardo Pinto. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 742<br />
Casiraghi, Miriam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Casorati, Giulia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498<br />
Cassani, Barbara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254<br />
Castello, Raffaele . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 460<br />
Castiello, Maria Carmina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Castle, Michael J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618<br />
Castleton, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363<br />
Castro, Maria G.. . . . . . . . . . . . . . . . . 59, 509, 510, 784, 787, 788, 789<br />
Castro-Perez, Jose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Casucci, Monica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 785<br />
Cataldi, Marcela P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 616<br />
Cathomen, Toni . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />
Cattaneo, Roberto. . . . . . . . . . . . . . . . . . . . . . . . . . . 514, 515, 517, 521<br />
Cattoglio, Claudia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298, 612<br />
Causton, Benjamin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272<br />
Cavazza, Alessia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />
Cavazzana-Calvo, Marina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 42<br />
Cayer, Marie-Pierre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5<br />
Cédrone, Frédéric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 576<br />
Cela, Racel G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54<br />
Cela, Racel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 820<br />
Cemazar, Maja. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448, 540<br />
Cerio, Rebecca J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 875<br />
Cerullo, Vincenzo. . . . . . . . . . . . . . . . . . . . . . . . . .55, 77, 295, 478, 795<br />
Cesana, Daniela . . . . . . . . . . . . . . . . . . . .383, 606, 607, 610, 611, 631<br />
Cesani, Martina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611<br />
Cha, Min-Ji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 740<br />
Chada, Sunil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883<br />
Chae, Su Young . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166, 817<br />
Chai, Jing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Chakkaramakkil, Santhosh V.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388<br />
Chamberlain, Jeffrey S. . . . . . .36, 76, 466, 472, 475, 762, 763, 770<br />
Chamberlain, Joel R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 757<br />
Champlin, Richard E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 353<br />
Chan, Chia-Ling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171<br />
Chan, Fung. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Chan, Jerry K. Y.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />
Chan, Jerry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Chan, Robert C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513<br />
Chan, Yiumo M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468<br />
Chanda, Diptiman. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615<br />
Chande, Ajit G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388<br />
Chandler, Randy J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 452, 453<br />
Chandrasekaran, Suma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 453<br />
Chang, Jong Wook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580<br />
Chang, Judy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Chang, Kai-Hsin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Chang, Lung-Ji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211, 724, 859<br />
Chang, Seung-Hee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .909, 926, 929<br />
Chang, Wen C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 352<br />
Chang, Wen-Chung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Chang, Wenting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 921<br />
Chang, Yu-Han . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70<br />
Chao, Miao-Fen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211<br />
Chapdelaine, Pierre. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428<br />
Chapman, Robert L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 751<br />
Charan, Rakshita. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 479<br />
Charrier, Sabine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589<br />
Chatterjee, Saswati . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .128, 329, 663<br />
Chauhan, Hemangina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
Chauveau, Christine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207<br />
Chavez, Christopher L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368<br />
Chayama, Kazuaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88<br />
Chee, ChitLai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Chekmasova, Alena A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495<br />
Chen, Alvin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200<br />
Chen, Anmin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 758, 769<br />
Chen, Cang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202<br />
Chen, Cheng-Yan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927<br />
Chen, Ching-I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Chen, Chris Y.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8<br />
Chen, Chuangfu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218<br />
Chen, Chun-Hao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640, 678<br />
Chen, Chunlian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52<br />
Chen, Dexi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672<br />
Chen, Dong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242, 516<br />
Chen, Hannah. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 412<br />
Chen, Heng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680<br />
Chen, Irvin S. Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609<br />
Chen, Jianzhu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253<br />
Chen, Jie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 318<br />
Chen, Jimmy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 897<br />
Chen, Jinzhong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .437, 438, 700<br />
Chen, John W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303<br />
Chen, Jun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163<br />
Chen, Kuan-Hung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 547<br />
Chen, Ling-Lan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 924<br />
Chen, Liping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .623, 625, 828<br />
Chen, Lu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232<br />
Chen, Nanhai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Chen, Qixian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
Chen, Sheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404<br />
Chen, ShuJen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 545<br />
Chen, Vincent C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 550, 579<br />
Chen, Xiaolan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36<br />
Chen, Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Chen, Yann-Jang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 862<br />
Chen, Yingchi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211<br />
Chen, Yi-Shen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 547<br />
Chen, Yun-Wen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 794<br />
Chen, Zhi-Ying . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424<br />
Chen, Zhu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Cheng, Angie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 849<br />
Cheng, Binbin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Cheng, Christopher . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
Cheng, Kun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 845<br />
Cheng, Linzhao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345<br />
Cheng, Seng H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85, 165, 201, 205<br />
Chen-Tsai, Yanru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368<br />
Cheraï, Mustapha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Cherel, Yan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 195, 207, 375<br />
Chernajovsky, Yuti . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238<br />
Cherqui, Stephanie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 712<br />
Chervin, Adam S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356<br />
Cherylene, Plewa A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671<br />
Chesnut, Jon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144<br />
Chester, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361<br />
Chew, Sing Yian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 844<br />
Chia, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Chiang, Andy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 828<br />
Chicoine, Louis G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69<br />
Chien, Yin-Hsiu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 724<br />
Childers, Martine K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Chillón, Miguel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 417<br />
Chinnasamy, Nachimuthu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228<br />
Chiocchia, Gilles. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Chiodo, Vince . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203<br />
Chiorini, Jay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Chiorini, John A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .332, 374, 657<br />
Chiriaco, Maria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267<br />
Chiu, Fang-Yao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 313<br />
Chivukula, Raghu R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867, 892<br />
Chiyo, Tomoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 764<br />
Cho, Chong-Su. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 909, 926<br />
Cho, Kyung-Hyun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 707<br />
Cho, Myung-Haing . . . . . . . . . . . . . . . . . . . . . . . . . . 246, 909, 926, 929<br />
Cho, Su Hee. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279, 549<br />
Choi, Donghoon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 734<br />
Choi, Eun-Young . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 548<br />
Choi, Il-Kyu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140, 421<br />
Choi, Uimook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345, 833<br />
Chong, Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253<br />
Choolani, Mahesh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46, 253<br />
Chorny, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 733, 738<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 155
156<br />
Abstract Author Index<br />
Chou, Bin-Kuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345<br />
Chou, Brian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174<br />
Chou, Ho-Yuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17<br />
Chou, Szu-Ting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />
Chou, Tsung-Han. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203<br />
Chow, Kevin K. H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 781, 913<br />
Christopherson, Peter W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 646<br />
Chu, Ching-Liang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 512<br />
Chu, Dave. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177<br />
Chu, David S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65<br />
Chu, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174, 843<br />
Chu, Donald . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Chu, Kirk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331, 487<br />
Chu, Kon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 880<br />
Chu, Kuang-Chung. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927<br />
Chu, Victoria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498<br />
Chuang, Lea-Yea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Chung, Daniel C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600, 667<br />
Chung, Janet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 493<br />
Chung, Jihwa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 917<br />
Chung, Vincent. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Ciancia, Claire . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 706<br />
Cicalese, Maria Pia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Ciccone, Carla. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457<br />
Ciceri, Fabio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .498, 604, 605<br />
Cichutek, Klaus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386<br />
Cieri, Nicoletta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80<br />
Ci<strong>of</strong>fi, William . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3<br />
Ciré, Séverine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Cisper, Neil J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504<br />
Ciuculescu, Felicia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 857<br />
Clark, K. Reed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69, 768, 867, 892<br />
Clark, Robert A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202<br />
Clay, Timonthy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289<br />
Clemens, Paula R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74, 476, 479<br />
Clement, Nathalie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 458<br />
Clifford, Brian C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Clifford, Luke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597<br />
Cloer, Caryn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567<br />
Cloutier, Denise A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />
Cmielewski, Patricia L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 273<br />
Coates, Joan R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 870<br />
Cocchiarella, Fabienne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298<br />
C<strong>of</strong>fey, Matt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361, 891<br />
Cohen, Justus B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 56<br />
Cohen, Yael C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 885<br />
Cohen-Haguenauer, Odile Y. D. . . . . . . . . . . . . . . . . . . . . . . . 383, 389<br />
Colcher, David. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Coleman, J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Coleman, Jessie S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371<br />
Colle, Marie-Anne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Colleti, E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 873<br />
Collier, Joel H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 691<br />
Collins, Sara A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535<br />
Colombatti, Marco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295<br />
Colombo, Daniele . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631<br />
Coluccio, Andrea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 633<br />
Completo, Gladys . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71<br />
Congo, Richard T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Conlon, Thomas J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />
Conlon, Thomas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199, 341<br />
Connelly, Sheila . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883<br />
Cooper, Laurence J. N. . . . . . . . . . . . . . . . . . . . 26, 224, 225, 234, 240,<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353, 354, 500, 508<br />
Cooper, Mario . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 296<br />
Cooper, Mark J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 748<br />
Corbeil, Jacques. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428<br />
Cordelier, Pierre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 878, 902<br />
Cornetta, Kenneth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .111, 112, 590<br />
Cornils, Kerstin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Coronado, Monica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586<br />
Corrales, Ricardo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 738<br />
Cortado, Ruth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Corti, Giorgio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .98, 612<br />
Cosset, François-Loïc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 876, 893<br />
Cossette, Travis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199<br />
Costa, Caroline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 876, 893<br />
Costinean, Stefan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
Cote, Paul J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Cotman, Susan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200<br />
Cotrim, Ana P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 642<br />
Cots, Dan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 417<br />
Cotte, Julio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Cotugno, Gabriella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 665<br />
Coukos, George . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 782<br />
Couture, Larry A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .550, 579, 864<br />
Couture, Sylvana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 550, 579<br />
Couturier, A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Covarrubias, L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 920<br />
Cox, Nancy R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 646<br />
Coyle, Walter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Cozzi, Andrea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Craig, Nancy L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Crain, Karen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 484<br />
Cramer, Frederik. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 905<br />
Creusat, Gaelle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180<br />
Crombleholme, Timothy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449<br />
Cronin, Michelle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535<br />
Crooks, Gay M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Crowther, Carol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563<br />
Cruz, Conrad R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84<br />
Cruz, Epifanio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 920<br />
Crystal, Ronald G.. . . . . . . . . 170, 195, 200, 210, 283, 652, 653, 821<br />
Cuddihy, Andrew R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Cummins, James H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 373<br />
Cunha, Ludmylla C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
CUPID Investigators, on Behalf <strong>of</strong> the . . . . . . . . . . . . . . . . . . . . . . 601<br />
Curiel, David T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .138, 238, 243, 519,<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 886, 887, 894, 895, 912<br />
Curinga, Gabrielle M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 687<br />
Curran, Kevin J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230<br />
Curtin, James . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510<br />
Cuturi, Maria Cristina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />
D<br />
D’Amico, Donald J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 653<br />
D’Apuzzo, Massimo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351<br />
D’On<strong>of</strong>rio, Philippe M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544<br />
Da, Xiaoyu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .320, 761, 772<br />
Dagnaes-Hansen, Frederik. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447<br />
Dai, Bingbing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 492<br />
Dai, Jian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338<br />
Dai, Lei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334<br />
Dai, Yao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Dale, David C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44<br />
Dalferro, Matteo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728<br />
Dalkara, D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 872<br />
Dama, Paola. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 722<br />
Damo, Martina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 829<br />
Danchuk, Svitlana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Dandri, Maura. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Dang, Dianne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277<br />
Dang, Jason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387<br />
Dang, Wei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Daood, Molly. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74<br />
Darocha, Sylvie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Darras, Vincent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 699, 881<br />
Darvish, Babak . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774<br />
Darvish, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457, 774<br />
Dasgupta, Anindya. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28, 778<br />
Dasgupta, Asim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609<br />
David<strong>of</strong>f, Andrew M.. . . . . . . . . . . . . . . . . . . . . . . . . . 46, 262, 587, 602<br />
Davidson, Beverly L. . . . . . . . . . . . . . . . .198, 271, 650, 837, 842, 870<br />
Davies, Neil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629<br />
Davis, Jeremy L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228<br />
Davis, Pamela B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 432<br />
Davydova, Julia. . . . . . . . . . . . 58, 146, 241, 525, 673, 674, 799, 911<br />
de Belin, Jackie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
De Bellis, Gianluca. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .98, 612<br />
de Boer, Helen H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .252, 254, 713<br />
De Geest, Bart. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737<br />
de Koning, Tom J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 715<br />
de Kruijf, Marcel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511<br />
De Leonibus, Elvira . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 722<br />
de Mollerat du Jeu, Xavier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 849<br />
de Paula, Daisy Bentes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 446<br />
De Toni, Enrico . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 793<br />
de Wal, Janneke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183<br />
De, Bishnu P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170, 283, 652, 821<br />
Dean, David A. . . . . . . . . . . . . . . . . . 12, 107, 149, 173, 280, 704, 905<br />
Debinski, Waldemar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
Debyser, Zeger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 486<br />
Deeks, Steven . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266, 598<br />
Del Bel, Elaine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .570, 850, 851<br />
Del Maschio, Alessandro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605<br />
Deloron, P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Denapoli, Priscila M. A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 742<br />
Denard, Jerome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661<br />
Deneault, Eric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 372<br />
Deniger, Drew C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224<br />
Denisenko, Oleg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 578, 852<br />
Denman, Cecele J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 508<br />
Denning, Gabriela. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189, 592<br />
Dennis, James E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 855<br />
Depuy, Jeannette . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 644<br />
Deschamps, Jack-Yves. . . . . . . . . . . . . . . . . . . . . . . . . . . .195, 207, 375<br />
Desseaux, Carole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425, 576<br />
Desviat, Lourdes R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557<br />
Dewhurst, Stephen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 676<br />
Dey, Aditi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363<br />
Deyle, David R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384, 474<br />
Dhaliwal, Anandika. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168<br />
Dhamne, Hemant R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388<br />
Di Cesare, Silvia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267<br />
Di Matteo, Gigliola . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267<br />
Di Paolo, Nelson C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409, 491<br />
Di Pasquale, Giovanni . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Di Serio, Clelia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98, 264, 612<br />
Di Stefano, Bruno. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93, 631<br />
Di, Wei Li . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759<br />
Diaconu, Iulia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55, 77, 295, 795<br />
Dias, João D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295<br />
Diaz, Margarita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 269<br />
Diaz, Rosa M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 358<br />
Diaz, Rosa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361<br />
Dicembrini, Ilaria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Dichek, David A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 732, 739<br />
Dick, John E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
Dickey, David D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399, 654<br />
Diehn, Maximilian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 541<br />
Dighe, Niraja . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46, 253<br />
DiGiusto, David L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99, 314, 586<br />
DiMattia, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 332<br />
Ding, Shinghua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 921<br />
Ding, Wei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672<br />
Dingli, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 538<br />
Diouf, Oumar. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496<br />
DiRosario, Juliann . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337<br />
Discher, Dennis E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />
Dixon, Tracy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261<br />
Dodge, James C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201<br />
Doering, Christopher B.. . . . . . . . . . . . . . . . . . . . . . 189, 592, 826, 873<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 157
158<br />
Abstract Author Index<br />
Doglioni, Claudio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610<br />
Doillon, Charles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
Dolinsek, Tanja . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 540<br />
Dollet, Sandra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 706<br />
Donate, Amy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 711<br />
Dondero, R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 896<br />
Dong, Lu-Jia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 859<br />
Donnelley, Martin W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278<br />
Donnelly, Eleanor M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651, 907<br />
Donsante, Anthony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 747<br />
Doritchamou, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Doronin, Konstantin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4<br />
Dotti, Gianpietro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 496, 785<br />
Doubrovina, Ekaterina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230<br />
Dow, Jennifer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52<br />
Dowey, Sarah N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345<br />
Downey, Harre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 708<br />
Doyon, Yannick. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Drescher, Charles. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 815<br />
Dreyfus, Patrick. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Drezek, Rebekah A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 779<br />
Driessen, Gertjan J. A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Dronadula, Nagadhara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 732<br />
Dropulic, Boro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189, 592<br />
Drouin, Mathieu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5<br />
Du, Liang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 732, 739<br />
Du, Liutao. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71<br />
Duan, Dongsheng. . . . . . . . . . . . . . . . . . . . . . . . . . . 309, 481, 688, 771<br />
Dubensky, T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Dubreil, Laurence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />
Duffy, Margaret R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6<br />
Dufour, Brett D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650<br />
DuFresne, Elizabeth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 664<br />
Dumont, Nellie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5<br />
Dunbar, Cynthia E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113, 310<br />
Duncker, Dirk-Jan D. J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713<br />
Durfee, Heather . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 773<br />
During, Matthew J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624<br />
Duros, Caroline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383, 389<br />
Durymanov, Mikhail O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Duvall, Craig L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 839, 841<br />
Duzgunes, Nejat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151<br />
E<br />
Eaves, Allen C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 860<br />
Ebert, Oliver. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 793<br />
Egan, James. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626<br />
Egan, Josephine M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Ehrhardt, Anja. . . . . . . . . . . . . . . . . . . . . .139, 299, 378, 413, 630, 679<br />
Eipel, Christian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411<br />
Eisterer, W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Ekblad, Maria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 807<br />
Ekstrom, Marta H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 704<br />
El-Amouri, Salim S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306<br />
Elash<strong>of</strong>f, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />
Elazar, Menashe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 487<br />
Elgstrand Wettergren, Erika . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 879<br />
Eliav, Uzi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320<br />
Ellis, Brian L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 634<br />
Ellis, Collin L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286<br />
Ellis, Scott . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
Elmallah, Mai K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />
Elsabahy, Mahmoud. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182<br />
Ely, Abdullah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563<br />
Emborg, Marina E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670<br />
Emery, David W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33, 251<br />
Emmerechts, Jan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737<br />
Endo, Ayumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 723<br />
Endo-Takahashi, Yoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483<br />
Engelhardt, John F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .270, 275, 660<br />
Engelhardt, Sarah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139<br />
Engler, Tatjana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .57, 416<br />
Enk, Alexander H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139<br />
Enkirch, Theresa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110<br />
Ennis, Jane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212<br />
Enoki, Tatsuji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 397, 407<br />
Enriquez de Salamanca, Rafael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Enssle, Joerg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 865<br />
Epp, Angela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366<br />
Epperly, Michael W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261<br />
Era, Takumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577<br />
Erbacher, Patrick. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 638<br />
Erger, Kirsten E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104, 199<br />
Erika, Schmidt. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57<br />
Ernstberger, Aaron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111, 590<br />
Ertl, Hildegund C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680<br />
Escutenaire, Sophie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 795<br />
Esfandiarifard, Saghi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774<br />
Eshhar, Zelig . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29<br />
Esko, Jeffrey D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />
Esposito, Irene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 793<br />
Esteban, Mariano. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916<br />
Estrada-V, Erendira . . . . . . . . . . . . . . . . . . . . . 886, 887, 894, 895, 920<br />
Eto, Yoshikatsu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714, 721<br />
Eubanks, Lisa M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 652<br />
Evangelio, Costanza . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Evans, Claire F.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Ewert, Kai K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171<br />
Exc<strong>of</strong>fon, Katherine J. D. A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 654<br />
Eymard, Bruno . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
F<br />
Fae, Kellen C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118<br />
Fagone, Paolo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379, 587<br />
Fahrendorff, Melanie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594<br />
Fairy, Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 860
Abstract Author Index<br />
Fakhfakh, Raouia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 471<br />
Fakhrai, Habib. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 814<br />
Falahati, Rustom. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250<br />
Falcione, Antonella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728<br />
Falcone, Laura. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 785<br />
Falk, Darin J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104, 901<br />
Falkenhagen, Alexander . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 897<br />
Fan, Shasha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245<br />
Fan, Xia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 919<br />
Fan, Yufei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 639<br />
Fang, Cheng-Chieh. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17<br />
Fargnoli, Anthony S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725<br />
Faria, Ana Paula P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570<br />
Farinelli, Giada. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267<br />
Farley, Raymond. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165, 272<br />
Farr, MaryJane. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Farrokhi, Catherine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509, 784<br />
Farrow, Nigel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281<br />
Farruggio, Alfonso P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368<br />
Fassas, Athanasios. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Fattah, Caroline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 729<br />
Faust, Susan M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291<br />
Federici, Thais . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651<br />
Feder<strong>of</strong>f, Howard J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39, 755<br />
Federspiel, Mark J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23, 364, 802, 888<br />
Fehlings, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544<br />
Fehse, Boris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572, 641<br />
Fender, Pascal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2, 18, 135<br />
Fenelon, Gilles. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Feng, Junli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366<br />
Feng, Yun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244<br />
Fernandez, Stephanie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 932<br />
Ferrari, Giuliana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298<br />
Ferraro, Bernadette. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504<br />
Ferreira, Nádia R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 851<br />
Ferrige, Georgina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
Ferro, Leda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263<br />
Ferrua, Francesca. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Ferry, Nicolas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124<br />
Fewell, Jason G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Fidler, Jonathan A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201<br />
Fieger, Philipp . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139<br />
Fielding, Adele K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363<br />
Filali, Ebtisam E. l. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 858<br />
Finegold, Milton. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 45, 48, 277<br />
Finn, Eric E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .36, 472<br />
Finn, Eric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76, 466<br />
Finocchi, Andrea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267, 604<br />
Fioravanti, Jessica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 776<br />
Fire, Andrew Z. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424<br />
Fischbeck, Kenneth H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 882<br />
Fischer, Alain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42<br />
Fishbein, Ilia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 733, 738<br />
Fisher, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270<br />
Fisher, Paul B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242<br />
Fisk, Nicholas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />
Fitch, Sally. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 463<br />
Flake, Alan W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 823<br />
Flanigan, Kevin M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 768<br />
Flannery, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 872<br />
Flatt, Justin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4<br />
Flebbe-Rehwaldt, Linda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250<br />
Fleming, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
Flinders, Colin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423<br />
Flotte, Terence R. . . . . . . . . . . . . . . . 47, 341, 400, 404, 555, 649, 827<br />
Flournoy, Camille A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 870<br />
Flynn Gilmer, Heather . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 775<br />
Flynn, Rowan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125<br />
Foldvari, Marianna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182<br />
Fong, Mei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141<br />
Fong, Yuman . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640, 678<br />
Fons, Michael P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701<br />
Fontana, Melissa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 545<br />
Fontanellas, Antonio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Fontes, Andrew D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144<br />
Forbes, Scott P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 738<br />
Forde, Patrick F.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511, 196<br />
Forman, Stephen J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38, 89, 351, 352<br />
Forsayeth, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39, 647, 746<br />
Fortinberry, Henry K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459<br />
Foster, Aaron E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .84, 779<br />
Foti, Stacey. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651, 871<br />
Foulad, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59, 787, 788<br />
Foust, Kevin D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392<br />
Foust, Kevin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 647<br />
Fraldi, Alessandro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401, 722<br />
Francis, Kevin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535<br />
Franco, Judith . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185<br />
Francoise, Antoine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Frecha, Cecilia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 876, 893<br />
Frederick, Amy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Frenk, Esther Z. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 652<br />
Frenzke, Marie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .514, 515, 517<br />
Friedline, Randall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555<br />
Friedman, Ge<strong>of</strong>frey. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 632<br />
Friedman, Robin C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561<br />
Frisch, Benoit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180<br />
Frisch, Frederique . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183<br />
Frisk, Per . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229<br />
Fromes, Yves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72<br />
Frondorf, Kathleen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7<br />
Fronza, Raffaele . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264<br />
Fruehauf, Stefan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Fu, Ailing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63<br />
Fu, Freddie H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 758, 769<br />
Fu, Haiqing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 159
160<br />
Abstract Author Index<br />
Fu, Haiyan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337<br />
Fuentes de Albin, Martha. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427<br />
Fujii, Tsutomu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Fujisawa, Masato . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Fujiwara, Hiroshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777<br />
Fujiwara, Toshiyoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 797, 800<br />
Fukuda, Takahiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 721<br />
Fukuhara, Hiroshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796<br />
Fukunaga, Yoshitaka. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451, 456<br />
Fuller, David D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />
Fürst, Katharina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411<br />
Fury, Brian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24<br />
Fusaki, Noemi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577<br />
G<br />
Gabellini, Davide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 757<br />
Gabriel, Nishanth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121<br />
Gabriel, Richard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 632<br />
Gaensler, Karin M. L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250<br />
Gagné, Claude . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183<br />
Gagnon, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381<br />
Gahan, Cormac G. M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535<br />
Gahl, William A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457<br />
Galanis, Evanthia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23, 31, 365, 891<br />
Galetto, Roman . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425, 576<br />
Galivo, Feorillo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .371, 574, 780<br />
Gallina, Pierangela. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610<br />
Galy, Anne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293, 589<br />
Gan, Chih Hao V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Gangeswaran, Rathi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516, 529<br />
Gao, Dongling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516<br />
Gao, Fei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Gao, Guangping. . . . . . . . . . . . . . . . . . . .400, 404, 555, 621, 649, 827<br />
Gao, Xueqin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 373<br />
Gao, Yangjun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321<br />
Garcia, Aida . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431<br />
Garcia, Luis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 661, 831<br />
Garcia-Bañuelos, Jesus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420<br />
Gardner, Agnes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586<br />
Gardner, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
Gargiulo, Annagiusi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .401, 542, 722<br />
Garwick-Coppens, Sara E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .75, 467<br />
Gasiorowski, Joshua Z.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 691<br />
Gasmi, Mehdi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589<br />
Gatti, Richard A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71<br />
Gattinoni, Luca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 350<br />
Gaudet, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183<br />
Gaussin, Armelle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383<br />
Gautney, Richard E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592<br />
Gazit, Dan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 370, 761, 772, 856<br />
Gazit, Zulma . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 370, 761, 772, 856<br />
Gebremedhin, Senait. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151<br />
Gee, Adrian P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
Gee, Adrian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496<br />
Gee, Samantha W. Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Geguchadze, Ramaz. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 465<br />
Gehl, Julie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447<br />
Gennery, Andrew R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93<br />
Genovese, Pietro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .498, 631, 632<br />
Gentner, Bernhard. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .94, 267<br />
Gerken, Claudia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .496, 781, 913<br />
Gersbach, Charles A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422<br />
Gerseny, Helen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 675<br />
Gerson, Stanton L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250<br />
Gesinger, Jonathan M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368<br />
Gessner, Debra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Gewen, Tan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 526<br />
Ghazi, Alexia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
Ghazizadeh, Soosan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 376<br />
Ghio, Domenico. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605<br />
Gholami, Sepideh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 678<br />
Ghoshal, Kalpana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
Giacca, Mauro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .532, 614, 728<br />
Giachelli, Cecilia M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 426, 741<br />
Giangrande, Paloma H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 743, 834<br />
Giannelli, Stefania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Gianni, Davide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 546<br />
Giannoni, Francesca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355, 786<br />
Giedlin, Martin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544<br />
Giedlin, Marty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598<br />
Giesen, Melanie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 857<br />
Giffear, Mary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Gijsbers, Rik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 486<br />
Gilbert, Marie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703<br />
Gilbert, Rénald . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143, 381<br />
Gill, Deborah R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 884<br />
Gillespie, George Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
Giordano, Frank A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Giorgio, Todd D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 839<br />
Girard, Mathilde . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 706<br />
Giustacchini, Alice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
Gjata, Bernard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Glader, B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Glascock, Jacqueline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 455<br />
Glazer, Peter M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
Glenn, Jeffrey S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 487<br />
Glimm, H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Glimm, Hanno . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223, 269, 343, 632<br />
Glorioso, Joseph C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 56<br />
Glushakova, Lyudmyla G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Gnidehou, S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Godbout, Jonathan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362<br />
Godwin, Simon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Goetzmann, Jason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400<br />
Goez, Anneliese . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 804<br />
Goh, Eyleen Lay Keow . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 844<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Goldowitz, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Gonen, Mithat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Gonzaga, Bruno C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570<br />
Gonzalez, Lorena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Goodman, Alan G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916<br />
Goodrich, LR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 871<br />
Gorbatyuk, Marina S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204<br />
Gordts, Stephanie C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737<br />
Gothelf, Anita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447<br />
Gottenberg, Jacques-Eric. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Gottfried, Lynn F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149<br />
Gottschalk, Stephen M.. . . . . . . . . . . . . .27, 220, 357, 496, 781, 913<br />
Gouble, Agnès . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425, 576<br />
Goudy, Kevin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .287, 290, 377<br />
Gould, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238<br />
Govindasamy, Lakshmanan. . . . . . . . . . . . . . . . . . 330, 332, 402, 405<br />
Gracey, Lia E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424<br />
Grada, Zakaria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
Grandi, Paola . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />
Grant, Rebecca. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 186, 196<br />
Gräslund, Torbjörn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 879<br />
Graves, Edward E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 541<br />
Graves, Scott S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623<br />
Gray, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Gray, John T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .259, 379, 587<br />
Gray, Steven S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651<br />
Gredler, Rachel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242<br />
Green, Karin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341<br />
Green, Victoria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208<br />
Greenberg, Barry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601<br />
Greenberg, Philip D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498<br />
Greenberger, Joel S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261<br />
Greene, Mike. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379<br />
Greenslade, Andrew. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 364<br />
Greentree, Stephen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183<br />
Greer, Brian B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 771<br />
Gregory, Philip D.. . . . . . . . . . . . . . . . . . 26, 49, 93, 99, 268, 314, 423,<br />
. . . . . . . . . . . . . . . . . . . . . 484, 498, 598, 631, 632, 633, 648, 689, 903<br />
Greig, Jenny A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 874<br />
Greiner, Dale L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
Greiner, Suzanne M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 364<br />
Grez, Manuel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267, 269, 347, 348<br />
Grieger, Josh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651<br />
Grieger, Joshua C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585<br />
Griesenbach, Uta. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .108, 165, 272<br />
Grieves, Jessica L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 617<br />
Griffiths, Duncan A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595<br />
Grilley, Bambi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
Grimm, Dirk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127, 394<br />
Grimstein, Christian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669<br />
Gritti, Angela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631<br />
Grompe, Markus . . . . . . . . . . . . . . . . . . . . . . . . .48, 187, 371, 463, 574<br />
Gross, Alecia K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Gross, David-Alexandre. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Grossardt, Christian. . . . . . . . . . . . . . . . . . . . . . . . . . 514, 521, 528, 798<br />
Grossman, Robert G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 781<br />
Groth, Amy C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
Grove, Nathan C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147, 414<br />
Grove, Nathan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3, 45, 277, 419<br />
Grover, Rajat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615<br />
Gruenert, Dieter C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Grunseich, Christopher . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 882<br />
Grünwald, V.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82<br />
Gu, Feng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 636<br />
Gu, Yixue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245<br />
Guelcher, Scott A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 841<br />
Güenechea, Guillermo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Guenther, Margaretha. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54<br />
Guenzel, Adam J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 658<br />
Guerlevik, Engin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790, 804<br />
Guerra, Susana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916<br />
Guh, Jinn-Yuh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Gui, Tong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 832<br />
Guilbault, Claire . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381<br />
Gul, Hilal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 318<br />
Guntani, Atsushi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Günzburg, Walter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Guo, Changsheng. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 463<br />
Guo, Fengjin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 758, 769<br />
Guo, Siqi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 708, 711<br />
Gupta, Mukesh K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 841<br />
Gurda, Brittney L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .332, 333, 374<br />
Gurruchaga, Jean-Marc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Guse, Kilian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54, 478<br />
Gussing, Fredrik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 879<br />
Guttridge, Denis C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96<br />
Guy, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203<br />
H<br />
Haase, Rudolf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413<br />
Haavisto, Elina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 795<br />
Haber, Tom. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 582<br />
Habib, Nagy A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559<br />
Habli, Mounira . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449<br />
Hacein-Bey-Abina, Salima . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 42<br />
Hacke, Katrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Hackett, Neil R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .195, 200, 652<br />
Hackett, Perry B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14<br />
Hadaczek, Piotr. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39<br />
Haddad, Dana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640, 678<br />
Haddad, Daniel J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Haddad, Hafedh. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Hagedorn, Claudia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390<br />
Haggerty, Carolyn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 729<br />
Haghighi, Ali . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 814<br />
Hajjar, Roger J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 668<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 161
162<br />
Abstract Author Index<br />
Hajjar, Roger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601<br />
Hakim, Chady H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 771<br />
Hakin, Chady H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309<br />
Hakkarainen, Tanja . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295<br />
Halbert, Christine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Hall, Christine A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 550<br />
Hall, Lindsay J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511<br />
Halldén, Gunnel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 801, 807<br />
Hamada, Katsuyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237, 418<br />
Hamakawa, Hiroyuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418<br />
Han, Joohee. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .58, 525<br />
Han, KuyLee. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833<br />
Han, Myung-Shin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 308<br />
Han, Sang W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 742<br />
Han, Sang Won. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 446<br />
Han, Yu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 915<br />
Handy, Chalonda R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651, 907<br />
Hanenberg, Helmut . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112<br />
Hannah, William. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 832<br />
Hannaman, Drew W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Hantraye, Philippe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Hao, Ergeng. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 868<br />
Hapke, G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Harada, Yui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523, 813<br />
Harada-Shiba, Mariko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .61, 181<br />
Harashima, Hideyoshi . . . . . . . . . . . . . . . . . . . . . . . 433, 444, 709, 835<br />
Harbottle, Richard P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 751<br />
Hardcastle, Jayson. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362<br />
Hardee, Cinnamon L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 786<br />
Hardee, Cinnamon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355<br />
Hardenberg, Gijs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334<br />
Harding-Smith, Rebekka E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 884<br />
Hareendran, Sangeetha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121<br />
Harel, Asaff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53<br />
Hargrove, Phillip W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262<br />
Harjeet, Singh S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234<br />
Harms, Nina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630<br />
Harper, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759<br />
Harper, Scott Q. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .75, 467<br />
Harrington, Kevin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361<br />
Harris, Dawn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Harris, Kyle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592<br />
Harrison, Frank . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 712<br />
Hart, Stephen L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156<br />
Hart, Stephen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
Hartline, Cassie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353<br />
Hasegawa, Mamoru . . . . . . . . . . . . . . . .103, 190, 222, 233, 523, 577<br />
Hashida, Mitsuru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .319, 430, 443<br />
Hashimoto, Yuuri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 797, 800<br />
Haskins, Mark E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43, 719, 726<br />
Hatano, Koji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227<br />
Hauck, Bernd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403<br />
Haugwitz, Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141<br />
Haurigot, Virginia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Hauschka, Stephen D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .36, 466<br />
Hauser, Michael A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 467<br />
Haushalter, Karl A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489<br />
Häusl, Martin A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139<br />
Hausl, Martin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .378, 413, 679<br />
Hauswirth, William W. . . . . . . . . . . . . . . . . . . . . . . . 199, 203, 204, 648<br />
Havranek, James . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />
Hawkins, Troy B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111<br />
Hawkins, Troy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 590<br />
Hay, John G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415<br />
Hayashi, Yasuhiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .433, 709, 835<br />
Hayashita-Kinoh, Hiromi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 764<br />
Hayes, Daniel J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176<br />
Hayes, Teresa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496<br />
He, Dongmei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321<br />
He, Ran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400, 404, 555, 649, 827<br />
He, Xianghui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 792, 866<br />
He, Yukai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213<br />
He, Zhihai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 771<br />
He, Zhimin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245<br />
Hean, Justin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563<br />
Hebbel, Robert P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 822<br />
Hebel, Henry L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597<br />
Hegde, Meenakshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27, 913<br />
Hege, Kristen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Heinen, Paul P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916<br />
Heldermon, Coy D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717<br />
Heller, Loree. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 711<br />
Heller, Richard. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .441, 708, 711<br />
Hellerbrand, Claus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 793<br />
Hemminki, Akseli. . . . . . . . . . . . . . . . . . . . 2, 18, 55, 77, 295, 478, 795<br />
Henley, Jill E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314<br />
Henschler, Reinhard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 857<br />
Hensel, Jonathan A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615<br />
Hentati, Fayçal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Herberman, Ronald B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 899<br />
Herdewijn, Piet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563<br />
Herijgers, Paul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737<br />
Herman, Andy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Hermiston, Michelle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Hernandez, Jessica A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225<br />
Herschman, Harvey R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />
Herson, Serge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Hervas-Stubbs, Sandra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Herzog, Erik D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717<br />
Herzog, Roland W.. . . . . . . . . . . . . . . . . .288, 296, 402, 619, 663, 825<br />
Heslop, Helen E. . . . . . . . . . . . . . . . . . . . . . . . . . . .20, 27, 496, 591, 913<br />
Hiatt, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277<br />
Hice, Robert H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Hickey, Raymond D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371<br />
Hickey, Raymond. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 574<br />
Hicks, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Hicks, Martin L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .170, 283, 652<br />
Hickstein, Dennis D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .258, 346, 613<br />
Higgs, Jerome T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615<br />
High, Katherine A. . . . . . . . . . . . . . . . . . . . . . . . .49, 403, 600, 602, 823<br />
Higuchi, Yuriko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 319<br />
Hikichi, Mina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359<br />
Hildebrandt, B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Hillestad, Matthew L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 658<br />
Hirabayashi, Yuka. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315<br />
Hirai, Yukihiko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88<br />
Hiralall, Johan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 858<br />
Hiraoka, Kei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535, 869<br />
Hirata, Roli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10, 636<br />
Hiroshima, Kenzo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Hirsch, Matthew L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620, 634<br />
Hitt, Mary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 808<br />
Ho, On . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 485<br />
Ho, Weng Hang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 859<br />
Hoare, Mike . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450<br />
Hodgson, Clague P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 694<br />
Hoeben, Rob C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
H<strong>of</strong>er, Ursula . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .99, 314<br />
H<strong>of</strong>fman, Brad E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 296<br />
Hogrel, Jean-Yves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 72<br />
Hole, Patrick. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595<br />
Holley, Rebecca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336<br />
Hollis, Roger P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423<br />
Hollis, Roger. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355<br />
Holmes, Michael C. . . . . . . . . . . . . . . . . . . . . . 26, 49, 93, 99, 268, 314,<br />
. . . . . . . . . . . . . . . . . . . . . 423, 484, 498, 598, 631, 632, 633, 689, 903<br />
Holt, Nathalia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314<br />
Holt, Robert A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Holzbaur, Erika L. F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618<br />
Homma, Yukio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796<br />
Hong, Seong-Ho . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 909<br />
Hong, Yuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213<br />
Hoogaars, Willem M. H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765<br />
Hoogstraten-Miller, Shelley . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457<br />
Horton, Lois . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Hosoyama, Sachiko Ohshima. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473<br />
Hossain, Fokhrul M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Hou, Jiangang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796<br />
Hou, Wei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 412<br />
Howard, Lynsey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 727, 853<br />
Howe, Ruth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718<br />
Howe, Simon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336<br />
Howe, Steven J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Howell, Craig A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834<br />
Howes, Rob . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 908<br />
Hoylaerts, Marc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737<br />
Hoyler, Birgit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110<br />
Hsieh, Matthew M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117, 385<br />
Hsieh, Ming-Kun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927<br />
Hsu, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .550, 579, 864<br />
Hsu, Jen-I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178<br />
Hsu, Shu-hao. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
Hsu, Yi-ling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 866<br />
Hu, Chuhong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285<br />
Hu, Hailiang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71<br />
Hu, Shiu-Lok . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 485<br />
Hu, Youjin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 697<br />
Hu, Yu-Chen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70<br />
Hu, Zebin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 675<br />
Huang, Baocheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129<br />
Huang, Jenny . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436<br />
Huang, Jeremiah W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 907<br />
Huang, Li T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 376<br />
Huang, Liang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302<br />
Huang, Li-Min . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211<br />
Huang, Patricia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Huang, Qian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 756<br />
Huang, Shu Hung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322<br />
Huang, Wenlin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Huang, Xueyin N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 659<br />
Huang, Ya-Hui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17<br />
Huard, Johnny . . . . . . . . . . . . . . . . . . . . . . . . . . .96, 367, 373, 758, 769<br />
Huard, Mathieu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 373<br />
Hubbard, Brian K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Hudacek, Andrew W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515<br />
Hui, David. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40<br />
Huizing, Marjan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457<br />
Hul, Helen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353<br />
Huls, Helen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 224, 225, 500<br />
Hung, Jui-Hung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555<br />
Hung, Min-Yuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Hung, Shih-Chieh . . . . . . . . . . . . . . . . . . . . . . . . . . . 313, 325, 862, 924<br />
Hung, Tsung-Jen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Hunter, Michael J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346<br />
Hunter, Michelle R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 501<br />
Huppert, Volker . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594<br />
Hurbult, Gregory D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201<br />
Hurtado, Daniela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 405<br />
Hurton, Lenka V.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 354<br />
Hurwitz, Mary Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137<br />
Hurwitz, Richard L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137<br />
Huseinovic, Angelina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569<br />
Huston, Marshall W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252<br />
Huyn, Steven. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145<br />
Huynh, Cong Truc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166<br />
Huynh, Dai Phu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166<br />
Hwang, Jae Youn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 843<br />
Hwang, Ki-Chul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 740<br />
Hwang, Mark E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167<br />
Hwang, Misako. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194, 646<br />
Hwang, Tae-Ho. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 163
164<br />
Abstract Author Index<br />
Hwu, Wuh-Liang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 458, 724<br />
Hyde, Stephen C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 884<br />
Hyland, Kendra A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255<br />
Hyodo, Mamoru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 709<br />
I<br />
Iankov, Ianko D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23, 365<br />
Iannitti, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3<br />
Ichikawa, Tomohiko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 813<br />
Ichwan, Brian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 310<br />
Icyuz, Mert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459<br />
Ida, Hiroyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714, 721<br />
Igarashi, Tsutomu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 754<br />
Ihn, Hironobu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577<br />
Iida, Akihiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577<br />
Iida, Hidehiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 581<br />
Ikarashi, Yoshinori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235<br />
Ikawa, Masahito . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Ikawa, Yasuhiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115<br />
Ikeda, Hiroaki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777<br />
Ikeda, Yasuhiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311<br />
Ikeda, Yutaka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305<br />
Ikramy, Khalil A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 433, 835<br />
Ildefonso, Cristhian J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137<br />
Ilett, Elizabeth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 780<br />
Imamura, Michio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88<br />
Imbrogno, Kara. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 769<br />
Imbrogno, Kayla. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367<br />
Inagaki, Akihito. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535, 869<br />
Ingle, Nilesh P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />
Ino, Yasushi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796<br />
Inoguchi, Hiroyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Inoue, Hiroyuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97, 222, 233, 861<br />
Inoue, Makoto . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103, 190, 222, 233<br />
Inoue, Tomoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .97, 233<br />
Ippodrino, Rudy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 614<br />
Ironside, Christina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257, 344<br />
Isaev, Dmitry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100<br />
Isaksson, Christina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301<br />
Isgrò, Antonella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267<br />
Ishida, Eri. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248<br />
Ishige, Nobuyuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714<br />
Ishii, Takehiko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
Ishii, Yuko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483<br />
Ishikawa, Kiyotake . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 668<br />
Ishiwata, Akira. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188<br />
Itaka, Keiji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
Itkin-Ansari, Pamela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 868<br />
Ito, Kensaku . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523<br />
Ito, Tomoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .152, 154, 237<br />
Itoh, Hiroyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Ivanovska, Irena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />
Ivics, Zoltan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />
Iwamoto, Takeo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 721<br />
Iwanaga, Yuzuru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315<br />
Izsvak, Zsuzsanna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />
Izuka, Sayoko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 721<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
J<br />
Jackson, Andrew . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .90, 740<br />
Jackson, George W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353<br />
Jackson, Robert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Jacob, Danielle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381<br />
Jacob, Samson T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
Jacobi, Ashley . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271<br />
Jacobs, Frank. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737<br />
Jacques, Sebastien . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Jaenisch, Rudolf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Jahn, Stephan C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619<br />
Jamali, Layli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Jamison, R. Aidan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278<br />
Jan, Caroline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Janda, Kim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .170, 283, 652<br />
Jang, Jae-Hyung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122<br />
Jang, Yeon Lim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166, 817<br />
Janke, Laura J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259<br />
Jansen, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566, 569<br />
Jansson, Volkmar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 767<br />
Janus, Jeffrey. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 854<br />
Jares, Alexander . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113<br />
Jarjour, Jordan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .35, 687<br />
Jarraya, Bechir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Jasti, Aparna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .111, 112, 590<br />
Jay, Chris M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457<br />
Jayandharan, Giridhara R.. . . . . . . . . . . . . . . . . . . . . . . . .121, 131, 619<br />
Jean, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 881<br />
Jensen, Michael C.. . . . . . . . . . . . . . . . . . . . . . . .38, 351, 352, 499, 501<br />
Jensen, Thomas G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 760<br />
Jeong, Chang Hyun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580<br />
Jeong, Hwa Yeon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158<br />
Jeong, Ji Hoon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .166, 734, 817<br />
Jeong, Wha Yeon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160<br />
Jessup, Mariell. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601<br />
Jeun, Sin-Soo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580<br />
Jiang, Bo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 739<br />
Jiang, Guozhong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529<br />
Jiang, Hao-Yuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327<br />
Jiang, Hu-Lin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 909, 926<br />
Jiang, Ming-Ming . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54<br />
Jin, Hee Kyung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 918<br />
Jin, Qingwen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211<br />
Jin, Seori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 707<br />
Jin, Sheng-Yu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
Abstract Author Index<br />
Jo, Dong-Gyu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 817<br />
Joensuu, Timo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77, 795<br />
Joglekar, Alok V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423<br />
Johana, Nuryanti . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />
Johnsen, Angela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Johnson, Aime K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194, 646<br />
Johnson, Gary M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 596<br />
Johnson, Jacob A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 646<br />
Johnson, Russell N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 174, 177<br />
Johnston, Ian C. D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594<br />
Johnston, Jennifer M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 826<br />
Johnston, Jennifer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189<br />
Jolly, Douglas J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Jones, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340<br />
Jones, Haven . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621<br />
Jones, Heather . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599<br />
Jones, Helen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449<br />
Jones, Jeffrey A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261<br />
Jones, Rachel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Jones, Simon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336, 716<br />
Jones, Steven J. M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Jones, Victoria J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194, 646<br />
Jonnalagadda, Mahesh. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 352<br />
Joo, Kye-Il . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132, 387<br />
Josephson, Neil C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366<br />
Joshi, Bharat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />
Joshi, Sadhna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 897<br />
Joubert, Vanessa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703<br />
Joung, J. Keith. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300, 686<br />
Judd, Justin H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 408<br />
Judge, Eoin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626<br />
June, Carl H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 782<br />
June, Carl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Jung, Daniel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5<br />
Jung, Hye S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Jung, Keun-Hwa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 880<br />
Jung, Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71<br />
Jung, Ulrike . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118<br />
Junghans, Richard P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
K<br />
Kabanov, Alexander V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 922<br />
Kacherovsky, Nataly A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 426<br />
Kadner, Karen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629<br />
Kaeppel, C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Kaeppel, Christine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46, 632<br />
Kafri, Tal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 832<br />
Kagawa, Shunsuke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 800<br />
Kaja, Aparna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 15<br />
Kajimoto, Kazuaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 835<br />
Kakarla, Sunitha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357, 781<br />
Kakkis, Emil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774<br />
Kaler, Stephen G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 747<br />
Kalies, Katrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506<br />
Kallai, Ilan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 370, 761, 772<br />
Kaluza, Karen K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 358<br />
Kaluza, Karen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 775<br />
Kamat, Rohan H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388<br />
Kamata, Wakako. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181<br />
Kamen, Amine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381<br />
Kamijima, Shuichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Kamimura, Kenya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627, 705<br />
Kaminsky, Stephen M. . . . . . . . . . . . . . . . . . . 170, 283, 652, 653, 821<br />
Kane, Nicole M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 727, 853<br />
Kaneda, Yasufumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227, 736<br />
Kanefuji, Tsutomu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 444, 627<br />
Kanegae, Kazuko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190<br />
Kanerva, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 295, 795<br />
Kang, Eunah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 685<br />
Kang, Jeong-hun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181<br />
Kang, Leong-Hun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150<br />
Kangasniemi, Lotta. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77, 795<br />
Kanzaki, Akiyuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Kao, Chun-Yu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70<br />
Kao, Yi-Hsuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 924<br />
Kapoor, Neena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
Karali, Marianthi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 542, 665<br />
Karan, Sukanya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199<br />
Karapetyan, Gevorg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320<br />
Kardos, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701<br />
Karimi-Busheri, Feridoun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 814<br />
Karlsson, Hannah. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229<br />
Karow, Marisa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368<br />
Kasahara, Noriyuki. . . . . . . . . . . . . . . . . . . . . . . .95, 524, 535, 559, 869<br />
Kasahara, Yuko Nitahara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473<br />
Kashiwakura, Yuji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190<br />
Kaspar, Brian K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392<br />
Kaspar, Brian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 647<br />
Kaspar, Roger L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427<br />
Kasper, Brian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 768<br />
Kassim, Sadik H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102<br />
Kastberger, Birgit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />
Kasuya, Hideki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Katakai, Yuko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88<br />
Kataoka, Kazunori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
Katari, Usha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 503<br />
Katayama, Kazufumi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 682<br />
Katayama, Yoshiki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150, 172<br />
Katebian, Behrod. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355<br />
Katz, Martin L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 870<br />
Katz, Michael G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725<br />
Kaufmann, Johanna K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 528<br />
Kaufmann, Kerstin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348<br />
Kaufmann, Stefan H. E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118<br />
Kaul, Sunil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 527<br />
Kaur, Balveen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 165
166<br />
Abstract Author Index<br />
Kaur, Kamaljit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
Kauss, M. Ariel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329<br />
Kavanagh, Heather . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626<br />
Kawabata, Kenji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 682<br />
Kawaguchi, Yoshifumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227<br />
Kawakami, Shigeru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .319, 430, 443<br />
Kawamura, Kiyoko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Kawano, Hirotaka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97, 861, 925<br />
Kay, Mark A. . . . . . . . . . . . . . . . . . . . . . 11, 86, 148, 331, 424, 487, 602<br />
Kayali, Refik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .71, 470<br />
Kaza, Niroop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615<br />
Kean, Thomas J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 855<br />
Keeler, Allison M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341<br />
Keilman, George W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623<br />
Keirnan, Jacqueline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 503<br />
Keiser, Megan K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198<br />
Keiser, Nicholas W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270, 660<br />
Kellar, Denise L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 500<br />
Kellar, Denise. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Kelleher, Michelle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
Kells, Adrain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 647<br />
Kells, Adrian P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206, 746<br />
Kelson, Kyle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509, 784<br />
Kemaladewi, Dwi U. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765<br />
Kemmerrer, Stephen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701<br />
Kemnade, Jan O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 783<br />
Kempuraj, Duraisamy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 655<br />
Kendra, K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 891<br />
Kennedy, Laura C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 779<br />
Kent, Oliver A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 892<br />
Keramaris, Elizabeth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 766<br />
Keramaris-Vrantsis, Elizabeth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468<br />
Kerami, Mariam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303, 307<br />
Kernan, Nancy A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230<br />
Kerns, Hannah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 349<br />
Keswani, Rahul K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167<br />
Keswani, Sundeep. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449<br />
Kew, Yvonne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 781<br />
Khai, Nign Cin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 898<br />
Khan, Amir S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22, 504<br />
Khan, Iram F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384, 474<br />
Khan, Rafat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Khanin, Raya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 727<br />
Khare, Reeti . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 60, 414<br />
Khayter, Cyd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300<br />
Khazi, Fayaz . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .49, 883<br />
Khim, Socheath . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260<br />
Kho, Jordan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 384, 474<br />
Khokher, Zeshan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774<br />
Khoury, Maroun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253<br />
Khramtsov, Yuri V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Khundkar, Tahsin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 752<br />
Kidokoro, Minoru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359<br />
Kiem, Hans-Peter . . . . . . . . . . . . . . . . . . . . . . .191, 226, 251, 257, 342,<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344, 372, 485, 637, 865<br />
Kienle, Eike. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 394<br />
Killedar, Smruti . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337<br />
Kim, Baek . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 676<br />
Kim, Dal-Soo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580<br />
Kim, Dong-Eun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297, 435<br />
Kim, Dongho. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 818<br />
Kim, Dukmi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 917<br />
Kim, Eunji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 543<br />
Kim, Hakkyun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86<br />
Kim, Hyun Ah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279, 549<br />
Kim, Jaerim. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 685<br />
Kim, Jaesung. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 527, 806<br />
Kim, Ji-Eun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 909, 929<br />
Kim, Jin-Soo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 543<br />
Kim, Jit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 687<br />
Kim, Jocelyn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219<br />
Kim, Joo-Hang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 818<br />
Kim, Jsaon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555<br />
Kim, Jung Seok. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160<br />
Kim, Jung Seol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158<br />
Kim, Kenneth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99<br />
Kim, Keun-Sik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158, 160, 297, 435<br />
Kim, Kyung-Bo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297<br />
Kim, Mi K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Kim, Minjung. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145, 421<br />
Kim, Myung Goo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166, 817<br />
Kim, Nahyun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 740<br />
Kim, Pyung-Hwan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145, 806<br />
Kim, Seho . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435<br />
Kim, Seong Muk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580<br />
Kim, So Y.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 818<br />
Kim, Soya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Kim, Sun Hwa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166, 734<br />
Kim, Sung Wan . . . . . . . . . . . . . . . . . . . . . . . . . 159, 161, 560, 685, 806<br />
Kim, Tae K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Kim, Tae-Il . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 560, 806<br />
Kim, Yong-Oock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140<br />
Kim, Yoon-Sang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262<br />
Kim, You-Kyoung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 909, 926<br />
Kimelman-Bleich, Nadav . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 772<br />
Kimpel, Janine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 486<br />
Kimura, En . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Kimura, Tsuyoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434<br />
King, Gwendalyn D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 787<br />
Kingsman, Susan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Kingston, H. M. Skip . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 465<br />
Kinnon, Christine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Kinoh, Hiroaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523<br />
Kinoh, Hiromi Hayashita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473<br />
Kirk, Kaitlyn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 868<br />
Kirn, David H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50, 599<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Kirsten, R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Kishida, Akio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434<br />
Kiss, Szilard. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 653<br />
Kitagawa, Teruyuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714<br />
Kitahara, Masahiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248<br />
Kitamura, Atsushi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282<br />
Klatzmann, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Klausner, Eytan A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 751<br />
Kleff, Veronika . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Klein, Christoph . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Klimash, June . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 644<br />
Klimczak, R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 872<br />
Klopp, Ann . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533<br />
Klüppel, Luciana M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 851<br />
Kneissl, Sabrina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110, 830<br />
Knocke, Sarah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790<br />
Knoepfler, Paul S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 575<br />
Knop, David R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 593<br />
Knowling, Stuart E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 554<br />
Knuteen, Russell. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718<br />
Knutson, Darlene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 775<br />
Ko, Kyung S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Kobayashi, Hiroshi. . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 714, 721, 805<br />
Kobinger, Gary P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212, 216<br />
Kobinger, Gary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429<br />
Kobner, Scott. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102<br />
Kocak, Ergun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624<br />
Koch, Walter J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725<br />
Kochanek, Stefan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .57, 416<br />
Kochetkova, Olga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 854<br />
Köchling, Joachim. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506, 507<br />
Koeberl, Dwight D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338, 339<br />
Koeberl, Dwight. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289<br />
Koeberle, Paulo D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544<br />
Koefoed, Mette J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 760<br />
Kogan, Scott . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Kohlbrenner, Erik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 668<br />
Kohn, Donald B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355, 423, 712, 786<br />
Koilkonda, Rajeshwari D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203<br />
Koirala, Adarsha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 748<br />
Koldej, Rachel M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256<br />
Kondratenko, Irina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Kong, Derek. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Kong, Seogkyoung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
Koniar, Brenda L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14<br />
Konieczny, Patryk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 475<br />
Konno, Shunichi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
Konopka, Krystyna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151<br />
Konstantinova, Pavlina . . . . . . . . . . . . . . . . . 562, 564, 566, 569, 847<br />
Koob, George . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283, 652<br />
Koons, Stephen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151<br />
Koornneef, Annemart . . . . . . . . . . . . . . . . . . . . . . . 562, 564, 569, 847<br />
Kordower, Jeffrey. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 870<br />
Koriyama, Hiroshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 736<br />
Korman, V. L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67<br />
Korman, V.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 836<br />
Kornegay, Joe N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52<br />
Korsgren, Olle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502<br />
Kosai, Ken-ichiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 898<br />
Koski, Anniina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77, 795<br />
Kota, Janaiah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867, 892<br />
Kotin, Robert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661<br />
Kottke, Timothy J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .358, 361, 780<br />
Koyama, Yoshiyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152, 237<br />
Kranjc, Simona . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448, 540<br />
Kranz, David M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356<br />
Krause, Anja. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210, 490<br />
Kren, B. T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67, 836<br />
Kren, Betsy T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427<br />
Kreppel, Florian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 147, 416<br />
Krishnamurthy, Sateesh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271<br />
Kroeger, Kurt M. . . . . . . . . . . . . . . . . . . . . .59, 509, 784, 787, 788, 789<br />
Kron, Matthias W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57<br />
Kroon, Evert. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 868<br />
Krsmanovic, Mihajlo L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Ku, Jin-Mo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71<br />
Kuan, Alex. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40<br />
Kuball, Jurgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498<br />
Kubicka, Stefan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790, 804<br />
Kubo, Shuji. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524, 805<br />
Kubodera, Takayuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88<br />
Kucharski, Cezary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162<br />
Kudva, Yogish . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311<br />
Kuehnel, Florian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790, 804<br />
Kuftinec, Gabriela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423<br />
Kühlcke, Klaus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Kuhn, Joseph. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Kuhr, Christian S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623<br />
Kumar, Padmasini . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Kumar, Priti. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .90, 740<br />
Kumar, Sanjay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 323<br />
Kume, Akihiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188, 573, 696, 791<br />
Kung, Hsiang-fu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 819<br />
Kuo, C-J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 873<br />
Kupsch, Jörg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 528<br />
Kuroda, Masayuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
Kurosaki, Hiromasa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 539<br />
Kurosaki, Mariko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 539<br />
Kurupati, Raj K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680<br />
Kushmeric, Martin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Kutay, Huban. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
Kutschera, Ina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42<br />
Kuwahara, Hiroya. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .92, 553<br />
Kuzmenko, Elena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390<br />
Kuzmickas, Ryan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300<br />
Kwon, Hyun-Mi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 167
168<br />
Abstract Author Index<br />
Kwon, Min J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Kwon, Oh-Joon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .145, 421, 685<br />
Kwon, Young Jik. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116, 164<br />
Kwong, Jun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 678<br />
Kyuragi, Ryoichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
L<br />
l’Homme, Bruno. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42<br />
La Perle, Krista. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
La Russa, Vincent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239<br />
Lacayo, Liliana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509, 784<br />
Lachmann, Nico. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32, 369<br />
Ladage, Dennis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 668<br />
Laforet, Pascal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Lagasse, Eric. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371, 574<br />
Lagisetty, Kiran H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231<br />
Lagresle, Chantal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Lahaye, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />
Lai, Chen Yi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312<br />
Lai, Chung Sheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322<br />
Lai, Raymond . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
Lai, Yi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309<br />
Lai, Yi-Hui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 522<br />
Lakshmipathy, Uma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144, 445<br />
Lalezari, Jay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598<br />
Lam, Viola C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Lamarre, Marven . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622<br />
Lamarre, Yann . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 471<br />
Lamb, Lawrence S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
Lampe, Johanna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515<br />
Landry, Breanne. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .155, 534, 810<br />
Lang, Victoria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 857<br />
Langford-Smith, Alexander W. W. . . . . . . . . . . . . . . . . . . . . . 336, 716<br />
Langford-Smith, Kia J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336, 716<br />
Lankester, Arjen C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Laprise, Stéphanie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Lapteva, Natalia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591, 783<br />
Lapus, Felycette G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 932<br />
Larcher, Fernando . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759<br />
Larochelle, Andre . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113, 310<br />
Larochelle, Nancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />
Larsen, John D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 914<br />
Laskey, Joseph A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Latella, Maria Carmela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />
Laufs, Stephanie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Laulund Christensen, Camilla. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 905<br />
Lauten, Melchior . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506, 507<br />
Lavasanifar, Afsaneh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
Lavertu, Marc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .699, 881, 904<br />
Lavi, Amir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 761<br />
Lavigne, Marc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389<br />
Lavilla-Alonso, Sergio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 684<br />
Lavrencak, Jaka. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448<br />
Law, Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3<br />
Lawrence, Roger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />
Lawson, Gregory W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Le Blanc, Shannon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281<br />
Le Guiner, Caroline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .72, 124<br />
Le, Uyenchi N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 917<br />
LeBec, Christine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Leber, Mathias F.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 521, 798<br />
Leber, Mathias Felix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 514<br />
Lech, Patrycja J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 538<br />
Lechman, Eric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
Lee, Albert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Lee, Benhur . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609<br />
Lee, Brendan H. I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54<br />
Lee, Brendan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 478, 820<br />
Lee, Chi-Lin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387<br />
Lee, Dean A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 240, 353, 508<br />
Lee, Donghoon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Lee, Doo Sung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166<br />
Lee, Eun K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285<br />
Lee, Gary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544, 598<br />
Lee, Gwang-Hyun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435<br />
Lee, Hyung Joo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 543<br />
Lee, Jessica. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Lee, Ki Jeong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671<br />
Lee, Kun-Ze . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104<br />
Lee, Lily . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141<br />
Lee, Min Hyung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 549<br />
Lee, Min Sang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166, 817<br />
Lee, Minhyung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .279, 710, 734<br />
Lee, Ni-Chung. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 458, 724<br />
Lee, Sang Ho . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Lee, Sang Kun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 880<br />
Lee, Sang-Kyung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 740<br />
Lee, Seung-Koo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 308<br />
Lee, Sharon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
Lee, Soon H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Lee, Soon-Tae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 880<br />
Lee, Soung-Kyung. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 421<br />
Lee, Tao-Chen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Lee, Won Jai. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140<br />
Lee, Woo Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622<br />
Lee, Yeon Kyung. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158, 160<br />
Lee, Young Won . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159<br />
Lee, Yuhan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166<br />
Lee, Yu-May . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 458<br />
Leen, Ann M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 503, 513, 591<br />
Legakis, Giannoulis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272<br />
Léger, Adrien. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124<br />
Leger, Andrew J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Legorreta–Herrera, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 920<br />
Lei-Butters, Diana C. M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270, 660<br />
Leif, Jean . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 169<br />
Abstract Author Index<br />
Lemaire, Frédéric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 576<br />
Lemay, Julie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390<br />
LeMeur, Guylène . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207<br />
Lemoine, François M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Lemoine, Nicholas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 801, 807<br />
Lemoine, Nick R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516<br />
Lemoine, Nick. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529<br />
Lemp, Nathan A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Leng, Qixin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />
Leo, Simone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606<br />
Leonard, Vincent H. J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 514<br />
Leopold, Philip L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153, 622<br />
Lepetit, Helene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Leroy, Stanley G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194, 646<br />
Lesniak, Maciej S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 683, 915<br />
Leturcq, France. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Levine, Bruce. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Levings, Megan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334<br />
Levitt, Jon M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 783<br />
Lévy, Camille . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 893<br />
Levy, Robert J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 733, 738<br />
Lewandrowski, Grant. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307<br />
Lewin, Alfred S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204, 901<br />
Li, Baozheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131<br />
Li, Chengjian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555<br />
Li, Chengwen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620<br />
Li, Chengyao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .218, 391, 930<br />
Li, Dejia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309, 481<br />
Li, Dinggang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 639<br />
Li, Dongling. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735<br />
Li, Haitang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265<br />
Li, Hojun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Li, Hongmei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 839<br />
Li, Hongshuai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 373<br />
Li, Hongwei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218, 391<br />
Li, Hui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102, 900<br />
Li, James . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Li, JianBin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52<br />
Li, Jianbin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 766<br />
Li, Juan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .52, 468<br />
Li, Julia J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 819<br />
Li, Li. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Li, Lijing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99, 314, 586<br />
Li, Liyuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 536<br />
Li, Mengxin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400, 404, 555, 621, 827<br />
Li, Mingyuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244<br />
Li, Senlin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202<br />
Li, Sheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333, 770<br />
Li, Songtao. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289, 339<br />
Li, Weidong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 792<br />
Li, Wen Chang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 805<br />
Li, Wenjuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438<br />
Li, Wenzhong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 677<br />
Li, Xiaopeng. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399<br />
Li, Xiaozhu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516<br />
Li, Yan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216, 244<br />
Li, Yanhua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 919<br />
Li, Yi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120, 384<br />
Li, Zong-Yi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135<br />
Li, ZongYi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2, 18, 497, 578<br />
Liang, Desheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 697, 698<br />
Liang, Huaping. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 919<br />
Liang, Keng-San. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171<br />
Liang, Yin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 859<br />
Liao, Amy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 910<br />
Liao, Jin-Lin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927<br />
Liao, Jiyuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97, 861, 925<br />
Liao, Tung-Nan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Liberski, Alexandra M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Libleau, Lise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207<br />
Lieber, Andre. . . . . . . . .2, 18, 78, 135, 226, 497, 578, 689, 815, 852<br />
Liikanen, Ilkka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295, 795<br />
Lim, Foong-Yen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449<br />
Limberis, Maria P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108, 214, 326, 545<br />
Lin, Amy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Lin, Chi-Chen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 512, 584<br />
Lin, Chii Mei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302<br />
Lin, Chin-Yu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70<br />
Lin, Chung-Ren . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 547<br />
Lin, Clayton . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168<br />
Lin, Feng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429<br />
Lin, Jacqueline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 294<br />
Lin, Jianping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186, 340<br />
Lin, Kun-Ju . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70<br />
Lin, Marie C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 819<br />
Lin, Matt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219<br />
Lin, Sin Daw. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322<br />
Lin, Xin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107<br />
Lin, Xubin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Lindemann, Dirk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112<br />
Linden, Rafael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 753<br />
Lindert, Steffen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4<br />
Lindqvist, Camilla . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229<br />
Lindstein, Tullia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291<br />
Linette, G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 891<br />
Ling, Changquan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Ling, Chen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131, 330, 402, 406<br />
Lins, Bridget. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327<br />
Linton, Gilda F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833<br />
Liou, Amiee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />
Lipps, Hans-Joachim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390<br />
Lipshutz, Gerald S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285<br />
Lisowski, Leszek . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331, 487<br />
Littman, Nick. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 903<br />
Liu, Chao-Lien. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 294<br />
Liu, Chunsheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 794
170<br />
Abstract Author Index<br />
Liu, Chunyan . . . . . . . . . . . . . . . . . . . . . . . .59, 509, 510, 784, 788, 789<br />
Liu, Dexi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .444, 627, 705<br />
Liu, Guo-Zheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Liu, Hao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496<br />
Liu, Jan-Jan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 316<br />
Liu, Jian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 467<br />
Liu, Katherine H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Liu, Li . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Liu, Mingdong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
Liu, Paul Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 773<br />
Liu, Pei-Qi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498<br />
Liu, Qing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .99, 586<br />
Liu, Shilian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 537<br />
Liu, Su-Fen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Liu, Xiaolin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 639<br />
Liu, Xiaoming . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270, 275<br />
Liu, Xiaoxuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 928<br />
Liu, Xionghao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 697, 698<br />
Liu, Xiu Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834<br />
Liu, Xiuying . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 743<br />
Liu, Yanxin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 537<br />
Liu, Yarong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132<br />
Liu, Ying. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226, 628<br />
Liu, Yuli. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 719, 726<br />
Liu, Z. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 896<br />
Lloyd, Clare M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272<br />
Lo Riso, Pietro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93<br />
Lo, Hanson . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 910<br />
Loader, Julie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
Lockey, Tim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379<br />
Loeb, Keith R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623<br />
Logg, Christopher . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Lombardo, Angelo . . . . . . . . . . . . . . . . . . . . . . .93, 498, 631, 632, 633<br />
Lomeli-R, Christian Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 886, 887<br />
Lopez, Patricia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Lopez, Veronica M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238<br />
Loreto, Andrea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Loretz, Carol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73<br />
Lorson, Christian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 455<br />
Loskog, Angelica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229<br />
Loskog, Angelika . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502<br />
Losordo, Douglas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Lotteau, Vincent. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 706<br />
Lou, Howard H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153, 622<br />
Louis, Sharon A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 860<br />
Louis-Jeune, Vedell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 668<br />
Lovelett, Emilie A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251<br />
Lovric, Jasmina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 614<br />
Lowe, Emily . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Lowenstein, Pedro R. . . . . . . . . . . . 59, 509, 510, 784, 787, 788, 789<br />
Lowes, Linda P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 768<br />
Lowy, Douglas R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 875<br />
Lu, Aiping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96, 367, 373, 769<br />
Lu, An. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84<br />
Lu, Chao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 848<br />
Lu, Connie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 382<br />
Lu, Dao-Pei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 859<br />
Lu, Jiamiao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11<br />
Lu, Jing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333<br />
Lu, Liang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930<br />
Lu, Peijuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .468, 567, 766<br />
Lu, Qi Long. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .468, 567, 766<br />
Lu, Taihe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259, 284<br />
Lu, Yi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 536<br />
Lu, Yuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Lu, Yuanqing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669<br />
Lu, Zhao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672<br />
Lubelski, Jacek . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133, 551<br />
Lubow, Jay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 843<br />
Lucke, Colleen E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504<br />
Lucking, Daniel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404<br />
Luetge, Fabienne. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />
Lukason, Michael J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 656<br />
Lukason, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 664<br />
Luke, Garry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 690, 692<br />
Luke, Jeremy M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 694<br />
Lulay, Christina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43, 343<br />
Lulka, Hubert. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 878<br />
Lundberg, Cecilia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301, 879<br />
Lundberg, Kathryn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 711<br />
Luo, Meihui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275<br />
Luo, Xiaoyan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339<br />
Luo, Yuxia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Lupo Stanghellini, Maria Tersa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605<br />
Lütgehetmann, Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Luxembourg, Alain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Luzi, Paola. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 720<br />
Lv, Yinghui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 923<br />
Lynn, Danielle L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
M<br />
Ma, Nan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 677<br />
Ma, Qiangzhong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 773<br />
Ma, Wenqin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131<br />
Ma, Zhijun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259<br />
Macauley, Shannon L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197<br />
Macedo, Antero . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728<br />
Machitani, Mitsuhiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 682<br />
Machluf, Marcelle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 582<br />
Machuca-R, Catalina. . . . . . . . . . . . . . . . . . . . . . . . . 886, 887, 894, 895<br />
MacLachlan, Timothy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 656<br />
MacLeod, A. Robert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Maczuga, Piotr . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 562, 564, 569, 847<br />
Mader, Emily K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 364<br />
Madinaveitia-V, JA. . . . . . . . . . . . . . . . . . . . . . . . . . . 886, 887, 894, 895
Abstract Author Index<br />
Madoiwa, Seiji. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188<br />
Maeda, Michiko Wada . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473<br />
Maeda, Yasushi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Maeder, Morgan L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300, 686<br />
Maehara, Yoshihiko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103, 523<br />
Maetzig, Tobias. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348<br />
Maeyama, Yoshihiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524<br />
Maezono, Rie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 898<br />
Magdaleno, Susan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 849<br />
Maggio, Aurelio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263<br />
Magharious, Mark M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544<br />
Magnani, Zulma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80, 498, 631, 785<br />
Maguire, Albert M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196, 600<br />
Maguire, Casey A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130<br />
Maguire, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626<br />
Mah, Cathryn S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104, 901<br />
Mahadev, Vaidehi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 501<br />
Mahdipoor, Parvin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 534, 810<br />
Mahmood, Faisal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447<br />
Mahmoud, Enas A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436<br />
Mahzad, Akbarpour . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287<br />
Maisner, Andrea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />
Maisonobe, Thierry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Maiti, Sourindra N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353<br />
Maiti, Sourindra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225<br />
Maitland, Stacy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194<br />
Maitra, Anirban. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 892<br />
Majzoub, Ramsey N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171<br />
Makkia, Rasha S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 748<br />
Malani, Nirav . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 612, 621, 635<br />
Maldonado, Maricela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168<br />
Malech, Harry L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345, 833<br />
Malech, Harry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379, 571<br />
Mali, Reut . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 445<br />
Malik, Punam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344, 613<br />
Malloy, Andrew . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595<br />
Mamman, Sara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260, 349<br />
Mancheño, Uxua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Mancini, Donna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601<br />
Mandel, Ronald J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 752<br />
Manfredi, Anna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 542<br />
Manfredsson, Fredric P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 752<br />
Mangeot, Philippe E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 706<br />
Maniar, Jay M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 424<br />
Manni, Elena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Manns, Michael P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790, 804<br />
Mannucci, Edoardo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Mano, Miguel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 614<br />
Manohar, Rohan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 574<br />
Manoli, Irini . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 452<br />
Manuel, Gidekel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519<br />
Manunta, Maria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
Mao, Hai-Quan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179<br />
Mao, Haoyu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204<br />
Mao, Yanxiong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 653<br />
Maples, Phil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457<br />
Maples, Phillip B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Maples, W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 891<br />
Marchadier, Dawn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102<br />
Marcotte, Joseph. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833<br />
Marcus, Assaf. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29<br />
Marcy, Guillaume. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 844<br />
Marie, Corinne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 695<br />
Mariette, Xavier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Marini, Frank C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533<br />
Marino, Michael P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />
Markelc, Bostjan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448, 540<br />
Markovic, SN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 891<br />
Markusic, David M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288, 663<br />
Maródi, Laszló. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Marozin, Sabrina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 793<br />
Marquez, Rebecca T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561<br />
Marrocco, Elena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 542<br />
Marschke, Christina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506<br />
Marsh, Christopher . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Marshall, Kathleen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600<br />
Marsic, Damien. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 405<br />
Martens, Anton C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 715<br />
Martin, Douglas R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194, 646<br />
Martin, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Martin, Paul T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69<br />
Martínez-F, Francisco . . . . . . . . . . . . . . . . . . . 886, 887, 894, 895, 920<br />
Martino, Ashley T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .288, 402, 619<br />
Martinson, Laura . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 868<br />
Marumoto, Tomotoshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97, 861, 925<br />
Marusich, Elena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725<br />
Maruyama, Kazuo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430, 483<br />
Maruyama, Riichiroh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523<br />
Marx, Howard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Marzioni, Daniela. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295<br />
Marzulli, Marco. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />
Mascoop, Ethan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 596<br />
Mason, Jeffrey B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185<br />
Massie, Bernard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143, 381<br />
Masurier, Carole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Matabosch, Xavier. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461<br />
Matalon, Reuben. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649<br />
Matar, Majed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Mathis, J. Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 530, 912<br />
Matsufuji, Hiroshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 898<br />
Matsui, Hayato . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 682<br />
Matsumoto, Tae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451, 456<br />
Matsumoto, Takuya. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Mattar, Citra N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />
Mattar, Citra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253<br />
Matyunina, Lilya. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 171
172<br />
Abstract Author Index<br />
Mauleon, Itsaso . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Mavilio, Fulvio . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16, 98, 298, 612, 633<br />
May, Shannon M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8<br />
Mayer, F.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Mazzacurati, Lucia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56<br />
McAnulty, Robin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
McBride, Jodi L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650, 837<br />
McBride, Martin W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 853<br />
McBryan, Tony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 853<br />
McCaffrey, Anton P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561<br />
McCarty, Douglas M. . . . . . . . . . . . . . . . . . . . . . . . . 337, 616, 617, 662<br />
McClure, Diane. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
McClure, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 727, 853<br />
McConnell, Bradley. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735<br />
McConnell, Kellie I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 666<br />
McConnell, Ruth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277<br />
McCormack, Natasha. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626<br />
McCoy, Jay R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701<br />
McCray, Jr., Paul B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271<br />
McCray, Paul B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114<br />
McDonald, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628<br />
McDonough, Samantha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .58, 410<br />
McDowell, Amy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
McGee, Jeannine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24<br />
McGinn, Arlo N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 560<br />
McGoogan, Katherine E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
McGowan, P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
McIlwraith, CW. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 871<br />
McIntosh, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Mcintosh, Jenny. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />
McIvor, R. Scott. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14, 255, 702, 877<br />
McKenna, Robert. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 332<br />
McLaren, David G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
McLeod, Andrea. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
McMannis, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 783<br />
McMenamin, Deirdre. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340, 874<br />
McNeer, Nicole Ali. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
McPhee, Scott W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 832<br />
McVey, John H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6<br />
Medina-Echeverz, José . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 776<br />
Medina-Kauwe, Lali . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 843<br />
Meecham, Robert Q. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718<br />
Mehta, Perdeep K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262<br />
Meijer, Dimphna H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 546<br />
Meili, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557<br />
Meisen, W. Hans. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362<br />
Melcher, Alan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361, 780<br />
Melero, Ignacio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Mena, Mayra G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 681<br />
Mena-Enriquez, Mayra. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420<br />
Mendell, Jerry R.. . . . . . . . . . . . . . . . . . . . . . . . . .69, 467, 768, 867, 892<br />
Mendell, Joshua T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867, 892<br />
Mendelsohn, Farrell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Mendes Madeira, Alexandra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207<br />
Mendizabal, Adam M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
Meng, Cuixiang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165, 272<br />
Menne, Stephan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Merella, Stefania. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .264, 606, 607<br />
Merkel, Christian A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 643<br />
Merling, Randall K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833<br />
Mermod, Nicolas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383<br />
Merry, Catherine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336<br />
Merten, Otto-Wilhelm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589<br />
Merzouki, A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 881<br />
Messer, Harald G. P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1<br />
Mezey, Jason G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 653<br />
Mezzadra, Riccardo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298<br />
Mi, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213<br />
Mi, Tiejuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 353<br />
Miao, Carol H. . . . . . . . . . . . . . . . . . . . . . . . . . . 294, 442, 623, 625, 828<br />
Miao, Carol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260<br />
Miccio, Annarita. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98, 298, 633<br />
Michael, Drew. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Michel, Sadelain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263<br />
Miest, Tanner S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515, 517<br />
Miest, Tanner. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 514<br />
Milbauer, Liming . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 822<br />
Millán, José L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451<br />
Millán, José. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 456<br />
Miller, Daniel G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125<br />
Miller, Darren. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281<br />
Miller, Dusty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Miller, Erin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329<br />
Miller, Jeffrey C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 632<br />
Miller, Jr., Francis J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 743<br />
Milligan, Graeme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 727, 853<br />
Miltenyi, Stefan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 594<br />
Mimuro, Jun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188<br />
Min, Jung-Joon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 917<br />
Min, Liang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282<br />
Minai-Tehrani, Arash. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 929<br />
Mineharu, Yohei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 787, 789<br />
Mineno, Junichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777<br />
Mingozzi, F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Mingozzi, Federico . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .403, 600, 823<br />
Minskaia, Ekaterina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 690<br />
Mintz, Paul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559<br />
Mir, Lluis M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703<br />
Miselli, Francesca. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 633<br />
Miskin, James . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603, 750<br />
Mitani, Ko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315<br />
Mitchell, James B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 642<br />
Mitrophanous, Kyriacos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603, 750<br />
Mitsuyasu, Ronald. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266, 598<br />
Mittra, Arjun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Miura, Yoshiaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .241, 674, 911<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Miura, Yoshie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 925<br />
Miura, Yoshie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .97, 861<br />
Mixson, Archibald J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />
Miyake, Koichi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451, 456, 723, 754<br />
Miyake, Noriko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 456, 723<br />
Miyamoto, Shohei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222, 233<br />
Miyamoto, Yasuhide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227<br />
Miyata, Satsuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 696<br />
Mizrahi, Olga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 856<br />
Mizuguchi, Hiroyuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 573, 682<br />
Mizukami, Hiroaki . . . . . . . . . . . . . . . . . . . . . . . .88, 188, 573, 696, 791<br />
Mizuno, Ryoichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 433<br />
Mizusawa, Hidehiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88, 92, 553<br />
Moase, Elaine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62<br />
Moats, Rex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320<br />
Mockaitis, Keithanne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111<br />
Mockenhaupt, Stefan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127<br />
Modlich, Ute . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348<br />
Moerer, Petra. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 715<br />
Moghimi, Babak. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 405, 825<br />
Moguche, Albanus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 349<br />
Mohammad, Husam K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 749<br />
Moiani, Arianna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298<br />
Moimas, Silvia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 532<br />
Molina Estévez, Francisco Javier . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Moll, Alyson L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176<br />
Monahan, Paul E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 832<br />
Mondino, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80<br />
Monnat Jr., Raymond J . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 900<br />
Monroe, W. Todd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176<br />
Monsurrò, Vladia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295<br />
Montane, Joel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334, 335<br />
Montazeri Aliabadi, Hamidreza . . . . . . . . . . . . . . . . . . .155, 534, 810<br />
Montesinos, Carlos A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261<br />
Montgomery, Chrystal L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69<br />
Montini, Eugenio. . . . . . . . . . . . . .264, 383, 606, 607, 610, 611, 829<br />
Montpetit, Alexandre. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428<br />
Montus, Marie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72<br />
Moom, Hyeong-Ho . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 734<br />
Moon, Anne. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50<br />
Moot, Robert. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .189, 778, 873<br />
Morachis, Jose M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436<br />
Morales, Pablo R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392<br />
Moran Cruz, Claudia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Morbitzer, Robert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />
Moreau, Aurélie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />
Moreno, Amira Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170, 283<br />
Moreno, Mario . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883, 899<br />
Morgan, Richard A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228, 231<br />
Mori, Shinji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 539<br />
Mori, Takeshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150, 172<br />
Morioka, Yuka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Morishita, Ryuichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 736<br />
Moritz, Thomas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32, 369<br />
Morizono, Hiroki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340<br />
Morizono, Kouki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609<br />
Morodomi, Yosuke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523, 813<br />
Morral, Nuria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 889<br />
Morris, John C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81, 410, 799<br />
Morris, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58<br />
Morris, Kevin V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 554<br />
Morrison, Nancy E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 646<br />
Moullier, Philippe. . . . . . . . . . . . . . . . . . . .72, 124, 195, 207, 375, 661<br />
Mroske, Cameron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128<br />
Mrugala, Maciej . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 342<br />
Mu, Xin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404, 555<br />
Mueller, Christian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341<br />
Mueller, Peter E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 482, 767<br />
Muench, Marcus O.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Muhammad, A. K. M. G.. . . . . . . . . . . . . . . . . . .59, 509, 784, 787, 788<br />
Muhammad, A. K. M. Ghulam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 789<br />
Muik, Alexander. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 641<br />
Mukai, Hidefumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443<br />
Mukherjee, Malini . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 913<br />
Mukhopadhyaya, Rabindranath . . . . . . . . . . . . . . . . . . . . . . . . . . . 388<br />
Mukumoto, Hanae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 812<br />
Muller, Christian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
Muller, Heike . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529<br />
Mulligan, Richard. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Mullins, Charles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 45<br />
Mundt, Bettina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790<br />
Munn, David H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213<br />
Muñoz, Nina M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 637<br />
Murakami, Masahiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92<br />
Murakami, Yusuke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222<br />
Muranski, Pawel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 350<br />
Murphy, Sam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Murray, Christopher B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163<br />
Murray, Elizabeth E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429<br />
Murtaugh, Michael P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427<br />
Murugesan, Selva . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883<br />
Musher, Benjamin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496<br />
Mussolino, Claudio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34<br />
Muthuramu, Ilayaraja. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737<br />
Muzyczka, Nicholas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 332<br />
Myers, Rae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 364<br />
N<br />
Naash, Muna I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 748<br />
Nace, Rebecca A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 802<br />
Nace, Rebecca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 360<br />
Nagai, Yoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97, 861, 925<br />
Nagasaki, Yukio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305<br />
Nagata, Tetsuya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 558<br />
Nagpal, Poonam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 173
174<br />
Abstract Author Index<br />
Naik, Shruthi K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 360, 802<br />
Nair, Sangeeta. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 243<br />
Naitza, Christopher S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . .397, 407, 659<br />
Nakagami, Futoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 736<br />
Nakagami, Hironori. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 736<br />
Nakai, Hiroyuki . . . . . . . . . . . 126, 129, 187, 397, 407, 476, 479, 659<br />
Nakamori, Masayuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Nakamura, Akinori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473<br />
Nakamura, Takafumi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359<br />
Nakamura, Tsutomu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Nakanishi, Masataka. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179<br />
Nakanishi, Yoichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .103, 222, 233<br />
Nakao, Akimasa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Nakashiro, Koh-ichi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418<br />
Nakauchi, Hiromitsu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312, 714<br />
Nalbantoglu, Josephine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />
Naldini, Luigi . . . . . . . . . . . . . . . . . . . . 93, 94, 267, 287, 290, 377, 498,<br />
. . . . . . . . . . . . . . . . . . . . . 604, 606, 607, 610, 611, 631, 632, 633, 829<br />
Nam, Hye Yeong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161, 806<br />
Nam, Kwangwoo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434<br />
Nam, Kyungmin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 685<br />
Naranjo, Araceli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351<br />
Narasimha, Pavitra. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 842<br />
Narisawa, Sonoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451, 456<br />
Narrow, Wade . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39<br />
Narumi, Kenta. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235<br />
Narusawa, Megumi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222, 233<br />
Nasimuzzaman, Md . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 608<br />
Nassar, Boulos S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399<br />
Nassar, Boulos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 654<br />
Nathwani, A. C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Nathwani, Amit C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587<br />
Nathwani, Amit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46<br />
Naundorf, Sonja. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343<br />
Navon, Gil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320<br />
Naylor, Stuart. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603, 750<br />
Nedeljkovic-Kurepa, Ana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 912<br />
Negishi, Yoichi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483<br />
Nègre, Didier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 876, 893<br />
Nehete, Pramod. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 488<br />
Nelson, Christopher E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 839, 841<br />
Nemunaitis, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457, 505<br />
Neri, Margherita. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 631<br />
Nettelbeck, Dirk M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139, 528<br />
Nettelbeck, Dirk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 378<br />
Newman, Nikki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272<br />
Ng, Joanna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Ng, Philip . . . . . . . . . . . . . . . . . . . . . . . . . 3, 45, 54, 136, 147, 277, 317,<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .414, 419, 460, 488, 509, 784<br />
Ng, Rainer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 763<br />
Ng, Robert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 396<br />
Ng, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3<br />
Ng, Yuk-Yin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Nguyen, Catherine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 928<br />
Nguyen, Juliane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565<br />
Nguyen, Quynh V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36<br />
Nguyen, Quynh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 466<br />
Ni, Weihua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Nibu, Ken-ichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Nice, Katie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 870<br />
Nichols, Timothy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 829<br />
Nickerson, Michael L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124<br />
Nicklin, Stuart A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 729<br />
Nicolai, C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Nicolaus, Anke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249<br />
Niebuhr, Birte . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Nienhuis, Arthur W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .256, 587, 602<br />
Niers, Johanna M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303, 307<br />
Nii, Takenobu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97, 861, 925<br />
Niidome, Takuro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150, 172<br />
Niizawa, Gabriela A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74, 476, 479<br />
Nik-Ahd, Farnoosh. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 470<br />
Nikhamin, Yan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495<br />
Nimesh, Surendra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 904<br />
Nishikawa, Makiya. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 812<br />
Nishikawa, Yoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520, 803<br />
Nishina, Kazutaka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .92, 553<br />
Nishina, Tomoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 553<br />
Nishiyama, Akiyo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473<br />
Nitahara-Kasahara, Yuko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 764<br />
Niu, Jing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672<br />
Nixon, Alan J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .316, 477, 480<br />
No, Daniel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774<br />
Noble, Misty L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .442, 623, 625<br />
Nokisalmi, Petri. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77, 795<br />
Nolta, Jan A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24<br />
Nomoto, Shuji. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Nonnenmacher, Matthieu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 398<br />
Nonomura, Norio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227<br />
Noordman, Yvet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133<br />
Norvell, Fabienne. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Noske, Nadja . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 630<br />
Nounou, Mohamed I.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735<br />
Noviello, Maddalena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605<br />
Nowicki, M. Oskar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362<br />
Nowrouzi, A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Nowrouzi, Ali. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 223, 343, 632<br />
Nukaya, Ikuei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777<br />
Nukiwa, Toshihiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 531<br />
Nuovo, Gerry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361, 891<br />
Nusco, Edoardo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 454<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
O<br />
O’Callaghan, Cristopher . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106<br />
O’Connor, Deirdre M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 907<br />
O’Dea, Shirley . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626
Abstract Author Index<br />
O’Donnell, Patricia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43, 726<br />
O’Malley, Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599<br />
O’Malley, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43<br />
O’Neill, Ann Marie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138<br />
O’Reilly, Richard J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230<br />
O’Sullivan, Gerald C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .511, 535, 906<br />
Oakland, Mayumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114<br />
Obach, Merce . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334, 335<br />
Oberg, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 801, 807<br />
Ochiya, Takahiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235<br />
Oda, Masafumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 705<br />
Odaka, Yoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 912<br />
Odegard, J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Odom, Guy L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 466, 472<br />
Odon, Valerie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692<br />
Oh, Anthony . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 370, 761, 772, 856<br />
Oh, Seeun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 818<br />
Oh, Wonil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 580<br />
Ohashi, Kazuo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190, 440<br />
Ohashi, Toya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714, 721<br />
Ohira, Shinga. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88<br />
Ohkouchi, Shinya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 531<br />
Ohlemiller, Kevin K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717<br />
Ohmine, Ken . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 791<br />
Ohmine, Seiga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311<br />
Ohmori, Tsukasa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188, 190<br />
Ojeda, Sergio R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650<br />
Okabe, Motohito . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312<br />
Okada, Hironori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473, 764<br />
Okada, Michiyo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97, 861, 925<br />
Okada, Starlyn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211<br />
Okada, Takashi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473, 764<br />
Okamoto, Sachiko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777<br />
Okamoto, Shinya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Okamura, Haruki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524<br />
Okamura, Nobutaka. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524<br />
Okano, Shinji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 861<br />
Okano, Teruo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190, 440<br />
Okazaki, Jin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Okazuka, Kiyoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251<br />
Olafsen, Tove . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609<br />
Olivares, Simon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224, 234, 354, 500<br />
Oliveira, Giacomo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605<br />
Oliveira, Satiro N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355<br />
Olsen, John C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274<br />
Olson, Erik M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 258<br />
Olson, Erik R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255<br />
Oneal, Michael J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410, 799<br />
Oneal, Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58<br />
Onimaru, Mitsuho. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Onishi, Akira. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 696<br />
Onodera, Masafumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312<br />
Onohara, Toshihiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Øpstad, Christer L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Opyrchal, Mateusz . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 365<br />
Orban, Paul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334<br />
Orimo, Hideo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 456<br />
Ortved, Kyla O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 477<br />
Osada, Kensuke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
Osada, Takuya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289<br />
Osborn, Mark J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 686<br />
Osborne, William R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44<br />
Ostberg, Julie R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38, 352<br />
Ostertag, Derek . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Osting, Susan M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670<br />
Ostrowska, Alina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 854<br />
Otani, Yuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443<br />
Otoi, Takeshige. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />
Otsu, Makoto. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312, 714<br />
Otsuka, Makoto . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154<br />
Otsuki, Naoki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Otte, Jürgen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 641<br />
Ou, Wu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31, 382<br />
Ouellet, Dominique L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 304<br />
Ousterout, David G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422<br />
Owusu-Boaitey, Nana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 830<br />
Ozawa, Keiya . . . . . . . . . . . . . . . . . . . . . . . . . . . . .88, 188, 573, 696, 791<br />
P<br />
Pacholska, Agnieszka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 816<br />
Pack, Daniel W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167<br />
Pagano, Claudio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Pagovich, Odelya E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 652<br />
Pahnke, Jens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411<br />
Pai, Sung-Yun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
Paila, Kalyan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 465<br />
Pala, Mauro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610<br />
Palapattu, Ganesh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513<br />
Paleari, Ylenia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298<br />
Palfi, Stephane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Palmer, Abbygail A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169<br />
Palmer, Donna J. . . . . . . . . . . . . . . . . . . . . . . . 3, 45, 54, 136, 147, 277,<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .317, 414, 419, 460, 488, 509, 784<br />
Pan, Dao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .40, 306<br />
Pan, Jason. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345<br />
Pandey, Sanjay K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Pandha, Hardev . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361<br />
Pang, Jijing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199<br />
Pankert, Teresa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 394<br />
Pankhong, Panyupa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Papayannopoulou, Thalia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
Pappen, Beena O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Pâques, Frédéric. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .425, 428, 576<br />
Pardo, Luis A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 570<br />
Pardo, Luis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 850, 851<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 175
176<br />
Abstract Author Index<br />
Pardridge, William M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63<br />
Paredes-Gamero, Edgar Julian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 446<br />
Park, Jae Hyung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 817<br />
Park, Jeong H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Park, Ji Hwan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279, 549<br />
Park, Jung-Heun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 707<br />
Park, Kkothanahreum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297<br />
Park, Morag . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Park, Sung-Jin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 929<br />
Park, Tae Gwan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166<br />
Park, Yong Serk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .158, 160, 435<br />
Parker, Alan L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6<br />
Parker, Matthew. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669<br />
Parker, Maura H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73<br />
Parrish, Colin R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 374<br />
Parsons, David W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .273, 278, 281<br />
Partali, Vassilia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Partanen, Kaarina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 795<br />
Paruzynski, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43, 343<br />
Paschon, David E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498, 648<br />
Paschon, David. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Passineau, Michael J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 465<br />
Pastore, Joseph. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Pastore, Nunzia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317, 454<br />
Patel, Ami . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212, 216<br />
Patel, Bella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363<br />
Patel, Ekta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211<br />
Patel, Manij. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274<br />
Patel, Priti . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />
Patil, Rajesh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179<br />
Patron, Juan P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118<br />
Paulk, Nicole K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48<br />
Paulmurugan, Ramasamy . . . . . . . . . . . . . . . . . . . . . . . .541, 644, 645<br />
Paulson, Henry L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 846<br />
Paul-Wetterberg, Gabriella. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229<br />
Pauly, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601<br />
Paweska, Janusz. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 556<br />
Paya, Monica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431<br />
Peccatori, Jacopo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605<br />
Pechnick, Robert N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509, 784<br />
Pedersen, Alexandra G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 760<br />
Pegram, Hollie J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239<br />
Pei, Duanqing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 863<br />
Pelled, Gadi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 370, 761, 772<br />
Pellenz, Stefan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 900<br />
Pellin, Danilo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .98, 612<br />
Pellina, Danilo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 264<br />
Penaud-Budloo, Magalie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124<br />
Pence, Casey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Peng, Bo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245<br />
Peng, Ching-An . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178<br />
Peng, Jianxiong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 698<br />
Peng, Kah-Whye. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .364, 794, 888<br />
Peng, Ling. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 928<br />
Peng, Yibing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213<br />
Penn, Marc S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Perebeov, Alexander . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 912<br />
Pereira, Linus Q. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 851<br />
Pérez, Belen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557<br />
Perez-Pinera, Pablo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422<br />
Perlson, Eran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618<br />
Perrin, George Q. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619<br />
Persons, Derek A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .262, 346, 608<br />
Persson, Jonas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2, 18, 78, 226, 815<br />
Pertschuk, Daniel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Peschanski, Marc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 706<br />
Pesonen, Sari. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 295, 795<br />
Petek, Lisa M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125<br />
Petrs-Silva, Hilda. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 753<br />
Petry, H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Petry, Harald . . . . . . . . . . . . . 133, 183, 551, 562, 564, 566, 569, 847<br />
Pettersson, Pelle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Pfaff, Nils . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369<br />
Pfizenmaier, Klaus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357<br />
Pham, Nhung P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 840<br />
Phan, Haley . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116<br />
Philipson-Weiner, Lindsey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504<br />
Phillips, JN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 871<br />
Phillips, Neil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148, 424<br />
Philpott, Nicola J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 822<br />
Philpott, Nicola. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255<br />
Piao, Wenying . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 553<br />
Piccolo, Pasquale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317, 460<br />
Pierce, Eric A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600<br />
Pierson, Tyler M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 882<br />
Pietruszka, Marvin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774<br />
Piguet, Françoise . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Pike, Lisa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307<br />
Pike-Overzet, Karin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Pikkarainen, Jere . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 816<br />
Pilla, James J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725<br />
Pinard, Maxime. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />
Pinnamaneni, Kranthi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Piovani, Bianca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588<br />
Pisera, Daniel A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 788<br />
Pitzer, Mark R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650<br />
Plati, Tiziana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611<br />
Plesa, Gabriela. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Plinkert, Peter K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 798<br />
Plotkin, Jason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Plump, Andrew S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Poddar, Minakshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96<br />
Poderycki, Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144<br />
Podetz-Pedersen, Kelly M. . . . . . . . . . . . . . . . . . . . . . . . . . 14, 702, 877<br />
Podhajcer, Osvaldo L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238, 519<br />
Podsak<strong>of</strong>f, Gregory M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 823<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Poeschla, Eric M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />
Pointreau, Adeline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 902<br />
Poirot, Laurent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425, 576<br />
Polach, Kevin J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Polacino, Patricia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 485<br />
Poletti, Valentina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98<br />
Pollok, Jörg-Matthias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Poncz, Mortimer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257<br />
Ponder, Katherine P. . . . . . . . . . . . . . . . . . . . . . . . . . . 43, 718, 719, 726<br />
Pondugula, Satyanarayana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256<br />
Ponnazhagan, Selvarangan. . . . . . . . . . . . . . . . . . . . . . . . . . . 323, 615<br />
Ponomarev, Vladimi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Poon, Steven . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Poon, Wai S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 819<br />
Porada, C. D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 873<br />
Porciatti, Vittorio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203<br />
Portales-Casamar, Elodie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Porteus, Matthew H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 634, 648<br />
Pouliot, Yannick . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86<br />
Poulsen, Hans Skovgaard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 905<br />
Powell, Jr., Daniel J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 782<br />
Powell, Suzanne Z. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 781<br />
Power, Shelby T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670<br />
Prantner, Andrew M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163<br />
Prausnitz, Mark R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 628<br />
Préat, Véronique. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 695<br />
Preston, Thomas J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69<br />
Preuss, Ellen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 641<br />
Price, Brandee A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Prieto, Jesús . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 776<br />
Prikhodko, Olga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71<br />
Prill, Jan-Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 416<br />
Prockop, Darwin J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105, 531<br />
Prosser, Megan E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499<br />
Proto, Jonathan D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367, 373<br />
Provasi, Elena. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80, 498, 631<br />
Provost, Nathalie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207<br />
Provost, Patrick . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 304<br />
Pruzynski, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347<br />
Psatha, Nikoleta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Puig, Meritxell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 417<br />
Pulicherla, Nagesh. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328<br />
Pulido, Jose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 780<br />
Pulliam-Leath, Anna C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112<br />
Pun, Suzie H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 174, 177, 426<br />
Pungente, Michael D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Puntel, Mariana . . . . . . . . . . . . . . . . . . . . . . . . . .59, 509, 784, 787, 789<br />
Puppo, Agostina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 542<br />
Puri, Nitin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 849<br />
Puri, Raj K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31<br />
Pützer, Brigitte M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411<br />
Q<br />
Qasim, Waseem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759<br />
Qian, Kun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 739<br />
Qiao, Chunping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .52, 468<br />
Qin, Elizabeth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717<br />
Qin, Qiuyue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185<br />
Qin, Yuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 639<br />
Qiu, Jianping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 652<br />
Qiu, Jinlang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218, 391<br />
Qu, Jinrong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30, 263<br />
Qu, Yanyan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232<br />
Quach, Eric T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 907<br />
Quetglas, Jose I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 776<br />
Quinn, Thomas P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141<br />
Quintanilla, Rene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144<br />
Quintino, Luis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301<br />
Quiviger, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Quiviger, Mickaël. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 695<br />
Qureshi, Ammar T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176<br />
R<br />
Rabinowitz, Joseph. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725<br />
Rader, Daniel J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102<br />
Radrizzani, Marina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 829<br />
Radu, Antonetta. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 823<br />
Radvanyi, Laszlo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225<br />
Raff, Gary W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286<br />
Rafi, Mohammad A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 720<br />
Raggi, Eugene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74<br />
Rah, Dong Kyun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140<br />
Rai, Lena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363<br />
Raimondi, Laura. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Raja, Srinivasa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 749<br />
Raki, Mari . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295<br />
Ralph, Scott . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Ramakrishnan, Aravind . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257<br />
Ramakrishnan, S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 702<br />
Ramamoothy, Meera . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718<br />
Ramirez, Juan C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431<br />
Ramlogan, Charmaine A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81<br />
Rammelt, Stefan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 469, 482<br />
Ramos, Julian N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 475, 762<br />
Ramsey, Austin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Randhawa, Sandeep . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 808<br />
Ranzani, Marco. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607, 610, 611, 829<br />
Rao, Anitha. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .99, 586<br />
Rao, Han Zhi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 720<br />
Rao, Mahadev . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228<br />
Rao, Nagesh P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Raoul, Sylvie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Rapti, Kleopatra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 668<br />
Raschke, James J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 670<br />
Rassi, Anahita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 177
178<br />
Abstract Author Index<br />
Ratner, Dmitry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404<br />
Rauschhuber, Christina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299, 378<br />
Rawlings, David J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35, 260, 349, 687<br />
Read, Stanley E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 897<br />
Rea-Ramsey, Angela. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Reay, Daniel P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74<br />
Rebar, Ed. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Rebar, Edward J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Recchia, Alessandra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 612, 633<br />
Reed, Charles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883<br />
Reed, S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Reichenbach, Janine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347, 390<br />
Reik, Andreas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 423, 498, 903<br />
Reilly, Meghan J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175, 914<br />
Reineke, Theresa M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68<br />
Reinhart, Bonnie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 56<br />
Reiser, Jakob . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31, 382<br />
Reiss, U. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Rementer, Cameron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 741<br />
Remy, Philippe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603<br />
Ren, Dong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 639<br />
Ren, Gaoying. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10, 474<br />
Ren, Yong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179<br />
Rentsendorj, Altan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 843<br />
Renzi, Christopher. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Resende, Fernando F. B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 850<br />
Ressler, Julie A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351<br />
Restifo, Nicholas P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 350<br />
Reuser, Arnold J. J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713<br />
Reynolds, Holly M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12<br />
Reyon, Deepak . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300<br />
Rhee, Byung D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Rice, Jennifer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Rice, Karen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45<br />
Richard, Magali. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 695<br />
Richardson, Dean W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185<br />
Richardson, Jason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212<br />
Richter, Maximilian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139<br />
Riddell, A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Riddell, Stanley R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Riera-Knorrenschild, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Riggs, Arthur D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 550<br />
Riggs, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 575<br />
Rigolet, Aude. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Riley, James L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292<br />
Rinkoski, Tommy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />
Ripamonti, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Rising, Aaron C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 752<br />
Ritsema, Tita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564<br />
Rivera, Angel A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 912<br />
Rivera, Hector . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128<br />
Rivers, Angela E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327<br />
Rivière, Isabelle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 230, 263, 791<br />
Rizzardi, Gian-Paolo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588<br />
Rizzi, Ermanno . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .98, 612<br />
Robbins, Paul D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .96, 367<br />
Robbins, S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Robbins, Zachary J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159<br />
Roberts, Alison . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Roberts, Jeffrey N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 875<br />
Roberts, Marie S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197<br />
Rocca, Céline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Rocchi, Palma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 928<br />
Rockey, William M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834<br />
Rodgers, John. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 820<br />
Rodichenko, Nikita S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Rodijk, Mark. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Rodino-Klapac, Louise R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69<br />
Rodriguez, Ron. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
Rodriguez, Stephen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 597<br />
Rodriguez-Lebron, Edgardo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 846<br />
Roeder, Ingo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Roescher, Nienke. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
R<strong>of</strong>fler, Steve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226<br />
Roh, Jae-Kyu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 880<br />
Rokkam, Venkata . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 726<br />
Rolling, Fabienne. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207<br />
Romano, Valentina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />
Romero, Norma B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Rommelfanger, Diana M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 358, 361<br />
Roncarolo, Maria-Grazia . . . . . . . . . . . . . . . . . . . . . 287, 290, 377, 604<br />
Rooney, Cliona M. . . . . . . . . . . . . . . . . . . . . . 15, 20, 84, 496, 503, 591<br />
Rosales, C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Rosales, Xiomara Q.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 768<br />
Rosas, Lucia E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 617<br />
Rose, Laura. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162<br />
Rose, Scott D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271<br />
Rosenberg, Jonathan B. . . . . . . . . . . . . . . . . . . . . . 170, 283, 652, 821<br />
Rosenberg, Steven A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228, 231<br />
Rosenkranz, Andrey A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Rosewell, Amanda. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .147, 277, 414<br />
Rosier-Montus, Marie-Françoise . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Ros<strong>of</strong>f, Howard. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 903<br />
Rossi, John J. . . . . . . . . . . . . . . . .89, 99, 118, 265, 304, 489, 493, 559<br />
Rossi, Paolo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267<br />
Rotella, Carlo Maria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Roth, Shoshannah L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 635<br />
Rothschilds, Adrienne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 442<br />
Rott, Yvonne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506, 507<br />
Roujeau, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Rouseau, Joël . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428<br />
Rouvinen-Lagerström, Noora . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />
Rouy, Didier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Rowley, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357<br />
Roy, Andre J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 592<br />
Roy, Jackie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Roy, Soumitra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19, 292<br />
Rozemuller, Henk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 715<br />
Rozengurt, Nora. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Ruben, Boado . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63<br />
Ruggeri, Marco. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203<br />
Ruggiero, Eliana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223<br />
Ruiz, Rafaela. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 889<br />
Ruozi, Giulia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728<br />
Rushing, Elisabeth J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 747<br />
Russell, David W.. . . . . . . . . . . . . . . . . . . . .10, 120, 258, 384, 474, 493<br />
Russell, Stephen J. . . . . . . . . 360, 364, 538, 794, 802, 877, 888, 893<br />
Rustagi, P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Rutcliffe, Sarah J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
Rutledge, John C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286<br />
Ruzo, Albert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
Ruzsics, Zsolt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 679<br />
Ryals, Renee. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199<br />
Ryan, Christine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355<br />
Ryan, Martin D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 690, 692<br />
Ryffel, Bernard. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Ryu, Byoung Y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260, 349, 637, 687<br />
S<br />
Sachidanandam, Ravi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37<br />
Sack, Brandon K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 825<br />
Sadeghi, Arian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502<br />
Sadelain, Michel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 230, 791<br />
Saenz, Dyana T.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />
Sætrom, Pål . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559<br />
Safinya, Cyrus R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171<br />
Sagawa, Hiroaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141<br />
Sagner, Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 507<br />
Saha, Sunandan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15<br />
Sahaghian, Arineh. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355<br />
Sahakyan, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Sahenk, Zarife . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .768, 69<br />
Sahin, Tevfik T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Saifuddin, Sameer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735<br />
Saini, Massimo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94<br />
Saito, Satoru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523, 813<br />
Saito, Yasushi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
Sakai, Atsushi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 723<br />
Sakamoto, Chika . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222, 233<br />
Sakamoto, K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 886, 895<br />
Sakamoto, Kouichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 898<br />
Sakata, Yoichi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188, 190<br />
Sakr, Hany I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 530<br />
Saksela, Kalle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 684<br />
Sakurai, Fuminori. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 682<br />
Salanti, A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Salazar-Montes, Adriana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420<br />
Salem, Alireza . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509, 784<br />
Saleme, Vera . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 742<br />
Salmon, Florence. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 551<br />
Salmons, Brian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 869<br />
Salomon, Daniel R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 712<br />
Salomoni, Monica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 604<br />
Salsman, Vita S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .496, 781, 913<br />
Saltzman, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 702<br />
Saltzman, W. Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
Salvatori, Francesca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588<br />
Samaranayake, Haritha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 816<br />
Samoto, Vivian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 742<br />
Sampath, Padma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 412<br />
Sampath, Prakash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
Sampedro, Ana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Samson, Mélanie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5<br />
Samuel, Isaac. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 655<br />
Samulski, R. Jude . . . . . . . . . 395, 548, 585, 620, 634, 651, 832, 871<br />
Sanchez, Ceidy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513<br />
Sanda, C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 873<br />
Sandadi, Samith. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495<br />
Sander, Jeffry D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300<br />
Sandoval, Ana S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 681<br />
Sandoval, Ivette M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Sandoval-Rodriguez, Ana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420<br />
Sandoval-Z, Hugo . . . . . . . . . . . . . . . . . . . . . . . . . . . 886, 887, 894, 895<br />
Sands, Mark S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197, 717<br />
Sangermano, Riccardo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 460<br />
Sankaranarayanan, Jagadis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436<br />
Sano, Asami . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434<br />
Santacruz, Rene A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202<br />
Santhekadur, Prasanna K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242<br />
Santillan, Jazmin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 681<br />
Sanvito, Francesca. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610<br />
Saraiva, Luisa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156<br />
Sardesai, Niranjan Y. . . . . . . . . . . . . . . . . . . . . . . . . . . 22, 429, 504, 701<br />
Sardi, Pablo S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205<br />
Sareen, Dhruv . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
Sargent, R. Ge<strong>of</strong>frey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Sarkar, Devanand. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242<br />
Sartori, Daniela . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 298<br />
Sarwari, Roya. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254<br />
Sasaki, Erika . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .97, 861<br />
Sasaki, Yoshihiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434<br />
Sastry, Jagannadha. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 488<br />
Sather, Blythe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260, 349<br />
Sauth<strong>of</strong>f, Harald . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415<br />
Sauvageau, Guy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 372<br />
Savoldo, Barbara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 785<br />
Sawall, Stefanie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .514, 521, 528<br />
Saxena, Romil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 889<br />
Scaramuzza, Samantha. . . . . . . . . . . . . . . . . . . . . . . . . . .264, 267, 604<br />
Scari, Puthupparampil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66<br />
Scaria, Abraham. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 656, 664<br />
Schache, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 804<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 179
180<br />
Abstract Author Index<br />
Schaer, Gary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Schaffer, David V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122, 654, 840, 872<br />
Schambach, Axel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 269, 348, 369<br />
Scharenberg, Andrew M. . . . . . . . . . . . . . . . . . . . . . . . . . . 35, 637, 687<br />
Schenkwein, Diana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109<br />
Scherer, Lisa J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489<br />
Scherman, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439, 695<br />
Scheule, Ronald K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165<br />
Schiestl, Robert H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Schietinger, Andrea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356<br />
Schiffer-Mannioui, Cécile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425<br />
Schiller, John T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 875<br />
Schirmbeck, Reinhold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57<br />
Schleifman, Erica B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
Schliesser, Maximilian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42<br />
Schmelzer, Leah. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392<br />
Schmid, Manfred . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347<br />
Schmidt, Anke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411<br />
Schmidt, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 87, 123<br />
Schmidt, Manfred . . . . . . . . . . . . . . . . . . . . .42, 43, 46, 223, 264, 269,<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .343, 383, 389, 607, 610, 611, 632<br />
Schmidt, Manuel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506, 507<br />
Schmidt, Warren N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561<br />
Schmoll, H. J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Schneider, Irene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386<br />
Scholler, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Scholler, Nathalie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163<br />
Scholz, Simone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 269, 389<br />
Schowalter, David B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 877<br />
Schreiber, Hans. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356<br />
Schreiber, Karin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356<br />
Schr<strong>of</strong>f, M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 87<br />
Schrump, David S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228<br />
Schubert, Kathryn M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371<br />
Schubert, Kathryn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 574<br />
Schultz, Brian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 762<br />
Schwartz, Marc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 910<br />
Schwarze, Ulrike. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 474<br />
Scimeca, Michael S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 316, 480<br />
Scott, David W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 830<br />
Scott, Emma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200<br />
Scott, Tristan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 556<br />
Segall, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502<br />
Seger, Reinhard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347, 390<br />
Segovia, Mercedes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />
Segura, Maria Mercedes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 417<br />
Segura, Tatiana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168<br />
Sekar, Thillai V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 644, 645<br />
Sekine, Shoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483<br />
Selby, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361, 780<br />
Semechkin, Andrey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100, 854<br />
Semechkin, Ruslan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100, 854<br />
Semenova, Ekaterina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 759<br />
Sénac, Julien S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 452<br />
Sénac, Julien S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 152, 452<br />
Sena-Esteves, Miguel . . . . . . . . . . . . . . .130, 194, 546, 646, 649, 745<br />
Senyukov, Vladimir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 508, 903<br />
Senzer, Neil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Sepe, Rosa Maria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317, 454<br />
Seppen, Jurgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 858<br />
Sergi Sergi, Lucia . . . . . . . . . . . . . . . . . . . . . . . 267, 377, 607, 610, 829<br />
Sergijenko, Ana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336, 716<br />
Serra, Montserrat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461<br />
Sersa, Gregor. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448, 540<br />
Servais, Laurent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72<br />
Sest, Maike . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 879<br />
Seth, Prem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 675<br />
Sevin, Caroline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Seyfried, Thomas N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 646<br />
Sgouramali, Eleni. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Sgualdino, Jacopo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606, 611<br />
Shababi, Monir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 455<br />
Shaban, Mona. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567<br />
Shackleton, Cedric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461<br />
Shafer-Weaver, Kimberly. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 899<br />
Shaffer, Donald R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
Shafiani, Shahin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 491<br />
Shah, Priya S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 840<br />
Shah, Vinit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Sharma, Anurag . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 490<br />
Sharma, Priyanka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7<br />
Sharma, Rajiv. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Sharon, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 808<br />
Shaw, Aaron. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 590<br />
Shawler, Daniel L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 814<br />
Shayakhmetov, Dmitry M. . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 409, 491<br />
Shedlock, Devon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Shen, Hong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157<br />
Shen, Shen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 393<br />
Shen, Xuefei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22, 429<br />
Shen, Ying. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415<br />
Sheng, Jackie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671<br />
Shenker, Larrisa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Sherman, Mark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Sherman, Warren. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101<br />
Sheyn, Dima . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 856<br />
Sheyn, Dmitriy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .320, 370, 761<br />
Shi, Donglu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449<br />
Shi, Juan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 537<br />
Shi, Julie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174, 177<br />
Shi, Junwen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391<br />
Shi, Weijie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247<br />
Shi, Yijun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 882<br />
Shi, Yimin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250<br />
Shibata, Masa-Aki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
Shida, Hisatoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Shields, Jordan E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189, 778<br />
Shih, Chia-Chiao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 512<br />
Shihabuddin, Lamya S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201, 205<br />
Shikada, Yasunori. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523<br />
Shikano, Toshio. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 803<br />
Shiku, Hiroshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777<br />
Shim, Min Suk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116, 164<br />
Shimada, Hideaki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Shimada, Takashi . . . . . . . . . . . . . . . . . . . . . . . . .88, 451, 456, 723, 754<br />
Shimada, Yohta. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 721<br />
Shimizu, Keiji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248<br />
Shimizu, Saki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Shimokawa, Mototsugu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Shin, Jin-Hong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 473, 771<br />
Shin, Ji-Young . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 909, 929<br />
Shin, Jung Ah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 740<br />
Shin, Young Eun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158, 160<br />
Shine, Jui-Hung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927<br />
Shirakawa, Toshiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Shirley, Shawna A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 441<br />
Shontz, Kim M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 892<br />
Shpall, Elizabeth J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20, 353<br />
Shukla, Ravi S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 845<br />
Shultz, Leonard D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90<br />
Shumann, Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 808<br />
Sibilia, Jean. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Sicard, Flavie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 878, 902<br />
Siegal, <strong>Gene</strong> P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459<br />
Siegel, Don L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186<br />
Siemann, Dietmar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Sievers, Richard E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Sikorski, Rachel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 412<br />
Silberg, Jonathan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 408<br />
Siler, Ulrich . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347, 390<br />
Silva, Guilherme. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735<br />
Silva, Simoneide S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 851<br />
Silve, Aude . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703<br />
Sim, Sotcheadt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 904<br />
Simone, Scholtz . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 383<br />
Simons, David L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Simpson, Dana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262<br />
Simpson, Elizabeth M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Sims, Jason. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423<br />
Sin, Jeong-Im . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236<br />
Sinai, Pedram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774<br />
Singh, Harjeet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224, 354<br />
Sinn, Patrick L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114<br />
Sirvente, Raquel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 742<br />
Siu, Karen K. W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278<br />
Sivaraman, Sara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130<br />
Skog, Johan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130<br />
Skuk, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 471<br />
Slater, John H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 666<br />
Slawin, Kevin M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 783<br />
Sleep, S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Sleep, Susan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379, 587<br />
Sleeper, Meg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 719, 726<br />
Slepushkin, V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Sliwka, Hans-Richard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153<br />
Slobodkin, Gregory. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Slough, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Slovin, Susan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Small, Juliana C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680<br />
Smerdou, Cristian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 776<br />
Smith, Bruce F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138<br />
Smith, Jeffrey S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136<br />
Smith, Julianne. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425, 576<br />
Smith, Laura J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329, 663<br />
Snapper, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Snyder, Brooke R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 907<br />
Snyder, Milo C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 442<br />
Snyder, Richard O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124<br />
Soballe, Kjeld. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 760<br />
Sobolev, Alexander S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Soden, Declan M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511<br />
Soe, Yatanar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Soldati, Corrado . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605<br />
Soldner, Frank . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Soltys, Stephen M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585<br />
Somanathan, Suryanarayan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292<br />
Somanchi, Srinivas S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 240<br />
Somia, Nikunj V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 877<br />
Sommer, Nadine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411<br />
Sondhi, Dolan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195, 200<br />
Song, Degang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 782<br />
Song, Jae J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 818<br />
Song, Lina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
Song, Liu-jiang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 824<br />
Song, Shuxian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625<br />
Song, Sihong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669<br />
Song, Xiao-Tong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84<br />
Sonpavde, Guru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 783<br />
Soong, Bing-Weng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 846<br />
Sorenson, Brent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 702<br />
Sorg, Ursula R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Sorge, Randy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Sorrentino, Brian P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .259, 284, 379<br />
Sorrentino, Cristina N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 722<br />
Sorrentino, Nicolina C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401<br />
Sorzano, Carlos Oscar S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916<br />
Sosale, Nisha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />
Soukhatcheva, Galina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334, 335<br />
Soustek, Meghan S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104, 901<br />
South, Andrew P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125<br />
Sowers, Anastasia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 642<br />
Spaeth, Erika L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 181
182<br />
Abstract Author Index<br />
Spampanato, Carmine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401, 722<br />
Sparks, Jeff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Sparwasser, Tim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790<br />
Speiser, Daniel E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228<br />
Spencer, David M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 783<br />
Spencer, H. Trent . . . . . . . . . . . . . . . . . . . .28, 826, 189, 592, 778, 873<br />
Spencer, Jacqueline F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 518<br />
Spengler, Ryan M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 837, 842<br />
Spratt, S. Kaye . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544<br />
Spriggs, David R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495<br />
Springer, Matthew L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Springfeld, Christoph. . . . . . . . . . . . . . . . . . . . . . . . . . . . .110, 515, 798<br />
Squillace, Karen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311<br />
Srivastava, Alok. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121<br />
Srivastava, Arun . . . . . 121, 131, 288, 330, 402, 406, 619, 663, 827<br />
Staal, Frank J. T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
Stachler, Matthew D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 662<br />
Stacpoole, Peter W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406<br />
Stamatoyannopoulos, George. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
Stamatoyannopoulos, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
Stanic, Bojana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 743<br />
Stapleton, Gary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3<br />
Starr, Renate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351<br />
Steel, Jason C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81<br />
Stefania, Merella. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611<br />
Stefanni, Alice C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Stefansk, Jolanta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Stegmüller, Carolin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139<br />
Stein, Stefan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 269<br />
Steines, Benjamin R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399, 654<br />
Steinh<strong>of</strong>f, Gustav . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 677<br />
Stephen, Gottschalk M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84<br />
Stewart, Phoebe L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4<br />
Stock, Stuart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 675<br />
Stocking, Carol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Stok, Merel M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713<br />
Stolz, Donna B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 858<br />
Stone, Jennifer D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356<br />
Storb, Rainer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73, 76<br />
Storici, Francesca. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 693<br />
Storkus, Walter J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232<br />
Stornaiuolo, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588<br />
Stout, Steven J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Strauss, Bryan E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 643<br />
Strauss, Robert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2, 18, 852<br />
Streeter, Jennifer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 743<br />
Stremmel, Wolfgang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110<br />
Stritzker, Jochen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Strob, Rainer F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623<br />
Struever, Nina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790, 804<br />
Stuckey, Samantha A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 693<br />
Stühmer, Walter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .570, 850, 851<br />
Su, Qin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400, 404, 555, 649, 827<br />
Su, Susan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 761<br />
Su, Xiaomin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 755<br />
Su, Yun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28<br />
Subat, Yosuf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71<br />
Subr, Vladimir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 416<br />
Suda, Takeshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627, 705<br />
Sudres, Muriel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Suerth, Julia D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348<br />
Suga, Tomohiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Sugae, Takashi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520<br />
Sugano, Hanako. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451<br />
Sugimoto, Hiroyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Suh, Junghae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 408, 666<br />
Sui, Hongshu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270<br />
Sule, Gautam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 478, 820<br />
Sullivan, Deborah E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Sullivan, Jennifer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 664<br />
Sullivan, Millicent O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .169, 175, 914<br />
Suman, V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 891<br />
Sun, Baodong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338<br />
Sun, Bingbing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157<br />
Sun, Bo K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 818<br />
Sun, Guihua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559<br />
Sun, Junjiang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 832<br />
Sun, Junwei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600<br />
Sun, Pengyu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391<br />
Sun, Samuel S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 442<br />
Sun, Samuel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625<br />
Sun, Wenchao. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 432<br />
Sun, Xingshen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270<br />
Sunshine, Abraham N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 642<br />
Surace, Enrico M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .401, 542, 722<br />
Suree, Tom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91<br />
Surosky, Richard. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544<br />
Suwanmanee, Thipparat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 832<br />
Suzuki, Hidenori. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 723<br />
Suzuki, Keiichiro. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315<br />
Suzuki, Masataka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54, 478, 820<br />
Suzuki, Ryo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430, 483<br />
Suzuki, Sachie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312<br />
Suzuki, Takayuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 682<br />
Svendsen, Clive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
Sverdlov, Eugene D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Svinartchouk, Fedor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661<br />
Swanson, Douglas J.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Swanson, Magdalena I. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Sweeney, Colin L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .345, 571, 833<br />
Sweeney, Lee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51<br />
Sweitzer, Sarah M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 749<br />
Swiderski, Piotr . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89<br />
Sysol, Justin R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 452<br />
Szabolcs, Paul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
Szakmary, Akos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Szalay, Aladar A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Szoka, Francis C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565, 568<br />
Szucs, Sylvia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649<br />
T<br />
Tabata, Toshiaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 577<br />
Tachibana, Yoichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181, 581<br />
Tacquet, Nicolas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Tada, Yuji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Tae, Hwang H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599<br />
Taejin, Song . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 678<br />
Tagalakis, Aristides D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106, 156<br />
Tagawa, Masatoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .282, 524, 805<br />
Täger, Maike. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Tahara, Hideaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 359<br />
Tahiri, Sanaa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79<br />
Tai, Chien-Kuo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 522<br />
Tai, David. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Tai, Khalid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301<br />
Tait, Andrew S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450<br />
Tak, Paul Peter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Takahashi, Atsushi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .97, 861<br />
Takahashi, Hiroshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 754<br />
Takahashi, Yuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 812<br />
Takakura, Yoshinobu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 812<br />
Takamatsu, Hideo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 898<br />
Takayama, Koichi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222, 233<br />
Takeda, Shin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 526, 803<br />
Takeda, Shin’ichi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .473, 558, 764<br />
Takiguchi, Yuichi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Takiya, Christina M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 742<br />
Talbott, Kendra T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504<br />
Tamamoto, Atsuko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524<br />
Tamsett, Thomas J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201<br />
Tan, Gewen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 520, 803<br />
Tan, Meng-qun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 824<br />
Tan, Rusung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334<br />
Tan, SzeHuey. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Tan, Wanlong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391<br />
Tanaka, Hiroyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172<br />
Tanaka, Shigeaki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
Tanaka, Shinji. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 732<br />
Tanaka, Yoshihiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233<br />
Tang, Qiushi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47<br />
Tang, Ru-Hang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468<br />
Tang, Ruhang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52<br />
Tang, T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 896<br />
Tang, Winson. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598<br />
Tang, Ying. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96, 367, 758, 769<br />
Tang, Yuqing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 773<br />
Tangney, Mark. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535<br />
Tani, Kenzaburo . . . . . . . . . . . . . . . . . . . . . . . . . .97, 222, 233, 861, 925<br />
Taniguchi, Akiyoshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 440<br />
Tanio, Masami. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462<br />
Tannous, Bakhos A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .130, 303, 307<br />
Tanoue, Kiyonori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 898<br />
Tao, Mi-Hua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17<br />
Tapscott, Stephen J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73, 76<br />
Tareen, S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Tatsumi, Kohei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190, 440<br />
Tatsumi, Koichiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Taub, Jason S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 651<br />
Tawackoli, Wafa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320, 761, 772, 856<br />
Taylor, Amy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262<br />
Taylor, C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 896<br />
Taylor, Clare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230, 263<br />
Taylor, Jennifer L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232<br />
Tazawa, Hiroshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 797, 800<br />
Tebbets, Jessica C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 373<br />
Tecedor, Luis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 870<br />
Teissie, Justin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448<br />
Temme, Achim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 521<br />
ten Dijke, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765<br />
Tennant, Bud C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215<br />
Teo, Marissa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Terada, Nobuyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 524<br />
Tesarfreund, Matthew . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
Tesfay, Mulu Z. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 888<br />
Tevz, Gregor. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448<br />
Thaci, Bart. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 683, 915<br />
Thatava, Tayaramma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311<br />
Thayapararajah, Mahinthan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 544<br />
Theisen, Linda. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .669, 881, 904<br />
Theobald, Matthias. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221<br />
Thibault, Marc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .699, 881, 904<br />
Thiel, William H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 743<br />
Thies, Verena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348<br />
‘t Hoen, Peter A. C.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765<br />
Thomas, Brandon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251<br />
Thomas, Darby L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 593<br />
Thomas, Terry E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 860<br />
Thomaschewski, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Thompson, Craig B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291<br />
Thompson, Cynthia D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 875<br />
Thompson, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 896<br />
Thompson, Jill M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . 358, 361, 775, 780<br />
Thompson, John A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459<br />
Thöny, Beat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557<br />
Thorne, Stephen H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 412<br />
Thornton, Charles A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Thornton, Mark. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 883, 899<br />
Thrasher, Adrian J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .268, 336, 759<br />
Throm, Robert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379<br />
Thyme, Summer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />
Tian, Jie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136<br />
Tian, Jing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 824<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 183
184<br />
Abstract Author Index<br />
Tiemann, Katrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89<br />
Tiffany, Matthew R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 568<br />
Tikoo, Suresh K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216<br />
Tilly, Gaëlle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375<br />
Tisdale, John F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117, 385<br />
Titze-de-Almeida, Ricardo . . . . . . . . . . . . . . . . . . . . . . . .570, 850, 851<br />
Tobari, Maiko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 539<br />
Tobolt, Diane K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427<br />
Todo, Tomoki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796<br />
Toh, HanChong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Toh, Kazuko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305<br />
Toita, Riki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150, 172<br />
Tojyo, Masahiko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237<br />
Tokumitsu, Ayako . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 315<br />
Tolar, Jakub . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 686<br />
Tolbot, D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67, 836<br />
Tompkins, Joshua D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 550, 579<br />
Tong, Alex W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Tong, Chun-Rong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 859<br />
Tonon, Giovanni. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 610<br />
Toole, Brian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533<br />
Torbett, Bruce E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 484<br />
Torikai, Hiroki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 903<br />
Toriyabe, Naoyuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 709<br />
Torok-Stord, Beverly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257<br />
Torrance, Chris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 908<br />
Torres, Raul. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431<br />
Toth, Karoly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 518<br />
Tötterman, Thomas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502<br />
Tran, Chy-Anh T. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 586<br />
Tran, Nancy H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 546<br />
Treanor, Louise M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284<br />
Treger, Janet A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95<br />
Treleaven, Christopher M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201<br />
Tremblay, Jacques P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428, 471<br />
Trobridge, Grant D. . . . . . . . . . . . . . . . . . . . . . . . . . . 342, 344, 485, 637<br />
Trono, Didier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267, 876<br />
Trujillo, Miguel A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58, 410, 799<br />
Trusov, Georgiy A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Tsai, Chih-Chien . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 313, 325, 862, 924<br />
Tsai, Kuo-Shu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 924<br />
Tsai, Richard K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />
Tschaika, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 87<br />
Tseng, Yu-Shan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 374<br />
Tsolaki, Eleftheria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Tsou, Wei-Ling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 846<br />
Tsukahara, Tomonori . . . . . . . . . . . . . . . . . . . . . . . . 188, 573, 696, 791<br />
Tsurumaki, Yuzuri. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796<br />
Tuddenham, E. G. D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 602<br />
Tuikue Ndam, N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Tung, Ching-Hsuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 308<br />
Turchiano, Giandomenico . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16<br />
Turkki, Vesa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109<br />
Turner, Anne-Marie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 554<br />
Turner, Jeff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212<br />
Turnis, Meghan E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84<br />
Turovets, Irina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 854<br />
Turovets, Nikolay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100, 854<br />
Tuschong, Laura M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 258, 346<br />
Twait, Erik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 655<br />
Twisk, Jaap . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183<br />
Tykodi, Scott S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Tyler, Betty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
Tysome, James . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
U<br />
Uchibori, Ryosuke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 573, 791<br />
Uchida, Naoya. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117, 385<br />
Uchida, Satoshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61<br />
Uchida, Yuji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Uchino, Katsuhisa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Uchino, Makoto . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Uchiyama, Makiko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Uchiyama, Toru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115<br />
Udagawa, Takeshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235<br />
Ueda, Yasuji . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523<br />
Ugarte, Magdalena. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557<br />
Ugolini, Matteo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55<br />
Ulasov, Alexey V.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64<br />
Ulasov, Ilya V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 683, 915<br />
Ulbrich, Karel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 416<br />
Ul-Hasan, Taihra B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128, 329<br />
Ulkoski, David . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Ulrich-Vinther, Michael . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 760<br />
Uludag, Hasan . . . . . . . . . . . . . . . . . . . . . . . . . . .62, 155, 162, 534, 810<br />
Umemoto, Yoshiaki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443<br />
Un, Keita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430<br />
Underwood, Mark A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286<br />
Ungefroren, Hendric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 507<br />
Unger, G. M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67, 836<br />
Unger, Gretchen M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427<br />
Ungerechts, Guy . . . . . . . . . . . . . . . . . . . . . . . 514, 515, 521, 528, 798<br />
Unzu, Carmen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184<br />
Urabe, Masashi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188, 573, 696, 791<br />
Urata, Yasuo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 797, 800<br />
Urban, Nicole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 815<br />
Urdahl, Kevin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 491<br />
Usas, Arvydas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 373<br />
Utoh, Rie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190<br />
V<br />
Vaena, Daniel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 834<br />
Vago, Luca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 605<br />
Valdmanis, Paul N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86<br />
Valero-Lapchik, Valderez Bastos. . . . . . . . . . . . . . . . . . . . . . . . . . . . 446<br />
Valles-Ayoub, Yadira . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 774
Abstract Author Index<br />
Van Craeyveld, Eline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 737<br />
van Deel, Elza E. D.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713<br />
van der Loo, Johannes C. M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613<br />
van der Valk, Marissa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671<br />
van Deventer, Sander. . . . . . . . . . . . . . . . . . . . . . . . 562, 847, 564, 566<br />
van Dongen, Jacques J. M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41<br />
van Heiningen, Sandra H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765<br />
Van Hoeven, N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
van Logtenstein, Richard . . . . . . . . . . . . . . . . . . . . . . . . .562, 847, 564<br />
van Ommen, Gert-Jan B.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765<br />
van Rensburg, Ruan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .578, 689, 852<br />
van Til, Niek N. P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 252, 254, 713, 715<br />
Van Vliet, Kim. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329<br />
Vandenberghe, Luk H. . . . . . . . . . . . . . . . . . . . . . . . 196, 292, 326, 333<br />
Vandermeulen, Gaëlle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 695<br />
Vanier, Marie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Vasseur, Virginie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293<br />
Velasquez, Fernando . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 642<br />
Venditti, Charles P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 452, 453<br />
Ventura-Gallegos, JL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 920<br />
Vera, Juan F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .503, 513, 591<br />
Verchere, C. Bruce . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334, 335<br />
Verfas, Patricia M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 747<br />
Verhoeyen, Els. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 876, 893<br />
Verrall, Ronald. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182<br />
Versteeg, Henk K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450<br />
Vetrini, Francesco . . . . . . . . . . . . . . . . . . . . . . 147, 277, 414, 419, 454<br />
Vets, S<strong>of</strong>ie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 486<br />
Vettor, Roberto. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 657<br />
Viale, Diego L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238<br />
Vickers, Selwyn M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146, 673<br />
Vickers, Selwyn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .58, 525<br />
Viecelli, Hiu Man . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557<br />
Vijayan, Aneesh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916<br />
Vile, Richard G. . . . . . . . . . . . . . . . . . . . . . . . . . 358, 361, 775, 780, 891<br />
Villa, Anna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254, 604<br />
Villegas-C, Hilda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 886, 887, 894, 895<br />
Villemejane, Julien . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703<br />
Vin, C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Vincent, Justin M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 694<br />
Vincent, Karen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 380<br />
Vinod, Sharma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629<br />
Viollet, Laurence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 768<br />
Viornery, Armelle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 589<br />
Visel, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 872<br />
Visser, Trudi T. P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .252, 254, 713<br />
Viwami, F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439<br />
Vlassov, Sasha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 849<br />
Vleck, Jan P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 596<br />
Vogel, Ashley. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Vogler, Carole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717<br />
Vogt, Thomas F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Voigtlander, Richard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413, 679<br />
Voit, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 72, 661<br />
Volin, Michael V. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 751<br />
Volpin, Monica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 607, 610<br />
Volz, Tassilo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
von Euler, Henrik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502<br />
von Kalle, Christ<strong>of</strong> . . . . . . . . . . . . .32, 42, 43, 46, 123, 223, 264, 269,<br />
. . . . . . . . . . . . 343, 347, 383, 389, 514, 521, 607, 610, 611, 632, 798<br />
von Laer, Dorothee. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 486, 641<br />
von Messling, Veronika . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515<br />
Voss, Ralf-Holger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221<br />
Vosters, Jelle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 831<br />
Voutila, Jon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559<br />
Vozza-Brown, Laura A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 445<br />
W<br />
Waddington, Simon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46, 253<br />
Wadhwa, Renu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 527<br />
Wadsworth, Samuel C. . . . . . . . . . . . . . . . . . . . . . . . . . . .380, 656, 664<br />
Wagemaker, Gerard G.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713<br />
Wagemaker, Gerard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .252, 254, 715<br />
Waks, Tova . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29<br />
Waldmann, Thomas A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81<br />
Walker, Christopher M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69<br />
Walker, Jon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 79<br />
Walker, Sherry M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 833<br />
Wallace, Lindsay M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .75, 467<br />
Wallraven, Gladice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Walsh, Christopher E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134<br />
Walsh, Colin L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565<br />
Walters, Glenn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341<br />
Wan, Limin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 700<br />
Wandless, Tom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301<br />
Wang, Bing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .96, 367, 476, 758, 769<br />
Wang, Bo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
Wang, Chien-Yuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 924<br />
Wang, Chi-Hsien . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468, 766<br />
Wang, Daren . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40<br />
Wang, Feng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 824<br />
Wang, Gui-qiang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213<br />
Wang, Hao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33<br />
Wang, Hexiao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529<br />
Wang, Hong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261<br />
Wang, Hongjie . . . . . . . . . . . . . . . . . . . . . . . . . .2, 18, 78, 135, 497, 689<br />
Wang, Hongmei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .345, 571, 833<br />
Wang, Jianbin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 484, 632<br />
Wang, Jiesheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178<br />
Wang, Jing-Bo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 859<br />
Wang, Jinjin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438, 700<br />
Wang, Juan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321<br />
Wang, Jun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 844<br />
Wang, Lan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821<br />
Wang, Lili . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186, 340<br />
Wang, Lisa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 357, 496<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 185
186<br />
Abstract Author Index<br />
Wang, P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83<br />
Wang, Peirong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120, 474<br />
Wang, Pengju . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516<br />
Wang, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220<br />
Wang, Pin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132, 219, 387, 492<br />
Wang, Qiang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333<br />
Wang, Qizhao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 848, 923<br />
Wang, Ran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437, 700<br />
Wang, Shaoying. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 845<br />
Wang, Shelley . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 598<br />
Wang, Shengdian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516<br />
Wang, Sin-Ting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 584<br />
Wang, Wenjing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218, 391<br />
Wang, Xiao Tian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 773<br />
Wang, Xiaoyin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Wang, Xiuli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Wang, Xiuyan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 230, 263<br />
Wang, Xu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438<br />
Wang, Xuefeng. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 828<br />
Wang, Yaohe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516, 529<br />
Wang, Yifeng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 792<br />
Wang, Ying-Jiin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 924<br />
Wang, Yuanzhi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218<br />
Wang, Yulei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 561<br />
Wang, Yupeng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35<br />
Wang, Yuqing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 898<br />
Wang, Zejing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76<br />
Wang, Zhongya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187, 463<br />
Ward, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450<br />
Ward, Peter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134<br />
Warlich, Michael. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572<br />
Warren, Edus H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Washington, Kareem N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 385<br />
Wasielewska, Teresa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
Wasserfall, Clive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 669<br />
Wasserman, Wyeth W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 744<br />
Watanabe, Atsushi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451<br />
Watanabe, Ayumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222<br />
Watanabe, Natsumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190<br />
Watanabe, Yoshihiko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 812<br />
Watchko, Jon F.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74<br />
Watson, Gordon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461<br />
Watts, Ashlee E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 316<br />
Watts, Korashon L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 372, 865<br />
Weaver, Eric A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 209, 488<br />
Webby, Richard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209<br />
Weber, Helga L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519<br />
Weber, Krist<strong>of</strong>fer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572, 641<br />
Weber, Michel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207<br />
Weber, Thomas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 398, 668<br />
Wee, Sunmee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283, 652<br />
Wei, Wei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 866<br />
Weichert, Wendy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 374<br />
Weigel-Van Aken, Kirsten A. K. . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 327<br />
Weikert, S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82<br />
Weinberg, Marco S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208, 556<br />
Weiner, David B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22, 504<br />
Weinzierl, Irina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 482<br />
Weismann, Cara M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 745<br />
Weissleder, Ralph. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303<br />
Weith, E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 87<br />
Welikson, Robert E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36<br />
Wellman, Jennifer M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 600<br />
Wels, Winfried S.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221<br />
Wels, Winfried . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27, 496<br />
Welsh, David A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Wen, Zhiping. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555<br />
Wenger, David A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 720<br />
Wensel, Theodore G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Wentworth, Bruce M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Wesselschmidt, Robin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579, 864<br />
West, Jennifer L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 666<br />
West, Richard A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100<br />
West, Richard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 854<br />
Westberg, Sara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502<br />
Westermann, Jürgen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506<br />
Wheeler, Thurman M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85<br />
Wherley, Jennifer P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 786<br />
White, Gary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 664<br />
Wicki, Jacqueline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 466<br />
Widdowson, Peter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 750<br />
Wiederholt, Kristin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 445, 849<br />
Wielgosz, Matthew. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256<br />
Wijaya, Cori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735<br />
Wilkinson, Fiona L.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336, 716<br />
Wilkinson, Leslie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 838<br />
Williams, David J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450<br />
Williams, Dewight R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4<br />
Williams, James A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 694<br />
Williams, Nathaniel P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257<br />
Williard, Deborah. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 655<br />
Wilson, James M. . . . . . . . . . . . . . . .19, 102, 108, 185, 186, 196, 214,<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . 291, 292, 326, 333, 340, 545, 621, 874<br />
Wilson, John H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Wilson, John . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591<br />
Wilson, Katherine M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165<br />
Wilson, Matthew H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 15<br />
Wilson, Steven P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 749<br />
Wininger, Fred A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 870<br />
Winkler, Thomas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113<br />
Winn, Michelle P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339<br />
Wirth, Thomas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249, 816<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Abstract Author Index<br />
Wittig, B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 87<br />
Wittig, Burghardt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506, 507<br />
Witting, Scott R. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 889<br />
Wohleb, Eric. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362<br />
Wohlfahrt, Martin E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 865<br />
Wojton, Jeffrey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362<br />
Wold, William S. M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 518<br />
Wolfe, John H.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618<br />
Wolfe, Thomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671<br />
Woller, Norman . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 790<br />
Wong, ChingLam W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38<br />
Wong, Han Hsi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529<br />
Wong, Jr., K. K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128<br />
Wong, K. K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329<br />
Wong, Shirley . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116<br />
Wong, Suet P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 751<br />
Wong, Sunnie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49<br />
Wongsrikeao, Pimprapar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />
Wongthida, Phonphimon . . . . . . . . . . . . . . . . . . . . . . . .358, 361, 780<br />
Woodard, Lauren E.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13<br />
Worgall, Stefan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210, 490<br />
Worth, Anna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513<br />
Wraith, J. Ed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336, 716<br />
Wright, Christine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351<br />
Wright, J. Fraser . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193, 587, 403, 600<br />
Wu, Anna M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609<br />
Wu, Bo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567<br />
Wu, Chih-Hsien. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 547<br />
Wu, Chuanfeng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113<br />
Wu, Hongju . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459<br />
Wu, Jingbo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391<br />
Wu, Joseph C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368<br />
Wu, Lily . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145<br />
Wu, Lingqian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 697, 698<br />
Wu, Meiting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 741<br />
Wu, Robert A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344<br />
Wu, Rui-Lin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 864<br />
Wu, Sheng Hua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322<br />
Wu, Susan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .718, 719, 726<br />
Wu, Tong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 859<br />
Wu, Wei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 672<br />
Wu, Xiaoping. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366<br />
Wulffraat, Nico M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 715<br />
Wynn, Rob . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716<br />
Wynn, Robert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336<br />
X<br />
Xiang, Yiwen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 327<br />
Xiao, Bin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 468<br />
Xiao, Di. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 697<br />
Xiao, Dong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391<br />
Xiao, Juan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193<br />
Xiao, Liang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219<br />
Xiao, Liying. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244<br />
Xiao, Ping-Jie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 395<br />
Xiao, Ru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196<br />
Xiao, Weidong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247, 848<br />
Xiao, Xiao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 468, 766<br />
Xie, Dan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Xie, Jianjun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113<br />
Xie, Jun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400, 404, 555, 621<br />
Xie, Qing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555<br />
Xie, Yiming . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 609<br />
Xing, James . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 318<br />
Xiong, Weidong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59, 509, 784, 789<br />
Xiong, Yang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245<br />
Xu, Lei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 766<br />
Xu, Mei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120<br />
Xu, Peng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 318<br />
Xu, Ruian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .247, 848, 923<br />
Xu, Yaqin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210<br />
Xu, Zhili . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136<br />
Xue, Jin-feng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 824<br />
Xue, Jing-lun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .437, 438, 700<br />
Xue, Yuan-Yuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437<br />
Y<br />
Yablonka-Reuveni, Zipora . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 475<br />
Yagi, Hiroya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188<br />
Yagiz, Kader . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59, 787, 788<br />
Yaiw, Koon-Chu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515<br />
Yamada, Suguru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Yamada, Yuma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 444<br />
Yamaguchi, Saori. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97, 861, 925<br />
Yamaguchi, Tomoko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 682<br />
Yamamoto, Masato. . . . . . . . 58, 146, 241, 525, 673, 674, 799, 911<br />
Yamamoto, Motoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 723<br />
Yamamura, Kazuo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .520, 526, 803<br />
Yamanaka, Makako. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282<br />
Yamaoka, Tetsuji. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181, 581<br />
Yamasaki, Satoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 673<br />
Yamashita, Fumiyoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . .319, 430, 443<br />
Yamashita, Satoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 770<br />
Yamauchi, Jun. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 835<br />
Yamauchi, Suguru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Yamazaki, Satoshi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312<br />
Yamazaki, Tomohiko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 440<br />
Yammine, Miriam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 928<br />
Yan, Jian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Yan, Ziying . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270, 660<br />
Yanay, Ofer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44<br />
Yáñez-Muñoz, Rafael J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268<br />
Yang, Baocheng. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930<br />
Yang, BC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 931<br />
Yang, Hsiao-Bai. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 924<br />
Yang, Hsueh-Ying L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 741<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 187
188<br />
Abstract Author Index<br />
Yang, Lili . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219, 492<br />
Yang, Ping. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 910<br />
Yang, Qing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 758, 769<br />
Yang, Shan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282, 805<br />
Yang, Yanu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Yang, Yu-Lin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Yang, Zih-Han . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276<br />
Yannaki, Evangelia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Yano, Shuya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 797, 800<br />
Yano, Tokujiro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523<br />
Yao, Gang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244<br />
Yao, Hong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 819<br />
Yao, Xiaoying. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 689<br />
Yarde, Danielle N.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 802<br />
Yardeni, Tal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457<br />
Yasui, Hiroyuki. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809<br />
Yasukawa, Masaki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777<br />
Yasumura, Eduardo G. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 742<br />
Yasuzaki, Yukari. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 444<br />
Yawata, Toshio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248<br />
Ye, B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 896<br />
Ye, Jingjing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 579<br />
Ye, Lin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464<br />
Ye, Peiqing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 294, 828<br />
Ye, Xianlin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930<br />
Ye, XL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 931<br />
Yeagy, Brian A.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 712<br />
Yeghiazarians, Yerem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Yen, Tzu-Chen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70<br />
Yew, Tu-Lai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .313, 862, 924<br />
Yiangou, Minas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192<br />
Ying, Lee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 461<br />
Ylä-Herttuala, Seppo . . . . . . . . . . . . . . . . . . . . . . . . . . . . .109, 249, 816<br />
Ylösmäki, Erkko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 684<br />
Ylostalo, Joni H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105<br />
Yockman, James W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159<br />
Yokoi, Takayuki . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714, 721<br />
Yokoo, Takeshi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 705<br />
Yokota, Takanori. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88, 92, 553<br />
Yokota, Toshifumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 558<br />
Yokota, Yosuke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222, 233<br />
Yonemitsu, Yoshikazu . . . . . . . . . . . . . . . . . . . . . . . . . . . .103, 523, 813<br />
Yong, Diao . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 923<br />
Yoo, Byoung Kwon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242<br />
Yoo, Ji Young . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 421<br />
Yoon, A.-Rum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 527<br />
Yoon, Chang S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 710<br />
Yoon, Sujin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297<br />
Yoshida, Eileen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 860<br />
Yoshida, Kie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .92, 553<br />
Yoshida, Kumi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .103, 523, 813<br />
Yoshida, Mitsuru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430<br />
Yoshida, Ryosuke. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 797, 800<br />
Yoshida, Teruhiko. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235<br />
Yoshida, Tsukihisa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523<br />
Yoshihara, Chieko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152, 237<br />
Yoshioka, Hir<strong>of</strong>umi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 777<br />
Yoshitomi, Toru. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305<br />
Younan, Patrick. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 485<br />
Young, Brittany A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 518<br />
Young, Joseph K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 779<br />
Yu, Kenneth K.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 494<br />
Yu, Kyeong-Nam . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246, 909, 926, 929<br />
Yu, Lianbo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 867<br />
Yu, Ping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81<br />
Yu, William . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415<br />
Yu, Yang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505<br />
Yu, Yong A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Yuan, Jinyun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 484<br />
Yuan, Ming. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529<br />
Yuan, Zuobiao. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 655<br />
Yudovich, David. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422<br />
Yue, Yang-bo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437<br />
Yue, Yongping. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309, 481<br />
Yuen, Carrie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Yugeta, Naoko . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 764<br />
Yumul, Roma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78, 226, 497<br />
Yun, Chae-Ok . . . . . . . . . . . . . . . . . . . . . .140, 145, 421, 527, 685, 806<br />
Yun, In Sik . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140<br />
Yun, Tae Jin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140<br />
Yun, Ui Jeong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 817<br />
Yvon, Eric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 913<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong><br />
Z<br />
Zabner, Joseph. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399, 654<br />
Zacchigna, Serena. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 532, 728<br />
Zacharias, Jeana. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 822<br />
Zadmehr, Ali . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59<br />
Zadorozhny, Victoria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 814<br />
Zaia, John A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99, 314, 586<br />
Zaiss, Anne K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142<br />
Zamore, Phillip D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .47, 555<br />
Zanetti, Gianluigi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 606, 611<br />
Zanzonico, Pat B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Zaoui, Karim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 514, 798<br />
Zaraspe, Kimberly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337<br />
Zegura, Bojana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 448<br />
Zeh, Herbert J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 599<br />
Zelenaia, Olga. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403<br />
Zeller, W. Jens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32<br />
Zeng, Yue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143<br />
Zentella- D, Alejandro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 887<br />
Zentella-Dehesa, A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 920<br />
Zentilin, Lorena . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .532, 614, 728<br />
Zerah, Michel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195<br />
Zerfas, Patricia M.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 453
Abstract Author Index<br />
Zhang, Ai-Hong (Allan) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 830<br />
Zhang, Aiwu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Zhang, Chun . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 919<br />
Zhang, Guisheng. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627, 705<br />
Zhang, Hongwei . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404, 555, 649, 827<br />
Zhang, Hui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218<br />
Zhang, Jane. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 493<br />
Zhang, Jian-Ping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 859<br />
Zhang, Jianqing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250<br />
Zhang, Jiuli. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Zhang, Lei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498<br />
Zhang, Ling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218, 391<br />
Zhang, Ping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289<br />
Zhang, Qian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 640<br />
Zhang, Steve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 648<br />
Zhang, Ting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418<br />
Zhang, Weibing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 376<br />
Zhang, Yadong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 688<br />
Zhang, Yan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 730<br />
Zhang, Yu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .363, 400, 404<br />
Zhang, Yuan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459<br />
Zhang, Yue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 677<br />
Zhang, Yulong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275<br />
Zhang, Zhenwei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 675<br />
Zhang, Zhixiang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 866<br />
Zhang, Zhong. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 751<br />
Zhao, Huifen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346<br />
Zhao, Huiren . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 671<br />
Zhao, Li . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 856<br />
Zhao, Xin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191<br />
Zheng, Changyu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 642, 657<br />
Zheng, Dexian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 537<br />
Zheng, Guopei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245<br />
Zheng, Hui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .52, 468<br />
Zheng, X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 931<br />
Zheng, X. Long. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193<br />
Zheng, Xin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930<br />
Zheng, Yi. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735<br />
Zheng, Zhaohui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266<br />
Zhili, Zheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231<br />
Zhong, Bonan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 865<br />
Zhong, Li. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400, 404, 555, 621, 827<br />
Zhong, Wen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 811<br />
Zhou, Dongbing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 792<br />
Zhou, Dongming. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680<br />
Zhou, Fei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 824<br />
Zhou, Heather H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 731<br />
Zhou, Jason . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 910<br />
Zhou, Jiehua . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89<br />
Zhou, Jinyuan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
Zhou, Qinghui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63<br />
Zhou, Shangzhen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .49, 403<br />
Zhou, Sheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259, 284<br />
Zhou, Xiangyang. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680<br />
Zhou, Xianzheng . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255<br />
Zhou, Xiaohuai. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 548<br />
Zhou, Yuanyue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Zhu, Jie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272<br />
Zhu, Liwei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 792, 866<br />
Zhu, Tsugumine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103<br />
Zhu, Weigang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930<br />
Zhu, Wen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210, 490<br />
Zhu, WG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 931<br />
Ziebermayr, R.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87<br />
Zilberman, Yoram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .320, 370, 761<br />
Ziliotto, Raul. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588<br />
Zilla, Peter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629<br />
Zillmer, Allen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567<br />
Zogovic-Kapsalis, Tatjana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100<br />
Zolotukhin, Irene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 663<br />
Zolotukhin, Sergei. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .330, 332, 405<br />
Zoltick, Philip W.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119<br />
Zou, Jizhong . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345<br />
Zsebo, Krisztina M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601<br />
Zuber, Guy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180<br />
Zucchelli, Eleonora . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 588<br />
Zwiebel, J . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 891<br />
Zwipp, Hans. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 469, 482<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 189
190<br />
Notes<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Notes<br />
14TH ANNUAL MEETING | SEATTLE, WA | MAY 18-21, 2011 191
192<br />
Notes<br />
FINAL PROGRAM <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong>
Announcing the <strong>American</strong><br />
<strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong><br />
<strong>Therapy</strong>’s 2011 Strategic Plan!<br />
In June 2010, the <strong>American</strong> <strong>Society</strong> <strong>of</strong> <strong>Gene</strong> & <strong>Cell</strong> <strong>Therapy</strong> (ASGCT) began a comprehensive<br />
strategic planning effort to chart the direction and future course <strong>of</strong> ASGCT. The strategic plan,<br />
adopted in April 2011, includes input from the ASGCT membership, key opinion leaders in gene<br />
and cell therapy, the <strong>Society</strong> leadership, and <strong>Society</strong> staff members.<br />
The ASGCT Board <strong>of</strong> Directors is excited to reveal the 2011 ASGCT Strategic Plan:<br />
ASGCT’S MISSION IS TO:<br />
Advance knowledge, awareness, and education leading to the discovery and clinical application<br />
<strong>of</strong> genetic and cellular therapies to alleviate human disease.<br />
ASGCT’S STRATEGIC VISION IS TO BE A:<br />
Catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to<br />
transform the practice <strong>of</strong> medicine by incorporating the use <strong>of</strong> genetic and cellular therapies to<br />
control and cure human disease.<br />
OVER THE NEXT FIVE YEARS, ASGCT’S GOALS ARE THE FOLLOWING:<br />
Goal 1: Expand and engage a diverse membership that increases ASGCT’s impact and<br />
effectiveness.<br />
Goal 2: Increase and diversify revenue and maintain appropriate reserves to support anticipated<br />
growth <strong>of</strong> mission aligned programs and services.<br />
Goal 3: Expand ASGCT’s preeminence by advancing novel nucleic acid, cell and tissue therapies.<br />
Goal 4: Expand public, governmental and industry support for nucleic acid, gene, cell and tissue<br />
therapies.<br />
Goal 5: Offer mission aligned, financially viable programs and services that will best serve our<br />
members and stakeholders and increase their impact in the field.<br />
Visit the ASGCT Exhibit<br />
Booth for more information<br />
on the new strategic plan!
Photo Credit: National Institutes <strong>of</strong> Health/Department<br />
<strong>of</strong> Health and Human Services<br />
Bethesda,<br />
Maryland<br />
Philadelphia,<br />
Pennsylvania<br />
Save-the-Date<br />
ASGCT 2011-2012 <strong>Program</strong>s<br />
NIH <strong>Gene</strong> <strong>Therapy</strong><br />
Symposium<br />
September 26-27, 2011<br />
Natcher Conference Facility, NIH<br />
Bethesda, Maryland, USA<br />
ASGCT 15th<br />
Annual Meeting<br />
May 16-20, 2012<br />
Philadelphia Convention Center<br />
Philadelphia, Pennsylvania, USA<br />
For more information or to register, visit the ASGCT website at www.asgct.org.<br />
ASGCT-0311-066